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Summary 
 
Background: Prostate cancer is now the most common type of cancer in men in the 
UK.  Physical effects of treatments have been well documented; however, the extent 
to which psycho-social factors may impact upon health-related quality of life (HRQoL) 
is limited.  Little is known about the self-management behaviours of men affected by 
prostate cancer or how they cope with prostate cancer.  Men living with and beyond 
prostate cancer have reported a lack of support in their pursuit to cope with the 
physical and psychological sequelae.  Social support may help men with self-
management, but may also buffer the relationship between coping and HRQoL.  
Most healthcare research has been conducted between individuals and is limited to 
aggregate group level effects, and has overlooked the importance of within-person 
experience and change over time.  Any future theoretically driven intervention study 
should be supported empirically at the level it is intended: “the individual man”.    
 
Aim: To assess the mechanism effect between the relationship that links coping and 
social support to HRQoL in a sample of men affected by prostate cancer using 
between individuals and within individual methodological approaches.  In addition, 
this thesis aimed to identify the actual self-management behaviours and social 
supportive experiences of men over the cancer journey, between and within 
individuals over time. 
 
Methods: A quantitative approach consisted of a prospective, longitudinal survey 
and single-case electronic diary data.  Clinical, demographic and survey data were 
collected at baseline (before treatment) and at 6 months follow-up. A sub-sample of 
n=12 participants completed an electronic behavioural diary for 1 month.  Men 
completed the electronic behavioural diary in the month following their treatment.  
The duration, timing and design of the behavioural diary were guided by 
methodological considerations, service users and clinicians’ comments.    
 
Findings:  The prospective longitudinal survey identified that baseline perceived 
social support was the most important social support construct that predicted HRQoL 
(β=0.266, p=0.021) and depression (β=0.243, p=0.029) at 6 months and explained 
approximately 30% of the variance of the dependent variables.  Moderation and 
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mediation effects were not identified from the prospective longitudinal findings.   
Testing theoretical models “within-individuals” over time demonstrated different 
results for main, moderating and mediating pathways that linked coping and social 
support to emotional outcome.  Men performed a number of self-management 
behaviours for urinary, bowel and sexual dysfunction, but often with little relief. 
 
Discussion/Relevance:  Real time data collection moves far beyond traditional 
retrospective evaluations, enabling a much clearer understanding of the individual 
patient experience over time.  The results from the series of single-case studies have 
demonstrated the one size does not fit all.  The findings from the prospective 
longitudinal study and the 11 single-case studies suggest that men may benefit from 
a supported self-management intervention study tailored to the “individual’s needs” 
of prostate cancer survivors. 
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Overview to this thesis 
 
Prostate cancer is a specific type of cancer that can only affect males.  The prostate is 
a gland, and forms part of the male reproductive system.  The prostate gland is 
usually the size and shape of a walnut and it is located underneath the bladder and 
surrounds the urethra.  Prostate cancer and its treatments have the potential to 
reduce health-related quality of life (HRQoL) for men living with and beyond prostate 
cancer.  A growing number of studies have measured HRQoL and, as yet, no 
literature review has been conducted to identify the predictor variables of HRQoL or 
has detailed how HRQoL changes over time in this patient group.  Chapter 1 presents 
a structured review of the empirical evidence that details the predictor variables of 
HRQoL and identifies how HRQoL changed over time for men affected by prostate 
cancer.  The findings from this review identified that, despite the proliferation of 
HRQoL literature in recent years, little is known about the influence of the 
relationship between social support and coping on HRQoL, or the self-management 
behaviours of prostate cancer survivors.  To ensure that the Ph.D. research questions 
were developed on the best available evidence it was necessary to conduct two 
further structured reviews of the empirical evidence.   
 
Chapter 2 presents a structured review of the empirical evidence that aimed to 
identify which types of social support has been found to influence HRQoL and details 
the mechanism effect that links coping and social support to HRQoL in men with 
prostate cancer.  The findings from this review demonstrated that few prospective 
longitudinal research designs have been implemented in this field to evaluate 
changes in social support provision.  It seems likely that the types of social support 
needs will change throughout the cancer trajectory.  Additional work is needed to 
assess how social supportive experiences change over time and this could be 
achieved through a prospective longitudinal design (to assess aggregate group 
effects) and case-based time series designs (to assess within-person change over 
time). Evaluating average group level effects and within-person design over time is an 
innovative approach which may expand and refine the propositions of social support 
theory.    
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A suitable theoretical framework to advance research in this area is the stress 
buffering model because it links social support and coping to HRQoL. Few studies 
have tested this theoretical framework in men affected by prostate cancer. The 
stress buffering model enabled the mechanism effect (main/moderation/mediation) 
of social support to be explored with coping and health-related outcomes for men 
affected by this disease.  The development of our understanding of the mechanism 
effect that links coping and social support to HRQoL will facilitate the development of 
appropriately targeted interventions that are theoretically driven.  Not only has social 
support been found to influence HRQoL but it may help men in their pursuit to self-
manage.     
 
Self-management for people affected by cancer is increasingly being recognised as a 
fundamental component of effective management of cancer care as a long-term 
condition.  Men are keen to engage as active partners in the management of their 
condition but men have voiced a number of unmet support needs that make 
effective self-management problematic.  Chapter 3 presents the third structured 
review of the empirical evidence that aimed to identify the self-management 
behaviours performed by men affected by prostate cancer and to establish whether 
self-management behaviours have been found to change over time.  The findings 
from this chapter demonstrated that very little research has assessed self-
management behaviours for prostate cancer survivors.  There were five papers 
included in this review and this underscores that this field is under-developed.  
Additional research is urgently needed to establish the self-management behaviours 
of men within different clinical characteristics and level of social support.  Developing 
this evidence base is very important because of the number of unmet support needs 
of these men, and the recent political drive for individuals to self-manage.   
 
In summary, chapters 1, 2 and 3 are structured reviews of the empirical evidence 
that were conducted to add quality and rigour in developing the researcher’s 
research questions.  The findings from these reviews identified that men affected by 
prostate cancer may experience profound physical and psychological sequelae. Little 
is known about how men cope with the aftermath problems associated with this 
disease, the self-management behaviours that men use, or the relationship between 
coping and social support in relation to HRQoL. Based upon the results of the 
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literature review in chapter 2, a suitable theoretical framework to assess the 
influence of the relationship between coping and social support on HRQoL is the 
stress buffering model.  This theoretical model was selected because it enabled 
main/moderation/mediation effects of social support and coping on HRQoL to be 
tested, and because very little research has tested the propositions of social support 
theory in men affected by prostate cancer.  Developing an understanding of the 
influence of social support on HRQoL was very important because of the unmet 
support needs of these men. 
 
Most healthcare research has been conducted to test aggregate group level effects 
and therefore, is restricted to hypothetical averages.  Such approaches overlook the 
importance of within-person experience and change over time.    Any future 
theoretically driven intervention study should be supported empirically at the level it 
is intended; the individual man.  Therefore, the aim of this Ph.D. study was to test the 
stress buffering model between and within individuals over time and to assess the 
self-management behaviours and the social supportive experiences. 
 
Chapter 4 identifies the research questions that addressed the aim of this Ph.D. 
study.  This chapter (4) opens with a critical introduction into the chosen 
methodology.  A quantitative approach consisted of a prospective longitudinal survey 
and 12 ecological momentary assessment (EMA) adapted/N-of-1 studies which were 
appropriate to address the overall study aim, and to answer the research questions.  
Participants were asked to complete a battery of questionnaires at baseline and 6 
months follow-up.  A sub-sample n=12 completed a daily electronic diary for a total 
duration of one month.  The duration, timing and design of the EMA adapted/N-of-1 
were guided by the literature and expert comment from the research steering group.  
 
This quantitative approach enabled the theoretical model to be tested between 
individuals and within-individuals over time to advance understanding of the 
propositions of social support theory, but uniquely positioned the individual man at 
the centre of the research.   This design enabled refinement of the propositions of 
social support theory.  The design and methods chosen in this Ph.D. captured insights 
into, and quantifiable data on, men’s social support and the self-management 
behaviours over the course of the cancer journey.  
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Chapter 5 presents the findings from the prospective longitudinal study and chapter 
6 presents the findings from the case series of 12 electronic behavioural diaries.  The 
clinical implications from the findings of this Ph.D. are discussed, and future 
directions for additional research are identified, in chapter 7.  
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1:  Health-related quality of life and prostate 
cancer 
1.1:  Abstract  
Background 
Prostate cancer and its treatments have the potential to reduce health-related 
quality of life (HRQoL) for men living with and beyond prostate cancer.  A growing 
number of studies have measured HRQoL and there is a pressing need to take stock 
of the existing evidence to identify predictors of HRQoL, and how HRQoL changes 
over time in this patient group.  It is anticipated that knowledge in this area will drive 
attempts to understand the predictors of HRQoL and inform future research aimed to 
improve HRQoL.   
Aim 
To critically evaluate the empirical evidence that has identified the predictor 
variables of HRQoL and assessed changes in HRQoL over time for prostate cancer 
survivors.   
Methods 
A structured review of empirical literature published between 2005 and 2012 was 
included.  Databases searched included: DARE, CDSR, Medline, CINAHL, PsycINFO, 
and ASSIA.  Research studies which identified predictor variables of HRQoL or 
assessed changes in HRQoL over time were included. 
Results 
104 publications were reviewed.  53 studies identified predictor variables of HRQoL 
and 77 studies identified changes in HRQoL over time.  Demographic (age, ethnicity, 
marital status, education), clinical variables (cancer stage, Gleason score, co-
morbidity, treatments and prostate-specific antigen [PSA]) and psycho-social 
variables (coping, self-efficacy, perceived stress, coping, depression and social 
support) have been identified as predictors of HRQoL.  Very few studies (six) 
investigated the influence of psycho-social variables on HRQoL.  Prospective 
longitudinal data identified that men can experience reduced general HRQoL in the 
months following treatment, but prostate cancer-specific HRQoL can be negatively 
affected for many years after treatment. 
Conclusion  
2 
 
 
 
Despite the proliferation of HRQoL literature in recent years, little is known about the 
influence of the relationship between social support and coping on HRQoL or the 
self-management behaviours of prostate cancer survivors.  There is a pressing need 
to address this knowledge deficit to improve patient-reported outcomes.  Moreover, 
developing an evidence base for self-management is a key feature of health care 
policy in the UK. 
1.2:  Introduction  
Prostate cancer is now the most prevalent type of cancer in men in the United 
Kingdom (UK) (Cancer Research UK, 2012, Information Services Division, 2012).  In 
2009, more than 40,841 men were diagnosed with prostate cancer in the UK (Cancer 
Research UK, 2012), with 10,000 men dying from this disease.  Prostate cancer for 
the most part is a disease of older men, and a diagnosis is less common for men 
below the age of 50 years (Burford et al., 2009). 
 
Four clinical procedures are commonly used to diagnose prostate cancer: digital 
rectal examination (DRE), the Prostate-Specific Antigen (PSA) blood test, trans-rectal 
ultrasound (TRUS) and needle biopsy (National Institute for Health and Clinical 
Excellence [NICE] 2008).  There are three key prognostic factors relevant to prostate 
cancer: PSA, Gleason Score and Tumour-Nodes-Metastases (TNM) staging (NICE, 
2008).  PSA is a protein specifically produced by the prostate gland, and the PSA 
blood test results are usually reported as nanograms of PSA per millilitre (ng/mL) of 
blood.    The Tumour-Nodes-Metastases (TNM) staging system is a way of recording 
how far the cancer has spread. The TNM staging system looks at the tumour (T), 
lymph nodes (N) and whether the cancer has metastasised (M) to other parts of the 
body.  The Gleason system looks at the pattern of prostate cancer cells. There are 
five patterns which are graded from 1-5; a grade of 1 appears very similar to normal 
prostate tissue, whereas, a grade of 5 appears very different to normal tissue. The 
prostate biopsy samples are individually graded, and then, the two most commonly 
occurring patterns are added together to get a Gleason score of between 2-10. Low-
grade cancers (a Gleason score of 6 or under) are usually slow-growing and less likely 
to spread.  A Gleason score of 7 is a moderate grade and high-grade tumours 
(Gleason scores of 8-10) are likely to grow faster and more likely to metastasize. 
(NICE, 2008).  The clinical presentation of these key prognostic factors informs the 
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treatment options available to men diagnosed with this disease (see table 1.1 and 
figures 1.1-1.2 for treatment overview), see NICE guidelines for in-depth clinical 
management.  
 Table 1.1 Treatment options available for localised prostate cancer  
 Low-risk men (PSA ≤ 
10ng/ml and Gleason 
score ≤ 6 and T1-2a 
Intermediate risk 
men (PSA 10-20 
ng/ml or Gleason 
score 7 or T2b-2c) 
High-risk men (PSA ≥ 
20ng/ml or Gleason 
score ≥ 8 to T3-T4) 
Watchful waiting    
Active surveillance   X 
Brachytherapy   X 
Prostatectomy    
Radiotherapy    
Cryotherapy X* X* X* 
High-intensity 
focused ultrasound 
X* X* X* 
 Preferred treatment,  Treatment Option, Not recommended, X*Not recommended other 
than in the context of clinical trials (NICE, 2008, p.34) 
 
 
T3a – T4 Prostate cancerT3a – T4 Prostate cancer
Men receiving radical 
radiotherapy
· Neoadjuvant hormonal 
therapy
· Adjuvant hormonal 
therapy for up to 3 years
en receiving radical 
radiotherapy
· eoadjuvant hor onal 
therapy
· Adjuvant hor onal 
therapy for up to 3 years
Hormone 
therapy alone
(see metastatic 
figure)
Hor one 
therapy alone
(see etastatic 
figure)
Bisphosphonates
Not recommended 
for the prevention 
of metastases
Bisphosphonates
ot reco ended 
for the prevention 
of etastases
Post-radical prostatectomy 
with extra-capsular spread
Post-radical prostatecto y 
ith extra-capsular spread
Men receiving radical 
prostatectomy
· Immediate post-op 
radiotherapy not 
recommended 
· Adjuvant hormonal therapy 
not recommended
en receiving radical 
prostatecto y
· I ediate post-op 
radiotherapy not 
reco ended 
· Adjuvant hor onal therapy 
not reco ended
 
(NICE, 2008, p.34) 
Figure 1.1 Treatment options available for locally advanced prostate cancer 
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Newly diagnosed or relapsing
Biopsy not required if high PSA and positive bone
l  i s  r r l si
i s  t r ir  if i    siti  
First line hormonal therapy
· luteinizing Hormone - Releasing Hormone analogue (LHRHa) or bilateral 
orchidectomy should be offered
· Intermittent androgen withdrawal may be offered
· Combined androgen blockage is not recommended
irst li  r l t r
 l t i izi  r  - l si  r  l  (L ) r il t r l 
rc i ct  s l   ff r
 I t r itt t r  it r l   ff r
 i  r  l c  is t r c
Hormone refractory disease
· Men with hormone refractory disease should be discussed at the multi-
disciplinary meeting and referred to oncology or palliative care if needed
· Palliative care should be available when needed not only at end of life
r  r fr ct r  is s
  it  r  r fr ct r  is s  s l   isc ss  t t  lti-
isci li r  ti   r f rr  t  c l  r lli ti  c r  if 
 lli ti  c r  s l   il l    t l  t  f lif
Chemotherapy
· Docetaxel if Karnofsky>=60%
· Up to 10 cycles
· Repeat cycles not recommended
t r
 c t l if r fs
  t   c cl s
 t c cl s t r c
Corticosteroids
E.g.Dexamethasone 0.5mg Daily
rtic st r i s
. . t s  .  il
 
(NICE, 2008, p.36) 
Figure 1.2 Treatment options available for metastatic prostate cancer 
 
There have been significant advancements in prostate cancer treatments that have 
reduced mortality rates (Gacci et al., 2009, Smith and Lindau, 2009, Jayadevappa et 
al., 2005).  Now, not only is quantity of life important, but patients’ quality of 
remaining life is crucial as men are living longer with this disease (Chen et al., 2009, 
Couper et al., 2009, Galbraith et al., 2008, Daubenmier et al., 2006, Dalkin et al., 
2006, Brar et al., 2005, Feigenberg et al., 2005, Jayadevappa et al., 2005).   
 
The disease and its treatments have the potential to cause substantial short- and 
long-term problems in this patient group (Maguire, 1989).  The delicate nature of 
treatments mean that men with prostate cancer often face a host of difficulties 
which can negatively affect HRQoL (Eton and Lepore, 2002), including physical and 
psychological problems (Cockle-Hearne and Faithfull, 2010, Gerbershagen et al., 
2008, Ene et al., 2006).  Problems associated with prostate cancer treatments 
include: urinary (urgency, frequency, incontinence) (Zelefsky et al., 2008), bowel 
(rectal bleeding, urgency in defecation, diarrhoea, and faecal leakage) (Al-Abany et 
al., 2002) and sexual dysfunction (impotence, loss of libido) (Gomella, 2007).  Other 
symptoms associated with therapies include: fatigue, weight gain, depression, 
osteopenia, anaemia, muscle atrophy, gynaecomastia, hot flushes and loss of 
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cognitive function (Cancer Research UK, 2011, Engstrom, 2008, Schneider et al., 
2007, Engstrom, 2005). Due to increasing survival rates (Jemal et al., 2011, Burford et 
al., 2009) the number of men dealing with the aftermath consequences of prostate 
cancer are set to rise (Korfage et al., 2007).  There is a growing concept of 
survivorship in people affected by cancer because many individuals will continue to 
live with long-term problems after treatment has finished.  Macmillan Cancer 
Support define the concept of survivorship as,   
 
"… someone who has completed initial cancer management and has no apparent 
evidence of active disease, or is living with progressive disease and may be receiving 
cancer treatment but is not in the terminal phase of illness (last six months of life), or 
has had cancer in the past”.  
      (Davies and Batehup, 2010) 
 
The Scottish Government (Department of Health Macmillan Cancer Support & NHS 
Improvement, 2010) acknowledges that further work is needed to fully understand 
the survivorship needs of individuals affected by cancer. This policy identifies that 
future work is needed to find ways of supporting and empowering patients, building 
confidence, and identifying sources of support which are needed to maintain the 
level of independence necessary for optimum quality of life.  Prostate cancer and its 
treatments can have a profound negative effect on HRQoL.  The identification of the 
predictor variables of HRQoL and how HRQoL changes over time is a helpful starting 
point to direct future research in this field for men living with and beyond prostate 
cancer.  
 
Definitions of HRQoL 
 
It is important to distinguish the different quality of life terms in the literature for the 
purpose of this thesis.  Examples of HRQoL measures include: disease- or population-
specific measures which are multi-domain and relevant to specific health problems 
such as cancer; the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire – Prostate (van Andel et al., 2003); or generic measures 
which can be used across population types that are also multi-domain measures of 
broader health status, for example the Short Form-36 (Ware and Sherbourne, 1992).  
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Individualised measures of quality of life enable respondents to nominate and weigh 
important areas of their own life, for example, the Schedule for Evaluation of 
Individual Quality of Life (O'Boyle et al., 1993) or the Patient Generated Index (Ruta 
et al., 1994).    The evaluation of quality of life is dynamic, multi-level and complex 
and clear use of quality of life terms are important to avoid confusion. 
 
The World Health Organisation (1947) has defined health as not merely the absence 
of disease, but to also include complete physical function, social function, role 
function, mental health and general health perceptions.  This early definition of 
health subsequently paved the way for HRQoL (O'Connor, 2004).  An early definition 
of HRQoL has been defined as a multi-dimensional concept that encompasses the 
physical, emotional, and social components associated with an illness or treatment 
(Revicki, 1989).  Elsewhere, HRQoL refers to the extent to which one’s usual or 
expected physical, emotional, and social well-being are affected by a medical 
condition or its treatments (Cella and Nowinski, 2002).  According to the World 
Health Organisation, HRQoL is a term used to describe psychological and social 
functioning as well as physical functioning and incorporates positive aspects of well-
being as well as negative aspects of disease and infirmity (Sloan, 2002).  To date, 
there is not a universally accepted definition of HRQoL (Bottomley, 2002, Bowling, 
2001).   
 
Yet, based on these definitions of HRQoL, it transpires that there is a consensus that 
HRQoL is a multi-dimensional construct that includes: physical, psychological and 
social aspects of patients’ well-being.  The Medical Research Council recommended 
that HRQoL assessments for patients with cancer should include the following: 
physical well-being (for example: symptoms, physical activity, self-care, toxicities’ 
from treatments), psychological well-being (for example: emotional distress, 
depression, anxiety, mood) and social well-being (for example: effects on social 
activities, work, recreation, relationships with friends and family) (Maguire, 1989).  In 
addition, researchers should implement a general HRQoL measure to evaluate the 
above multi-dimensional domains, supplemented with a disease-specific assessment.    
 
The recommendations by the Medical Research Council to use multi-dimensional 
measures of HRQoL are supported in more recent literature (Bottomley, 2002) and 
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have been widely applied and reproduced in many prostate cancer studies 
(Roeloffzen et al., 2010, Namiki et al., 2009a, Smith et al., 2009, Zavala et al., 2009, 
White et al., 2008, Litwin et al., 2007a, Northouse et al., 2007a, Jayadevappa et al., 
2007, Daubenmier et al., 2006, Brar et al., 2005).  The rationale for assessing general 
multi-dimensional domains of HRQoL in addition to disease-specific domains of 
HRQoL is because HRQoL tends to differ according to the cancer stage and 
treatments (Kobuke et al., 2009, Cella and Nowinski, 2002).  Incorporating measures 
in this way allows a sensitive and holistic evaluation of the problems associated with 
having prostate cancer, responsive to the stage of disease, and specific treatments 
(Bowling, 2001, Sommers and Ramsey, 1999, Hopkins, 1992).     Finally, HRQoL 
instruments in prostate cancer should have demonstrated reliability and validity 
(Eton and Lepore, 2002, Sommers and Ramsey, 1999) (see table 1.2 for an overview 
of HRQoL instruments used in prostate cancer studies). 
Table 1.2 Instruments Used to measure HRQoL in prostate cancer research 
Instrument Items      Cronbach’s 
              Alpha (range  
              from low to 
                  high) 
Mode of 
administration 
Comments 
Generic Measures of HRQoL 
 
Medical Outcomes Study 36-Item  
(Ware and Sherbourne, 1992) 
Used in: (White et al., 2008, Jayadevappa et 
al., 2006, Daubenmier et al., 2006, Ficarra et 
al., 2006) 
 
 
 
 
Nottingham Health Profile (NHP) 
(Hunt and McEwan, 1980) 
Used in: (Joly et al., 1998, Hunter et al., 1995) 
 
 
 
 
 
 
Cancer-specific measures of HRQoL 
 
 
European Organisation for Research and 
Treatment of Cancer Quality of Life 
Questionnaire – Cancer 30 (EORTC – C30) 
(Aaronson et al., 1993)  
Used in: (Galvao et al., 2010, Roeloffzen et al., 
2010, Fransson, 2008, Buron et al., 2007, 
Choo et al., 2007, Van Gellekom et al., 2005, 
Fransson et al., 2001, Albertsen et al., 1997) 
 
 
 
 
 
 
 
36           low of 0.65 
               to high of  
               0.94 
   
 
 
 
 
 
38           low of 0.77  
                to high of  
                0 85  
   
 
 
 
 
 
 
 
 
30           low of 0.70 
                to a high of 
                 0.90 
 
 
 
 
 
 
 
 
 
 
 
 
Self or interviewer 
 
 
 
 
 
 
 
 
Self 
 
 
 
 
 
 
 
 
 
 
 
Self 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eight scales measure 
physical, psychological 
and social functioning, 
including subjective 
mental health status and 
vitality, bodily pain and 
general health 
perceptions.   
 
Includes a number of 
subscales for energy, 
pain, emotional 
reactions, sleep, social 
isolation and mobility.  
The performance section 
includes occupation, 
home tasks, sex life, 
social life, hobbies, 
holidays and personal 
relationships.   
 
Multiple domains are 
assessed, physical, role, 
emotional, cognitive and 
social functioning, 
individual symptoms 
(dyspnoea, insomnia, 
appetite loss, 
constipation, diarrhoea, 
nausea and vomiting, 
pain, fatigue).  In addition 
financial difficulties 
related to cancer.  A 
prostate cancer-specific 
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Functional Living Index (FLIC)  
(Schipper et al., 1984) 
Used in: (Turner et al., 2001, Braslis et al., 
1995, Lim et al., 1995, Cassileth et al., 1992) 
 
 
Functional Assessment of Cancer Therapy –
General (FACT-G) 
(Cella et al., 1993) 
Used in: (Ahles et al., 2004, Bradley et al., 
2004, Knight et al., 2001, Tefilli et al., 1998, 
Esper et al., 1997, Shrader-Bogen et al., 1997) 
 
Rotterdam Symptom Checklist (RSCL) 
(de Haes et al., 1990) 
Used in: (Duncan et al., 2000) 
 
Prostate Cancer-Specific Measures 
 
Functional Assessment of Cancer Therapy – 
Prostate (FACT-P) 
(Esper et al., 1997) 
Used in:  (Fujimura et al., 2009, Arai et al., 
2008, Joseph et al., 2008, Feigenberg et al., 
2005) 
 
University of California at Los Angeles 
(UCLA) Prostate Cancer Index 
(Litwin et al., 1998a) 
Used in: (Namiki et al., 2009b, Namiki et al., 
2008, Prezioso et al., 2007a, Yoshimura et al., 
2007, Namiki et al., 2006a, Korfage et al., 
2005, Kakehi et al., 2002) 
 
Expanded Prostate Cancer Index (EPIC) 
(WEI et al., 2000) 
Used in: (Guedea et al., 2009, Sugimoto et al., 
2009, Ash et al., 2007, Merrick et al., 2003) 
 
 
International Prostate Symptom Score (IPSS) 
(Barry et al., 1992) 
Used in: (Meyer et al., 2009, Ash et al., 2007, 
Feigenberg et al., 2005, Egawa et al., 2001, 
Lee et al., 2000) 
 
 
 
 
 
European Organisation for Research and 
Treatment of Cancer Quality of Life 
Questionnaire – Prostate  (EORTC – PR25) 
(van Andel et al., 2008) 
Used in: (Berry et al., 2006, Geinitz et al., 
2006, Vordermark et al., 2006) 
 
 
 
 
22        low of 0.64  
             to high of 
             0.87 
 
 
 
28         low of 0.65 
             to high of 
             0.89 
 
 
 
 
27         low of 0.83 
             to high of 
             0.90 
 
 
 
47        Low of 0.65 
            to high of 
            0.69 
 
 
 
 
20        Low of 0.65 
            to high of  
            0.93 
 
 
 
 
 
32      Low of 0.74 
          to high of  
          0.94 
 
 
 
7       Low of 0.86 
         to high of 
         0.92 
 
 
 
 
 
 
 
25     Low of 0.70 
         To a high of 
         0.86 
 
 
 
 
 
 
 
 
Self 
 
 
 
 
 
Self 
 
 
 
 
 
 
Self 
 
 
 
 
 
Self 
 
 
 
 
 
 
Self 
 
 
 
 
 
 
 
Self 
 
 
 
 
 
Self 
 
 
 
 
 
 
 
 
 
Self 
supplement developed to 
address prostate specific 
problems. 
 
Assess quality of life for 
patients undergoing their 
treatment.  Assesses 
psychological, social and 
physical functioning.   
 
Measures physical, 
social/family, emotional, 
functional well-being and 
the relationship with 
physician.   
 
 
Measuring psychological 
distress, activity level 
scale and overall 
evaluation of life for 
cancer patients.   
 
Measures sexual, bowel, 
bladder function and pain 
domains. 
 
 
 
 
Measures sexual, urinary 
and bowel function and 
bother.  It also assesses 
the overall satisfaction 
with the prostate cancer 
treatment. 
 
 
Measures sexual, urinary, 
and hormonal function 
and bother.  It also 
measures satisfaction 
with treatment. 
 
Designed for benign 
prostatic hyperplasia 
(BPH) assesses urinary 
symptoms only: 
frequency, nocturia, 
weak urinary stream, 
hesitancy, intermittence, 
incomplete emptying and 
urgency 
 
Used in conjunction with 
the EORTC-C30, this 
measure assesses 
urinary, bowel, sexual 
symptoms and 
functioning, in addition 
to specific side-effects of 
prostate cancer 
treatment. 
 
Cancer-specific HRQoL is an important research outcome in prostate cancer studies 
(Albaugh and Hacker, 2008, O'Connor, 2004, Adolfsson, 2003, Efficace et al., 2003, 
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Sloan and Varricchio, 2001, Bowling, 2001, Eton et al., 2001, Aaronson, 1988).  
Furthermore, cancer-specific HRQoL should be based on patients’ own self-reports of 
their subjective experience of the multi-dimensional domains (O'Connor, 2004, 
Bowling, 2001, Bowling, 1991).  Consequently, patients’ thoughts, feelings, and 
ratings of their HRQoL cannot be assumed, and HRQoL should be rated from the 
patient’s own self-reports (Litwin et al., 1998b, Lieberman et al., 1996, Sprangers and 
Aaronson, 1992, Jachuck, 1982).   
 
In summary, the operational definition of HRQoL for this structured literature review 
is based on patients’ own self-reports of the multi-dimensional domains of health, 
including general and disease-specific HRQoL, using standardised instruments.   
1.3 Methodology 
1.3.1 Aim  
The overall aim of this review was to find out what predicts HRQoL for men affected 
by prostate cancer and how HRQoL changes over time.   
Review questions 
The review specifically was driven to answer the following questions: 
1) What predicts HRQoL in men affected by prostate cancer? 
2) How does HRQoL change over the prostate cancer journey? 
1.3.2 Methods  
A structured review of empirical evidence was conducted that aimed to include 
qualitative and quantitative research to generate a broad overview of existing 
knowledge in this area (Webb and Roe, 2007, Whittemore, 2005).  This wide 
inclusion enabled a diverse range of methodologies to be included.  Most 
traditional systematic review methodologies are limited to randomised control 
trials (RCT) and, therefore, would exclude prospective longitudinal evaluations of 
HRQoL for men affected by prostate cancer.  While systematic reviews in their 
current format answer questions, for example which intervention works, it fails to 
adequately address some nursing questions related to caring or the impact of 
illness or treatment (McCourt, 2005, Thomas et al., 2004, Evans and Pearson, 
2001, Dixon-Woods and Fitzpatrick, 2001, Black, 1996).  A structured review was 
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chosen as an appropriate method that was well suited to address the research 
questions.   
 
This review was based on guidance provided by the Centre for Reviews and 
Dissemination (2008) to ensure that the methods implemented were as rigorous 
and transparent as possible.  The process for this review included nine steps: 
1) Formulation of the research questions 
2) Setting up the review team  
3) Developing review protocol  
4) Searching and identifying the research evidence 
5) Rating the studies for inclusion based on inclusion/exclusion criteria 
6) Data extraction using pro forma checklist 
7) Quality assessment 
8) Results synthesis 
9) Dissemination 
1.3.3 Literature review team 
The review team consisted of members of the Ph.D. candidate’s supervisory team.  It 
is good practice to have a minimum of 2 reviewers involved to minimise bias and 
error during all stages of the review (The Cochrane Collaboration, 2009, Centre for 
Reviews and Dissemination, 2008, Bero et al., 1998).  There were 3 reviewers 
working at all stages in this review. 
1.3.4 Searching and identifying the research evidence 
The search process began with searching the Database of Abstracts of Reviews of 
Effects (DARE) and the Cochrane Database of Systematic Reviews (CDSR).  No 
previous work had addressed the specific aims and research questions for the current 
review and, therefore, undertaking the review was appropriate and necessary.  The 
search strategy began with taking each research question and breaking it down into 
the key words as follows: prostate cancer, prostate carcinoma, health-related quality 
of life, quality of life, longitudinal, treatments, sexual function, well-being, 
depression, impotence, incontinence, bowel symptoms.  The key words were 
mapped to each electronic database or by using the appropriate MeSH (medical 
subject heading) term.  Truncation, wildcards and Boolean logic were used.  Free 
searches using the key words were also undertaken to try and generate more hits.  
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Individual searches rather than combined database searches were undertaken 
because this ensured all relevant hits were identified.  Citation searches and 
backward chain-linking were undertaken. The search strategy included searching a 
number of electronic databases (see table 1.3) and grey literature, such as: Google, 
unpublished theses, and finally, hand searching of relevant urological journals. 
Table 1.3 Electronic databases searched 
Applied Social Sciences Index and Abstracts (ASSIA) 
British Nursing Index (BNI) 
PsycInfo 
Web of Science 
Google Scholar 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
MEDLINE 
Scopus 
EMBASE 
Index to Theses  
Database of Abstracts of Reviews of Effects (DARE) 
Cochrane Database of Systematic Reviews (CDSR) 
 
Guidance was provided on three occasions by a Medical Librarian (at the University 
of Dundee) to facilitate the search in accessing grey literature, because this is 
acknowledged as difficult for researchers to obtain (Webb and Roe, 2007). 
1.3.5 Inclusion and exclusion of studies 
Recent studies acknowledged that clinical practices and surgical techniques have 
changed significantly over the years, for example, introducing laparoscopic and 
robotic techniques and nerve-sparing surgery.  Therefore, data presented in earlier 
papers will no longer be an accurate representation of patient reports in current 
healthcare due to out-dated clinical management (Osoba, 2011, Eton and Lepore, 
2002, Litwin et al., 2001).  As a result, only studies in the last 5 years would meet the 
inclusion criteria with the underpinning clinical rationale. 
 
To promote an approach for synthesising the level of evidence presented in research 
studies, a grading hierarchy was used to assess the level of evidence presented.  
There are numerous grading hierarchy systems available that acknowledged 
experimental methods (RCTs) as the gold standard for evaluation.  The Department 
of Health in the National Service Framework (2001) identified the “typologies of 
supporting evidence” which identify the levels of evidence by research design (see 
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table 1.4). This framework was used because it has been applied to both peer-
reviewed and non-peer reviewed research (Anderson et al., 2004). 
Table 1.4 Evidence categories used by the Department of Health in the National Service 
Framework  
Typologies of supporting evidence 
A1 Systematic reviews, which include at least one randomised control trial (RCT), e.g. systematic reviews 
from Cochrane. 
A2 Other systematic and high quality reviews. 
B1 Individual RCTs. 
B2 Individual non-randomized, experimental/interventional studies. 
B3 Individual well-designed non-experimental studies, controlling statistically if appropriate.  Includes 
case control, longitudinal, cohort, matched pairs or cross-sectional random sample methodologies, and 
well-designed qualitative studies, well-designed analytical studies, including secondary analysis. 
C1 Descriptive and other research or evaluations not in B (e.g. convenience samples). 
C2 Case studies and examples of good practice. 
D Summary review articles and discussions of relevant literature and conference proceedings not 
otherwise classified. 
 
Based on the typologies used within the Department of Health this review included 
research studies at the level of B3-A1 for inclusion in the current review.  This review 
excluded studies at the level of evidence D-C1.  See table 1.5 for a summary of 
inclusion criteria and rationales. 
Table 1.5 Inclusion criteria 
Criteria Rationale 
Levels of evidence B3-A1. 
 
 
 
Does this title/abstract identify predictor variables 
of HRQoL? 
 
 
Does this title/abstract indicate how HRQoL 
changes over time? 
 
 
 
 
 
Published between 2005- to current date. 
 
 
 
 
 
 
 
English text only 
 
 
Grey Literature 
 
 
Allows for the inclusion of quantitative and 
qualitative methods, identifying the levels of 
evidence by study design.   
 
This is the 1
st
 key focus of the review; to establish 
what the predictor variables are for HRQoL in men 
with prostate cancer. 
 
This is the 2
nd
 key focus of the review; to establish 
how HRQoL changes over the prostate cancer 
patient journey. 
 
The articles had to address, at minimum, one of 
the above questions to be considered for inclusion. 
 
Recent literature acknowledges that clinical 
practices have changed.  Bias is possible when 
integrating patients’ reports of HRQoL from some 
time back, as patients are no longer treated by 
those provisions.  Thus, earlier HRQoL reports 
have the potential to be inaccurate in current 
healthcare. 
 
Secondary to budget constraints due to translation 
costs. 
 
To try and minimise the risk of publication bias, 
and provide a detailed account of the HRQoL in 
prostate cancer. 
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Prostate cancer patients only 
 
 
 
 
No limitation of the geographical country 
 
The papers would include studies that are focused 
on men with prostate cancer only; this is the 
primary context of the review and, as a result, 
other cancer sites would be excluded. 
 
To capture the broad range of HRQoL prostate 
cancer studies existing, worldwide. 
 
The reviewers used a pro forma checklist to rate the titles and abstracts based on the 
inclusion criteria (see appendix 1.1 for pro forma checklist).  The pro forma checklist 
was piloted among the review team.  All of the references in the review were 
managed using the software package Endnote x4. 
1.3.6 Quality assessment 
The quality assessment of individual research studies is fundamental to a meaningful 
review (Verhagen et al., 2001, Harbour, 2001, Bero et al., 1998) and rating the levels 
of evidence alone is inadequate (Webb and Roe, 2007, Dixon-Woods et al., 2005).  
However, there is little agreement on how to quality assess studies with diverse 
methodologies (Dixon-Woods et al., 2005).  A recent review funded by the Health 
Technology Assessment (Shaw et al., 2009) developed two quality assessment tools 
for diverse methodologies, one quality assessment tool for qualitative methods, and 
one quality assessment tool for quantitative methods.  Shaw’s quality assessment 
tools were applied to this review (see appendix 1.2).     
 
The quality assessment provided a relative quality rating, rather than an absolute 
quality rating (Verhagen et al., 2001).  To minimise the potential for bias, the quality 
assessment tools were piloted on full-text research studies to establish agreement 
among the reviewers on the application of the quality assessment tools.  
1.3.7 Data extraction 
Key information from the studies was extracted using narrative data extraction 
sheets.  The key information extracted is identified in table 1.6.  The data extraction 
sheets provided consistency in the data extracted from studies and was designed 
based on recommendations from Cochrane guidelines and the Centre for Reviews 
and Dissemination (The Cochrane Collaboration, 2009, Centre for Reviews and 
Dissemination, 2008). 
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Table 1.6 Data extraction 
Unique reference number (for reviewers’ reference) 
Authors (s) 
Year of publication 
Country  
Overall aim of the study 
Participants characteristics (age, race, education, social class, cancer stage, cancer treatments)  
Number of patients approached, and the number of patients consented (identify the possibility of 
selection bias) 
Methods – study design, time points for data collection, measures (variables in the study), intervention 
details, method of randomisation, and participants’ attrition rates. 
Overall findings and conclusions 
Limitations 
1.3.8 Evidence synthesis 
A narrative synthesis and tabulation of primary research studies was used to 
generate broad findings and conclusions (Webb and Roe, 2007).  More specifically, 
the review undertook the steps (see table 1.7) to provide a thorough interpretation 
of primary sources, as suggested by Whittemore (2005).  The recommendations of 
Whittemore have been applied to several reviews (Flinkman et al., 2010, Da Silva et 
al., 2010, Walsh et al., 2009, Kennedy et al., 2008), and provide a basis to promote 
rigour in combining diverse evidence sources. 
Table 1.7 Key steps in the analysis 
Elements Description 
Data reduction 
 
 
 
 
 
 
 
 
 
 
Data comparison 
 
 
 
 
 
 
Conclusion drawing and verification 
 
 
 
This phase involved managing the data from the 
primary sources.  The review used a sub-group 
classification, initially separating the qualitative 
and quantitative evidence, and then grouping the 
levels of evidence (for example; all observational 
studies, and all of the intervention RCTs).  These 
groups were then sub-grouped, into studies that 
identified predictors and change of HRQoL over 
time.   This phase enabled analysis by topic and 
research question.  
 
This stage was an iterative process of examining 
the tabulated data in order to identify patterns, 
themes or relationships.  This required a number of 
strategies, such as counting, making comparisons, 
and establishing common and unusual findings 
from primary sources.  
 
This is the final stage in the analysis.  Once 
patterns and relationships have been established, 
this stage required confirmation from the primary 
data sources for accuracy and confirmability.   
 
15 
 
 
 
1.4 Findings 
Based on recommendations for the Preferred Reporting of Items for Systematic 
Reviews and Meta-analyses (PRISMA statement), the flowchart below (see figure 1.3) 
illustrates the data identification and data synthesis for this review (Moher, 2009). 
973 records identified through database searching 12 records identified through other sources
187 duplicates removed
Identification
Screening
798 records (titles and abstracts) screened against the 
inclusion/exclusion criteria
679 records excluded
119 full text articles assessed for eligibility against the 
inclusion/exclusion criteria
15 full text articles excluded for the 
following reasons:
· 8 studies did not meet the 
inclusion criteria
· 4 did not report HRQoL
· 2 Studies were duplicate 
publications
· 1 pharmaceutical study
104 Studies included
Eligibility
Included
 
Figure 1.3 PRISMA: Flow of information through the different phases of the HRQoL review 
(Moher, 2009) 
Inter-rater reliability analysis was established using the Kappa statistic in two steps.  
The ratings of the initial application of the inclusion/exclusion pro forma checklist 
was found to be Kappa = 0.64 (p <.0.001).  Discussions then took place to review 
areas of disagreement on the application of the pro forma checklist on the 
publications.  The Kappa statistic was then reapplied and was Kappa = 0.94 (p 
<.0.001) which demonstrates an almost perfect level of agreement (< 0 less than 
chance of agreement, 0.01-0.20 slight agreement, 0.21-0.40 fair agreement, 0.41-
0.60 moderate agreement, 0.61-0.80 substantial agreement, 0.81-0.99 almost 
perfect agreement (Viera and Garrette, 2005).  Disagreement was generally a result 
of slightly different interpretations of the title/abstracts of the reviewed publications.  
A consensus was reached by discussion in all cases. 
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The kappa statistic was unsuccessful in determining the reviewer consistency of the 
application of the quality assessment checklists.  This was because the reviewer data 
in SPSS was asymmetrical in the Chi-squared tables.  This issue has been reported 
elsewhere (Pikora et al., 2002).  The level of agreement was calculated by hand using 
the formula, agreements/ (agreements + disagreements) x 100 (Araujo, 1985).  The 
percentage of agreement in the quality assessment of research studies was 83.3% 
agreement.  Disagreement was generally a result of slightly different interpretations.  
A consensus was reached by discussion in all cases. 
Altogether, 104 papers were included in the review (see appendix 1.3 for data 
extracted).  One-hundred-and-four papers are a large number and this reflects the 
growth in worldwide research in this area, and reinforces the pressing need to take 
account of the evidence.  The findings will address the following research questions: 
1) What predicts HRQoL in men affected by prostate cancer? 
2) How does HRQoL change over the prostate cancer journey? 
1.4.1 Predictors of HRQoL 
There were a range of methodologies (see table 1.8) all using quantitative methods 
which identified predictors of HRQoL.  The 53 studies were conducted in America 
(39), Canada (2), Italy (2), Netherlands (1), Germany (1), Australia (2), Japan (4), UK 
(1) and Sweden (1).  Sample sizes ranged from N=30 to N=1642 with a total sample 
size of N=16,689 in the 53 review papers.   
Table 1.8 Methodologies of studies identifying predictors of HRQoL 
Type of study                                                                                               Number 
Prospective longitudinal    39 
Intervention/RCT   10 
Prospective longitudinal with match controls  3 
Cross-sectional random samples  1 
 
Studies have identified predictor variables for HRQoL across all stages of prostate 
cancer - localised, locally advanced and metastatic.  There are very few studies that 
have identified predictors of HRQoL in relation to specific treatment modality.  
Consequently, it was not possible to identify the predictors of HRQoL for each 
treatment modality and therefore, the findings will be presented based on cancer 
stage. 
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Predictors of general HRQoL  
The predictors of general HRQoL for men with localised prostate cancer can be 
classified into three groups of variables: demographic, clinical and psycho-social 
variables.  These are summarised in table 1.9. 
Table 1.9 Localised prostate cancer predictors of general HRQoL 
Demographic variables predictive of higher HRQoL: 
Employed: (Diefenbach et al., 2008
ǂ
) 
Married: (Diefenbach et al., 2008
ǂ
)  
Younger men: (Lev et al., 2009
ǂ
, Diefenbach et al., 2008
ǂ
, Eller et al., 2006
ǂ
) 
White ethnic origin: (Lev et al., 2009
ǂ
, Diefenbach et al., 2008
ǂ
, Eller et al., 2006
ǂ
) 
Demographic variables predictive of lower HRQoL: 
Lower education level was associated with a lower HRQoL: (Ficarra et al., 2006
§
)  
Clinical variables predictive of a lower HRQoL: 
Higher Gleason score: (Diefenbach et al., 2008
ǂ
) 
Co-morbidities: (Sanda et al., 2008
ǂ
, Gacci et al., 2008
ǂ
) 
Larger prostate gland: (Gacci et al., 2008
ǂ
)   
Disease-specific domains: urine, bowel and sexual function (Queenan et al., 2010
§
, 
Eller et al., 2006
ǂ
, Lev et al., 2004
§
) 
Individual treatments predictive of a lower HRQoL: 
Hormone therapy: (Sanda et al., 2008
ǂ
, Prezioso et al., 2007b
§
) 
Radical prostatectomy is more likely to reduce HRQoL compared to laparoscopic 
radical prostatectomy: (Miller et al., 2007
ǂ
) 
Radical prostatectomy is more likely to reduce HRQoL compared to Brachytherapy: 
(Kobuke et al., 2009
§
) 
Other studies report not finding any relationship between the clinical variables: PSA, Gleason 
score, pathological stage, (Kobuke et al., 2009
§
) and treatment (Litwin et al., 2007
§
) with 
HRQoL. 
Psycho-social variables predictive of lower HRQoL: 
Depression: (Lev et al., 2009
ǂ
, Eller et al., 2006
ǂ
) 
Perceived stress: (Eller et al., 2006
ǂ
) 
Psycho-social variables predictive of higher HRQoL: 
Coping styles (positive attitude): (Eller et al., 2006
ǂ
) 
Self-efficacy: (Roberts et al., 2006
ǂ
) 
               Social support:(Roberts et al., 2006
ǂ
) 
Key:
 ǂ 
multivariate analysis used, 
§ 
correlational analysis used 
 
Only two studies in this review assessed predictors of locally advanced cancer.  The 
remaining studies included mixed populations of men with localised and locally 
advanced prostate cancer participants.   The predictors of general HRQoL for 
localised/locally advanced prostate cancer are summarised together in table 1.10.   
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Table 1.10 Localised/locally advanced prostate cancer predictors of general HRQoL 
Demographic variables predictive of lower HRQoL 
Increasing age: (White et al., 2008
ǂ
, Krupski et al., 2005a
ǂ
, Miller et al., 2005
ǂ
) 
Hispanic/African American ethnic origin:  (Jayadevappa et al., 2007
ǂ
, Krupski et al., 
2005b
ǂ
) 
Demographic variables predictive of higher HRQoL: 
White ethnic origin: (Jayadevappa et al., 2006
ǂ
)  
Higher education: (Jayadevappa et al., 2006
ǂ
) 
Married:  (Jayadevappa et al., 2006
ǂ
) 
Clinical variables predictive of a lower HRQoL: 
Co-morbidity: (Poll-Franse, 2008
§
, Krupski et al., 2005a
ǂ
) 
Higher Gleason score:  (Jayadevappa et al., 2006
ǂ
, Brar et al., 2005
ǂ
) 
Higher Tumour Node Metastases (TNM) classification:  (Jayadevappa et al., 2006
ǂ
) 
Individual treatments predictive of a lower HRQoL:  
Hormone therapy: (Lips et al., 2007
ǂ
) 
Radical prostatectomy: (Krupski et al., 2005a
ǂ
) 
Conformal radiotherapy had lower HRQoL compared to intensity modulated 
radiotherapy: (Lips et al., 2007
ǂ
) 
Laparoscopic radical prostatectomy: (Miller et al., 2007
ǂ
)   
Psycho-social variables predictive of lower HRQoL:
 
 
Depression: (Monahan et al., 2007
ǂ
) 
Predictors for higher HRQoL: 
Social support: (Queenan et al., 2010 
§
)  
Key:
 ǂ 
multivariate analysis used, 
§ 
correlational analysis used 
 
Seven studies identified predictors of general HRQoL for men with metastatic 
prostate cancer.  Three studies included samples with all stages of disease (localised, 
locally advanced and metastatic disease).   For the summary of the predictor 
variables see table 1.11 for summary. 
Table 1.11 Metastatic prostate cancer predictors of general HRQoL 
Demographic variables predictive of lower HRQoL: 
Increasing age: (Spry et al., 2006) 
Clinical variables predictive of a lower HRQoL: 
Higher TNM classification: (Berglund et al., 2007
§
)* 
Metastatic disease:  (Berglund et al., 2007
§
)* 
Skeletal morbidity: (DePuy et al., 2007
ǂ
) 
Hormone therapy: (Spry et al., 2006
§
) 
Patients with metastatic cancer who had better HRQoL scores predicted better survival: 
(Sullivan et al., 2006
ǂ
) 
Psycho-social variables predictive of higher HRQoL: 
Spirituality: (Zavala et al., 2009
ǂ
) 
Positive coping (active coping):  (Kershaw et al., 2008
ǂ
)* 
*Studies that included all stages of disease. 
Key:
 ǂ 
multivariate analysis used, 
§ 
correlational analysis used 
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Predictors of prostate cancer-specific HRQoL 
The findings for predictor variables of prostate cancer-specific HRQoL (urinary, bowel 
and sexual dysfunction) for men with localised disease are summarised in table 1.12. 
Table 1.12 Localised prostate cancer predictors of prostate cancer-specific HRQoL 
Predictor variables for worse urinary function: 
Demographic:   
African American ethnic origin: (Sanda et al., 2008
ǂ
) 
Increasing age: (Namiki et al., 2009c
ǂ
, Sanda et al., 2008
ǂ
)
 
 
Clinical:   
Hormone therapy: (Roeloffzen et al., 2010
ǂ
) 
Initial prostate specific antigen (PSA) level: (Roeloffzen et al., 2010
ǂ
, Sanda et al., 
2008
ǂ
) 
Co-morbidity: (Namiki et al., 2009d
ǂ
) 
Brachytherapy patients are more likely to experience urinary irritation and 
obstruction than men treated with radiotherapy: (Pinkawa et al., 2009a
ǂ
) 
Nerve-sparing surgical techniques were not predictive of an improved urinary function: 
(Rogers et al., 2006
ǂ
, Dalkin et al., 2006
ǂ
)  
Predictor variables for worse bowel function: 
Demographic: 
Increasing age:  (Sanda et al., 2008
ǂ
) 
Clinical: 
Larger prostate size:  (Roeloffzen et al., 2010
ǂ
, Sanda et al., 2008
ǂ
) 
Neoadjuvant hormone therapy:  (Sanda et al., 2008
ǂ
)   
Co-morbidity: (Sanda et al., 2008
ǂ
) 
Radiotherapy patients are more likely to experience proctitis than brachytherapy 
patients: (Pinkawa et al., 2009a
ǂ
)  
Predictor variables for worse sexual function: 
Demographic: 
Increasing age: (Roeloffzen et al., 2010
ǂ
, Sanda et al., 2008
ǂ
) 
Clinical: 
Initial PSA level: (Roeloffzen et al., 2010
ǂ
, Sanda et al., 2008
ǂ
) 
Hormone therapy:  (Roeloffzen et al., 2010
ǂ
, Smith et al., 2009
ǂ
) 
Radical prostatectomy: (Sanda et al., 2008
ǂ
) 
Better sexual functioning: 
Nerve-sparing techniques: (Sanda et al., 2008
ǂ
, Rogers et al., 2006
ǂ
)   
Key:
 ǂ 
multivariate analysis used, 
§ 
correlational analysis used 
 
The findings for predictor variables of prostate cancer-specific HRQoL (urinary, bowel 
and sexual dysfunction) for men with localised/locally advanced disease are 
summarised in table 1.13. 
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Table 1.13 Localised/locally advanced prostate cancer predictors of prostate cancer-specific 
HRQoL 
Predictor variables for worse urinary function: 
Demographics 
Older age:  (Miller et al., 2005
ǂ
) 
Lower education level: (Jayadevappa et al., 2005
ǂ
) 
African/American ethnic origin: (Jayadevappa et al., 2007
ǂ
) 
Country of residence: (Namiki et al., 2009a
ǂ
)  
Predictor variables for better urinary function: 
Married was predictive of better urinary function: (Jayadevappa et al., 2005
ǂ
) 
Clinical 
Radical prostatectomy:  (Namiki et al., 2009d
ǂ
, Jayadevappa et al., 2007
ǂ
, Monahan 
et al., 2007
ǂ
, Krupski et al., 2005a
ǂ
) 
Smaller prostate size: (Pinkawa et al., 2009b
ǂ
) 
Hormone therapy:  (Pinkawa et al., 2009c
ǂ
, Wu et al., 2008
ǂ
) 
Radiotherapy: (Jayadevappa et al., 2007
ǂ
) 
Psycho-social:  
Depression: (Monahan et al., 2007
ǂ
) 
Predictor variables of worse bowel function: 
Demographics 
Hispanic ethnic origin: (Krupski et al., 2005b
ǂ
) 
Clinical 
Radiotherapy:  (Jayadevappa et al., 2007
ǂ
) 
Co-morbidity: (Jayadevappa et al., 2005
ǂ
) 
Treatment: (Wu et al., 2008
ǂ
, Jayadevappa et al., 2005
ǂ
)  
Psycho-social: 
Depression: (Monahan et al., 2007
ǂ
) 
Predictor variables of worse sexual function: 
Demographics 
Age:  (Krupski et al., 2005a
ǂ
) 
Married: (Jayadevappa et al., 2005
ǂ
) 
Clinical 
RP:  (Namiki et al., 2009c
ǂ
, Jayadevappa et al., 2007
ǂ
, Krupski et al., 2005a
ǂ
) 
Co-morbidities: (van de Poll-Franse et al., 2008a
ǂ
, Jayadevappa et al., 2006
ǂ
) 
Baseline sexual function: (Jayadevappa et al., 2005
ǂ
) 
Transforming Growth Factor beta1/physiology (TGFBI) genotypes: (Peters et al., 
2008
ǂ
) 
Hormone therapy:  (Stephens et al., 2007
ǂ
, Wu et al., 2007
ǂ
) 
Nerve-sparing surgical techniques improves sexual function: (Namiki et al., 2009c
ǂ
, 
Inoue et al., 2009
ǂ
) 
Psycho-social: 
Depression: (Monahan et al., 2007
ǂ
) 
Key:
 ǂ 
multivariate analysis used, 
§ 
correlational analysis used 
 
The findings for predictor variables of disease-specific HRQoL (urinary, bowel and 
sexual dysfunction) for men with metastatic cancer are summarised in table 1.14. 
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Table 1.14 Metastatic prostate cancer predictors of prostate cancer-specific HRQoL 
Predictor variables for worse urinary function: 
Demographics 
Increasing age: (Gacci et al., 2009
 ǂ
) 
Clinical 
Higher PSA level :  (Gacci et al., 2009
 ǂ
) 
TNM classification:  (Gacci et al., 2009
 ǂ
) 
Hormone therapy:  (Gacci et al., 2009
 ǂ
) 
Predictor variables of bowel function: 
There were no predictor variables identified from primary research studies. 
Predictor variables for worse sexual function: 
Demographics 
Increasing  age:  (Gacci et al., 2009
 ǂ
) 
Clinical 
PSA:  (Gacci et al., 2009
 ǂ
) 
TNM classification: (Gacci et al., 2009
 ǂ
) 
Gleason Score: (Gacci et al., 2009
 ǂ
) 
Hormone therapy: (Gacci et al., 2009
 ǂ
) 
Nerve-sparing surgical techniques predictive of better sexual function: (Gacci et al., 
2009
 ǂ
) 
Key:
 ǂ 
multivariate analysis used, 
§ 
correlational analysis used 
 
Interventions aimed at improving HRQoL 
In total there were 10 intervention studies (Galvao et al., 2010, Parker et al., 2009, 
Berglund et al., 2007, Northouse et al., 2007b, Monga et al., 2007, Culos-Reed et al., 
2007, Daubenmier et al., 2006, Zhang et al., 2006, Carmack Taylor et al., 2006, 
Penedo et al., 2006) that aimed to improve HRQoL. These papers had a limited scope 
in the geographical areas that they were conducted in ranging from: seven in 
America, one in Australia, one in Sweden, and one in Canada.  None of the reviewed 
studies were conducted in the UK.  The intervention studies aimed to improve HRQoL 
were grouped together according to the type of intervention, namely: 1) physical 
activity, 2) stress management and 3) lifestyle and supportive interventions. 
 
Studies that delivered physical activity, strength training and aerobic exercise (Galvao 
et al., 2010, Berglund et al., 2007, Monga et al., 2007, Culos-Reed et al., 2007) 
reported different intervention effects on HRQoL (see appendix 1.3 for full 
intervention details).  Galvao’s intervention consisted of progressive resistance and 
aerobic training delivered twice a week by exercise physiologist (Galvao et al., 2010).  
The study sample (N=57) was heterogeneous in clinical characteristics and the time 
since diagnosis was not reported.  The control group was standard care but there was 
no description of what standard care was.  A significant intervention effect was found 
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for a HRQoL for general health, vitality, physical health (as measured by SF-36), and 
physical role and cognitive function (as measured by the EORTC-C30).  There are a 
number of limitations to this study that are worthy of acknowledgment.  Prostate 
cancer-specific symptoms were not assessed in this study and therefore, changes in 
urinary, bowel and sexual dysfunction remain unknown.  The follow-up was limited 
to 12 weeks after the intervention and, therefore, it is unclear whether or not the 
intervention effect would be sustained in the longer term, such as one year and 
beyond.  Lastly, as part of the inclusion criteria, the study participants had to be able 
to walk 300m and this limits the generalisabilty of the findings to less physically able 
men.   
 
A further intervention delivered an exercise programme 3 times per week for a total 
of two months (Monga et al., 2007).  The participants (n=11) exercised in the 
morning before their radiotherapy by performing a 10-minute warm-up, 30 minutes 
of aerobic exercise and 10 minutes of cool-down.  A significant intervention effect 
was found on improved HRQoL (as measured by the FACT-G) for physical function, 
physical well-being and social well-being compared to the control group (n=10).  The 
control group was blinded to the intervention arm and received standard care.  There 
was no description of what standard care was.  The study sample was very small and 
limits the generalisabilty of the findings.  Furthermore, the follow-up was limited to 
completion of radiotherapy treatment, consequently the long-term changes in 
HRQoL are not known.   
 
The third reviewed exercise intervention study (Culos-Reed et al., 2007) provided a 
12-week individualised fitness programme (n=31) delivered by a certified fitness 
professional.  In addition, group-based exercise classes were conducted every two 
weeks over the 12-week intervention.  The study sample had heterogeneous clinical 
characteristics and the mean time since diagnosis was 33.9 months (SD 42.1).  HRQoL 
(as measured by EORTC C30) improved for physical function, social function and 
fatigue from before the intervention to after the intervention (12 weeks).  At four 
months post-intervention, global HRQoL was significantly worse than pre-
intervention scores.  The findings suggest that long-term benefits of exercise 
interventions are not maintained.  There are a number of important methodological 
limitations to this study that are worthy of discussion.  This study did not have a 
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control group and, therefore, the findings are treated with caution because in the 
absence of a comparison group it is impossible to know how HRQoL would have been 
affected without the intervention.  Prostate cancer-specific HRQoL was not assessed 
in Culos-Reed’s study and it is possible that urinary, bowel or sexual dysfunction may 
have predicted worsening global HRQoL (Culos-Reed et al., 2007).  Lastly, physical 
activity was assessed using a self-report questionnaire and the bias of this approach 
could have been minimised by using a pedometer as an objective assessment of 
physical activity. 
 
The last reviewed exercise intervention study (Berglund et al., 2007) had 4 study 
groups: 1) physical exercise delivered by a physiotherapist, 2) information provision 
delivered by a specialist nurse, 3) combined physical exercise and information 
provision and 4) control group which was standard care.  The study sample (N=211) 
had different clinical characteristics and were all recruited within 6 months of their 
prostate cancer diagnosis.  No intervention effect was identified for the 3 study 
conditions on improved HRQoL as measured by the EORTC C30.  The randomisation 
procedure was not described and, therefore, bias is possible in the allocation of 
participants to the study conditions.  Selection and attrition biases are possible and 
limit the generalisabilty of the study findings.  Lastly, prostate cancer-specific HRQoL 
was not measured and the intervention effect on urinary, bowel and sexual 
dysfunction are unclear and will remain unknown.  
 
Stress-management interventions (Parker et al., 2009, Daubenmier et al., 2006, 
Penedo et al., 2006) reported different intervention effects on HRQoL.  Daubenmier’s 
study intervention aimed to educated men on stress management skills and healthy 
lifestyle changes through diet and exercise.  The study sample (N=93) were men with 
localised prostate cancer on the active surveillance programme.  Daubenmier used a 
minimisation approach to randomisation for the intervention arm (n=44) and to the 
control group (n=49) and, therefore, lacks proper randomisation and may have 
introduced bias in the results.  No intervention effect was found for improved HRQoL 
as measured by SF-36 and the UCLA-PCI.  The study sample was biased in favour of 
white educated men and limits the generalisabilty of the findings to other minority 
groups.  Selection and attrition bias are likely in this study and the study sample was 
not representative of the wider population.     
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Parker’s intervention study (Parker et al., 2009) had three study groups: 1) stress 
management delivered by a clinical psychologist, 2) supportive attention for psycho-
social and medical history delivered by a clinical psychologist, and 3) standard care 
(see appendix 1.3 for further intervention detail).  The study sample (N=164) were 
men undergoing radical prostatectomy for localised/locally advanced prostate 
cancer.  HRQoL was assessed using SF-36 and UCLA-PCI at one month before surgery, 
one and six weeks after surgery, and six and twelve months after surgery.  The 
participants in the stress management arm had higher physical function (SF-36) at 
twelve months compared to the two other study conditions (supportive attention 
and standard care).  No additional significant differences were identified between the 
study condition for HRQoL scores (general and prostate cancer-specific).   
 
The last stress management intervention study (Penedo et al., 2006) delivered a ten-
week cognitive-behavioural stress management programme that included the 
following: coping strategies, assertiveness skills, relaxation skills and breathing 
exercises.  A clinical psychologist delivered the intervention to men (mean time since 
diagnosis 16 months, SD 4.9) diagnosed with localised prostate cancer treated by 
either radical prostatectomy or radiotherapy.  A significant intervention effect was 
found for improved HRQoL (as measured by FACT-G) for physical well-being, 
emotional well-being, global well-being and sexual function (as measured by the 
EPIC).  Penedo’s study follow-up was restricted to after the intervention and, 
therefore, the longer-term influence of the intervention on HRQoL is unknown.  
Penedos’ study screened for major cognitive impairment, and used this as an 
exclusion criterion.  This exclusion limits the generalisabilty of the findings to more 
psychologically compromised individuals.  This is a limitation, and the results may not 
reflect the ageing population of men with prostate cancer with its likelihood of co-
morbidity.   
 
Lifestyle/educational and supportive intervention studies (Zhang et al., 2007, 
Northouse et al., 2007b, Carmack Taylor et al., 2006) did not report any 
improvements in HRQoL.  Zhang’s intervention (Zhang et al., 2007) had two study 
conditions: 1) a social support group which lasted for 1-2 hours facilitated by a 
clinical psychologist and 2) biofeedback sessions to teach pelvic floor exercises by a 
physiotherapist.  No intervention effect was found on HRQoL as measured by SF-36, 
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or for improved urinary incontinence as measured by a visual analogue scale.   This 
study did not have a control group and therefore, the findings are treated with 
caution because in the absence of a comparison group it is impossible to know how 
HRQoL would have been affected without the intervention.  Prostate cancer-specific 
HRQoL was not assessed using a validated instrument and caution is taken in the 
interpretation of the results.  A final limitation to this study was that the study was 
underpowered (N=29) and biased in favour of white educated men and thus limits 
the generalisabilty of their findings. 
 
The third supportive intervention study (Northouse et al., 2007b) had two study 
conditions: 1) supportive/educational intervention, and 2) a control group which was 
standard care.  The intervention included the following: coping skills, optimistic 
attitude, uncertainty reduction and symptoms management delivered by a specialist 
nurse.  No intervention effect was found for improved HRQoL as measures by the 
FACT-G and FACT-P.  There are a few limitations to this study.  All of the study 
participants (N=263) were married and, therefore, the results are not generalisable 
to single men.  Importantly, the randomisation procedure was not described in 
sufficient detail; consequently bias is possible in the allocation of study participants 
to the study arms.  As a result, caution is taken in the interpretation of these findings. 
 
The final intervention study reviewed (Carmack Taylor et al., 2006) had three study 
conditions: 1) lifestyle programme which educated men about regular exercise, 
healthy diet through goal setting and coping skills, 2) the educational social support 
group discussed the side effects of treatment and prostate cancer, and 3) control 
group was standard care.  The study sample (N=134) consisted of men treated by 
hormone therapy for a mean time of 32.7 months and the time since diagnosis was 
not reported.  Overall, no significant difference was found between the three study 
conditions at 6 and 12 months for HRQoL as measures by the SF-36.  This study did 
not measure prostate cancer-specific HRQoL and, consequently, the intervention 
effect on urinary, bowel and sexual dysfunction was not assessed.  Selection bias was 
also possible for this study and limits the generalisabilty of the findings.   
 
It is unclear why the three intervention studies (Carmack-Taylor, Northouse, and 
Zhang) did not find any improvements for HRQoL. One possible explanation to 
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account for these findings is due to the homogeneous nature of marital and 
educational demographics across the three studies.  Approximately 80-100% of the 
participants across the three studies were married, and over 76% had completed 
college degrees.  As a result, it is possible that participants had high perceived social 
support due to being married, and, as a result, the supportive intervention had little 
impact. Furthermore, due to their being educated, it is possible individuals were self-
sufficiently proactive in lifestyle modifications and sourcing educational materials, 
and further information/education had little impact.     
1.4.2 HRQoL change over time 
All of the studies that reported changes in HRQoL over time had a prospective 
longitudinal design (see table 1.14 for quantitative methods).  In total, 77 studies 
assessed change over time and were conducted in America (42), Japan (13), 
Netherlands (6), UK (3), Canada (3), Sweden (2), Italy (2), Germany (2), Australia (2), 
Spain (1), and France (1).  Sample sizes ranged from N=46 to N=2204 with a total 
sample size of N=23,381 across all of the studies.   
Table 1.15 Methodologies of studies identifying change overtime for HRQoL 
Type of study                                                                                               Number 
Prospective longitudinal    70 
Prospective longitudinal with match controls  7 
 
The studies that report changes over time have been grouped together by specific 
treatment modality.  This grouping allowed a systematic and thorough understanding 
of the changes in general and prostate cancer-specific HRQoL based on individual 
treatments. 
 
Radical prostatectomy  
Measures used to assess general HRQoL for men treated by radical surgery included 
the SF-36, FACT-G and the EORTC C30.  Overall, general domains of HRQoL are 
affected in the short-term, but recovery is reported during three and six months 
post-surgery.  The physical component (as measured by the SF-36) significantly 
(P<0.001) worsened at six weeks (Kouba et al., 2007) and at three months post-
surgery (Namiki et al., 2005a).  Role-physical functioning and vitality (as measured by 
the SF-36) significantly worsened from before treatment to assessment at three 
months (Inoue et al., 2009, Jayadevappa et al., 2006, Namiki et al., 2005a).  Social 
27 
 
 
 
well-being (as measured by FACT-G) also significantly worsens at three months post-
surgery (Ward-Smith and Mehl, 2007).  However, a rapid recovery is identified at 
three months after surgery for most general domains of HRQoL (Hashine et al., 2008, 
Namiki et al., 2008, Miller et al., 2007, Ene et al., 2006).  Other researchers identify 
recovery of HRQoL at six months post-surgery (Kobuke et al., 2009, Inoue et al., 2009, 
Buron et al., 2007, Namiki et al., 2006a, Jayadevappa et al., 2006, Namiki et al., 
2005a).  Not all of the reviewed studies assessed HRQoL at both three and six 
months.  Therefore, it is only possible to say that general domains of HRQoL for men 
treated by surgical techniques are likely to recover sometime between three and six 
months post-surgery.        
 
Financial difficulties, pain levels, physical functioning and social functioning (as 
measured by EORTC C30) (Davison et al., 2007) were significantly worse at twelve 
months post-surgery than before treatment.  Other longitudinal studies have 
demonstrated recovery of HRQoL to pre-treatment score (all multidimensional 
domains) at twelve months post-surgery (Guedea et al., 2009, Ficarra et al., 2006, 
Dalkin et al., 2006, Soderdahl et al., 2005) that is maintained through to twenty-four 
months (Guedea et al., 2009, Dalkin et al., 2006).  One explanation that may explain 
the different results in Davison’s study was that 30% of study participants received 
adjuvant hormone therapy.  Due to the effects of adjuvant hormone therapy, men 
may have reported worse HRQoL compared to men who had surgery alone.  
Therefore, this bias may have influenced Davison’s findings.   In summary, there is a 
trend of recovery of general HRQoL that occurs somewhere between 3-6 months, 
that is maintained at longer term follow-up, but most domains of HRQoL have 
recovered to pre-treatment levels at twelve months post-surgery, with the one 
exception being for men on adjuvant hormone therapy.   
 
Prostate cancer-specific HRQoL was measured using the EPIC, UCLA-PCI and EORTC-
PR25 for men treated by radical surgery.  Obstructive and irritative urinary symptoms 
are experienced at one month post-surgery, with recovery of symptoms at three 
months (Guedea et al., 2009).  Men treated by surgical techniques often experience 
urinary incontinence, that is to say, at one month (Guedea et al., 2009), three months 
(Inoue et al., 2009), six months (Ball et al., 2006), twelve months (Namiki et al., 
2006a, Latini et al., 2006), twenty-four months (Guedea et al., 2009, Buron et al., 
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2007), thirty-six months (Chen et al., 2009), forty-eight months and sixty months  
(Namiki et al., 2006b) after surgery.  The prevalence of urinary incontinence has been 
reported to be 20% of patients at three months, 12% at six months, and 8% at twelve 
months (Ficarra et al., 2006), with longer follow-up data identifying 8% of men are 
still incontinent at five years (Inoue et al., 2009).  Patients treated by surgical 
techniques experience significantly worse urinary incontinence compared to 
brachytherapy (Guedea et al., 2009, Buron et al., 2007, Soderdahl et al., 2005) and 
radiotherapy (Guedea et al., 2009).  
 
To clarify, the magnitude of urinary incontinence in the longer term, studies have 
measured incontinence pad usage.  Most men (88%) reported that they did not use 
incontinence pads at twelve months post-surgery, with little change at twenty-four 
months (89%) (Dalkin et al., 2006, Rogers et al., 2006).   Men who do wear pads at 
twelve months often do not truly need them for incontinence, but often use them as 
a safety liner (Dalkin et al., 2006).  Consequently, assessment of urinary incontinence 
by counting pad usage is problematic and may not accurately detail the frequency of 
incontinence.   
 
Sexual dysfunction is the other major problem for men treated with surgery.  Studies 
have identified an increase in sexual problems at three months (Kouba et al., 2007, 
Namiki et al., 2005b), six months (Buron et al., 2007, Diefenbach and Mohamed, 
2007, Kouba et al., 2007, Namiki et al., 2005a), twelve months (Kobuke et al., 2009, 
Diefenbach and Mohamed, 2007, Dalkin et al., 2006, Latini et al., 2006, Soderdahl et 
al., 2005, Namiki et al., 2005b), twenty-four months (Namiki et al., 2009c, Dalkin et 
al., 2006),  thirty-six months, forty-eight months, and sixty months, (Namiki et al., 
2009c) compared to pre-surgery patient reports.  There is some evidence to suggest 
that nerve-sparing surgical techniques may improve penile rehabilitation for some 
men.  One study identified that 60.5% of men treated by nerve-sparing LRP were 
engaging in intercourse at twelve months (Rogers et al., 2006).  However, sexual 
dysfunction is prevalent over time despite the surgical approach used (open RP, LRP 
and Da Vinci Robotic prostatectomy) (Ball et al., 2006).  Furthermore, sexual 
dysfunction is common in men before surgery (Guedea et al., 2009, Davison et al., 
2007, Buron et al., 2007).  Comparison studies have shown that men treated by 
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surgery report the worse sexual function at twelve months compared to 
brachytherapy (Namiki et al., 2006b, Soderdahl et al., 2005). 
 
Men with locally advanced disease treated with RP and adjuvant hormone therapy 
report more severe bowel, urinary and sexual dysfunction at 6 weeks, twelve 
months, twenty-four months, thirty-six months, forty-eight months and sixty months, 
compared to surgery alone (Moinpour et al., 2008).   
 
Brachytherapy (BT) 
Measures used to assess general HRQoL for men treated by BT included the SF-36, 
FACT-G and the EORTC C30.  Short-term declines in general HRQoL domains are 
experienced at two months after BT with recovery in HRQoL at six months, that is 
maintained through to twelve months (Vordermark et al., 2009, Soderdahl et al., 
2005), eighteen months, and twenty-four months (Buron et al., 2007).  Role 
functioning and pain has been reported to gradually worsen over time in this patient 
group, at both, six and twelve months after treatment (Van Gellekom et al., 2005).  
Improvements in emotional functioning have been reported at the following 
trajectories: one, six, twelve and twenty four-months with patient scores exceeding 
pre-treatment scores at twenty-four months (Van Gellekom et al., 2005).  Other 
researchers identify general HRQoL was not affected at any follow-up time points in 
both the short-term and long-term follow-up (Kobuke et al., 2009, Caffo et al., 2006, 
Namiki et al., 2006b).  The different results between these studies could have been 
confounded by changes/innovations in treatment.  Caution is taken in the 
interpretation of the results because some patients may have viewed BT as a modern 
treatment option, whereby patients may have believed that BT may avoid some of 
the well-known side effects of existing treatments; consequently, their optimistic 
view of BT may have influenced their responses. 
 
Prostate cancer-specific HRQoL was measured using the FACT-P, AUA, IPSS, UCLA-PCI 
and EORTC-PR25 for men treated by BT.  Obstructive and irritative urinary symptoms 
are reported problematic at one month (Vordermark et al., 2009, Ball et al., 2006), 
three months (Nguyen et al., 2009, Namiki et al., 2006b), with recovery at twelve 
months (Vordermark et al., 2009) that is maintained at sixteen months (Pinkawa et 
al., 2009a), twenty-four months (Guedea et al., 2009, Ash et al., 2007, Buron et al., 
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2007, Caffo et al., 2006, Van Gellekom et al., 2005, Soderdahl et al., 2005), thirty-six 
months (Chen et al., 2008, Caffo et al., 2006) and forty-eight months (Caffo et al., 
2006).  These data suggest that obstructive and irritative symptoms are experienced 
in the short-term but improve over time.  
 
Short-term problems with urinary incontinence have been reported at three and six 
months, with recovery occurring somewhere between six and nine months, and was 
reported to improve over pre-treatment scores at twelve months (Feigenberg et al., 
2005).  Other published data identified that at twenty-four months after treatment, 
19.7% of men reported that urinary incontinence was worse than at baseline (Buron 
et al., 2007).  The reports of urinary incontinence recovery are contradictory and 
inconsistent.  Buron’s study participants had substantial co-morbidities (2007), 
whereas Feigenberg’s study participants did not have co-morbidities (Feigenberg et 
al., 2005), which may account for the differing findings of urinary incontinence for BT 
patients. 
 
Worsening sexual function is demonstrated at one month (Ball et al., 2006) and at six 
months after BT (Diefenbach and Mohamed, 2007, Ash et al., 2007, Buron et al., 
2007, Soderdahl et al., 2005).  Sexual function gradually improves at one year 
(Soderdahl et al., 2005) and two years, (Ash et al., 2007, Buron et al., 2007, Van 
Gellekom et al., 2005), two and a half years (Nguyen et al., 2009) and at three years 
(Chen et al., 2008) but is still statistically worse than at pre-treatment scores.  
However, BT patients have a better sexual function compared to RP and RT patients, 
consistently over the course from three months to one year post-treatment (Chen et 
al., 2008, Buron et al., 2007, Soderdahl et al., 2005). 
 
Significant declines in bowel function have been experienced at one month post-BT 
(Nguyen et al., 2009, Ash et al., 2007, Ball et al., 2006) but fully recovered by one 
year post-treatment (Caffo et al., 2006, Soderdahl et al., 2005).   
 
Radiotherapy (RT) 
Measures used to assess general HRQoL for men treated by RT included the SF-36, 
FACT-G and the EORTC C30.  Prospective longitudinal data demonstrated that 
physical well-being for men treated by RT declined midway through RT, after RT, at 
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four weeks, and at two months after treatment (Monga et al., 2005).  In addition, 
emotional and physical problems have been reported to worsen at three months 
after RT (Namiki et al., 2006c).  Improvements in physical and emotional scores 
consistently improved over baseline scores at six months through to 3 years post-RT 
(Lips et al., 2009).  Other researchers report that global and functional domains of 
HRQoL did not significantly change from pre-treatment scores over the course of a 
two-year follow-up (Choo et al., 2007).  Individual symptoms (fatigue, pain, insomnia 
and diarrhoea) have been found to worsen during RT, at two months after RT, 
through to 2 years after RT (Choo et al., 2007).    
 
Men treated by combination therapy (hormone therapy and RT) for the treatment of 
locally advanced disease have reported the worse HRQoL compared to RT alone 
(Stephens et al., 2007).  However, combination therapy has been shown to have 
better tumour control and overall survival for men with locally advanced disease 
compared to RT alone (Pinkawa et al., 2008).   
 
Prostate cancer-specific HRQoL was measured using the FACT-P, UCLA-PCI and 
EORTC-PR25 for men treated by RT.  Prospective data have identified that only 6% of 
men report an increase in urinary dysfunction at the end of RT, which later lost 
statistical significance at two months after treatment (Choo et al., 2007), through to 
two years after treatment (Namiki et al., 2006c).  Longer term follow-up data have 
identified that 19% of patients report pad usage to manage urinary incontinence at 
ten years after diagnosis (Fransson et al., 2009a).  Data have identified a limit in daily 
activities caused by urinary symptoms at four, eight and fifteen years compared to 
age match controls (Fransson et al., 2009a).  Age match control studies reiterate 
similar findings; at approximately 8 years after diagnosis, men experience worse 
urinary function than age matched controls (Thong et al., 2009).  In summary, the 
reviewed studies suggest that men treated with RT are likely to experience minimal 
urinary dysfunction after RT, but may experience urinary problems in the long-term. 
 
Bowel dysfunction is commonly reported in men treated by RT.  Bowel function 
significantly worsens during RT, at the end of RT (Namiki et al., 2006c), two months 
(Pinkawa et al., 2009a), six months (Choo et al., 2007), twelve months (Lev et al., 
2009) and at sixteen months after RT, compared to pre-treatment scores (Pinkawa et 
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al., 2009a).   Longer term prospective data have identified that men have been found 
to experience rectal urgency, diarrhoea and cramp pain at eighteen months, 2 years 
and at 5 years after diagnosis (Namiki et al., 2009b).   
 
Men treated by combination therapy (hormone therapy and RT) have been found to 
experience the following symptoms: fatigue, pain, insomnia, diarrhoea, at six, ten, 
fourteen, eighteen, and twenty-two months after starting treatment.  Men treated 
with combination treatment reported the highest sexual dysfunction and worse 
physical well-being whilst on hormone therapy (Stephens et al., 2007).  Longer 
follow-up studies have found that urinary and sexual function problems persist at five 
years after combination treatment (Wahlgren et al., 2007).  Recoveries of general 
HRQoL and sexual functioning have reported at nine months after completing 
hormone therapy (Wu et al., 2008).  However, men treated by combination therapy 
can experience the poorest urinary, bowel, and sexual function at six weeks and 
sixteen months after RT, compared to RT alone (Pinkawa et al., 2008).  In summary, 
the trends from the presented findings suggest that men on combination therapy 
have been found to experience worse HRQoL outcomes, compared to RT alone. 
 
Sexual dysfunction is another major problem for men treated by RT. Sexual function 
problems are common prior to RT, with approximately 50% of men having 
experienced sexual dysfunction before RT (Howlett et al., 2010).  Interestingly, age 
matched control studies have identified that at baseline, 22.3% of controls, and 
27.6% of patients were unable to obtain an erection (Smith et al., 2009).  A different 
clinical picture emerged after RT, whereby age matched control studies have clarified 
that sexual function is significantly worse for patients rather than control groups at 
one, two, and five years post-treatment (Thong et al., 2009).   A gradual worsening in 
sexual function was reported by patients  at three, six, twelve, eighteen months 
(Pinkawa et al., 2009a, Robinson et al., 2009), and at three years post-treatment 
(Robinson et al., 2009).  Evidence suggests sexual function in this patient group does 
not show any trend of improvement over time. 
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Watchful waiting (WW) 
Evaluating change in general and disease-specific HRQoL over time for the WW 
patient group is limited. Comparison studies have shown that men under WW scored 
higher for general HRQoL before treatment, after completion of treatment, and at 
one year follow-up post-treatment, when compared to men treated with radical 
prostatectomy, radiotherapy and hormone therapy (Couper et al., 2009).  In addition, 
men under WW have reported better urinary, bowel and sexual function when 
compared to the other treatments modalities at twelve months (Couper et al., 2009, 
Fransson et al., 2009a). However, longer follow-up studies acknowledge that physical 
functioning, insomnia and financial difficulties significantly worsen at four and ten 
years after diagnosis for WW (Fransson et al., 2009a).  At five years post-diagnosis, 
men under WW have been found to have the poorest HRQoL compared to men 
receiving radiotherapy (Galbraith et al., 2005).  Furthermore, 7% of WW patients 
have reported wearing pads for urinary incontinence at 10 years after diagnosis 
(Fransson et al., 2009b).  Problems with sexual function have been reported at 
diagnosis, six months and twelve months (Diefenbach and Mohamed, 2007).   
 
In summary, the evidence suggests that HRQoL is maintained up to the 1st year 
following diagnosis, but with longer term (4-10 years) negative consequences on 
general and disease-specific HRQoL.  It is unclear how HRQoL is affected at one to 
three years post-diagnosis.  Thus, additional research would be helpful to clarify 
changes in HRQoL at this time point (1 – 3 years).    
  
Hormone therapy 
There were very few studies in this review that assessed changes in HRQoL for men 
receiving hormone therapy alone. In men diagnosed with metastatic cancer, 
significant improvements were identified for HRQoL (as measured by the SF-36) for 
the following scales: pain (at 3 and 12 months), emotional-role, mental well-being (at 
6 months), and vitality (at 12 months), when compared to pre-treatment scores (Kato 
et al., 2007).  Urinary function was improved at six and twelve months for some men 
(Kato et al., 2007).  However, sexual dysfunction can be experienced at three, six and 
twelve months after treatment (Kato et al., 2007).  Prostate cancer that has 
metastasised to the bone carries an increased risk of skeletal related events (i.e. 
bone fractures and spinal cord compression).  Men treated with hormone therapy 
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who experienced a skeletal-related morbidity have been found to have poor physical 
well-being and worsening pain, with poorer survival than men without skeletal 
morbidity treated by hormone therapy (DePuy et al., 2007).  From the reviewed 
publications it is unclear how HRQoL changes after one year and beyond, following 
hormone therapy.  Prospective longitudinal data suggest that men treated with 
hormone therapy can experience far worse HRQoL scores than men treated with the 
following: brachytherapy, radical prostatectomy, radiotherapy and watchful waiting 
(Couper et al., 2009, Gacci et al., 2009, Sanda et al., 2008, Ash et al., 2007). 
1.5 Discussion 
This review was specifically carried out to address the following questions: 1) what 
are the predictor variables of HRQoL in men affected by prostate cancer? 2) How 
does HRQoL change over the prostate cancer journey?  Evidence has addressed both 
research questions; however, it is difficult to produce absolute conclusions about 
what predicts HRQoL, and how HRQoL changes over time, because of the 
heterogeneous methods used in the studies included in this review.  Broad 
summaries/trends from the presented evidence are identified for both questions, 
which was the intention for this review.  The volume of HRQoL studies included in 
this review underscores the recognition among quality of life researchers that the 
morbidity of this disease is substantial, and men may experience physical and 
psychological problems for many months, and years, following treatment.   
  
Predictor variables of general and disease-specific HRQoL were demographic, clinical 
and psychological-social variables.  The most common predictor variables across all 
stages of disease were demographics variables (age, ethnicity, marital status, level of 
education), clinical variables (co-morbidity, Gleason, TNM classification, treatments, 
and PSA) and psycho-social variables (depression, coping, self-efficacy, perceived 
stress and social support).  This review has identified that psycho-social variables can 
influence HRQoL, but little (Queenan et al., 2010, Lev et al., 2009, Zavala et al., 2009, 
Kershaw et al., 2008, Eller et al., 2006, Roberts et al., 2006)  psycho-social research 
was evaluated in this review.  Surprisingly, most of the research reviewed has been 
devoted to physical aspects and side-effects of cancer and treatment, and very little 
research has assessed emotional distress, and explored the relationship between 
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coping and social support on HRQoL (Bloch et al., 2007), which is puzzling, given the 
profound negative effects on HRQoL.     
 
This area would be worthy of further research because the reviewed studies were 
limited to men with localised disease and, therefore, we currently do not know how 
the psycho-social variables influence HRQoL for men with locally advanced or 
metastatic disease.  Noteworthy, none of these studies were conducted in the UK.  
This lack demonstrates the need for additional research that will assess the coping 
and social support processes that may influence HRQoL in prostate cancer survivors 
across all stages of disease, namely: localised, locally advanced and metastatic 
disease.  It is anticipated that addressing this knowledge gap will provide useful 
insights as to how men can be better supported to self-manage their condition and 
improve HRQoL.  In line with this knowledge gap, men living with prostate cancer 
report that their highest unmet support needs are psychological needs related to 
emotions and coping (Sanda et al., 2008) and physical needs related to the 
management of side effects of the disease, associated treatments and on-going 
issues related to recurrence (Carter et al., 2011, Ream et al., 2008, Boberg et al., 
2003).   
 
For the most part, general HRQoL domains recover within the year following 
treatments.  However, it is apparent that specific treatments host different 
consequences for urinary, bowels and sexual dysfunction.   Men treated by surgical 
approaches often experience poorer outcomes for urinary and sexual dysfunction, 
compared to brachytherapy, radiotherapy and watchful waiting.  Whereas, men 
treated by radiotherapy or brachytherapy often report poorer bowel function 
compared to men treated by surgical techniques. 
 
The physical effects of treatments (urinary, bowel and sexual dysfunction) cause 
profound problems over time for men living with prostate cancer.  Sexual dysfunction 
has been reported to be associated with having the disease and following 
treatments.  The greatest declines in sexual function have been reported within 6 
months following treatments, and longer follow-up data at 5 years post treatment, 
have indicated that sexual function never regained pre-treatment scores.  Qualitative 
studies have described the impact of sexual dysfunction in men affected by prostate 
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cancer, as a “sense of grief”, “sex life is zero”, and men also described their 
experiences as not feeling like a “whole man” (Ames et al., 2008, Hedestig et al., 
2008).  These experiential accounts support extending additional psycho-social 
research for prostate cancer survivors.   
      
Urinary problems are predictive of general domains of HRQoL (Lev et al., 2009, Eller 
et al., 2006) and rich experiential accounts have identified some of the issues that 
men can experience. Qualitative accounts identify that men have had to change their 
clothes several times daily, and describe their inability of being able to lead a social 
life due to urinary incontinence, and have voiced worries about the odour from wet 
pads (Hedestig et al., 2005).  This identifies the magnitude of patient experience and 
the pressing need to research self-management for men with prostate cancer.   
 
One of the most apparent limitations of the HRQoL evidence and a possible source of 
bias was the lack of data on the usage of post-treatment aids, and modifications to 
lifestyle that men use to manage their dysfunction, for example: taking medications, 
changes to lifestyle, and using vacuum devices for impotence.  The influences of self-
management strategies used by men were not measured in any of the reviewed 
publications. It is likely that self-management strategies used to alleviate problems 
would influence HRQoL scores over time.   Evidence that identifies the self-
management behaviours and the relief of such behaviours would be worthy of 
further research. 
 
A trend across the reviewed publications acknowledges HRQoL for general and 
disease-specific domains are at their worst during the first 6 months following 
treatment. Most baseline reports in longitudinal studies have used pre-treatment, 
and not pre-diagnosis, to measure comparison in HRQoL over time. It is not possible 
to undertake pre-diagnosis evaluations due to feasibility issues for the majority of 
studies in this field.  One study however, identified that mental health significantly 
worsened from pre-diagnosis (assessment at prostate cancer biopsies) to one month 
after diagnosis (Korfage et al., 2006). Thus, it is likely that pre-treatment scores at 
baseline are an underestimation of the psychological consequences associated with a 
diagnosis with prostate cancer.  Therefore, assessing the influences of coping and 
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social support on HRQoL earlier in the cancer trajectory would be helpful to better 
understand how to support men affected by this disease.  
 
There were a number of methodological limitations that featured across a number of 
publications.  Often the study samples were limited to men who were: white, 
educated, and married, and as such, they limit the generalisabilty of findings to other 
minority groups.  This was a limitation that featured across a number of publications 
(Howlett et al., 2010, Parker et al., 2009, Chen et al., 2008, Davison et al., 2007, 
Daubenmier et al., 2006, Carmack Taylor et al., 2006, Roberts et al., 2006) whereas 
some researchers did not provide any demographic data (Roeloffzen et al., 2010, 
Gacci et al., 2009, Pinkawa et al., 2009a, Korfage et al., 2007, Wood et al., 2007, Ash 
et al., 2007, Prezioso et al., 2007b, Dalkin et al., 2006, Sullivan et al., 2006, Van 
Gellekom et al., 2005).  Bias is possible due to confounding demographic variables 
and limits the generalisabilty of these findings to wider population groups.  Another 
key limitation was the potential for recruitment and attrition bias in the publications 
(Roeloffzen et al., 2010, Thong et al., 2009, Couper et al., 2009, Chen et al., 2008, van 
de Poll-Franse et al., 2008b, Anger et al., 2007, Ash et al., 2007, Galbraith et al., 2005, 
Van Gellekom et al., 2005, Brar et al., 2005).  It is possible that the samples consisted 
of men in good health that enabled participation in the studies, compared to men 
with poorer health and who, therefore, were less able to take part.    However, the 
influence of this bias will remain unknown and the findings are treated with caution. 
 
Often the sample sizes in the studies were small, which resulted in underpowered 
analyses (Fransson et al., 2009a, Zavala et al., 2009, Nguyen et al., 2009, Zhang et al., 
2007, Monga et al., 2007, Culos-Reed et al., 2007, Penedo et al., 2007, Carmack 
Taylor et al., 2006, Jayadevappa et al., 2006, Namiki et al., 2006c).  For these studies 
there is a risk that a type two statistical error was made, for example, believing that 
HRQoL did not change over time, when in fact HRQoL did.  A type one statistical error 
was possible for one study (Galvao et al., 2010) whereby they performed a large 
number of statistical comparisons on the data set.  Galvao and colleagues did not use 
a bonferroni adjustment (setting a more stringent alpha level of each comparison); 
therefore, caution is taken in the interpretation of these findings. 
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One of the difficulties in interpreting changes in HRQoL over time was that some 
researchers did not use a baseline HRQoL comparison score, for example, before 
treatment score.  This was a limitation that featured across a small number (10) of 
studies  (Fransson et al., 2009a, Smith et al., 2009, Thong et al., 2009, White et al., 
2008, Wood et al., 2007, Zhang et al., 2007, Roberts et al., 2006, Brar et al., 2005, 
Galbraith et al., 2005, Miller et al., 2005).  For these studies the impact of treatment 
on HRQoL early in the cancer trajectory and beyond is not clear.  It would be helpful 
to aid interpretation that future research in this field used pre-treatment HRQoL 
scores as a baseline assessment to evaluate changes in HRQoL over time.  
 
One of the challenges in this review was the diverse methodology of the studies 
included.  This review has generated broad summaries and conclusions about what 
predicts HRQoL and identified how HRQoL changes over the cancer journey.  The 
findings from this review recommend that further research is needed to identify the 
influence of coping and social support on HRQoL and the self-management 
behaviours for men affected by prostate cancer.  
 
1.6 Conclusion 
This review has provided an opportunity to summarise the trend of predictor 
variables and recovery in HRQoL, which is useful to clinicians and patients, but has 
also allowed prioritisation of research needs.  This review identified a number of 
demographic variables (age, ethnicity, marital status, level of education) and clinical 
variables (co-morbidity, Gleason score, TNM classification, treatments, and PSA) that 
can predict HRQoL for men with prostate cancer.  Yet, despite the abundance of 
HRQoL literature and widely recognised consequences of having prostate cancer, 
little is known about how men cope with the aftermath problems associated with 
this disease, the self-management strategies that men use, or the relationship 
between coping and social support on HRQoL during the pre-treatment to six month 
post-treatment trajectory.  For the most part, general HRQoL returns to pre-
treatment scores by twelve months after treatment, therefore exploring potential 
predictors sooner in the cancer journey may provide an opportunity to restore 
HRQoL sooner for men affected by this condition.   
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In conclusion, this structured review has identified a number of important knowledge 
gaps around the following issues: the influence of coping and social support on 
HRQoL, and establishing the self-management behaviours used by men over time.  
To effectively develop additional research to address these knowledge gaps, it was 
necessary to conduct two further structured literature reviews to understand the 
current state of the evidence in relation to: 1) the influence of social support on 
HRQoL, and 2) the self-management strategies used by men.   Chapter two and 
chapter three are structured reviews of the evidence that were conducted to ensure 
that this Ph.D. study was developed based upon the best available evidence. 
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2.0 Social support 
2.1 Abstract 
Background 
Men have reported a lack of support in their pursuit to cope with the problems 
associated with this disease and its treatments.  Little is known about the mechanism 
effect or the type of social support that links coping to HRQoL.  Knowledge in this 
area can help to identify men who are at risk of impaired HRQoL and provide 
directions for future research. 
Aim  
A structured review of empirical literature was undertaken to describe the types of 
social support that influence HRQoL and the mechanism effect through which social 
support influences coping and HRQoL. 
Methods 
The search architecture used the following key words: prostate cancer, prostate 
carcinoma, health-related quality of life, quality of life, social support, support 
groups, coping, adjustment, and psycho-social.  Databases searched were CINAHL, 
Medline, PsycInfo, ASSIA, and BNI (from the earliest date available to 2012).  A 
narrative synthesis of the included papers was undertaken. 
Results 
107 studies were assessed for potential inclusion and 11 publications were included 
in the review.   The literature predominately assessed main effects of perceived 
social support on HRQoL, and few studies assessed moderation and mediation 
effects.  Perceived social support was frequently assessed, but few studies evaluated 
the effects of received social support or satisfaction with social support on HRQoL.   
Conclusion 
Additional research should include a multidimensional inventory of the social support 
constructs.  This will accurately detail how each of the social support constructs 
influence coping and HRQoL over time.  This may provide the basis for the 
development of appropriately targeted social support interventions for prostate 
cancer survivors, which are theoretically driven.  Future research should be tailored 
to meet the individual man’s social support needs. 
41 
 
 
2.2 Introduction 
Social support for many people is an intuitive term that is used to describe help that 
is given and received from others in a difficult situation.  Research into the role of 
social support and its relationship to health outcomes has received a lot of attention; 
however, there are conceptual and methodological problems in the study of social 
support that are not yet resolved (Cohen et al., 2000; Hupcey, 1998; Callaghan and 
Morrissey, 1993).  These challenges are reflected in the range of existing social 
support definitions.  One of the earliest definitions of social support was by Cobb 
(1976) and he defined social support as, “the individual belief that one is cared for 
and loved, esteemed and valued, and belongs to a network of communication and 
mutual obligations” (p.289).  Elsewhere, social support refers to an exchange of 
resources between at least two people, perceived by the provider, or recipient, to be 
intended to enhance the well-being of the recipient (Schumaker and Bronwell, 1984).  
Other investigators have defined social support as, the perceived availability of 
people whom the individual trusts and who make one feel cared for, and valued, as a 
person (Thoits, 1986).  More recently, social support has been defined as, “the 
function and quality of social relationships, such as perceived availability of help or 
support actually received” (Schwarzer et al., 2003, p.3).  Suffice to say, there is not a 
consensus over an agreed definition of social support (Hupcey, 1998), but what can 
be appreciated from these definitions, is that social support is complex and multi-
faceted.  The term social support is characterised by looseness and a breadth of 
measurement approaches to social support that have been previously depicted so 
clearly by Wortman (1984) and others (Callaghan and Morrissey, 1993; Koasa et al., 
1991; Broadhead and Kaplan, 1989; Dunkel-Schetter, 1984).   
 
Social support measures have been operationalised in the following ways: 
structurally (for example: size of support network, marital status, frequency of social 
interations, membership in specific environments) or by functionality (for example: 
emotional, informational, instrumental support) (Cohen et al., 2000; Callaghan and 
Morrissey, 1993).  In addition, functional social support (emotional, informational 
and instrumental support) can be derived from a variety of sources (for example: 
partner, sibling, friend, colleague, or doctor, nurse) that can either be received or 
perceived to be available (Schwarzer et al., 2003; Kobasa et al, 1991).    
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Within the social support literature, there is an important measurement distinction 
between perceived social support and received social support (Schwarzer et al., 
2003, Cohen et al., 2000).  Perceived social support is a construct that is used to 
describe social support anticipated at a time of need in the future (Procidano and 
Heller, 1983, Sarason et al., 1983), whereas received social support is based upon 
retrospective accounts of received social support in the past (Barrera et al., 1981).  
Moreover, perceived and received social support constructs can be further 
distinguished by the following types: emotional, informational, and instrumental 
(Crighton, 2002, Cohen et al., 2000, Cohen, 1988, Cohen and McKay, 1984).  
Emotional support generally comes from family and close friends, and is the most 
commonly recognised form of social support. It includes the provision of empathy, 
concern, caring, love, and trust (Cohen et al., 2000).  Informational support includes 
advice and suggestions from members of a person’s social network that may assist 
the person to respond to personal or situational demands (Cohen et al., 2000). 
Instrumental support includes help in the form of money, time, practical assistance, 
and other explicit interventions on the person’s behalf from members of their social 
network (Helgeson et al., 2006, Helgeson, 2003, Helgeson and Cohen, 1996).   
 
In the previous discussion about how social support has been defined, and what 
constitutes social support, it is conceptually very important to consider social support 
as a multidimensional construct, and not as a unitary construct.  Thus it is very 
apparent that social support in healthcare research is complex, and there is a need to 
reflect upon what social support might mean for men with prostate cancer. 
 
For many patients and family members, a diagnosis of prostate cancer can lead to 
many ambiguities, such as whether the cancer will recur, whether the cancer will 
prove fatal, or will it lead to permanent physical problems and disability.  For these 
reasons, and for many others, the experience of prostate cancer is uniquely stressful; 
and social support has been demonstrated to be beneficial in coping with prostate 
cancer’s associated stressors (Roberts et al., 2006).  For men affected by prostate 
cancer, the meaning of social support might relate to the functional aspects of social 
support such as: emotional, informational and instrumental support that can be 
received or perceived from a variety of sources that may include: partner, children, 
siblings, doctors, nurses, other healthcare professionals, other men with prostate 
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cancer, friends, colleagues, religious leaders, and members of online peer-support 
forums.  Specifically within the cancer field, patients have described their meaning of 
functional aspects of social support as: emotional support (love/concern, 
understanding, reassurance and encouragement), instrumental support (aid or 
assistance) and informational support (advice, information or a problem-solving 
nature) that were provided by a variety of sources including: family members, 
healthcare professionals, friends, and work colleagues (Dunkel-Schetter, 1984).  
Therefore, for the purpose of this thesis social support is defined as, a 
multidimensional construct that includes evaluations of perceived, received and 
satisfaction with the following typologies of support: emotional, information and 
instrumental support, within a person’s social network, as illustrated in figure 2.1.   
 
     
Figure 2.1 Conceptual model of social suppot  
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The links between social support and health date back to over a century ago.  A 
French Sociologist (Durkheim, 1858-1917) observed that suicides frequently occurred 
among individuals who had less social ties and weaker social connections.  More 
recently, social support is generally associated with improved physical health and 
psychological well-being in different patient groups, such as: colorectal cancer 
(Goldzweig et al., 2009), testicular cancer (Tuinman et al., 2010), breast cancer 
(Wittenberg et al., 2010, Talley et al., 2010), prostate cancer (Kershaw et al., 2008, 
Roberts et al., 2006, Kinsinger et al., 2006),  heart disease (Janevic et al., 2004), 
ischemic stroke (Huang et al., 2010), multiple sclerosis (Bambara et al., 2011),  mixed 
cancer groups (Cicero et al., 2009) and patients with metastatic disease (Rodin et al., 
2007).  Social support has been linked to the reduced incidence of stroke (Maselko et 
al., 2009), improved mortality for patient with cardiovascular disease (Kravdal and 
Syse, 2011, Malyutina et al., 2004, Cohen, 1988), and improved mortality for 
survivors of prostate cancer (Krongrad et al., 1996).  Furthermore, social support is 
linked to improved HRQoL for cancer patients (Helgeson, 2003, Helgeson and Cohen, 
1996).  The link between social support and improved health outcomes can be 
explained by the propositions of social support theory.  
 
There are two dominant theoretical frameworks that link social support to improved 
physical and mental well-being:  the Main Effects Model (Cohen et al., 2000) and the 
Stress Buffering Model (Cohen and Wills, 1985).  According to the main effects 
model, people with high social support (perceived or received social support) have 
better physical and mental health compared to those with low social support, 
regardless of the levels of stress (Cohen et al., 2000, Cohen, 1988, Cohen and Wills, 
1985, Cohen and McKay, 1984, Cohen and Hoberman, 1983).  Social support studies 
have identified the main effects of social support on HRQoL and are in keeping with 
the main effects theoretical model (Mehnert et al., 2010, Zhou et al., 2010a, Ah Von 
et al., 2007, Simoni et al., 2006, Doeglas et al., 1994, Cohen, 1988).  The relationship 
between social support and HRQoL for the main effects model is believed to be linear 
(Helgeson, 2003), whereas, the stress buffering hypothesis states that social support 
(perceived and received social support resources) is associated with improved 
physical and mental health only when individuals are exposed to stressful conditions 
(Christie et al., 2009, Cohen et al., 2000, Cohen, 1988, Cohen and Wills, 1985, Cohen 
and McKay, 1984, Cohen and Hoberman, 1983).  Thus, under conditions of high 
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stress, social support is believed to act as a buffer (moderator) against the adverse 
effects of that stressor. The term “buffering” is used because it is believed, according 
to this theory, that social support lessens the pathogenic effects of a stressor, for 
example, a cancer diagnosis or living with a chronic illness. In general terms, this type 
of association, in which the relationship between two variables depends on the level 
of a third, is known as a moderation effect (Aiken and West, 1991, Cohen and McKay, 
1984).   The third variable – the stress buffer – is the moderator. Moderation effects 
are tested statistically by examining the interaction between two predictor variables 
on the dependent variable. Thus, in order to test the stress buffering hypothesis, one 
must include an interaction term in statistical analyses (moderation analyses are 
clearly explained in chapter 4, section 4.7.7 of this thesis).  
 
The stress buffering perspective states that coping performances are enhanced when 
social support (Cohen et al., 2000) is high, and is very closely related to Lazarus and 
Folkman’s (1984) theory on stress and coping.  The transactional process of stress 
and coping theory dominates social support research (Lakey and Orehek, 2011) and 
has been applied to cancer studies (Lehto et al., 2005, Laubmeier et al., 2004, 
Wonghongkul et al., 2000, Parle and Maguire, 1995, Carver et al., 1993), and details 
the central importance of social support on improving HRQoL and emotional 
outcome (see figure 2.2 for social support theoretical model).   
Stress Effect: Prostate 
Cancer
· Coping
Social Support
Perceived Support
Received Support
Satisfaction with Support
Health Status
· HRQoL
· Anxiety and 
Depression
B
Buffer
A
CC
KEY
A=Direct effect
B=Moderation effect
C=Mediation effect
  
Figure 2.2 Social support theoretical model (Cohen et al., 2000) 
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In line with Schwarzer’s (2003) definition of social support, researchers have 
developed standardised instruments to measure perceived social support and 
received social support (see table 2.1).   
Table 2.1 Instrument to measures of social support 
Study Name and 
acronym 
Number 
of items 
Reliability Measurement 
(Henderson 
et al., 1980) 
 
 
 
 
(Procidano 
and Heller, 
1983) 
 
 
 
(Sarason et 
al., 1983) 
 
 
 
(Cohen and 
McKay, 
1984) 
 
 
 
(Power et 
al., 1988) 
 
 
 
(Barrera et 
al., 1981) 
 
 
 
 
 
(Dunkel-
Schetter et 
al., 1987) 
 
 
 
 
 
 
 
(Schulz and 
Schwarzer, 
Interview 
Schedule for 
Social 
Interactions 
(ISSI) 
 
Perceived 
Support from 
Friends and 
Family (PSS) 
 
 
Social Support 
Questionnaire 
(SSQ) 
 
 
Interpersonal 
Support 
Evaluation List 
(ISEL) 
 
 
Significant 
Other Scale 
(SOS) 
 
 
Inventory of 
Socially 
Supportive 
Behaviours 
(ISSB) 
 
 
UCLA Social 
Support 
Interview (UCLA 
SSI) 
 
 
Cancer-specific 
measures 
 
 
Berlin Social 
Support Scale 
24 
 
 
 
 
 
40 
 
 
 
 
 
27 
 
 
 
 
40 
 
 
 
 
 
56 
 
 
 
 
40 
 
 
 
 
 
 
70 
 
 
 
 
 
 
 
 
 
45 
 
0.71 
 
 
 
 
 
0.90  
 
 
 
 
 
(Family) 
0.88 
(Friends 
0.97 
 
Scales 0.70 
to 0.90 
 
 
 
 
Scales 0.73 
to 0.83 
 
 
 
>0.90 for 
all scales 
 
 
 
 
 
Reliability 
not 
reported 
 
 
 
 
 
 
 
Scales 0.63 
to 0.83 
Perceived 
emotional 
attachment 
 
 
 
Perceived 
emotional/inform
ational support 
 
 
 
Perceived 
emotional 
support 
 
 
Perceived 
emotional, 
instrumental, 
companionship 
support 
 
Perceived 
emotional and 
instrumental 
support 
 
Received 
emotional, 
informational, 
instrumental, 
companionship 
support 
 
Received 
emotional, 
informational, 
instrumental 
support 
 
 
 
 
 
Perceived, 
received 
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2003) 
 
 
 
 
 
(Bottomley, 
1995) 
(BSSS) 
 
 
 
 
 
Bottomley 
Cancer Social 
Support Scale 
(BCSSS) 
 
 
 
 
 
 
9 
 
 
 
 
 
 
 
Scales 0.76 
to 0.77  
emotional, 
informational, 
instrumental and 
satisfaction of 
support 
 
Perceived 
emotional and 
confident support 
 
Many of the general measures of social support are inappropriate for use in cancer 
because reliability and validity have not been established for cancer patients.  The 
content of the social support measures maybe relevant only to general populations 
and not for people affected by cancer.  There are only two instruments (Berlin Social 
Support Scale and Bottomley Cancer Social Support Scale) that have been developed 
to evaluate cancer-specific social support.  Both cancer-specific measures are reliable 
and valid, but the Berlin Social Support Scale would be the strongest candidate 
instrument for future research for a number of important reasons.  The Berlin Social 
Support Scale (BSSS) is a multi-dimensional inventory of the social support constructs 
that includes received, perceived and satisfaction with social support that may refine 
the propositions of existing social support theory.  Furthermore, the validity and 
reliability of the BSSS has been previously established for men affected by prostate 
cancer (Scholz et al., 2008) whereas, the Bottomley Social Support Scale has not 
previously been used in prostate cancer patients.   
 
Coping is also central to the propositions of social support theory.  The coping and 
stress process and are best described as a transactional process that depends on the 
availability of support (internal/external resources) and personality assets (Cooper 
and Watson, 1991) of the person.  According to the transactional process of stress 
and coping, social support represents one resource factor, among others, that 
influences cognitive appraisal of stressful encounters.  Coping, then, is a result of 
cognitive appraisal, and the more social support that is available, positive coping 
efforts are believed to be better facilitated (Lakey and Orehek, 2011).  An association 
between coping and HRQoL for men affected by prostate cancer has been identified 
(Zhou et al., 2010a, Couper et al., 2010, Ahmad et al., 2005). 
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Specifically, a diagnosis of prostate cancer can trigger a number of life-altering 
decisions that can induce stress, for example: diagnosis, treatment-making decisions, 
after-effects of treatment, and financial difficulties.   Coping is always related to the 
specific demands (stressors) of a given situation and how individuals appraise these 
tasks as taxing, or exceeding their resources.  In this context, men can experience 
severe and enduring decrements in HRQoL (as identified in chapter 1) and social 
support might help men in their pursuit to cope with the profound physical and 
psychological sequelae (Department of Health Macmillan Cancer Support & NHS 
Improvement, 2010, Boehmer and Babayan, 2005, Boberg et al., 2003).  For the 
purpose of this thesis, living with prostate cancer is conceptualised as the stressor.  
 
Coping can generally be defined as cognitive and/or behavioural attempts to manage 
situations that are appraised as stressful to an individual (Roesch et al., 2005).  For 
the purpose of this thesis, coping is defined as “constantly changing cognitive and 
behavioural efforts to manage specific external or internal demands that are 
appraised as taxing or exceeding the resources of a person” (Lazarus and Folkman, 
1984, p.141).  Coping is one link in a stress process, contingent on appraisal, which 
involves judging the personal significance of a stressful encounter.  The assessment 
of coping is a description of the behaviours and cognitions of a person dealing with a 
stressful encounter.  Given the dynamic nature and complexity of coping, a range of 
standardised measures have been developed to measure different levels of 
specificity of coping and these include: dispositional coping styles (Carver et al., 
1989), situation specific coping (Folkman and Lazarus, 1988, McCrae, 1984, Bilings 
and Moos, 1984, Bilings and Moos, 1981) and cancer-specific assessment of coping 
(Watson et al., 1988a).  This is not an extensive list of coping instruments, but 
illustrates the different levels of assessment of coping.  Many of the measures of 
coping are inappropriate for use in prostate cancer patients because reliability and 
validity have not been established in this patient group and the content may be more 
relevant to general populations, and not for people affected by cancer.  In order to 
understand coping, it is necessary to examine coping in the context of the problems 
with which people with cancer are affected.      
 
In particular, the adjustment to cancer has been defined as the cognitive and 
behavioural responses that patients make to their diagnosis of cancer (Watson and 
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Homewood, 2008, Greer et al., 1989, Watson et al., 1988a).  Watson and colleagues 
in 1984 developed a standardised measure (Mental Adjustment to Cancer [MAC] 
Scale) to assess patients’ coping styles in relation to their cancer.    This instrument 
evaluates five dimensions of coping styles: fighting spirit, helplessness or 
hopelessness, anxious preoccupation, fatalism and avoidance.  This instrument has 
demonstrated reliability and validity in breast cancer (Carlsson et al., 2005, Inoue et 
al., 2003, Okano et al., 2001, Osborne et al., 1999, Schnoll et al., 1998), lung cancer 
(Mulcare et al., 2011, Uchitomi et al., 2003), laryngeal cancer (Johansson et al., 2011) 
and prostate cancer (Couper et al., 2010, Shields et al., 2004).  Therefore, the MAC 
Scale is considered the strongest candidate instrument for additional research in this 
area. 
 
Researchers using standardised instruments that provide an assessment of coping, 
including the MAC Scale, imply that people can be characterised by particular styles 
of coping, and that they continue to apply the same kind of coping strategies over 
time. This dispositional implication helps to reduce the complexity of coping 
assessment, but the uniqueness of situational-specific coping responses for people 
affected by cancer are not accurately measured, if at all.  One approach that may 
adequately capture coping responses over time could be case-based time series 
design methodologies to capture daily changing in coping cognitions and behaviours 
(Borckardt et al., 2008).  Extending the field using real time data collection 
methodologies would be a worthwhile step to understand the individual man’s 
coping experiences as they unfold over time.  
 
In the context of prostate cancer, little evidence details how men cope or has 
identified the relationship that links social support and coping to HRQoL (Bloch et 
al., 2007, Roesch et al., 2005).  Social support has recently been identified as an 
important target for potential psycho-social work aimed at improving HRQoL for 
men living with and beyond prostate cancer (Zhou et al., 2010a).  To advance the 
field further there is a need to establish the current evidence base to identify the 
mechanism effect that links social support to HRQoL for prostate cancer survivors.  
The purpose of this structured review was to describe the type of social support 
that can influence HRQoL and to identify the mechanism effect through which 
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social support influences HRQoL for men affected by prostate cancer.  Two 
research questions were used to guide this structured review:    
 
2.3 Review questions: 
1) What types of social support (perceived, received and satisfaction) influence 
HRQoL for men living with prostate cancer? 
2) What are the mechanism (main/moderation/mediation) effects of social 
support on HRQoL for men with prostate cancer? 
2.4 Methods 
A review of qualitative and quantitative research was generated to provide a 
broad overview of existing knowledge in this field (Webb and Roe, 2007).  
Guidance provided by the Centre for Reviews and Dissemination (2008) was used 
to promote rigour and transparency for the review methodology.  The steps 
involved included: 
1) Formulation of the research questions 
2) Developing review protocol  
3) Searching and identifying the research evidence 
4) Rating the studies for inclusion based on inclusion/exclusion criteria 
5) Data extraction using a pro forma sheet 
6) Quality assessment 
7) Results synthesis 
2.4.1 Searching and identifying the evidence  
The search architecture used the following key words: prostate cancer, prostate 
carcinoma, health-related quality of life, quality of life, social support, support 
groups, coping, adjustment, and psycho-social.  Databases searched were CINAHL, 
Medline, PsycInfo, ASSIA, and BNI, and key words were mapped to each electronic 
database using the appropriate MeSH (medical subject heading) term, or used free 
search terms around prostate cancer and social support.  Databases were searched 
from earliest date available using truncation, wildcards and Boolean logic.  Literature 
was searched from the earliest date available to ensure all relevant hits were 
identified.  Sourcing grey literature has been recognised as problematic (Webb and 
Roe, 2007) and, therefore, grey literature searches were performed in Index to 
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Theses, Google Scholar, and Google.  All of the publications were managed using the 
software package Endnote X4. 
2.4.2 Inclusion and exclusion of studies 
Level of evidence was categorised by the Department of Health in the National 
Service Framework (2001) (see table 2.2). This framework was used because it has 
been applied to peer-reviewed and non-peer reviewed research (Anderson et al., 
2004). 
Table 2.2 Evidence categories used by the Department of Health in the National Service 
Framework. 
Typologies of supporting evidence 
A1 Systematic reviews, which include at least one randomized control trial (RCT), e.g. systematic reviews 
from Cochrane. 
A2 Other systematic and high quality reviews. 
B1 Individual RCTs. 
B2 Individual non-randomized, experimental/interventional studies. 
B3 Individual well-designed non-experimental studies, controlling statistically if appropriate.  Includes 
case control, longitudinal, cohort, matched pairs or cross-sectional random sample methodologies, and 
well-designed qualitative studies, well-designed analytical studies including secondary analysis. 
C1 Descriptive and other research or evaluations not in B (e.g. convenience samples). 
C2 Case studies and examples of good practice. 
D Summary review articles and discussions of relevant literature and conference proceedings not 
otherwise classified. 
 
Based on this typology, this review included research at the level of C1-A1 for 
inclusion.  This review excluded studies at the level of evidence D-C2.  See table 2.3 
for summary of inclusion criteria and rationale.  For the purposes of this review and 
thesis a social support intervention is broadly defined as, an intervention that 
includes any of the following social support typologies: informational, emotional or 
instrumental support. 
Table 2.3 Inclusion criteria  
Criteria Rationale 
Levels of evidence C1-A1 
 
 
 
Does this title/abstract indicate how social support 
(types) can influence HRQoL for men with prostate 
cancer? 
 
Does this title/abstract identify the mechanism by 
which social support operates in relation to HRQoL 
for men with prostate cancer? 
 
(The publications had to address at minimum, one 
of the above questions to be considered for 
inclusion) 
Allowed for the inclusion of quantitative and 
qualitative methods, identifying the levels of 
evidence by study design.   
 
This is the 1
st
 key focus of the review; to establish 
which types of social support influence HRQoL for 
men with prostate cancer. 
 
This is the 2nd key focus of the review; to 
establish the mechanism through which social 
support operates in influencing HRQoL.  
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English text only 
 
 
Grey Literature 
 
Prostate cancer patients only 
 
 
Quantitiative studies must include a measure 
social support 
 
 
No geographical limitation  
 
Budget constraints and the costs involved for 
translation 
 
To try and minimise the risk of publication bias 
 
This is the primary context of the review; 
therefore other cancer sites would be excluded. 
 
To clearly identify the mechanism effect of social 
support 
 
To capture a broad range of social support 
evidence worldwide. 
 
The publications (titles and abstracts) found by the search strategy were reviewed 
independently by 3 members of the research team (2 of the researcher’s Ph.D. 
supervisors and the researcher) using a pro forma checklist to make decisions to 
include or not include studies, based on the criteria presented in Table 2.3.  
Publications meeting the inclusion criteria were retrieved in full text.   
2.4.3 Quality assessment 
Two quality assessment appraisal tools were used; one quantitative appraisal tool 
and one qualitative appraisal tool (Shaw et al., 2009).  The quality assessment 
appraisal tools enabled a plethora of methodologies to be evaluated within this 
structured review. 
2.4.4 Data extraction  
Key information from the studies was extracted using narrative data extraction 
sheets.  Data extraction was developed based on recommendations from Cochrane 
Guidelines (2009) and guided by the review questions (see table 2.4). 
Table 2.4 Data extraction 
· Unique reference number (for reviewers reference) 
· Authors 
· Year of publication 
· Country  
· Overall aim of the study 
· Participants’ characteristics (age, race, education, cancer stage, cancer treatments)  
· Number of patients approached, and the number of patients consented (identify the 
possibility of selection bias) 
· Methods – study design, time points for data collection, measures (variables in the study), 
intervention details, method of randomization, and participants’ attrition rates. 
· Overall findings and conclusions 
· Limitations 
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2.4.5 Evidence synthesis 
The review used a narrative synthesis and tabulation of primary research studies to 
generate broad findings and conclusions.  More specifically, the review undertook 
the following steps: data reduction (sub-group classification based on levels of 
evidence and the review questions), data comparison (iterative process of making 
comparisons and identifying relationships) and finally, conclusion and verification 
(checked primary data sources for accuracy and confirmability) (Whittemore, 2005).  
This process has been applied to several structured literature reviews, including 
cancer (Flinkman et al., 2010, Da Silva et al., 2010, Kennedy et al., 2008).      
2.5 Findings - overview of studies 
Of the 107 publications retrieved from the search, 74 were excluded following the 
application of the inclusion/exclusion criteria (see figure 2.2).  This left 33 
publications reviewed in full, and 22 articles were excluded (Queenan et al., 2010, 
Galvao et al., 2010, Christie et al., 2009, Parker et al., 2009, Penedo et al., 2007, 
Monga et al., 2007, Culos-Reed et al., 2007, Northouse et al., 2007b, Berglund et al., 
2007, Siegel et al., 2007, Luszczynska et al., 2007a, Voerman et al., 2007, Jones et al., 
2006, Penedo et al., 2006, Kinsinger et al., 2006, Steginga et al., 2005, Eton et al., 
2004, Weber et al., 2004, Lepore et al., 2003, Robinson et al., 1999b, Krongrad et al., 
1996) because they did not meet inclusion criteria (see figure 2.2).  This left 11 
publications which fully met the inclusion criteria: two intervention studies, six 
prospective longitudinal surveys and three cross-sectional surveys.  An inter-rater 
reliability analysis using the Kappa statistic was performed to determine consistency 
among reviewers using the inclusion/exclusion proforma.  The results demonstrate 
almost perfect agreement, Kappa= 0.922, p<0.001 (Viera and Garrette, 2005).   
 
Eleven quantitative designs and no qualitative publications were included in the 
review.  This is a relatively small number of publications and indicates the lack of 
research in this field.  The studies were mainly conducted in America and European 
countries, but none of the studies were conducted in the UK.  Samples sizes varied 
from N=30 to N=511 with a total sample N=1847 across all of the publications.  Based 
on the Departments of Health (2001) typologies of evidence, most of the publications 
were classified as B2 (interventional studies), B3 (longitudinal surveys) and C1 (cross-
sectional convenience samples). 
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150 records identified through database searching 7 records identified through other sources
50 duplicates removed
Identification
Screening
107 records (titles and abstracts) screened against the 
inclusion/exclusion criteria
74 records excluded
33 full text articles assessed for eligibility against the 
inclusion/exclusion criteria
22 full text articles excluded for the 
following reasons:
N=1 sample included mixed cancer 
sites
N=10 context of the study did not 
test main /moderation/mediation 
effects of social support on HRQoL
N=11 did not measure social support
11 Studies included
Eligibility
Included
 
Figure 2.3 PRISMA: Flow of information through the different phases of the social support 
review (Moher, 2009) 
 
All of the publications included in this review reported findings pertinent to 
understanding the main effects of social support on HRQoL.  Only 4 publications 
(Zhou et al., 2010a, Scholz et al., 2008, Carmack Taylor et al., 2006, Roberts et al., 
2006) reported findings relevant to understanding the moderation and mediating 
effects of social support on HRQoL.  Table 2.5 provides an overview of the included 
publications and full data extraction is available in appendix 2.1.   
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Table 2.5 Overview of studies included in this review 
Reference Country Design Sample and trajectory Social support measurement Main 
effect 
tested 
Moderation/m
ediation effect 
tested 
Results 
(Carmack 
Taylor et al., 
2007, 
Carmack 
Taylor et al., 
2006) 
 
(Weber et 
al., 2004) 
 
 
 
 
(Scholz et al., 
2008) 
 
 
 
 
(Roberts et 
al., 2006) 
 
 
 
(Kershaw et 
al., 2008) 
 
 
 
(Andel et al., 
2004) 
 
 
 
 
USA 
 
 
 
 
 
 
USA 
 
 
 
 
 
Germany 
 
 
 
 
 
USA 
 
 
 
 
USA 
 
 
 
 
Netherland
s 
 
Intervention study - 3 
groups:  1) lifestyle 
programme, 2)  
educational support, 
3) control 
 
 
Intervention study –  2 
groups:   1) dyadic 
peer supportive 
partners, 2) control 
 
 
Prospective 
longitudinal survey 
 
 
 
 
Prospective 
longitudinal survey 
 
 
 
Prospective 
longitudinal survey 
 
 
 
Prospective 
longitudinal survey 
N=134 men receiving hormone 
therapy continually for 1 year 
(mean time on HT 32.7 months).  
Time since diagnosis not reported. 
 
 
 
N=30 men treated by laparoscopic 
radical prostatectomy, 6 weeks 
post-surgery 
 
 
 
N=77 men treated with 
laparoscopic radical prostatectomy, 
2 weeks and 6 months after surgery 
 
 
 
N=93 men with localised disease, 
various treatment modalities.  Time 
since treatment range 7-120, mean 
46.7 days, SD not reported. 
 
N=134 men with various 
treatments and stages of disease.   
Time since diagnosis not reported. 
 
 
N=138 men treated with radical 
prostatectomy and external beam 
radiotherapy for localised and 
locally advanced disease.  Before 
treatment and 1 year follow-up 
 
Perceived social support 
(Interpersonal Support 
Evaluation Checklist) (Cohen 
and Hoberman, 1983) 
 
 
 
Received social support 
(Inventory of Social Support) 
(Barrera et al., 1981) 
 
 
 
Received and provided social 
support (Berlin Social 
Support Scale)(Schulz and 
Schwarzer, 2003) 
 
 
Perceived social support 
(Social Provisions Scale) 
(Curtona and Russell, 1987) 
 
 
Perceived social support 
(Personal Resource 
Questionnaire) (Brandt and 
Weinert, 1981) 
 
Perceived social support 
(Social Support 
Questionnaire) (Sarason et 
al., 1983) 
 
Yes 
 
 
 
 
 
 
Yes 
 
 
 
 
 
Yes 
 
 
 
 
 
Yes 
 
 
 
 
Yes 
 
 
 
 
Yes 
 
Yes 
 
 
 
 
 
 
No 
 
 
 
 
 
Yes 
 
 
 
 
 
Yes 
 
 
 
 
No 
 
 
 
 
No 
 
No significant differences were found 
between the study conditions on HRQoL.  
Moderation effect – participation in a 
group benefited those with greater 
anxiety and depression or with the least 
social support compared to the control.   
 
No significant changes in social support 
over time.   No significant differences 
were found between the study conditions 
on HRQoL.   
 
No main effects on HRQoL.  Participants 
with low HRQoL (T1) was associated with 
high HRQoL (T2) when they had more 
social support (T1).   
 
 
 
Social support was significantly related to 
HRQoL.  Coping mediated the relationship 
between social support and HRQoL. 
 
Social support did not have a main effect 
with HRQoL.  Social support had a 
significant relationship with coping.  
Coping and appraisal predicted HRQoL 
 
Social support and coping were associated 
with HRQoL. 
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Reference Country Design Sample and trajectory Social support 
measurement 
Main 
effect 
tested 
Moderation
/mediation 
effect tested 
Results 
(Visser et al., 
2003) 
 
 
 
 
(Zhou et al., 
2010a, Zhou 
et al., 2010b) 
 
 
 
 
 
(Poole et al., 
2001) 
 
 
 
(Rondorf-
Klym and 
Colling, 
2003) 
 
(Mehnert et 
al., 2010) 
Amsterdam 
 
 
 
 
 
USA 
 
 
 
 
 
 
 
Canada 
 
 
 
 
USA 
 
 
 
 
Germany 
 
Prospective 
longitudinal survey 
 
 
 
 
Prospective 
longitudinal survey 
 
 
 
 
 
 
Cross-sectional survey 
 
 
 
 
Cross-sectional survey 
 
 
 
 
Cross-sectional survey 
 
N=23 men with prostate cancer 
(clinical variables not reported) and 
N=37 men with benign prostatic 
hyperplasia.   Before diagnosis and 
3 months follow-up) 
 
N=180 men with localised disease 
treated with radical prostatectomy 
and external beam radiotherapy. 
10.6 months (SD 4.8) since 
treatment, 15.4 (SD 6.2) months 
since diagnosis. 
 
 
N=240 men with different 
treatment modalities, stages not 
reported.  27 (SD 34.7) months 
since diagnosis. 
 
N=88 men treated with radical 
prostatectomy for localised 
disease.  12-24 months after 
surgery 
 
N=511 men treated with radical 
prostatectomy.  27 month (mean) 
since surgery. 
 
Perceived social support 
(Social Support 
Questionnaire) (Sarason et 
al., 1983) 
 
 
Perceived social support 
(Social Support 
Questionnaire) (Sarason et 
al., 1983) 
 
 
 
 
Perceived social support 
(Social Support 
Questionnaire) (Sarason et 
al., 1983) 
 
Perceived social support 
(Personal Resource 
Questionnaire) (Brandt and 
Weinert, 1981) 
 
Perceived social support 
(Illness Specific Social 
Support) (Revenson et al., 
1991) 
 
Yes 
 
 
 
 
 
Yes 
 
 
 
 
 
 
 
Yes 
 
 
 
 
Yes 
 
 
 
 
Yes 
 
No 
 
 
 
 
 
Yes 
 
 
 
 
 
 
 
No 
 
 
 
 
No 
 
 
 
 
No 
Social support and coping was related to 
HRQoL. 
 
 
 
 
Social support was a main predictor of 
HRQoL. The relationship between Social 
support and HRQoL was partially 
mediated by perceived stress.  Social 
support and HRQoL was partially 
mediated by coping.  
 
 
No difference between attenders (support 
group) and non-attenders for coping,  
HRQoL or social support scores. 
 
 
Social support had a main effect on 
HRQoL. 
 
 
 
Social support had a main effect on 
HRQoL.   
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2.5.1 Findings  
 
Interventions (two studies) 
Two interventions studies (Carmack Taylor et al., 2007, Weber et al., 2004) were 
reviewed.  One study (Carmack Taylor et al., 2007) used a lifestyle/educational 
intervention and the other study (Weber et al., 2004) used peer support as the 
intervention component to improve HRQoL.  Carmack Taylor and colleagues 
developed three study conditions for men undergoing hormone therapy: 1) lifestyle 
programme, 2) education support, and 3) standard care group.  The lifestyle 
programme encouraged men to take regular exercise, set goals, supported men to 
overcome barriers, and educated men on caloric intake and exercise. The educational 
support group was based on group discussion on prostate cancer topics such as:  
diet, exercise, side-effects of hormone therapy, and sexuality.  The control condition 
was standard care, although there was no description of what standard care was.  No 
statistically significant differences in HRQoL (as measured by SF-36) scores were 
found between the 3 groups from baseline (men on hormone therapy for 32.7 
months, mean time) and at six and twelve months.  The researchers did not perform 
mediation analyses of social support and physical activity because HRQoL did not 
change over time, which was the dependent variable of interest.  Furthermore, 
perceived social support did not significantly change at six or twelve months.  
However, at 6 months, participation in a group (lifestyle or educational support) only 
benefited men who had the worst distress (anxiety and depression) or the lowest 
perceived social support scores at baseline, compared to the control group (Carmack 
Taylor et al., 2007).  This result indicates a moderating (buffering) effect because 
social support was most helpful to men when they experienced high levels of stress.  
This moderating effect is linked to the stress buffering model, in that social support is 
only helpful to individuals when under high levels of stress. 
 
These finding should be viewed with caution as there are a number of limitations to 
Carmack Taylor’s study.  In total, 948 men were invited to take part in the study, but 
only N=134 consented to take part, which is a 14.1% consent rate.  Differences 
between men who consented to take part and men who did not consent were not 
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assessed.  Therefore, recruitment bias is possible and the findings may not be 
generalisable to the wider population.  This study was also underpowered and was at 
risk of a type two statistical error.    
 
The second intervention study included in this review (Weber et al., 2004) tested the 
effects of a dyadic peer support (one-to-one) in a population (N= 30) of men treated 
by radical prostatectomy.  The supportive partners (N=10) were long-term survivors 
of prostate cancer (9 white, 1 black), with a mean age 68.2 years, and a stable PSA for 
one year prior to the study.  The supportive partners underwent a 2-hour training 
session, but the researchers did not specify who delivered the training.  Each dyad 
met eight times during an eight-week period in a relaxed atmosphere where a 
private conversation could take place about problems that may have been 
encountered.  Overall, no statistically significant intervention effect was found on 
HRQoL, and no difference was found for received social support scores at four and 
eight weeks post intervention.  The findings from this study (Weber et al., 2004) did 
not identify a main effect of social support and moderation/mediation effects were 
not tested.  The findings from this study are difficult to generalise to the wider 
prostate cancer population because the results are limited to men who were mostly 
white, married and educated, and all treated by radical prostatectomy.  This 
intervention study (similar to Carmack Taylor) had a high consent refusal rate (70%) 
(Weber et al., 2004).  No statistical comparisons were reported to check for 
recruitment bias between the men who had consented to the study and those men 
who did not consent.  Caution is taken in the interpretation of the results as medical 
or demographic variables may have biased recruitment.  Participant attrition was not 
identified in Weber’s study and 16% of participant attrition was reported in Carmack 
Taylor’s study.  Carmack Taylor did not identify the form of analysis that they 
implemented, for example, completed cases versus intention to treat (Schulz et al., 
2010).  Consequently, bias maybe possible if the participants lost from the study 
were different from those included in the results, but this remains unknown. 
 
There are two common findings across both intervention studies reviewed: 1) no 
overall intervention effect on improving HRQoL, and 2) the high refusal rate of 
participation in the studies.  There are a number of possible explanations for the 
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similarities between the findings.  One explanation to account for no intervention 
effect may be due to aggregate group level statistics.  Thus, the interventions may 
have been effective in improving HRQoL for some individuals, but because of the 
average group statistics used; such an effect was not detected.  This seems a likely 
explanation because Carmack-Taylor and colleagues demonstrated, based on 
secondary moderation analyses, that their intervention was only beneficial for men 
in distress or with limited social support at baseline (Carmack Taylor et al., 2007).  
Targeting future interventions to select participants who are in most need may be 
helpful to tailor interventions to the individual man’s needs (Cockle-Hearne and 
Faithfull, 2010).  A further point for consideration was the low consent rates across 
both intervention studies.  Noteworthy, both studies did not report patient 
involvement in the intervention design, and therefore may not have addressed men’s 
preferences of the intervention or the needs of these men. Thus, the studies do not 
reflect the Medical Research Council’s (Craig et al., 2008) framework for complex 
interventions because of the lack of patient involvement in the development of the 
interventions.    
 
In summary, the findings from (Weber et al., 2004) did not identify a main effect of 
received social support, whereas Carmack Taylor identified at six months post-
treatment, participation in a group (lifestyle or educational support) only benefited 
men who had the worst distress (anxiety and depression) or the lowest perceived 
social support scores at baseline, compared to the control group (Carmack Taylor et 
al., 2007).  Carmack Taylor’s result indicates a moderating (buffering) effect because 
social support was helpful to men when they experienced high levels of stress.    
 
Cross-sectional and longitudinal surveys (nine studies) 
All of the reviewed studies used standardised instruments to measure social support.  
Eight of the nine studies measured perceived social support and one study measured 
received social support.  Perceived social support was found to have a main effect on 
HRQoL for a number of studies (Zhou et al., 2010a, Mehnert et al., 2010, Roberts et 
al., 2006, Van Andel et al., 2003, Visser et al., 2003, Rondorf-Klym and Colling, 2003).  
These studies provide support for the main effects theoretical model (Cohen et al., 
2000), in that perceived social support had a positive effect on improving HRQoL for 
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prostate cancer survivors.  Received social support provision was measured in one 
study only (Scholz et al., 2008) but it did not have a main effect with HRQoL.  Thus 
the construct of perceived social support appears to be more strongly related to 
HRQoL compared to received social support on HRQoL, and this has been reported 
elsewhere (Helgeson et al., 2006).   However, caution is given in the interpretation of 
some of the findings due to some methodological limitations.  A common limitation 
to three studies (Kershaw et al., 2008, Roberts et al., 2006, Rondorf-Klym and Colling, 
2003) was that the study samples were not representative of the prostate cancer 
population and, therefore, this limited the generalisabilty of the findings.  
Specifically, minority groups were under-represented in the study samples, for 
example, men of different ethnic groups and of a lower educational level.  A further 
difficulty in the interpretation of the findings from three studies (Zhou et al., 2010a, 
Kershaw et al., 2008, Roberts et al., 2006) was that baseline social support and 
HRQoL was not assessed before treatment. Consequently, it is difficult to identify 
change over time and to understand the influences of coping and social support on 
HRQoL at diagnosis, which can be a particularly difficult and traumatic time for men.   
 
Only four publications (Zhou et al., 2010b, Scholz et al., 2008, Carmack Taylor et al., 
2007, Roberts et al., 2006) illustrated moderation and mediation effects through 
which social support operated with HRQoL.  Carmack Taylor conducted a moderation 
analysis and identified that participation in a group benefited participants with the 
greatest distress (anxiety and depression), or with least social support, compared to 
the control group (see appendix 2.1 for full details of the intervention).  Although this 
study demonstrated findings that may be broadly related to the buffering hypothesis, 
the limitation with these data is that they do not expand knowledge and 
understanding about how coping and social support are linked to HRQoL.  A further 
study (Scholz et al., 2008) found a similar moderation effect.  Scholz and colleagues 
performed simple slope analysis (Aiken and West, 1991) based on 1 standard 
deviation (SD) above and 1 SD below the mean values for the moderator variable 
(received social support).  Findings demonstrated that low HRQoL (at time 1) was 
associated with a higher HRQoL (at time 2), when social support is high (at time 1), 
whereas, when HRQoL is high (at time 1), social support had little influence on 
improving HRQoL (at time 2).  Scholz’s findings have similar interpretation to the 
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buffering hypothesis because this theory states that social support is only helpful 
under conditions of high stress (Cohen et al., 2000).  Both studies (Scholz et al., 2008, 
Carmack Taylor et al., 2007) have a similar interpretation to the buffering hypothesis 
in that social support is only helpful under conditions of high stress (Cohen et al., 
2000). 
 
Other researchers (Roberts et al., 2006) examined how perceived social support and 
coping influenced HRQoL in a population (N=89) of men with localised disease (mixed 
treatment modality).  The findings identified the main effects of social support and 
coping (positive coping) on HRQoL, but also mediation was demonstrated.  Data 
identify that social support (Time 1, several months after treatment) and HRQoL 
(Time 2, 3 months follow-up) were partially mediated by positive coping (Time 1) 
(Sobels test, Z=2.84, p=.0.004).  These data suggest that perceived social support was 
related to HRQoL because of improved coping.   However, Roberts did not test 
buffering (moderation) effects of social support and, therefore, these data provide 
support for the main effects model, but not for the stress buffering model.  This 
study has provided some evidence of a causal pathway linking social support and 
coping to HRQoL.  There are a few limitations to Robert’s study that should be noted.  
The researchers did not have adequate representation from individuals from 
minority groups and of lower socio-economic status; predominantly the study sample 
was white, married, educated and of a higher socio-economic status.  Furthermore, 
the study was limited to men with localised disease, and therefore the influences of 
coping and social support on HRQoL for men with more aggressive cancer (locally 
advanced and metastatic disease) remains unknown.  Finally, baseline evaluations 
were assessed following completion of initial treatment; therefore these data do not 
detail the mechanism of coping and social support on HRQoL during critical periods 
surrounding diagnosis and follow-up testing, for example, at six months follow-up.   
 
More recently, researchers assessed the influence of perceived social support and 
coping on HRQoL for men with localised prostate cancer (Zhou et al., 2010b).  Data 
demonstrated a main effect of perceived social support (β=0.15, p<0.01) at baseline 
(approx 10 months post-treatment) on HRQoL at 2 year follow-up.  Furthermore, 
mediation analyses were performed to examine whether positive coping mediated 
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the relationship between perceived social support and HRQoL.  Data identified that 
the relationship between social support and HRQoL was partially mediated by 
positive coping (Sobels test, Z= -2.29, p<.05).  These findings suggest that social 
support is related to HRQoL because of positive coping efforts.  In addition, perceived 
social support and positive coping were longitudinal predictors of HRQoL.  This study 
targeted post-treatment adjustment and, therefore, the researchers did not assess 
the availability of social support and coping styles before treatment.  These data 
cannot determine the extent to which having adequate social support and coping 
styles during the early cancer trajectory may relate to long-term adjustment in this 
population.   This study did not examine the relationship between social support and 
negative coping efforts and thus, additional work would enrich understanding of the 
influence of social support and coping (positive and negative) on HRQoL.   
 
In summary, main effects of perceived social support on HRQoL have been identified 
across many of the reviewed studies.  Received social support did not have a main 
effect on HRQoL but operated through moderation effects.  Finally, social support 
was significantly related to HRQoL because of positive coping efforts.  
2.6 Discussion  
In this structured review the types and effects of social support on influencing HRQoL 
for men with prostate cancer were considered.  The importance of social support as a 
resource for people affected by cancer is not a new concept, but specifically, prostate 
cancer survivors have reported a lack of support for their unmet physical and 
psychological problems (Ream et al., 2008, Boberg et al., 2003, Lintz et al., 2003).  
HRQoL is likely to be affected by the psychological and social factors that unfold over 
time as men manage, learn from, and adjust to the changes caused by prostate 
cancer and its associated treatments (Roberts et al., 2006).  It is likely that social 
support needs will also change over time.  Understanding the mechanism effect of 
how coping and social support operate on HRQoL over time can help to identify men 
who are at high risk and suggest directions for intervention.  This concept has 
recently been supported elsewhere (Roesch et al., 2005).  
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This review has illustrated a pressing need for additional work to understand the 
influences of psycho-social factors on men’s HRQoL.  To this end, current health care 
policy in the UK (Department of Health Macmillan Cancer Support & NHS 
Improvement, 2010, The Scottish Government, 2008, Scottish Executive, 2004) has 
acknowledged the need for tailored support for individuals with cancer and details 
the need for additional research in this field.  This review has provided evidence 
which has addressed the two review questions, but this field is still in its infancy, is 
under-developed, and under-researched.  In relation to the first research question, 
the reviewed data have identified that perceived social support and received social 
support has been found to influence HRQoL for prostate cancer survivors.  None of 
the reviewed studies evaluated the influence of satisfaction with social support on 
HRQoL.  None of the studies identified how emotional, informational and 
instrumental facets of support provision may affect HRQoL or change over time.  
Data which detail changes in social support (informational, emotional, instrumental) 
provision for men throughout the prostate cancer journey would provide useful 
insights into how men can be better supported.  
 
Within the general cancer social support literature, there is evidence to suggest that 
informational, instrumental and emotional support are positive resources for 
adjustment to cancer, but some cancer patients have voiced negative/unhelpful 
experiences of social support.  For people affected by cancer sources of unhelpful 
social support have been identified from: family, healthcare professionals, friends, 
work colleagues, and strangers (Dunkel-Schetter, 1984).  Examples of unhelpful 
support have been described as doctors appearing unfeeling towards a patient’s 
emotions, or when clinical care has been provided without appropriate informational 
or emotional support (Dunkel-Schetter, 1984).  Other areas of unhelpful social 
support include sources of informational support.  There is some evidence to suggest 
that when information is provided by family members it can be viewed as unhelpful; 
whereas, when informational support has been provided by healthcare professionals 
it is generally viewed as more helpful (Dunkel-Schetter, 1984; Wortman, 1984).  For 
people affected by cancer positive experiences of social support have been described 
as the expression of feelings (emotional support) “being with me when I needed 
somebody”, or the appropriate provision of informational support “he spelled it right 
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out for me, he told me it might not be malignant or it might be, and he told me the 
different types of treatment I might have … not in medical terms, but in lay terms you 
could understand” (Dunkel-Schetter, 1984 p.85).  By drawing on the broader social 
support literature in cancer, it has clearly demonstrated that not all provisions of 
social support for people affected by cancer are viewed as positive or helpful.  This 
review has identified a dearth of prostate cancer research, whereby little is known 
about the relationship between informational, instrumental and emotional support 
on HRQoL.  As a recommendation for future social support research in prostate 
cancer, researchers should evaluate the following typologies of social support: 
informational, emotional, and instrumental support to inform the existing evidence-
base.         
 
The findings which addressed the second review question (what are the mechanism 
[main/moderation/mediation] effects of social support on HRQoL?) identified that 
social support can influence coping and HRQoL through main, moderating, and 
mediating effects.   Specifically, several studies (Mehnert et al., 2010, Roberts et al., 
2006, Visser et al., 2003, Rondorf-Klym and Colling, 2003) provided support for the 
main effects model, thus identifying the benefits of perceived social support on 
HRQoL.  The provision of received social support did not have any main effects with 
HRQoL, but operated through moderation analysis.  Several publications provided 
support for the stress buffering model (Scholz et al., 2008, Carmack Taylor et al., 
2007), although for one (Carmack Taylor et al., 2007), this was not the implicit aim of 
the study.  
 
A major limitation that featured across the majority of the studies was the absence of 
a multi-dimensional inventory of the social support constructs, namely: perceived 
social support, received social support and satisfaction with social support, within the 
context of each individual study.  Nine of the eleven studies measured perceived 
social support only, and two studies measured received social support.  Therefore, 
existing evidence is largely restricted to the assessment of perceived social support.  
Perceived social support has been found to reflect more of personality disposition 
(Sarason et al., 1986) rather than actual social support transitions, and thus 
intervention design can be difficult to design for personality-level constructs.   
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To overcome this constraint, additional work should include a multi-dimensional 
cancer-specific inventory of the social support constructs to further develop and 
refine the propositions of social support theory.   This represents a considerable 
knowledge gap and additional research would help to clarify the mechanism effect 
through which the social support constructs influence coping with prostate cancer, 
and its relationship with HRQoL.  Developing empirical research which is theoretically 
driven is a prerequisite to the Medical Research Council’s framework for complex 
interventions (Craig et al., 2008), and therefore, developing and refining our 
theoretical understanding of the social support constructs has never been so 
important.   
 
The lack of studies conducted in the UK suggests room for improvement and 
additional research in this field.  Furthermore, data only support aggregate group 
level effects.  Healthcare research has almost been exclusively restricted to aggregate 
group level effects, and has neglected the importance of within-person experience 
and change over time.   One of the major limitations of the studies included in this 
review is that of average effects.  Thus, applying theoretical constructs to individuals 
will enrich and expand empirical reach to tailor interventions at the individual level of 
change (Borckardt et al., 2008).  The other major limitation of existing research in this 
field is retrospective memory recall.  Questionnaires are prone to serious errors and 
biases as a result of autobiographical memory, and this places demands on the 
participant to accurately recall their experiences (for example, recalling experiences 
in the past month) (Shiffman et al., 2008, Stone et al., 2005, Stone et al., 2004, Stone 
et al., 2003a, Stone and Shiffman, 2002).  When participants are asked how they felt 
or how often some event occurred, they rely on heuristic strategies to estimate an 
answer; they will rely on experiences that are important for them or recent, to 
provide an answer to the question (Schwartz and Stone, 1998).  Consequently, the 
real-life validity of the data presented from questionnaire based studies is unknown 
(Jones and Johnston, 2011). In addition, ecological fallacy can also be problematic in 
the interpretation of group level questionnaire data, whereby inferences about the 
nature of “individuals” have been incorrectly based on aggregate statistics (Bowling, 
2002).  To overcome the limitations of aggregate group level effects and 
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retrospective memory recall, one approach that could be used to advance the field 
further is case-based time series studies.     
 
Case-based time series studies (Molenaar, 2004) can form the pre-clinical and 
theoretical modelling stages of the Medical Research Council’s framework for 
complex interventions (Craig et al., 2008).  The case-based time series methodology 
is low-cost and has the potential to be very effective in facilitating the early 
development stages of interventions.  Empirically, testing within-person change over 
time would demonstrate the optimum types of social support that influence HRQoL, 
whilst assessing changes in coping efforts and self-management behaviours for men 
living with and beyond prostate cancer and their influence on HRQoL.    
 
Both intervention studies that were reviewed used peer support to form part of the 
intervention (Carmack Taylor et al., 2007, Weber et al., 2004) but had poor efficacy in 
improving HRQoL.  Interestingly, evidence demonstrated that men with prostate 
cancer infrequently attend support groups (Krizek et al., 1999) and men have 
reported little interest in using psycho-social services (Krizek et al., 1999).  Moreover, 
users (men with prostate cancer) of peer support did not have increased HRQoL, 
more satisfaction, or different coping styles, compared to non-users of peer support 
(Poole et al., 2001).  Whilst the benefits of peer support have been acknowledged 
elsewhere (Steginga et al., 2004), currently this is an emerging evidence base and it is 
difficult to reach firm conclusions about the efficacy of this type of support provision.  
Additional research in this field should include an evaluation of cancer support 
services to provide a holistic assessment of social support for this patient group.      
 
A restriction to the evidence base presented in this review was the geographical 
specificity, because the studies were predominately conducted in the USA.  Often the 
samples were mostly white, married, and well educated.  Thus the findings are not 
generalisable to minority groups or worldwide.  Despite these limitations, this is an 
emerging body of evidence that has identified main, moderation and mediation 
effects of social support on HRQoL prostate cancer survivors. Prostate cancer is now 
the most common cancer diagnosed in men in the UK, and the number of men set to 
deal with the aftermath consequences of the disease and its treatments are set to 
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rise.  Therefore, understanding the influence of social support and coping on HRQoL 
for men affect by prostate cancer is a priority which may contribute towards 
understanding the needs of these men.   
     
One of the major challenges of this structured review was combining heterogeneous 
methodologies.  Despite this challenge, this review has enabled a broad summary of 
the evidence which has facilitated a refinement of future research directions in this 
area.  
2.7 Conclusions and research direction 
Few prospective longitudinal research designs have been implemented in this field to 
evaluate changes in social support provision.  It seems likely that the types of social 
support needs will change throughout the cancer trajectory.  Additional work is 
needed to assess how social supportive experiences change over time and this could 
be achieved through prospective longitudinal designs (to assess aggregate group 
effects) and case-based time series designs (to assess within-person change over 
time). Evaluating average group level effects and within-person change over time is 
an innovative approach which may expand and refine the propositions of social 
support theory.  
 
A suitable theoretical framework to advance research in this area is the stress 
buffering model because it links social support and coping to HRQoL.  Few studies 
have tested this theoretical framework within samples of prostate cancer survivors. 
Importantly, the stress buffering model will enable the effects of social support to be 
explored with coping and health-related outcomes for this patient group.  In 
addition, future research should test main and mediation effects between the 
relationship of social support and coping on HRQoL, because developing an 
understanding of the mechanism effect that links coping and social support to HRQoL 
will facilitate the development of appropriately targeted interventions that are 
theoretically driven.   
 
However, social support may not only improve HRQoL, but may also help men in 
their pursuit to self-manage their condition.  Chapter 1 detailed that men living with 
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prostate cancer (all stages of cancer) can experience reduced HRQoL over time, but 
little is known about men’s self-management behaviours, or the relief achieved from 
self-management.  Chapter 3 will review empirical evidence to identify men’s self-
management behaviours and establish how they change over time. 
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3.0 Self-management 
3.1 Abstract  
Background 
Self-management for people affected by cancer is increasingly being recognised as a 
fundamental component of effective management of cancer care as a long-term 
condition.  Men are keen to engage as active partners in the management of their 
condition but men have voiced a number of unmet support needs that make 
effective self-management problematic.  Identifying men’s self-management 
behaviours and evaluating how self-management changes over time may provide 
valuable insights into how men can be better supported to self-manage. 
Aim 
To review existing research studies that have identified the self-management 
behaviours for men affected by prostate cancer and that have assessed whether self-
management changes over time.   
Methods 
A structured review of the literature was performed.  Databases searched included: 
DARE, CDSR, Medline, CINAHL, PsycINFO, and ASSIA.  Included studies detailed self-
management behaviours or assessed changes in self-management over time for men 
affected by prostate cancer. 
Results 
111 publications were retrieved from the search and 5 publications were included.  
Men performed a variety of self-management behaviours for psychological problems 
and for a number of physical symptoms.  Only one study assessed changes in self-
management behaviours over time and was limited to men treated by radiotherapy.           
Conclusion  
Additional research is needed to identify men’s self-management behaviours based 
on different clinical characteristics and different support needs that will generate 
valuable insights into how men can be better supported to self-manage. 
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3.2 Introduction 
Less than 20% of men diagnosed with prostate cancer will die from this disease, and 
93% of men will survive for at least 5 years post-diagnosis (Jemal et al., 2011, Roesch 
et al., 2005).  Therefore, quality of life issues and coping with the chronic physical and 
psychological problems (as identified from chapter 1 and 2), have never been so 
important (Guedea et al., 2009) in this patient group.  Prostate cancer is managed as 
a chronic illness requiring long-term surveillance (Oliffe et al., 2009, Hoffman et al., 
2006), and in some cases, long-term treatment (Fransson, 2008, Ott and Fulton, 
2005).   
 
The Institute of Medicine (McCorkle et al., 2011) identifies six major phases within 
the cancer care continuum: prevention, early detection, diagnosis, treatment, 
survivorship and end-of-life care. This continuum illustrates that cancer care extends 
beyond the treatment phase and requires long-term care provision.  Worldwide 
enablement of self-management for people affected by cancer is increasingly being 
recognised as a fundamental component of effective management of cancer care as 
a long-term condition (McCorkle et al., 2011, Department of Health Macmillan 
Cancer Support & NHS Improvement, 2010, Fenlon and Foster, 2009, Wilson, 2008).    
With an increase in the number of men living with and beyond prostate cancer, 
patient engagement in self-management has been advocated as a way of improving 
physical and psychological well-being (Campbell et al., 2011, McCorkle et al., 2011, 
The Scottish Government, 2008, Wilson, 2008, Beckmann et al., 2007).  
 
However, the terms self-care, self-management, and self-management support are 
often confused, but this is a complex area, although definitions are improving (Jones 
et al., 2011, Wilson, 2008, Beckmann et al., 2007, Earle, 2007).  The following 
continuum illustrates why such terms often become confused and are often used 
interchangeably, but they do represent similar notions.  Self-care can be viewed as a 
continuum starting from the individual responsibility that people take in managing 
daily lifestyle choices, maintaining health and preventing illness (Chambers, 2006).  
Next along the continuum are behaviours that are associated with the treatment of 
minor ailments (Porteous et al., 2007), and the final point on the continuum has been 
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described as healthcare professionals together with patients, helping individuals to 
cope with long-term conditions.  Self-care or self-management have been defined 
together as a combined term as, “an individual’s efforts to advance optimal health, 
prevent illness, recognise symptoms as early as possible, and cope with or manage 
chronic conditions” (Curtin and Mapes, 2001, p386).  Thus, defining self-care and 
self-management together only conflates the confusion in the literature.     
 
Others have defined the terms separately, as self-care refers to an individual’s 
actions focussing on preventative measures in order to gain or maintain a level of 
health, whereas self-management is focussed upon disease management generally 
guided at some point by a clinician and involves the individual making therapeutic 
adjustments to a treatment regime (Wilson, 2008).  Specifically, Wilson’s definition of 
self-management is suitable within cancer care because this requires long-term 
planning and on-going relationships between cancer patients and their care 
providers. Clark (1991) acknowledges that, in general, self-care is interpreted as 
preventative behaviours that are performed by healthy people at home, whereas 
self-management is a term used to reduce the impact of disease and to cope with the 
psychosocial problems in collaboration with healthcare providers.   
 
Self-management can be suggested as a forming of coping (Jones et al., 2011).   The 
assessment of self-management in this patient group may provide an evaluation of 
coping that is cancer-specific, treatment-specific and symptom-specific (Ahmad et al., 
2005).  There is a similarity between self-management and coping, in that, they both 
involve cognitive and/or behavioural attempts to manage the problems associated 
with cancer and its treatment.   Conceptually, the way in which a person copes or 
appraises the physical and psychological problems in everyday life will influence the 
type of self-management behaviour performed.   
 
Self-management has been further defined as, “the individual’s ability to manage 
symptoms, treatment, physical, psychosocial consequences and lifestyle changes 
inherent in living with a chronic condition.  Efficacious self-management 
encompasses the ability to monitor one’s condition and to affect cognitive, 
behavioural, and emotional responses necessary to maintain a satisfactory quality of 
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life” (Barlow et al., 2002, p 177).   Within cancer literature, the term self-
management refers to an iterative process whereby individual responses and 
behaviours are used to cope with the physical and psychological consequences of 
cancer (McCorkle et al., 2011).   
 
For the purposes of this thesis self-management is conceptualised as an activity that 
is complex and requires a complex set of skills and activities to manage the physical 
and psychological consequences of prostate cancer.  Such activities might include the 
the individual to acquire, understand, and evaluate information appropriate to 
manage their condition, but to also use that information in decision-making. Self-
management might also include mobilising resources, that is to say, identifying and 
activating resources in a timely manner, and the ability to recognise one’s own 
personal limitations or need for support.  Finally, self-management might also 
include collaborating with healthcare professionals and services to make decisions in 
partnership, and to have the ability to negotiate to get one’s needs met successfully.   
 
There has been an emphasis within recent healthcare policy in the UK “Better Cancer 
Care: An Action Plan” to encourage individuals with cancer to have greater 
involvement in the management of their condition (The Scottish Government, 2008).  
Self-management for people affected by cancer can be important for several reasons.  
Primarily, men living with prostate cancer have unique knowledge and experience of 
living with cancer and the effects of treatment, therefore, men can contribute to the 
effective management of these (Hubbard et al., 2007).  Men’s follow-up care will take 
place in an outpatient setting, and therefore almost all men will have to manage the 
after-effects of cancer and treatments, unsupervised by healthcare professionals, in 
their homes.  Consequently, men are being encouraged to participate in their self-
management (Hubbard et al., 2007). 
 
Men who have had prostate cancer are keen to engage as active partners in the 
management of their long-term condition (Mroz et al., 2010, Breau et al., 2003), but 
they experienced a lack of awareness of available resources (Breau et al., 2003).  
Prostate cancer survivors have reported unmet informational needs around the 
following aspects of self-management: management of side-effects, lack of 
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awareness of appropriate signposting to healthcare professionals, and a lack of 
dietary and physical exercise advice.  Consequently, there is now a growing interest 
in the development of supported self-management interventions for men who have 
had prostate cancer (Faithfull et al., 2011, Department of Health Macmillan Cancer 
Support & NHS Improvement, 2010, Cockle-Hearne and Faithfull, 2010).  
 
A recent self-management intervention study (Faithfull et al., 2011) demonstrated 
acceptability of self-management interventions for prostate cancer survivors in the 
UK.  The study was quasi-experimental design (Faithfull et al., 2011), aimed at 
improving the self-management of lower urinary tract symptoms (LUTS) for men 
(N=15) treated with neoadjuvant hormone therapy and radiotherapy for localised 
disease.  The intervention was based upon cognitive behavioural therapy which 
aimed to improve: coping strategies, problem solving, informational and emotional 
support, self-monitoring of urinary symptoms (bladder diary), and pelvic floor 
exercises.  A Prostate Cancer Specialist Nurse delivered the intervention.  The 
primary outcome was International Prostate Symptom Score (IPSS), followed by a 
number of secondary outcomes: bladder diaries (frequency and volume), HRQoL 
(EORTC C30 and PR25), and self-efficacy.  Overall, the intervention demonstrated a 
significant improvement in the IPSS scores, improvements in urinary frequency 
(bladder diaries), and men reported less emotional distress after the intervention.  
No improvements were identified for HRQoL (physical, social, role or cognitive 
function, global quality of life) or self-management self-efficacy. 
 
There are several methodological limitations to this study (Faithfull et al., 2011) that 
are worthy of acknowledgement.  The sample size was small (N=15) and 
underpowered and limits the generalisabilty of the findings to wider populations.  An 
important limitation to the study design was the absence of a control group.  
Without a control group it is difficult to exclude the possibility that urinary symptoms 
could have naturally improved over time (Hashine et al., 2005).  This study used 
paper and pen diaries and, therefore, forward and backfilling bias of the bladder 
diary is possible (Bolger et al., 2003). Faithfull’s study did not measure the self-report 
of self-management behaviours and, therefore, it is possible that the participants 
could have used additional self-management behaviours that may have influenced 
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IPSS scores.  Despite these limitations, this study has demonstrated acceptability for 
supported self-management interventions for men affected by prostate cancer.   
 
In summary, identifying the self-management strategies used by prostate cancer 
survivors is a very important step towards the development of additional supported 
self-management interventions (Oliffe et al., 2009).  The assessment of self-
management strategies will facilitate an understanding of the barriers encountered 
while self-managing, and provide useful insights into how men can be better 
supported to self-manage (Cockle-Hearne and Faithfull, 2010, Davies and Batehup, 
2010). 
 
The purpose of this structured review was to identify the self-management 
behaviours that men with prostate cancer use and evaluate where or not self-
management changes over time.  Two research questions were used to guide this 
structured review: 
Research questions: 
1) What are the self-management behaviours used by prostate cancer 
survivors? 
2) How does self-management behaviours used by prostate cancer survivors’ 
change over time? 
3.3 Methods 
A review of qualitative and quantitative research evidence was generated (Centre for 
Reviews and Dissemination, 2008, Webb and Roe, 2007, Whittemore, 2005).  The 
searches were restricted to the search terms “prostate cancer”, “prostate 
carcinoma”, “self-care” and “self-management” (see table 3.1 for search strategy).  
Databases searched were CINAHL, Medline, PsycInfo, ASSIA, and BNI and key words 
were mapped to each electronic database using the appropriate MeSH term, or used 
free search terms.  Databases were searched from earliest date available to 2012 
using truncation, wildcards and Boolean logic.  Additional searches were performed 
in Index to Theses, Google Scholar, and Google.  All of the publications were 
managed using the software package Endnote X4.   
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Table 3.1 Search strategy 
Search strategy 
1. (Subject heading “prostate carcinoma”) or (subject heading “prostate cancer”) 
2. (subject heading “self-care”) or (subject heading “self-management”) 
3. 1 and 2 
 
The titles and abstracts found by the search strategy were reviewed independently 
by three members of the research team (two of the researcher’s Ph.D. supervisors 
and the researcher) using a pro forma checklist. The pro forma checklist was based 
on the inclusion criteria (see table 3.2 for inclusion criteria) which facilitated the 
decision-making process to retrieve full-text articles or not.   Publications which met 
the inclusion criteria were retrieved in full text.  Any disagreements were completely 
resolved through discussion.   
Table 3.2 Inclusion criteria 
Criteria Rationale 
English text only 
 
Prostate cancer participants only 
 
 
Worldwide literature was included 
  
 
Does this title/abstract indicate self-management 
strategies used for prostate cancer survivors?  
 
 
Does this title/abstract identify how self-management 
changes over time? 
 
(The publications had to address at minimum, one of the 
above questions to be considered for inclusion)  
Budget constraints and the costs involved for translation 
 
This is the primary context of the review; therefore other 
cancer sites are excluded. 
 
To capture a broad range of self-management 
behaviours worldwide. 
 
This is the 1st key focus of the review; to identify the self-
report of self-management strategies for prostate cancer 
survivors. 
 
This is the 2nd key focus of the review; to identify 
whether or not self-management strategies changes 
over time. 
 
 
 
 
 
An assessment of the methodological quality of full-text articles was performed.   
Two quality assessment tools (Shaw et al., 2009) were used because they enabled a 
wide range of research design to be evaluated.  One tool assessed qualitative 
research designs and the other tool evaluated quantitative research. Key information 
from the studies was extracted using narrative data extraction sheets.  The data 
extraction was developed based on recommendations from Cochrane Guidelines 
(2009).  The review used a narrative synthesis and tabulation of primary research 
studies to generate broad findings and conclusions (Whittemore, 2005).  
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3.4 Results   
Of the 111 publications retrieved from the search, 95 were excluded following the 
application of the inclusion criteria (see figure 3.1).  This left 16 publications reviewed 
in full, and 11 articles (Faithfull et al., 2011, Cockle-Hearne and Faithfull, 2010, 
Beckmann et al., 2007, Evans et al., 2007, Lev et al., 2007, Ott and Fulton, 2005, 
Barqawi et al., 2004, Breau et al., 2003, Davison et al., 2002, Landis et al., 2002, 
Wong et al., 2000) were excluded (see figure 3.1 for reasons for exclusion).  This left 
5 publications which met the inclusion criteria (2 intervention studies, 1 prospective 
longitudinal survey, and 2 cross-sectional qualitative studies).  An inter-rater 
reliability analysis using the Kappa statistic demonstrated a high level of agreement 
kappa= 0.848, p<0.001 (Viera and Garrette, 2005) among the reviewers. 
 
113 records identified through database searching 13 records identified through other sources
19 duplicates removed
Identification
Screening
107 records (titles and abstracts) screened against the 
inclusion/exclusion criteria
95 records excluded
16 full text articles assessed for eligibility against the 
inclusion/exclusion criteria
11 full text articles excluded for the 
following reasons:
n=8: did not identify self-report of 
self-management strategies
n= 2 mixed cancer sites
n=1 sample was not prostate cancer
5 Studies included
Eligibility
Included
 
Figure 3.1 PRISMA: Flow of information through different phases of the self-management 
review (Moher, 2009)  
 
This review included five publications which indicate a lack of research in this field. 
Two of the studies were conducted in Canada, one in Korea, one in the UK, and one 
in the USA.  The sample sizes were small (N=14 to N=70) with a total sample N=198 
across all of the publications.  Based on the Department of Health’s (2001) typologies 
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of supporting evidence, the studies ranged from C1 (qualitative research) to B2 
(quasi-experimental intervention studies).   One qualitative study sampled men 
undergoing the active surveillance programme for localised prostate cancer (Oliffe et 
al., 2009), and the other qualitative study sampled men with different treatment 
modalities (Mroz et al., 2010).  The three quantitative studies included samples of 
men treated with radiotherapy (Wilson et al., 2010) radical prostatectomy (Kim, 
2011) and hormone therapy (Hamm et al., 2000).  This is an emerging evidence base 
that includes qualitative data and quantitative data based on samples treated by 
different modalities.  All of the publications (five) reported findings pertinent to 
understanding the self-management strategies that men used to manage their 
condition and only 2 studies assessed how self-management strategies changed 
overtime.  Table 3.3 provides an overview of included publications and full data 
extraction is available in appendix 3.1.   
  
 
 
 
7
8 
Table 3.3 Studies focused on identifying the self-management strategies to manage prostate cancer and assessed change over time. 
Author 
and 
Date                    
Design     Sample                                                        Self-
management 
strategies   
assessed          
Change 
overtime 
assessed                      
                               Results 
(Wilson 
et al., 
2010) 
 
 
 
 
 
 
 
 
 
(Kim, 
2011) 
 
 
(Hamm 
et al., 
2000) 
 
 
 
(Oliffe 
et al., 
2009) 
 
 
 
 
 
(Mroz 
et al., 
Intervention study: 
quasi-experimental 
design. Follow-up 3 
weeks into EBRT,                                                                                                  
final treatment, 3 
and 6 months.    
                
 
 
 
 
 
Intervention study:  
quasi-experimental 
design.  Follow-up 2 
months post-surgery 
 
Prospective 
longitudinal design: 
Follow-up assessed 
over 5 visits (1, 2, 3, 
4, 12 months).  
 
Qualitative, cross-
sectional design.  
 
 
 
 
 
 
Qualitative, cross-
70 men before 
EBRT 
 
 
 
 
 
 
 
 
 
69 men before 
RP 
 
 
 
20 men  (all at 
different 
trajectories) 
self-injection of 
HT 
 
25 men <2 
years on the 
active 
surveillance 
programme  
 
 
 
14 men < 5 
      Yes       
 
 
 
 
 
 
 
 
 
 
Yes                 
 
 
 
 
Yes         
 
 
 
 
 
Yes      
 
 
 
 
 
 
 
Yes       
Yes   
 
 
 
 
 
 
 
 
 
 
No 
 
 
 
 
Yes 
 
 
 
 
 
No 
 
 
 
 
 
 
 
No 
Most common side effects of EBRT include: skin reactions, dietary problems, emotional reactions and 
fatigue.  Mean of 8 EBRT side-effects were reported (min of 1 and max of 27) reported symptoms.  Side-
effects onset day 11 (SD 6) into EBRT, lasted approx 8 days.  Severity of symptoms 2.8 (mean, SD 0.6), 
ranged from 1.0 to 4.3 (5 point scale, with 5 being the most severe).  Maintaining skin integrity by n=52, 
used on average 2 out of 5 self-care behaviours, most common “was avoiding exposure of treated area to 
direct sunlight”. Self-management for diet reported by n=57, used 5 of 12 self-care options, most common 
“eating foods high in protein”, Self-care for emotional adjustment was reported by n=53, reported 6 of the 
12 self-care options, most common “making a special effort to maintain a positive attitude and consciously 
trying to think more positively”. 60% of participants reported taking more rest periods as self-care 
strategies to alleviate fatigue. Self-care actions significantly increased overtime from BL to 6M (12.2, SD 
7.0 vs. 13.9 SD 6.1; t=1.94, P=.05).    Intervention had no effect. 
 
Self-management activity score of the experimental group 30.39 points, control group 29.64 points 
(possible score range from 9 – 36).  No description is given to interpretation of the scores or a description 
of the actual self-care strategies.   
 
 
Men self-injection demonstrated good compliance for a subsample.  55% of the men injected 5 times over 
12 months, demonstrating 100% compliance to treatment regime.  No additional self-care was reported in 
this publication. Reasons for non-compliance:  too intricate, partners concerns, interference of work 
commitments, difficulties with travel.   
 
Over-arching theme of “Uncertainly” emerged, “…when you are told you have cancer, I mean it sticks with 
you, cancer is cancer, I don’t care if I have low grade or not and nobody could tell me that there’s no 
cancer growth there, there’s no, um, spreading of cancer, they can’t tell men that, which really frustrates 
me”.  Self-management of uncertainty was managed by 2 strategies “living a normal life” and “doing 
something extra”.   The theme of living a normal life reflected men’s positions to view their cancer as 
benign (n=14) “get out of jail free card”.  Self-management related to “doing something extra”, which 
focussed on dietary modifications “ to go on AS has more to do with diet change…it goes hand in hand”.  
Men reported eating less, taking supplements including saw palmetto, green tea, tomatoes, pomegranate 
juice.   
 
  
 
 
 
7
9 
2010) sectional design years since 
diagnosis, 
mixed 
treatments 
Diet change self-management included the following themes: “pre-cancer diet perceptions’”, “diet and 
health understandings”, “perceptions of prostate cancer”, and their need to “do something” for self-care.  
Cancer was viewed as a chronic condition required on-going management and men expressed a need to 
“do something” about it.  “…PSA shows up well then I’ll probably get a little excited again and then go on, 
figure out what to do.  But then I’ll probably start learning a lot more about fine-tuning my diet or 
whatever…”  Overall perceptions influenced the dietary eating habits and included a number of sub-
themes: 1) already had a healthy diet; “I’ve always eaten healthily and I will continue to eat healthily but 
I’m not expecting it to cure cancer”, 2) diet does not affect prostate cancer recovery “It’s not a disease 
that once you have got it diet’s going to do much for you”.  3) Won the war, “you might as well go out and 
do what you want”, 4) diet and health understandings, “I want to live a longer life and I want to live it 
well... diet is one of the few things I can do”.   
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3.4.1 What are the self-management strategies used by prostate 
cancer survivors? 
 
This section begins with an overview of the approaches used to measure the self-
management behaviours for men affected by prostate cancer.  Three quantitative 
studies (Kim, 2011, Wilson et al., 2010, Hamm et al., 2000) assessed men’s self-
management behaviours by different approaches and an overview of the 
measurements used are summarised in table 3.4.   
Table 3.4 Overview of measurement approaches for self-management behaviours for men 
affected by prostate cancer 
Author Sample 
characteristic 
Measurement Items Validity and reliability 
(Wilson 
et al., 
2010) 
 
 
 
 
 
 
 
 
(Kim, 
2011) 
 
 
 
 
 
 
 
 
(Hamm 
et al., 
2000) 
N=70 EBRT  
 
 
 
 
 
 
 
 
 
 
N=69 RP 
 
 
 
 
 
 
 
 
 
N=20 men 
self-injecting  
HT* 
Self-care log 
(SCL) (Dodd, 
1982) 
 
 
 
 
 
 
 
 
Self-care 
activity 
questionnaire  
 
 
 
 
 
 
 
No 
questionnaire 
measurement 
2 components: 1) list of 56 
possible side effects 2) self-
management behaviours, 
perceived effectiveness, and 
severity of symptoms 
(Developed for patients 
receiving chemotherapy). 
 
 
 
 
10 items: usage of incontinence 
pads, frequency of pelvic floor 
exercises, and self-management 
strategies for the following: 
haematuria, constipation, 
activities restrictions, smoking 
cessation, hospital 
appointments, and utilising 
family support systems 
 
Verbal reports from participants 
at clinical visit with regards to 
compliance to self-injected HT* 
Content validity: expert critique (10 
oncologist, 4 patients, 4 specialist 
nurses) 
 
Convergent validity: using the symptom 
scale of the SCL, the SCL correlated with 
the Omega Screening Questionnaire 
(r=.39, p<.001) and physical problems 
documented in the medical notes, (r=.47, 
p<.001). 
 
Reliability:  Dodd (1982) demonstrated 
good reproducibility (85%) of the SCL 
when in interview format.  Cronbach’s 
alpha not reported. 
 
Content validity: Expert critique 
(Urologist Professors’ and specialist 
nurse.  But patients’ comments were not 
included. 
 
Reliability: Internal consistent reliability; 
Cronbach’s alpha 0.64 
 
Blood assessment of PSA and 
testosterone as a measurement of 
adherence to self-injected HT. 
*HT (Hormone therapy) 
  
Hamm et al., (2000) identified that men can self-inject hormone therapy as a self-
management behaviour for the treatment of prostate cancer.   Hamm’s study did not 
use an instrument to assess self-management strategies, but verification of 
medication adherence (the self-management behaviour) was assessed during verbal 
consultation at clinics and assessed using blood tests (PSA and testosterone levels).   
Hamm’s study did not detail additional self-management strategies that men may 
have performed, for example, the self-management strategies used to relieve 
symptoms associated with the hormone therapy.   
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Kim (2011) assessed the self-management behaviours for men who had undergone 
radical prostatectomy.  Kim developed the Self Care Activity Questionnaire for the 
purpose of her research.  This instrument had 10 items and assessed the following:  
usage of incontinence pads, frequency of pelvic floor exercises, and self-management 
strategies used for haematuria, constipation, activity restrictions, smoking cessation, 
hospital appointments, and utilising family support systems. One limitation to Kim’s 
instrument was the non-assessment of self-management behaviours used to relieve 
sexual dysfunction because impotence can be problematic for men after surgery 
(Darst, 2007, Kendirci et al., 2006, Bokhour et al., 2001).  Internal consistency 
(Cronbach’s alpha .64) of Kim’s instrument was unsatisfactory based on 
recommendations from Rattray and Jones (2005).  Face validity was assessed through 
comment from healthcare professionals only, thus no comment was sought from 
men treated by surgery.  This lack raises a concern about the content validity because 
no comment from men affected by this condition was sought during the 
development of the Self Care Activity Questionnaire.  This challenges the content 
representativeness and relevance in accurately capturing men’s experiences of self-
management (Lynn, 1986).  
 
Wilson (2010) used Dodd’s (Dodd, 1997, Dodd, 1982) Self-Care Log (SCL) for the 
evaluation of self-management behaviours for men treated with neoadjuvant 
hormone therapy and radiotherapy.  One of the major strengths of the SCL is the 
identification of a) symptoms, b) self-management behaviours, and c) perceived 
relief of self-management actions.  The SCL has been used in the measurement of 
self-management actions of cancer patients undergoing chemotherapy and 
radiotherapy (Kidd et al., 2008, Wong et al., 2006, Borthwick et al., 2003, Richardson 
and Ream, 1997, Nail et al., 1991, Dodd, 1982).  Content validity was established by 
expert critique from: 10 oncologist, 4 patients, 4 specialist nurses, and is in keeping 
with recommendations from Lynn (Lynn, 1986).  Convergent validity was 
demonstrated by correlating the symptom scale of the SCL with the Omega Screening 
Questionnaire (r=.39, p<.001) and also correlating the symptoms scale of the SCL 
with the physical problems documented in the medical notes (r=.47, p<.001).  
Internal consistency of the SCL has not been reported, however Dodd reported a 
good level of reproducibility (85%) when comparing the written SCL with the SCL in 
interview format.  Based on the reviewed studies that quantitatively measured self-
management actions for prostate cancer survivors, the SCL would be the strongest 
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instrument for additional research in this field because of a number of important 
considerations: 1) this instrument has been widely applied to previous self-
management research for people affected by cancer, 2) reliability and validity of this 
instrument has been demonstrated, and 3) the SCL evaluates the identification of a) 
symptoms, b) self-management behaviours, and c) perceived relief from self-
management actions.   
 
Self-management behaviours 
This section will present the findings to address the first research question: what are 
the self-management behaviours used by prostate cancer survivors?  A number of 
self-management strategies were reported by men (N=70) treated with radiotherapy 
to relieve a range of physical and psychological factors: skin reactions, dietary 
problems, emotional reactions and fatigue (Wilson et al., 2010).  Maintaining skin 
integrity was reported by 52 men who used on average 2 out of 5 self-management 
behaviours, the most common reported self-management behaviour was, “avoiding 
exposure of treated area to direct sunlight”.  Dietary modification was reported by 57 
men and used on average 5 of the 12 self-management options and the most 
common action reported was “eating foods high in protein”.  Self-reports of self-
management for emotional adjustment was reported by 53 men and used 6 of the 12 
self-management options and the most frequent self-management action, “making a 
special effort to maintain a positive attitude and consciously trying to think more 
positively”.  Over half (60%) of the sample reported taking more rest periods as self-
management strategies to alleviate fatigue.  This study used the SCL (Dodd, 1982) 
and has provided a useful insight into the behaviours of men treated with 
radiotherapy.  
 
Kim (2011) developed an instrument to measure self-management behaviours in a 
sample (N=69) treated by radical prostatectomy.  The findings from Kim’s study are 
very difficult for the reader to interpret.  The data presented from Kim’s study 
identified a value of 30.39 to represent self-management activity, but it is unclear 
what this represents: the mean, median or total score and the actual self-
management actions were not reported.  Kim’s intervention (see appendix 3.1 for 
intervention overview) promoted self-management in the following areas: 
symptoms, catheter management, urinary incontinence, post-surgery exercise, diet 
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and defecation, pelvic floor exercises, which provides anecdotal evidence of proxy 
self-management activities for men treated by surgery.   
The last quantitative paper in this review (Hamm et al., 2000) identified men who 
self-injected hormone therapy for the treatment of their cancer, but this publication 
did not identify other self-management behaviours.  For example, the self-
management behaviours used to relieve the side-effects of hormone therapy: 
nausea, decrease in appetite, constipation or diarrhoea, gynecomastia, sleeping 
difficulties, sweats and flushes, depression, impotence and osteoporosis (Cancer 
Research UK, 2011, Couper et al., 2009) were not assessed.   
An overview of the self-management behaviours across the reviewed publications 
are presented in table 3.5.  The findings from the three quantitative studies have 
identified that this is an emerging evidence base, but little is known regarding the 
self-management behaviours or the effectiveness of mens’ actions in alleviating 
problems/symptoms.   There are large gaps in the evidence whereby it is unclear how 
self-management differs across the stages of cancer (localised, locally advanced and 
metastatic).  This area would be worthy of further research to assess the 
problems/symptoms experienced and the self-management behaviours used to 
identify opportunities towards developing better supportive care.  
Table 3.5 Overview of the self-management strategies identified from the reviewed 
quantitative publications  
Author Stage and 
treatments 
Problems/symptoms Self-management action 
Wilson 
et al., 
2010 
 
Cancer stage no 
reported 
N=70 treated with 
radiotherapy 
Skin reactions 
Dietary problems 
Emotional problems 
Fatigue 
 
The most common self-management action 
was only reported in the publication: 
Avoiding exposure of treated area to direct 
sunlight 
Eating food high in protein 
Reducing risk of infection by avoiding 
crowds or people with colds and by washing 
hands more often 
Making a special effort to maintain a 
positive attitude and consciously trying to 
think more positively 
Taking rest periods and getting help with 
chores 
Hamm 
et al., 
2000 
Locally 
advanced/metastatic 
cancer 
N=20 men treated 
with hormone 
therapy 
Not assessed Self-injection of hormone therapy (five 
injections over the course of twelve months) 
Kim, 
2011 
Localised and locally 
advance cancer 
N=69 men treat with 
radical 
No assessed 
 
 
 
Self-management activity was reported as a 
value of 30.39, it is unclear whether this 
value represents the mean, median, mode, 
and total score.  The author does not 
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prostatectomy identify self-management behaviours.  
Proxy accounts of self-management may 
include: symptoms, catheter management, 
urinary incontinence, post-surgery exercise, 
diet and defecation and pelvic floor 
exercises. 
 
Two studies included in this review provided qualitative insights into men’s 
experiences of self-management.   A cross-sectional study (Oliffe et al., 2009) 
explored men’s (N=25) self-management behaviours who underwent active 
surveillance.  Findings identified an overarching theme of “uncertainty” which was 
associated with men’s experience of active surveillance.  Uncertainty has been 
described as a psychological stressor that occurs as a consequence of being unable to 
determine the meaning of an illness-related event, and the inability to predict illness 
outcomes accurately (Mishel, 1990, Mishel, 1988).  Men spoke about their worries of 
their cancer spreading and the following quote represents this, 
  
“… when you are told you have cancer, I mean it sticks with you, cancer is cancer, I 
don’t care if I have low grade or not and nobody could tell me that there’s no cancer 
growth there, there’s no, um, spreading of cancer, they can’t tell me that, which 
really frustrates me.” 
                      (Oliffe et al., 2009, p.435). 
 
This quotation highlights that this man experienced uncertainty of cancer 
progression, and illuminates the psychological impact of the active surveillance 
programme.  This man understood that his cancer was not aggressive, but this did 
not appear to lessen the psychological impact of a prostate cancer diagnosis.  This 
quote may represent that this man was concerned about the monitoring techniques 
(digital examination, PSA, prostate biopsies) used and their sensitivity to detect 
subtle changes in his cancer progression.    Other men spoke about the uncertainty of 
coping with treatment-induced side effects of erectile dysfunction,  
 
“You know, a man’s identity I guess is pretty much what women say, it’s all about 
your penis [laughs] you know … that’s the way we’re programmed so I just want to 
do everything to save my penis.” 
                      (Oliffe et al., 2009, p.436). 
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This quote may represent this man’s masculinity and the strategy of being on the 
active surveillance programme as a means to avoiding the devastating consequences 
related to curative treatments: impotence, urinary incontinence and bowel 
problems.  The third area of uncertainty was related to the result of the digital 
examination, PSA and prostate biopsies, 
 
“It’s a little scary … every time I come up to my six months visit … I have a little bit of 
anxiety and then we do the digital and everything is fine … and the PSA is fine … 
phew got another six months.” 
                   (Oliffe et al., 2009, p.436). 
 
Oliffe identified that men appraised uncertainty as a psychological stressor and used 
two self-management strategies: “living a normal life” and “doing something extra” 
to cope with the psychological impact of uncertainty (stressor).  The theme of “living 
a normal life” reflected men’s (n=14) perception of their cancer as benign (Oliffe et 
al, 2009), 
 
“The way Dr [name] explained it ... the anxiety side was completely gone.  If 
somebody turns around and says that you know five years down the road or ten 
years down the road that nothing immediate ... no pills or anything like that ... just 
leave it alone and keep it under active surveillance and that takes all the anxiety and 
everything ... from that point it’s a less consideration than possibly having a 
toothache.” 
                        (Oliffe et al., 2009, p.436). 
 
The second emergent theme of “doing something extra” was focussed on dietary 
modifications, 
 
“… to go on active surveillance has more to do with diet change … it goes hand in 
hand.” 
                        (Oliffe et al., 2009, p.438). 
 
“… taking anything whether it’s proven or not ... if there is a hint that it will slow the 
growth or reduce cancer in general.” 
                        (Oliffe et al., 2009, p.438). 
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Men also spoke about eating less, and taking supplements which included: saw 
palmetto, green tea, tomatoes, and pomegranate juice.   
 
The findings from Oliffe’s study can be linked to Lazarus and Folkman’s (1984) theory 
of stress and coping.  According to the transactional model, one’s 
interpretation/appraisal of a stressful event (uncertainty of active surveillance) is 
believed to determine how one would cope with this experience.  The findings 
presented here identified different coping strategies that emerged from the data, 
“living a normal life” and “doing something extra”.  Men who appraised the stressor 
of uncertainty as benign are likely to have adjusted to being on active surveillance by 
“living a normal life” because men identified their anxiety was completely gone 
(Oliffe et al., 2009).  For others, uncertainty was appraised as a stressor, and men 
used dietary modifications as a self-management behaviour to reduce the worry of 
cancer progression and thus, aimed to avoid the sequelae of physical and 
psychological problems related to curative treatments.       
 
This study has provided useful insights into the self-management experiences for 
men undergoing active surveillance that can be linked to the stress and coping 
theory.  The limitation to this study is the cross-sectional qualitative design and 
therefore, it is not possible to capture changes in self-management behaviours over 
time.  Survey data have identified that men undergoing active surveillance can 
experience urinary, bowel, and sexual dysfunction (Thong et al., 2009), yet Oliffe did 
not report any self-management behaviours related to these problems.  It may be 
however, that coping with the uncertainty was more salient for the men in Oliffe’s 
study, and this would seem a likely explanation because the experience of 
uncertainly has been reported elsewhere (Hegarty et al., 2008).   
 
 A further study (Mroz et al., 2010) explored men’s perceptions of their diet change 
in a mixed treatment sample at different cancer trajectories.  Prostate cancer 
survivors’ self-management of diet change was complex and involved a number of 
factors, and these included:  pre-cancer diet perceptions, diet and health 
understandings, perceptions of prostate cancer, and “their need to do something for 
self-management”.  Men expressed a need to modify their diet to increase overall 
health and survival.  Some of the dietary modifications included: taking lycopene, 
selenium, soy products, tomatoes, broccoli, fruit and vegetables and reducing red 
87 
 
  
meat.  The following quotes represent the need to modify dietary intake to increase 
overall health and survival, 
 
“Now I have finished my prostate cancer treatment, it’s like, Okay, now we’re going 
to get smart about what we’re doing about diet and be sure that we don’t adversely 
influence the healing by what we are eating.” 
        (Mroz et al., 2010, p.402). 
 
“I want to live a longer life and I want to live it well in the absence of disease and diet 
is one of the few things I can do that would help.” 
      (Mroz et al., 2010, p.402). 
 
Mroz’s study could also be linked to the stress and coping theory (Lazarus and 
Folkman, 1984) because positioning diet change can be a positive coping behaviour.  
Men conceptualised their prostate cancer as a chronic condition that was associated 
with reduced health and overall survival (stressor).  Following men’s individual 
appraisals of the stressful encounter (health problems) men may have used dietary 
modifications to cope with the adverse effects of this stressor.  Mroz’s study 
identified diet change as self-management behaviour for men treated for prostate 
cancer.  One of the limitations to Mroz’s study is the homogeneity of demographic 
variables within the sample.  The sample was mostly retired, college educated and 
affluent, and therefore, limits the transferability of the results to people who are of 
different demographic groups.  Additional self-management strategies were not 
reported in this paper, such as self-management for urinary, bowel and sexual 
dysfunction problems.  One possible explanation for this deficit is that the researcher 
represented himself as a nutritional student to the participants.  Bias is possible 
because the men may have discussed their experiences differently with someone 
who did not have a nutritional background.  Due to the limitation of the cross-
sectional qualitative design, changes in self-management experiences over time were 
not assessed.   
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3.4.2 How do self-management strategies used by prostate 
cancer survivors’ change over time? 
 
Of the reviewed studies, only two studies (Wilson et al., 2010, Hamm et al., 2000) 
have provided evidence to advance understanding of change over time.  Hamm and 
colleagues demonstrated the potential for men to treat their prostate cancer through 
self-injection of hormone therapy.  Hamm identified that men (n=11) self-injected 
hormone therapy on five occasions over the course of 1 year, whereas, Wilson’s 
study identified a significant increase over time in self-management activities from 
before radiotherapy to 6 months follow-up (12.2, SD 7.0 vs. 13.9 SD 6.1; t=1.94, 
P=.05).  The main symptoms experienced included skin reactions, dietary problems, 
emotional problems, and fatigue, but Wilson did not identify how individual self-
management behaviours changed in relation to the symptoms experienced over 
time.  The findings presented here suggest that self-management behaviours may 
increase over time, but there are gaps in current knowledge that will be addressed in 
the discussion.  
3.5 Discussion 
There were a number of methodological limitations that featured across the 
reviewed publications.  Two quantitative studies (Wilson et al., 2010, Hamm et al., 
2000) did not conduct a power calculation to define their sample sizes, nor did they 
provide a rationale for not performing this analysis.  It is possible that Wilson’s and 
Hamm’s studies lacked statistical power to make statistical judgments about self-
management that were accurate and reliable.  Four (Kim, 2011, Wilson et al., 2010, 
Mroz et al., 2010, Hamm et al., 2000) studies did not identify the total number of 
participants approached and therefore, selection bias is possible.  Consequently, the 
study populations may not have adequately reflected the spectrum of characteristics 
of men affected with prostate cancer (Sica, 2006) and this lack limits the 
generalisabilty of their findings.   
 
Attrition was reported in one study (Hamm et al., 2000) of the three prospective 
longitudinal designs.  Hamm’s study aimed to test the feasibility and acceptability of 
men self-injecting hormone therapy.  The attrition rate in Hamm’s study was very 
high (45%) and men withdrew their consent for a number of reasons, including the 
following:  injection technique was too intricate, concerns from partners, and 
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travelling distances.  Self-injecting hormone therapy was only acceptable to 55% 
(n=11) of the original sample.  Hamm and colleagues did not statistically test for 
unique characteristics between the men lost from the study and those men who 
remained in the study.  Consequently, the remaining sample (n=11) may not be 
representative of the original sample and limits the generalisabilty of their findings.   
The sample sizes for the two qualitative research studies were N=14 (Mroz et al., 
2010) and N=25 (Oliffe et al., 2009) and both studies used convenience sampling.  
The researchers did not sample men who were representative of the entire 
population, and thus limits the transferability of the results.  However, the qualitative 
studies in this review have provided a useful insight into men’s experience of self-
management in relation to prostate cancer.  The findings from both studies (Mroz et 
al., 2010, Oliffe et al., 2009) can be theoretically linked to the Lazarus and Folkman’s 
(1984) stress and coping theory.  Coping with everyday problems (stressors) has been 
associated with the type of self-management behaviours used by people affected by 
cancer (Foster and Fenlon, 2011) and has been identified for prostate cancer 
survivors (Oliffe et al., 2009).  Conceptually, the outcome of self-management is to 
minimise the effect of cancer on physical health and functioning, and to cope with 
the psychological sequelae (Jones et al., 2011). 
 
The studies reviewed identified self-management behaviours for men undergoing 
active surveillance (dietary modifications), mixed treatment group (dietary 
modifications), hormone therapy (self-injecting) and radiotherapy (avoiding exposure 
of treated area to direct sunlight, dietary modifications, reducing risk of infection by 
good hygiene, maintaining a positive attitude, taking rest periods and getting help 
with chores).  Self-management was performed for psychological and physical 
problems, namely: psychological problems: uncertainty and emotional problems, and 
physical symptoms: skin reactions, fatigue and dietary problems.  However, men can 
experience a number of additional problems/toxicities associated with prostate 
cancer that the current state of the evidence does not address.  Such problems 
include: urinary (urgency, infrequency, incontinence) (Zelefsky et al., 2008), bowel 
(rectal bleeding, urgency in defecation, diarrhoea, and faecal leakage) (Al-Abany et 
al., 2002) and sexual dysfunction (impotence, loss of libido) (Gomella, 2007).   
 
The evidence does not sufficiently detail how self-management behaviours change 
over time in relation to the toxicities experienced as a result of prostate cancer and 
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treatment.  Only one study (Wilson et al., 2010) assessed change over time using a 
standardised instrument (SCL, Dodd, 1984).  Wilson and colleagues detailed that self-
management increased over time, from beyond the acute treatment phase to 6 
months after radiotherapy.  Caution is given to the interpretation of these findings 
because co-morbidity was not measured in this sample.  Increases in self-
management behaviours could be a consequence of an increase in general symptoms 
and not as a direct result of prostate cancer.   To overcome the potential for co-
morbidity bias in future research, co-morbidity should be measured and controlled 
for in the research design (Kerr et al., 2007).  Wilson did not detail which self-
management behaviours increased over time.  Therefore, additional research should 
detail which specific areas of self-management increase over time to tailor support as 
appropriate. 
 
A further limitation to Wilson’s study was the use of paper and pen diaries to assess 
change over time. Participants can forward and backfill paper diaries, and this 
method consequently reduces the accuracy and reliability of data collected (Stone et 
al., 2003b).  One possible method to overcome the limitation of paper and pen 
diaries is electronic diaries with compliance-enhancing features.  Electronic diaries 
with compliance-enhancing features can remove the bias of forward and backfilling 
effectively, whilst accurately evaluating changes in the variables of interest over time 
(Blondin et al., 2010, Piasecki et al., 2007, Gaertner et al., 2004).  Innovative 
technology such as electronic diaries would have the potential to effectively capture 
self-management over time for prostate cancer survivors.  Acceptability of electronic 
means of data collection has been demonstrated in participants with long-term 
conditions (Kerkenbush and Lasome, 2003, Peters et al., 2000) and cancer groups 
(Badr et al., 2010, McCann et al., 2009, Kearney et al., 2009, Forbat et al., 2009).  
Electronic diaries would have the potential to overcome some of the methodological 
limitations to accurately evaluate self-management behaviours over time.  
 
This review has identified that research in the UK is very limited, although there is an 
emerging interest in self-management interventions for prostate cancer survivors 
(Faithfull et al., 2011, Cockle-Hearne and Faithfull, 2010).  The findings from this 
review identified that little is known regarding the actual self-management 
behaviours used by men across all stages of disease/treatment modalities and this 
has been reported elsewhere (Flynn and Groot, 2009).  Additional research that aims 
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to assess the dynamic nature of self-management behaviours across different clinical 
characteristics will provide useful insights in to how men can be better supported to 
self-manage their condition.  Work in this area is paramount because men have 
voiced a number of physical and psychological unmet needs related to their self-
management. 
 
Men with prostate cancer have reported that they have unmet support needs 
(Boberg et al., 2003, Lintz et al., 2003) which resulted in them frequently having to 
cope with the physical and psychological sequelae of their treatment on their own.  
The identified areas of unmet needs include psychological distress, sexuality-related 
issues and the management of enduring lower urinary tract symptoms (Ream et al., 
2008).  Men with prostate cancer have voiced a need for informational support, 
particularly regarding the side-effects of the disease, associated treatments and on-
going issues related to recurrence (Carter et al., 2011, Boberg et al., 2003). Prostate 
cancer survivors are keen to engage as active partners in the management of their 
condition (Mroz et al., 2010), but men often feel inadequately supported to do so 
(Department of Health Macmillan Cancer Support & NHS Improvement, 2010, Breau 
et al., 2003).  
 
Social support has been found to improve participation in self-management of long-
term conditions (Schiøtz et al., 2012, Gallant, 2003, Barrera et al., 2002, Gleeson-
Kreig et al., 2002).  Therefore, social support (discussed in chapter 2, section 2.6) has 
the potential to influence the appraisal of everyday problems and subsequently 
improve coping efforts, but social support may also improve participation in self-
management for men affected by prostate cancer.  Given the distinct number of 
unmet support needs for men affected by this disease, social support has the 
potential to influence coping and self-management for men and improve subsequent 
HRQoL.  Currently, the role of social support and self-management has not been 
evaluated for men affected by prostate cancer, but this area would be worthy of 
additional research.  Knowledge in this area may identify directions for self-
management support.   
 
 Limitations 
It is important to acknowledge the potential limitation of the search strategy used in 
this review. The search terms used had a high level of specificity, and therefore, the 
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search terms may not have been sensitive in identifying all of the relevant literatures.  
An important omission in this review was that “coping and adjustment” were not 
included in the search terms, and as a result, it is possible that not all relevant 
literatures were included and reviewed.  Furthermore, a potential limitation of the 
review methodology was that the inclusion criteria consisted of the levels of 
evidence, and therefore, potentially relevant studies may have been excluded 
because of research design, for example, Cockle-Hearne and Faithfull, (2010).   
3.6 Overall summary of the chapter  
This review has identified that very little research has assessed self-management 
behaviours for prostate cancer survivors.  There were five papers included in this 
review and this underscores that this field is under-developed.  Additional research is 
urgently needed to develop this evidence base through the identification of the self-
management behaviours for men affected by prostate cancer with different clinical 
characteristics and levels of social support.  Knowledge in this area is important 
because of the number of unmet support needs of these men, and the recent 
political drive for individuals to self-manage (The Scottish Government, 2008).  The 
current state of the evidence has a number of methodological limitations that limits 
the transferability and generalisation of the findings to the wider prostate cancer 
population.   
 
This is an emerging evidence base that has identified men can experience 
psychological and physical problems for which men perform self-management.  Men 
can experience a number of additional problems/symptoms for which they perform 
self-management but currently no data exist which details such self-management 
behaviours.  Only one study assessed changes in self-management over time, but 
was limited to men treated by radiotherapy.  The current state of the evidence does 
not detail how men’s self-management behaviours change in relation to severity of 
cancer stage or individual treatment modality.  Identifying self-management 
behaviours for men with different clinical characteristics and different support needs 
may generate valuable insights into how men can be better supported to self-
manage. 
 
In summary, this structured review has identified that little is known about the self-
management behaviours or details how they change over time.  Therefore, this Ph.D. 
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study will identify the actual self-management behaviours for men with different 
clinical characteristics/support needs and evaluate how self-management changes 
over time.   
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4.0 Methodology  
4.1 Abstract 
Background 
Chapters 1, 2, and 3 identified that little is known about the influence of social 
support and coping on HRQoL for men affected by prostate cancer.  Furthermore, 
very little evidence details the self-management behaviours of men affected by 
prostate cancer, or how self-management changes over time.  The assessment of 
self-management behaviours can be considered as a specific type of coping that is 
cancer-specific, treatment-specific and symptom-specific.  Identifying the self-
management behaviours for men with different clinical characteristics and different 
support needs may generate valuable insights into how men can be better supported 
to self-manage. 
Aims 
The purpose of this Ph.D. study was to test the mechanism effect of coping and social 
support on HRQoL between individuals and within individuals over time.  This Ph.D. 
study also aimed to identify the self-management behaviours of men affected by 
prostate cancer over time.   
Methods 
A quantitative approach consisted of a prospective longitudinal survey and 12 
ecological momentary assessment (EMA) adapted/ N-of-1 studies which were 
appropriate to address the overall study aim.  The methodological considerations of 
the prospective longitudinal survey and the EMA adapted/ N-of-1 case study will be 
critically considered in the introduction of this methodology chapter.  Participants 
were asked to complete a battery of questionnaires at baseline and 6 months follow-
up (HADS, EORTC C30 + PR25, PSS, MAC Scale, BSSS, self-care self-efficacy, prostate 
specific self-care diary).  A sub-sample (n=12) completed a daily electronic diary for a 
total duration of one month.  The duration, timing and design of the EMA adapted/N-
of-1 were guided by the literature and expert comment from the Ph.D. steering 
group.  
Relevance 
This methodology aimed to test the theoretical model between people and within 
individuals over time to advance understanding, but uniquely positioned the 
individual man at the centre of this research.   This design enabled refinement of the 
propositions of social support theory.  The design and methods chosen in this Ph.D. 
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study were important for providing insights into, and quantifiable data on, men’s 
social support and self-management behaviours over the course of their cancer 
journey.  
4.2 Introduction  
This chapter describes the methods used in this Ph.D..  Chapter 1 identified that 
prostate cancer survivors’ HRQoL improves by 12 months after diagnosis, but men 
can experience enduring urinary, bowel and sexual dysfunction for many years 
following treatment.  Assessing changes earlier in the cancer trajectory may provide 
useful insights into how HRQoL can be improved and restored sooner in the cancer 
journey.  For example, understanding men’s experience of the potential barriers to 
self-manage earlier in the cancer journey may provide useful insights for the 
development of appropriately targeted interventions.  The findings from the HRQoL 
structured review (chapter 1) identified a number of demographic variables (age, 
ethnicity, marital status, education), clinical variables (co-morbidity, Gleason, TNM 
classification, treatments, and PSA) and psycho-social variables (anxiety and 
depression, coping, self-efficacy, perceived stress and social support) that have been 
found to predict HRQoL for men affected by prostate cancer.     
 
Little psycho-social research (Zhou et al., 2010a, Zhou et al., 2010b, Kershaw et al., 
2008, Roberts et al., 2006, Visser et al., 2003, Van Andel et al., 2003) has been 
conducted to identify the relationship between coping and social support on HRQoL 
during the pre-treatment to six month post treatment trajectory (Bloch et al., 2007).  
The importance of social support as a resource for people affect by cancer is not a 
new concept, but specifically, prostate cancer survivors have reported a lack of 
support for their unmet physical and psychological problems (Ream et al., 2008, 
Boberg et al., 2003, Lintz et al., 2003).  HRQoL is likely to be affected by the 
psychological and social factors that unfold over time as men manage, learn from, 
and adjust to the changes caused by prostate cancer and its associated treatments 
(Roberts et al., 2006).  The findings presented in chapter 3 identified that little 
evidence exists that details the self-management behaviours which can be 
considered as a form of coping that is cancer-specific, treatment-specific and 
symptom-specific (Ahmad et al., 2005).  Understanding the mechanism effect of how 
coping and social support operate on HRQoL over time can help to identify men who 
are at high risk and suggest directions for intervention (Roesch et al., 2005).  
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Few prospective longitudinal research designs have been implemented to evaluate 
changes in social support provision.  It seems likely that the types of social support 
needs will change throughout the cancer trajectory.  Additional work is needed to 
assess how social supportive experiences change over time and this could be 
achieved through prospective longitudinal designs (to assess aggregate group effects) 
and case-based time series designs (to assess within-person change over time). 
Evaluating average group level effects and within-person change over time is an 
innovative approach which may expand and refine the propositions of social support 
theory.  
 
A suitable theoretical framework to advance research in this area is the stress 
buffering model (Cohen et al., 2000, Cohen, 1988, Cohen and Wills, 1985, Cohen and 
McKay, 1984) because it links coping and social support to HRQoL.  Few studies have 
tested this theoretical framework within samples of men living with and beyond 
prostate cancer. Importantly, the stress buffering model will enable the effects of 
social support to be explored with coping and health-related outcomes for this 
patient group.  Future research should test main and mediation effects between the 
relationship of social support and coping on HRQoL, because developing an 
understanding of the mechanism effect that links coping and social support to HRQoL 
will facilitate the development of appropriately targeted interventions that are 
theoretically driven.     
 
The purpose of this Ph.D. study was to test mechanism effect of coping and social 
support on HRQoL between individuals and within individuals, capturing change over 
time.  In addition, this research aimed to assess the self-management behaviours of 
men affected by prostate cancer.  A quantitative approach combining prospective 
longitudinal surveys and 12 ecological momentary assessment (EMA) adapted/ N-of-
1 studies was considered appropriate to address the aim of the Ph.D. study.  A 
prospective longitudinal survey aimed to assess change over time and predictors of 
HRQoL outcomes (Galvao et al., 2010, Parker et al., 2009, Carmack Taylor et al., 2006, 
Holmbeck, 2002).  The prospective longitudinal survey was used to test the social 
support theoretical model (Cohen et al., 2000, Cohen, 1988, Cohen and Wills, 1985, 
Cohen and McKay, 1984) across a group level effect (between individuals).   
Prospective longitudinal surveys have a number of problems associated with them, 
for example, retrospective memory recall and ecological fallacy (Bolger et al., 2003, 
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Bowling, 2002, Holmbeck, 2002).  To overcome the problems inherent in the 
prospective survey design a series of EMA adapted/N-of-1 studies was conducted 
(Molenaar, 2004).  The problems associated with the prospective longitudinal survey 
and the EMA adapted/N-of-1 will be considered in greater detail. 
Prospective longitudinal survey design 
The prospective longitudinal survey design in healthcare research has many 
advantages.  A prospective longitudinal design enables change over time to be 
assessed for HRQoL in prostate cancer survivors (Ash et al., 2007) and prediction of 
study outcomes, that is to say HRQoL (Zhou et al., 2010a), and, therefore, is well 
suited to address the aim of this Ph.D..  This design does have some limitations that 
are acknowledged.  Although the prospective longitudinal survey design was 
prospective, it included retrospective questioning about experiences that occurred in 
the past.  Memory recall bias is possible due to collecting retrospective self-reports 
about real-world behaviour through questionnaires. Questionnaires are prone to 
errors and biases as a result of autobiographical memory, because it is difficult for 
participants to accurately recall their experiences (for example, recalling experiences 
in the past month) (Shiffman et al., 2008, Stone et al., 2005, Stone et al., 2004, Stone 
et al., 2003b, Stone et al., 2003c, Stone and Shiffman, 2002).  When participants are 
asked how they felt or how often some event occurred they rely on heuristic 
strategies to estimate an answer and often participants rely on experiences that are 
recent or important for them to provide an answer (Schwartz and Stone, 1998).  
Therefore, the “real-life” validity of the data presented from questionnaire based 
studies is unknown (Jones and Johnston, 2011).  Ecological inference fallacy can also 
be problematic in the interpretation of group level questionnaire data, whereby 
inferences about the nature of “individuals” are incorrectly based on aggregate 
statistics (Bowling, 2002).  Clinically, this is important because any theory 
underpinning an intervention should be supported empirically at the level to which it 
is applied; to the “individual patient”.    
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Ecological Momentary Assessment (EMA) adapted/N-of-1 
To overcome the limitations of the prospective longitudinal survey, an ecological 
momentary assessment (Stone and Shiffman, 1994) has been shown to capture 
experiences as they occur in real time and minimises recall for the participant.  
The EMA design allows the capture of data of interest repeatedly in real time in 
the participants’ natural environment (Shiffman et al., 2008).  Researchers are 
now using the EMA approach to assess health-related symptoms and behaviours 
in patients with a variety of conditions, including pain (Aaron et al., 2005, Stone et 
al., 2003c), asthma (Hyland et al., 1993), heart disease (Kinne et al., 2001), 
arthritis (Lefebvre et al., 1999) and cancer (Kearney et al., 2009, Curran et al., 
2004).  The EMA approach has been shown to capture participants’ experiences 
over time which may vary from days, weeks or months (Shiffman et al., 2008).  
There are different methods of conducting EMAs but the method of choice is 
through the application of an electronic diary (Schwartz and Stone, 1998).  The 
advantages of electronic versus paper dairies have been reviewed elsewhere 
(Piasecki et al., 2007, Stone et al., 2003b) and such benefits include: reduced data 
fabrication, increased participant compliance and better accuracy and efficiency 
in data collection.   The cardinal advantage to using this approach is that the 
electronic diary data are collected in real time, which is date and time stamped (at 
the time of data entry), and therefore minimises the risk of introducing 
retrospective memory recall (Stone et al., 2005, Stone et al., 2004).  EMA data can 
provide information about within individual variability and what predictors 
determine the outcome variable of interest (Bolger et al., 2003).   This approach 
enables researchers to examine events as they occur in participants’ naturalistic 
environments and to explore the correlates, predictors and outcomes of interest 
in real-life time (Shiffman et al., 2008, Piasecki et al., 2007).  
 
The EMA electronic diary approach can be interval, signal and event contingent 
protocol for diary data collection (Bolger et al., 2003).  An interval contingent 
design requires participants to record their self-report at predetermined intervals.  
Signal contingent data collection prompts the participant by a signalling device 
(i.e. an audio prompting device) to provide a diary report at fixed or random time 
intervals.  Event contingent protocols are based on particular incidents of interest 
whereby participants complete a self-report each time an experience of interest 
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occurs.  In order to facilitate reliable and valid data, the participant must be 
committed and dedicated to complete the full electronic diary (i.e. several times 
over the course of a day, for a total of one month).  This, in turn, places a 
substantial demand on the participant because of repeated audio prompts for 
data collection (Piasecki et al., 2007).   
 
Little is known about the effect of completing the electronic diary on the 
respondents’ experiences.  Electronic diary approaches may be exposed to several 
methodological complexities, namely: reactance, habituation, increased 
complexity and gradual entrainment (Bolger et al., 2003).  Reactance occurs when 
the participant’s behaviour changes as a result of completing the diary.  A reactive 
measure is one that changes the phenomenon it is designed to assess.  This is 
desirable if measurement occurs as part of an intervention aimed at changing 
behaviour, but is problematic when measurement over time is used only to assess 
the phenomenon of interest.  Several studies have tested the reactivity of the 
EMA diary in participants with chronic pain (Aaron et al., 2005, Stone et al., 2003c, 
Cruise et al., 1996) and alcohol abuse (Litt et al., 1998) (see table 4.1 for examples 
of reactivity studies).   
 
 
  
  
1
0
0
 
Table 4.1 Studies measuring reactivity of diaries 
Author, 
year/country 
Aim Study: operational 
definition of 
reactivity 
Participants Methods Findings 
Aaron et al., 
(2005) 
USA 
 
 
 
 
 
 
 
 
Stone et al., 
(2003) 
USA 
 
 
 
 
 
 
 
 
Cruise et al., 
(1996) 
USA 
 
 
 
 
 
Litt et al., 
(1998) 
USA  
Examine reactivity in 
repeated measures 
electronic diary for pain. 
 
 
 
 
 
 
 
 
Examine reactivity in 
repeated measures 
electronic diary for pain. 
 
 
 
 
 
 
 
 
Examine reactive effects 
of repeated measures 
wristwatch and paper 
diary 
 
 
 
 
Examine reactive effects 
of repeated measures 
wristwatch and paper 
diary in alcohol-depended 
men 
 
Testing for 
average change in 
pain over time 
 
 
 
 
 
 
 
 
Testing for 
average change in 
pain over time 
 
 
 
 
 
 
 
 
Testing for 
average change in 
pain and mood 
over time 
 
 
 
 
Testing for 
average change in 
alcohol intake and 
abstinence days 
 
 
N=71 participants with 
chronic 
temporomandibular 
pain  
Demographics: N=71 
female (86%), age 38 
years, SD 12, white 93%. 
 
 
 
 
N=91 participants with 
chronic pain 
Demographics: Sample 
primarily white, female, 
married. Means range: 
49.0 to 53.5 years 
 
 
 
 
 
N=35 participants with 
rheumatoid arthritis  
Demographics: 10 men 
and 25 females, mean 
age 52.4, SD 12.3, 
predominantly married 
and  well educated 
 
N=27 men with alcohol 
dependency 
Demographics:  mean 
age 46.6 years, SD 7.8, 
33% married 
Daily electronic diary Palm OS: 
2 weeks, 3 daily data entries 
audio prompted at 
predetermined times by 
participants.  Compensation 
payment for adherence to data 
collection protocol.   
 
 
 
 
Daily electronic diary Sony Clie:   
4 groups:   
A: control no EMA (n=23), B: 3 
entries per day (n=23), C: 6 
entries per day (n=22), D: 12 
entries per day (n=24), all for 
14 days.  Audio prompted.  
Compensation payment for 
adherence to data collection 
protocol.    
 
Pre-programmed wrist-watch 
(Seiko RC-4000 Wristmac) and 
paper diary.  1 week, 7 daily 
audio prompts to signal data 
collection 8am – 9 pm  
 
 
 
Pre-programmed wristwatch 
and paper diary.  1 week, 8 
daily signals 8am -10pm. 
Compensation payment for 
adherence to data collection 
protocol 
 
Response rate approx 91% for N=71.  Diary 
was not reactive based upon the non-
significant change over time in pain scores. 
Subjective participant reports assessed 
using study feedback questionnaire 
identified approximately 75% of participants 
reported the electronic diary affected their 
pain, affected their daily activities (50%), 
their mood (39%) and their beliefs about 
their pain.   
 
Diary was not reactive based upon the non-
significant change over time in pain scores 
in relation to the frequency of data 
collection.  Significantly different response 
rates for the 3 EMA groups but overall 
compliance rates high.  12 entries per day 
reported the most burden form the EMA 
schedule compared to the other 2 EMA 
groups. 
 
 
Diary was not reactive based upon the non-
significant change over time in pain scores 
or mood scores in relation to the frequency 
of data collection  
 
 
 
 
Diary was not reactive based upon non-
significant change over time in the number 
of days drinking and abstinence in relation 
to the frequency of data collection.  70% of 
men reported the EMA approach made 
them aware of the drinking problems and 
therefore made them drink less   
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Reactivity of the EMA approach has been examined using both paper-based (Litt 
et al., 1998, Cruise et al., 1996) and electronic-based (Aaron et al., 2005, Stone et 
al., 2003a) approaches which did not find any reactive effects of the EMA 
approach (see table 4.1).  There are a number of methodological limitations which 
featured in each of the studies.  Participants who used a paper-and-pencil 
recording diary may have fabricated their answers by forward and backfilling their 
diaries, and may have introduced retrospective memory recall (Litt et al., 1998, 
Cruise et al., 1996).  Cruise’s study had 50% missing data in the participants’ 
paper-based diaries and, therefore, was at risk of a type two statistical error; for 
example, believing that pain levels did not change over time, when, in fact, pain 
levels may have changed.  Lastly, both of the studies that included paper-based 
EMA approaches had small study samples (Cruise N=35 and Litt N=27) and that, 
therefore, limits the generalisabilty of their study findings because the 
participants were not representative of the wider population.   
 
For the electronic diary studies (Aaron et al., 2005, Stone et al., 2003a) they were 
biased in favour of white females, and this sample therefore limits the 
generalisabilty of the findings to men and to people from different ethnic groups.  
It is possible that reactive effects of the EMA approach may have been masked by 
the study designs.  Across the four reviewed studies (Aaron et al., 2005, Stone et 
al., 2003a, Cruise et al., 1996, Litt et al., 1998), data collection was limited to 
either 1 week or 2 weeks and these durations may not have been long enough to 
detect reactive effects.  The salient and chronic nature of pain and alcoholism in 
the study samples may have produced reactive effects earlier in the course of 
their illnesses.  In other words, participants may have been “informally” 
monitoring their pain levels and cravings for alcohol for some time, so reactive 
effects would have already taken place.  Three studies (Litt et al., 1998, Aaron et 
al., 2005, Stone et al., 2003a) used payment as an incentive for adherence to the 
study protocol.  Payment may have influenced response rates and the potential of 
reactive effects.    
 
Finally, it is important to acknowledge the limitations of the operational definition 
of reactivity.  Commonly, a lack of reactive effect for daily pain scores and alcohol 
intake was defined by the absence of any statistically significant change in the 
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variable of interest over time (Aaron et al., 2005, Stone et al., 2003a).  Using such 
criteria is problematic for a number of reasons to evaluate reactivity to the EMA 
diary.  If a significant change in pain scores was observed within the reviewed 
studies, the assumption that the change was due to reactivity is questionable.  
Patients’ pain can change due to a number of factors, including regression to the 
mean (Bowling, 2002), treatment modifications, and altered health states over 
time.   Testing reactivity in this way assumes that reactivity is a gradual build-up of 
the effect of the EMA diary, whereas reactive effects may happen on the first day 
of data collection and subsequently remain unchanged.  Importantly, all of the 
reviewed studies measured reactivity as a gradual change in average scores of the 
variable of interest over time.  In addition, reactivity could be observed as a 
change in associations between two or more variables over time.  This 
relationship was not assessed.   
 
A further key limitation to Aaron, Litt and Cruise’s studies was the lack of a control 
group and, therefore, the findings are treated with caution. In the absence of a 
comparison group, it is impossible to know how changes in the variables of 
interest would have been affected without the EMA approach.  None of the 
reviewed studies identified any statistically significant reactive effects; however, 
due to a number of limitations which featured in each study, the findings are 
treated with caution.  
 
Subjective reports were assessed using a study feedback questionnaire and a 
debriefing interview at the end of data collection (Aaron et al., 2005, Litt et al., 
1998).   Aaron identified that 75% of the study participants reported that the 
electronic diary affected their pain, daily activities (50%) and their mood (39%).  In 
addition, Litt and colleagues identified that 70% of men identified that the EMA 
approach made them more aware of their drinking problem and, therefore, made 
them drink less. Both studies identified that the EMA process may have been 
reactive but the statistical results indicate otherwise, because the quantitative 
findings failed to reach statistical significance.  The subjective reports may have 
been affected by retrospective memory recall.  There are a number of problems 
with the evidence base for reactivity of the EMA approach.  It is unlikely that 
reactivity would threaten the validity of this method, but additional research 
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would useful for different patient groups, in particular, people affected by cancer, 
given the context of this research. 
 
A further consideration to the EMA approach is habituation.  Habituation has 
been described as the development of habitual responses when completing the 
diary, that is to say, a tendency to skim over questions that rarely apply to the 
participants’ experience (Bolger et al., 2003).  To date, no research has explored 
the influence of habituation on diary data collection and remains unknown.  
Repeated exposure to diary questions over time may change participants’ 
understanding of a particular construct, in particular, increased complexity and 
gradual entrainment (Bolger et al., 2003).  Increased complexity refers to the 
development of a more advanced understanding of a particular construct as a 
result of repeated exposure to the surveyed domain, whereas, gradual 
entrainment has been described as participants changing their conceptualisation 
of their illness to fit with those measured in the diary.  Bolger and colleagues have 
suggested such complexities are possible, but to date, no study has formally 
tested for increased complexity or gradual entrainment in diary studies.  In 
summary, there is very little evidence to support that the complexities 
acknowledged in the aforementioned occur in the participant experience, or pose 
a threat to the diaries validity (Suedfeld and Pennebaker, 1997, Thomas and 
Diener, 1990).  
 
The EMA electronic diary has not been applied to men with prostate cancer and 
therefore, recruitment and compliance rates for the EMA electronic diary are 
unknown for this patient group.  A potential strategy to test the feasibility of this 
method and to assess change over time is to use single-case studies (n of 1) 
(Borckardt et al., 2008, Molenaar, 2004, Crane et al., 2003).  Single-case designs 
have been described as a repeated-measure design in which a single participant is 
observed over time, whereby the individual serves as their own control and a 
number of observations are taken over a set period of time (Lillie et al., 2011).  
Single-case studies are also commonly known as N-of-1.  Single-case studies (N-of- 
1) enable researchers to monitor behaviour change over time.  Usually the 
participant is monitored though the use of a daily diary to test the relationships 
between independent and dependent variables of interest (Hadert and Quinn, 
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2008).  This design requires a very small number of participants but enables 
assessment of an “individual” and how variables of interest changes over time, 
and reduces retrospective memory recall.  The value of this design has enabled a 
better understanding of symptom management (Crane et al., 2003) and has been 
applied to cancer research (Bruera et al., 1992), albeit not prostate cancer 
patients specifically. 
 
To address the aim of this Ph.D. study, an EMA adapted/n-of-1 design was 
conducted to assess change over time, and test the social support theoretical 
model (Cohen et al., 2000) within individuals.   The rationale for the EMA adaption 
in the current study was based on a number of important factors.  The EMA 
method has not been applied to this patient group, and therefore there were a 
number of unknown factors, and these include:  a) agreement to complete the 
diary, and b) participant adherence to data collection protocol.  
 
The innovative EMA adapted/N-of-1 design has the potential to expanded 
empirical reach to capture patient experience as it unfolds in real time, and would 
enable the social support theoretical model (Cohen et al., 2000)  to be tested 
within individuals (Molenaar, 2004).  The EMA adapted/N-of-1 study aimed to 
overcome some of the problems associated with the prospective longitudinal 
survey.  The complementary methodology aimed to understand change over time 
based on group level effects, and within the individuals (Bolger et al., 2003).  
Ultimately, the researcher considered the complementary methodology offered a 
broad, rich and in-depth understanding that would contribute to a better 
knowledge of men’s experiences of social support, coping and self-management 
in relation to physical and psychological well-being.   
 
The following chapter identifies the research aim, research questions and the 
methods chosen for the prospective, longitudinal survey and the EMA adapted/N-of-
1 studies to address the questions.  The planned analysis, and data screening and 
cleaning in preparation for statistical analysis are also described. 
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4.3 Aim of the study   
The aim of this Ph.D. study was to test the mechanism effect of coping and social 
support on HRQoL between individuals and within individuals affected by prostate 
cancer.  This Ph.D. also aimed to identify the self-management behaviours of men 
affected by prostate cancer over time.   
4.4 Research questions  
To meet the aim of the study, specific research questions were informed and justified 
by the findings from the structured literature reviews in chapters 1, 2, and 3:  
 
Questionnaire survey 
1. Approximately 1 month after a prostate cancer diagnosis, this study will 
examine the following question. What is the relationship between demographic 
(age, socio-economic status, educational level) and clinical (staging, PSA, Gleason 
Score and treatment) variables in men affected by prostate cancer and the 
following: 
a) coping, 
b) social support, 
c) health-related quality of life, 
e) anxiety and depression, 
e) self-efficacy, 
f) stress, 
g) self-management? 
 
2. How does the following change between recruitment 1 month after 
diagnosis (time 1) and 7 months after diagnosis (time 2):  
a) coping, 
b) social support,  
c) health-related quality of life, 
e) anxiety and depression, 
e) self-efficacy, 
f) stress, 
g) self-management? 
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3. Controlling for baseline (time 1; 1 month after diagnosis) 
characteristics/variables, does social support (perceived, received and 
satisfaction level) moderate/mediate the relationship between coping and a) 
anxiety,  b) depression, c) health-related quality of life, at time 2 (7 months after 
diagnosis)? 
EMA adapted/N-of-1 (electronic behavioural diary) 
In men affected by prostate cancer: 
 
1a. Which patient characteristics influence agreement to complete the EMA 
adapted/N-of-1 data?  
 
1b. What are the response rates of participants filling in a diary over several weeks? 
 
2a. What are the daily self-management behaviours in real time and do they change 
over time? 
 
2b. What are the daily social supportive experiences in real time and do they change 
over time? 
 
2c. Do social supportive experiences have a main effect, or do they 
moderate/mediate the relationship between coping and mood in real time? 
 
4.5 Theoretical framework 
The stress buffering model (Cohen et al., 2000, Cohen, 1988, Cohen and Wills, 1985, 
Cohen and McKay, 1984, Cohen and Hoberman, 1983) was considered appropriate as 
the theoretical framework for this study because it enabled 
main/moderation/mediation effects of social support, coping, and physical and 
psychological well-being to be tested. This theoretical model suggests that these 
effects exist.  Chapter 2 demonstrated that social support has been found to be a 
predictor of HRQoL, but little is known about the mechanisms through which social 
support operates with coping and HRQoL in prostate cancer survivors, that is to say, 
main/moderation/mediation effects.  The analysis will test the prediction of this 
framework (Cohen et al., 2000) for main/moderation/mediation effects of social 
support and coping on physical and psychological well-being in prostate cancer 
survivors.  This model has been tested in participants with long-term conditions 
(Pereira and Canavarro, 2009, Newsham, 1998, Doeglas et al., 1994) and in cancer 
(Gremore et al., 2011, Carpenter et al., 2010, Kroenke et al., 2006), however, this 
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model has been researched in prostate cancer to a much lesser extent.  Testing this 
model between and within prostate cancer survivors was hoped to advance the 
current evidence base.  The theoretical framework includes several components that 
were of particular interest in this study, namely:  social support, coping, and physical 
and psychological well-being (see figure 4.1 for theoretical model).     
Stress Effect: Prostate 
Cancer
· Coping
· HRQoL
· Anxiety and Depression
· Self-efficacy
· Self-management
· Stress
Social Support
Health Status
· HRQoL
· Anxiety and 
Depression
B
Buffer
A
CC
KEY
A=Direct effect
B=Moderation effect
C=Mediation effect
 
Figure 4.1 Stress Buffering Model – Study Model 
4.5.1 Participant characteristics 
 
This study was designed to recruit men diagnosed with prostate cancer (of all 
stages and treatments) at approximately 1 month after diagnosis but before 
treatment from 2 teaching hospitals (Ninewells Hospital and Perth Royal 
Infirmary) in Scotland.  Recruitment took place between April 2010 and March 
2011.  Inclusion criteria included patients over 18 years of age, with an awareness 
of their cancer diagnosis, before receiving treatment for their prostate cancer and 
able to give informed consent. Exclusion criteria were those patients identified by 
their clinical care team to be physically or psychologically unfit to take part in the 
study, and therefore unable to give informed consent.   
4.5.2 Prospective survey sample size calculation 
 
A power analysis was conducted using the software package G*Power (G*Power, 
2008).  This calculation assumed effect size (f²) of 0.15 (a medium effect size) 
(Petrie and Sabin, 2005), alpha level of 0.05, and power of 0.80, and the number 
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of predictors as 10.   The software package calculated the optimum sample size as 
90.  Given that there were 230 new prostate cancer patients in NHS Tayside each 
year (on the advice from staff at the clinical site where the research was being 
conducted), it seemed reasonable to assume that it would be possible to recruit 
108 patients (over a one-year period) to the study, which would allow for some 
attrition given the nature of the longitudinal design.  However, the actual number 
of men diagnosed with prostate cancer during the recruitment phase of this 
research was considerably less than previously advised by clinical staff.  To ensure 
that each regression analysis was powered sufficiently, the researcher used the 
following power calculation equation: N=50 + 8m (where m is the number of 
independent variables) as detailed in chapter 5.       
4.6 Prospective, longitudinal survey 
4.6.1 Methods of the prospective, longitudinal survey 
 
In relation to the research questions, the questionnaire survey was used to assess 1) 
the relationship between demographic and clinical variables with self-efficacy, 
coping, social support, stress,  self-management, anxiety and depression and HRQoL, 
2) evaluate changes in self-efficacy, coping, social support, stress,  self-management, 
anxiety and depression and HRQoL, at approximately 1 month after diagnosis and 7 
months follow-up, and 3) to test whether social support has a main effect, or 
whether social support moderates/mediates  the relationship between coping and a) 
anxiety, b) depression, and c) HRQoL.  Participants completed the questionnaire 
survey at approximately 1 month after diagnosis (before treatment) and 
approximately 7 months after diagnosis.   
4.6.2 Socio-demographic variables 
Date of birth was obtained from medical records and confirmed with the patient.  
Marital status, education and employment were obtained verbally from the 
participant.  Deprivation was assessed using the Scottish Index of Multiple 
Deprivation (SIMD) (Scottish Government, 2009).   The SIMD combines 38 indicators 
across 7 domains, namely: income, employment, health, education, skills and 
training, housing, geographic access and crime.   Scores are calculated using 
postcodes and represents a “relative” measure of deprivation in any one 
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geographical area. The term “relative” means, for example, that the index can tell if 
an area is more or less deprived than another area, but not by how much, and it will 
not determine individual deprivation.  The SIMD compares geographical areas from 
the most deprived (rank 1) to the least deprived (rank 6,505) data zones.  Commonly, 
quintiles (20%) are used to determine wider concentrations of deprived areas in 
Scotland (see table 4.2).   
Table 4.2 SIMD rank 
  
SIMD 
Rank   
Quintile (20%) From To 
1 1 1301 
2 1302 2602 
3 2603 3903 
4 3904 5204 
5 5205 6505 
 
The scores formed a categorical variable with five categories (one being the most 
deprived to five being the least deprived).  For full methodology of the SIMD, see the 
SIMD technical report (Office of the Chief Statistician, 2009).  Age, marital status, 
education, employment and deprivation variables were used to describe the sample 
and to address the research questions.  These variables were also important to 
identify bias for agreement to complete the electronic behavioural diary, in addition 
to assess section bias (using age variable only, due to NHS ethics restrictions for 
confidentiality of the patients) and attrition bias.   
4.6.3 Clinical variables 
Cancer stage, PSA, Gleason score, treatments and co-morbidity were collected from 
medical records.  These variables were used to describe the sample and to identify 
bias for agreement to complete the electronic behavioural diary, and those who did 
not, in addition to assess attrition bias and selection bias (using cancer stage and 
treatment only, due to NHS ethics restrictions for confidentiality reasons).   
4.6.4 Questionnaire instruments  
 
Perceived Stress Scale (PSS) (Cohen et al., 1983) 
The Perceived Stress Scale (PSS) is a 10-item questionnaire commonly used for 
measuring the perception of stress.  The items are designed to measure how 
unpredictable, uncontrollable, and overloaded respondents find their lives; in 
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particular, it measures the perceived degree to which environmental demands 
exceed abilities to cope (Cohen et al., 1983) in the past month.  The instrument is 
easy to understand and takes minutes to complete (Cohen and Williamson, 1988).   
Respondents are asked to report their thoughts and feelings during the past month.   
The PSS has been widely applied to clinical settings: meningitis (Burns et al., 2002), 
respiratory tract infections (Fondell et al., 2011), bacterial vaginosis in human 
pregnancy (Harville et al., 2007, Culhane et al., 2001), wound healing (Ebrecht et al., 
2004), skin disorders (Garg et al., 2001), interstitial cystitis (Gottsch et al., 2011), 
survivors of suicide (Mitchell et al., 2008) and prostate cancer (Stone et al., 1999). 
Internal reliability has been demonstrated using the Cronbach’s alpha statistic 0.87 in 
prostate cancer participants (Stone et al, 1999). Validity has been demonstrated with 
significant correlations found in poor diabetic control of blood sugar levels (Surwit et 
al., 2002).  The scoring of the PSS are obtained by reverse scoring the responses (e.g. 
0=4, 1=3, 2=2, 3=1, 4=0) to the four positively weighted questions (items 4, 5, 7 and 
8) and then adding together all the scores across all the items.  No normative data 
are available for the PSS in prostate cancer respondents; however, normative data 
are available within a non-clinical sample of 2,387 respondents in the United Stated 
(Cohen, 1994) see table 4.3. 
Table 4.3 Norm Table for the PSS 10-item questionnaire  
  Category N Mean S.D. 
Gender 
Male 
Female 
Age 
18-29 
30-44 
45-54 
55-64 
65 & older 
Race 
White 
Hispanic 
Black 
Other minority 
 
926 
1406 
 
645 
750 
285 
282 
296 
 
1924 
98 
176 
50 
 
12.1 
13.7 
 
14.2 
13.0 
12.6 
11.9 
12.0 
 
12.8 
14.0 
14.7 
14.1 
 
5.9 
6.6 
 
6.2 
6.2 
6.1 
6.9 
6.3 
 
6.2 
6.9 
7.2 
5.0 
 
Berlin Social Support Scale (BSSS) (Schulz and Schwarzer, 2003) 
This 38-item questionnaire was developed for the study of social support in cancer 
participants (Schulz and Schwarzer, 2003).  This instrument has a multidimensional 
design that assesses the following constructs: perceived social support (item 
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numbers 1-8), received social support (item number 24-38), need for support (item 
numbers 9-12), support-seeking (item numbers 13-17), protective buffering (item 
numbers 18-23) and satisfaction level (item number 38) with social support in the 
past month.  The authors of this questionnaire have not defined what is meant by 
“protective buffering” and this scale includes the following items: I kept all bad news 
from her/him, I avoided everything that could upset, her/him, I showed strength in 
her/his presence, I did not let him notice how bad and depressed I felt, I avoided any 
criticism, and I pretended to be very strong, although I did not feel that way.     The 
BSSS has been applied to clinical settings in the following patient groups: depression 
(Wojtyna et al., 2007), HIV (Luszczynska et al., 2007b), stem cell transplantation 
(Herzberg et al., 2010), prostate cancer participants (Scholz et al., 2008) and mixed 
cancer sites (Boehmer et al., 2007, Luszczynska et al., 2007a, Luszczynska et al., 
2005).  The Cronbach’s alpha statistics for the subscales are as follows: perceived 
social support 0.83, received social support 0.83, need of support 0.63, seeking 
support 0.81, protective buffering 0.82.  Validity has also been identified in a number 
of studies (Scholz et al., 2008, Schulz and Schwarzer, 2003).  The respondents rate 
their agreement level with statements on a four-point rating scale (1 strongly agree, 
2 somewhat agree, 3 somewhat disagree, and 4 strongly disagree).  Negative items 
(items 4, 5, 6, and 12) are reversed-scored.  Scale scores are generated by calculating 
a mean score.  No normative data are available for the BSSS questionnaire.   
 
Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983) 
This 14-item questionnaire assesses anxiety (7 items) and depression (7 items) 
(Snaith and Zigmond, 1988, Snaith and Zigmond, 1986, Zigmond and Snaith, 1983) in 
non-psychiatric patients.  This measure asks respondents to report how they have 
being feeling in the past week.  An exploratory factor analysis of the HADS was 
carried out on 568 newly diagnosed cancer participants by Moorey et al. (1991).  
Reliability has been demonstrated for the anxiety and depression scales, with 
Cronbach’s alpha at 0.93 and 0.90, respectively.  Validity of this measure has been 
identified in a number of cancer studies, including prostate cancer studies (Jadhav et 
al., 2010, Zenger et al., 2010, Nelson et al., 2009, Avery et al., 2008, Gerbershagen et 
al., 2008, Burnet et al., 2007, Brindle et al., 2006, Bisson et al., 2002).  Each item is 
scored from 0 to 3, so the total score ranges from 0 to 21 for both of the subscales.  
Higher scores indicate greater anxiety and depression.  A score of 8 – 10 on each 
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subscale would indicate the possibility of anxiety and depression, whereas a score of 
11 and above would indicate probable anxiety and depression.  The HADS is a 
screening measure of possible anxiety and depression and actual cases of anxiety and 
depression would have to be confirmed by a clinical psychiatrist.  In a sample of 568 
newly diagnosed cancer participants, Moorey et al., (1991) found a mean score for 
the anxiety and depression subscale scores of 5.44 (SD 4.07, range 0-19) and 3.02 (SD 
2.98, range 0-15) respectively.    
 
Mental Adjustment to Cancer Scale (MAC Scale) (Watson et al., 1988a) 
This 40-item questionnaire provides an assessment of participants’ “psychological 
adjustment” (coping response) to the diagnosis of cancer.  It is an instrument 
developed specifically for the assessment of coping styles in cancer participants. This 
instrument is internationally used and widely implemented in cancer studies; mostly 
breast cancer (Carlsson et al., 2005, Inoue et al., 2003, Okano et al., 2001, Osborne et 
al., 1999, Schnoll et al., 1998), but also in other cancer groups, namely: lung cancer 
(Mulcare et al., 2011, Uchitomi et al., 2003), laryngeal cancer (Johansson et al., 2011) 
and prostate cancer (Couper et al., 2010, Shields et al., 2004). It has five subscales: 
fighting spirit, helpless/hopeless, anxious preoccupation, fatalistic, and avoidance.  
The number of items in each subscale and score ranges are detailed in table 4.4 
below:  
Table 4.4 Subscale item break down for the MAC scale 
 
Subscale Item numbers Number of items Possible 
range of 
scores 
Fighting spirit 
 
 
 
Helpless/Hopeless 
 
Anxious 
preoccupation 
 
Fatalistic 
 
Avoidance 
4, 5, 6, 11, 13, 16, 18, 20, 26, 27, 
28, 31, 32, 34, 39, 40 
2, 9, 17, 23, 25, 36 
 
2, 9, 17, 23, 25, 36 
 
1, 3, 10, 14, 19, 21, 22, 29, 37 
 
 
7, 8, 12, 15, 24, 30, 33, 35 
 
38 
16 
 
 
 
6 
 
9 
 
 
8 
 
1 
16-24 
 
 
 
2-24 
 
9-36 
 
 
8-32 
 
1-4 
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Internal reliability has been demonstrated with Cronbach’s alpha results for fighting 
spirit at 0.84, anxious preoccupation at 0.65, fatalistic at 0.65, and helpless/hopeless 
at 0.79, with good test-retest reliability (Watson et al., 1988a). More recently, the 
psychometric properties of the MAC scale have been revisited in a varied sample of 
cancer participants (Watson and Homewood, 2008) and the original five styles of 
coping can be subsumed to provide two factors of positive adjustment (item 
numbers: 4, 6, 11, 12, 13, 15, 16, 18, 20, 26, 27, 28, 31, 32, 34, 39, 40) and negative 
adjustment (item numbers: 2, 3, 7, 9, 14, 17, 21, 22, 23, 24, 25, 30, 35, 36, 37, 38) 
scores for general analysis requirements with demonstrated reliability at 0.84 and 
0.84, respectively.  Validity of this measure has been identified through significant 
correlations with the HADS (Watson and Homewood, 2008, Greer et al., 1989).  The 
respondents rate their agreement level with statements on a four-point rating scale 
(1 definitely does not apply to me, 2 does not apply to me, 3 applies to me, 4 
definitely applies to me) for how they are feel at present.   Score are calculated for 
each subscale and indicate the extent to which a particular coping style is being used.   
The new 2 factor cut-off points (positive and negative adjustment) were tested in 
1255 patients with various cancer diagnoses and the reference scores are detailed 
below: 
Table 4.5 MAC scale scores for positive and negative adjustment 
 Negative adjustment Positive adjustment 
Statistics 
N 
Valid missing 
Mean 
Std. Deviation 
Range 
Minimum 
Maximum 
 
1148 
112 
29.37 
6.81 
37.00 
16.00 
53.00 
 
1156 
104 
54.06 
6.74 
49.00 
19.00 
68.00 
 
Self-care self-efficacy Scale (SE Scale) (Schwarzer and Jersualem, 1992) 
This 7-item questionnaire measure allows the evaluation of general beliefs in one’s 
ability to respond to and control environmental demands and challenges.  This is the 
belief that one can perform a novel or a difficult task, or cope with adversity in 
various domains of human functioning.  The general self-efficacy measurement has 
114 
 
 
 
good reliability from 23 nations, with Cronbach’s alpha ranging from 0.76 - 0.90 with 
good test-retest reliability (Schwarzer and Jerusalem, 1995).  Previous cancer studies 
have used the SE Scale for general self-efficacy beliefs (Boehmer et al., 2007, 
Luszczynska et al., 2005).  The SE scale is designed to assess generalised self-efficacy 
beliefs (Schwarzer and Jerusalem, 1992); however, Bandura (1997) proposed that 
self-efficacy should be measured in the context of the specific task to be performed.  
He argues that generalised measures of self-efficacy lack specificity and sensitivity 
(Bandura, 1997).  General measures do not provide an assessment of the specific task 
or context of one’s belief or confidence to perform a particular behaviour (Bandura, 
1997). The SE Scale (Schwarzer and Jersualem, 1992) was modified to encompass a 
specific self-care self-efficacy measure for the context of this study, the scores range 
from a minimum of 1 to a maximum of 4.  No normative data exists for this 
questionnaire.    
 
EORTC Quality of Life (QLQ C30) Prostate module (PR25) (Aaronson et al., 1993) 
This 30-item questionnaire is an integrated measurement system for health-related 
quality of life (HRQoL) in cancer participants.  This is an internationally-recognised 
instrument developed over ten years, and has been used in more than 2200 cancer 
studies (Fayers et al., 2001) and, specifically, prostate cancer studies (Galvao et al., 
2010, Queenan et al., 2010, Berglund et al., 2007, Culos-Reed et al., 2007, Augustin et 
al., 2002).  It evaluates the following functional scales: physical, role, emotional, 
cognitive and social; symptoms: fatigue, nausea and vomiting, pain, dyspnoea, 
insomnia, appetite lose, constipation, diarrhoea; financial difficulties; and global 
health status/quality of life.  The number of items in each subscale and the score 
ranges are detailed in table 4.6.  
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Table 4.6 Subscale item break down for the EORTC C30 
 Number of items Item range* Item numbers 
Global health status/quality of 
life 
Global health status/QOL 
 
Functional scales 
Physical functioning 
Role functioning 
Emotional functioning 
Cognitive functioning 
Social functioning 
 
Symptom scales / items 
Fatigue 
Nausea and vomiting 
Pain 
Dyspnoea 
Insomnia 
Appetite loss 
Constipation 
Diarrhoea 
Financial difficulties 
 
 
2 
 
 
5 
2 
4 
2 
2 
 
 
3 
2 
2 
1 
1 
1 
1 
1 
1 
 
 
6 
 
 
3 
3 
3 
3 
3 
 
 
3 
3 
3 
3 
3 
3 
3 
3 
3 
 
 
29, 30 
 
 
1 to 5 
6, 7 
21 to 24 
20, 25 
26, 27 
 
 
10, 12, 18 
14, 15 
9, 19 
8 
11 
13 
16 
17 
28 
*Item range is the difference between the possible maximum and the minimum response to individual items; most 
items takes values from 1 to 4, giving a range =3 
(Fayers et al., 2001, p.7) 
 
Respondents are asked to report scores in the past week. Internal reliability for the 
subscales has been identified from 0.70 to 0.90, and validity has also been reported 
(Aaronson et al., 1993).  A high score in HRQoL represents high HRQoL, but a high 
score for symptoms scale represents a high level of symptomatology.  Normative 
data is detailed in table 4.7 for a heterogeneous sample (all prostate cancer stages). 
Table 4.7 Normative data for EORTC C30 
Constructed scales Mean (SD) Median IQR 
Global health status/quality 
of life 
Global health status/QOL 
Functional scales 
Physical functioning 
Role functioning 
Emotional functioning 
Cognitive functioning 
Social functioning 
Symptom scales / items 
Fatigue 
Nausea and vomiting 
Pain 
Dyspnoea 
Insomnia 
Appetite loss 
Constipation 
Diarrhoea 
Financial difficulties 
  
 
 
68.4 
 
80.2 
82.7 
76.6 
83.2 
80.2 
 
26.9 
5.1 
23.3 
16.8 
24.5 
10.4 
14.6 
8.4 
9.0 
 
 
(22.2) 
 
(25.6) 
(28.2) 
(23) 
(20.8) 
(27.2) 
 
(26.6) 
(14.2) 
(30.3) 
(25.7) 
(30.5) 
(23.6) 
(27.2) 
(19.4) 
(21.5) 
 
 
66.7 
 
93.3 
100 
83.3 
83.3 
100 
 
22.2 
0 
0 
0 
0 
0 
0 
0 
0 
 
 
[50-83.3] 
 
[66.7-100] 
[66.7-100] 
[66.7-100] 
[66.7-100] 
[66.7-100] 
 
[0-44.4] 
[0-0] 
[0-33.3] 
[0-33.3] 
[0-33.3] 
[0-0] 
[0-33.3] 
[0-0] 
[0-0] 
 
       (Scott et al., 2008, p.268) 
 The Prostate Model for the EORTC Quality of Life (QLQ C30) tool (PR25) was used in 
this thesis to assess disease-specific HRQoL.  It is a 25-item questionnaire designed 
for use among participants with localised, locally advanced and metastatic prostate 
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cancer.  The subscales assess urinary symptoms, bowel symptoms, treatment-related 
side-effects and sexual functioning and are detailed in table 4.8. 
Table 4.8 Subscale item break down for the EORTC PR25 
 Number of items Item range* Item numbers 
Functional scales 
Sexual activity 
Sexual functioning 
 
Symptom scales 
Urinary symptoms 
Bowel symptoms 
Hormonal treatment-related Symptoms 
Incontinence aid 
 
2 
4 
 
 
8 
4 
6 
1 
 
3 
3 
 
 
3 
3 
3 
3 
 
20, 21 
22-25 
 
 
1, 7, 9 
10-13 
14-19 
8 
*Item range is the difference between the possible maximum and the minimum response to individual items; most 
items takes values from 1 to 4, giving a range =3  
(van Andel, et al., 2008) 
 
The PR25 questionnaire was tested in a cross-cultural sample of cancer participants 
in 13 countries to confirm hypothesized scale structure, and demonstrates 
acceptable psychometric properties and clinical validity, and internal reliability 
ranges from a low of 0.70 to a high of 0.86 (van Andel et al., 2008).  Currently, there 
are no normative data available for the PR25.   
 
Self-care Log (SCL) (Dodd, 1982) 
This questionnaire measures self-care activities for cancer participants and has 
been predominately used in the study of side-effects and self-care following 
radiotherapy and chemotherapy (Wilson et al., 2010, Kidd et al., 2008, Wong et 
al., 2006, Borthwick et al., 2003, Schumacher et al., 2002, Richardson and Ream, 
1997, Dodd, 1997, Foltz et al., 1996, Nail et al., 1991, Dodd, 1982). Drawing on the 
work of previous research (Wilson et al., 2010, Dodd, 1997, Nail et al., 1991, 
Dodd, 1982), the questionnaire used consisted of 1) the major complaint: urinary, 
bowel, sexual dysfunction, other; 2) self-care actions taken; 3) effectiveness of the 
action, and 4) the sources of suggestions for self-care, see table 4.9 for subscale 
overview. 
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Table 4.9 Subscale break down for the self-care log 
Subscale Item numbers Number of items Possible range 
of scores 
Major Complaint 
Urinary 
Bowel  
Sexual  
Other 
 
Self-care actions 
Urinary 
Bowel 
Sexual 
Other 
 
Effectiveness of self-care actions 
Urinary 
Bowel 
Sexual 
Other 
 
Self-care suggestions 
 
1 
2 
3 
4a-4b 
 
 
1a-1o 
2a-2r 
3a-3o 
4aa-4ae, 4bf-4bj 
 
 
1a-1o 
2a-2r 
3a-3o 
4aa-4ae, 4bf-4bj 
 
5 
 
1 
1 
1 
2 
 
 
15 
18 
15 
10 
 
 
15 
18 
15 
10 
 
8 
 
0-1 
0-1 
0-1 
0-1 
 
 
0-15 
0-18 
0-15 
0-10 
 
 
0-5 
0-5 
0-5 
0-5 
 
0-8 
 
Content validity of the prostate self-care log was established though discussions 
with prostate cancer patients and cancer healthcare professionals at NHS Tayside, 
where this research was being conducted.  No normative data was available for 
the self-care log. 
4.6.5 Procedures 
 
Recruitment procedure 
 
1. Ethics and Research and Development approval was granted for 
this study (10/S1402/7).  The researcher acted in accordance with 
the regulations of the ICH Good Clinical Practice guidelines.  
2. See appendices 4.1 to 4.9 for study documentation (participant 
information sheet, consent form, letters, and survey).  
 
· All patients meeting the inclusion criteria were identified from NHS 
Tayside Urology Multi-disciplinary Team (MDT) Meetings.  All new 
prostate cancer patients within NHS Tayside are discussed at this MDT 
meeting.   
·  An introductory letter, Patient Information Sheet (PIS) and suggested 
time of appointment were sent to patients who met the inclusion criteria.  
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The option for an alternative date and time was included in the reply 
form. 
· Potential participants were given a minimum of 24 hours to consider their 
participation in the research to ensure informed consent. 
· At the appointment, the researcher checked with the patient that they 
read and understood the PIS, any questions were answered by the 
researcher and explanations were provided to ensure informed consent.  
Participants willing to take part in the study were asked to sign a study 
consent form. 
· Consenting participants were given a copy of the signed consent form; 
one copy was filed in the study master file and one copy was filed in the 
patient’s medical notes.   
· A letter was sent to the participant’s General Practitioner (GP) informing 
them of their patient’s participation in the study.  The GP was sent the 
researcher’s contact details in case the GP wanted to discuss their 
patient’s participation in the study.  
 
Data Collection Procedure - Prospective Longitudinal Survey 
 
· Clinical data (PSA, cancer stage, treatment, Gleason Score and co-
morbidities) were obtained from medical records and demographics (date 
of birth, education, marital status, and employment) were obtained 
verbally from the participant. 
· The questionnaire survey data were collected at two time points: time 1 
(after consent [before treatment at approximately 1 month after 
diagnosis]), and time 2 (6 months follow-up).  Participants were given a 
stamped addressed envelope for the return of the questionnaire at time 1 
and time 2.  A 14-day questionnaire reminder letter was sent to 
participants at time 1 and time 2 if the questionnaire was not returned to 
the researcher within 14 days of them having received the questionnaire. 
· Basic demographics (age, cancer stage and treatment, and reason for 
non-participation) were collected for the non-recruits to provide a 
comparison between recruits and non-recruits.   
119 
 
 
 
·  All participants were given a unique study number and all data were 
securely stored in a locked filing cabinet, in a locked room at the 
University of Dundee.  Electronic data were held on a secure University 
network, with access via a password-protected PC. 
4.6.6 Ethical considerations 
 
Participants identified as being at risk of having anxiety and depression (HADS 
score ≥11) had their GP notified by letter.  This step was necessary in order to 
provide a duty of care to the patient.  Participants gave their informed consent on 
the study consent form to enable the researcher to notify their GP.  The 
researcher also notified the patient of their results by telephone when the HAD 
score was ≥11.   
4.6.7 Statistical analysis (prospective longitudinal survey)  
 
Data were double-entered into SPSS version 17.0 to check for discrepancies in the 
data set (Bowling, 2002).  Prior to the analysis, variables were examined for accuracy 
of data entry, missing values and the assumptions of the proposed analysis.  This 
verification was done through traditional exploratory analysis (Tabachnick and Fidell, 
2007).  Normality distributions of the variables were checked by statistical and 
graphical methods.  Skewness and Kurtosis significance values were assessed using 
the Kolmogorov-Smirnov (K-S) test and a histogram was plotted for each variable.  
Appropriate transformations (Tabachnick and Fidell, 2007) of the variables were 
performed to reduce skewness, kurtosis, the impact of outliners, and to improve 
normality, linearity and homoscedasticity.  To address the research questions, 
statistical analysis was performed using parametric tests (Pearson Product Moment 
Correlations, t-tests, repeated measures ANOVA and multiple regression analyses). 
 
Internal reliability of the measures (HADS, EORTC C30, PR25, MAC scale, SE Scale, 
PSS, SCL, BSSS) was evaluated using Cronbach’s alpha statistic (Tabachnick and Fidell, 
2007, Field, 2005).  
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4.7 EMA adapted/N-of-1  
4.7.1 Electronic diary development 
 
The EMA adapted/N-of-1 methodology has not been applied to prostate cancer 
participants before and, therefore, the electronic diary had to be developed.  The 
researcher convened a Ph.D. Steering Group (service users [men with prostate 
cancer], clinicians and research supervisors) to inform the development of the 
electronic diary (see appendix 4.10 for an example of the Steering Group 
documentation).  Informed guidance was essential for the diary development, as the 
EMA adapted/N-of-1 method is extending the field in this patient group.  In addition 
to the advice and comments from the steering group, there was an extensive pilot 
phase of the diary.    
 
The pilot was a two-phase process; “phase 1” involved 11 electronic diary pilots 
among colleagues and acquaintances, with “phase 2” consisting of 3 electronic diary 
pilots directly involving men with prostate cancer.  The pilot enabled the researcher 
to resolve any technical issues and systematically gather feedback on the contents 
and scheduling of the diary (see appendix 4.11 for the results of the pilot).  
4.7.2 Scheduling of EMA Adapted/N-of-1 data collection 
 
For case-based time series analysis, a minimum of 30-60 data points are needed 
(Borckardt et al., 2008).  To account for missing data, the current study aimed to 
capture 90 data points. Each participant collected data for 1 month prompted by 
audio alarm to complete the diary at 3 pre-determined intervals per day (totalling 90 
data points). In addition, the participants could complete an incident entry at any 
time throughout the 1-month period.  The timings of the data collection were 
determined by the participants’ lifestyle, for example, sleeping and waking times, 
and employment commitments.  The data collection timings were at equally-spaced 
time intervals throughout the day, for example, at 8am, 2pm, and 8pm, and 9am, 
3pm, and 9pm.  The “snooze function” enabled a delay for the diary entry from 5 to 
60 minutes if it was inconvenient for the participant to complete the diary entry.  
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4.7.3 Equipment and materials 
 
A small handheld PDA with diary software was used for each participant.  The Dell 
Axim X51 (with Microsoft Mobile Windows Professional 6.0) was supported by 
Pocket Interview Version 0.8.4 which was developed at the School of Computing, 
University of Dundee (Morrison et al., 2009).  The behavioural diary collects mobile 
electronic data which is encrypted using an RC4 cipter (Morrison et al., 2009) to 
ensure data is secure.  These precautions conform to recent NHS Scotland standards 
for data held on laptops, memory stick and all other mobile devices.   
4.7.4 Data collection procedure (EMA Adapted/N-of-1) 
 
A written Standard Operating Procedure (SOP) was developed (see appendix 4.12 for 
SOP) to ensure that each diary was accurately set up in the same step-wise process, 
across all 12 electronic diaries.  The participants were instructed verbally by the 
researcher on the diary usage and were given written instructions (see appendix 4.13 
for the written instructions).  A battery charger was provided to enable the 
participants to recharge the PDA battery every few days over the course of the 
month.  The researcher contacted the participants by telephone 24 hours after 
starting the electronic diary, to answer any questions and resolve any issues that may 
have arisen.  At the end of the 1-month period, the researcher met again with the 
participant to collect the PDA and retrieve the stored data on the device.  The 
electronic diary respondents were interviewed by the researcher to explore their 
experience of completing the diary; this data are not presented as a part of this 
thesis.  
 
4.7.5 Measures Repeated Daily 
 
Researchers have to develop diary instruments (Bolger et al., 2003) as there are no 
standardised instruments available for electronic behavioural diaries.  The content of 
the diary questions were mapped to the constructs of the questionnaires (see 
appendix 4.14 for diary schedule and screenshot examples of the PDA).  The items 
were informed by the literature and comment from clinicians and prostate cancer 
patients.  The diary structure included 7 questions at standard entry, 12 questions at 
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end-of-day entry, and 5 questions at incident entry.  Most question items were 
presented on the PDA using a visual analogue scale (VAS) from 0-100 scale.  The 
question items presented on the diary consisted of a ‘standard diary entry’ 
(completed 3 times per day), an ‘end-of-day entry’ (completed once per day, 
immediately following the third standard entry each day), and an ‘incident entry’ that 
could be completed at any time throughout the 1-month period (see table 4.3 for 
overview and variables).   
Table 4.10 Diary structure overview 
Enquiry Variables Frequency 
Standard Entry Negative and positive affect 
Coping (positive and negative) 
Social support (perceived and received) 
Self-management demand 
Self-management control 
Self-management self-efficacy 
3 times per day, for a 
total of 1 month (n=93)  
End of Day Entry Self-management behaviours (urinary, bowel and 
sexual dysfunction) 
Additional self-management behaviours 
Self-management relief of symptoms 
Self-efficacy 
Satisfaction social support 
Most demanding self-management action 
Medication change 
Quality of life  
Once per day, for a total 
of 1 month (n=31) 
Incident Entry Description of participants challenging 
experience  
Coping (positive and negative)  
Perceived and received social support 
Sought social support 
Positive and negative affect 
Event contingent (any 
time throughout 1-
month period)  
 
 
MOOD:  Mood was assessed at the standard entry and the incident entry.  Positive 
and negative affect (Aaron et al., 2005, Affeck et al., 1998, Watson et al., 1988b) was 
assessed by asking the participants, “How are you feeling just now? … tired, alert, 
happy, nervous, frustrated, sad, stressed, energetic, and angry” using the scale “not 
at all/extremely” (0-100) for each state of affect.  This spectrum enabled positive and 
negative states of affect to be captured.   
 
COPING:  Coping was assessed at the standard entry and the incident entry.  The 
coping styles (fighting spirit, helpless/hopeless, anxious preoccupation, fatalistic, 
avoidance) were based upon the Mental Adjustment to Cancer Scale (Watson and 
Homewood, 2008, Watson et al., 1988a). Participants were asked to rate each of the 
following statements taken from the MAC scale: “I tried to keep a positive attitude” 
(positive attitude), “I felt like giving up” (helpless/hopeless), “I felt problems with my 
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health prevent me from planning ahead” (anxious preoccupation), “I felt that nothing 
I can do will make a difference” (fatalistic), and “I tried not to think about it” 
(avoidance) using the response scale “not at all/always” (0-100) to rate each of the 
coping styles statements.  These items were chosen based on comment and 
collective agreement from the research steering group.  
  
PERCEIVED SELF-EFFICACY:  Self-efficacy was assessed at the standard entry and end-
of-day entry. The question items were based on Schwarzer and Jerusalem’s (1995) 
self-efficacy beliefs.  At the standard entry, participants were asked to “Think about 
the last few hours” and at the end of day, “Overall today I feel that”, rating the 
following statements “I can always manage to complete self-care activities that are 
difficult for me” and “I am confident in carrying out my self-care activities”.    The 
statements were anchored by “not at all/always” on a 0-100 scale.  These items were 
chosen based on comment and collective agreement from the research steering 
group.  
 
SOCIAL SUPPORT:  This was measured at the standard entry, incident entry and at 
the end of day entry.  Participants were asked about perceived, received and 
satisfaction with social support.  The questionnaire items were based on a multi-
dimensional assessment of social support (Schulz and Schwarzer, 2003) and 
underpinned by the theoretical model (Cohen et al., 2000, Cohen, 1988, Cohen and 
Wills, 1985, Cohen and McKay, 1984, Cohen and Hoberman, 1983).  Participants were 
asked, “How much support have you had in the last few hours?” (received social 
support), rating the following four scales “financial, emotional, informational and 
practical”, with all scales anchored by the endpoints, “none/a lot” on a 0-100 scale.  
Perceived social support was measured by asking “Do you have enough available 
support from people around you?” and rated by offering the same scales as received 
social support.  During the standard entry, participants were also asked “Have you 
sought out support in the last few hours?” and used a check box to indicate “yes or 
no”.   
 
At the incident entry, the question, “Did you seek out support to help with this 
experience?” was asked, using a check box to indicate “yes or no”.  Perceived support 
was also asked at the incident entry, “Did you have enough support available from 
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people around you?” and “was that enough support?”  Both items used the response 
scale “not at all/always” (0-100).   
SELF-MANAGEMENT DEMAND AND SELF-MANAGEMENT CONTROL:  Participants 
were asked at the standard entry to “Think about self-care activity in the past few 
hours” and rate the following statements “How demanding has self-care been for 
you?” (self-care demand) with the response scale “not at all/extremely” (0-100) and 
“how much control have you had over your self-care?” (self-care control) anchored by 
“not at all/completely” (0-100) (Cohen et al., 2000).  At the end-of-day entry, “What 
was your most demanding self-care task that you had to do today?” was asked, and, 
using a keyboard, the participant tapped the letters to form words on the PDA to 
answer the question. 
 
SELF-MANAGEMENT BEHAVIOURS: The actual self-management behaviours were 
assessed at the end-of-day entry.  The questions addressed 1) the major complaint, 
2) actions taken, and 3) effectiveness of the action.  The self-management questions 
were based on previous self-management diary research within cancer (Kim, 2011, 
Wilson et al., 2010, Dodd, 1997, Nail et al., 1991, Dodd, 1982) and from comment 
from the steering group/pilot. 
To enquire about urinary self-management, “What types of self-care actions have 
you used today to help with your waterworks (urine)?” was asked, and this was  
answered by selecting the appropriate check box to indicate “yes” to various self-
care actions, such as “took medication, found out information, increased fluid intake, 
used pads, used catheters, …”  For bowel self-management enquiry “what types of 
self-care actions have you used today to help with your bowels?” responding to “took 
medication, increased fluid intake, changed diet, used pads, comfort (hot water 
bottles) …”  Lastly, for sexual function self-management, “What types of self-care 
actions have you used today to help with your sexual function?” was asked, with 
participants responding “yes” to “took medication, found out information, used a 
penis pump, shared my feelings …”  To enquire about how effective the self-
management actions were in relieving the symptoms (individually for urine, bowel 
and sexual self-care), the question, “Generally, did your self-care actions relieve the 
problem?” was anchored by “not at all/completely” (0-100). 
125 
 
 
 
To assess other self-management activities for additional problems or symptoms, 
“Did you use any other self-care activities (not already mentioned) to help alleviate 
your symptoms/problems today?” was asked, with participants responding by 
selecting the box to indicate “yes or no”.   If “yes” was selected, the request to 
“Please describe the problem/symptom for which you carried out your self-care” and 
“Please describe the self-care tasks” was offered, and the participant responded by 
tapping letters to form words.  To assess about the effectiveness of the action, the 
question, “Generally, did your self-care actions relieve this problem?” was anchored 
by “not at all/completely” (0-100). 
HEALTH-RELATED QUALITY OF LIFE/SYMPTOMS:  Items were based on the EORTC 
quality of life instruments for cancer participants that include general and disease-
specific HRQoL (Aaronson et al., 1993).  Items were asked at the end of day: “How 
would you rate your quality of life today?” anchored by “very poor/excellent” on a 0-
100 scale, and “To what extent have you experienced the following symptoms today? 
(blood in the urine, constipation, diarrhoea, nausea, pain, tiredness, unable to sleep, 
urgency to pass urine, urinate frequently day, urinate frequently night, vomiting, 
impotence)” with each symptom anchored to the end points “not at all/always” on a 
0-100 scale.   
Participants were also asked “Has there been any change to your 
treatment/medication today?”, and answered by selecting the appropriate check box 
to indicate “yes or no”.  If “yes”, the option, “Please describe what the treatment 
change was” was offered, with the participant responding by tapping letters on the 
keyboard to form words.   
4.7.6 Sampling framework 
 
The participants were identified from a sampling framework defined by: cancer stage 
(localised, locally advanced, metastatic), having a partner or not, and self-reports of 
social support (using the Berlin Social Support Scale [BSSS] at baseline recruitment).  
Research using the BSSS questionnaire was reviewed (Scholz et al., 2008, Luszczynska 
et al., 2007a, Boehmer et al., 2007, Schwarzer et al., 2006, Luszczynska et al., 2005) 
to establish previously reported data on the mean and SD for men with prostate 
cancer to guide the sampling framework (see appendix 4.15 for overview of the 
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studies).  This sampling framework criteria was important for a number of reasons: 1) 
this enabled self-management behaviours to be assessed based on the severity of 
cancer stage, and 2) to explore the influence of social support on self-management 
behaviours for men affected by prostate cancer (Department of Health Macmillan 
Cancer Support & NHS Improvement, 2010, Ream et al., 2008, Boberg et al., 2003, 
Lintz et al., 2003).  
 
The sampling framework used the means and SDs for current study participants 
(N=11) during the first 2 months of active recruitment.  The mean was found to be 
3.2 (SD 0.6, [range 2.2 to 4.0]) and participants were recruited using 1 SD (3.8) above 
to indicate high social support and 1 SD (2.6) below to indicate low social support 
(see table 4.4 for sampling framework). 
Table 4.11 Sampling framework for electronic behavioural diaries 
 Partner No partner 
Localised 3.8 ≥ to indicate high social support 
2.6 ≤ to indicate low social support 
3.8 ≥ to indicate high social support 
2.6 ≤ to indicate low social support 
Locally advanced 3.8 ≥ to indicate high social support 
2.6 ≤ to indicate low social support 
3.8 ≥ to indicate high social support 
2.6 ≤ to indicate low social support 
Metastatic 3.8 ≥ to indicate high social support 
2.6 ≤ to indicate low social support 
3.8 ≥ to indicate high social support 
2.6 ≤ to indicate low social support 
 Total = 12 individual case studies. 
 
Participants completed the electronic diary during their 6 months of participation in 
the study (see table 4.5 for data collection timings).  The timings for data collection 
were informed by clinicians and prostate cancer patients. 
Table 4.12 Diary data collection timing 
Treatment Timing of  data collection 
Radical Prostatectomy (RP) 1 month following RP 
External Beam Radiotherapy (EBRT) 1 month following EBRT 
Hormone therapy No timing restrictions (as soon as possible) 
Active surveillance (AS) No timing restrictions (as soon as possible) 
Brachytherapy (BT) 1 month following BT 
 
The mean and SD for the BSSS (social support) was re-evaluated at approximately 4 
months into active recruitment (N=25).  The mean was found to be 3.6 (SD 0.4), 
calculating the values for the sampling framework as ≤ 3.2 to indicate low social 
support, and 4.0 to indicate high social support such that, the social support values 
guiding the sampling framework earlier in the study were considered appropriate. 
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4.7.7 Statistical analysis (electronic diary) 
 
The electronic behavioural diary data were coded using XML coding and transferred 
into Microsoft Access (this formed part of the Pocket Interview software).  
Subsequently, the data were transferred to SPSS version 17.0 to undertake the 
analysis. 
 
Preliminary analysis (Diary Data) 
Prior to the analysis, variables were examined for accuracy of data entry, missing 
values and the assumptions of the proposed analysis.  This was done through 
traditional exploratory analysis (Tabachnick and Fidell, 2007).  Normality distributions 
of the variables were checked by statistical and graphical methods.  Skewness and 
Kurtosis significance values were checked, the Kolmogorov-Smirnov (K-S) test was 
performed and a histogram plotted for each variable.  Appropriate transformations 
(Tabachnick and Fidell, 2007) of the variables were performed to reduce skewness, 
kurtosis, the impact of outliners, and to improve normality, linearity and 
homoscedasticity.   
 
Autocorrelation and pre-whitening of variables 
The data from the single-case studies has the potential to violate the assumption of 
independence in regression and correlation analysis (Borckardt et al., 2008).  
Therefore, all variables at standard entry (positive affect, negative affect, positive 
coping, negative coping, perceived social support, received social support, self-care 
self-efficacy, self-care demand and self-care control [individually performed for each 
case study]) were examined for autocorrelation using autocorrelograms produced in 
SPSS (Tabachnick and Fidell, 2007).  If a significant autocorrelation was found, a 
statistical correction, known as pre-whitening (Cromwell et al., 1994), was used to 
remove the autocorrelation.  By removing the autocorrelation, inferential statistics 
can be used because the assumption of independence of the data points has been 
met (Crane et al., 2003, Cromwell et al., 1994).  Removing autocorrelation in time 
series data is essential because without correcting the violated assumption of data 
independence it may result in inaccurate P Values, and increase the risk of a type 1 or 
type 2 errors (Borckardt et al., 2008, Tabachnick and Fidell, 2007, Crane et al., 2003, 
Cromwell et al., 1994). 
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The pre-whitening procedure has been described by (Tabachnick and Fidell, 2007, 
Crane et al., 2003) and involves examining the partial plots of autocorrelograms, and 
then creating a new lagged variable based on the number of lag displayed on the 
plot.  In other words, a plot displaying a first-order autocorrelation would require 
producing a new time series variable with a lag of 1, using the original variable.  The 
second step in the pre-whitening procedure requires linear regression.  The new 
lagged variable (IV) is used to predict the original variable (non-lagged series) (DV).  
The unstandardized residuals of the regression analysis become the new pre-
whitened variable.  The final step in the pre-whitening procedure was to undertake a 
quality check.  This was done by plotting and checking an autocorrelogram of the pre-
whitened variable and ensured that the pre-whitening procedure worked in 
eliminating the presence of autocorrelation in the series. 
 
When variables did not meet the assumptions for analyses, transformations were 
required (Tabachnick and Fidell, 2007).  Transformations of the variables are detailed 
individually within the presented case studies. Pearson’s product moment correlation 
analysis was performed between all the variables (including unaltered and altered 
[pre-whitened/transformed] variables).  This enabled the researcher to check that 
the alterations made to the variables did not result in any unexplained relationships 
(this was performed individually across all of the case studies).   Significant 
relationships were considered at the traditional P<0.05 level (Tabachnick and Fidell, 
2007). 
 
Moderation  
Multiple regression analysis was used to examine moderator effects of figure 4.2.  
The variables included in the regression were guided by the theoretical model (Cohen 
et al., 2000, Cohen, 1988, Cohen and Wills, 1985, Cohen and McKay, 1984) and 
having correlations between variables with P<0.15 (Tabachnick and Fidell, 2007).  The 
predictor variable and moderator variable were standardised, so that they had a 
mean of 0 and a standard deviation of 1.  Descriptive statistics were undertaken to 
verify that they were standardised correctly.  Standardising the variables makes it 
easier to plot significant moderation effects and reduces problems of 
multicollinearity (high correlations) among the variables in the regression equation 
(Frazier et al., 2004, Aiken and West, 1991).     The product term was formed by 
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multiplying the standardized predictor and standardized moderator variables 
together.   
 
 
Figure 4.2 Moderation effect  
 
The variables were then entered into hierarchical multiple regression analyses in 
specified blocks.  The first step involved entering the standardised predictor and 
standardised moderator variable, and lastly, to include the product term in the 
model (Frazier et al., 2004, Aiken and West, 1991).   
 
 Mediation 
To test for mediation effects requires performing 3 multiple regression analyses 
(Frazier et al., 2004, Baron and Kenny, 1986).  The first step was to establish that the 
predictor was related to the outcome.  This was achieved by testing the effects of the 
predictor variable on the outcome variable (testing Path C, as indicated in figure 4.3).  
If path ‘c’ was significant, then the first step in mediation was met.  The second step 
was to establish that the predictor and mediator variables were related.  This was 
undertaken by a second regression analysis between the predictor (X) (predictor) on 
the mediator (M) (outcome).  Thus, if path ‘a’ was significant, then the second 
condition for mediation holds. The last step was to test the outcome variable (Y) 
simultaneously on the mediator variable (M) and the predictor variable (X).    If the 
mediator variable (M) was related to outcome variable (Y) then the third step for 
mediation had been met.  Path ‘b’ is estimated by controlling for the effects of the 
predictor.   
 
Predictor variable (X) 
Coping 
Moderator variable (M) 
Perceived or received social support 
Outcome variable (Y) 
Negative affect 
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Figure 4.3 Mediation effects 
 
Interpretation involved identifying that the strength of the relationship between the 
predictor and outcome variables becomes significantly reduced when the mediation 
variable is added to the model.  The Sobel’s test (1982) was also performed to 
establish whether the indirect effect of the independent variable to a dependent 
variable through a mediator variable was significant.  Hayes (2009) identifies that the 
Sobel’s test requires large sample sizes and the assumption that the sampling 
distribution of the indirect effect is normal.  Hayes recommends, in addition to 
Sobel’s tests, that bootstrapping procedures are used because no assumptions about 
the normality is inferred or limited to large sample sizes.  Bootstrapping calculates 
estimates of the indirect effect at 95% and 99% confidence intervals (CI) for the 
population of n  (Preacher and Hayes, 2004).  Bootstrapped sample estimates of the 
indirect effect are interpreted by identifying whether zero is located within the 95% 
CIs.  If zero is not presented within the 95% CI, it can be concluded that a significant 
mediation effect has occurred.  Bootstrapping procedures are based on 5000 random 
resamples of the data, and, as a result, when repeated, the CIs may differ slightly. 
The researcher therefore only reported the results of the first bootstrapping 
procedure.  The Sobel’s test and the 5000 bootstrapped resamples were calculated 
using an SPSS script downloaded from Hayes’ website http://www.afhayes.com/spss-
sas-and-mplus-macros-and-code.html (Preacher and Hayes, 2004). 
4.7.8 Managing data collection (electronic diary) 
 
Several issues were important in the process of data collection during the study.  It 
was important that participants in the study did not feel overburdened or confused 
by what they were asked to do. All instructions and data collection tools were 
practical, simple and not too long in their completion, to reduce respondent 
Predictor variable (X) 
Coping 
Mediator variable (M) 
Perceived or received 
social support 
Outcome variable (Y) 
Negative affect Path A Path B 
Path C 
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confusion and burden. The questionnaire pack was piloted to a small group of 6 men 
and the results identified that the men took between 15-20 minutes to complete the 
questionnaire pack and, therefore, the length of time was acceptable.  Recruitment 
rates were monitored on a monthly basis by using an Excel graph to plot the actual 
recruitment figures against the projected recruitment target.  This graph was shared 
with the Ph.D. supervisors to monitor potential problems and to discuss solutions.  It 
became apparent during the recruitment phase of the project that the number of 
new prostate cancer patients in NHS Tayside was less than the anticipated 230 each 
year.  The researcher attended the clinical sites every week and kept clinical staff 
informed of the study progress through monthly clinical effectiveness meetings, but 
the number of new prostate cancer cases was substantially less than expected. To 
check that the analysis of the prospective longitudinal survey was adequately 
powered, a power calculation for each multiple regression was performed.  
Tabachnick and Fidell (2007) recommend a minimum sample size for multiple 
regression of N ≥ 50 + 8m (where m is the number of independent variables); the 
results of the sample size calculations are reported in chapter 5 (prospective, 
longitudinal results).  The reasons why patients refused to participate in the study, or 
withdrew from the study, were recorded to assess selection and attrition bias.   
 
4.8 Summary 
 This chapter has detailed the research questions, the methods chosen and the 
analysis strategies to address the overall aim and questions set for this study.  The 
purpose of this Ph.D. research was to test the mechanism effect of coping and social 
support on HRQoL between individuals and within individuals affected by prostate 
cancer.  This Ph.D. also aimed to identify the self-management behaviours of men 
affected by prostate cancer over time.  This study followed a quantitative approach 
complemented by a prospective, longitudinal survey, and 12 EMA adapted/N-of-1 
studies.  This approach enabled the theoretical model to be tested between people 
and within-person change over time to advance understanding, but uniquely 
positioning the individual patient at the centre of the research.  This chapter 
highlighted that the design and methods chosen in the current study were important 
for providing insights into, and quantifiable data on, men’s social support and self-
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management behaviours over the course of their cancer journey. The following 
chapter discusses the findings from the prospective longitudinal survey. 
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5.0 Results prospective longitudinal survey  
 
5.1 Abstract 
Background 
Few prospective longitudinal research designs have been implemented to evaluate 
changes in coping, social support and self-management in men affected by prostate 
cancer over time.  The implementation of this prospective longitudinal design 
captured change over time and allowed prediction of HRQoL outcomes which 
addressed the research questions.  Developing an understanding of the mechanism 
effect that links coping and social support to HRQoL over time can help to identify 
men who are at high risk of inadequate support and suggest directions for 
appropriately targeted interventions at an earlier stage in the cancer journey. 
Aim 
To test the mechanism effects between coping and social support on HRQoL using 
group level statistics.  In addition, the prospective longitudinal survey method was 
used to assess the self-management behaviours for men affected by prostate cancer 
over time.  
Methods 
Participants were asked to complete a battery of questionnaires (QLQ C30 and PR25, 
Self-Efficacy Scale, MAC Scale, HADS, PSS, Self-Management Log and BSSS) at 
baseline (approximately 1 month after diagnosis) and at 6 months follow-up 
(approximately 7 months after diagnosis).  Clinical (cancer stage, PSA, Gleason score, 
treatments, and co-morbidity) and demographic (age, marital status, education, 
employment, and deprivation) data were also collected.  Statistical analysis was 
performed in SPSS version 17.0 using parametric tests (repeated measures ANOVA, 
one-way between groups analysis of variance, paired t-tests, bivariate correlations 
and hierarchical multiple regression) and non-parametric tests (Chi² test, Mann-
Whitney U and McNemar’s test).  
Results 
Perceived social support (approximately 1 month after diagnosis) was the most 
important social support construct that predicted global quality of life and depression 
at six months.  Satisfaction with social support (approximately 1 month after 
diagnosis) had a main effect on depression scores at six months.  Social support 
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constructs did not moderate/mediate the relationship between coping and HRQoL.  
Men performed a number of self-management behaviours but did not achieve 
complete symptom control.  Secondly, self-care self-efficacy significantly reduced at 
six months.  Global quality of life demonstrated a clinically small relevance and 
statistically significant decrease at six months, but functional domains of health-
related quality of life were mostly unaffected.  Disease-specific domains of health-
related quality of life were affected in this population and an increase in bowel and 
sexual dysfunction was identified at six months. 
Conclusion  
These findings support the main effects social support model, but the propositions of 
the stress buffering model were not supported in this prospective longitudinal 
survey.  These findings perhaps provide support towards the development of an 
intervention study to improve quality of life, self-care self-efficacy and improve 
patients’ symptom management.  The finding from the individual case studies 
(chapter 6) may provide useful insight to indicate the content of such an intervention 
study.   
5.2 Introduction 
Few prospective longitudinal research designs have been implemented to evaluate 
changes in coping, social support and the self-management behaviours of men 
affected by prostate cancer over time.  The implementation of this prospective 
longitudinal design captured change over time and allowed prediction of HRQoL 
outcomes which addressed the research questions.   HRQoL is likely to be affected by 
the psychological and social factors that unfold over time as men manage, learn 
from, and adjust to the changes caused by prostate cancer and its associated 
treatments (Roberts et al., 2006).  Little research (Zhou et al., 2010a, Zhou et al., 
2010b, Kershaw et al., 2008, Roberts et al., 2006, Visser et al., 2003, Van Andel et al., 
2003) has been conducted to identify the relationship between coping and social 
support on HRQoL at one month after diagnosis and at six months follow-up (Bloch et 
al., 2007).  Understanding the mechanism effect of how coping and social support 
operate on HRQoL over time can help to identify men who are at high risk of 
inadequate support and suggest directions for appropriately targeted interventions 
at an earlier stage in the cancer journey (Roesch et al., 2005).  
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5.3 Research questions 
This prospective longitudinal study addressed the following questions: 
 
1 Approximately 1 month after a prostate cancer diagnosis, what is the 
relationship between demographic (age, socio-economic status, educational 
level) and clinical (staging, PSA, Gleason Score, co-morbidity, treatments) 
variables in men affected by prostate cancer and the following: 
a) coping, 
b) social support,  
c) health-related quality of life, 
e) anxiety and depression, 
e) self-efficacy, 
f) stress, 
g) self-management? 
 
2 How does the following change between recruitment 1 month after diagnosis 
(time 1) and 7 months after diagnosis (time 2):  
a) coping, 
b) social support, 
c) health-related quality of life, 
e) anxiety and depression, 
e) self-efficacy, 
f) stress, 
g) self-management? 
 
3 Controlling for baseline (time 1; 1 month after diagnosis) 
characteristics/variables, does social support (perceived, received and 
satisfaction level) have a main effect, or does it moderate/mediate the 
relationship between coping and a) anxiety,  b) depression, and c) health-
related quality of life, at time 2 (7 months after diagnosis)? 
 
5.4 Methods 
Rationale and justification for methods used in this prospective, longitudinal survey 
study are detailed in chapter 4, section 4.2.  Briefly, participants were asked to 
complete a battery of questionnaires (Prostate Cancer-Specific Self-Management 
Log, EORTC Quality of life [QLQ C30 and PR25], Self-Efficacy Scale, Mental 
Adjustment to Cancer Scale, Hospital Anxiety and Depression Scale, Perceived Stress 
Scale, and the Berlin Social Support Scale) at baseline (approximately 1 month after 
diagnosis) and at 6 months follow-up (approximately 7 months after diagnosis).  
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Clinical (cancer stage, PSA, Gleason score, treatments, and co-morbidity) and 
demographic (age, marital status, education, employment, and deprivation) data 
were also collected.   
5.4.1 Statistical analysis 
 
Data were double-entered in to SPSS version 17.0 and variables were examined for 
accuracy of data entry, missing values and univariate outliners.  Normality of each 
variable was assessed using statistical (Kolmogorov-Smirnov test and Z-scores for 
skewness and kurtosis) and graphical methods (histograms with normality plots and 
Q-Q plots).  Scale reliability was assessed using Cronbach’s alpha statistic and 
reviewing corrected item-domain items and Alpha if item deleted. Statistical analysis 
was performed using parametric tests (repeated measures ANOVA, one-way 
between groups analysis of variance, paired t-tests, bivariate correlations and 
hierarchical multiple regression) and non-parametric tests (Chi² test, Mann-Whitney 
U and McNemar’s test).  Hierarchical multiple regression analyses were performed to 
test main, moderation and mediation effects of baseline coping and social support 
variables on anxiety, depression, and global quality of life  at six months.  Prior to the 
regression analysis the evaluations of the assumptions were checked according to 
guidelines from Tabachnick and Fidell (2007) and Field (2005).  To check the 
assumptions of multiple regression analysis, a series of heuristics are detailed in table 
5.1. 
Table 5.1 Checklist of assessing assumptions of multiple regression analysis based on 
guidance suggested by Tabachnick and Fidell (2007) and Field (2005).  
Assumption Check 
No perfect 
multicollinearity 
Scan the correlation matrix of all predictor variables (a correlation 
above .80 suggests multicollinearity). 
Assess the Collinearity diagnostics (variance inflation factor values of 
greater than 10 may be of concern) and the tolerance statistic 
(values below 0.1 indicate serious problems and value below 0.2 are 
worthy of concern).  
Outliners Review critical Mahalanobis distances. 
Check the cook’s distances (any value greater than 1 indicate a case 
might be influencing the model). 
Non-zero variance The predictor variables should have some variation in value. 
Homoscedasticity, 
linearity and 
normality 
Review scatterplots (plot *ZRESID against *ZPRED for histogram and 
normality probability plot) 
Independence of 
errors 
The Durbin-Watson test (values of less than 1 and greater than 3 are 
cause for concern). 
Sample size N=50 + 8m (where m is the number of independent variables) 
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 5.5 Results  
5.5.1 Characteristics of the participants 
A total number of 109 men newly diagnosed with prostate cancer were invited to 
take part in the study during April 2012 to March 2011.  Seventy-four men consented 
(67.9 % participation rate) and thirty-four men declined to take part, and one man 
was excluded because he had already started his radiotherapy (see table 5.2 for an 
overview of recruitment). 
Table 5.2 Recruitment overview 
Total number of participants approached 109 
Refusing to consent 31 
Refused with reasons:  
 
Patient said “he felt that too much going on after 
diagnosis and the effects of his hormone therapy”   
 
Patient given 2 weeks prognosis to live                  
 
Patient did not see the benefit for him taking part in 
the study                                  
 
Too much going on with tests and awaiting results                                                                              
 
 
1 
 
 
1 
 
1 
 
 
1 
Total consented participants 74 (67.9%) 
 
Distributions of age, cancer stage and cancer treatments between consented and 
non-consented patients are displayed in table 5.3.  Age (non-consented group) was 
negatively skewed and the Kolmogorov-Smirnoff (K-S) was statistically significant K-
S=.263, p=0.000.  Various transformations (Tabachnick and Fidell, 2007) were applied 
to this variable but did not achieve normality.  Therefore, the Mann-Whitney U-test 
was used as the alternative to the parametric t-test for independent samples (Field, 
2005).  There was no statistical significant difference in age between the consented 
and non-consented groups U (109) = 1145.05, Z =-0.972, ns.   Using Chi² test there 
was no statistical significant difference for cancer stage (Chi² = 3.522, df 2, ns) and 
cancer treatments (Chi² = 3.966, df 4, ns) between the consented and non-consented 
groups. 
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Table 5.3 Distributions of age, cancer stage and cancer treatments between consented and 
non-consented patients 
 Consented (N=74) Non-consented (N=35) 
Age (mean, SD, min-max) 70.05 (8.05) 51-86 71.08 (8.02) 54-85 (*median 
74) 
Cancer stage: 
Localised 
Locally advanced 
Metastatic  
 
n=32 (43.2%) 
n=33 (44.6%) 
n=9 (12.2%) 
 
n=9 (25.7%) 
n=22 (62.9%) 
n=4 (11.4%) 
Treatment: 
Watchful waiting 
Retropubic radical prostatectomy 
Laparoscopic radical prostatectomy 
Radiotherapy 
Hormone therapy 
Active surveillance 
Hormone therapy and 
radiotherapy 
Chemotherapy and hormone 
therapy 
 
n=3 (4.1%) 
n=1 (1.4%) 
n=8 (10.8%) 
n=6 (8.1%) 
n=14 (18.9%) 
n=9 (12.2%) 
n=33 (44.6%) 
 
n=0 
 
1 (2.9%) 
1 (2.9%) 
1 (2.9%) 
7 (20%) 
5 (14.3%) 
5 (14.3%) 
14 (40%) 
 
1 (2.9%) 
 *Median value presented for data not normally distributed. 
5.5.2 Participant attrition 
Participant numbers (n=74) reduced between baseline and 6 months follow-up 
(n=68) by six participants.  Table 5.4 describes the reasons for participant attrition at 
six months.   
Table 5.4 Reasons for participant attrition 
Sample attrition at 6 months  
Refused consent n=5 
Deceased n=1 
 
Table 5.5 displays the distributions of clinical and demographic data for both of the 
groups. Overall, the response rate was good at six months follow-up (91.9%).   
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Table 5.5 Distributions of demographic and clinical variables between those who completed 
the 6 months questionnaire and those who did not complete the 6 months questionnaire  
Sample at 6 months n =68 Participants lost from 
the study n=6 
Mean age (SD, range) 69.4 (7.97, 51-84)  77.5 (4.51, 73-86) 
Education 
High school 
Further education 
Higher education 
Trade qualification 
No qualifications 
 
n=6 
n=13 
n=17 
n=27 
n=5 
 
n=1 
n=2 
n=1 
n=0 
n=2 
Employment 
Employed  
Retired 
Unemployed 
 
n=23 
n=43 
n=2 
 
n=0 
n=6 
n=0 
Deprivation 
Most deprived      1 
                                2 
                                3 
                                4 
Least deprived      5 
 
n=4 
n=5 
n=12 
n=31 
n=16 
 
n=0 
n=1 
n=1 
n=2 
n=2 
Cancer stage 
Localised 
Locally advanced 
Metastatic disease 
 
n=32 
n=29 
n=7 
 
n=0 
n=4 
n=2 
Cancer treatment 
Watchful waiting 
Active surveillance 
Retropubic radical prostatectomy 
Laparoscopic radical prostatectomy 
Radiotherapy 
Neoadjuvant hormone therapy + 
radiotherapy 
Hormone therapy 
 
n=3 
n=8 
n=1 
n=8 
n=6 
n=32 
 
n=10 
 
n=0 
n=1 
n=0 
n=0 
n=0 
n=1 
 
n=4 
Gleason Score 
6 
7 
8 
9 
 
n=30 
n=20 
n=9 
n=9 
 
n=1 
n=2 
n=2 
n=1 
Prostate Specific Antigen (median, min-max) *14.55 (4.8-
300.0) 
* 17.2 (12.1-134.9) 
Co-morbidity 
No pre-existing co-morbidity 
1 co-morbidity 
2 co-morbidities 
3 co-morbidities 
4 co-morbidities 
5 co-morbidities 
 
 
n=22 
n=8 
n=18 
n=10 
n=5 
n=5 
 
 
n=1 
n=3 
n=0 
n=1 
n=0 
n=1 
 
*Median value presented for data not normally distributed. 
The frequencies of existing health problems are displayed in figure 5.1.  The most 
prevalent co-morbidities were hypertension (45.9%) and arthritis (21.6%); this data 
are similar to those reported by Klabunde et al. (2005).   
140 
 
 
 
 
Figure 5.1 Distributions of co-morbidity (N=74)  
5.5.3 Completion rates of HADS, MAC Scale, EORTC C30 and PR25, 
Self-management log, Self-Efficacy Scale, PSS and BSSS. 
 
Seventy-two participants completed the questionnaires at baseline and sixty-eight 
participants completed the questionnaires at six months follow-up.  Two participants 
did not complete the survey at baseline because one participant withdrew from the 
study after consent, and the other did not return his survey.  Four participants did 
not return their 6 months follow-up questionnaire.   
 
HADS 
There were no missing data at baseline but there was one single missing item on the 
depression scale at 6 month follow-up.  The missing value was replaced with the 
participant’s mean depression score (Tabachnick and Fidell, 2007). 
 
MAC SCALE 
At baseline there were seven missing items (two missing items on the 
Helpless/Hopeless scale, three missing items on the Pre-anxious Occupation scale 
and two missing items on the Fighting Spirit scale) for three participants’ data.  There 
were two missing items at 6 months follow-up (one item on Fighting Spirit scale and 
one item on the Fatalistic scale) for two participants’ data.  The missing items for 
each subscale were replaced with the individual participant’s mean score for each 
subscale, for the five participants’ data (Tabachnick and Fidell, 2007). 
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EORTC C30 
At baseline the global quality of life scale items were missing from one participant’s 
data and his data were excluded from any further analysis that utilised this variable.  
There were no further missing items at baseline.  
 
At six months, one participant did not complete the first full page of the C30; as a 
result, the functional scales (physical functioning, role functioning, emotional 
functioning, cognitive functioning and social functioning) and single symptom items 
(vomiting, nausea, appetite loss, fatigue, breathlessness, pain) are missing.  This 
participant was excluded from further analysis using these subscales.  There were no 
further missing data at 6 months follow-up. 
 
EORTC PR25 
At baseline one participant did not complete the Sexual Activity scale and seven 
participants did not complete the Bowel Function scale.  Participants (n=8) who 
omitted more than 5% of items were excluded from the analysis (Tabachnick and 
Fidell, 2007).   There were no further missing data at baseline.    
 
At six months one participant did not complete the Urinary Function scale and was 
excluded in any further analysis using this variable.  One single item was missing from 
the Urinary Function scale and was replaced with the participant’s mean score for his 
urinary function scale (Tabachnick and Fidell, 2007).  Eight participants did not 
complete the Bowel Function scale and one participant did not complete the 
Treatment Related Symptoms scale and were excluded from any further analysis that 
utilised these variables.  One single item was missing from the sexual activity scale 
and this value was not replaced with the participant’s mean score as there were only 
two items in this scale.   
 
SELF-MANAGEMENT SELF-EFFICACY SCALE 
There were no missing data at baseline.  Two single items were missing at six month 
follow-up and the missing values were replaced with the participant’s mean score 
(Tabachnick and Fidell, 2007). 
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SELF-MANAGEMENT LOG 
One participant did not complete the self-management log at baseline.  There were 
no missing data at 6 month follow-up. 
 
PERCEIVED STRESS SCALE 
There were no missing data at baseline or at 6 months follow-up. 
 
BERLIN SOCIAL SUPPORT SCALE 
At baseline two participants did not complete the Received Social Support scale and 
the Satisfaction with Social Support scale and were excluded from any further 
analysis that utilised this variable.   There was no further missing data at baseline. 
   
At six months follow-up one participant did not complete the Perceived Social 
Support scale and was excluded from any further analysis that utilised this variable. 
Two participants had a single item missing on the Received Support scale and these 
values were replaced with the participants’ individual mean score for this variable.    
There were no other missing data. 
 
5.5.4 Data screening 
 
Normality of distributions of all the variables at baseline and six months were 
assessed using the Kolmogorov-Smirnov (K-S) test and Z-scores, histograms with 
normality plots and Q-Q plots.  To assess the significance of the z-score, values 
greater than 1.96 was significant at p<0.05, above 2.58 was significant at p<0.01 and 
above 3.29 was significant at p<0.001 (Field, 2005).  Variables that were non-normal 
in distribution were transformed (Tabachnick and Fidell, 2007) to reduce skewness 
and kurtosis, reduce the impact of univariate outliners, and to improve normality, 
linearity and homoscedasticity.  Variables displaying skewness and kurtosis were 
transformed using a square root transformation (PSA, received social support at 
baseline, global quality of life at baseline at six months, fatigue at baseline and at six 
months, urinary symptoms at baseline and at six months, and treatment symptoms 
at baseline and at six months) and a log transformation (depression at baseline and 
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at six months).  Normality of distribution was re-assessed after the transformation 
had been applied to variables to ensure normality of distribution had been achieved.   
 
PSA was positively skewed and positively kurtotic and the K-S (68) =.289, p=.000, and 
displayed one univariate outliner.  A square root transformation was successfully 
applied and achieved normality of distribution.  Depression scores at baseline and at 
six months were significantly positively skewed and successfully transformed using a 
log transformation (Field, 2005).  Anxiety scores at baseline and at six months were 
significantly positively skewed and a square root transformation was applied and 
achieved normality in distribution for these variables.   Global quality of life values at 
baseline and at six months were significantly negatively skewed and positively 
kurtotic and a square root transformation was applied to both variables and achieved 
normality in distribution.    Received social support at baseline was significantly 
positively skewed and kurtotic and the K-S (65) =0.263, P=0.000.  A square root 
transformation was applied to the following variables: baseline received social 
support, treatment symptoms, urinary symptoms, and fatigue, and the 
transformations achieved normality for these variables.    
5.5.5 Reliability analysis 
 
Reliability of the subscales at baseline and six months were assessed using the 
Cronbach’s alpha statistic.  Acceptable Cronbach’s values are recommended at ≥0.70 
and having corrected item-total correlations above 0.3 (Tabachnick and Fidell, 2007, 
Field, 2005).  All subscale scales met the recommended criteria except for the EORTC 
C30 cognitive function at baseline (Cronbach’s alpha 0.55) and at six months 
(Cronbach’s alpha 0.58).  It is acknowledged that item numbers in a scale will affect 
the value of the Cronbach’s alpha (Field, 2005). The cognitive function subscale had 
only 2 items but had item correlations above 0.3, therefore the reliability of this 
subscale was considered to be satisfactory (Field, 2005).  The EORTC PR25 bowel 
symptoms scale and the treatment symptoms scale at baseline and at six months did 
not meet the recommended Cronbach’s alpha level.  At baseline, the bowel 
symptoms scale (0.51) had two items with correlations less than 0.3 and one item 
with correlations less than 0.3 at six months.  The Cronbach’s alpha value would not 
have improved if the items with correlations <0.3 were deleted; therefore the items 
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were not removed from the subscale.  Treatment symptoms at baseline (0.41) and 
treatment symptoms at six months (0.59) had item correlations less than the 
recommended >0.3 for four items at baseline and two items at six months.  The 
reliability of the scale did not improve after assessing the Alpha if Item deleted for 
the items with correlations less than 0.3, therefore these items were not removed 
from the scales. 
5.5.6 Baseline associations with demographic and clinical 
variables with the questionnaire survey 
 
To address the first research question a one-way between groups’ analysis of 
variance was performed to investigate differences in categorical variables, namely: 
demographic: socio-economic and education; and clinical variables: cancer staging, 
treatments; and Gleason score with the following dependent continuous variables: 
anxiety (square root), depression (log), and global quality of life (square root).    No statistically 
significant differences were found between clinical and demographic variables with 
anxiety square root, depression log, and global quality of life square root.   
 
A one way between groups’ analysis of variance was used to assess differences in 
demographic (socio-economic and education) and clinical variables (cancer staging, 
treatments, and Gleason score) with self-management self-efficacy, coping, social 
support (perceived, received and satisfaction) and perceived stress.  No statistical 
difference was found between clinical and demographic variables with the following: 
self-management self-efficacy, perceived social support, received social support square 
root, satisfaction with social support and perceived stress. The results of the one-way 
between groups’ analysis of variance are detailed in appendix 5.1  
 
There was a statistically significant difference between negative coping scores for the 
four SIMD (socio-economic) groups F (4, 63) =3.52, p=0.012.  The mean scores and 
SD’s across the SIMD groups are as follows: SIMD 1 most deprived, 31.75 (SD 10.34); 
SIMD 2, 38.2 (SD 5.76); SIMD 3, 26.67 (SD 3.89); SIMD 4 least deprived, 28.88 (SD 
6.58).   The effect size was calculated using eta squared and was 0.18, indicating a 
large effect size (Cohen 1988).  Post-hoc comparisons using the Tukey HSD test 
indicated that the mean for SIMD groups 3 and 4 (least deprived) were significantly 
different from SIMD groups 1 and 2 (most deprived).  Therefore, men in lower socio-
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economic groups are more likely to report higher negative coping following a 
prostate cancer diagnosis.  No significant differences were found between negative 
coping and the following variables: level of education, cancer stage, treatment and 
Gleason score. 
 
A one-way between groups’ analysis of variance was conducted to explore the 
impact of levels of education on the scores of positive coping.  There was a 
statistically significant difference in positive coping scores and level of education F (2, 
65) =3.78, p=0.02.  The mean score for the 3 education groups are as follows: high 
school education 54, 24 (SD 6.69), further education (i.e. college) 51, 69 (SD 5.97), 
higher education (i.e. university) 49.59 (SD 5.59).   The effect size calculated using eta 
squared was 0.10, indicating a large effect size (Cohen 1988).  Post-hoc comparisons 
using the Turkey HSD test indicated that the mean score for higher education (i.e. 
university) was significantly different from high school education.  Men with a lower 
level of education are more likely to have higher positive coping than those 
individuals with a higher level education.  No significant differences were found 
between positive coping scores and the following variables: socio-economic status, 
cancer stage, treatment and Gleason score. 
 
Chi² tests were used to explore the relationship between two categorical variables.  
Chi² tests demonstrated no statistical significant differences between the self-
management of urinary, bowel and sexual dysfunction with the following variables: 
socio-economic, educational level, cancer stage, treatments, and Gleason score.   
 
A Pearson’s product-moment correlation were performed with continuous 
demographic (age) and clinical variables (PSA and number of co-morbidities) with the 
following continuous baseline survey variables: positive coping, negative coping, 
anxiety square root, depression log, self-management self-efficacy, perceived stress, 
perceived social support, received social support square root, satisfaction with social 
support, EORTC C30 subscales and the EORTC PR25 subscales.  Preliminary analyses 
were performed to ensure no violation of the assumptions of normality, linearity and 
homoscedasticity.  The results of the Pearson’s product-moment correlation 
coefficients are details in table 5.6. 
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Table 5.6 Pearson’s’ product-moment correlations coefficients between clinical and 
demographic variables at baseline and the questionnaire survey variables at baseline 
 Age  PSA Square root Number of co-
morbidities 
MAC Scale, positive coping 0.000 -0.176 -0.267** 
MAC Scale, negative coping -0.115 -0.072 0.091 
Perceived stress -0.183* -0.221* 0.194* 
Self-management self-efficacy -0.086 0.181* 0.138 
Received social support Square root 0.178* 0.030 0.307** 
Perceived social support  -0.182* -0.221* -0.152 
Satisfaction social support -0.026 0.086 0.002 
HADS, Anxiety Square root -0.114 -0.131 0.106 
HADS, Depression Log 0.362*** -0.120 0.411*** 
EORTC C30, Physical function -0.504*** -0.078 -0.467*** 
EORTC C30, Role function -0.401*** 0.038 -0.278** 
EORTC C30, Emotional function 0.007 0.049 -0.096 
EORTC C30, Cognitive function -0.290** 0.070 -0.193 
EORTC C30, Social function -0.166 0.070 -0.234* 
EORTC C30, Global quality of life Square root -0.390*** -0.081 -0.459*** 
EORTC C30, Nausea and vomiting -0.335*** -0.165 -0.087 
EORTC C30, Pain 0.162 0.189* 0.225 
EORTC C30, Dyspnoea 0.396*** 0.110 0.342** 
EORTC C30, Insomnia 0.051 -0.196* 0.145 
EORTC C30, Appetite loss 0.014 0.027 -0.014 
EORTC C30, Constipation 0.147 0.226* 0.059 
EORTC C30, Diarrhoea 0.145 0.278* 0.109 
EORTC C30, Fatigue Square root 0.290** 0.160 0.354** 
EORTC C30, Financial difficulties -0.068 -0.143 0.031 
EORTC PR25, Urinary symptoms Square root 0.232* -0.038 0.149 
EORTC PR25, Bowel symptoms 0.071 0.013 -0.107 
EORTC PR25, Treatment symptoms -0.076 0.212* -0.058 
EORTC PR25, Incontinence aid -0.153 -0.227 0.000 
EORTC PR25, Sexual activity -0.329*** -0.190* 0.196 
EORTC PR25, Sexual function 0.162 0.150 0.223 
*significant level p<0.15, ** significant level p<0.05, ***significant level p<0.01 (n=68) 
 
Age had a number of statistically significant associations at the p<0.01 level with the 
following variables: depression log (r= 0.362), physical function (r=-0.504), role 
function (r=-0.401), global quality of life square root (r=-0.390), nausea and vomiting (r=-
0.335), dyspnoea (r=0.396), and sexual activity (r=-0.329).  The significant 
associations with age are in keeping with existing research (Gacci et al., 2009, White 
et al., 2008, Jayadevappa et al., 2005).  PSA square root did not have any statistically 
significant associations on global quality of life, anxiety and depression, and is similar 
to data published by (Lintz et al., 2003).  The number of co-morbidities had a number 
of moderate, positive correlations with depression log (r=0.411, p<0.01), dyspnoea 
(r=0.342, p<0.05) and fatigue square root (r=0.354, p<0.05.  Co-morbidity had negative 
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associations with physical function (r=-0.467, p<0.01), role function (r=-0.278, 
p<0.05) and global quality of life square root (r=-0.459, p<0.01).  
5.5.7 Assessing change over time from baseline to six months for 
the questionnaire survey variables 
 
To answer the second research question, paired sampled t-tests were performed to 
explore changes in the mean scores of the questionnaire survey variables at time 1 
(baseline) and time 2 (six months follow-up).   
 
HADS   
The results of the paired sampled t-tests are displayed in table 5.7.  No statistical 
significant difference was found in the mean scores for anxiety square root, depression 
(t=0.480, ns) and depression log, (t=-1.097, ns) between baseline and six months. 
 Table 5.7 Results of the paired samples t-tests and reliability analysis using Cronbach’s 
alpha statistic for HADS 
 Anxiety N Cronbach’s α Mean (SD) t value and 
significance 
Baseline  68 0.82 4.62 (3.34) t(67)=0.480, ns 
Six months  68 0.85 4.53 (3.67)  
Depression  
Baseline  68 0.78 2.88 (2.76) t(67)=-1.097, ns 
Six months 68 0.74 3.32 (2.93)  
 
The “cut-off” scores recommended by Zigmond and Snaith (1983) were used to 
calculate non-cases (0-7), possible cases (8-10) and probable cases (11+) of anxiety 
and depression.  The distribution of participants categorised with these cut-off scores 
are displayed in table 5.8.   
Table 5.8 Percentage distribution of participants defined by HADS cut-off scores at each 
time point 
Anxiety Non-cases (0-7) Possible cases (8-10) Probable cases (11 
+) 
Baseline n=57 (83.8%) n=8 (11.8%) n=3 (4.4%) 
Six months n=53 (77.9%) n=9 (13.2%) n=6 (8.8%) 
Depression  
Baseline n=68 (92.6%) n=4 (5.9%) n=1 (1.5%) 
Six months n=61 (89.7%) n=5 (7.4%) n=2 (2.9%) 
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MAC Scale 
The results of the paired sampled t-tests are displayed in table 5.9.  No statistically 
significant difference was found in the mean scores for positive coping (t=0.796, ns) 
and negative coping (t=0.802 ns) between baseline and six months.   
Table 5.9 Results of the paired samples t-tests and reliability analysis using Cronbach’s 
alpha statistic for MAC Scale 
Positive coping N Cronbach’s α Mean (SD) t value and 
significance 
Baseline 68 0.83 52.15 (7.53) t(67)=0.796, ns 
Six months 68 0.83 51.99 (7.48)  
Negative coping  
Baseline 68 0.77 29.21 (6.53) t(67)=0.802, ns 
Six months 68 0.84 25.56 (7.35)  
        
Self-management self-efficacy 
The results of the paired sampled t-tests are displayed in table 5.10.  A statistically 
significant difference was found between the mean scores for self-management self-
efficacy (t=3.17, p=0.002) at baseline and six months.  The mean self-management 
self-efficacy score at baseline worsened from 3.8 (SD.37) to 3.49 (SD.85) at six 
months, see figure 5.2.  
Table 5.10 Results of the paired samples t-tests and reliability analysis using Cronbach’s 
alpha statistic for self-management self-efficacy scale 
Self-management 
self-efficacy 
N Cronbach’s α Mean (SD) t value and 
significance 
Baseline 68 0.89 3.80 (0.37) t(67)=3.17, p=0.002 
Six months 68 0.96 3.49 (0.85)  
 
             
Figure 5.2 Mean self-management self-efficacy scores and error bars at baseline and at six 
months follow-up                   
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Perceived Stress Scale 
No statistically significant difference was found in the mean scores for perceived 
stress (t=-1.85, ns) at baseline and six months (see table 5.11).   
Table 5.11 Results of the paired samples t-tests and reliability analysis using Cronbach’s 
alpha statistic for perceived stress scale 
Perceived stress N Cronbach’s α Mean (SD) t value and 
significance 
Baseline 68 0.89 10.29 (5.81) t(67)=-1.85, ns 
Six months 68 0.96 11.74 (7.50)  
 
Social support 
Paired sampled t-tests identified no statistically significant difference in the mean 
scores for perceived social support (t=-1.42, ns) and mean score for satisfaction level 
of social support (t=1.00, ns) (see table 5.12).  A statistical significant difference was 
found in the mean scores for received social support (t=-2.19, p=0.031) at baseline 
and six months.  A trend of increased received social support is displayed in figure 
5.3.     
Table 5.12 Results of the paired samples t-tests and reliability analysis using Cronbach’s 
alpha statistic for perceived stress scale 
Berlin social support 
scale 
 
N Cronbach’s α Mean (SD) t value and 
significance 
Perceived social support  
Baseline  67 0.87 2.61 (1.21) t(66)=-1.42, ns 
Six months  67 0.88 2.78 (1.21)  
Received social support  
Baseline  66 0.86 1.68 (.81) t(65)=-2.19, p=0.031 
Six months 66 0.87 1.97 (.99)  
Satisfaction of social 
support 
 
Baseline 64 Single item 3.89 (.40) t(63)=1.00, ns 
Six months 64 Single item 3.83 (.49)  
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Figure 5.3 Mean received social support scores and error bars at baseline and at six months 
follow-up      
 
The distributions of participants’ usage of additional cancer support services, namely: 
1) prostate cancer support groups; 2) additional support services (for example online 
prostate cancer forums); and 3) Maggie’s Cancer Care Centre, are displayed in table 
5.13.  At baseline no men engaged with prostate cancer support groups and at six 
months follow-up, four men (5.9%) reported attending a prostate cancer support 
group every several months.  No men reported using additional cancer support 
services at baseline or at six months follow-up.       
 
At baseline, seven men (10.3%) reported attending Maggie’s Cancer Care Centre, 
four men reported using the centre on a daily basis and three men attended the 
centre every several months.  The number of men attending Maggie’s increased from 
10.3% at baseline to 16.2% at six months (see table 5.13 for the frequencies of 
attendance).  The main themes of support provision received at Maggie’s included: 
informational support, Government benefit informational support, prostate cancer 
peer support and an individual counselling session. At six months follow-up, 83.8% of 
the participants did not use Maggie’s cancer care centre for additional help or 
support. 
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Table 5.13 Distributions of the frequencies of participants usage of cancer services (n=68) 
 User of prostate 
cancer support 
group  
Frequency of attendance 
of support group 
Baseline  
Yes 
No 
 
n=0 
n=68 
 
N/A 
Six months 
Yes 
No 
 
n=4 (5.9%) 
n=64 (95.1%) 
 
Every several months n=4 
N/A 
 Additional cancer 
support (i.e. online 
prostate cancer 
forums) 
Frequency of usage of 
additional cancer 
support 
Baseline 
Yes 
No 
 
n=0 
n=68 
 
N/A n=68 
Six months 
Yes 
No 
 
n=0 
n=68 
 
N/A n=68 
 User of Maggie’s 
Cancer Care Centre 
Frequency of attendance 
of Maggie’s Cancer Care 
Centre 
Type of Support used at Maggie’s Cancer Care 
Centre 
Baseline 
Yes 
 
 
No 
 
n=7 (10.3%) 
 
 
n=61 (89.7%) 
 
Daily n=4 
Every several months n=3 
 
N/A =n=61 
 
Government benefit support information  n=1 
Informational support n=6 
 
Six Months 
Yes 
 
 
 
 
No 
 
n=11(16.2%) 
 
 
 
 
n=57 (83.8%) 
 
Several times monthly 
n=3 
Monthly n=1 
Every several months n=6 
Yearly n=1 
N/A n=57 
 
Government benefit support information n=3 
Individual psychology session n=1 
Prostate cancer networking group n=1 
Informational support n=6 
 
EORTC C30 Health-related quality of life 
The results of the paired sampled t-tests demonstrated no statistical significant 
difference for role function, cognitive function, emotional function and social 
function at baseline and six months (see table 5.14).  Global quality of life (t=2.35, 
p=0.021) and physical function (t=2.82, p=0.006) significantly reduced over time from 
baseline to six months (see table 5.14).  
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Table 5.14 Results of the paired samples t-tests and reliability analysis using Cronbach’s 
alpha statistic for the EORTC C30 subscales                                                                                                       
EORTC C30 
 
n Cronbach’s α Mean (SD) t value and 
significance 
Global quality of life  
Baseline  67 0.84 78.48 (14.29) t(66)=2.35, p=0.021 
Six months 67 0.85 73.28 (16.78)  
Physical function  
Baseline 67 0.72 87.55 (15.91) t(66)=2.82, p=0.006 
Six months 67 0.81 82.59 (16.89)  
Role function  
Baseline 67 0.83 87.06 (22.06) t(66)=1.72, ns 
Six months 67 0.91 82.09 (27.11)  
Cognitive function  
Baseline 68 0.55 83.82 (17.74) t(68)=-1.19, ns 
Six months 68 0.58 81.37 (20.87)  
Emotional function  
Baseline 68 0.84 79.90 (19.44) t(67)=-0.20, ns 
Six months 68 0.88 79.53 (20.94)  
Social function  
Baseline 68 0.87 86.76 (21.66) t(67)=0.21, ns 
Six months 68 0.75 86.03 (19.66)  
 
The results of the paired sampled t-tests demonstrated no statistical significant 
difference for dyspnoea, pain, diarrhoea, and financial difficulties (see table 5.15).  A 
statistically significant difference was found for increased appetite loss (t=-2.41, 
p=0.019), fatigue (t=-2.431, p=0.018) and constipation (t=-2.19, p=0.032) from 
baseline to six months. 
Table 5.15 Results of the paired samples t-tests for the EORTC C30 single item scales 
EORTC Individual 
items 
N Mean (SD) t value and 
significance 
Dyspnoea   
Baseline 67 21.89 (30.56) t(66)=0.000, ns 
Six months  21.89 (28.16)  
Pain  
Baseline 67 9.45 (15.41) t(66)=1.405, ns 
Six months  12.44 (17.49)  
Appetite loss  
Baseline 67 2.49 (8.84) t(66)=-2.41, p=0.019 
Six months  6.97 (14.83)  
Constipation  
Baseline 68 9.80 (20.81) t(67)=-2.19, p=0.032 
Six months  14.71 (22.59)  
Diarrhoea  
Baseline 68 9.31 (22.19) t(67)=-0.646, ns 
Six months  11.27 (16.89)  
Fatigue  
Baseline  67 19.06 (2.52) t(66)=-2.431, p=0.018 
Six months  21.38 (2.61)  
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Financial difficulties  
Baseline  68 8.33 (21.85) t(67)=0.000, ns 
Six months   8.33 (18.55)  
 
                    
EORTC PR25 Disease-specific health-related quality of life 
The results of the paired sampled t-tests demonstrated a statistically significant 
increase in bowel symptoms (t=-2.97, p=0.004) and treatment related symptoms (t=-
5.04, p=0.000) at six months, see table 5.16.    No statistically significant change was 
identified for urinary symptoms.    Sexual activity statistically reduced at six months 
(t=-1.74, p=0.045).  At baseline, twenty-eight men were sexually active (41.2%) and 
the number of men sexually active at six months reduced to fifteen (22.1%).  
Table 5.16 Results of the paired samples t-tests and reliability analysis using Cronbach’s 
alpha statistic for the EORTC PR25 subscales                                                                                                       
EORTC PR25 
 
N Cronbach’s α Mean (SD) t value and 
significance 
Urinary symptoms  
Baseline  67 0.85 17.06 (2.08) t(66)=-0.722, ns 
Six months  67 0.85 18.47 (2.26)  
Bowel symptoms  
Baseline  55 0.51 5.45 (9.10) t(54)=-2.97, p=0.004 
Six months 55 0.57 11.06 (14.62)  
Treatment 
symptoms 
 
Baseline 67 0.41 9.37 (10.11) t(66)=-5.04, p=0.000 
Six months 67 0.59 17.16 (15.62)  
Sexual activity  
Baseline 64 0.88 45.12 (5.64) t(63)=-1.74, p=0.045 
Six months 64 0.79 39.11 (4.89)  
Sexual function  
Baseline 15 0.57 31.11 (21.24) t(14)=3.70, p=0.002 
Six months 15 0.79 56.11 (29.79)  
 
Sexual functioning significantly improved from baseline to six months for men (n=15) 
who were sexually active (t=3.70, p=0.002) (see figure 5.6).   
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Figure 5.4 Mean sexual function scores and error bars at baseline and at six months follow-
up 
 
Self-management log  
The McNemar’s test was used to assess statistical differences between two related 
groups for categorical data (Petrie and Sabin, 2005) measured at two time points 
(baseline and six months).  The McNemar’s test compared the frequency of men who 
performed self-management and those individuals who did not perform self-
management, at baseline and at six months.  Separate McNemar’s tests were 
performed to assess differences in the frequncies of urinary, bowel and sexual 
dysfunction self-management at baseline and six months.   
 
Urinary self-management 
Using the McNemar’s test, a significant difference was found in the number of men 
(n=68, across the whole sample) performing urinary self-management at baseline 
and at six months p=0.024.  The percentage of men performing urinary self-
management decreased from 51.5% at baseline to 38.6% of men at six months.        
The self-management behaviours for urinary symptoms are displayed for localised 
prostate cancer in figure 5.7.  Men diganosied with localised prostate cancer 
performed a number of self-management behaviours to alleviate urinary symptoms 
at baseline and at six months.  
155 
 
 
 
0 2 4 6 8 10 12
Took medication
Found out information
Used pads
Increased fluid intake
Performed pelvic floor exercises
Avoided heavy lifting
Kept a toileting diary
Reduced caffeine intake
Shared my feelings
Received counselling
Took advice from a continence advisor
Took no liquids after 6pm
Avoided constipation
Took advice from a physiotherapist
1
2
2
11
0
2
0
7
5
1
2
1
3
0
1
2
5
5
3
3
2
8
4
2
4
0
5
2
Frequency of self-management
Urinary self-management behaviours for men with localised prostate cancer
Urinary self-management
for men with localised
prostate cancer six
months follow-up (n=10)
Urinary self-management
for men with localised
prostate cancer baseline
(n=15)
 
Figure 5.5 Frequency distributions of urinary self-managment for men with localised 
prostate cancer 
 
The effectiveness of self-management behaviours for symptom relief was measured 
using self-reports on a 1-5 scale (1 = no relief, 2 = got a little relief, 3 = got some 
relief, 4 = got quite a bit of relief, 5 = completly relieved).  A total maximum mean 
score of 5.0 for self-management relief would indicate complete symptom relief.  The 
mean score for urinary self-management symptom relief was 2.62 (SD 1.15) at 
baseline, and 3.64 (SD 1.26) at six months for men with localised prostate cancer.   
 
The urinary self-management behaviours performed by men with locally advanced 
prostate cancer are displayed in figure 5.8.  The mean score for urinary management 
relief for participatns with locally advanced prostate cancer was 3.12 (SD 1.30) at 
baseline and 2.45 (SD .85) at six months. 
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Figure 5.6 Frequency distribtions of urinary self-management behaviours for men with 
locally advanced prostate cancer 
 
The self-management behaviours to allaivate urinary symptoms for men with 
metastatic prostate cancer  are displayed in figure 5.9.  The mean score for urinary 
self-management symptom relief was 3.10 (SD .82) at baseline and 3.58 (SD .52) at 
six months.  Noticably, there were not as many self-management behaviours 
performed by men with metastatic cancer compared to men with localised or locally 
advanced cancer. 
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Figure 5.6 Frequency distributions of urinary self-management behaviours for men with 
metastatic prostate cancer 
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Descriptively, men with localised and locally advanced prostate cancer performed a 
greater variety of self-management behaviours for urinary problems compared to 
participants with metastatic prostate cancer.  Overall, men (localised, locally 
advanced and metastatic cancer) who performed urinary self-management at 
baseline and at six months did not achieve complete symptom relief through self-
management behaviours. 
 
Bowel self-management 
The percentage of men (based on all participants [n=68] in the study) performing 
bowel self-management significantly increased from 14.9% at baseline to 30.9% at six 
months (McNemar’s test p=0.002).  The self-management behaviours for bowel 
symptoms are displayed for localised prostate cancer in figure 5.9.  The mean score 
for bowel symptom relief from self-management actions was 3.5 (SD  0.71) at 
baseline and 3.26 (SD 0.80) at six months, but overall, the number of men with 
localised prostate cancer performing self-management for bowel problems at 
baseline (n=2) and six months (n=4) were small compared to the number of men 
performing urinary self-management. 
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Figure 5.7 Distributions of bowel self-management behaviours for men with localised 
prostate cancer 
158 
 
 
 
 
The self-management behaviours for bowel symptoms are displayed in figure 5.10 
for men with locally advanced prostate cancer.  The mean score for bowel symptom 
relief from self-management was 2.72 (SD  0.83) at baseline and 3.33 (SD 0.58) at six 
months.  The number of men with locally advanced prostate who performed bowel 
self-management increased from five men at baseline to eleven men at six months. 
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Figure 5.8 Distributions of bowel self-management behaviours for men with locally 
advanced prostate cancer 
The bowel self-management behaviours for men affected by metastatic cancer are 
displayed in figure 5.11.  The mean score for bowel symptom relief from self-
management was 3.82 (SD  0.70) at baseline and 3.0 (SD 0.79) at six months.  The 
number of men performing self-management for bowel problems increased from 
baseline (n=2) and six months (n=6).   
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Figure 5.9 Distributions of bowel self-management behaviours for men with metastatic 
prostate cancer 
 
In summary, bowel self-management was most frequently reported by men with 
locally advanced prostate cancer.   Men (localised, locally advanced and metastatic 
cancer) who performed bowel self-management at baseline and at six months did 
not achieve complete relief through their self-management behaviours. 
 
Sexual function self-management 
The percentage of men (based on all participants [n=68] in the study) reporting self-
management for sexual dysfunction increased from 45.6% at baseline to 52.9% at six 
months, however was not statistically significant (McNemar’s test, ns).  The 
frequencies of sexual function self-management behaviours for men with localised 
disease are displayed in figure 5.12.  Fourteen men (43.7%) with localised cancer 
performed sexual function at baseline and sixteen (50%) men performed sexual 
function self-management at six months.  The mean score for sexual function relief 
from self-management was 2.57 (SD 1.46) at baseline and 1.5 (SD 0.87) at six months.  
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Figure 5.10 Distributions of sexual function self-management behaviours for men with 
localised prostate cancer 
 
Fifteen men (51.7%) with locally advanced cancer performed sexual function self-
management at baseline and sixteen men (55.2%) performed sexual function self-
management at six months (see figure 5.13).  The mean score for sexual function 
self-management relief for men with locally advanced cancer was 1.94 (SD 0.99) at 
baseline and 2.1 (SD 1.47) at six months.   
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Figure 5.11 Distributions of sexual function self-management behaviours for men with 
locally advanced prostate cancer 
 
Men with metastatic prostate cancer performed very little self-management for 
sexual function at baseline (28.6%, n=2) and at six months (57.1%, n=4) (see figure 
5.14).  At baseline, two men reported erectile dysfunction for which they performed 
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self-management, but one man did report his self-management behaviours.  At six 
months, four men reported erectile dysfunction, but two participants did not provide 
data which described their sexual function self-management behaviours.  The mean 
score for sexual function relief was 3.0 (SD.0) at baseline and 2.0 (SD.0) at six months.     
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Figure 5.12 Distributions of sexual function self-management behaviours for men with 
metastatic prostate cancer 
 
In summary, the number of men performing sexual function self-managment 
increased from baseline to six months.  Men performed a variety of self-management 
actions, however these had little efficacy in improving erectyle dsyfunction.  
 
Suggestions for self-management 
 
The distributions of suggestions for self-management behaviours are idenitified in 
figure 5.15.  Overall, men most received suggestions for self-management from their 
partners at baseline (n=32 [47.1%]) and at six months (n=42 [61.7%]).  The second 
most frequent source of information for self-managenment actions were from 
doctors, and the least frequent source of information for self-management was from 
the physiotherapists and other cancer patients.   
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Figure 5.13 Distribution of suggestions for self-management behaviours for all participants 
(n=68) 
 
5.5.8 Main, moderation and mediation effects of coping and 
social support on health-related quality of life, anxiety and 
depression at 6 months. 
 
To address the third research question, a series of hierarchical multiple regression 
analyses were performed to tests for main, moderation and mediation effects of 
coping and social support at baseline on a) quality of life, b) anxiety, and c) 
depression at six months.   Hierarchical multiple regression analysis was used 
because this methods assumes a theoretical or logical approach to the order in which 
variables are entered into the regression model.  A bivariate correlation analysis was 
performed to identify univariate predictors for inclusion in the hierarchical multiple 
regression analysis.  Variables at the less stringent p<0.15 were considered for 
inclusion (Tabachnick and Fidell, 2007) to ensure all potential predictors were 
included in the model.      
 
Prior to the analysis the underlying assumptions were check according to suggestion 
by Tabachnick and Fidell (2007) and Field (2005) (see section 5.4.1).  A detailed 
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explanation of the analytical steps performed to test for moderation and mediation 
effects are identified in chapter 4 (section 4.7.7). 
 
Global quality of life square root at six months as the dependent variable  
 
A bivariate correlation analysis was performed with global quality of life square root at six 
months and at all baseline variables.  Prior to conducting the Pearson’s product-
moment correlations, preliminary analyses were performed to ensure no violation of 
the assumptions of normality, linearity and homoscedasticity.  The results of the 
Pearson’s product-moment correlation coefficients are details in table 5.17.   
Table 5.17 Bivariate correlations with Global quality of life square root at six months and study 
variables at baseline 
Baseline study variables Global quality of life square root at six months 
MAC Scale, positive coping 0.151 
MAC Scale, negative coping -0.182* 
Perceived stress -0.259** 
Self-management self-efficacy 0.081 
Received social support Square root -0.161 
Perceived social support  0.348*** 
Satisfaction social support 0.350*** 
HADS, Anxiety Square root -0.086 
HADS, Depression Log -0.236* 
EORTC C30, Physical function 0.315*** 
EORTC C30, Role function 0.354*** 
EORTC C30, Emotional function 0.294** 
EORTC C30, Cognitive function 0.258** 
EORTC C30, Social function 0.350*** 
EORTC C30, Global quality of life Square root 0.483*** 
EORTC C30, Nausea and vomiting 0.019 
EORTC C30, Pain -0.147 
EORTC C30, Dyspnoea -0.223* 
EORTC C30, Insomnia -0.160 
EORTC C30, Appetite loss -0.082 
EORTC C30, Constipation -0.290** 
EORTC C30, Diarrhoea -0.328*** 
EORTC C30, Fatigue Square root -0.468*** 
EORTC C30, Financial difficulties -0.142 
EORTC PR25, Urinary symptoms Square root -0.180* 
EORTC PR25, Bowel symptoms -0.330*** 
EORTC PR25, Treatment symptoms -0.335*** 
EORTC PR25, Incontinence aid -0.036 
EORTC PR25, Sexual activity 0.182* 
EORTC PR25, Sexual function -0.184 
Number of co morbidities -0.168 
Age -0.260** 
PSA square root -0.238* 
*significant level p<0.15, ** significant level p<0.05, ***significant level p<0.01 (n=68) 
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Three baseline variables (global quality of life square root, negative coping centred and 
perceived social support centred) were entered in to the equation in three steps 
because of their central importance in addressing the third research question.  
Negative coping and perceived social support variables were centred and a product 
term was calculated to test for moderation effects, based on guidance from 
(Tabachnick and Fidell, 2007, Holmbeck, 2002, Aiken and West, 1991).  At step one: 
baseline global quality of life square root was entered; at step two: negative coping centred 
and perceived social support centred; and at step three: the product term for negative 
coping centred*perceived social support centred.  The sample size (n=67) was just below 
the recommend sample size calculation (50+8m=74) (Tabachnick and Fidell, 2007) 
and therefore, adding additional predictors would have largely under powered the 
analysis. The limitations of this statistical approach will be addressed in the 
discussion.  The results of the hierarchical multiple regression analysis are displayed 
in table 5.18. 
 
Goodness of model fit was checked and was considered satisfactory and no 
multivariate outliners were identified.  Collinearly statistics and Durbin-Watson test 
were acceptable and scatterplots indicate no violation of normality, linearity or 
homoscedasticity.  Global quality of life square root  (β=0.325, p=0.006) and perceived 
social support (β=0.272 p=0.016) at baseline had a statistically significant effect on 
global quality of life square root at six months.  Negative coping at baseline did not 
significantly predict global quality of life at six months and no moderation effects 
were demonstrated.  Model three explained 29.6% (adjusted R2) of the variance of 
global quality of life at six months (see table 5.18). 
 
A second hierarchical multiple regression analysis was performed with negative 
coping and satisfaction of social support on global quality of life square root at six 
months.  The three baseline variables (global quality of life square root, negative coping 
centred and satisfaction of social support centred) were entered in to the equation in 
three steps because of their central importance in addressing the third research 
question.  Negative coping and satisfaction of social support variables were centred 
and a product term was calculated to test for moderation effects.  At step one: global 
quality of life square root were entered; at step two: negative coping centred and 
satisfaction of social support centred; and at step three: the product term negative 
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coping centred*satisfaction with social support centred was entered.  The sample size was 
just below (n=67) the sample size calculation (50+8m=74) (Tabachnick and Fidell, 
2007) and therefore, adding additional predictors would have largely under-powered 
the analysis.  Prior to the analysis, the underlying assumptions were checked.  The 
results of the hierarchical multiple regressions are displayed in table 5.19. 
 
Goodness of model fit was checked and was considered satisfactory.  Collinearly 
statistics and Durbin-Watson test were acceptable, no multivariate outliners 
identified, and scatterplots indicate no violation of normality, linearity or 
homoscedasticity.     Satisfaction with social support (β=0.278 p=0.014) and global 
quality of life square root (β=0.401, p=0.001) at baseline had a statistically significant main 
effect on global quality of life square root at six months.  Satisfaction with social support 
did not moderate the relationship between negative coping and global quality of life 
at six months.   Model two explained 25.0% (adjusted R2) of the variance of global 
quality of life at six months (see table 5.19).   
 
Mediation effects of were not tested because negative coping at baseline was not a 
significant predictor of global quality of life square root at six months. 
  
 
 
1
6
6
 
Table 5.18 Hierarchical multiple regression analysis with baseline global quality of life, negative coping and perceived social support scores at baseline on global quality 
of life square root at six months as the dependent variable 
Model                                                                R Square change      R         R
2              
Adjusted
 
R
2                    
B     SE B              β              Significance
 
One:  Constant                                                                                                                                               3.468    1.147  0.004**  
Baseline global quality of life square root                  .233                    0.483 0.233   0.221***  0.575   0.129  0.483 0 .000***         
Two:  Constant                                                                                                                                         4.561 1.198  0.000*** 
Baseline global quality of life square root                  .068          0.548 0.300  0.267*** 0.451 0.135 0.378  0.001**                                                              
Baseline Negative coping centred                                                                                                                                                                 0.019 0.017  -0.118 0.267 
Baseline Perceived social support centred                                                                                                          0.223 0.094 0.266 0.021* 
Three: Constant                                                                                                                                            5.117 1.211  0.000 
 Baseline global quality of life square root                 .038                   0.582 0.338 0.296***  0.387 0.137 0.325 0.006**                                                        
 Baseline Negative coping centred                                                                                                                                                       -0.019 0.017  -0.118  0.267 
 Baseline Perceived social support centred                                                                                                                                             0.228 0.092 0.272 0.016* 
Baseline Negative coping centred X Perceived social support centred                                                                            0.026 0.014 0.202 0.064 
*significant level p<0.05, ** significant level p<0.01, ***significance level p<0.001 (n=67) 
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Table 5.19 Hierarchical multiple regression analysis with global quality of life, negative coping and satisfaction of social support scores at baseline on global quality of 
life square root at six months as the dependent variable 
Model                                                             R Square change             R   R
2  
Adjusted
 
R
2    
B    SE B  β                   Significance
 
One:  Constant                                                                                                                                 3.395 1.278   0.010** 
Baseline Global quality of life square root             .208 0.456 0.208 0.195*** 0.582 0.148 0.456 0.000***         
Two:  Constant                                                                            4.010 1.270  0.002* 
Baseline Global quality of life square root             .078            0.534 0.286 0.250** 0.513 0.142 0.401  0.001**                                                              
Baseline Negative coping centred                                                                                                                                                                     -0.006  0.017 -0.038 0.733 
 Baseline Satisfaction of social support centred                                                                                    0.687 0.273 0.278  0.014* 
Three: Constant                                                                                                                           4.048 1.310  0.003 
 Baseline Global quality of life square root            .000                 0.535 0.286 0.238 0.509 0.146 0.398 0.001**                                                        
 Baseline Negative coping centred                                                                                                                                                                            -0.007 0.018 -0.042 0.716 
  Baseline Satisfaction social support centred                                                                                                                                               0.650 0.380 0.263 0.092 
  Baseline Negative coping centred X Satisfaction of social support centred                                                                           0.009 0.067 0.022  0.889 
*significant level p<0.05, ** significant level p<0.01, ***significant level p<0.001 (n=67) 
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Anxiety square root at six months as the dependent variable  
 
A bivariate correlation analysis was performed with anxiety square root at six months and 
all baseline variables.  Prior to conducting the Pearson’s product-moment 
correlations, preliminary analyses were performed to ensure no violation of the 
assumptions of normality, linearity and homoscedasticity.  The results of the 
Pearson’s product-moment correlation coefficients are details in table 5.20.   
Table 5.20 Bivariate correlations with anxiety square root at six months and study variables at 
baseline 
Baseline study variables Anxiety square root at six months 
MAC Scale, positive coping -0.083 
MAC Scale, negative coping 0.512*** 
Perceived stress 0.478*** 
Self-management self-efficacy -0.026 
Received social support Square root 0.124 
Perceived social support  0.169 
Satisfaction social support -0.201* 
HADS, Anxiety Square root 0.454*** 
HADS, Depression Log 0.263** 
EORTC C30, Physical function -0.010 
EORTC C30, Role function -0.205* 
EORTC C30, Emotional function -0.579*** 
EORTC C30, Cognitive function -0.257** 
EORTC C30, Social function -0.342*** 
EORTC C30, Global quality of life Square root -0.278** 
EORTC C30, Nausea and vomiting 0.240** 
EORTC C30, Pain 0.012 
EORTC C30, Dyspnoea 0.051 
EORTC C30, Insomnia 0.412*** 
EORTC C30, Appetite loss 0.129 
EORTC C30, Constipation 0.208* 
EORTC C30, Diarrhoea 0.188* 
EORTC C30, Fatigue Square root 0.229* 
EORTC C30, Financial difficulties 0.112 
EORTC PR25, Urinary symptoms Square root 0.061 
EORTC PR25, Bowel symptoms 0.317** 
EORTC PR25, Treatment symptoms 0.346*** 
EORTC PR25, Incontinence aid 0.046 
EORTC PR25, Sexual activity 0.067 
EORTC PR25, Sexual function 0.070 
Number of co morbidities 0.076 
Age -0.012 
PSA square root -0.120 
*significant level p<0.15, ** significant level p<0.05, ***significant level p<0.01 (n=68) 
 
Three baseline variables (anxiety square root, negative coping centred and satisfaction with 
social support centred) were entered in to the equation in three steps because of their 
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central importance in addressing the third research question.   Negative coping and 
satisfaction with social support variables were centred and a product term was 
calculated to test for moderation effects.   At step one: anxiety square root was entered; 
at step two: negative coping centred and satisfaction with social support centred; and at 
step three: the product term negative coping centred*satisfaction with social support 
centred.  The sample size was just below (n=67) the sample size calculation (50+8m=74) 
(Tabachnick and Fidell, 2007) and therefore, adding additional predictors would have 
largely under-powered the analysis.  The results of the hierarchical multiple 
regression analysis are displayed in table 5.21. 
 
Goodness of model fit was checked and was considered satisfactory.  Collinearly 
statistics and Durbin-Watson test were acceptable, no multivariate outliners 
identified, and scatterplots indicate no violation of normality, linearity or 
homoscedasticity.  After controlling for baseline anxiety square root scores, negative 
coping at baseline was a significant predictor of anxiety square root (β=0.359, p=0.010).  
Satisfaction with social support at baseline did not demonstrate main or moderating 
effects with negative coping on anxiety square root scores at six months.  Model two 
explained 28.5% (adjusted R2) of the variance of anxiety square root at six months (see 
table 5.21). 
 
Mediation effects were not tested because satisfaction with social support at 
baseline was not a significant predictor of global quality of life square root at six months. 
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Table 5.21  Hierarchical multiple regression analysis with anxiety, negative coping and satisfaction of social support scores at baseline on anxiety  square root at six months 
as the dependent variable 
Model                                               R Square change                                R        R
2                
Adjusted
 
R
2  
B    SE B   β           Significance
 
One:  Constant                                                                                                               1.045 0.286    0.001** 
Baseline Anxiety square root                          .221                           0.470  0.221 0.209*** 0.515 0.121    0.470    0.000***         
Two:  Constant                                                                                                                   1.637 .342  .000*** 
 Baseline Anxiety square root                          .097          0.564  0.318 0.285**  0.250 0.147 0.229   0.094                                                              
 Baseline Negative coping centred                                                                                  0.043 0.016 0.359  0.010* 
 Baseline  Satisfaction with social support centred                                      -0.240 0.209 -0.127  0.236 
Three: Constant                                                                                           1.693 0.364   0.000*** 
 Baseline   Anxiety  square root                       .002   0.566 0.320  0.275  0.222    0.160  0.203  0.170                                                        
 Baseline     Negative coping centred                                                                                                                                                                 0.046 0.018 0.389  0.012* 
 Baseline  Satisfaction with social support centred                                                                                                                            -0.150 0.299 -0.076  0.618 
 Baseline Negative coping centred X Satisfaction with social support centred                                        -0.026  0.054 -0.076   0.638 
*significant level p<0.05, ** significant level p<0.01, ***significant level p<0.001 (n=67) 
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Depression log at six months as the dependent variable  
A bivariate correlation analysis was performed with depression log at six months and 
all baseline variables.  Preliminary analyses were performed to ensure no violation of 
the assumptions of normality, linearity and homoscedasticity.  The results of the 
Pearson’s product-moment correlation coefficients are details in table 5.22.   
Table 5.22 Bivariate correlations with depression log at six months and study variables at 
baseline 
Baseline study variables depression log at six months 
MAC Scale, positive coping -0.034 
MAC Scale, negative coping 0.415*** 
Perceived stress 0.321*** 
Self-management self-efficacy -0.138 
Received social support Square root 0.172 
Perceived social support  -0.223* 
Satisfaction social support -0.234* 
HADS, Anxiety Square root 0.252** 
HADS, Depression Log 0.306** 
EORTC C30, Physical function -0.292** 
EORTC C30, Role function -0.357*** 
EORTC C30, Emotional function -0.442*** 
EORTC C30, Cognitive function -0.338*** 
EORTC C30, Social function -0.388*** 
EORTC C30, Global quality of life Square root -0.419*** 
EORTC C30, Nausea and vomiting 0.128 
EORTC C30, Pain 0.123 
EORTC C30, Dyspnoea 0.198* 
EORTC C30, Insomnia 0.357*** 
EORTC C30, Appetite loss 0.094 
EORTC C30, Constipation 0.105 
EORTC C30, Diarrhoea 0.247** 
EORTC C30, Fatigue Square root 0.324*** 
EORTC C30, Financial difficulties 0.139 
EORTC PR25, Urinary symptoms Square root 0.101 
EORTC PR25, Bowel symptoms 0.355*** 
EORTC PR25, Treatment symptoms 0.263** 
EORTC PR25, Incontinence aid 0.098 
EORTC PR25, Sexual activity 0.056 
EORTC PR25, Sexual function 0.148 
Number of co morbidities 0.211* 
Age 0.249** 
PSA square root -0.141 
*significant level p<0.15, ** significant level p<0.05, ***significant level p<0.01 (n=68) 
 
Three baseline variables (depression log, negative coping centred and satisfaction with 
social support centred) were entered in to the equation in three steps because of their 
central importance in addressing the third research question.  Negative coping and 
satisfaction with social support variables were centred and a product term was 
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calculated to test for moderation effects.   At step one: depression log was entered; at 
step two: negative coping centred and satisfaction with social support centred; and at step 
three: the product term negative coping centred*satisfaction with social support centred 
was entered.  The sample size was just below (n=67) the sample size calculation 
(50+8m=74) (Tabachnick and Fidell, 2007) and therefore, adding additional predictors 
would have largely under-powered the analysis.  The results of the hierarchical 
multiple regression analysis are displayed in table 5.23. 
 
Goodness of model fit was checked and was considered satisfactory.  Collinearly 
statistics and Durbin-Watson test were acceptable, no multivariate outliners 
identified, and scatterplots indicate no violation of normality, linearity or 
homoscedasticity.  After controlling for baseline depression log scores, negative 
coping at baseline was a significant predictor of depression log (β=0.337, p=0.007) at 
six months.  Satisfaction with social support at baseline did not demonstrate a main 
on depression scores at six months.  Furthermore, satisfaction with social support did 
not moderate the relationship between negative coping and depression log at six 
months.   Overall, model two explained 19.5% (adjusted R2) of the variance of 
depression log at six months (see table 5.23).  Mediation effects were not tested 
because satisfaction with social support at baseline was not a significant predictor of 
depression log at six months. 
 
A second hierarchical multiple regression analysis was performed with negative 
coping and perceived social support on depression log at six months.  The three 
baseline variables (depression log, negative coping centred and perceived social support 
centred) were entered in to the equation in three steps because of their central 
importance in addressing the third research question.  Negative coping and 
perceived social support variables were centred and a product term was calculated 
to test for moderation effects.  At step one: depression log; at step two: negative 
coping centred and perceived social support centred; and at step three: the product term 
negative coping centred*perceived social support centred was entered.  The sample size 
was just below (n=67) the sample size calculation (50+8m=74) (Tabachnick and Fidell, 
2007) and therefore, adding additional predictors would have largely under-powered 
the analysis. Prior to the analysis, the underlying assumptions were checked.  The 
results of the hierarchical multiple regressions are displayed in table 5.24. 
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After controlling for baseline depression log scores, negative coping (β=0.381, 
p=0.002) and perceived social support (β=-0.243, p=0.029) at baseline had a 
significant main effects and explained 22.3% (adjusted R2) of the variance of 
depression log scores at six months.  Perceived social support did not moderate the 
relationship between negative coping and depression, p>0.05.  Mediation effects 
were not possible because perceived social support and negative coping scores at 
baseline were not significantly related (β -0.077, p=0.534).   
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Table 5.23 Hierarchical multiple regression analysis with depression, negative coping and satisfaction with social support scores at baseline on depression log at six 
months as the dependent variable 
Model                                                     R Square change         R   R
2  
Adjusted
 
R
2  
B SE B β  Significance
 
One:  Constant                                                                                                                                     0.384 0.068   0.000*** 
Baseline  Depression log                                       .093                            0.305 0.093 0.079*   0.307 0.120  0.305 0.013*         
Two:  Constant                                                                                             0.454 0.068   0.000*** 
 Baseline  Depression log                                    .139                      0.482 0.232 0.195** 0.165 0.121  0.163  0.178                                                              
 Baseline Negative coping centred                                                                                                                                                                                  0.015 0.005  0.337 0.007** 
 Baseline  Satisfaction with social support centred                                                                            -0.132 0.082  -0.180    0.114 
Three: Constant                                                                                                                                            0.462 0.069      0.000*** 
Baseline  Depression  log                                   .007                       0.489 0.239 0.189  0.138  0.127  0.137 0.279                                                        
Baseline Negative coping centred                                                                                                                                                                            0.016  0.006  0.370  0.006** 
Baseline Satisfaction with social support centred                                                                                                            -0.076 0.117  -0.097 0.544 
Baseline Negative coping centred X Satisfaction with social support centred                                                                         -0.015  0.021     -0.120 0.466 
*significant level p<0.05, ** significant level p<0.01, ***significant level p<0.001 (n=67) 
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Table 5.24 Hierarchical multiple regression analysis with depression, negative coping and perceived of social support scores at baseline on depression log at six months as 
the dependent variable 
Model                                                   R Square change      R  R
2  
Adjusted
 
R
2  
B SE B  β                      Significance
 
One:  Constant                                                                                          0.386 0.069  0.000*** 
 Baseline Depression log                                 .094               0.306 0.094 0.080*  0.315 0.121 0.306 0.011*         
Two:  Constant                                                                                                                                0.456 0.067     0.000*** 
 Baseline Depression log                                  .165            0.508 0.258 0.223**  0.154  0.120 0.150 0.203                                                              
 Baseline Negative coping centred                                                                                            0.017 0.005 0.381 0.002** 
 Baseline Perceived social support centred                                                                     -0.054 0.026   -0.243   0.029* 
Three: Constant                                                                                                              0.476 0.066     0.000*** 
 Baseline Depression  log                                  .041     0.547   0.299   0.254   0.141 0.117  0.137  0.234                                                        
 Baseline Negative coping centred                                                                                            0.017 0.005 0.378 0.002** 
 Baseline  Perceived  social support centred                                                    -0.059 0.026 -0.243 0.026* 
 Baseline Negative coping centred X Perceived social support centred                          -0.007   0.004  -0.202  0.060 
*significant level p<0.05, ** significant level p<0.01, ***significant level p<0.001 (n=67) 
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5.6 Discussion   
This prospective longitudinal survey was acceptable for the participants because 
there was very little attrition and missing data.  The standardised measures used 
were reliable and valid.  No selection bias was demonstrated between the 
participants who did not consent to take part in the study for age, cancer stage and 
treatment.  The response rate for the study was 67.9% and this result is similar to 
that reported by van de Poll-Franse et al. (2008b), Fransson (2008), Diefenbach and 
Mohamed (2007), and Miller et al. (2007).  Six men (8.1%) were lost from the study at 
the six months data collection and they were more likely to be older.  The sample 
sizes for the five regression analyses were marginally below the recommended 
sample size based the on guidance from Tabachnick and Fidell (2007) and therefore, 
some caution should be taken in the interpretation of the findings.  Each regression 
model explained approximately 30% of the variance of the dependent variables 
(Anxiety square root, depression log, and global quality of life square root) which left a 
proportion of variance unexplained by the model and is similar to that reported 
elsewhere (Zhou et al., 2010a, Roberts et al., 2006).  The number of independent 
variables entered into the analyses could have been increased but this would have 
caused the analyses to be significantly underpowered.  Therefore, acknowledging 
additional variables (such as symptoms, co-morbidity, age, etc.) may have had a 
significant multivariate contribution; the five regression analyses performed 
controlled for appropriate baseline variables to test the social support theoretical 
model and were sufficiently powered. 
 
The HADS (Snaith and Zigmond, 1986) was acceptable to participants and had very 
little missing data.  No statistically significant difference was found in the means 
scores for anxiety and depression scores at baseline and at six months. The mean 
score for anxiety and depression at baseline (4.62 & 2.88) and at six months (4.53 & 
3.32) are similar to published studies (Berglund et al., 2007, Ene et al., 2006, Brindle 
et al., 2006).  Using the cut-off scores (Zigmond and Snaith, 1983) at baseline, 7.4% of 
men were identified as having possible/probable depression and 10.3% of men at six 
months.  An (arbitrary) trend of increased depression at six months is not surprising 
because men can face a host of problems which may affect their emotional outcome.   
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Negative coping and perceived social support at baseline had a significant main effect 
on depression at six months.  This provides support the main effect theoretical model 
(Cohen and Wills, 1985) because participants who reported high perceived social 
support at baseline (β=-0.243, p=0.026) had lower depression scores at six months.  
There were no associations with received social support and satisfaction with social 
support variables at baseline with depression scores at six months.  These data 
demonstrate that perceived social support is a longitudinal predictor of emotional 
outcome and this is in keeping with published studies (Zhou et al., 2010a, Roberts et 
al., 2006).   On closer scrutiny, Zhou and Roberts investigated the effects of perceived 
social support only; therefore the findings in the present study add an important 
perspective on the support processes for emotional outcome.  When considering the 
following social support constructs: received social support, perceived social support 
and satisfaction of social support, perceived social support was the most important 
social support predictor of depression at six months.   
 
Depression scores (at six months) were negatively correlated with all of the EORTC 
functional scales (physical function, role function, emotional function, cognitive 
function and social function at baseline) and this is similar to data presented by Ene 
et al. (2006).  Depression (at six months) also had a number of positive associations 
with the following variables at baseline: perceived stress, insomnia, fatigue, 
treatment symptoms, bowel symptoms and age, and these associations have been 
demonstrated in published studies (Monahan et al., 2007, Ene et al., 2006, Monga et 
al., 2005).  The significant correlations between the baseline variables and depression 
at six months in the aforementioned results could have been entered into the 
regression equation; however this would have increased the number of independent 
variables and resulted in reduced statistical power due to a small sample size.  
Approximately 70% of the variance of depression scores at six months was not 
accounted for by the following baseline variables: depression scores, negative coping 
and perceived social support.  Therefore, further study with a larger sample size 
would be helpful to explore the influences of such variables on depression scores 
over time. 
 
After controlling for baseline anxiety scores, baseline negative coping (β=0.359, 
p=0.010) was a significant longitudinal predictor of anxiety scores at six months.  
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Received social support and perceived social support variables had no association 
with anxiety at six months.  Satisfaction with social support was entered into the 
regression equation at p<0.15, and did not significantly predict anxiety scores at six 
months.  Therefore, social support variables (perceived, received and satisfaction 
with social support) did not have any main or moderation (buffering) effects, and 
mediation was not tested because the conditions for mediation analysis were not 
met.  These data do not support existing theoretical models (main effects and stress 
buffering) linking social support to anxiety and the reasons as to why are not clear.  
Previous cross-section studies have identified an association between perceived 
social support and anxiety (Balderson and Towell, 2003) for men affected by prostate 
cancer, but such retrospective cross-sectional designs are prone to bias.  Such 
designs cannot identify a causal pathway linking social support to emotional outcome 
over time, specifically, cross-sectional designs cannot determine facts about “time 
order” of social support and anxiety; in other words, whether one variable preceded 
the other.  This Ph.D. study has identified that baseline social support constructs do 
not significantly predict anxiety score at six months. 
 
Global quality of life (EORTC C30) at six months was positively associated with the 
EORTC C30 functional scales and negatively related to individual symptoms scales.  
The hierarchical multiple regression analysis demonstrated longitudinal predictors of 
global quality of life at six months with the following baseline variables: global quality 
of life, perceived social support and satisfaction with social support.  The correlation 
coefficients identified baseline positive coping had no association with quality of life 
at six months, and negative coping was entered in to the regression equation at 
p<0.15, but did not significantly predict global quality of life.  Baseline global quality 
of life (β=0.325, p=.006) and perceived social support (β=0.272, p=0.016) explained 
29.6% (adjusted R2) of the variance of global quality of life at six months.  Whereas, 
baseline global quality of life (β=0.401, p=0.001) and satisfaction with social support 
(β=0.278, p=0.014) explained 25.0% (adjusted R2) of the variance of global quality of 
life at six months.  These data identify that perceived social support explained a 
slightly greater proportion of the variance of global quality of life compared to the 
satisfaction with social support construct.  These data support the main effect 
theoretical model for perceived and satisfaction with social support on global quality 
of life.  Received social support was insufficiently associated with global quality of 
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life, and therefore did not meet the criteria to be entered into the regression 
equation.  There were no moderation (buffering) effects with negative coping, and a) 
perceived social support, and b) satisfaction with social support, and the conditions 
for mediation analysis did not hold.   
 
The findings identified that baseline positive coping and received social support had 
no relationship with anxiety, depression and global quality of life at six months. 
Baseline perceived social support was found to have a main effect on depression and 
global quality of life at six months, and baseline satisfaction with social support had a 
main effect on global quality of life at six months only.  Therefore, negative coping, 
perceived social support and satisfaction with social support were the most 
important longitudinal predictors of global quality of life and depression at six 
months.  These analyses did not demonstrate any moderating (buffering effects) or 
mediating effects with negative coping and social support (perceived and satisfaction 
with social support) on the dependent variables. These data support that perceived 
social support and satisfaction with social support had a positive influence on health-
related outcomes regardless of the level of negative coping scores.  These data 
support the main effect theoretical model (Cohen and Wills, 1985)  based on 
aggregate group level effects and is in keeping with published studies (Zhou et al., 
2010a, Zhou et al., 2010b, Queenan et al., 2010, Kershaw et al., 2008, Visser et al., 
2003, Rondorf-Klym and Colling, 2003).  Overall, perceived social support was the 
most important social support construct that predicted depression and health-
related quality of life.   
 
There was little change in perceived social support at baseline and at six months 
follow-up (t=-1.42, ns) and suggests that perceptions of availability of social support 
are relatively stable over time; this is in keeping with the work of Sarason et al.  
(1986). Received social support significantly increased over time (t=-2.10, p=0.031) 
with no change in satisfaction with social support over time (t=1.00, ns).   Descriptive 
data suggested an overall trend of increased usage of additional cancer support 
services, but the large majority of men did not engage with additional cancer support 
services at baseline or at six months follow-up.  These data are consistent with those 
published by Krizek et al. (1999), demonstrating that a minority of men will engage 
with additional support services, leaving a substantial percentage of men who do not 
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use additional support services.  It maybe that the majority of men are, a) not 
interested in such support services, b) men feel that such services do not meet their 
care needs, or c) men have a negative attitude towards support services.    The 
current study identified less than 20% of men participated in additional cancer 
support services, such as Maggie’s Cancer Care Centre and this is similar to the data 
published by (Shapiro et al., 2004) who reported 22% of men expressed an interest in 
cancer support services, such as peer support.  Data have demonstrated factors that 
influence men’s participation in additional cancer support services and these include 
the following variables: lower age, higher socio-economic status, low perceived social 
support and a positive attitude towards receiving additional cancer support 
(Voerman et al., 2007).  The current study did not explore determinates of 
participation in additional cancer support services and this element would be worthy 
of further research.  
 
The mean score for received social support was 1.68 (SD 0.40) at one month 
following a prostate cancer diagnosis and 1.97 (SD 0.99) at six months follow-up.  The 
total possible maximum mean score is 4.0, indicating that men scored almost half of 
the total maximum mean score for the received social support scale.  Cancer studies 
that have previously used the BSSS in cancer populations identify that men in this 
current study scored consistently less on the received social support scale overtime 
when compared to published data (Boehmer et al., 2007, Luszczynska et al., 2007a, 
Schwarzer et al., 2006, Luszczynska et al., 2005).  Previous studies have reported the 
mean score for received social support >3.70 in cancer populations using this 
instrument.  There are several possible explanations to account for men reporting 
less received social support compared to previously published data.  The published 
studies (Boehmer et al., 2007, Luszczynska et al., 2007a, Schwarzer et al., 2006, 
Luszczynska et al., 2005) were limited to cancer participants undergoing surgery only, 
therefore it is possible, due to the invasive nature of surgery, that participants 
consistently reported a higher amount of received social support.  This current study 
consisted of a heterogeneous population of men with different treatment modalities, 
with nine men treated by surgical techniques.  However, no statistical association 
with cancer treatment and level of received social support was demonstrated using a 
one-way between group analysis of variance, and thus would seem an unlikely 
explanation.  From the reviewed studies, the samples had mixed cancer sites, mixed 
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gender and the samples were non-UK.  Different cancer sites, gender and cultural 
differences could influence support provision, furthermore, social support may affect 
specific cancer populations in unique ways, given the distinct physical and 
psychological challenges associated with each cancer (Zhou et al., 2010a).  Thus, 
additional research would be helpful to advance understanding in this area.   
 
The EORTC C30 and PR25 were well accepted by participants and had very little 
missing data.  Reliability was acceptable for all scales except for cognitive function 
(>0.55), bowel symptoms (>0.51) and treatment symptoms (>0.41).  It could be that 
these scales performed poorly in this the study sample.    The Cronbach’s alpha 
coefficients reported here demonstrate similar reliability coefficients to that of 
several recently published studies (Roeloffzen et al., 2010, Vordermark et al., 2009, 
van Andel et al., 2008, Lips et al., 2007, Spry et al., 2006).     
 
There were a number of statistically significant changes in health-related quality of 
life at six months.  Global quality of life significantly decreased at six months follow-
up (t=2.35, p=0.021).  There were no significant changes in the functional scales (role 
function, cognitive function, emotional function and social function) except for a 
significant decrease in physical function at six months.  A number of statistically 
significant increases over time were identified for fatigue, constipation and appetite 
loss, but no change was demonstrated for the following symptoms: dyspnoea, pain, 
diarrhoea, and financial difficulties. Osoba et al. (1999) suggest that a change of ≥20 
points on a standardised measure (scale range of 0-100) represents a clinically large 
change, a change of 10-20 points indicates a moderate change, and 5-10 points is 
indicative of a small clinical change.  The guidelines from Osoba have been applied to 
published prostate cancer studies (Lips et al., 2009, Stephens et al., 2007, Buron et 
al., 2007, Lips et al., 2007, Spry et al., 2006), and are useful to understand the clinical 
relevance of HRQoL data for the current study.  Using the guidance from Osoba, 
global quality of life scores reduced over time and showed a small clinically relevant 
change (score change >5.2, on a 0-100 scale); this is similar to the results of Buron et 
al. (2007).   
 
There were no statistically significant changes in the functional scales apart from the 
physical function scores at six months, which reduced over baseline scores and was 
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approaching a small clinical change (score difference >4.96, on a 0-100 scale).  This 
result is in keeping with existing studies that have demonstrated very little 
deterioration or change in scores over time for functional domains of quality of life 
for prostate cancer survivors (Hashine et al., 2009, Kato et al., 2007, Namiki et al., 
2006b, Robinson et al., 1999a). Appetite loss, constipation and fatigue were 
significantly worse over time at six months.  The score changes for the three 
symptoms as follows: appetite loss (score difference >4.48), constipation (score 
difference >4.91), fatigue (score difference >2.32) and were not clinically significant 
<5 (0-100 scale), and other researchers have published similar findings (Lips et al., 
2009, Spry et al., 2006, Robinson et al., 1999a).   
 
Overall, the results in the current study appear to be consistent with others.  Due to 
the limited follow-up period, it was not possible to assess for changes in HRQoL 
beyond six months, to confirm whether the population would have returned to 
baseline scores by twelve months.  However, studies with longer follow-ups identify 
that differences in global quality of life scores are no longer statistically significant or 
clinically relevant at twelve months (Lips e al., 2009, Spry et al., 2006). The recovery 
of global quality of life would remain unknown for the current population in this 
study, but these data suggest recovery may be possible around twelve months.   
 
Statistically significant increases were identified for bowel symptoms and treatment 
symptoms at six months, but not for urinary symptoms; this result was similar to the 
findings of Diefenbach and Mohamed (2007).  The change in scores represent a small 
clinically significant change for bowel (>5.61) and treatment symptoms (>7.79) at 
follow-up, and these are similar to Lips et al., (2007).  Sexual activity also statistically 
(t=-1.74, p<0.05) reduced over time and represented a small clinically significant 
change (<6.1).  At one month after diagnosis, twenty-eight (41.2%) men were 
sexually active and at six months, fifteen men (22.1%) were sexually active.  Reduced 
sexual activity for men living with prostate cancer has been widely demonstrated in 
published studies assessing change over time (Roeloffzen et al., 2010, Smith et al., 
2009, Nguyen et al., 2009, Davison et al., 2007, Kato et al., 2007, Namiki et al., 2007, 
Jayadevappa et al., 2006, Feigenberg et al., 2005).   
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In keeping with the clinically relevant and statistically significant increase in bowel 
symptoms at six months, a statistically significant increase in bowel self-management 
was also identified at six months (McNemar’s test p=0.002).  The overall percentage 
of men who performed bowel self-management increased from 14.9% at baseline to 
30.9% of men at six months.  There were few men with localised disease who 
performed bowel self-management at baseline (two men) and at six months (four 
men).  Men with localised prostate cancer performed a number of bowel self-
management behaviours such as: “changed diet”, “increased fluid intake”, “shared 
thoughts and feelings”, “took rest/sleep” and “took advice from a continence 
advisor”.  For men with localised prostate cancer, their self-management behaviours 
did not provide complete bowel symptom relief, but overall the percentage of men 
who performed bowel self-management was low at baseline (6.2%) and at six 
months (12.5%). 
 
Bowel self-management was most frequently reported by men who had locally 
advanced prostate cancer in comparison to men with localised or metastatic disease.  
This was an expected result because locally advanced prostate cancer is often treated 
with neoadjuvant hormone therapy and radiotherapy (Stephens et al., 2007).  
Radiotherapy can cause bowel problems as an after-effect of this treatment.  A large 
body of prospective data have demonstrated an increase in bowel problems 
following radiotherapy (Fransson et al., 2009a, Thong et al., 2009, Guedea et al., 
2009, Pinkawa et al., 2009a, Robinson et al., 2009, Lips et al., 2009, Choo et al., 2007, 
Jayadevappa et al., 2006, Namiki et al., 2004) and would therefore explain the trend 
of increased bowel self-management for men with locally advanced disease.  Of the 
men who were diagnosed with locally advanced cancer, five men (17.2%) performed 
bowel self-management behaviours at baseline and eleven (37.9%) men performed 
bowel self-management behaviours at six months.  The increase in bowel self-
management behaviours is similar to that reported by (Wilson et al., 2010); however, 
Wilson did not report participants’ perceived effectiveness of the self-management 
strategies performed by the participants.  Therefore, unfortunately, it is not possible 
to compare these data.  For the participants who performed bowel self-management 
with locally advanced prostate cancer, the mean score for perceived effectiveness of 
self-management behaviours was 2.72 (SD.83) at baseline and 3.33 (SD.58) at six 
months. A trend of improved symptom relief was observed over time, but 
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participants did not achieve complete relief of their bowel problems through their 
self-management actions. 
 
Similarly, men with metastatic disease did not achieve complete relief from their 
bowel self-management over time, and the number of men performing bowel self-
care increased from two men at baseline to six men at follow-up.  Several trends 
were common across all stages of cancer; firstly the number of men performing 
bowel self-care increased at six months, secondly men performed a number of self-
management behaviours across all stages of cancer, and lastly, data indicate that 
men did not achieve complete relief of bowel problems from their self-management 
behaviours.  
 
The overall percentage of men performing urinary self-management statistically 
reduced from 51.5% at baseline to 38.6% at six months.  Men diagnosed with 
localised and locally advanced prostate cancer performed a great variety of urinary 
self-management behaviours compared to men with metastatic disease. It is 
important to acknowledge that there were few men with metastatic cancer in the 
study (nine men, 12.2%) and therefore, may not be representative of all men with 
metastatic cancer.  The urinary self-management behaviours reported by men across 
all stages of disease included the following examples: “increased fluid intake”, 
“reduced caffeine intake”, “used pads”, “avoided heavy lifting” and “took 
medication”.  For men with localised prostate cancer the number of men who 
performed urinary self-management reduced from fifteen men (46.8%) at baseline, 
to ten men (31.2%) at follow-up.  A similar trend was identified for men with locally 
advanced and metastatic cancer, whereby the number of men performing urinary 
self-management reduced over time.  This result is in keeping with published studies 
that have identified an improvement in urinary dysfunction over time (Sanda et al., 
2008, Choo et al., 2007, Brar et al., 2005), and thus the number of men performing 
urinary self-management could be assumed to reduce over time.   
 
The overall percentage of men performing self-management for sexual dysfunction 
increased over time from 45.6% of men at baseline, to 52.9% of men at six months, 
but this result was not statistically significant.  Across all stages of cancer the number 
of men performing self-management for sexual dysfunction increased.   Men 
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reported a number of strategies to improve their sexual function and examples 
included the following: “took medication”, “took rest”, “limited alcohol intake”, 
shared my thoughts and feelings”, “found out information” and “took advice from 
the doctor”.  Men (all stages) reported little relief from their sexual function self-
management behaviours.  Based on the stage of cancer the mean scores at six 
months for sexual function self-management relief are as follows: for men with 
localised disease the mean score was 1.5 (SD.87), for men with locally advanced 
cancer 2.1 (SD 1.47), and for men with metastatic cancer 2.0 (SD 0).  The total 
maximum mean score possible was 5.0, which would indicate complete relief of 
problems based on self-management actions, and thus men consistently reported 
little relief from their self-management across all stages of prostate cancer.  Common 
to all stages of disease and treatment modalities is a worsening sexual function for a 
man living with prostate cancer.  This finding has been widely demonstrated in the 
literature (Roeloffzen et al., 2010, Smith et al., 2009, Lips et al., 2009, Robinson et al., 
2009, Diefenbach et al., 2008, Diefenbach and Mohamed, 2007, Davison et al., 2007, 
Buron et al., 2007, Kato et al., 2007, Jayadevappa et al., 2006, Jayadevappa et al., 
2005, Monga et al., 2005), therefore, it is not surprising that men report an increase 
in sexual function self-management over time.  But what is interesting, is that, 
despite a large number of self-management strategies used, men, unfortunately, do 
not have much improvement in their sexual function. 
 
In summary, men with prostate cancer can perform a number of self-management 
behaviours for urinary, bowel and sexual dysfunction, often with little relief in 
alleviating their symptoms over time.  In addition, self-management self-efficacy 
scores at six months were significantly reduced (t=3.17, p=0.002) compared to 
baseline.  This finding suggests that prostate cancer survivors experience a decline in 
their belief to perform self-management with confidence and ease over time.  
Interestingly, men reported a greater number of suggestions for their self-
management from “others” at six months.  The most frequent source of self-
management suggestions came from men’s partners and their doctors at both 
baseline and at six months.  There are several possible explanations for the lower 
self-management self-efficacy scores over time.  One explanation could be because 
men frequently reported receiving self-management suggestions from their partners, 
and the assistance provided could have been from an overprotective individual, and 
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thus reduced men’s autonomy, thereby making them feel incapable of self-managing 
their condition.  A further explanation might be, because men performed a number 
of self-management strategies which often, did not completely relieve the 
problems/symptom experienced, this could lower/reduced men’s beliefs in their 
confidence and how easy they find their self-management.  This area is worthy of 
further research to advance understanding of self-management self-efficacy over 
time.   
5.7 Conclusion  
This prospective longitudinal survey evaluated change over time and tested existing 
theoretical social support models linking support to health outcomes.  The measures 
used in this study were reliable and had very little missing data.  This study used a 
multi-dimensional assessment of social support which identified that perceived social 
support was the most important predictor of global quality of life and depression at 
six months.  Satisfaction with social support at one month after a prostate cancer 
diagnosis had a main effect on depression scores at six months.  This study provided 
support for the main effects model for certain aspects of social support, but did not 
demonstrate moderating (buffering) or mediation effects of social support with 
negative coping on health outcomes in this patient group.  Received social support at 
baseline did not have any association with the dependent variables, and would 
suggest that perceptions of availability of help are more important that objective 
accounts of social support received. 
 
No statistically significant changes were identified over time in anxiety and 
depression scores.  Global quality of life demonstrated a clinically small relevant and 
statistically significant decrease at six months, but functional domains of health-
related quality of life were mostly unaffected.  Disease-specific domains of health-
related quality of life were affected in this population and an increase in bowel and 
sexual dysfunction was identified at six months. 
 
In keeping with the increase in bowel and sexual dysfunction at six months, the 
number of men performing bowel and sexual function self-management behaviours 
increased.  The self-management data presented from this longitudinal survey have 
demonstrated an important insight into the self-management behaviours for men 
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living with this condition.  Two key finding emerged from the self-management data.  
Firstly, men performed a number of self-management behaviours but did not achieve 
complete symptom control.  Secondly, this study identified that self-management 
self-efficacy significantly reduced at six months.  This area would benefit from further 
research to establish why self-efficacy reduced at six months, and subsequently, to 
identify areas for intervention. These findings perhaps provide support to the 
development of an intervention study to improve quality of life, self-management 
self-efficacy and improve patients’ symptom management.  The findings from the 
individual case studies may provide useful insight to indicate the content of such an 
intervention study.  
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6. RESULTS – EMA Adapted/N-of-1 
6.1 Short chapter abstract 
Background 
Most healthcare research and the findings from the prospective longitudinal study 
(chapter 5) were restricted to aggregate group level effects, introduced 
retrospective memory recall bias, and overlooked the importance of within-person 
experience.  To overcome the limitations of aggregate group level effects and to 
build upon the findings in chapter 5, a sensible approach to advance this field 
further was to use case-based time series studies.  The EMA adapted/N-of-1 case 
series was used test the mechanism effects between coping and social support on 
emotional outcome, within individuals over time.  The EMA adapted/N-of-1 case 
series was also used to assess the self-management behaviours and social 
supportive experiences of men affected by prostate cancer over time.  This is the 
first study that has assessed the feasibility of real time data collection methods in 
prostate cancer survivors.       
Aim 
To test the mechanism effects between coping and social support on emotional 
outcome, within individuals over time.  In addition, the EMA adapted/N-of-1 case 
series was used to assess the self-management behaviours and social supportive 
experiences of men affected by prostate cancer over time.  
Methods 
A Research Steering Group informed the development of the EMA adapted/N-of-1 
case series.  Twelve EMA adapted/N-of-1 studies were purposively sampled based 
upon the following criteria: cancer stage, level of social support, marital status and 
existing co-morbidity.  Data collection was managed by using the Dell Axim X51 
and Pocket Interview software.  Data collection commenced within several weeks 
following primary treatment.  Self-reports were collected for 31 days prompted by 
an audio alarm three times per day (a total of 93 data entries) for each of the 
twelve case studies.  The structure of the diary consisted of a standard entry, end-
of-day entry and incident entry.  Data were analysed using traditional exploratory 
analysis, autocorrelograms, pre-whitening of variables, correlation and multiple 
regression.  Data were analysed using SPSS version 17.0. 
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Results 
Two participants had response rates >80% and nine participants had response 
rates >90%, and one man’s data was lost due to a technical problem.  Men used 
social support as a form of self-management behaviour among many other 
strategies to improve urinary, bowel and sexual dysfunction, but often with little 
relief.  A common theme across all of the 11 case studies was that men very 
frequently experienced a range of symptoms for which they did not perform any 
self-management.  Testing the propositions of social support theory “within 
individuals” over time demonstrated different results for main, moderation and 
mediating pathways that linked coping and social support to emotional outcome.  
For two men, negative effects of social support were identified and this finding 
suggests that not all support provisions are helpful.  For six men the propositions 
of social support theory did not hold with person design. 
Conclusion  
This unique study has identified the limitations of aggregate group level effects 
because this study has demonstrated that one size does not fit all.  Real time data 
collection moves far beyond traditional retrospective evaluations, enabling a much 
clearer understanding of the patient experience throughout the cancer journey.  
This study has demonstrated the feasibility and acceptability of e-health 
technologies for men affected by prostate cancer.  These findings build upon the 
results in chapter 5 and suggest that men may benefit from a supported self-
management intervention study, tailored to the “individual needs” of prostate 
cancer survivors.  However, future research is needed to identify the content of 
the intervention.     
 
6.2 Introduction 
This chapter reports and discusses the findings from the EMA adapted/N-of-1 
series.  The findings from the prospective longitudinal study (chapter 5) were 
restricted to aggregate group level effects, and overlooked the importance of 
within-person experience and change over time (see chapter 4, section 4.2).  
Although the longitudinal survey was prospective it included retrospective 
questioning and, therefore, retrospective memory recall bias was possible 
(Shiffman et al., 2008, Stone et al., 2005, Stone et al., 2004, Stone et al., 2003a, 
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Stone and Shiffman, 2002).  Consequently, the real-life validity of the data 
presented from the prospective longitudinal study is unknown (Jones and 
Johnston, 2011). To overcome the limitations of aggregate group level effects and 
retrospective memory recall bias, a sensible approach to advance the field further 
was to use N-of-1 time series studies.  N-of-1 time series studies (Molenaar, 2004) 
can form the pre-clinical and theoretical modelling stages of the Medical Research 
Council’s framework for complex interventions (Craig et al., 2008).  Applying 
theoretical constructs to individuals will enrich and expand empirical reach to 
tailor interventions at the individual level of change (Borckardt et al., 2008) and 
can reduce retrospective memory recall bias.   
 
The EMA adapted/N-of-1 case series was used to test the propositions of social 
support theory (Cohen et al., 2000, Cohen, 1988, Cohen and McKay, 1984) within 
individuals.  Empirically testing theoretical models within individuals can identify 
the potential for future interventions that are theoretically driven and 
appropriately targeted.   In relation to the research questions, this EMA 
adapted/N-of-1 series was used to test the mechanism effect between coping and 
social support on emotional outcome, within individuals over time.  In addition, 
the EMA adapted/N-of-1 series was used to assess the self-management 
behaviours and the social supportive experiences of men affected by prostate 
cancer over time.  This is the first study that has assessed the feasibility of real 
time data collection methods in prostate cancer survivors.  It was important to 
identify any potential bias in agreement to complete the electronic diary and to 
establish questionnaire response rates.  This case series has provided a unique 
insight into the individual experiences of eleven men with different clinical 
characteristics, demographic backgrounds, and level of social support, which 
allowed for some replication.   
 
6.3 Research questions 
The series of EMA adapted/N-of-1 studies addressed the following questions: 
 
In prostate cancer survivors: 
1a. What patient characteristics influence agreement to complete the EMA 
adapted/N-of-1 data?  
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1b. What are the response rates of participants filling out a diary over several 
weeks? 
 
2a. What are the daily self-management behaviours in real time and do they 
change over time? 
 
2b. What are the daily social supportive experiences in real time and do they 
change over time? 
 
2c. Do social supportive experiences have a main effect, or do they 
moderate/mediate the relationship between coping and mood in real time? 
 
6.4 Methods 
A Research Steering Group informed the development of the EMA adapted/N-of-1 
case series.  Twelve EMA adapted/N-of-1 studies were purposively sampled based 
upon the following criteria: cancer stage, level of social support, marital status and 
existing co-morbidity.  Data collection was managed by using the Dell Axim X51 
and Pocket Interview software.  Data collection commenced within several weeks 
following primary treatment.  Self-reports were collected for 31 days prompted by 
an audio alarm three times per day (a total of 93 data entries) for each of the 
twelve case studies.  The structure of the diary consisted of a standard entry, end-
of-day entry and incident entry.  The content of the diary questions was mapped 
to the constructs of the questionnaires and the items were informed by the 
literature and comment from clinicians and prostate cancer patients (see appendix 
4.14 for diary schedule and screenshot examples of the PDA).  Most question 
items were presented on the PDA using a visual analogue scale (VAS) from 0-100 
scale.  The question items presented on the diary consisted of a ‘standard diary 
entry’ (completed 3 times per day), an ‘end-of-day entry’ (completed once per day, 
immediately following the third standard entry each day), and an ‘incident entry’ 
that could be completed at any time throughout the 1-month period (see table 6.1 
for an overview of the measurements used in the diary).   
Table 6.1 An overview of the measurements used in the diary 
Enquiry Subscale and variables Number 
of items 
Data presented in 
this chapter 
Standard 
Entry 
(3 times per 
day, for a 
total of 1 
Negative affect* 
How do you feel just now? (0-100) 
Nervous, Frustrated, Sad, Angry, Stressed, Tired 
Positive affect*   
How do you feel just now? (0-100) 
6 
 
 
3 
 
Yes 
 
 
Yes 
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month 
(n=93) 
Alert, Happy, Energetic 
Positive coping 
Please rate each of the following statements which 
describes how you have coped in the past few hours with 
your self-care? (0-100) 
I tried to keep a positive attitude   
Negative coping*   
Please rate each of the following statements which 
describes how you have coped in the past few hours with 
your self-care? (0-100) 
I felt like giving up, I felt problems with my health 
prevented me from planning ahead, I felt that nothing I can 
do will make a difference, I tried not to think about it  
Perceived social support* 
Do you have enough available support from people around 
you? (0-100) 
Financial, Emotional, Practical, Informational 
Received social support* 
How much support have you received in the past few 
hours? (0-100) 
Financial, Emotional, Practical, Informational 
Sought social support  
Have you sought out social support in the past few hours? 
(yes/no) 
Self-management demand 
How demanding has self-care been for you? (0-100) 
Self-management control 
How much control have you had over your self-care? (0-
100) 
Self-management self-efficacy*  
I can always manage to complete self-care tasks that are 
difficult for me (0-100), I am confident in carrying out my 
self-care activities (0-100) 
 
1 
 
 
 
 
4 
 
 
 
 
 
 
4 
 
 
 
4 
 
 
 
1 
 
 
1 
 
1 
 
 
2 
 
Yes 
 
 
 
 
Yes 
 
 
 
 
 
 
Yes 
 
 
 
Yes 
 
 
 
Yes 
 
 
Yes 
 
Yes 
 
 
Yes 
 
 
 
End of Day 
Entry 
(Once per 
day, for a 
total of 1 
month 
(n=31) 
Urinary self-management behaviours  
What types of self-care have you used today to help with 
your water works (urine)? (tick box) 
None, Took medication, Found out information, Increased 
fluid intake, Used pads, Used catheters, Used urine sheaths 
Pelvic floor exercises, Avoided heavy lifting, Kept a toileting 
diary, Avoided caffeine based drinks, Shared my feelings,  
Other (free text) 
Bowel self-management behaviours  
What types of self-care have you used today to help with 
your bowels? (tick box) 
None, Took medication, Increased fluid intake, Changed 
diet, Used pads, Did pelvic floor exercises, Kept a toileting 
diary, Found out information, Comfort (hot water bottle), 
shared my feelings, Other (free text) 
Sexual function self-management behaviours  
What types of self-care have you used today to help with 
your sexual function? (tick box) 
None, Took medication, Found out information, Tried to 
lose weight (if overweight), Limited alcohol intake, Stopped 
smoking (if smoker), Used a penis pump, Took exercise, 
Found ways to reduce stress, Shared my feelings, Other 
(free text) 
13 
 
 
 
 
 
 
 
11 
 
 
 
 
 
 
11 
 
 
 
 
 
 
 
Yes 
 
 
 
 
 
 
 
Yes 
 
 
 
 
 
 
Yes 
 
 
 
 
 
 
 
Enquiry Subscale and variables Number 
of items 
Data presented in 
this chapter 
End of Day 
Entry 
(Once per 
day, for a 
total of 1 
month 
(n=31) 
 
 
 
 
 
Urinary self-management relief  
Generally, did your self-care actions relieve the problem? 
(0-100) 
Bowel self-management relief 
Generally, did your self-care actions relieve the problem? 
(0-100) 
Sexual-function self-management relief  
Generally, did your self-care actions relieve the problem? 
(0-100) 
Overall, self-care self-efficacy* 
Overall today I feel that: (0-100) 
I can always manage to complete self-care activities that 
1 
 
 
1 
 
 
1 
 
 
2 
 
 
Yes 
 
 
Yes 
 
 
Yes 
 
 
Yes 
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are difficult for me, I am confident in carrying out my self-
care activities 
Symptoms 
To what extent have you experienced the following 
symptoms today? (0-100) 
Blood in the urine, Constipation, Diarrhoea, Nausea, Pain, 
Tiredness, Unable to sleep, Urgency to pass urine, Urinary 
frequency (day and night), Vomiting, Impotence, Other 
symptom (free text) 
Most demanding self-care 
What was your most demanding self-care task that you had 
to do today? (free text) 
Satisfaction with social support* 
How satisfied were you with your support today? (0-100) 
Financial, Emotional, Information, Practice 
Thoughts and feelings 
Were you able to discuss your thoughts and feelings today? 
Did you want to discuss your thoughts and feelings today? 
(0-100) 
Quality of Life 
How would you rate your quality of life today? (0-100 
 
 
14 
 
 
 
 
 
 
 
1 
 
4 
 
 
2 
 
 
 
1 
 
 
 
Yes 
 
 
 
 
 
 
 
Yes 
 
 
Yes 
 
 
Yes 
 
 
 
Yes 
 
Incident 
Entry 
(Event 
contingent 
(any time 
throughout 
1-month 
period)  
 
Negative affect*  
How do you feel just now? (0-100) 
Nervous, Frustrated, Sad, Angry, Stressed, Tired 
Positive affect*   
How do you feel just now? (0-100) 
Alert, Happy, Energetic 
Experience 
Please describe your experience that was very demanding 
for you? (free text) 
Positive coping 
Please rate each of the following statements which 
describes how you have coped with this experience?(0-100) 
I tried to keep a positive attitude   
Negative coping*   
Please rate each of the following statements which 
describes how you have coped with this experience?(0-100) 
I felt like giving up, I felt problems with my health 
prevented me from planning ahead, I felt that nothing I can 
do will make a difference, I tried not to think about it  
Sought support 
Did you seek support to help with this experience? (Yes/no) 
Perceived social support 
Did you have enough support available from people around 
you? Was that enough support? (0-100) 
6 
 
 
3 
 
 
 
1 
 
 
1 
 
 
 
 
4 
 
 
 
 
1 
 
2 
Yes 
 
 
Yes 
 
 
 
Yes 
 
 
Yes 
 
 
 
 
Yes 
 
 
 
 
Yes 
 
Yes 
 
· Summary score used in the analysis. 
This study measured satisfaction with social support over time, and the 
interpretation of a “low score” in satisfaction with social support, should not be 
interpreted as “dissatisfaction” with social support, because this construct was not 
explicitly measured.  The symptoms that were assessed in the diary included the 
following: blood in the urine, constipation, diarrhoea, nausea, pain, tiredness, 
unable to sleep, urgency to pass urine, urinary frequency (day and night), 
vomiting, impotence, and other symptoms (free text).  These particular symptoms 
were assessed because of the clinical heterogeneity (various treatments and 
cancer stages) across the case studies, and the length of the diary entry, such that, 
the diary entry was not too long for the participants to complete.  The symptoms 
194 
 
 
 
chosen were informed by the EORTC C30 and PR25, discussions with clinicians, and 
men with prostate cancer.  A number of symptoms were not explicitly assessed, 
and included the following: pain/proctitis, leakage of stools, hot flushes, painful 
nipples or breasts, blood in stools, oedema, bloated abdomen, weight loss, weight 
gain; but the participants were given an opportunity to share these symptoms by 
“free text” in the diary entry.  It is important to acknowledge that the participants 
may not have used the “free text” option to report additional symptoms; 
therefore, the symptoms experienced could be unrelated to the self-management 
behaviours reported.  For example, constipation and diarrhoea were explicitly 
assessed, but not blood in stools, or proctitis, and therefore; the reported 
behaviours could be related to other symptoms for which no data was captured.  
Each of the self-management behaviours were chosen through discussions with 
clinicians, men with prostate cancer and from the literature reviewed in chapter 3.  
The researcher considered it to be very important to include a response option for 
“other” (free text option) self-management behaviours which captured additional 
self-management that the standard response would have missed. 
 
For a detailed overview of the methods used in the series of EMA adapted/N-of-1 
studies (chapter 4, section 4.7). 
6.4.1 Statistical analysis 
The diary data were transferred from Microsoft Access into SPSS version 17.0.  The 
standard entry variables were examined for autocorrelation using 
autocorrelograms (Tabachnick and Fidell, 2007) produced in SPSS.  Variables that 
displayed autocorrelation were pre-whitened based on guidance from previous 
studies (Borckardt et al., 2008, Crane et al., 2003, Cromwell et al., 1994).  Pre-
whitened variables were examined using autocorrelograms to check that the 
autocorrelation was successfully removed from the variable.   When variables did 
not meet the assumptions for a particular analysis, transformations were 
performed (Tabachnick and Fidell, 2007).  Transformations of the variables are 
detailed individually within each case study.  Statistical analysis was performed 
using parametric tests (paired t-tests, bivariate correlations and hierarchical 
multiple regression) and non-parametric tests (Chi² tests).  Hierarchical multiple 
regression analyses were performed to test for main, moderation and mediation 
195 
 
 
 
effects of coping (positive and negative) and social support (perceived and 
received) variables on emotional outcome, (see chapter 4, section 4.7.7) for a 
description of moderation and mediation analysis.  Prior to each regression 
analysis, the evaluation of the assumptions were checked (see appendix 6.1 for the 
heuristics used in the statistical analysis for EMA adapted/N-of-1 data).    
6.5 Results 
6.5.1 Characteristics of the participants 
Seventy-four men consented to take part in the prospective longitudinal study and 
of those 74 men, 62 (83.8%) consented to take part in the EMA adapted/N-of-1 
study.  A sampling framework (see chapter 4, section 4.7.6 for sampling 
framework) was applied to the 62 men who agreed to take part in the EMA 
adapted/N-of-study (see figure 6.1 for an overview). 
Total number of consented participants N=74
Total number of participants willing to complete the EMA adapted/N-of-1 study n=62 
(83.8%)
N=12 EMA adapted/N-of-1 studies purposively sampled based upon clinical characteristics and level of social support
N4 localised 
prostate cancer
N=5 locally advanced 
prostate cancer
N=3 metastatic prostate 
cancer
Partner No Partner Partner No Partner
No PartnerPartner
Mr B Active 
Surveillance
Low social support
Mr A Active 
Surveillance
High social support
Mr D Laparoscopic 
Radical Prostatectomy
High social support
Mr C Laparoscopic 
Radical Prostatectomy
High social support
*100/25 
Hormone 
Therapy
Low social 
support
No one
*Mr G Hormone 
Therapy and 
radiotherapy
Low social support
Mr E Hormone 
Therapy and 
radiotherapy
High social support
Mr F Hormone 
Therapy and 
radiotherapy
High social support
*Mr I Hormone 
Therapy and 
radiotherapy
Low social 
support
Mr H Hormone 
Therapy and 
radiotherapy
High social 
support
Mr J Hormone 
Therapy 
Low social 
support
Mr K Hormone 
Therapy 
High social 
support
*Participants have existing co-morbidity
 
Figure 6.1 Overview of the participants who completed the EMA adapted/N-of-1  
Unfortunately, participant 100/25’s (highlighted in red, in figure 6.1) data were not 
recorded on the PDA throughout his one-month period of data collection and, 
therefore, could not be included.  The participant verbally expressed good 
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compliance with the diary data collection schedule, but he did not “tap” the “finish 
button” at the end of each diary entry.  As a limitation of the diary software, the 
self-report data were not recorded and were unable to be retrieved, as informed 
by the software programme developer.  No other participants met the sampling 
framework criteria (see chapter 4, section 4.7.6 for sampling framework).  Eleven 
men completed the EMA adapted/N-of-1 data entry within their 6 months of 
participation in the study.  The specific timings for each treatment modality are 
detailed in chapter 4, section 4.7.6. 
 
Research questions 
6.5.2 Which patient characteristics influence agreement to 
complete real time data collection of the N-of-1 single-case 
data? 
Comparisons were performed with demographic (age, education, employment, 
socio-economic, marital) and clinical (cancer stage, cancer treatment, PSA, Gleason 
score and co-morbidity) variables to identify differences between those consenting 
for the diary (n=62, 83.8%) and those who did not consent (n=12, 16.2%) (see table 
6.2).  This analysis was undertaken by independent sample t-tests and Chi² test.   
Table 6.2 Comparisons of clinical and demographic variables between those who 
consented to complete the EMA adapted/N-of-1 data and those who did not consented 
to the EMA adapted/N-of-1 data collection 
Variables Consented to 
complete the 
electronic diary 
(n=62, 83.8%) 
Did not consent to 
completing the 
electronic diary 
(n=12, 16.2%) 
Comparisons 
Age (years) at study consent 69.7 (SD 7.8) 72.0 (SD 9.4) t(72)=0.914, p=0.361 
Education 
High school 
Further education  
Higher education 
Trade qualification 
No qualifications  
 
9.7% (n=6) 
22.6% (n=14) 
22.6% (n=14) 
40.3%(n=25) 
4.8% (n=3) 
 
8.3% (n=1) 
8.3% (n=1) 
33.3% (n=4) 
16.8% (n=2) 
33.3% (n=4) 
 
The assumption for ‘minimum 
expected cell frequency’ was not 
met for the Chi² -test. 
School leaving age (years) 16.2 (SD 1.4) 15.9 (SD 1.5) t(72)=-1.232, p=0.221 
Employment 
Unemployed 
Employed 
Retired 
 
3.2% (n2) 
29.0% (n18) 
67.7% (n42) 
 
0% (n0) 
41.7% (n5)  
58.3% (n7) 
The Chi²-test was performed 
with employed and retired 
categories only, because the 
participants in the unemployed 
categories (n=2) were very small 
for the entire study sample. 
 

2  (1)=0.626, p=0.431 Fisher’s 
Exact Test p=0.502, (2-tailed). 
Socio-economic (SIMD) 
1 most deprived 
2 
3 
 
3.2% (n2) 
6.5% (n4) 
16.1% (n10) 
 
16.7% (n2) 
16.7% (n2) 
25.0% (n3) 
 
The assumption for ‘minimum 
expected cell frequency’ was not 
met for the Chi²-test. 
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4 
5 Least deprived 
48.4% (n30) 
25.8% (n16) 
25.0% (n3) 
16.7% (n2) 
Martial 
Partner 
No partner 
 
80.6% (n50) 
19.4% (n12) 
 
83.3% (n10) 
16.7% (n2) 
 

2  (1)=0.047, p=0.833. Fisher’s 
Exact Test p=1.0 (2-tailed) 
Cancer stage 
Localised 
Locally advanced 
Metastatic 
 
43.5% (n27) 
50.0% (n31) 
6.5% (n4) 
 
41.7% (n5) 
16.7% (n2) 
41.7% (n5) 
 

2 (2)=12.765, p=0.002, Cramer’s 
V statistic =0.415, p=0.002.** 
Cancer treatment 
Watchful waiting 
RRP 
LRP 
EBRT 
Hormone therapy 
Active surveillance 
Hormone therapy and EBRT 
 
4.8% (n3) 
1.6% (n1) 
11.3% (n7) 
9.7%  (n6) 
14.5%  (n9) 
11.3%  (n7) 
46.8% (n29) 
 
0% (n0) 
0% (n0) 
8.3% (n1) 
0% (n0) 
41.7% (n5) 
16.7% (n2) 
33.3% (n4) 
 
The assumption for ‘minimum 
expected cell frequency’ was not 
met for the Chi²-test. 
PSA 26.1 (SD 31.8) 56.6 (SD 86.6) t(11.6)=1.205, p= 0.253  
 
Gleason 
Low grade (2-4) 
Intermediate grade (5-7) 
High grade (8-10) 
 
0 % (n0) 
74.2% (n46) 
25.8% (n16) 
 
0% (n0) 
58.3% (n7) 
41.7% (n5) 
 

2  (1)=1.244, p=0.262. Fisher’s 
Exact Test p=0.303, 2-tailed) 
Existing co-morbidity (yes) 
 
71.0% (n44) 58.3% (n7) 2  (1)=0.749, p=0.384 Fisher’s 
Exact Test p=0.498, (2-tailed) 
*p<0.05, **p<0.01 
The independent samples t-tests identified no significant differences between 
those consenting to complete the diary and those who did not for the following 
variables: age, school leaving age and PSA level.  No significant differences were 
found between the groups for employment, marital status, Gleason score and pre-
existing co-morbidity (Fisher’s exact test all P>0.05, 2-tailed).  Assumptions for the 
Chi²-test were not met for socio-economic, education and treatment and 
therefore, it was not possible to explore the relationships among these variables.  
A significant association was found between cancer stage and whether or not 
participants consented to complete the diary: 2 (2)=12.765, p=0.002, Cramer’s V 
statistic =0.415, p=0.002.  Of those men with metastatic disease, significantly 
fewer than expected were willing to participate in the diary study.  However, 
caution is taken in the interpretation of this result due to the small number of 
study participants.  
 
6.5.3 What are the response rates of participants filling a diary 
over several weeks? 
 
The response rates for the diary data collection were very high; see table 6.3 for an 
overview of the response rates.  Two participants had response rates greater than 
80%, and nine participants demonstrated a response rate greater than 90%.  
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Table 6.3 Electronic diary response rates 
Participant 
and social 
support 
 
 
Response 
rate 
Cancer 
stage and 
treatment 
Co-
morbidity 
Age Education-
highest 
qualification 
Employment Socio-economic 
(SIMD 1 most 
deprived – 5 least 
deprived) 
Diary 
Schedule 
Mr A  
Partner    
High 
support    
94.6% Localised 
prostate 
cancer  
AS 
No 73 HNC Retired 4 10am, 
4pm, 
10pm 
Mr B  
Partner    
Low 
support 
90.3% Localised 
prostate 
cancer 
AS 
No 61 BA Employed 4 10am, 
4pm, 
10pm 
Mr C  
Partner     
High 
support    
87% Localised 
prostate 
cancer 
LRP 
No 51 No 
qualification 
Employed 2 8am, 
2pm, 
8pm 
Mr D 
Partner  
High 
support    
97.7% Localised 
prostate 
cancer 
LRP 
No 59 Trade 
qualification 
Retired 5 10am,    
4pm, 
10pm 
Mr E  
Partner     
High 
support    
97.9% Locally 
advanced 
prostate 
cancer 
HT and 
EBRT 
No 65 Trade 
qualification 
Retired 4 10am, 
4pm, 
10pm 
Mr F  
Partner  
High 
support    
90.3% Locally 
advanced 
prostate 
cancer 
HT and 
EBRT 
No 57 Trade 
qualification 
Employed 1 10am, 
4pm, 
10pm 
Mr G 
Partner 
Low 
support 
97.9% Locally 
advanced 
prostate 
cancer 
HT and 
EBRT 
Yes 
Asthma 
Hypertensi
on 
Depression 
64 HND Retired 4 10am, 
4pm, 
10pm 
Mr H  
No partner 
High 
support    
97.8% Locally 
advanced 
prostate 
cancer 
HT and 
EBRT 
No 73 Trade 
qualification 
Employed 4 9am, 
3pm, 
9pm 
Mr I  
No partner 
Low 
support 
81.7% Locally 
advanced 
prostate 
cancer 
HT and 
EBRT 
Yes 
 
Asthma 
Hypertensi
on 
73 Post graduate 
HND 
Retired 4 9am, 
3pm, 
9pm 
Mr J  
Partner 
Low 
support 
94.6% Metastatic 
disease 
HT 
No 73 A levels Retired 3 9am, 
3pm, 
9pm 
Mr K  
Partner 
High 
support    
91.3% Metastatic 
disease 
HT 
No 72 Trade 
qualification 
Retired 5 10am, 
4pm, 
10pm 
AS (Active surveillance), LRP (Laparoscopic radical prostatectomy), HT (Hormone therapy), 
EBRT (External beam radiotherapy) 
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6.5.4 What are the daily self-management behaviours in real time 
and do they change over time? 
The self-management behaviours (for all the 11 men) were mainly related to three 
areas: urinary, bowel and sexual dysfunction, but men also experienced other 
problems for which they performed self-management.  Table 6.4 provides a brief 
summary of the symptoms experienced and the self-management actions performed 
to relieve/prevent the symptoms across the eleven case studies.   
Table 6.4 Brief summary of symptoms experienced and the self-management actions 
performed to relieve the symptoms across the eleven case studies 
 Symptoms Self-management behaviours 
Urinary 
dysfunction 
Urinary urgency 
Urinary incontinence 
Urinary frequency (during day) 
Urinary frequency (during the night) 
Blood in the urine 
Took medication 
Found out information 
Increased fluid intake 
Used pads 
Used catheter sheaths 
Avoided heavy lifting 
Reduced caffeine intake 
Shared thoughts and feelings 
Drank cranberry juice 
Reduced alcohol 
Kept a toileting diary 
Washed incontinence pads 
Mind over matter strategies 
Bowel 
dysfunction 
Constipation 
Diarrhoea 
Rectal pain 
Bleeding from anus 
Took medication 
Took a high fibre diet 
Took califig/fybogel 
Applied anusol  
Changed fluid intake 
Used pads 
Shared my thoughts and feelings 
Changed diet 
Kept a toileting diary 
Took exercise 
Sexual 
dysfunction 
Impotence Found out information 
Shared thoughts and feelings 
Took medication 
Limited alcohol intake 
Reduced stress 
Other Ankle oedema Went for a walk 
Took furosamide pill 
Elevated feet when sitting 
Other Infected surgical wound Dressed wound  
Sought help from nurse and doctor 
Changed and emptied wound drainage bag 
Took antibiotic tablets 
Other Poor sleeping patterns/problems with relaxation Increased amitriptyline dosage 
Took a large whisky before bed 
 
Other Morning sickness Took anti-sickness tablets 
Other Radiation burns to abdomen and penis Applied gel given from doctor 
Applied savlon and aqueous cream 
Wiped tip of penis after urinating 
 
The number of days that men performed self-management to relieve urinary, bowel 
and sexual dysfunction varied across the eleven single-case studies (see table 6.5).  
Men diagnosed with localised and locally advanced prostate cancer performed self-
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management for urinary, bowel, and sexual dysfunction over time.  However, the 
men (Mr J and Mr K) diagnosed with metastatic cancer did not report any self-
management behaviours over the one-month period of data collection. 
Table 6.5 The number of days that self-management was performed over 1 month to relieve 
urinary, bowel and sexual dysfunction across the eleven case studies.  
 Social support Clinical details Self-
management 
of urinary 
symptoms 
Self-
management 
of bowel 
symptoms 
Self-
management 
of sexual 
function 
symptoms 
Mr A  Partner high 
support 
Localised 
cancer AS 
5 days None None 
Mr B Partner low 
support 
Localised 
cancer AS 
29 days None  None 
Mr C  Partner high 
support 
Localised 
cancer 
LRP 
31 days 8 days 1 day 
Mr D  Partner high 
support 
Localised 
cancer 
LRP 
30 days None  None 
Mr E  Partner high 
support 
Locally 
advanced 
cancer HT and 
EBRT 
None 3 days None  
Mr F  Partner high 
support 
Locally 
advanced 
cancer HT and 
EBRT 
25 days 3 days None 
Mr G  Partner low 
support 
Locally 
advanced 
cancer HT and 
EBRT 
31 days 31 days None 
Mr H No partner high 
support 
Locally 
advanced 
cancer HT and 
EBRT 
12 days 13 days 11 days 
Mr I  No partner low 
support 
Locally 
advanced 
cancer HT and 
EBRT 
30 days 30 days 1 day 
Mr J  Partner low 
support 
Metastatic 
cancer HT 
None None None 
Mr K  Partner high 
support 
Metastatic 
cancer HT 
None None None 
AS (Active surveillance), LRP (Laparoscopic radical prostatectomy), HT (Hormone therapy), 
EBRT (External beam radiotherapy) 
 
To understand the individual man’s experience of self-management and change over 
time, the following section identifies the self-management behaviours, symptoms 
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experienced, and the self-management relief of symptoms over time, within the 
context of each single-case study.   
 
Mr A (localised cancer- active surveillance) 
 
Mr A was a 73-year-old married man who reported high social support.  He 
performed urinary self-management on 5 days and reported good relief from these as 
illustrated from the blue line in figure 6.2.  The actual self-management behaviours 
were not reported.  Urinary symptoms were not frequently experienced over time as 
illustrated in Figure 6.2.  No further self-management behaviours were performed. 
 
 
Figure 6.2 Mr A: Frequency of urinary symptoms and self-management relief of urinary 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
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Mr B (localised cancer- active surveillance) 
 
Mr B experienced urinary frequency and urinary urgency every day (see the green, 
orange and purple lines in figure 6.3) and he took medication daily as his only self-
management behaviour.  No trend of symptom relief was observed over time (see 
blue line in figure 6.3), except for on the 07.12.10, whereby Mr B indicated improved 
urinary symptoms.  No further self-management was performed. 
   
 
Figure 6.3 Mr B: Frequency of urinary symptoms and self-management relief of urinary 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
 
Mr A and Mr B were both diagnosed with localised prostate cancer and were under 
active surveillance, but both men displayed different urinary symptoms over time.  Mr 
B experienced more frequent urinary symptoms over time compared to Mr A.  The 
two men did not have pre-existing health problems and had no previous prostate 
cancer treatment to account for the different urinary symptom profiles over time.  It 
203 
 
 
 
is possible that physiologically, Mr B’s prostate cancer tumour was closer to his lower 
urinary tract to account for his urinary symptoms (Krupski et al., 2003), but this will 
remain unknown.  Both men were married, but Mr A reported high social support 
whereas Mr B had low social support.  It may be that Mr B was not aware of available 
resources to help with his self-management of his urinary symptoms and this has 
been reported elsewhere (Ream et al., 2008), but ultimately, this will remain 
unknown. 
 
Mr C (Localised cancer – Laparoscopic radical prostatectomy) 
 
Mr C was a 51-year-old married man who reported high social support.  Nine self-
management behaviours were performed to relieve urinary symptoms (see figure 6.4 
for self-management strategies).  Urinary symptoms were frequently experienced and 
no visible trend of relief from self-management strategies was observed over time 
(see figure 6.5), but on 26.02.10, self-management appears to be effective in relieving 
urinary symptoms.  One explanation to account for improved symptoms over time 
could be due to successful self-management behaviours, but recognising that urinary 
symptoms may have naturally improved over time as part of post-surgery recovery 
(Lee et al., 2001).  Mr A and Mr B both had localised prostate cancer but the 
frequency of their urinary symptoms over time remained fairly stable.  Whereas Mr C, 
who had invasive surgery for his localised cancer and the frequency of his urinary 
symptoms were more erratic, shows a trend of symptom improvement over time (see 
orange, green and purple lines in figure 6.5 for urinary symptoms).   
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0 4 8 12 16 20 24 28 32 36 40 44
Took medication
Found out information
Increased fluid intake
Shared my feelings
Used urine sheaths
Performed pelvic floor exercises
Avoided heavy lifting
Kept a toileting diary
Used pads
23
2
10
2
23
31
3
10
28
Frequency of self-management behaviours
Urinary self-management behaviours performed
 
Figure 6.4 Mr C: Distribution of urinary self-management behaviours 
 
Figure 6.5 Mr C: Frequency of urinary symptoms and self-management relief of urinary 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
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Bowel symptoms were experienced less frequently and constipation was the only 
reported symptom over time (see green line in figure 6.6).  Mr C took medication as 
his only bowel self-management action on eight days and reported good relief from 
this (see blue line in figure 6.6).    
       
 
 
Figure 6.6 Mr C: Frequency of bowel symptoms and self-management relief of 
bowel symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
 
Impotence was frequently experienced over time (see the red line in figure 6.7).   Self-
management was performed on one occasion which was sharing his thoughts and 
feelings and finding out information.  He indicated good relief from his behaviours 
(see blue line in figure 6.7).   Mr C experienced impotence every day but only 
performed self-management on one occasion (25.02.2011).   One possible 
explanation is that reduced sexual function did not bother Mr C at this stage in his 
recovery (1 month post-surgery) but acknowledging sexual function self-management 
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may increase over time as he adjusts to living with erectile dysfunction (Nelson et al., 
2011, Nelson et al., 2009), but this will remain unknown.   
 
 
Figure 6.7 Mr C: Frequency of sexual dysfunction and self-management relief of sexual 
dysfunction displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
                 
Self-management was performed for relief of severe rectal pain (see table 6.6).  
Experiencing rectal pain following radical prostatectomy has been reported elsewhere 
(Moore and Estey, 1999).  
Table 6.6 Mr C: Other symptoms, self-management behaviours and relief 
Date Symptoms Self-management behaviour Relief (0-100) 
26.02.2011 Severe rectal 
pain 
Tramadol taken  100 
A higher score displayed is interpreted as higher relief of self-management 
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  Mr D (Localised cancer – Laparoscopic radical prostatectomy) 
Mr D was a 59-year-old man with high social support.  Similar to Mr C, Mr D had a 
radical prostatectomy and performed urinary self-management daily to relieve 
urinary symptoms.  Mr D performed two self-management behaviours (took 
medication [on 25 days] and used pads [on 29 days]) and reported good relief from 
these over time (see the blue line in figure 6.8).   A clear visual trend of improved 
urinary frequency at night (purple line in figure below) is observed over time.  
 
Figure 6.8 Mr D: Frequency of urinary symptoms and self-management relief of urinary 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
 
Mr D performed additional self-management for oedema and post-operative wound 
care (see appendix 6.2 for additional self-management behaviours and relief).    
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Mr E (locally advanced cancer – hormone therapy and radiotherapy) 
Mr E was a married 63-year-old man with high social support.  He took medication on 
three days for diarrhoea (see purple line for diarrhoea in figure 6.9) which was an 
infrequent symptom experienced.  This time series plot indicates good relief from 
bowel self-management (blue line), and may suggest a lag (time period between two 
observations) between bowel self-management and diarrhoea.  Therefore, Mr E may 
have performed self-management as prevention rather than a cure.  No other self-
management behaviours were reported. 
       
 
Figure 6.9 Mr E: Frequency of bowel symptoms and self-management relief of bowel 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
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Mr F (locally advanced cancer – hormone therapy and radiotherapy) 
Mr F was a 57-year-old married man and reported high social support.  Mr E and Mr F 
had the same clinical staging and were treated by the same treatment modality, but 
Mr F experienced urinary symptoms over time, whereas Mr E did not.  This result 
could be explained by the toxicities caused by radiotherapy (Fonteyne et al., 2009) 
that were experienced by Mr F and not Mr E.    Four urinary self-management actions 
were performed (see figure 6.10) with good relief from these over time (see blue line 
in figure 6.11).   
0 4 8 12 16 20 24 28
Took medication
Avoided caffeine
Increased fluid intake
Shared my thoughts and feelings
25
1
17
11
Frequency of self-management behaviours
Urinary self-management behaviours performed
 
Figure 6.10 Mr F: Distribution of urinary self-management behaviours 
210 
 
 
 
        
 
Figure 6.11 Mr F: Frequency of urinary symptoms and self-management relief of urinary 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
 
Diarrhoea was the most frequent symptom experienced over time (see the purple line 
in figure 6.12).  Mr F took medication and shared his thoughts and feelings on three 
days and reported good symptom relief from these (see blue line in figure 6.12).   
Similar to Mr E, Mr F’s time series plot indicates a lag (time period between two 
observations) between self-management and diarrhoea, on the 10.08.10 and the 
21.08.12.    Mr E may have performed self-management for prevention of bowel 
symptoms but also for symptom relief.  No other self-care behaviours were reported. 
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Figure 6.12 Mr F: Frequency of bowel symptoms and self-management relief of bowel 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
 
Mr G (locally advanced cancer – hormone therapy and radiotherapy) 
This is the case of Mr G, who was a 64-year-old man who was married and reported 
low social support.  This gentleman has pre-existing health problems of asthma, 
hypertension and depression.  Mr G frequently experienced urinary symptoms over 
time (see purple, orange and green lines in figure 6.13) and performed four urinary 
self-management behaviours (see figure 6.14). 
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Figure 6.13 Mr G: Frequency of urinary symptoms and self-management relief of urinary 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
 
0 4 8 12 16 20 24 28 32
Took medication
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Frequency of self-management behaviours
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Figure 6.14 Mr G: Distribution of urinary self-management behaviours   
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No trends of improved urinary symptoms were observed over time.  In comparison, 
Mr F displayed an obvious trend of improved urinary symptoms over time (see figure 
6.11), but Mr G did not, and both men had the same stage of cancer and treatment 
modality.  The difference in symptoms could be explained by toxicities following 
radiotherapy, but could also be associated with social support.  Mr F had high social 
support and mobilised his social support as self-management behaviour to relieve his 
symptoms, whereas Mr G had low social support and did not use social support in his 
self-management.  It could be that social support improved Mr F’s coping efforts 
when self-managing his symptoms, but this is speculative.   
 
Constipation was frequently experienced by Mr G (see green line in figure 6.15) and 
three self-management behaviours performed (see figure 6.16).  Good self-
management of constipation can be seen during 02.12.10 to 06.12.10 (see blue line in 
figure 6.15) but overall constipation did not improve over time.    
                
 
Figure 6.15 Mr G: Frequency of bowel symptoms and self-management relief of bowel 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
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Figure 6.16 Mr G: Distribution of bowel self-care behaviours 
 
Self-management was performed for additional symptoms which included:  bowel 
complaints, sleeping, and stress problems (see table 6.7).   
Table 6.7 Mr G: Additional symptoms, self-management behaviours and relief   
Date Symptom Self-management behaviour Relief 
(0-100) 
19.11.2010 
 
25.11.2010 
28.11.2010 
03.12.2010 
14.12.2010 
 
19.12.2010 
Poor sleeping pattern 
 
Bleeding from anus 
Poor sleeping pattern 
Frequent toilet visits 
Poor sleeping pattern 
caused by stress 
Problems with 
relaxation 
Took more amitriptyline to help sleep 
through the night 
Applied anusol ointment to anus 
Had a little whisky 
Took larger dose of amitriptyline 100mg 
Took a large whisky before bedtime 
 
Took a large whisky before bedtime 
89 
 
62 
60 
69 
66 
 
81 
A higher score displayed is interpreted as higher relief of self-management 
 
Mr H (locally advanced cancer – hormone therapy and radiotherapy) 
 
Mr H was a 73-year-old man who was single and reported high social support.  Mr H 
frequently experienced urinary symptoms over time (see red, green, orange and 
purple lines in figure 6.17).  From 07/02/20011 to 19/02/2011, five urinary self-
management behaviours were performed (see figure 6.18) with good relief (see blue 
line in figure 6.17), but his self-management did not alleviate his urinary symptoms. 
Mr H did not report any urinary self-management after 19/02/2011 and therefore, 
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the interpretation is confined to between 07/02/2011 and 19/02/2011.  If the 
participant did not perform self-management, the diary was programmed not to 
enquire about relief from self-management behaviours and therefore, the “0 score” 
(blue line for relief of urinary self-management) in the time series plot is the default.  
The reasons as to why Mr H discontinued his urinary self-management are unknown, 
but one explanation could be that he discontinued his self-management strategies 
because no symptom control was achieved between 07/02/2011 and 19/02/2011 
and, consequently, he may have felt that his self-management strategies were 
inadequate to improve his symptoms and he did not see the benefits in continuing.  
Alternatively, Mr H may have ignored his symptoms as a form of self-management 
through avoidance, a form of coping (Ahmad et al., 2005). 
 
Figure 6.17 Mr H: Frequency of urinary symptoms and self-management relief of urinary 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
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Figure 6.18 Mr H:  Distribution of urinary self-management behaviours   
 
Constipation and diarrhoea were frequently experienced symptoms over time (see 
green and orange lines in figure 6.19).  Mr H performed four bowel self-management 
strategies (see figure 6.20) with good relief, but after 23/02/2011, no bowel self-
management was reported.  The “0 score” in the time series plot after 23/02/2011 is 
the default for the electronic diary (same interpretation as Mr H’s urinary self-
management relief in figure 6.17).  The reasons as to why Mr H discontinued his 
bowel self-management strategies are unclear because he continued to experience 
bowel symptoms frequently over time.   
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Figure 6.19 Mr H: Frequency of bowel symptoms and self-management relief of bowel 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
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Figure 6.20 Mr H: Distribution of bowel self-management behaviours 
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Four sexual function self-management behaviours were performed to improve penile 
rehabilitation, see figure 6.21.  Sexual function self-management was performed on 
eleven days with good relief but his self-management behaviours did not improve his 
impotence over time, see figure 6.22. 
0 4 8 12 16
Took medication
Limited alcohol intake
Reduced stress
Shared my thoughts and feelings
8
6
1
2
Frequency of self-management behaviours
Sexual function self-management behaviours performed
 
Figure 6.21 Mr H: Distribution of sexual function self-management behaviours 
 
          
Figure 6.22 Mr H: Frequency of impotence and self-management relief of impotence 
displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
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Mr H reported other self-management behaviours for additional problems which are 
displayed in table 6.8. 
Table 6.8 Mr H: Additional symptoms, self-management behaviours and relief.   
Date  Symptom Self-management 
behaviour 
Relief ( 0-100 scale) 
19/02/2011 Radiation burns on my tummy 
and penis – very painful 
Applied Gel from the 
doctor at Ninewells 
20 
06/03/2011 Morning sickness Took anti-sickness 
tablets  
88 
A higher score displayed is interpreted as higher relief of self-management 
 
Mr I (locally advanced cancer – hormone therapy and radiotherapy) 
Mr I was a 73-year-old man who was single and reported low social support.  This 
man experienced four urinary symptoms over time (displayed in figure 6.23) and 
performed six urinary self-management behaviours (see figure 6.24).  No obvious 
trend of improved symptom relief was achieved from self-management strategies 
(see blue line in figure 6.23).  Similar to Mr B and Mr G, Mr I also had low social 
support and all three men identified inadequate symptom relief from their self-
management behaviours.  This commonality will be further discussed in the general 
discussion. 
  
Figure 6.23 Mr I: Frequency of urinary symptoms and self-management relief of urinary 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
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Figure 6.24 Mr I: Distribution of urinary self-management behaviours  
 
Eight bowel self-care actions were performed (see figure 6.25) with good relief from 
constipation over time (see blue see figure 6.26).   
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Figure 6.25 Mr I: Distribution of bowel self-management behaviours  
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Figure 6.26 Mr I: Frequency of bowel symptoms and self-management relief of bowel 
symptoms displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
 
Mr I experienced impotence frequently (see red line in figure 6.27) and performed 
sexual function self-management on one day.  Taking medication was the only self-
management behaviour reported and he reported little relief from this (see blue line 
in figure 6.27).    
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Figure 6.27 Mr I: Frequency of impotence and self-management relief of impotence 
displaying change over time.   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom and better relief of self-management actions. 
 
Mr I performed other self-management to relieve symptoms related to the after 
effects of radiotherapy (see table 6.9).  Generally, his self-management behaviours 
had little relief in alleviating his discomfort.   
Table 6.9 Mr I: Additional symptoms, self-management behaviours and relief. 
Date Symptom Self-management behaviour Relief (0-100 
scale) 
18.12.2010 
 
 
 
23.12.2010 
Friction soreness tip of 
penis – from radiotherapy 
effects 
 
Friction discomfort at 
glands of penis 
Applied aqueous cream (am) and 
wiped the tip with tissue after 
urinating 
 
Application of savlon and I do not 
know if it is at all effective but the 
condition worries me 
29 
 
 
 
25 
A higher score displayed is interpreted as the higher relief of self-management   
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Mr J (metastatic cancer – hormone therapy) 
This is the case of Mr J who was a 73-year-old married man with low social support.  
This man did not perform any self-management behaviours over the course of his 
data collection.  This man frequently experienced a number of urinary symptoms and 
impotence over time (see figure 6.28).  The reasons as to why Mr J did not perform 
self-management behaviours to relieve his symptoms are unclear.  One possible 
explanation could be that Mr J experienced inadequate support to help him to self-
manage his condition, but alternative explanations will be addressed in the 
discussion.  
               
 
Figure 6.28 Mr J: Most frequent symptoms experienced over time   
The ratings (0–100).  A higher score displayed is interpreted as a higher frequency of the 
symptom 
 
Mr K (metastatic cancer – hormone therapy) 
Mr K was a 72-year-old married man with high social support.  Similar to Mr J, Mr K 
did not perform any self-management behaviours to relieve symptoms experienced 
(see figure 6.29 for Mr K’s most frequent symptoms).  The reasons as to why Mr K did 
not perform self-management strategies are unclear, but explanations will be 
addressed in the discussion.   An interesting comparison between Mr K and Mr J is 
that both men experienced symptoms, but Mr J experienced more frequent 
symptoms compared to Mr K.  Both men had similar clinical characteristics but Mr J 
had low social support while Mr K had high support.  The relationship between social 
support and self-management will be explored in the discussion.   
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Figure 6.29 Mr K: Most frequent symptoms experienced over time.   
The ratings (0 – 100).  A higher score displayed is interpreted as a higher frequency of 
symptom  
 
In summary, men performed a variety of self-management behaviours with the most 
frequent self-management behaviours being performed by men who had received 
surgery and radiotherapy (see table 6.4).  The number of days that self-management 
was performed varied between the participants as did the relief of their self-
management.  Sexual function self-management was infrequently performed across 
the eleven case studies and the reasons for this are unclear.  Alternative explanations 
will be addressed in the general discussion.  A commonality was identified among the 
men (Mr B, Mr G, Mr I) who had low social support and reported inadequate 
symptom relief of their self-management behaviours.  The relationship between 
social support and self-management will be explored in discussion.  Moreover, 
differences and similarities between the eleven case studies will be discussed in the 
general discussion, as will the limitations of the electronic diary approach.  
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6.5.5 What are the daily social supportive experiences in real time 
and do they change over time?  
 
Changes in perceived availability of social support, received social support and 
satisfaction with social support was assessed over time within the context of each 
case study.   
Mr A (localised prostate cancer – active surveillance) 
Mr A reported high received and perceived social support over time (see the blue and 
green lines in figure 6.30).  At the start of data collection (see the red line) a reduced 
score in satisfaction with social support is observed, but overall Mr A was satisfied 
with his social support over time.       
  
Figure 6.30 Mr A: Perceived, received and satisfaction with social support displaying change 
over time 
The ratings (0–100).  A higher score displayed is interpreted as more social support and a 
higher level of satisfaction. 
 
 
Mr B (localised prostate cancer – active surveillance) 
Mr B received no social support over time (see the blue line in figure 6.31) and had 
variation in his perceived social support.  A trend of reduced satisfaction with social 
support can be seen (see red line in figure 6.31) over time.   
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Figure 6.31 Mr B: Perceived, received and satisfaction with social support displaying change 
over time.   
The ratings (0–100).  A higher score displayed is interpreted as more social support and a 
higher level of satisfaction. 
 
Mr C (localised prostate cancer – laparoscopic radical prostatectomy) 
Mr C reported low perceived social support initially, however, following the date 
04.02.2011; there is no variation in his perceptions of his social support (see green 
line in figure 6.32) over time.  Mr C received social support at the start of his data 
collection and after 09.02.2011 he did not receive any social support.  Mr C was 
satisfied with his social support over time. 
 
Figure 6.32 Mr C: Perceived, received and satisfaction with social support displaying change 
over time.   
The ratings (0–100).  A higher score displayed is interpreted as more social support and a 
higher level of satisfaction. 
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Mr D (localised prostate cancer – laparoscopic radical prostatectomy) 
Mr D had variability in the amount of received social support he had at the start of his 
data collection (see blue line in figure 6.33) but over time he received very little 
support and had reduced satisfaction levels with social support over time.  
 
Figure 6.33 Mr D: Perceived, received and satisfaction with social support displaying change 
over time.   
The ratings (0–100).  A higher score displayed is interpreted as more social support and a 
higher level of satisfaction. 
 
Mr E (locally advanced cancer – hormone therapy and radiotherapy) 
Mr E’s perceived social support reduced over time (see green line in figure 6.34) and 
he reported a reduced score for satisfaction with social support over time.  Mr E 
received very little social support throughout the one-month period.   
 
 
Figure 6.34 Mr E: Perceived, received and satisfaction with social support displaying change 
over time.  The ratings (0–100).   
A higher score displayed is interpreted as more social support and a higher level of 
satisfaction. 
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Mr F (locally advanced cancer – hormone therapy and radiotherapy) 
Figure 6.35 illustrates very little variance in Mr F’s high (>90, 0-100 scale) perceived 
social support and level of satisfaction over time (see green and red lines).  Mr F 
intermittently received a lot of social support throughout the month (see blue line).       
 
Figure 6.35 Mr F: Perceived, received and satisfaction with social support 1 displaying 
change over time.   
The ratings (0 – 100).  A higher score displayed is interpreted as more social support and a 
higher level of satisfaction. 
 
Mr G (locally advanced cancer – hormone therapy and radiotherapy) 
Mr G received very little social support and reported a lack of satisfaction with his 
social support over time (see blue and red lines in figure 6.36).  He also had reduced 
(<50, 0-100 scale) perceived social support with no visual trend over time. 
 
Figure 6.36 Mr G: Perceived, received and satisfaction with social support displaying change 
over time.   
The ratings (0–100).  A higher score displayed is interpreted as more social support and a 
higher level of satisfaction. 
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Mr H (locally advanced cancer – hormone therapy and radiotherapy) 
Mr H had variation in his perceived social support over time (see green line in figure 
6.37).  He received little social support over time and reported variability in his level 
of satisfaction with his social support over time.   
 
Figure 6.37 Mr H: Perceived, received and satisfaction with social support displaying change 
over time.   
The ratings (0–100).  A higher score displayed is interpreted as more social support and a 
higher level of satisfaction. 
 
Mr I (locally advanced cancer – hormone therapy and radiotherapy) 
Mr I received little social support and had low perceived social support over time (see 
blue and green lines in figure 6.38).  Overall, Mr I reported a lack of satisfaction with 
his social support (<40, 0-100 scale).      
 
Figure 6.38 Mr I: Perceived, received and satisfaction with social support displaying change 
over time.   
The ratings (0–100).  A higher score displayed is interpreted as more social support and a 
higher level of satisfaction. 
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Mr J (metastatic cancer – hormone therapy) 
Mr J had little variation between his scores for received, perceived and satisfaction 
with social support constructs over time (see figure 6.39).  Overall, Mr J received 
social support over. 
 
Figure 6.39 Mr J: Perceived, received and satisfaction with social support displaying change 
over time.   
The ratings (0–100).  A higher score displayed is interpreted as more social support and a 
higher level of satisfaction. 
 
Mr K (metastatic cancer – hormone therapy) 
Mr K received little social support and had high perceived social support, with 
variation in his satisfaction levels with social support over time (see figure 6.40). 
 
Figure 6.40 Mr K: Perceived, received and satisfaction with social support displaying change 
over time.   
The ratings (0–100).  A higher score displayed is interpreted as more social support and a 
higher level of satisfaction. 
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This case series of eleven men (Mr A to Mr K) identified that social support constructs 
displayed a certain degree of variance over time, and demonstrates that traditional 
instruments cannot accurately detail the intra-individual experience over time and 
the changes in social support provision.   Importantly, all these men (apart from Mr, 
A, Mr C and Mr F) reported a lack of satisfaction with their support over time and this 
result would suggest that further research is needed to understand the impact of 
inadequate support provision on patient reported outcomes, such as negative affect.   
6.5.6 Do social supportive experiences moderate/mediate the 
relationship between coping and mood in real time? 
 
Preliminary Analysis 
The standard entry variables were examined for autocorrelation using 
autocorrelograms (Tabachnick and Fidell, 2007) produced in SPSS.  Variables that 
displayed autocorrelation were pre-whitened based on guidance from (Borckardt et 
al., 2008, Crane et al., 2003, Cromwell et al., 1994).  Pre-whitened variables were 
examined using autocorrelograms to check that the autocorrelation was successfully 
removed from the variable.   When variables did not meet the assumptions for a 
particular analysis, transformations were performed (Tabachnick and Fidell, 2007).  
Descriptive statistics were performed for standard, end-of-day and incident entries 
for each individual case study.  A Pearson product-moment correlation analysis was 
performed for all of the continuous variables (received social support, perceived 
social support, positive coping, negative coping, negative affect, positive affect, self-
management demand, self-management control, self-management self-efficacy) at 
the standard data entry enquiry.  Prior to each regression analysis the evaluation of 
the assumptions of a particular analysis were checked (see appendix 6.1 for heuristics 
used).  Mr A’s preliminary analyses are detailed in the following section and the 
remaining preliminary analyses for the ten remaining case studies are detailed in 
appendix 6.3. 
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Exemplar of preliminary analysis: Case study Mr A  
 
Mr A is a married 73-year-old gentleman who was diagnosed with localised prostate 
cancer and on the active surveillance programme.    
Preliminary analysis– Mr A 
Significant autocorrelations were found for positive affect (at a lag of 3), received 
social support and self-management control (both at a lag of 1).  No other variables in 
the data series displayed autocorrelation.  The pre-whitening procedure was 
successfully applied to these variables and removed the presence of autocorrelation. 
 
Negative coping displayed positive skewness and kurtosis and the Kolmogorov-
Smirnov (K-S) test was significant, D(88) = 0.169, p<0.001.  A square root 
transformation was applied to negative coping and this reduced the impact of outliers 
and improved normality of distribution.  Self-efficacy was positively skewed due to 
the presence of one univariate outlier and the transformations were unsuccessful.  
The outlier value was replaced with the next highest  extreme value plus 1 unit 
(80+1=81), thus the value of 81 was imputed (Tabachnick and Fidell, 2007) and 
achieved normality, K-M (88) =0.084, P=0.173. 
 
Descriptive statistics – Mr A 
Descriptive statistics for the continuous variables are displayed in table 6.10 and 6.11.   
Mr A reported a high quality of life scores, high received and perceived social support, 
with overall satisfaction with support. This gentleman had a high level of self-care 
self-efficacy.   No incident entries were completed over the one-month data collection 
period.  
Table 6.10 Mr A: Standard entry: means, standard deviations, minimum and maximum 
values for psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Self-management demand 
Self-management control 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
88 
88 
88 
88 
88 
88 
88 
88 
88 
1 
77 
81 
0 
1.6 
41.6 
79 
66 
80 
32 
100 
100 
34.7 
30.6 
97.7 
98.5 
98.7 
99 
9.44 
90.3 
90.9 
12.4 
9.4 
78.9 
90.8 
91.4 
91.4 
4.7 
4.6 
4.4 
5.5 
5.7 
11.2 
3.8 
5.3 
4 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable. 
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Table 6.11 Mr A: End-of-day entry: means, standard deviations, minimum and maximum 
values for psychological and social support variables, untransformed.   
End-of-day entry variables N Minimum Maximum Mean SD 
Satisfaction with social 
support  
 
Were you able to discuss your 
thoughts and feelings today?  
 
Did you want to discuss your 
feelings today? 
 
Overall, self-care self-efficacy 
 
Quality of life 
27 
 
 
27 
 
 
27 
 
 
27 
 
27 
64.7 
 
 
11.0 
 
 
2.0 
 
 
86.5 
 
70.0 
96.7 
 
 
90.0 
 
 
51.0 
 
 
98.0 
 
100.0 
87.5 
 
 
64.7 
 
 
15.3 
 
 
92.7 
 
89.8 
7.7 
 
 
24.1 
 
 
9.9 
 
 
3.2 
 
5.8 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable. 
 
Symptoms were assessed at the end-of-day entry (see table 6.12).  A range of 
symptoms were experienced by Mr A.   
Table 6.12 Mr A: Self-reports of symptoms enquired about at end of day entry.  Means, 
standard deviations, minimum and maximum values, untransformed.   
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the 
day 
Urinate frequently at night 
Vomiting 
27 
27 
27 
27 
27 
27 
27 
27 
27 
27 
27 
27 
0 
0 
0 
2 
0 
0 
2 
0 
0 
0 
0 
2 
47 
17 
15 
45 
14 
32 
47 
13 
17 
52 
16 
11 
7.6 
5.6 
6.1 
16.7 
6.3 
6.6 
11.7 
7.1 
7.1 
10.8 
7.4 
5.7 
8.9 
3.9 
3.7 
10.4 
3.9 
6.1 
9.2 
3.6 
4.3 
10.3 
3.5 
2.8 
The ratings are: (0=not at all, 100=always).  A higher score is interpreted as the higher 
frequency of the symptom. 
 
The results of the Pearson product-moment correlation for all the variables at the 
standard entry are presented in table 6.13 for Mr A. 
 
 
 
 
  
 
 
2
3
4 
Table 6.13 Pearson’s product moment correlation coefficients between all variables (unaltered and altered variables) for Mr A 
                                                                  1 2     3   4  5  6 7      8         9          10            11      12     13     14     15 
1) Positive coping                                1 
2) Negative coping                            0.346**  1 
3) SQRT negative coping                    0.382** 0.956**  1 
4) Positive affect                                0.202   -0.099    -0.142      1 
5) Positive affect (PreW lag 3)                    0.192    -0.075    -0.116     0.952**  1 
6) SQRT positive affect (PreW lag 3)     0.156     -0.050    -0.092      0.896** 0.923** 1 
7) Negative affect                            -0.430** 0.254*   0.283**  -0.186     -0.168  -0.084       1 
8) SQRT negative affect                       0.419**  0.268*    0.299** -0.183     -0.15  -0.069    0.982**  1 
9) Self-efficacy                                    0.440**  -0.349** -0.340**  0.279** 0.253* 0.277** -0.338** -0.353**  1 
10) Received social support      0.361**  -0.257*  -0.211*   0.193      0.150  0.187     -0.319** 0.347* 0.385**   1 
11) Received social support (PreW lag 1)  0.165      -0.044     -0.021      0.167       0.154   0.212   -0.116      -0.150      0.093      0.844**  1 
12) Perceived social support               0.447** -0.282** -0.276** 0.216*     0.191   0.116  -0.405**  -0.425**  0.417**  0.614**   0.426**  1 
13) Demand                                         0.363**  0.433**  0.445 -0.025      -0.003  0.063   0.391**   0.417**  0.317** -0.281**   -0.148    -0.417**  1 
14) Control                                         0.483**  -0.264*   -0.287** 0.144    0.109    0.064  -0.445**   0-.462**   0.493**  0 .581**   0.333** 0.584**-0.422**     1 
15) Control (PreW lag 1)              0.350**  -0.080       -0.124     0 .092       0.064   0.009    -0.330**  -0.349**   0.241*     0.333**   0.273*  0.379**-0.350** 0.880* 1 
*p<0.05, **p<0.01 (2-tailed) 
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MODERATIONS  
Moderation analyses were performed to test the theoretical model (see figure 6.41) 
with variables in the standard diary entry (assessed 3 times per day).  The 
assumptions were checked and analyses were only performed with variables 
correlated with the dependent variable (negative affect) at P values <0.15 
(Tabachnick and Fidell, 2007) for each case study.   
 
 
 
 
 
Figure 6.41 Moderation analysis 
 
Mr A (localised prostate cancer – active surveillance) 
Positive coping (r= -0.419, P<0.01), negative coping square root (r= 0.299, P<0.01) and 
perceived social support (r= -0.425, P<0.01) had a significant correlation with 
negative affect square root.  Received social support (PreW lag 1) did not have an association 
with negative affect square root (P>0.15) and therefore, the moderation analyses were 
only performed with perceived social support (see table 6.13). 
 
A significant main effect  was found for positive coping and perceived social support 
(unstandardized regression co-efficient -0.257 and -0.227, respectively) on negative 
affect square root,  explaining 23.4% of variance of  negative affect square root, (F-ratio 
13.864, P<0.001).  Perceived social support did not moderate the relationship 
between positive coping and negative affect (see table 6.14).       
Table 6.14 Mr A Moderation: Positive coping and negative affect square root moderated by 
perceived social support 
Step and variable                                 B           SE B      β       R² Adj R² 
Step 1 
Constant 2.954    0.080 
Z score positive coping 0.246**  0.090**   -0.286**  
Z score perceived social support    -0.255**  0.090**   -0.297**    0.246**     0.228** 
Step 2 
Constant  2.909   0.087 
Z score positive coping   -0.257**   0.090**  -0.299**   
Z score perceived social support -0.227*  0.093*  -0.264* 
Z score positive coping X  0.101  0.078   0.125     0.261**   0.234** 
Z score perceived social support 
Dependant variable negative affect square root *p<0.05, **P<0.01 n=88 
IV Coping (positive or 
negative coping 
M Social support (perceived or received) 
 DV Negative affect 
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Perceived social support had a significant relationship with negative affect square root, 
explaining 19.8% of the variance of negative affect square root (F-ratio 11.722, P<0.001).  
Perceived social support did not moderate the relationship between negative coping 
and negative affect (see table 6.15).   
Table 6.15 Mr A Moderation: Negative coping square root and negative affect square root 
moderated by perceived social support 
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant  2.931  0.085 
Z score negative coping square root 0.169  0.086  0.197  
Z score perceived support  -0.318**  0.086**  -0.371**  0.216**   0.198** 
Step 2 
Constant                           2.931  0.085 
Z score negative coping square root  0.164   0.086   0.191 
Z score perceived support   -0.304**  0.087**  -0.354**  
Z score negative coping square root X    -0.084   0.082  -0.100  0.226**  0.198** 
Z score perceived support 
Dependant variable negative affect square root *p<0.05, **P<0.01 n=88 
 
Mr B (localised prostate cancer – active surveillance) 
Positive coping (preW lag 1) (r= -0.360, P<0.01) and received social support (r=0.199, 
P=0.073, p=<0.15) was associated with negative affect (preW lag 2).  Negative coping (preW 
lag 3) and perceived social support (preW lag 1) did not have any associations with negative 
affect (preW lag 2).  The analyses were conducted with positive coping and received 
social support only. 
 
Received social support moderated the relationship between positive coping (preW lag 1)  
and negative affect (preW lag 2) (see table 6.16) which explained 25.8% of the variance of 
negative affect (preW lag 2), F-ratio=10.379, P<0.001 (see figure 6.42 for the interaction 
effect).  Low positive coping is associated with high negative affect (mood) under 
conditions of low received social support, but high positive coping is associated with 
high negative affect when received social support is high.  
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Table 6.16 Mr B Moderation: Positive coping PreW 1 and negative affect PreW 2  moderated by 
received social support 
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant 0.159     0.194 
Z score positive coping PreW 1 -0.732** 0.186**  -0.402**  
Z score received support  1.486*  0.576*  0.264*  0.197**  0.177** 
Step 2 
Constant                           -0.072  0.199 
Z score positive coping PreW 1 -0.354  0.215  -0.194  
Z score received support   0.553  0.624  0.098  
Z score positive coping  PreW 1 X    2.525**  0.814** 0.384**  0.285**  0.258** 
Z score received support 
Dependant variable negative affect preW 2 *p<0.05, **P<0.01 n=83 
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Figure 6.42 Mr B: Positive coping (preW lag 1) and negative affect (preW lag 2). moderated by 
received social support 
 
Mr C (localised prostate cancer – laparoscopic radical prostatectomy) 
Negative coping (r=0.440, P<0.001), positive coping (r= -0.525, P<0.001) and received 
social support (preW lag 1) (r= 0.192, P=0.090, at P<.15) were correlated with square root 
negative affect (PreW lag 1).  No associations were found with perceived social support, 
and therefore, the analyses were performed with received social support only. 
 
Only positive coping was found to have a significant relationship with negative affect 
(see table 6.16). No moderation effects were found for positive coping and received 
social support (preW lag 1) on negative affect (preW lag 1) (see table 6.17).   
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Table 6.17 Mr C Positive coping and negative affect (preW lag 1). moderated by received social 
support (preW lag 1). 
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant 3.358 0.072 
Z score positive coping -0.376** 0.074** -0.507** 
Z score received support PreW 1 0.064 0.074 0.085 0.282** 0.263** 
Step 2 
Constant                           3.348 0.073 
Z score positive coping -0.348** 0.081** -0.469**  
Z score received support PreW 1   0.034 0.083 0.045  
Z score positive coping  X    -0.047 0.056 -0.101 0.289**  0.260** 
Z score received support PreW 1 
Dependant variable square root negative affect (preW lag 1)*p<0.05, **P<0.01, n=79 
 
Received social support (preW lag 1) moderated the relationship between negative 
coping and square root negative affect (preW lag 1), see table 6.18.  The moderation 
interaction explained 22.3% of the variance of square root negative affect (preW lag 1), F-
ratio 8.468, P<0.001 (see figure 6.43 for interaction effect).  Low negative coping is 
associated with high negative affect under conditions of low received social support. 
Table 6.18 Mr C: Results moderation of negative coping and received social support (preW lag 1) 
on square root negative affect (preW lag 1). 
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant 3.347 0.076 
Z score negative coping 0.332** 0.085** 0.422** 
Z score received support PreW 1 0.044 0.081 0.059 0.197** 0.176** 
Step 2 
Constant                           3.309 0.076 
Z score negative coping 0.278** 0.086** 0.354**  
Z score received support PreW 1   -0.122 0.105 -0.163  
Z score negative coping  X    0.133* 0.056* 0.346* 0.253** 0.223** 
Z score received support PreW 1 
Dependent variable square root negative affect (preW lag 1)*p<0.05, **P<0.01, n=79 
 
 
239 
 
 
 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
low med high
N
e
ga
ti
ve
 a
ff
e
ct
   
  
Negative coping     
Moderation                    
Received social
support
high
med
low
 
Figure 6.43 Mr C: Negative coping and negative affect (preW lag 2). moderated by received social 
support  
 
Mr D (localised prostate cancer – laparoscopic radical prostatectomy) 
 
Positive coping (r=0.020, P=0.845), square root negative coping (preW lag 2) (r=0.124, 
P=0.234) and perceived social support (preW lag 1) (r=0.073, P=0.481) was not 
significantly correlated with negative affect (preW lag 1).  The analyses were not 
performed because of the non-association between the predictor variables (positive 
coping and negative coping) and the dependent variable (negative affect). 
 
Mr E (locally advanced prostate cancer – hormone therapy and radiotherapy) 
 
For Mr E, negative affect did not have any associations with positive coping, negative 
coping and perceived social support variables, but a significant relationship was 
found with negative affect and received social support (r=0.440, p<0.05).   The 
analyses were not performed because of the non-association between the predictors 
and the dependent variable.    
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Mr F (locally advanced prostate cancer – hormone therapy and radiotherapy) 
Negative coping (log) (r=0.266, P<0.05) had a significant association with negative 
affect (log), but positive coping (r=-0.048, P=.663) was unrelated to negative affect (log).  
Received and perceived social support was associated with negative affect (log) at 
P<0.15 level. 
 
A significant moderation effect was found between negative coping (log) and received 
social support and explained 11.9% of the variance of negative affect (log), F-ratio 
4.456, p=0.006 (see table 6.19).  High negative coping is associated with negative 
affect (mood) under conditions of low received social support (see figure 6.44 for the 
interaction effect).    
Table 6.19 Mr F: Negative coping (log) and negative affect (log) moderated by received social 
support 
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant 2.109 0.084 
Z score negative coping (log) 0.193* 0.085* 0.254* 
Z score received support -0.091 0.086 -0.188 0.087* 0.061* 
Step 2 
Constant                           2.085 0.082 
Z score negative coping (log) 0.412** 0.123** 0.542**  
Z score received support    -0.101 0.083 -0.132   
Z score negative coping (log)   X    -0.136*  0.057* -0.388** 0.153* 0.119* 
Z score received support  
Dependant variable negative affect (log) *p<0.05, **p<0.01 n=78 
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Figure 6.44 Mr F: Negative coping (log) and negative affect (log) moderated by received social 
support 
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The moderation was repeated with perceived social support and a significant 
moderation interaction effect was found (see table 6.20).  The relationship between 
negative coping and negative affect was moderated by perceived social support 
which explained 11.9% of the variance of negative affect (log), (F-ration 4.674, 
p=0.005).  The interaction effects are displayed in figure 6.45.  The interaction term is 
statistically significant but the moderation figure resembles a main effect because 
there was no negative coping X perceived social support interaction (Cohen and 
Wills, 1985).   
Table 6.20 Mr F: Negative coping (log) and negative affect (log) moderated by perceived social 
support 
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant 2.103 0.083 
Z score negative coping (log) 0.196* 0.093* 0.254* 
Z score perceived support 0.019 0.093 0.024 0.087** 0.063** 
Step 2 
Constant                           2.034 0.083 
Z score negative coping (log) 0.282* 0.095* 0.367*   
Z score perceived support    0.397* 0.166* 0.516*    
Z score negative coping (log)   X    0.150** 0.055** 0.619** 0.153** 0.119** 
Z score perceived support  
Dependant variable negative affect (log) *p<0.05, **p<0.01, n=78 
Moderation effects of negative coping and perceived social support on negative affect                  
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Figure 6.45 Mr F: Negative coping (log) and negative affect (log) moderated by perceived social 
support 
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Mr G (locally advanced prostate cancer – hormone therapy and radiotherapy) 
 For Mr G, negative coping (preW lag 1) and square root received social support (preW lag 1) 
(at the P<0.15) were associated to square root negative affect (preW lag 1).  No 
associations were found with positive coping or perceived social support with square 
root negative affect (preW lag 1) and therefore, the analyses were performed with 
negative coping and received social support only.  No main or moderations effects 
were found see table 6.21. 
Table 6.21 Mr G: Negative coping (preW lag 1) and square root negative affect (preW lag 1) 
moderated by square root received social support (preW lag 1)  
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant 4.406 0.127 
Z score negative coping (preW 1) 0.235 0.129 0.186  
Z score received support (preW 1) 0.181 0.129 0.143 0.059 0.039 
Step 2 
Constant                           4.402 0.129 
Z score negative coping (preW 1) 0.234 0.129 0.185   
Z score received support (preW 1)    0.185 0.130 0.146    
Z score negative coping (preW 1) X    0.045  0.129 0.036 0.061 0.030 
Z score received support (preW 1) 
Dependant variables square root negative affect (preW lag 1) *p<0.05, **p<0.01, n=92 
 
Mr H (locally advanced prostate cancer – hormone therapy and radiotherapy) 
Positive coping (r=-0.278, P<0.01), negative coping (r=0.331, P<0.01), perceived social 
support (preW lag 1) (r=-0.266, P<0.05) and received social support (preW 1) (r=0.184, 
P=0.083 at the P<0.15 level) was associated with negative affect (preW lag 1).  Received 
social support (preW 1) and perceived social support (preW 1) did not moderate the 
relationship between positive coping and negative affect (see tables 6.22 and 6.23).  
In addition, received and perceived social support did not moderate the relationship 
between negative coping and negative affect (see table 6.24 and 6.25).  Main effects 
were found for positive coping, negative coping and perceived social support (preW 1) 
on negative effect.   
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Table 6.22 Mr H: Positive coping and negative affect (preW lag 1) moderated by received social 
support 
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant -0.050 1.373 
Z score positive coping -3.790** 1.384** -0.277  
Z score received support (preW 1) 2.478 1.381 0.182 0.110** 0.090 
Step 2 
Constant                           -0.055 1.379 
Z score positive coping -3.761** 1.391** -0.275**   
Z score received support (preW 1)    2.473 1.386  0.181     
Z score positive coping    X    -0.625      1.188 -0.053 0.113 0.082 
Z score received support (preW 1) 
Dependant variable negative affect (preW lag 1) *p<0.05, **p<0.01, n=90 
 
Table 6.23 Mr H: Positive coping and negative affect (preW lag 1) moderated by perceived social 
support (preW lag 1)  
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant -0.041 1.368 
Z score positive coping -3.057* 1.430* -0.223*   
Z score perceived support (preW 1) -2.819* 1.427* -0.207* 0.117** 0.097** 
Step 2 
Constant                            0.159 1.434 
Z score positive coping -3.457* 1.654* -0.253*   
Z score perceived support(preW 1) -2.738 1.443 -0.201     
Z score positive coping    X    -0.781      1.600 -0.057 0.120** 0.089** 
Z score perceived support (preW 1) 
Dependant variable negative affect (preW lag 1) *p<0.05, **p<0.01, n=90 
Table 6.24 Mr H: Negative coping and negative affect (preW lag 1) moderated by perceived 
social support (preW lag 1)   
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant -0.096 1.341 
Z score negative coping 4.045** 1.404** 0.290   
Z score perceived support (preW 1) -2.850* 1.375* -0.209 0.152** 0.132** 
Step 2 
Constant                            -0.339 1.366 
Z score negative coping 4.165** 1.410** 0.299**   
Z score perceived support(preW 1) -3.278* 1.488* -0.240     
Z score negative coping    X    -1.259 1.327 -0.100 0.161** 0.131** 
Z score perceived support (preW 1) 
Dependant variable negative affect (preW lag 1) *p<0.05, **p<0.01, n=90 
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Table 6.25 Mr H: Negative coping and negative affect (preW lag 1) moderated by received social 
support (preW 1) 
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant -0.102 1.361 
Z score negative coping 4.298** 1.420** 0.308**    
Z score received support (preW 1) 1.754 1.391 0.128 0.152** 0.132** 
Step 2 
Constant                            -0.296 1.389 
Z score negative coping 4.234** 1.426** 0.304**   
Z score received support(preW 1) 1.674 1.399 0.123     
Z score negative coping    X    1.130    1.503 0.076 0.161** 0.131** 
Z score received support (preW 1) 
Dependant variable negative affect (preW lag 1) *p<0.05, **p<0.01, n=90 
 
Mr I (locally advanced prostate cancer – hormone therapy and radiotherapy) 
 
Positive coping and square root received social support (preW lag 2) was not associated 
with negative affect square root.  Negative coping (preW lag 1) and square root perceived 
social support (preW lag 2) was associated with negative affect square root at the p<0.15 
level.  The analysis was only performed with negative coping and perceived social 
support only.  No moderation or main effects were found for Mr I (see table 6.26). 
Table 6.26 Mr I: Negative coping (preW lag 1) and negative affect (square root) moderated by 
square root perceived social support (preW lag 2)  
Step and variable                                 B          SE B      β       R² Adj R² 
Step 1 
Constant 4.216 0.063 
Z score negative coping  (preW 1) 0.053 0.068   
Z score perceived support (preW 2) -0.101 0.064 -0.183 0.045 0.018 
Step 2 
Constant                           4.226 0.063 
Z score negative coping (preW 1) 0.046 0.067 0.079   
Z score perceived support(preW 2) -0.081 0.065 -0.147     
Z score negative coping  (preW 1)    X    -0.095 0.070  0.160 0.070 0.030 
Z score perceived support (preW 2) 
Dependant variable negative affect (square root) *p<0.05, **p<0.01, n=74 
 
Mr J (metastatic cancer – hormone therapy) 
Positive coping (PreW lag 1) (r=0.297, P<0.01) and square root negative coping (PreW lag 1) (at 
the p<0.15 level) was associated with negative affect (preW lag 1).  Perceived and 
received social support did not have any associations with negative affect (preW lag 1) 
and therefore, the analyses were not performed because the conditions were not 
met.  
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Mr K (metastatic cancer – hormone therapy) 
Perceived social support (preW lag 1) (r=0.223, P<0.05) was significantly related to 
negative affect (preW lag 1).  Positive coping (preW lag 1) and square root negative coping (preW 
lag 1) was unrelated to negative affect.  Therefore, the analyses were not performed 
because of the non-association with the independent variables. 
MEDIATION 
Building upon the moderation analyses, mediation analyses were undertaken to 
establish whether social support (perceived and received) mediates the relationship 
between coping (positive and negative) and negative affect (see figure 6.46). 
 
Figure 6.46 Mediation model 
 
Mr A (localised prostate cancer – active surveillance) 
Perceived social support partially mediated the relationship between negative coping 
square root and negative affect square root (see table 6.27), the beta weight reduced from 
0.299 (path c) to 0.197 (path c’) when controlling for perceived social support.  The 
other conditions for mediation were met (see figure 47) and the Sobel’s test found 
that the mediation effect was significant (Z=2.11, P<0.05).  Using the bootstrapping 
procedure, similar results were obtained and at the 95% confidence interval the 
indirect effect coefficient did not cross zero (point estimate =0.0315 LL, 0.2390 UL). 
 
 
 
 
 
Coping  (positive and 
negative) (X) 
Social support (perceived 
and received) (M) 
 Negative affect (Y) 
Path A Path B 
Path C’ 
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Table 6.27 Mr A: Negative coping square root and negative affect square root partially mediated by 
perceived social support 
Step and variable  B            SE B      β      R² 
Step 1 (path C) 
Constant                                     1.844  0.392 
Outcome: SQRT Negative affect        
Predictor:  SQRT Negative coping     0.324**   0.111   0.299**    0.089 
 
Step 2 (Path A)   
Constant                                       6.233   1.867 
Outcome: Perceived social support      
Predictor:  SQRT Negative coping      -1.411**    0.531    -0.276**    0.076 
 
Step 3 (path b and c’) 
Constant                                            9.387      2.066 
Outcome: SQRT Negative affect                        
Mediator: Perceived social support (path b)  -0.078***    0.021   -0.371*** 
Predictor: SQRT Negative coping    0.213*        0.108         0.197*    0.216 
*P<0.05, **P<0.01, P<0.001, n=88 
 
 
 
 
 
 
 
 
 
 
 
Perceived social support also partially mediated the relationship between positive 
coping and negative affect square root (see table 6.28); the beta weight reduced from -
0.419 (path c) to -0.286 (path c’) when controlling for perceived social support.  The 
other conditions for mediation were met (see figure 48) and the Sobel’s test found 
that the mediation effect was significant (Z=-2.36, P<0.05).  Using the bootstrapping 
procedure, similar results were obtained and at the 95% confidence interval the 
indirect effect coefficient did not cross zero (point estimate = -.0455 LL, -.0090 UL). 
 
 
 
 
 
Perceived 
social support 
SQRT NA SQRT negative coping 
0.299** (0.197*) 
-0.276** -0.371*** 
Figure 6.47 Beta weights for the relationship between SQRT negative coping and SQRT NA 
partially mediated by perceived social support for Mr A.   
The beta weights for SQRT negative coping and SQRT NA controlling for perceived social support 
are in the parentheses *P<0.05, **P<0.01, ***P<0.001 
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Table 6.28 Mr A: Positive coping and negative affect square root partially mediated by perceived 
social support 
Step and variable                  B        SE B        β         R² 
Step 1 (path C) 
Constant                                  10.372       1.736 
Outcome: SQRT negative affect   
Predictor:  Positive coping               -0.082***    0.019            -0.419***      0.175                           
 
Step 2 (Path A) 
Constant                                                  53.968            8.084 
Outcome: Perceived social support      
Predictor: Positive coping                    0.411***    0.089       0.447***    0.200 
      
Step 3 (path b and c’) 
Constant                                            13.761    2.058 
Outcome: SQRT Negative affect                        
Mediator: Perceived social support (path b)  -0.063**     0.022        -0.297** 
Predictor: Positive coping                                  -0.056**       0.020  -0.286**  0.246 
 
*P<0.05, **P<0.01, P<0.001, n=88 
 
 
 
 
 
Mediation was not possible for Mr B, Mr C, Mr D, Mr E, Mr F, Mr G or Mr I because 
the conditions for mediation were not met.    
 
Mr H (locally advanced prostate cancer – hormone therapy and radiotherapy) 
 
Received social support (preW lag 1) did not mediate the relationship between positive 
coping/negative coping and negative affect (preW lag 1), because the conditions were not 
met.  Perceived social support (preW lag 1) partially mediated the relationship between 
positive coping and negative affect (preW lag 1) because the beta weight dropped from -
0.278, P<0.01 to -0.233, P<0.05 and all the conditions for mediation were met (see 
Perceived 
social support 
SQRT NA Positive coping 
-0.419*** (-0.286**) 
0.447*
** 
-0.297** 
Figure 6.48 Beta weights for the relationship between positive coping and SQRT NA partially 
mediated by perceived social support for Mr A 
The beta weights for positive coping and SQRT NA controlling for perceived social support are 
in the parentheses *P<0.05, **P<0.01, ***P<0.001 
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table 6.29 and figure 6.49).  However, the Sobel’s test was non-significant Z=-1.502, 
P=0.1331 and when using the bootstrapping procedure similar results were obtained 
(point estimate = -0.3128 LL, 0.0213 UL).  Therefore, perceived social support (preW lag 1) 
did not partially mediate the relationship between positive coping and negative 
affect (preW lag 1). 
Table 6.29 Mr H: Positive coping and negative affect (preW lag1) partially mediated by 
perceived social support (preW lag1) 
Step and variable                         B          SE B          β            R² 
Step 1 (path C) 
Constant                                                            52.413 19.329 
Outcome:  Negative affect (preW lag1)                                                  
Predictor:  Positive coping                  -0.582**  0.214  -0.278** 0.077 
 
Step 2 (Path A) 
Constant                                    -65.317        25.272 
Outcome: Perceived social support(preW lag1)      
Predictor: Positive coping                         0.725*      0.280*    0.266*     0.071 
 
Step 3 (path b and c’)  
Constant                                                              42.059       19.727 
Outcome: Negative affect (preW lag1)                        
Mediator: Perceived social support (preWlag1) (path b)  -0.159*   0.080             -0.207* 
Predictor: Positive coping                                 -0.467*     0.218          -0.223*       0.117 
*P<0.05, **P<0.01, P<0.001, n=88 
 
 
 
 
 
 
 
 
 
 
 
 
 
A second mediation analysis was performed with negative coping and negative affect 
mediated by perceived social support (see table 6.30 and figure 6.50).  The conditions 
for mediation were met for mediation but the Sobel’s test (Z=1.31, P=0.1888) was  
Perceived 
social support 
(preW lag 1) 
NA (preW lag 1) Positive coping  
-0.582** (-0.467*) 
0.725* -0.159* 
Figure 6.49 Beta weights for the relationship between positive coping and SQRT NA partially 
mediated by perceived social support for Mr H.   
The beta weights for positive coping and SQRT NA controlling for perceived social support are in the 
parentheses *P<0.05, **P<0.01, ***P<0.001 
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non-significant and the zero was in the 95% confidence interval (CI) bootstrapped 
sample (lower limit 95% CI -0.0072, upper limit CI 0.1769) therefore, partial 
mediation was not present. 
Table 6.30 Mr H: Negative coping and negative affect (preW lag1) partially mediated by 
perceived social support (preW lag1) 
Step and variable                                 B         SE B              β          R² 
Step 1 (path C) 
Constant                                                        -13.253                  4.247 
Outcome: Negative affect (PreW lag 1)                
Predictor: Negative coping                         0.441** 0.134**  0.331**   0.110** 
 
Step 2 (Path A) 
Constant                                                         10.272                 5.750   
Outcome: Perceived social support  (PreW lag 1)    
Predictor: Negative coping                                         -0.181           -0.197              0.039          0.079 
Step 3 (path b and c’) 
Constant                                                                     -11.607     4.245 
Outcome: Negative affect (PreW lag 1)                        
Mediator: Perceived social support (PreW lag 1) (path b) -0.160* 0.077*    -0.209*           
Predictor: Negative coping                                      0.386**  0.134**    0.290**    0.152*                                                        
 
 
 
 
A summary of main, moderation and mediation effects across all of the eleven case 
studies are presented in table 6.31.  In relation to the sampling framework, no 
pattern of results are identified for main, moderation and mediation effects for social 
support with cancer stage, level of social support and co-morbidity. No 
commonalities or differences are identified when comparing the variables in table 
6.2 (section 6.5.3) for the following: socio-economic status, level of education, 
employment status, age or co-morbidity.    
 
 
 
Perceived 
social support 
(preW lag 1) 
NA (preW lag 1) Negative 
coping  
0.331** (0.290**) 
-0.197* 
-0.209* 
Figure 6.50 Beta weights for the relationship between positive coping and SQRT NA partially mediated 
mediated by perceived social support for Mr H.   
The beta weights for positive coping and SQRT NA controlling for perceived social support are in the 
parentheses *P<0.05, **P<0.01, ***P<0.001 
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Table 6.31 Summary of main, moderation and mediation effects across the eleven case 
studies 
Sampling 
framework 
criteria) 
Main effects Moderation effects Mediation effects 
Mr A (localised 
cancer/high 
support) 
Positive coping  
Negative coping 
Perceived social 
support 
None Yes – negative coping and 
negative affect is partially 
mediated by perceived social 
support.  Positive coping and 
negative affect is partially 
mediated by perceived social 
support 
Mr B  
(localised 
cancer/low 
support) 
Positive coping 
Received social 
support 
Yes – high positive coping is associated with 
high negative affect under conditions of 
high received social support.  Low negative 
coping is associated with high negative 
affect when received social support is low. 
None 
Mr C 
(localised 
cancer/high 
support) 
Positive coping 
Negative coping 
Yes – low negative coping is associated with 
high negative affect under conditions of low 
received social support. 
None 
Mr D (localised 
cancer/high 
support) 
None None None 
Mr E (locally 
advanced 
cancer/high 
support) 
None None None 
Mr F (locally 
advanced 
cancer/high 
support) 
Negative coping Yes – High negative coping was associated 
with high negative affect under conditions 
of low received social support.  High 
negative coping is associated with high 
negative affect under conditions of high 
perceived social support 
None 
Mr G (locally 
advanced 
cancer/low 
support) 
None None None 
Mr H (locally 
advanced 
cancer/high 
support) 
Negative coping 
Positive coping 
Perceived social 
support 
None Conditions for mediation met - 
negative coping and negative 
affect partially mediated by 
perceived social support.  
Positive coping and negative 
affect is partially mediated by 
perceived social support. But 
Sobel’s test and bootstrapping 
results were non-significant, 
thus mediation not present. 
Mr I (locally 
advanced 
cancer/low 
support) 
None None None 
Mr J 
(metastatic 
cancer/low 
support) 
None None None 
Mr K 
(metastatic 
cancer/high 
support) 
None None None 
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6.6 N-of-1 Discussion 
Each single-case study will be discussed separately followed by a general discussion 
across the 11 case studies.   The limitations of the diary methodology will be 
acknowledged in the general discussion. 
 
Mr A (Localised Prostate Cancer, Active Surveillance, High Support)  
Mr A was a married, 73-year-old gentleman with localised prostate cancer 
undergoing the active surveillance programme.  The electronic diary was well 
accepted by Mr A and he demonstrated a good compliance rate of 94.6%.   Coping 
and perceived availability of social support both demonstrated a main effect on 
emotional outcome and provided support for the main effect theoretical model 
(Cohen and Wills, 1985) because perceived social support significantly reduced 
negative affect for Mr A.  This significant result demonstrates that the main effects 
model (Cohen and Wills, 1985) holds within-person design.  Mediation effects were 
also identified for perceived social support whereby coping was related to negative 
affect partially because of perceived social support.  Mr A’s results have enabled a 
stronger theoretical grasp of the mechanism effect through which social support 
operates by the identification of a mediating pathway.  The findings did not support 
the buffering model and received social support did not have any associations with 
coping or negative affect.  For Mr A, perceived social support was the most important 
predictor of emotional outcome.  This finding is in keeping with (Zhou et al., 2010a, 
Roberts et al., 2006) and with the findings in chapter 5 (prospective longitudinal 
study), albeit average group level findings. 
 
Although Mr A did not receive treatment for his prostate cancer, he still frequently 
experienced urinary symptoms over the one-month period of data collection and 
performed urinary self-management on five occasions.  Unfortunately, Mr A did not 
detail his urinary self-management strategies but reported good symptom relief from 
these.  Mr A’s self-report of urinary dysfunction is in keeping with existing published 
data (Thong et al., 2009, Hoffman et al., 2006) which has identified men undergoing 
active surveillance reported urinary dysfunction.  Mr A did not report any additional 
self-management behaviours however, he experienced the following symptoms: 
impotence, tiredness and constipation but he did not perform self-management 
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behaviours to relieve these symptoms.  It is unclear as to why Mr A did not report 
self-management behaviours to relieve his symptoms, but there are a few possible 
explanations.  
 
One possible explanation is around self-care self-efficacy, which is a construct that 
refers to an individual’s confidence in their actions and beliefs about performing their 
self-management behaviours.  Low self-efficacy has been linked to patients’ 
withdrawal of participation in self-management because they believe that they 
cannot influence the outcome regardless of their ability (Cockle-Hearne and Faithfull, 
2010).  However, in the case of Mr A, this would seem an unlikely explanation 
because his self-care self-efficacy was very high 92.7 (SD 3.2) (0-100 scale).  
 
 Alternatively, it is possible that, although Mr A experienced impotence, constipation 
and tiredness, he may not have been bothered by his symptoms and therefore, did 
not feel the need to perform self-management.  It is identified that people with 
cancer who view their symptoms as “normal” are not bothered by them and 
consequently, people do not seek health care for symptom relief (O'Rourke, 2007). 
This man may have viewed his symptoms as normal due to increasing age and the 
effects of his cancer, and, as such, was not bothered by them.  This study did not 
have a measurement of symptom bother or severity.  Mr A did not perform self-
management for his symptoms (impotence, constipation and tiredness) and it could 
be suggested that he was not bothered by them, but this will remain unknown.  A 
final explanation could be that Mr A did not report self-management behaviours to 
relieve these symptoms, in particular, self-management for impotence, because he 
provided socially desirable responses (Lonnqvis et al., 2007) but this would seem 
unlikely because he reported that he experienced impotence. 
 
In summary, the main effects theoretical model was supported within-person design 
and a mediating pathway was identified that linked coping to emotional outcome 
because of perceived availability of social support.  This man performed urinary self-
management with good relief, but no additional self-management behaviours were 
identified.  Additional symptoms were experienced (impotence, constipation and 
tiredness) but no self-management behaviours were performed.  
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Mr B (Localised Prostate Cancer, Active Surveillance, Low Support) 
In the case of Mr B, he was a married 61-year-old gentleman diagnosed with 
localised prostate cancer undergoing the active surveillance programme.   Mr B 
demonstrated a good electronic diary compliance rate of 90.3%.   Positive coping and 
received social support both demonstrated a main effect on emotional outcome for 
Mr B.  However, the propositions of the main effects theoretical model (Cohen et al., 
2000, Cohen and Wills, 1985, Cohen and McKay, 1984) were not supported because 
received social support (β=.264, p<.05) predicted an increase in negative effect.  This 
is a paradoxical result.  The main effect model has the underlying assumption social 
support transactions are related to successful adaption for individuals and linked 
improved health outcomes. For Mr B, received social support did not have a 
favourable relationship on improved emotional outcome; quite the reverse, received 
social support significantly predicted greater emotional distress.   
 
This result is in keeping with findings that have demonstrated receiving social 
support is associated with negative health outcomes for some individuals (Scholz et 
al., 2008, Schwarzer et al., 2006).  There are a number of possible explanations to 
account for the negative effect of the receipt of social support for Mr B.   One 
possible explanation is that Mr B’s receipt of social support was mismatched to his 
“need for support”.  Some individuals produce better coping efforts and coping styles 
when one masters challenges alone, without help from others, and will only resort to 
receipt of assistance in the worst circumstances (Schwarzer and Knoll, 2007).  For Mr 
B, the negative effect of social support provision may have reduced his autonomy 
and caused him to feel incapable of self-managing his condition.  Furthermore, Mr B 
reported a reduced level of satisfaction with his social support (61.1, SD 18.5, 0-100 
scale) over time which would be in keeping with this explanation.  Although these 
data cannot confirm that Mr B’s receipt of social support was mismatched to his 
needs, additional research would be important to match the provision of support and 
the needs of the support receiver within-person design.  The stress and coping 
matching hypothesis (Cohen and McKay, 1984, Cutrona, 1990) posits that the type of 
social support matches the demands of the stressor, which promotes coping efforts 
and reduced the demands on the individual.  For example, having someone lend you 
financial resources may be helpful during a time of temporary job loss, but would be 
useless during the bereavement of a loved one.  For Mr B, it is possible that his 
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received social support provision was mismatched to his needs which could explain a) 
his lack of satisfaction with his social support, and b) the increases in negative affect.  
It is possible that individuals may also misperceive and under-report the amount of 
support they believe they receive.  Negative affect can cloud perceptions of helpful 
acts or undermine beliefs about how much others care.  Future work incorporating a 
didactic perspective may help to understand patients’ and partners’ experiences of 
support provision exchange, and would appear to be a worthwhile step to advance 
knowledge in this area.     
 
Perceived social support did not significantly predict emotional outcome of Mr B.  
Relationships between the stress and coping process are complex and multivariate, 
and the research question was constrained to testing coping, social support on 
emotional outcome through exploring main, moderating and mediating pathways.  
Perceptions of availability of social support are believed to lead to appraising 
potentially threatening situations less stressful (Cohen et al., 2000).  Mr B reported 
moderate perceived social support overtime (71.2, SD 22.6, 0-100 scale). It is possible 
for Mr B, his perceptions of his availability of social support facilitated positive coping 
efforts by appraising stressful situations less harmful for him, but this cannot be 
confirmed within the current study.  Additional work in this area may clarify how 
appraisal and additional variables such as demand, control and self-efficacy are 
linked to social support processes and health in men affected by prostate cancer.   
 
Mr B performed urinary self-management every day throughout his one-month 
period of data collection.  His urinary self-management was limited to taking only 
medication and his urinary symptoms did not display a trend of improvement over 
time.  It could be speculated that additional self-management behaviours may have 
improved Mr B’s symptom relief, but this would remain unknown.   Mr B had high 
self-care self-efficacy and, therefore, it is likely that he found his self-management 
easy and he felt confident in his ability to self-manage.  But Mr B reported low 
perceived social support and reduced satisfaction levels with social support over 
time.  It is possible that Mr B may have experienced a lack of awareness of available 
support to help with his self-management of his urinary symptoms and this has been 
acknowledged in a fairly recent publication (Ream et al., 2008) for men affected by 
prostate cancer. 
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In summary, received social support was found to predict greater emotional distress 
for Mr B.  The main effects model and the stress buffering model did not hold within-
person design.   This case study had identified the negative effects of social support 
on health outcomes and suggests that stress and coping matching hypothesis would 
be worthy of further research.  Mr B frequently experienced urinary symptoms, but 
only performed one incident of self-management behaviour with little relief. 
 
Mr C (Localised Prostate Cancer, Laparoscopic Radical Prostatectomy, High 
Support)  
Mr C was a married, 51-year-old gentleman with localised prostate cancer and was 
treated by a laparoscopic prostatectomy.   The electronic diary was well accepted by 
Mr A and he demonstrated a good diary completion rate of 87%.  Negative coping 
and positive coping predicted negative affect.  However, the social support variables 
(perceived and received social support) had no relationship with emotional outcome.  
Mr C reported high perceived social support with an overall high level of satisfaction 
with his social support but were unrelated with emotional outcome.  This result does 
not fit with existing aggregate group level effects linking perceptions of social support 
to improved health outcomes for men affected by prostate cancer (Zhou et al., 
2010a, Roberts et al., 2006, Rondorf-Klym and Colling, 2003).  The non-association 
with perceived social support and negative affect is unclear.  Thus for Mr C, perceived 
social support was not linked to improved health outcomes, but a significant 
moderation effect was identified.  Low negative coping was association with high 
negative affect under conditions of low received social support.   Interestingly, Mr C 
reported high availability of social support meaning that he anticipated receiving a 
high level of social support in times of need.  These findings suggest that Mr C was 
unable to mobilise his receipt of social support when he needed it.   Additional work 
is needed that will incorporate a dyadic perspective on social support exchange for 
men affected by prostate cancer and support providers.  This approach may provide 
valuable insights into how men self-manage at the individual level.  
 
Mr C performed urinary self-management every day over the course of one month to 
relieve urinary incontinence, urinary urgency and urinary frequency.  He performed 
nine urinary self-management behaviours with a trend of symptom relief over time.  
Based on the number of times self-management was performed and the variety of 
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strategies used by Mr C, this result would suggest that Mr C may have been bothered 
by his symptoms.  Elsewhere it has been identified that urinary dysfunction after 
surgery has been reported as the most bothersome symptom (Weber et al., 2008) 
compared to sexual and bowel bother.  Mr C may have been bothered by his urinary 
symptoms and performed self-management behaviours to reduce the degree of 
annoyance, dysfunction and discomfort of his symptoms, but this will remain 
unknown.   
 
Bowel symptoms were less frequently experienced over time by Mr C and this is in 
keeping with existing research (Sanda et al., 2008, Shrader-Bogen et al., 1997) for 
men treated by surgery.  Bowel dysfunction is less common in men treated by radical 
prostatectomy, compared to urinary and sexual dysfunction.  Mr C frequently 
experienced erectile dysfunction over time but he performed self-management only 
on one occasion.  It is possible that sexual bother was not experienced by Mr C at this 
point in his recovery (1 month following surgery) and therefore, performing self-
management for sexual potency was not as important as urinary self-management at 
this stage in his recovery.  It is possible Mr C may perform sexual function self-
management over time as he adjusts to living with erectile dysfunction (Nelson et al., 
2011) because sexual bother has been identified at one year post-surgery (Gacci et 
al., 2005).  Ultimately, this will remain unknown for Mr C. 
 
In summary, the main effects model did not hold within-person design but a 
significant moderation effect was identified.  High negative coping was associated 
with high negative affect under conditions of low received social support.  This 
suggests that Mr C was not able to mobilise his social support when he needed it or 
that the support he received was not matched to his needs.  Mr C performed urinary 
self-management every day throughout the course of the month and there was a 
trend of improved symptoms over time.  Based on the frequency and variety of 
urinary self-management it is possible that urinary dysfunction was the most 
bothersome after effect of surgery for Mr C.  Bowel and sexual function self-
management were less frequently performed over time but recognising that sexual 
function self-management frequency may change as Mr C adjusts to living with 
erectile dysfunction.       
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Mr D (Localised Prostate Cancer, Laparoscopic Radical Prostatectomy, High 
Support) 
In the case of Mr D, he was a married 59-year-old man with localised prostate cancer 
and treated by laparoscopic radical prostatectomy.  The diary was well accepted and 
he had a good diary response rate (97.7%).  Negative coping, positive coping, 
received and perceived social support did not have any associations with negative 
affect and therefore, the main effects model and the buffering hypothesis did not 
hold within-person design.  The non-association among the variables may have been 
supressed because of the little variance displayed in negative affect.  The theoretical 
relationship between social support and health is well established, albeit in group-
based studies.  The theoretical models did not apply to Mr D at the individual person 
experience.   
 
Other variables may have predicted negative affect for Mr D that were not explored 
because the research question aimed to test coping and social support on negative 
affect which was underpinned by the social support theories.  The social support 
theories have not been tested within-person design before and therefore, data only 
support group-based studies, between-participant studies and are limited to average 
effects.  Despite the prominence of testing theory on group-level studies, it is 
assumed that the theory will apply to individuals (Molenaar, 2004).  One explanation 
is that the constructs may operate differently over time when applied to individuals 
and this seems a likely explanation, because Mr B identified negative consequences 
of social support on health, and, for Mr D, no associations were identified. 
 
Mr D performed urinary self-management every day and reported good relief from 
his self-management behaviours, similar to that of Mr C.  He performed two urinary 
self-management behaviours, whereas Mr C (who received the same treatment as 
Mr D) performed nine urinary self-management behaviours.  The increased variety of 
self-management behaviours performed by Mr C, compared to Mr D, could be 
explained by urinary symptoms.  Mr C experienced more urinary symptoms 
compared to Mr D over time and therefore, Mr C’s increased urinary dysfunction 
may account for this.  Bowel symptoms and impotence were infrequently 
experienced by Mr D and he did not perform bowel and sexual function self-
management.  Mr C reported impotence very frequently throughout the one-month 
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period, which was dissimilar to Mr D.  It is likely however, that Mr D was impotent at 
this stage in his recovery due to nerve damage following surgery (Kouba et al., 2007, 
Ball et al., 2006, Namiki et al., 2004) but did not report impotence.  It may be that Mr 
D did not experience impotence because he was not sexually aroused over the one-
month period of data collection.  Thus he did not report impotence.  Alternatively, it 
is also possible that Mr D did not report impotence because he provided socially 
desirable responses (Lonnqvis et al., 2007) because he was embarrassed, but this will 
remain unknown. 
 
Additional self-management behaviours were performed for an infected surgical 
wound and for ankle oedema.  Mr D performed four self-management behaviours for 
his wound management and three self-management behaviours for his ankle 
oedema.  These were complications following Mr D’s surgery that Mr C did not 
experience.  Mr D performed wound self-management almost every day and his self-
management behaviours included the following: dressed the wound, sought help 
from nurse and doctor, changed and emptied wound drainage bag and took 
antibiotics.  Is seems that Mr D was able to mobilise his support (help from 
healthcare professionals) to assist him to self-management his wound infection. 
 
In summary, the results show no relationship between coping and social support on 
emotional outcome for Mr D.  Mr D performed self-management for 3 
problems/symptoms following his treatment and these included: urinary symptoms, 
wound infection and ankle oedema.  Based on the frequency of Mr D’s self-
management behaviours it is possible that urinary dysfunction and his wound 
infection were most bothersome for him at this point in his cancer trajectory.   
 
 
Mr E (Locally Advanced Cancer, Neoadjuvant Hormone Therapy and Radiotherapy, 
High Support)  
Mr E was a 65-year-old married man with high social support.  This man was 
diagnosed with locally advanced prostate cancer and was treated with neoadjuvant 
hormone therapy and radiotherapy.  The diary was well accepted and he had a good 
diary response rate of 97.9%.  For Mr E, negative affect did not have any associations 
with coping variables or perceived social support. The propositions of the social 
259 
 
 
 
support theories were not supported by Mr E.  These results are similar to Mr D’s, 
because both men’s (Mr E and Mr D) data did not empirically support the theoretical 
models of social support.  The reason as to why the theoretical models did not apply 
to Mr E and Mr D are unclear, but will be explored over the course of the emerging 
discussion.   
 
Mr E performed bowel self-management only on three days with good relief.  He 
took medication as his only self-management behaviour.  Interestingly, there was a 
lag between his bowel self-management and his diarrhoea which suggested Mr E 
may have performed self-management as prevention, rather than a cure.  No other 
self-management behaviours were reported, but Mr E frequently experienced 
impotence and urinary symptoms over time.  It is possible that Mr E did not perform 
urinary and sexual function self-management for his symptoms for a number of 
reasons.  This man was dissatisfied with his social support and therefore, it is possible 
that he did not have access to appropriate informational or practical support that 
was personalised to his needs to help him to self-manage his symptoms.  However, 
he reported high self-care self-efficacy and therefore, it would seem likely that Mr E 
had ease and confidence in his ability to manage his symptoms. This leads to an 
alternative explanation related to symptom bother.  Using the frequency of self-
management behaviours as a proxy measure for symptom bother (but recognising 
the limitations of this), it is possible that his impotence and urinary symptoms did not 
cause him annoyance or discomfort.  This seems a likely explanation because over 
time, Mr E reported low scores of negative affect scores.  Similarly, Mr A experienced 
sexual dysfunction but he did not report sexual function self-management 
behaviours to relief his impotence.  It is possible that both Mr A and Mr E viewed 
their symptoms as “normal” and consequently, they did not seek health care for 
symptom relief (O'Rourke, 2007).  Impotence is a common side effect of hormone 
therapy because this type of therapy stops testosterone production (Cancer Research 
UK, 2011).  Mr E may have adjusted to living the side effects of his treatment, and 
this was not significantly impacting on his quality of life because he reported very 
high quality of life scores (99.2, SD 11.2, 0-100 scale).  However, the impact of his 
urinary and sexual dysfunction has the potential to become bothersome and affect 
his quality of life at a later stage in his survivorship journey, but this will remain 
unknown. 
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In summary, the propositions of the social support theories were not supported by 
Mr E’s results.  Mr E performed self-management for diarrhoea and no additional 
self-management behaviours were identified.  Impotence and urinary symptoms 
were experienced but no self-management was performed. 
 
Mr F (Locally Advanced Cancer, Neoadjuvant Hormone Therapy and Radiotherapy, 
High Support)  
This gentleman was 57-year-old married man who was diagnosed with locally 
advanced prostate cancer and was treated with hormone therapy and radiotherapy.  
For Mr F, negative coping had a main effect on negative affect, but positive coping 
had no association with the dependent variable.  Similarly, received and perceived 
social support did not have a main effect and therefore, these results do not support 
the main effects theoretical model.  A significant moderating effect was identified for 
received social support.  The results identified that high negative coping was 
associated with high negative affect under conditions of low received social support. 
This finding was similar to Mr C who was diagnosed with localised prostate cancer 
and treated by surgery.   
 
Interestingly, Mr F reported high perceived availability of social support with very 
little variance over time.  This suggests that although Mr F had high perceptions of 
availability of social support at a time of need, his actual receipt of social support 
may not have been matched to his support needs over time.  One possible 
explanation could be related to Mr F’s stage of his cancer journey.  Potentially, his 
social network may have withdrawn their social support unconsciously/consciously 
because Mr F had passed the acute phase of the cancer continuum (diagnosis and 
treatment).  This is a probable explanation and a similar finding has been reported 
elsewhere (Visser et al., 2003).   
 
A second moderating effect was identified for Mr F and the results indicate that high 
negative coping is associated with high negative affect under conditions of high 
perceived social support.  This is a paradoxical finding and does not support the 
propositions of the social support theories.  Existing social support theories 
postulates that perceptions of perceived social support will influence the appraisal of 
stressful encounters and will therefore, increase coping efforts.  For Mr F, the 
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interaction term was statistically significant, but the moderation figure resembled a 
main effect because there was no coping X social support interaction pattern (Cohen 
and Wills, 1985) (figure 6.42).  It maybe that Mr F’s negative coping is associated with 
negative affect regardless of the level of perceived availability of social support.  Mr F 
may have become accustomed to high perceived social support over time with little 
variance.  This may suggest that when Mr F coped negatively his perceptions of his 
social support did not have a protective effect in reducing psychological distress over 
time.  It maybe that low received social support is more likely to influence negative 
coping and negative affect than perceived social support. 
 
Urinary symptoms were frequently experienced over time and Mr F performed four 
urinary self-management behaviours over time with good relief.  Mr E had the same 
cancer stage and was treated by the same treatment modality as Mr F, but Mr F did 
not experienced urinary symptoms.  The difference in the symptoms profiles of these 
two men could be explained by the toxicities caused by treatment (Fonteyne et al., 
2009) that were experienced by Mr F and not Mr E.  Mr F frequently experienced 
diarrhoea and performed two self-management strategies with good relief.  Similarly, 
both men (Mr F and Mr E) identified a lag between self-management and bowel 
symptoms and this result would suggest that self-management was performed for 
prevention and also cure.  No additional self-management was reported by Mr F, 
however, Mr F frequently experienced impotence over time but no self-management 
was reported.  This finding has also been identified for Mr A and Mr E and so far, 
several explanations have been identified, but this commonality will be explored 
further in the general discussion.   
   
In summary, negative coping was associated with negative affect under conditions of 
low received social support.  Mr F performed urinary and bowel self-management for 
symptoms over time.  Furthermore, impotence was a frequently experienced 
symptom but no self-management was reported. 
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Mr G (Locally Advanced Cancer, Neoadjuvant Hormone Therapy and Radiotherapy, 
Low Support)  
 
Mr G was a married 64-year-old man with low social support.  Coping and social 
support variables did not have any association with negative affect.  These findings 
suggest that in situations experienced by Mr G, social support was not salient.  The 
non-significant results suggest poor applicability of the social support theory in this 
case study. The findings do not support the social support theoretical models within-
person design.  This finding is similar to the results of Mr D and Mr E and therefore, 
the commonality of these findings will be further teased out in the general 
discussion.  Specifically, for Mr G, he received very little social support over time and 
he was very dissatisfied with his social support.  He also had low perceived social 
support over time.  Surprisingly, received and perceived social support did not have 
any significant correlations with negative affect.  According to social support theory, 
a negative correlation was anticipated between social support and negative affect.  
The emerging counter-theoretical relationships that have emerged across the three 
case studies (Mr G, Mr D and Mr E) may suggest that an intervention targeting social 
support would not be effective for these men, and demonstrates the need for a 
personalised approach and further work in this area. 
 
Mr G frequently experienced urinary symptoms over time and performed self-
management (four) behaviours every day.  No trend of improved urinary symptoms 
or increased self-management relief was observed over time.  Whereas, Mr F who 
had the same stage of cancer and received the same treatment as Mr G, displayed an 
obvious trend of improved urinary symptoms and good relief from his self-
management over time, while Mr G did not.  The difference in results between the 
two men could be related to the effects of treatment, but could also be related to 
social support.  Mr F had high social support and mobilised his social support as a 
self-management behaviour for symptom relief, whereas Mr G reported low social 
support and did not use social support in his self-management.  It could be that social 
support improved Mr F’s coping efforts and was a resource to support his self-
management.  Interestingly, this emergent comparison was also identified between 
Mr A and Mr B. It might be considered that men who had high social support 
mobilised their support as self-management behaviour and improved symptom relief 
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was identified over time, whereas men with low social support did not use support as 
self-management behaviour and no obvious trend of symptom relief was identified.  
This is a tentative association but would be worthy of further research. 
 
Mr G performed bowel self-management every day as a prevention and cure from 
constipation.  This gentleman completed three incident entries related to his self-
management of his bowel dysfunction.  An example of one of his incidents included: 
“accidentally defecated into my underpants”, this identifies the physical and 
psychological problems that men may experience following treatment for prostate 
cancer.  Mr G did not seek support to help cope with his incident experiences.  Bowel 
dysfunction is common following radiotherapy and therefore, the results of this case 
study are in keeping with existing studies (Berg et al., 2009, Fonteyne et al., 2009).  
Additional self-management was performed for problems with stress and sleeping 
problems.  Noteworthy, none of the reviewed case studies (Mr A, Mr B, Mr C, Mr D, 
Mr E, Mr F) performed self-management for stress. The divergent self-management 
performed by Mr G is likely to be related to his pre-existing health problems of 
depression, asthma and hypertension.  The six previously reviewed case studies did 
not have any pre-existing health problems.  It is possible that Mr G’s additional self-
management was related to his pre-existing health problems.   
 
In summary, the propositions of social support theory did not hold within-person for 
Mr G.  This result is similar to that of My D and Mr E.  In relation to the sampling 
framework criteria, the three men (Mr G, Mr D and Mr E) differed in clinical 
characteristics and level of social support.  The reasons as to why social support and 
coping had no significant relationship with emotional outcome for these men will be 
addressed in the main discussion.  Mr G performed self-management behaviours for 
bowel dysfunction every day and performed additional self-management for stress 
and sleeping problems.   
 
Mr H (Locally Advanced Cancer, Neoadjuvant Hormone Therapy and Radiotherapy, 
High Support)  
 
Mr H was a single man (no partner) who was 73 years of age.  Positive and negative 
coping were found to have significant relationships with negative affect.  Perceived 
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social support significantly predicted less negative affect and therefore, supports the 
main effects theoretical model (Cohen et al., 2000, Cohen and Wills, 1985, Cohen and 
McKay, 1984).  No moderating or mediating pathways were identified for the social 
support constructs (perceived and received social support) between coping and 
emotional outcome.  Received social support did not have any significant 
associations with negative affect, and suggests perceived social support was more 
relevant in predicting negative affect in the case study, and this finding was similar to 
Mr A.  There were emerging commonalities for both these men because they were 
both 73 years old, had a high socio-economic status with high social support.              
 
Mr H frequently experienced urinary symptoms and performed five urinary self-
management behaviours with good relief; however, the frequency of urinary 
symptoms did not decrease over time.  Bowel dysfunction was also experienced daily 
and he performed four bowel self-management behaviours.  A commonality between 
Mr H’s urinary and bowel self-management behaviours was that at approximately 
two weeks into Mr H’s diary data collection, he stopped performing self-
management for urinary and bowel dysfunction, but he continued to experience 
urinary and bowel dysfunction for the remaining 2 weeks of data collection.  The 
reasons for Mr H discontinuing his self-management behaviours are unclear, but 
several possible explanations are considered.  The measures used in this study did 
not assess symptom severity or symptoms bother and therefore, it is possible that 
Mr H was not bothered by his symptoms and, consequently, he did not take actions 
to relieve his symptoms.  An alternative explanation could be related to low self-care 
self-efficacy, but this would appear to be an unlikely explanation because he had high 
self-care self-efficacy.  This is a new emergent finding that has not been previously 
identified across the seven (Mr A, Mr B, Mr C, Mr D, Mr E, Mr F, Mr G) cases so far.  
In terms of clinical characteristics, Mr E, Mr F, and Mr G also had similar clinical 
characteristics to Mr H (locally advanced prostate cancer and were treated with 
neoadjuvant hormone therapy and radiotherapy), but this finding was only identified 
in this case study (Mr H).  There was a spread of demographic characteristics within 
each of the cases and therefore, no obvious distinction can be made to explain Mr H 
discontinuing his self-management.  The discontinuation of Mr H’s urinary and bowel 
self-management could be related to his sexual function. 
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Sexual function self-management was frequently performed throughout the one-
month period of data collection.  Using the frequency of self-management 
behaviours as a proxy (but recognising the limitations of this approach) of symptom 
bother, Mr H may have had higher sexual function bother at this stage in his cancer 
journey compared to urinary and bowel bother.  His data identifies that he continued 
his sexual function self-management, but discontinued his urinary and bowel self-
management over time.  This is a tentative assumption and therefore, should be 
treated with caution because, ultimately, this will remain unknown. 
 
In summary, coping (positive and negative) and perceived social support significantly 
predicted negative affect and supports the propositions of the main effects 
theoretical model within-person design.   Mr H experienced urinary, bowel and 
sexual dysfunction and performed a number of self-management behaviours with 
good relief.  However, this gentleman continued to frequently experience urinary and 
bowel symptoms for which he did not perform self-management.     
 
Mr I (Locally Advanced Cancer, Neoadjuvant Hormone Therapy and Radiotherapy, 
Low Support)  
 
Mr I was a 73-year-old man, single and reported low social support.  This gentleman 
was treated with neoadjuvant hormone therapy and radiotherapy for locally 
advanced prostate cancer.  Coping (positive and negative) and social support 
variables did not have any significant relationship with negative affect.  
Consequently, the propositions of the social support theory did not hold for Mr I and 
this is similar to Mr D, Mr E and Mr G.  Interestingly, the four men differed in terms of 
having a partner or not, level of social support and clinical characteristics, but these 
men were all retired and from a higher socio-economic background.  The influence of 
being retired and from a higher socio-economic background is considered with 
caution because significant effects of social support have been identified with other 
participants with similar demographic characteristics (for example, Mr A, Mr B, and 
Mr H).   
 
Urinary symptoms were experienced daily and Mr I performed six urinary self-
management behaviours.  No obvious trend of improved symptom relief was 
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achieved from self-management strategies for Mr I and this is similar to Mr B and Mr 
G.  All three men (Mr B, Mr G and Mr I) had low social support and, therefore, for 
these men they may not have had access to the appropriate social support to help 
them to self-manage their symptoms, for example, informational or practical 
support.  This is a tentative association which has been identified from the sampling 
framework and will be further considered in the general discussion. 
 
Bowel self-management behaviours were performed daily for diarrhoea and this was 
similar to Mr F, Mr G and Mr H (all treated by radiotherapy).   This commonality is in 
keeping with existing prospective data that identifies men can often experience 
bowel dysfunction following radiotherapy treatment  (Berg et al., 2009, Namiki et al., 
2006c) but this the first exploratory study which has identified actual self-
management behaviours in this patient group.  Mr I also reported erectile 
dysfunction daily and performed self-management for this on one occasion with little 
relief, and this finding was also identified for Mr C.  The similarity of these findings 
may indicate that often men experience erectile dysfunction and attempt self-
management but do not continue their behaviours over time.  The reasons as to why 
men do not continue their sexual function self-management over time is worthy of 
further research to address any supportive care needs for this population.    
 
In summary, the propositions of social support theory did not hold for Mr I (similar to 
Mr D, Mr E, and Mr G). Urinary, bowel and sexual function self-management was 
performed during the month following radiotherapy.    However, this man reported 
little relief from his urinary and sexual function self-management behaviours over 
time. 
 
Mr J (Metastatic Cancer, Hormone Therapy, Low Support)  
 
Mr J was a 73-year-old married man with low social support.  This man was 
diagnosed with metastatic prostate cancer and treated with hormone therapy.  The 
social support constructs did not have any association with emotional outcome and 
therefore, the propositions of social support theory did not hold for Mr J.  This 
finding featured in four previously reviewed case studies (Mr D, Mr E, Mr G, and Mr 
I).  All four of these men had a different stage of cancer, treatment modality with a 
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spread of demographic characteristics and will be considered in the general 
discussion. 
 
Mr J had the worse cancer staging compared to the previously reviewed studies but 
he did not report any self-management behaviours over time.  This finding was 
counter-intuitive to the researcher’s assumptions, because evidence has identified 
that men treated by hormone therapy often reported the worse HRQoL compared to 
other treatment modalities (Couper et al., 2009, Gacci et al., 2009, Sanda et al., 2008, 
Ash et al., 2007).  Furthermore, men treated by hormone therapy can experience the 
following symptoms: nausea, decreased appetite, constipation and diarrhoea, 
gynecomastia, sleeping difficulties, sweats and flushes, depression and impotence 
(Cancer Research UK, 2011, Couper et al., 2009).  Mr J frequently experienced 
impotence and urinary urgency during the day and night but did not report any self-
management behaviours to relieve his symptoms.  Due to the limitation of not having 
a measurement of symptom severity or symptom bother, it is possible that he did not 
perform self-management because 1) his symptoms were not severe, and 2) his 
symptoms did not bother him.  Alternatively, Mr J was married with low social 
support and therefore, a further explanation could be that he did not have access to 
appropriate support (informational, practical, and emotional) to assist him in the self-
management of his symptoms. This area would be worthy of additional research to 
provide useful insights to the influence of symptom bother on the frequency of self-
management behaviours and the influence of low social support.   
 
In summary, Mr J did not support the propositions of social support theory and this 
finding was similar to Mr D, Mr E, Mr G and Mr I.  No self-management behaviours 
were reported, although Mr J frequently experienced urinary and sexual dysfunction.   
 
  Mr K (Metastatic Cancer, Hormone Therapy, High Support)  
 
Mr K was a married 72-year-old man who had metastatic prostate cancer and was 
treated with hormone therapy.  There were no associations between the social 
support constructs and negative affect and therefore, the propositions of social 
support theory did not hold within-person for Mr K.  This is a finding that has 
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featured in five (Mr D, Mr E, Mr G, Mr I and Mr J) of the previously discussed cases 
and this will be further considered in the general discussion. 
 
Mr K did not report any self-management behaviours and this finding was similar to 
Mr J who also had the same cancer stage and treatment modality.  Mr K did 
experience a number of symptoms every day and these included: pain, tiredness, 
unable to sleep, urinary urgency and urinary frequency, but he did not perform any 
self-management behaviours.  An interesting contrast between Mr K and Mr J is that 
the frequency of symptoms for Mr J was higher compared to Mr K.  Mr J, who 
experienced a higher frequency of symptoms, had low social support, whereas Mr K, 
who experienced less frequent symptoms, had high social support.  Whilst this is a 
tentative association that should be treated with caution, it is also related to a 
previously identified emergent theme.  Men with low social support (Mr B, Mr G, and 
Mr I) displayed no trend of improved symptom relief from their self-management 
strategies.  It is possible that social support may influence patient appraisal of 
stressful encounters (in this case frequency of symptoms) and minimise the effect of 
the stressor (symptoms).  This was not tested using inferential statistics and 
therefore caution should be taken, but this is an emergent association that would be 
worthy of further research. 
 
In summary, the propositions of the social support theories were not supported by 
Mr K’s results. No self-management behaviours were reported, although a number of 
symptoms were experienced daily.    
 
6.6.1 General discussion  
The EMA adapted/N-of-1 design was acceptable for these men, which was 
demonstrated by the very high response rates.  The eleven men were purposively 
sampled based on cancer stage (which enabled a broad range of treatment 
modalities to be studied) and different levels of social support.  Four men (Mr A, Mr 
B, Mr C and Mr D) had localised cancer, five men (Mr E, Mr F, Mr G, Mr H and Mr I) 
had locally advanced cancer, and two men (Mr I and Mr J) had metastatic cancer.  
Together the eleven case studies have provided mixed findings for the propositions 
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of social support theories which (anecdotally) did not appear to be related to clinical 
characteristics or level of social support.   
 
Two men (Mr A and Mr H) provided support for the propositions of the main effects 
social support model (Cohen et al., 2000, Cohen, 1988, Cohen and Hoberman, 1983) 
within-person design.  For these men (Mr A and Mr H), perceived social support 
(perceived availability of social support at a time of need) was the most important 
social support construct that predicted emotional outcome.  For these men, received 
social support did not significantly predict negative affect but perceived social 
support did.  The findings from these two case studies suggest an exciting, but 
tentative, dimension to existing social support theory.  Perceived social support was 
found to partially mediate the relationship between coping (positive and negative) 
and negative affect in both case studies (Mr A and Mr H).  These finding have 
identified a causal link between coping and emotional outcome because of perceived 
social support for these men at that stage in their illness and in the situations 
reported.  Clinically, this is an important finding (identified for Mr A and Mr H) 
because perceived social support bridged the relationship between negative coping 
and negative affect.  The conditions for mediation were met based on the 
recommendations from Baron and Kenny (1986) for both men.  The results of the 
Sobel’s test and the bootstrapping procedure were significant for Mr A and non-
significant for Mr H.  In the aforementioned, this is a tentative conclusion because 
statistically significant results were only identified for Mr A (based on Sobel’s test and 
bootstrapping results), but not for Mr H.  This area would be worthy of further 
research to replicate perceived social support as a partial mediator between coping 
and negative affect.     
 
The stress buffering model (moderation effects) (Cohen et al., 2000, Cohen, 1988, 
Cohen and McKay, 1984) was supported by three men (Mr B, Mr C and Mr F).  A 
similar moderation effect was found across the three case studies, but the three men 
differed in clinical characteristics and level of social support.  Negative coping was 
associated with negative affect when received social support was low.   These 
findings suggest that men do not always receive the appropriate support when they 
are experiencing negative coping and negative affect.  This unique within-person 
assessment over time (Mr B, Mr C and Mr F) has demonstrated replication of this 
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moderating effect for three case studies.  It has also identified a clinical area that 
would be worthy of further research.  Additional work is needed to identify what 
types of support are most helpful to men and in what circumstances over the course 
of the prostate cancer journey.  Surprisingly, negative effects of social support were 
also identified on emotional outcome. 
 
For 2 men (Mr B and Mr F) received social support was predictive of higher negative 
affect and moderation effects were identified.  For Mr B, received social support was 
a significant predictor of higher negative affect and, positive coping was associated 
with negative affect when received social support was high.   These findings would be 
indicative that not all provisions of support are helpful.  This is a paradoxical finding 
and does not support the main effects theoretical model or the stress buffering 
model.  According to the social support theory (Cohen et al., 2000, Cohen, 1988, 
Cohen and McKay, 1984), social support transactions are related to successful 
adaption and linked to improved health outcomes.  These results may suggest that 
social support can be potentially harmful for some men.  This result is in keeping with 
findings that have demonstrated the negative consequences of social support on 
health outcomes (Scholz et al., 2008, Schwarzer et al., 2006).      
 
For six men (Mr D, Mr E, Mr G, Mr I and Mr J and Mr K) the propositions of social 
support theory were not supported at that stage in their illness and in the reported 
situations.  The research design for the EMA adapted/N-of-1 has allowed replication, 
and this adds strength to this Ph.D. study.  For these six men (Mr D, Mr E, Mr G, Mr I, 
Mr J and Mr K), they had a range of cancer stages, treatments and level of social 
support, among additional clinical and demographic variables.  The sampling 
framework criteria enabled the propositions of social support theory to be tested 
with individuals with high support, and in individuals with low support.  These six 
men (Mr D, Mr E, Mr G, Mr I, Mr J and Mr K) reported a range of high and low social 
support, but this did not influence the mechanism effect of social support on 
emotional outcome.    No emergent commonality is evident to explain these non-
statistically significant findings for social support theory for these six individuals.    
 
Collectively, these findings suggest that social support intervention would not be 
appropriate for these (six) men, because the theorised process for social support 
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does not “work” for these individuals, and thus perhaps a social support intervention 
may not work.  It is interesting that most theories, including social support theories, 
are within-person models, but most models are tested between people (such as the 
prospective surveys identified in chapter 2 and the results in chapter 5).  In particular, 
the main effects model (Cohen et al., 2000, Cohen and Wills, 1985, Cohen and 
McKay, 1984) and the stress buffering model (Cohen et al., 2000, Cohen, 1988, Cohen 
and McKay, 1984) have been supported in prostate cancer studies (Zhou et al., 
2010a, Zhou et al., 2010b, Scholz et al., 2008, Visser et al., 2003), but when applied to 
the “individual man”, the theory does not hold within-person design for these six 
men at this stage in their cancer journey.  This innovative Ph.D. study has 
demonstrated that the propositions of social support theory are supported between 
people (chapter 2 and chapter 5), but it does not hold within-person design for these 
six men (Mr D, Mr E, Mr G, Mr I and Mr J and Mr K).    
                
There are a number of possible explanations to account for this finding.  
Interestingly, the majority of men (80%) in this Ph.D. study did not use additional 
cancer support services, such as: Support Groups or Maggie’s Cancer Care Centre.  
These data are consistent with those published by Shapiro et al., (2004) and Krizek et 
al., (1999), who reported that only 22% of men expressed an interest in cancer 
support services.  Therefore, clinically, does current healthcare effectively meet the 
supportive care needs for men affected by prostate cancer?  It is apparent that for 
the majority of men who are affected by prostate cancer, they are unlikely to 
participate in the supportive services available to them.  This case series (six) 
identified no relationship between coping and social support, or on emotional well-
being; and for two men (Mr B and Mr F), negative effects of social support were 
identified.  Clinically, this phenomenon requires additional research because the 
benefits of social support for men affected by prostate cancer are unclear based on 
the results of the case series.   
 
Descriptively, men treated with invasive treatment (surgery and radiotherapy) (Mr C, 
Mr D, Mr E, Mr F, Mr G, Mr H) performed self-management behaviours more 
frequently over time compared to men (Mr A, Mr B and Mr J and Mr K) treated 
conservatively.  Men performed self-management behaviours to reduce the effects 
of their prostate cancer and side effects from their treatment.  Three men (Mr B, Mr 
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G, and Mr I) reported little relief from their self-management behaviours and all 
three men reported low social support.  For these men they may not have had access 
to the appropriate social support to help them to self-manage their symptoms, for 
example, informational or practical support.  Alternatively, social support was not 
salient in particular situations.  A further interesting finding was that men (Mr J and 
Mr K) with the most severe stage of cancer (metastatic cancer) who were treated by 
hormone therapy did not report any self-management behaviours.  As identified in 
chapter 1, men treated with hormone therapy can often experience the worse 
HRQoL (Couper et al., 2009, Gacci et al., 2009, Sanda et al., 2008, Ash et al., 2007, 
DePuy et al., 2007, Kato et al., 2007).  Both men experienced a number of frequent 
symptoms every day and these included: pain, tiredness, unable to sleep, urinary 
urgency and urinary frequency.  It is possible that for these men (Mr J and Mr K), they 
were not bothered by their symptoms, and therefore, they did not feel it necessary 
to perform self-management. One explanation could be related to symptom severity, 
symptom bother, and the relevance of time in relation to treatment, among many 
other factors, that influenced mens’ self-management behaviours, or, lack of. 
 
The symptom experience includes an individual’s perception of a symptom, 
evaluation of the meaning of a symptom, and response to a symptom (Dodd et al., 
2001).  Perception of a symptom signifies whether an individual notices a change 
from the way they usually feel, or behave.  Individuals evaluate their symptoms by 
making judgements about the severity, cause, treatability, and effect of the 
symptoms on their daily lives.  Responses to symptoms can include the following: 
psychological, physiological, sociocultural and behavioural components (Dodd et al., 
2001; Lenz et al., 1997).  Thus, for men with prostate cancer symptom experience is 
complex, and conceptualised as a multidimensional experience, with a number of 
factors that may influence a man’s decision to perform self-management of their 
symptoms.  Such factors might include: symptoms intensity (strength or severity), 
timing (duration and frequency of occurrence), level of perceived distress (degree of 
discomfort or bother) (Lenz et al., 1997), and perceived self-efficacy (Bandura, 1997). 
 
Symptom intensity refers to the severity, or strength, of a symptoms being 
experienced.  Whereas, the time dimension includes the frequency in which a 
symptom occurs, the duration of a symptom, or can represent the timing of a 
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symptom occurrence relative to specific activities (for example, the temporal 
association of nausea and food intake).  The distress dimension of symptom 
experience refers to the degree to which a person is bothered by their symptoms.  
Patients are often asked to indicate how much they are bothered by a symptom to 
gain an understanding of how they are interpreting the experience, and the meaning 
they are assigning to the symptom experience.        
 
Further research is needed to understand the relationship between symptom 
experience and self-management for men living with and beyond prostate cancer.  
For example, at what stage in a man’s recovery from treatment does self-
management of sexual dysfunction become salient?  Some qualitative research 
would be advantageous in this area to explore factors that influence a man’s decision 
to perform self-management over time.   
 
Strengths and limitations of the EMA adapted/N-of-1 
There are a number of strengths to the EMA adapted/N-of-1 design.  This is the first 
study that has explored the feasibility of real time data collection methods within 
“individual men” affected by prostate cancer over time.  This study assessed self-
management behaviours and tested social support theory (Cohen et al., 2000, Cohen, 
1988, Cohen and McKay, 1984) in eleven men with different clinical characteristics 
and demographic backgrounds, enabling some replication.  This study has provided a 
unique insight into the individual experiences of men that minimised retrospective 
memory recall and reduced data fabrication. This is one of the first studies to 
examine real time self-management behaviours for men affected by prostate cancer 
with a range of treatment modalities and stage of cancer.   However, there are a few 
limitations to what can be concluded from this case series (11).  This study assessed 
men’s experiences three times per day for one month and therefore, assessment of 
self-management behaviours and social supportive experiences beyond the period 
assessed in this Ph.D. study is unknown.  Given the distinct benefits of real time data, 
additional research using innovative technology is needed to identify the survivorship 
needs of men at different stages of the cancer journey.   
 
The regression analyses were sufficiently powered in the seven case studies (Mr A, 
Mr B, Mr C, Mr F, Mr G, Mr H and Mr I) based on recommendations from Tabachnick 
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and Fidell (2007).  However, each regression model explained approximately 30% of 
the variance of the dependent variable (negative affect) which left a proportion of 
the variance unexplained by the model.  The amount of variance explained by testing 
the propositions of social support theory was similar between the prospective 
longitudinal study (chapter 5) and these case studies.  Additional variables may have 
had a significant multivariate contribution, but this would have under-powered the 
regression analyses in the case studies.  The measures used in the study appeared 
valid and reliable, but because the case studies reported here used measurements 
relatively untested in single-case designs, the reliability is unclear.  The measures 
used in the EMA adapted/N-of-1 were developed based upon existing standardised 
instruments, and face validity was checked by feedback from patients and clinicians 
and from the results of the pilot. Establishing the reliability of the diary questionnaire 
is somewhat problematic because of autocorrelation and pre-whitening procedures.  
The influences of autocorrelation and pre-whitening of variables on Cronbach’s alpha 
statistic are unknown and therefore, Cronbach’s alpha testing was not performed in 
the eleven case studies.  Some caution should be taken in the interpretation of these 
findings as this may have introduced measurement error.  Testing the propositions of 
social support theory and assessing self-management behaviours within individuals 
affected by prostate cancer using a repeated measurement design, is uncharted 
territory for nursing research.   Future research using repeated measures in within-
person designs is needed to support or refute these findings because of the 
uncertainty of comparing group-based findings to single-case data.  Therefore, the 
conclusions from these eleven case studies should be considered provisional.    
 
A number of symptoms were not explicitly assessed, and included the following: 
pain/proctitis, leakage of stools, hot flushes, painful nipples or breasts, blood in 
stools, oedema, bloated abdomen, weight loss, weight gain; but the participants 
were given an opportunity to share these symptoms by “free text” in the diary entry.  
It is important to acknowledge that the participants may not have used the “free 
text” option to report additional symptoms; therefore, the symptoms experienced 
could be unrelated to the self-management behaviours reported.  For example, 
constipation and diarrhoea was explicitly assessed, but not blood in stools, or 
proctitis, and therefore; the reported behaviours could be related to other symptoms 
for which no data was captured.  
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There is an important distinction between statistical significance and clinical 
significance, and this is an area which has been contested by researchers over the 
years.  Statistical significance refers to real differences, as opposed to ones that are 
illusory, questionable or unreliable.  A statistically significant result indicates that we 
can be confident that study findings are not by chance (Ogles et al., 2001).  For 
example, statistical tests comparing the mean and variance differences which are 
found beyond the range of chance (usually at the .05 alpha levels) are usually 
deemed as “statistically significant”.  One of the problems for clinicians who attempt 
to make practical applications of the statistically significant results is the lack of 
information regarding the clinical significance of research findings, and this is a 
particular limitation of the EMA adapted/N-of-1 case series.   Clinical significance 
refers to changes that are practically meaningful for a patient and clinician (Jacobson 
and Truax, 1991; Jacobson et al., 1999; Kendall, 1999; McGlinchey et al., 2002; Turner 
and Turk, 2008).  Little guidance exists to establish the clinical significance for EMA 
adapted/N-of-1 research designs.  There are a number of potential clinically relevant 
findings and these included: perceived social support bridged the relationship 
between coping and negative affect, negative effects of social support were found, 
an arbitrary association was found for invasive treatments and increased number of 
self-management behaviours performed, and finally, men reported little relief from 
self-management behaviours.  Ultimately, the clinical significance of these findings 
will remain unknown.  However, one approach that may have provided an account of 
the clinical significance of these findings would have been to explore these findings 
with the patient using qualitative interviews.             
 
6.7 Conclusion  
Collectively, the findings from the eleven case studies have provided mixed support 
for the propositions for social support theory and it appears that one size does not fit 
all.  Three men provided support for the main effects and stress buffering model, two 
men identified negative effects of social support, and men (six men) did not support 
existing social support theory.  The propositions of social support theory are 
supported between people (chapter 2 and chapter 5), but failed to work within these 
six men, and negative effects of social support were also identified for two men.  
These results suggest that the development of a social support intervention would 
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potentially benefit 3 individuals from this case (11) series.  The negative effects of 
social support for two men cannot be ignored, and completely contradicts social 
support propositions. Therefore, future research would be important for testing and 
developing social support theory at the within-person level. 
 
Variance was identified when examining the social support constructs (perceived, 
received and satisfaction with social support) over time.  These findings demonstrate 
that traditional standardised instruments cannot accurately detail the intra-individual 
social supportive experiences over time.  Importantly, all of the men, with the 
exception of Mr A, Mr C and Mr F, reported reduced satisfaction levels with their 
support over time and thus additional work are needed in this area.    
 
The number of days that men performed self-management to relieve urinary, bowel 
and sexual dysfunction varied across the eleven single-case studies.  Men treated 
with invasive treatment (surgery and radiotherapy) (Mr C, Mr D, Mr E, Mr F, Mr G, Mr 
H) performed self-management behaviours more frequently over time compared to 
men (Mr A, Mr B and Mr J and Mr K) treated conservatively.   Each individual man 
performed self-management behaviours to reduce the effects of their prostate 
cancer and side effects from their treatment.   
 
Men diagnosed with localised and locally advanced cancer performed self-
management, but men diagnosed with metastatic cancer did not perform self-
management.  Additional future research would be helpful to understand why men 
with metastatic cancer did not report any self-management.  A common theme 
across the eleven case studies was that men frequently experienced a range of 
symptoms, including: tiredness, urinary symptoms, bowel symptoms and impotence, 
but no self-management behaviours were reported.  Future research is needed to 
understanding the relationship between symptom severity, bother, and frequency 
with self-management behaviours, and is a prerequisite to further advance 
knowledge and understanding in the area of self-management support.  An 
understanding in this area is urgently needed and has been informed from the results 
of these eleven case studies and from the findings from chapter 5.  Knowledge in this 
area may enable tailored evidence-based self-management advice to be provided 
and tailored to the individual needs for men affected by prostate cancer survivors.    
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7.0 Summary, clinical implications, and future 
research 
 
This innovative Ph.D. study has added to the HRQoL, social support, and self-
management literatures reviewed in chapters 1, 2, and 3.  The knowledge 
contribution from this study will be identified and discussed in relation to HRQoL, 
social support and self-management.  There are a number of strengths to this Ph.D. 
study that have complemented the existing methodological and clinical implications 
in this field.  However, there are a number of limitations that featured in this Ph.D. 
study and these shall be acknowledged and detailed.  This chapter concludes with 
the next steps for taking forward this important research and details future plans for 
Post-Doctoral research and activity.   
 
7.1 Health-related quality of life 
The HRQoL findings from the prospective longitudinal study (chapter 5) are in 
keeping with the literatures analysed in chapter 1, and build upon the literatures 
reviewed in chapter 2.   Global quality of life (EORTC C30) was positively associated 
with the EORTC C30 functional scales and negatively correlated with the individual 
symptom scales. The finding from the hierarchical multiple regression analyses 
demonstrated longitudinal predictors of global quality of life at six months with the 
following baseline variables: global quality of life, perceived social support and 
satisfaction with social support, and adds to the HRQoL evidence-base.  This Ph.D. 
study used a multidimensional approach to social support measurement and has 
added clarification to the existing knowledge-base.  Perceived social support and 
satisfaction with social support were longitudinal predictors of HRQoL at 6 months, 
but received social support at baseline was not.  The correlation coefficients 
identified baseline positive coping had no association with global quality of life at six 
months, and baseline negative coping was entered into the regression equation at 
<.15, but did not significantly predict global quality of life for prostate cancer 
survivors.  The clinical implications of the regression analyses, suggest that perceived 
social support and satisfaction with social support at diagnosis could be a potential 
intervention target to improve HRQoL at 6 months after diagnosis.  Perceived social 
support has been found to reflect more of a personality disposition (Sarason et al., 
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1986) that is intertwined with optimism, rather than actual social support 
transactions.  Thus, intervention design could be problematic for this construct 
because altering personality-level variables are difficult to design.  One approach to 
improving men’s perceived social support could be cognitive behavioural therapy 
(Sheldon, 2011).  Cognitive behavioural therapy is an evidence-based psychological 
approach that is practiced by a range of healthcare professionals and therefore, 
could have the potential to improve men’s perceptions of social support.   
 
Ideally, future research should be designed to evaluate the extent to which HRQoL 
can be influenced by the typologies of social support (informational, emotional, 
financial, and instrumental) which are provided by different sources (for example, 
family members, clinicians, specialist nurses, and friends) and at different time points 
in the cancer journey.  There needs to be a complementary transition in social 
support cancer research, from using standardised measures (aggregate group level 
approaches), towards the study of more explicit, specific behaviours that occur 
between a man with prostate cancer, and those individuals in his support network.  
Future work is needed to advance our understanding into the perspective of the 
provider, as well as the recipient, in obtaining judgements about the effectiveness of 
the typologies of social support, social support interactions, over the cancer 
continuum in relation to HRQoL.   
 
There were a number of statistically significant and clinically relevant changes in 
HRQoL over time.   Global quality of life scores reduced over time and were found to 
have a small clinically relevant change (Osoba, 2011, Osoba, 2000).    For the most 
part, functional domains of HRQoL were mostly unaffected (role function, cognitive 
function, emotional function, and social function) except for reduced physical 
function scores at six months.  Overall, the EORTC functional scores were similar to 
normative EORTC C30 data (Scott et al., 2008) and are in keeping with studies 
reviewed in chapter 1 (Hashine et al., 2009, Kato et al., 2007, Namiki et al., 2006b, 
Robinson et al., 1999a).  A number of statistically significant increases were found for 
the following symptoms: fatigue, constipation and appetite loss, but not for 
dyspnoea, pain, diarrhoea, and financial difficulties.   Appetite loss, constipation and 
fatigue were significantly worse at six months, but not clinically significant (Osoba, 
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2011, Osoba, 2000) and this is similar to other published work (Lips et al., 2009, Spry 
et al., 2006, Robinson et al., 1999a).   
Statistically significant increases were identified for bowel symptoms and treatment 
symptoms at six months, and represented small clinical changes; but urinary 
symptoms did not significantly change over time.  Sexual activity statistically reduced 
over time and represented a small clinically significant change.  At one month after 
diagnosis, twenty-eight (41.2%) men were sexually active, and at six months fifteen 
men (22.1%) were sexually active.  Reduced sexual activity for men living with 
prostate cancer has been widely demonstrated in published studies which assessed 
change over time (Roeloffzen et al., 2010, Smith et al., 2009, Nguyen et al., 2009, 
Davison et al., 2007, Kato et al., 2007, Namiki et al., 2007, Jayadevappa et al., 2006, 
Feigenberg et al., 2005).  Overall, the results for HRQoL in the current study appear 
to be consistent with other published data.  Due to the limited follow-up period, it 
was not possible to evaluate changes in HRQoL beyond six months.   
7.2 Social support 
The findings from chapter 5 and 6 explored the underlying mechanism effect 
between coping and social support on HRQoL between individuals and within 
individuals over time.  These findings have built upon the literatures analysed in 
chapter 2, and inform a number of important implications for social support theory.  
This Ph.D. study was theoretically driven and has enhanced and refined our 
understanding of the social support constructs, and the propositions of social support 
theory (Cohen et al., 2000, Cohen, 1988, Cohen and Wills, 1985, Cohen and McKay, 
1984, Cohen and Hoberman, 1983) for men affected by prostate cancer.  Chapter 5 
presented the findings from the prospective longitudinal study (aggregate group level 
effects) which used a multidimensional assessment of the social support constructs.  
The findings from chapter 5 identified perceived social support and satisfaction with 
social support (baseline, before treatment) predicted better global quality of life at 
six months, but only perceived social support (at baseline) predicted less depression 
at six months.  Received social support did not have any significant relationship with 
the dependent variables (anxiety, depression and global quality of life).  In addition, 
the social support constructs (perceived, received and satisfaction with social 
support) did not have a significant relationship with anxiety at six months.  
Collectively, the findings from the multiple regression analyses would indicate that 
280 
 
 
 
perceived social support at baseline was the most important social support construct 
that predicted better global quality of life and less depression at six months, and this 
is in keeping with existing literatures (Zhou et al., 2010a, Mehnert et al., 2010, Andel 
et al., 2004, Visser et al., 2003, Rondorf-Klym and Colling, 2003).   
 
Existing studies (Zhou et al., 2010a, Mehnert et al., 2010, Andel et al., 2004, Visser et 
al., 2003, Rondorf-Klym and Colling, 2003) did not use a multidimensional assessment 
of social support, but rather, the social support assessment was restricted to 
perceived social support only.  Therefore, this Ph.D. study adds an important 
dimension because of the three social support constructs assessed (perceived social 
support, received social support and satisfaction with social support); perceived 
social support and satisfaction with social support were found to predict better 
health outcomes for men at 6 months.   
 
Based on the findings from the prospective longitudinal survey, no moderation or 
mediating effects were identified between coping and social support on global 
quality of life, anxiety, and depression. The buffering model (Cohen et al., 2000, 
Cohen, 1988, Cohen and Wills, 1985, Cohen and McKay, 1984, Cohen and Hoberman, 
1983) was not supported.  Based on these results alone it could be assumed that 
perceived social support could be considered as a potential psycho-social factor that 
may improve HRQoL and this has been supported elsewhere (Zhou et al., 2010a, 
Zhou et al., 2010b).  However, the findings from the series of eleven case studies 
challenge the suitability of such an intervention for “all men” affected by prostate 
cancer. 
 
The series of EMA adapted/N-of-1 case studies evaluated change over time and 
tested existing theoretical social support models within eleven individuals over time.  
Collectively, different results were obtained across the eleven men that linked coping 
and social support to emotional outcome.  The findings for two men (Mr A and Mr H) 
provided support for the propositions of the main effects model (Cohen et al., 2000, 
Cohen, 1988).  Perceived social support (perceived social support at a time of need) 
was the most important social support construct that predicted emotional outcome.  
The findings for these case studies (Mr A and Mr H) suggest an exciting, but tentative, 
dimension to social support theory.  Perceived social support was found to partially 
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mediate the relationship between negative coping and emotional outcome for Mr A 
and Mr H.  An intervention targeting perceived social support to improve HRQoL as 
identified from the prospective longitudinal study (chapter 5) and recommended by 
(Zhou et al., 2010a, Zhou et al., 2010b) may have been suitable for both of these 
men. Yet, for others, it would appear that targeting perceived social support for an 
intervention study would not be appropriate.  For other men, received social support 
was more important.  
 
The findings from three case studies (Mr B, Mr C and Mr F) identified a similar 
moderation effect and support the buffering model within-person design (Cohen et 
al., 2000, Cohen, 1988, Cohen and McKay, 1984).  Negative coping was associated 
with emotional outcome when received social support was low for these three men.  
These findings suggest that men do not always receive appropriate social support 
when they are experiencing negative coping and negative affect.  Clinically, this is an 
important area for future research.  Additional research is needed to identify what 
types of social support (informational, emotional, practical and financial) are most 
helpful to men, and from which support provider, and in what circumstances over 
the course of living with and beyond prostate cancer.  There is a notion that social 
support has a positive effect on influencing physical and psychological well-being, but 
quite the reverse was identified for two men.  Negative effects of social support were 
identified for Mr B and Mr F.   
 
Received social support was predictive of higher negative affect, and positive coping 
was associated with negative affect when received social support was high.  
Importantly, these findings are indicative that not all provisions of social support are 
helpful for prostate cancer survivors.  These findings (Mr B and Mr F) would suggest 
that their social support was mismatched to their needs.  A further explanation is 
that some individuals produce better coping efforts when one masters challenges 
alone, without help from others, and will only resort to the receipt of social support 
in the worst circumstances.  Alternatively, a man with prostate cancer can experience 
stress and difficulties with their interpersonal relationships.  A man’s uncertainties 
and fears can increase their need for support; while the intense fears and the stigma 
associated with the disease, may create communication problems that decrease their 
access to social support.  For example, a man with prostate cancer who faces sexual 
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problems can elicit negative feelings and frustrations in others because of his own 
expression of frustrations and fears in coping with erectile dysfunction.  This can lead 
others to behave towards a man with prostate cancer in ways that are unsupportive 
because of communication barriers.  The support needs of men with prostate cancer 
may vary with the adaptive challenges they confront, for example, coping with 
diagnosis, the physical and psychological problems after treatment; thus it is 
important that men have access to multiple types of social support (information, 
emotional and instrumental) as they need it.  This reinforces the need for further 
research to identify what types of social support are most helpful to men, and in 
what circumstances over the cancer journey.   
 
For six men, the propositions of social support theory were not supported at all.  The 
findings from the series of case studies would suggest that developing an 
intervention study based on the propositions of social support theory would not be 
appropriate for all men.  This is perhaps in keeping with the results in chapter 2 and 
chapter 5, because only a small minority (20% of the study population) participated 
in cancer support services and this has been reported elsewhere (Shapiro et al., 2004, 
Krizek et al., 1999).  In addition, previously published social support intervention 
studies (Zhang et al., 2007, Northouse et al., 2007b, Carmack Taylor et al., 2006) did 
not have a significant effect on improved HRQoL for men affected by prostate cancer.  
The findings from this case series (Molenaar, 2004) have informed the theoretical 
modelling stage of the Medical Research Council’s framework for complex 
interventions (Craig et al., 2008). These findings suggest that underpinning a future 
intervention study by the propositions of social support theory would not be suitable 
for all men, because these findings have demonstrated that one size does not fit all.   
 
7.3 Self-management 
The findings from the prospective longitudinal study (chapter 5) have built upon the 
literatures analysed in chapter 3.   This study has identified that men performed a 
number of self-management behaviours for urinary, bowel, and sexual dysfunction 
across all stages of disease; and this adds to the existing evidence-base.  At six 
months, urinary self-management significantly reduced, bowel self-management 
significantly increased, and sexual function self-management increased over time; 
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but failed to reach statistical significance.  The clinical relevance of these findings is in 
keeping with the clinical characteristics of the study sample, because most men were 
treated with radiotherapy, and bowel problems are prevalent in men treated by this 
modality.  A commonality across all stages of the disease was that men reported little 
relief from their self-management behaviours over time.  There are a number of 
explanations to explain why men may have reported little relief from their self-
management.  One possible explanation relates to the sources of self-management 
advice.  The most frequent source of self-management advice came from men’s 
partners’.  It can be argued that partners (to the exception of partners with expert 
healthcare knowledge) do not have an appropriate level for knowledge; for example, 
educating men on the usage of penile inserts, or penis pumps for the self-
management of erectile dysfunction; but partners could be ideally suited to offer 
emotional support, for example.  Further work is needed to establish why men 
frequently sourced self-management suggestions from their partners, and not from 
healthcare professionals, as an important step towards developing our 
understanding of the implications of partners providing self-management advice 
from the man’s perspective, but also from the partner’s perspective.    
 
A further important contribution to the evidence-base is surrounding self-efficacy.  
Self-efficacy scores at six months were found to be statistically worse when 
compared to baseline (chapter 5).  These data suggest that men living with and 
beyond cancer may experience a decline in their belief to perform self-management 
with confidence and ease over time.  This is a key clinical finding that would be 
worthy of future research to advance our understanding as to why men may 
experience a reduction in self-management self-efficacy over time.   In the 
aforementioned, men reported little relief from their self-management behaviours 
over time, and this could be related to men’s reduced self-efficacy scores at six 
months.  According to Bandura’s theory of self-efficacy, self-efficacy is the belief that 
a person can master a situation, and produce a positive outcome.  In keeping with 
Bandura’s theory, men consistently reported little relief from their self-management 
behaviours for urinary, bowel and sexual dysfunction, which may have reduce mens’ 
confidence and ease to perform their self-management over time.    Improving men’s 
self-efficacy would be an important intervention target, but additional research is 
prior needed to ensure intervention work is appropriately informed.   
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The findings from the EMA adapted/N-of-1 case series complemented and extended 
the contribution of the prospective longitudinal self-management findings.   
Descriptively, men treated with invasive treatment (surgery and radiotherapy) (Mr C, 
Mr D, Mr E, Mr F, Mr G and Mr H) performed self-management behaviours more 
frequently over time compared to men (Mr A, Mr B, Mr J and Mr K) treated 
conservatively.  The self-management behaviours were mainly related to three areas: 
urinary, bowel and sexual dysfunction, but men also experienced other problems for 
which they performed self-management and these included: radiation burns, 
infected surgical wound, ankle oedema, stress and relaxation problems.  Variation 
was identified across the eleven case studies for the following: symptoms, self-
management behaviours and self-management relief.  A clinically important theme 
was identified from the case series in that men frequently experienced a range of 
symptoms but did not perform any self-management.  The reasons as to why men 
did not perform self-management for these symptoms are unclear and several 
explanations have been discussed in this thesis.  Key to advancing the field of self-
management for men living with and beyond cancer is knowledge into men’s 
symptom experience.  Symptom experience is complex with a number of factors that 
may influence a man’s decision to perform self-management of their symptoms.  
Area’s for future research should focus on developing our understanding of the 
following: symptoms intensity (strength or severity), timing (duration and frequency 
of occurrence), level of perceived distress (degree of discomfort or bother) (Lenz et 
al., 1997), and perceived self-efficacy (Bandura, 1997), as potential antecedents for 
self-management behaviour.   A suitable theoretical framework that could be used in 
for future research is the Theory of Symptom Self-Management (Hoffman, 2013) 
because it identifies multiple components such as:  patient characteristics, symptom 
assessment, perceived self-efficacy for symptom management, symptom self-
management behaviours, and performance outcomes.   Developing our knowledge 
and understanding in this area may shed a very helpful clinical insight into the 
changes in symptoms experienced and their relationship to self-management 
behaviour, and subsequent HRQoL.  Currently, this area is massively under-
researched and is considered as a very important target for future work.       
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7.4 Study limitations 
There were a number of methodological limitations that featured in the prospective 
longitudinal study and the EMA adapted/N-of-1 series.  The regression analyses 
performed were very marginally underpowered in both the longitudinal study and 
the EMA adapted/N-of-1 series and therefore, it was not appropriate to add 
additional predictors as this would have caused the analyses to be significantly 
underpowered.  It is very likely that other variables would have had a significant 
multivariate contribution to the regression models, but were not included.  In 
addition, a large number of statistical tests were performed that may have resulted 
in a type 1 statistical error.  To overcome this limitation in future studies it would be 
advisable to use a bonferroni adjustment (setting a more stringent alpha level for 
each comparison).  As a result, some caution should be taken in the interpretation of 
these findings, and requires the study to be replicated with large sample sizes.   One 
suggestion would be to consider a multi-centre study to increase the sample size and 
generalisabilty of future findings.   
 
The measures used in the longitudinal study were reliable and valid, but 
retrospective memory recall bias was likely.  In addition, this study only followed men 
up to six months; therefore changes beyond 6 months are unknown for this study 
sample.  The measures used in the electronic behavioural diary appeared valid and 
reliable.  Face validity of the content of the diary schedule was verified through 
expert comment from urological clinicians and prostate cancer patients.  However, 
reliability of the diary schedule was not demonstrated and therefore, a degree of 
caution should be taken in the interpretation of the findings.  There is a growing 
interest in real time data collection technologies in healthcare research, but very 
little guidance exists how to establish reliability in N-of-1 diary studies, due to the 
influence of autocorrelation and pre-whitening.  Future research studies using N-of-1 
diary methods should give due caution and explore statistical approaches to establish 
reliability.  One approach that might be considered in the future, with the benefit of 
hindsight, would be to develop the diary measures in conjunction with each study 
participant.  This strategy could be used to help reflect and capture the individual 
patient’s meaning of a particular construct.  In addition, the EMA adapted/N-of-1 
method is a new innovative approach that has never been applied to prostate cancer 
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survivors before.  Therefore, this made the interpretation of the findings challenging 
because no existing data was available to compare the EMA adapted/N-of-1 findings 
to.  In terms of lessons learned, it would have been extremely valuable to have 
conducted a semi-structured interview with each participant following the analysis of 
their diary data, with the purpose to confirm, refute, and explore the findings with 
each individual study participant.  A further limitation to the EMA adapted/N-of-1 
design was that the questionnaire schedule asked about men’s experiences over the 
past few hours; and thus may have introduced a small amount of memory recall. 
 
It is important to acknowledge the potential limitation of the search strategy used in 
the self-management review (chapter 3). The search terms used had a high level of 
specificity, and therefore, the search terms may not have been sensitive in 
identifying all relevant literatures for the self-management review.  An important 
omission in this review was that “coping and adjustment” were not included in the 
search terms, and as a result, it is possible that not all relevant literatures were 
reviewed.  Furthermore, a potential limitation of the review method used was that 
inclusion criteria consisted of the levels of evidence, and therefore, potentially 
relevant studies may have been excluded because of research design. 
 
An important consideration for bias exists in the diary assessment of symptoms.  The 
symptoms chosen were informed by the EORTC C30 and PR25, discussions with 
clinicians, and men with prostate cancer.  A number of symptoms were not explicitly 
assessed, and included the following: pain/proctitis, leakage of stools, hot flushes, 
painful nipples or breasts, blood in stools, oedema, bloated abdomen, weight loss, 
weight gain; however, the participants were given an opportunity to share these 
symptoms by “free text” in the diary entry.  It is important to acknowledge that the 
participants may not have used the “free text” option to report additional symptoms.  
As a result, the symptoms conveyed could have been unrelated to the self-
management behaviours reported.  For example, constipation and diarrhoea was 
explicitly assessed, but not blood in stools, or proctitis, and therefore; the reported 
behaviours could be related to other symptoms for which no data was captured.   
 
The standardised measures used in the prospective longitudinal study had 
demonstrated reliability and validity and have been used in many prostate cancer 
287 
 
 
 
studies, which added strength to the study, and enabled comparison of the study 
findings.  However, it is possible that some of the standardised measures may have 
been measuring the same construct, that is to say, the HADS, MAC Scale, EORTC C30 
and PSS.  For example, negative coping on the MAC Scale was significantly correlated 
(r=.512, p<.01) with anxiety on the HADS scale.  A potential exists that the 
relationships between the constructs measured could have been an artefact of 
standardised instruments measuring the same thing.  Therefore, a degree of caution 
should be taken in the interpretation of the findings.                    
 
7.5 Methodological and clinical implications 
The findings from this Ph.D. study have identified men may benefit from an 
intervention study to improve HRQoL, self-management self-efficacy and symptom 
management.  However, the content and theoretical model to develop such an 
intervention study would have to be considered.  The findings from the case series 
identified that “one size does not fit all” and therefore, future interventions should 
be tailored to the “individual man’s needs”.  This, however, is a very challenging and 
ambitious prospect for the most talented of researchers.  A prerequisite to nursing 
care is to ensure that the care delivered is holistic and personalised to the individual 
needs of each patient, and future research should be developed on this premise.   
 
The findings from the longitudinal survey (chapter 5) and EMA adapted/N-of-1 series 
(chapter 6) identified a number of important clinical implications.  No statistically 
significant changes were identified over time in anxiety and depression scores.  
However, using the cut-off scores as recommended by (Snaith and Zigmond, 1986) a 
trend (arbitrary) for increased anxiety and depression was identified for some 
individuals at six months.  Healthcare professionals should have awareness that 
emotional distress is likely for some men who are affected by prostate cancer and 
they should screen for, and treat, as appropriate.  Global quality of life demonstrated 
a clinically small and statistically significant decrease at six months, but the functional 
domains of the EORTC C30 were mostly unaffected, and this is very similar to other 
research in this field.  Disease-specific domains were affected and an increase in 
bowel and sexual dysfunction was identified at six months.  This is in keeping with 
literatures analysed in chapter 1.  The findings from the EMA adapted N-of-1 series 
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identified that men can also experience a number of additional problems, such as: 
urinary symptoms, radiation burns, post-operative wound infection, ankle oedema, 
stress and relaxation problems for which men performed self-management.  Overall, 
men reported little relief from their self-management behaviours and these results 
would, therefore, indicate that men may benefit from self-management support 
from healthcare professionals.   
 
Men frequently relied on self-management suggestions from their partners at both, 
pre-treatment and at six months follow-up; and specialist nurses were infrequently 
reported as a source for self-management suggestions.  Arguably, specialist nurses 
are ideally suited to provide expert evidence-based self-management advice and 
support (Ream et al., 2009, Faithfull et al., 2001), and therefore, clinically the current 
service provision and access to specialist nurses perhaps should be reviewed.  
Elsewhere, it is acknowledged that not all men with prostate cancer have access to a 
prostate cancer specialist nurse (National Audit Office and Department of Health 
2005), and equity of access is increasingly more difficult to achieve due to the 
financial constraints within the NHS.  Whilst access to specialist nurses may have 
been problematic, men do not always verbalise their concerns aloud to healthcare 
professionals because of embarrassment, and feeling of shame in their altered 
physical condition (George and Fleming, 2009, Braider, 2010).  Importantly, this Ph.D. 
study has added an important contribution to this field, because the feasibility of real 
time patient reported outcomes in the home environment has been demonstrated.  
This innovative approach enabled the men to share their symptoms, supportive 
experiences, coping efforts, and self-management behaviours; without having to 
verbalise their concerns aloud.  The use of mobile information and communication 
technology may be seen as a means to identify, and manage, the support needs of 
prostate cancer survivors in the future but additional field work is needed. 
 
A further clinical consideration was that men reported a lack of satisfaction with their 
social support over time.  Men should receive the right types of social support 
(information, emotional, instrumental, and financial) to match their individual needs 
over the cancer journey.  The findings would suggest that further research is urgently 
needed to identify what are the optimum types of social support, and in what 
circumstances for men living with and beyond prostate cancer.  The findings also 
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identified negative effects of social support and thus, not all types of social support 
are helpful for men with prostate cancer.  One approach in the short-term could be 
to utilise the Bottomley Cancer Support Scale as a screening tool in clinical practice to 
identify men who may be at risk of inadequate social support provision.  This 
questionnaire has only 9 items and therefore, would not be overly time-consuming in 
clinical practice.   
 
A further clinical consideration was that only a small minority (approximately 20%) of 
men used additional cancer support services such as Maggie’s Cancer Care Centre or 
Prostate Cancer Support Groups.  This is not a new emergent finding and is in 
keeping with existing literatures, but this is a really important and, clinically, very 
relevant area to understand; how are the other 80% of men living with and beyond 
prostate cancer being supported?  Perhaps this outcome challenges the suitability of 
additional cancer support services for the majority of men affected by prostate 
cancer.  This area would be worthy of additional research to identify men’s 
preferences for additional cancer support services.   
 
This Ph.D. study has identified a number of areas for future research and perhaps 
supports the development of an intervention study aimed at improving health-
related quality of life, self-care self-efficacy and men’s symptom self-management.  
However, the content of such an intervention would have to be further considered, 
as would the theoretical model.  Collectively, the findings from the eleven case 
studies have provided mixed support for the propositions of social support theory 
and it appears that one size does not fit all.  Therefore, any future intervention study 
should be tailored to meet “individual man’s needs”.    
 
This unique Ph.D. study has demonstrated the limitations of aggregate group level 
effects because such approaches inhibit our understanding of the individual person 
experience over time.  Real time data collection moves far beyond traditional 
retrospective evaluations, enabling a much clearer understanding of person 
experience over time whilst minimising retrospective memory recall bias.  This Ph.D. 
study has demonstrated the feasibility and acceptability of e-health technologies in 
men affected by prostate cancer, and therefore, using such methodological 
approaches in the future would be considered appropriate and beneficial. 
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7.6 Future plans 
This study has contributed towards the first stage of the MRC’s framework for 
complex interventions.  However, additional future research is required to inform the 
content of such an intervention study.  This Ph.D. study has identified areas for 
potential intervention and these include: self-management self-efficacy, HRQoL, and 
symptom self-management.  Symptom experience for a man living with and beyond 
prostate cancer is complex, and there are a number of potential antecedents that 
may influence a man’s decision, and ability, to perform self-management.   Post-
doctoral research will focus on developing and expanding the evidence-base to 
explore and identify antecedents of self-management for men living with and beyond 
prostate cancer.  Areas for future research will focus on developing the knowledge-
base for a range of clinical (for example: stage, treatment, existing co-morbidity) and 
demographic (for example: age, marital status, education, employment, socio-
economic status) characteristics across the following areas of symptom experience: 
symptom intensity (strength or severity), timing (duration and frequency of 
occurrence), level of perceived distress (degree of discomfort or bother) (Lenz et al., 
1997), and perceived self-efficacy, as potential predictors of self-management.  A 
potential theoretical model might include the Theory of Symptom Self-Management 
(Hoffman, 2013) because it includes multiple components that would be helpful for 
nurses and clinicians to identify the numerous factors that may contribute to a man’s 
experience of self-management. 
 
Developing the knowledge-base that identifies which antecedents can influence a 
man’s decision, and ability to self-manage, is a prerequisite to informing the content 
of a self-management support intervention study.  Further work is also needed to 
establish why men frequently sourced self-management suggestions from their 
partners, and not from healthcare professionals, to understand the implications of 
partners providing self-management advice from the man’s perspective, but also 
from the partner’s perspective. 
 
The Ph.D. study has illuminated the need for a complementary shift in social support 
cancer research, from using multidimensional standardised measures which are 
analysed using aggregate group level statistics; towards the study of more explicit, 
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specific behaviours that occur between a man with prostate cancer, and those 
individuals in his support network (including family, friends, healthcare professionals, 
etc.).  Future work will also focus on advancing an understanding into the perspective 
of the support provider, as well as the recipient, in obtaining judgements about the 
effectiveness of the typologies of social support, and social support interactions over 
the cancer journey. 
 
This exploratory Ph.D. study has provided a foundation to inform future research 
directions in this important field.  In conjunction with taking forward the future 
research endeavours, a publication plan has been developed to disseminate the 
original contribution of this Ph.D. in peer-reviewed journals.    
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Appendix 1.1 Inclusion/Exclusion Pro forma Checklist 
Abstract Inclusion/Exclusion Checklist 
Database____________________________________________________________________________________________ 
Abstract number______________________________________________________________________________________ 
Authors and Year_____________________________________________________________________________________ 
Inclusion                       
                TICK 
1. Levels of evidence A1-B3 (RCTs and systematic reviews, Individual well-designed non-experimental studies, controlling 
statistically if appropriate.  Includes case control, longitudinal, cohort, matched pairs or cross-sectional random sample 
methodologies, and well-designed qualitative studies, well-designed analytical studies including secondary analysis) 
 
2.  Does this title/abstract identify predictor variables of HRQoL and how HRQoL changes overtime?  
3.  Identifies change overtime only.  
4.  Published between 2005 and 2010?  
Exclusion               TICK 
1. Levels of evidence D-C1 (descriptive and other research or evaluations not in B (e.g. convenience samples, case studies and 
examples of good practice, summary review articles and discussions of relevant literature and conference proceedings not 
otherwise classified).  Cross-sectional convenience samples. 
 
2.  Pharmacological intervention studies/with the exception of hormonal treatment.  
3.  Has other cancer sites included in paper i.e. Breast cancer  
3.  Does not identify either predictor variables of HRQoL, or how HRQoL changes over time.  
4.  Published before 2005?  
Instruction: Retrieval of full-text article 
 
                        YES (Tick) 
 
       No (Tick)    Not Sure (Tick) 
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Appendix 1.2 Quality Assessment Tools  
Quality assessment for qualitative studies  (Shaw et al., 2009)   
 Criteria Yes 
(2/good) 
Partial 
(1/fair) 
No 
(0/poor) 
score 
 Study aims & context 
1. Is the research 
question 
sufficiently 
described? 
Research question clearly 
identified by the end of the 
research process, if not at the 
outset. 
Research question or 
objective is 
vaguely/incompletely 
reported. 
Question or objective is 
not reported, or is 
incomprehensible. 
 
2. Is qualitative 
method 
appropriate? 
Qualitative method is 
appropriate for the aims and 
the qualitative framework is 
identified and justified. 
Qualitative method 
appropriate but the 
methodological 
framework unclear or 
not adequately 
justified. 
Qualitative methods 
inappropriate for the 
aims. 
 
3. Is the 
setting/context 
clearly 
described? 
Context/setting is clearly 
described, permitting the reader 
to relate the findings to other 
settings. 
The context/setting is 
partially described. 
The context/setting is not 
described. 
 
 Sampling 
4. Is the sampling 
strategy clearly 
described? 
Sampling strategy & rationale 
clearly described and justified.  
Sampling strategy not 
clearly described or is 
not fully justified. 
Sampling not described.  
5. Is sampling 
method likely 
to recruit all 
relevant cases? 
(purposive, 
theoretical 
sampling) 
Sample includes the full range of 
relevant, possible cases (more 
than simple convenience 
sample) permitting conceptual 
(rather than statistical) 
generalisations. 
Sampling was 
purposive but does 
not include the full 
range of possible 
cases. 
No attempt made to 
sample purposively or 
theoretically, or sampling 
strategy not described. 
 
6. Are relevant 
characteristics 
of sample 
given? 
Relevant details of the 
characteristics of sample given.  
Incomplete details of 
sample characteristics 
given. 
No details of sample 
characteristics given. 
 
7. Is rationale for 
sample size 
(e.g. data 
saturation) 
given? 
Gives rationale for termination 
of data collection e.g. data 
saturation. 
Reasons for sample 
size implied or no firm 
rationale.  
No reason given for 
sample size. 
 
 Data collection 
8. Are methods of 
data collection 
clearly 
described? 
Data collection methods are 
systematic and clearly described 
allowing an audit trail such that 
procedures could be replicated. 
Data collection 
methods not clearly 
described. Difficult to 
determine if 
systematic or 
replicable. 
Data collection 
procedures are not 
described. 
 
9. Is method of 
data collection 
appropriate for 
research 
question and 
paradigm? 
Data collection methods are 
appropriate for the research 
aims and the methodological 
and analytical framework. 
The appropriateness 
of data collection 
methods are unclear.  
Data collection 
inappropriate for the 
aims and methodological 
framework. 
 
10 Has the 
researcher 
verified the 
data 
(e.g. by 
triangulation)? 
More than one method of data 
collection carried out or more 
than one analyst involved, or 
other methods of verification 
employed (e.g. member 
checking or line of questioning 
during interview).  
Unclear whether 
triangulation or other 
types of verification 
used. 
No triangulation or other 
methods of verification 
described. 
 
 Data analysis 
11 Are data 
analysis 
methods clearly 
described? 
 
Systematic analytic method 
clearly described such that 
procedures could be replicated. 
Analytic methods not 
clearly described. 
Analytic methods not 
described. 
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 Criteria Yes 
(2/good) 
Partial 
(1/fair) 
No 
(0/poor) 
score 
12 Are data 
analysis 
methods 
appropriate? 
Analytic methods seem 
appropriate & are well-
described. 
Analytic methods only 
partially described 
and/or some concerns 
about 
appropriateness. 
Analytic methods not 
described and/or 
appropriate. 
 
13  Are competing 
accounts/devia
nt data taken 
into account? 
Account given of negative or 
deviant cases in the analysis. 
Analysis of deviant or 
negative cases not 
clearly described. 
No account given of 
negative or deviant cases. 
 
 Reflexivity 
14 To what extent 
is the 
researcher 
reflective? 
The researcher explicitly 
assessed the likely impact of 
their own personal 
characteristics and the methods 
used on the data obtained. 
Possible sources of 
influence on the data 
obtained were 
mentioned, but the 
likely impact of the 
influence was not 
discussed. 
No evidence of reflexivity 
in the report. 
 
 Conclusions 
15  Are the 
interpretations 
and conclusions 
supported by 
the data? 
The interpretations are clearly 
described and supported by the 
data and are evidenced by 
sufficient participant quotes. 
The conclusions are 
unclear or only 
partially supported by 
the data, or there is 
insufficient raw data 
to support 
conclusions. 
Conclusions are not 
identified or are felt not 
to be supported by the 
data or conclusions are 
absent. 
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Quality assessment for quantitative studies (Shaw et al., 2009)   
Criteria Yes 
(2/good) 
Partial 
(1/fair) 
No 
(0/poor) 
N/A 
 
Score 
Study aims  
1. 
 
 
Is the 
hypothesis/aim/objective of 
the study clearly & 
sufficiently described? 
Easily identified in 
introduction/method. Specifies: 
purpose, subjects/target population, 
and specific interventions/ 
associations under investigation. 
Vague/incomplete reporting or some info has to be 
gathered from parts of the paper other than 
intro/background/ 
objective section. 
Question or objective not 
reported/ 
incomprehensible. 
  
Study design & sample characteristics  
2. 
 
 
Is the study design well 
described & appropriate? 
(If study question not given, 
infer from conclusions). 
Design easily identified, well 
described and appropriate. 
Design and/or study question not clearly described, 
or design only partially addresses study question. 
Design does not answer study 
question or design is poorly 
described. 
  
3. Is the method of 
patient/control group 
selection described and 
appropriate? 
 
Described and appropriate. 
Inclusion/exclusion criteria described 
and defined. 
Selection methods (and inclusion/exclusion 
criteria) not completely described, but no obvious 
inappropriateness. Or selection strategy likely 
introduces bias but not enough to seriously distort 
results. 
No information/ 
inappropriate information provided 
or selection bias which likely 
distorts results. 
  
4. Are the characteristics of 
patient/control group(s) 
clearly described (i.e. age 
range, health 
characteristic/s)? 
Sufficient relevant demographic 
information. Reproducible criteria 
used to categorise participants 
clearly defined. 
 
Poorly defined criteria or incomplete demographic 
information. 
No baseline/demographic info 
provided. 
  
5. Were patients/participants 
randomised to intervention 
groups? 
 
If randomisation appropriate: 
Evidence of randomisation with a 
description of the method used (e.g. 
random number tables, block 
design). 
Randomisation mentioned but method is not (i.e. 
may be possible that randomisation not true). 
Random allocation not mentioned 
although it would have been 
feasible and appropriate (and 
possible done). 
Study has no control group i.e. 
observational/ 
surveys/case-control. Or 
adequate justification for non 
randomisation. given. 
 
6. For RCT’s only: 
Was 
randomisation/allocation 
concealed from patients? 
Evidence the next allocation was 
concealed from both parties 
(recruiter and patient/carer) at the 
point of consent 
(e.g. remote randomisation). 
Allocation concealment reported but not 
described. 
Allocation concealment would have 
been possible (and was possibly 
done) but not reported. 
Allocation concealment not 
possible due to study design 
(e.g. cluster randomised trial). 
 
   
7. 
Have the characteristics of 
patients lost to follow-up 
been described? 
Losses adequately reported & not 
likely to affect results. 
 
Losses not well reported, but small & not likely to 
affect results. 
No information or losses large and 
likely to affect results. 
No patients lost to follow-up. 
 
 
8. Are intervention(s) clearly 
described? 
Defined and reproducible. Partially defined, but insufficient detail to 
reproduce design. 
Not described. Not possible/ 
appropriate – e.g. observational 
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 Criteria Yes 
(2/good) 
Partial 
(1/fair) 
No 
(0/poor) 
N/A 
 
Score 
9. Are the main outcomes to be 
measured clearly described in 
the introduction/method? 
 
Defined and measured according to 
reproducible criteria. 
Definition leaves room for subjectivity, or not 
sure (i.e. not reported in detail, but probably 
acceptable). Or precise definition(s) are 
missing, but no evidence of major problems. 
Or instrument/mode of assessment(s) not 
reported. 
Main outcomes first mentioned in 
results section. Or measures not 
defined/inconsistent/ 
poorly defined. 
  
10 If possible, was an attempt 
made to blind those 
measuring the main 
outcomes of the 
intervention? 
Assessor blind to intervention/study 
group. 
Inadequate blinding: i.e. assessor may have 
been aware of group participant assigned to. 
No attempt made to blind assessor. Not possible/ 
appropriate – e.g. 
observational/ before & 
after study. 
 
11 Are population 
characteristics (if measured & 
described) controlled for and 
adequately described? 
 
Appropriate control at design/analysis 
stage or randomised study with 
comparable baseline characteristics. 
Incomplete control/ 
description. Or not considered but unlikely to 
seriously influence results. 
Not controlled for and likely to 
seriously influence results. 
  
12 Are the main findings clearly 
described? 
Simple outcome data (e.g. 
mean/prevalence) reported for all major 
findings. 
Incomplete or inappropriate descriptive 
statistics. 
 
No/inadequate descriptive statistics.   
13 Are methods of analysis 
adequately described and 
appropriate? 
Described and appropriate. Not reported but probably appropriate or 
some tests appropriate, some not. 
Methods not described and cannot 
be determined. 
  
14 Are estimates of variance 
reported for the main 
results? 
Appropriate estimates provided (SD/SE, 
confidence intervals). 
 
Undefined or estimates provided for some but 
not all outcomes. 
No information.   
15 In trials/cohort studies, do 
analyses adjust for different 
lengths of follow-up, or in 
case-control studies, is the 
time between intervention 
and outcome the same for 
cases/controls? 
Different lengths of follow-up adjusted 
for (e.g. survival analysis) and 
adequately described. 
Different lengths of follow-up probably 
adjusted for but not adequately described. 
Differences in follow-up ignored. Cross-sectional design or 
same length of follow-up. 
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Appendix 1.3 Extracted Data for HRQoL Review  
Ordered by study design 
Author 
(year) 
Quality score 
Aim Participants (demographics and clinical data)  Methods (Study Design, sampling method) Overall findings and limitations 
Daubenmier 
et al., 2006 
USA 
30/24 80% -
B1 
 
 
 
 
Assess the 
impact of 
lifestyle 
changes on 
HRQoL, 
perceived 
stress and 
sexual 
function in 
men on the 
active 
surveillance 
programme.   
PARTICIPANTS: N=93  
 
DEMOGRAPHICS:  Age Intervention group (n=44) 64.8 
(SD7.1), control group (n=49) 66.5 (SD7.6), Race Intervention 
group 84.1 white, 6.8 black, Latino 4.5, Asian American 2.3 
Other, 2.3, Control Group white 96, black 2, Latino 0, Asian 
American 2, Other 0., Married living with partner 
Intervention Group 66, Control Group 76.  Education 
Intervention group 96% college and above, Control group 
96% college and above. 
 
CLINICAL:  PSA Intervention Group 6.3 (SD 1.7) Control 
Group 6.3 (SD 1.7), Gleason score of less than 7 in the 
biopsy-documented PC group.  Localised cancer 
A randomized consent design was used to limit the amount 
of lifestyle information the control participants would 
receive. 
DESIGN:  Randomized control trial (RCT) (2 groups) 
 
TIMEPOINTS:  Baseline (before randomisation) and at 12 
months after randomization. 
 
MEASURES:  SF-36, Perceived Stress Scale, University of 
California Los Angeles Prostate Cancer Index (UCLA-PCI 
only the sexual function subscale, Lifestyle Index  
 
INTERVENTION:  Participants asked to eat plant-based 
vegan diet with 10% of total calories from fat, 3 hours 
per week of moderate exercise and 1 hour per day stress 
management practice (stretching, breathing techniques, 
etc.).  After a 1 week residential retreat, weekly support 
group meetings were held aimed at improving protocol 
adherence. 
 
 
At 12months the intervention group made significant positive 
changes to the lifestyle index compared to the control group.  BL 
intervention group 0.46 (SD 0.3), 12M 1.06 (SD 0.5), BL control 
group 0.63 (SD 0.4), 12M 0.59 (SD 0.3) (<P=0.005).   There were 
no significant changes in HRQoL between BL and 12M.  At BL 
multiple regression analysis indicated that greater lifestyle index 
scores were related to greater Physical HRQoL scores (controlling 
for age, education and BMI (F = 8.71 P<0.0001, R²= 0.28) 
 
LIMITATIONS:  Study sample was biased in favour of white 
educated men.  Study sample limited to men undergoing active 
surveillance.  
Zhang et al., 
(2006) 
USA 
21/26 81% – 
B1 
 
Assess the 
efficacy of 
support 
group and 
pelvic floor 
exercise 
training on 
HRQoL.   
PARTICIPANTS:  196 participants screened for inclusion, 58 
participants (30%) were identified as experiencing urinary 
incontinence during the past week and eligible for the study, 
N=33 (57%) consented.        
 
DEMOGRAPHICS:  Age control group (mean 60.0, SD 6.9), 
support group (mean 62.1, SD 5.7) Race control group (13 
white, 2 African-American), support group (8 white, 6 
African-American).  Martial control group (80% married, 
6.7% single, 13.3 divorced) support group (78.6% married, 
7.1% single, 14.3% separated), Education control group (60% 
had college associated degrees) support group (47% had 
college associated degrees). 
 
DESIGN:  RCT (2 groups) 
 
TIMEPOINTS:  Baselines before intervention and 3 
months follow-up. 
 
MEASURES:  Demographics data was collected.  No 
clinical data was collected.  McCorkle and Young 
Symptom Distress Scale (SDS), Medical Outcomes Study 
Physical Functioning (MOS-PF), Illness Intrusiveness Scale 
(IIL), Social Adjustment Scale (SAS), Profile of Mood 
States (POMS), Urinary Incontinence was assessed on a 
0-10 V visual analogue scale (VAS) 0 indicated 
“completely dry” and 10 indicated “completely 
incontinent”.     
There was no difference in global HRQoL scores in either group at 
3 months.  The support group reported significantly fewer 
limitations to performing vigorous activities than the control 
group at 3 months (P=0.026).  Correlations were found with 
greater urinary incontinence was significantly associated with 
greater symptom distress, more functional limitations, .and higher 
anxiety and depression (P=0.01) at both baselines and 3 months.   
 
LIMITATIONS:  Treatment modalities for the study sample were 
not identified.  Limited follow-up of 3 months.  Small 
underpowered study.  Cancer-specific HRQoL instrument was not 
used and data may not have been sensitive to capture a full 
understanding for HRQoL for the men in this study. 
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CLINICAL: T1 – T3 stages, men were screened for urinary 
incontinence and were asked a single question about 
bladder control, taken from the Barthel Index.   
 
RANDOMIZATION: This process is not clear from the paper. 
 
ATTRITION:  N=33 consented, N=3 participants withdrew 
due changes in work schedules, N=1 dropped out due to 
dissatisfaction with the assignment to the control group.  
Total of N=29 participant in results.   
 
INTERVENTION:   N=29 45 minute biofeedback session 
(licensed physical therapist) to teach pelvic floor muscle 
exercises (PFME).  After the biofeedback session the 
participants were randomized to 2 groups, control group 
(N=15) and social support group (N=14).   
Social support group instructed to attend for 6 weeks for 
2 session per week, over the period of 3 months.  Each 
group consisted of 4-5 participants’ and lasted 90-120 
minutes facilitated by a licensed health psychologist.   
Galvao et al., 
(2010) 
Australia 
34/34 100% 
– B1 
 
 
Examine the 
impact of a 
combined 
resistance 
and aerobic 
exercise 
programme 
to improve 
HRQoL.  
PARTICIPANTS:  N=97 screened for inclusion, N=57 
consented [Excluded N=40, N=19 other commitments, N=10 
refused, M=3 unable to walk 300m, N=3 already exercising, 
N=4 GP refused, N=1 illness]  
 
DEMOGRAPHICS:  Age Intervention group (mean 69.5, SD 
7.3), Control group (mean 70.1, SD 7.3),  Race no data, 
Martial Intervention group (89.7% married), Control group 
(78.6% married),    Education Intervention group (51.7% 
post-secondary education),  Control group (71.4% post-
secondary education) Employment Intervention group 
(13.8% employed) Control group (7.1% employed). 
 
CLINICAL:  Cancer stage Intervention group (93.1% localized, 
6.9% nodal metastasis), Control group (89.3% localized, 
nodal metastasis 10.7%).  Gleason Intervention group (mean 
7.2, SD 1.6), Control group (mean 7.5, SD 1.0). Hormone 
therapy. 
 
RANDOMIZATION: Randomization was assigned to 2 arms; 
exercise (intervention), or to the usual care (control).  The 
allocation sequence was concealed from the project co-
ordinator and exercise physiologist involved in assigning 
participants to groups.   
DESIGN: RCT (2 groups) 
 
TIME POINTS:  At baseline and at 12 weeks after the 
intervention. 
 
MEASURES:  Whole body, regional lean mass and 
percent fat measured by DXA.  Numerous resistance 
exercise tests, cardiovascular was assessed by walking 
400m, SF-36, EORTC-C30, blood samples (testosterone, 
PSA, insulin, glucose, CRP, lipids).  
 
ATTRITION:  N=29 (intervention) of those N=1 
discontinued the intervention, N=29 analysed (N=4 had 
missing data for the EORTC-C30); N=28 (N=1 lost to 
follow-up, N=28 analysed (N=3 missing data for the 
EORTC-C30, N=1 missing SF-36) 
 
INTERVENTION:  The exercise group undertook 
progressive resistance and aerobic training twice a week 
for 12 weeks.  Sessions were conducted in small groups 
of one to five participants under supervision from 
exercise physiologist.  Participants were encourages to 
maintain normal activity and usual diet patterns.    
Intervention group showed better score change for general health 
(P=0.022), vitality (P=0.019) and the physical health (P=0.020) (SF-
36).  C30 identified better score change role (P=0.001), cognitive 
(P=0.007), fatigue (P=0.021), Nausea (P=0.025) and dyspnoea 
(P=0.017) for intervention group.   
 
LIMITATIONS:  This study had a short follow-up; therefore, it 
would be unclear whether this intervention would sustainable in 
the longer term.  There were a large number of comparisons 
made, therefore there is a possibility that some findings occurred 
by chance. 
 
 
Carmack 
Taylor et al., 
Evaluate the 
efficacy of a 
PARTICIPANTS:  The total number of participants approached 
N=1093, well presented flow diagram of recruitment and 
DESIGN:  RCT (3 groups) 
 
There were no significant differences between HRQoL at 6 or 12 
months between the groups (across all the components of the 
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(2006) 
USA 
26/32 81% – 
B1 
 
lifestyle 
programme 
on HRQoL  
screening.  N=134 participants consented.    
 
N=46 allocated to the Lifestyle programme. 
N=51 allocated to the Education Support 
N=37 Standard Care. 
 
ALLOCATION:  Based on HRQoL, BMI and time on HT.  The 
participants were assigned a 1:1:1 ratio, to ensure equal 
numbers in the groups.  Allocation was conducted by the 
statistician or data manager. 
 
DEMOGRAPHICS:   Age 69.2 years (range 44.8-89.0).  Race 
white 73.1%, Black/African American 20.1%, Other 6.7%.  
Employment 54.4% retired, 40.3% working, 6.7% other.  
Education College degrees or advanced degree 76%. Marital 
married 82.8%.   
 
CLINICAL:  At baseline participants has been on the 
androgen-ablation therapy average of 32.7 months.  N=12 by 
orchidectomy and N=122 by HT.  
 
TIME POINTS:  Baseline, 6 months and 12 months. 
 
MEASURES:  Demographic and clinical data, SF-36, 
Centres for Epidemiological Studies (CES-D), State Scale 
of the State/Trait Inventory (STAI) Brief Pain Inventory 
(Short Form), Interpersonal Support Evaluation List 
(ISEL), 7-Day physical Activity Recall, Stage of 
Motivational Readiness for Physical Activity, Process for 
Change of Physical Activity, Decisional Balance for 
Physical Activity Questionnaire, Physical Activity Self-
Efficacy Questionnaire. 
Six-minute walk test, Body Mass Index (BMI) 
 
ATTRITION:  Low attrition rates at 6 and 12 months,  6% 
dropped out, N=5 from the Lifestyle arm, N=2 from the 
Education Support, N=1 Standard care group.  6 months 
data was collected in 83% of the sample, 12 months 
84%. 
 
INTERVENTION:  8 men per group, orientation then for 6 
months 16 weekly sessions, and 4 biweekly sessions (1 
and half hours).  Lifestyle Programme:   encouraged to 
take regular exercise, though self-monitoring, goal-
setting, overcoming barriers, understanding their caloric 
intake and exercise expenditure.  Educational Support: 
group discussion about diet, PC, side-effects of 
androgen-ablation and sexuality.  Control group: 
Standard Care. 
measures).  It was hypothesized that social support would 
improve as a result of the group interventions; the results 
indicated that social support did not significantly change over the 
6 and 12 months follow-up.  Overall, this intervention study did 
not report any significant changes in HRQoL over the 6 – 12 
months folll0w-up. 
 
LIMITATIONS:  Validity and reliability was not reported on all the 
measures.  It was reported that the sample size lacked power to 
run the study analysis.  Bias is possible as a result of the allocation 
process. 
Berglund et 
al., (2007) 
Sweden 
27/32 84%  – 
B1 
Evaluate a 
psychosocial 
rehabilitatio
n 
programme 
for men with 
PC. 
PARTICIPANTS: N=424 participants were approached, N=228 
accepted, N=17 did not return baseline questionnaires 
resulting in a sample of N=211. 
 
DEMOGRAPHICS:  Age 69 years (range 43-86) Education was 
not evenly distributed across the groups P<0.05.  College 
graduate 24%, Higher certificate 7%, Secondary school 10%, 
Vocational school 21%, Elementary school 37%.  Marital 
married 80%, Employment retired 70%. 
 
CLINICAL:  Within 6 months of diagnosis, WW N=76 (36%), 
RP N=50 (24%), RT N=21 (10%) HT N=52 (24%), Not known 
N=14 (7%).  Metastases N=42 (20%), Curative treatment 
DESIGN:  RCT (4 groups) 
 
TIME POINTS:    Baseline, 2 weeks after intervention,  
 
MEASURES:  No demographic data.  Clinical, HADS, 
EORTC-C30.   
 
ATTRITION:  From the N=211, N=23 withdrew because of 
dissatisfaction of allocation, N=19 no questionnaires at 6 
and 12 months. N=158 for the analysis.   
 
INTERVENTION:  The 3 interventions were made up of 
seven sessions and groups size varied from 3 to 10 
Overall there were no significant difference between men taking 
part in the interventions and anxiety and depression.  The 
intervention groups did not show any change in HRQoL across the 
groups, but it was the severity of cancer stage that predicted 
HRQoL.  Men with metastasis generally had a lower HRQoL than 
men without metastasis on physical function, role function, and 
financial difficulties (P<0.05).   
 
LIMITATIONS:  Only 7 sessions might not have been enough to 
obtain a significant change on outcome.  4 study reduced the 
statistical power.  Selection bias is possible and attrition bias. 
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N=76 (36%), no metastases, no curative treatment N=93 
(44%).   
participants.  The scheduling over time was not reported. 
Physical training (Phys):  Led by an experienced PT for 
60 minutes physical training followed by a 15 minute 
coffee break.  This programme included physical 
movement, fitness training, and relaxation, breathing 
exercises, slow breathing and pelvic floor.  Information 
(Info):  Led by a nurse for 60 minutes of information, 
followed by a 15 minute coffee break.  This included 
giving information about prostate cancer, treatments 
and side-effects, and actions how to deal with side-
effects.  Participants had the opportunity to discuss their 
reactions to having cancer and share their experiences.  
Demonstration of how to use incontinence or sexual 
aids, were undertaken as part of this session.  Info + 
Phys: this combined both participants has physical 
training them their information session, the total length 
was 135 minutes.  Control: The standard care they 
received as part of their standard care at their hospital. 
Parker et al., 
(2009) 
USA 
28/34 82% – 
B1 
 
Evaluating a 
stress 
managemen
t 
intervention 
study  
PARTICIPANTS:  N=221 approached, N=164 randomized  
 
DEMOGRAPHICS:  Age Standard care (control group) 60.9 
years (SD 5.9), Supportive attention group 60.7 years (SD 
7.2), Stress management group 59.8 years (SD 6.9), Race 
standard care white 92%, supportive attention group 70%, 
stress management group 71% (P=0.01), Marital married 
standard care group 85%, supportive attention 90%, stress 
management group 81%, Education college and higher 
standard care group 73%, supportive attention group 85%, 
stress management group 82%.   
 
CLINICAL:  T1 to T3 disease. 
 
RANDOMIZATION:  Use “minimization approach” which 
results in better balance of demographics in the groups.  The 
characteristic used was age <60, >60 years, partner (living 
with partner of not), type of surgical procedure (nerve 
sparing or not).  The data collection assistant was blinded to 
the participant randomization. 
DESIGN:  RCT (3 groups) 
 
TIME POINTS:  I month before RP, 1 week before RP, 6 
weeks after surgery, 6 and 12 months after surgery. 
 
MEASURES:  Demographic and clinical data. Profile of 
mood states, Impact of Events Scale, SF-36, and UCLA-
PCI. 
 
ATTRITION: N=164 baseline assessment, N=5 dropped 
out because of a lack of time to participate, left N=159 
for randomization. 
 
INTERVENTIONS:  Stress management (SM):  2, 60-90 
minutes individual sessions with a clinical psychologist 
and stress management guide, booster session in the 
morning of surgery and 48 hours after surgery.  
Supportive attention (SA):  2, 60-90 minutes individual 
sessions with a clinical psychologist focussing on 
psychosocial and medical history in a semi-structured 
format.  Psychologist used empathy and reflective 
listening skills.  Participants also had 2 booster sessions 
in the morning before surgery and 48 hours after 
There were significant differences in mood shortly before and 
after surgery.  However, at 6 and 12 months there were no 
significant differences between the groups (all P>0.05).  
Participants in the SM had higher physical function scores than 
men in the SC (P=0.0009) at 12 months No other significant 
differences for group comparisons.   Prostate specific HRQoL: 
urinary function (P=0.0001), urinary bother (P=0.0001), urinary 
limitation (P=0.0001), sexual function (P=0.004) worsened from 
baseline to 6 weeks, 6 months after surgery, but began to 
improve at 12 months after RP.  In summary SM group had short-
term improvement for mood disturbance.  Men in the SM have 
reported better physical function than other groups at 12 months.  
There were no difference between groups for the prostate 
cancer-specific HRQoL. 
 
LIMITATIONS:  Sample biased in favour of white, educated and 
married men.  Existing co-morbidities were not reported and may 
have influenced the results.  Bias is possible in randomization. 
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surgery.  Standard Care (SC):  This group had no 
meetings with a clinical psychologist and only received 
standard care. 
 
 
Northouse et 
al., (2007) 
USA 
27/32  84%  - 
B1 
 
 
A dyad study 
assessing the 
impact of 
the family 
based 
intervention. 
PARTICIPANTS:  N=429 participants were approached, N=263 
patient-spouse dyads were groups together based on stage 
of illness and treatment, than participants were randomized 
to either the control group or intervention group (selection 
rate of 68.7%). 
 
DEMOGRAPHICS:  Age participants 63 years (mean, SD 9.1), 
partners 59 (mean, SD 9.7), Race white 84%, Education 
mean 16 years of education both participants and partners. 
 
CLINICAL:  NEWLY DIAGNOSIED: 65% were in diagnosed 
phase; 60% RP, 40% RT. BIOCHEMICAL RELAPSE:  14% of the 
sample had biochemical relapse; 50% were being managed 
under observation, 50% HT, ADVANCE STAGE: 21% in 
advance (Mets) stage; 36% treated with HT, 64% receiving 
HT and chemo 
 
RAMDOMIZATION:  The data collection nurses were 
randomized to the stratification.  The type of randomization 
was not reported. 
DESIGN:  RCT (2 groups) 
 
TIME POINTS:  Baseline (before intervention), 4, 8, 12 
months after intervention. 
 
MEASURES: Demographic and clinical data, SF-12, FACT-
G, FACT-P, Appraisal of Illness or Appraisal of Care giving 
Scales, Brief Coping Orientations to Problems 
Experienced Scale, Lewis Cancer Self-efficacy Scale, 
Communication assess with the Lewis Mutuality and 
Interpersonal Sensitivity Scale, Symptoms Scale of the 
Omega Screening Questionnaire, EPIC,  
 
ATTRITION:   N=263, 235 (90%) completed 4 months 
assessment, N=218 completed (83%) both 8 and 12 
months follow-up. 
 
INTERVENTION GROUP:  Supportive-educational 
intervention called FOCUS that was initially piloted in 
breast cancer.  It consisted 3 X 90 minutes home visits 
and 2 X 30 minutes telephone calls sessions spaced 2 
weeks apart and deliver between baseline and 4 months.  
All sessions were aimed at family involvement, optimistic 
attitude, coping skills and uncertainty reduction and 
symptom management.  All delivered by intervention 
nurses trained by the PI of the study.  CONTROL GROUP:  
Received standard care from hospital. 
There were no differences in HRQoL in either study group.   There 
were also no difference in disease-specific HRQoL.   
 
Partners reported the most positive benefit from the intervention, 
better physical HRQoL at 8 and 12 months compared to their 
partner controls.  A clear point is that partners of men with 
prostate cancer should be included in intervention studies in the 
future giving the clear benefits from these reported findings. 
 
LIMITATIONS:  The results are limited to men with partners; men 
without partners were not included in this study.  Bias is possible 
in randomization.   
Monga et al., 
(2007) 
USA 
28/32 87%  - 
B1 
Assess the 
impact of 
exercise in 
improving 
fatigue and 
HRQoL  
PARTICIPANTS:  N=35 participants approached, N=30 
participants consented. 
 
DEMOGRAPHICS:  Age intervention group 68 mean (SD 4.2) 
years, control 70.6 mean (SD 5.3) years.  Race white 
intervention group N=3, black N=7, Hispanic N=1, control 
group white N=4, black N=5, Hispanic N=1, Marital married 
intervention N=7, control N=7 (there are no significant 
differences in clinical demographics between the groups).  
DESIGN:  RCT (2 groups) 
 
TIME POINTS:  before and after RT. 
 
MEASURES:  Demographic and clinical data,   
Cardiovascular fitness, flexibility, strength, fatigue, FACT-
P and FACT-G, BDI (Depression)  
 
ATTRITION:  N=30 participants consented, N=5 
Intervention group (stand and sit test, flexibility, physical 
functioning scale, physical well-being scale, social well-being, 
FACT-P) showed statistical improvements from pre-RT to post-RT.  
Control group reported significantly worse post-RT scores on the 
physical function scale and the social well-being scales compared 
to pre-RT scores. 
 
LIMITATIONS:  Small N in the groups. 
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CLINICAL:  All the participants received 7 to 8 weeks of RT, 
68-70Gy. 
 
 
withdrew, N=4 discontinued, leaving N=21 reported in 
this paper.  Missing data was not reported. 
 
INTERVENTION: Exercise intervention group N=11 
(structured exercise 3 time per week for 8 weeks) before 
RT in the morning, consisting of a 10 minutes warm-up, 
30 minutes aerobic session and 5-10 minutes cool-down.   
 
Control group N=10 usual care (unaware of the control 
arm). 
Culos-Reed 
et al., (2007) 
Canada 
23/24 95% – 
B2 
 
 
Assess 
impact of 
exercise 
intervention 
on HRQoL 
PARTICIPANTS:  N=121 participants were approached, N=63 
ineligible, N=27 refused, N=31 consented to take part. 
 
DEMOGRAPHICS:  Age 64.8 mean (SD 9.8) years, Education 
college and higher 51.6%, high school and less 48.4%.  
Employment retired 51.6%, employed 32.3%, sick leave 
12.9%, other 3.2%.  Marital married/partner 90.3%. 
 
CLINICAL:  Time since diagnosis month 33.9 mean (SD 42.1).  
Break down of clinical data not reported, i.e. cancer stage, 
previous treatments in addition to current HT. 
DESIGN:  Before and after intervention study (1 group, 
no control) 
 
TIME POINTS:  Baseline (consent), immediately after the 
intervention programme at 12 weeks, and 4 months 
follow-up after intervention. 
 
MEASURES:  Demographic and clinical data, EORTC-C30, 
Fatigue Severity Scale, Leisure Score Index of the Godin 
Leisure Time Exercise Questionnaire) Cardiovascular and 
strength, BMI height, waist to hip ratio. 
 
ATTRITION:  N=31, N=18 completed the 4 months follow-
up (58%).  There was no significant difference between 
responders and non-responders.  81% attended 5 or 6 
sessions, 16% attended 4 sessions. 
 
INTERVENTION:  12 week theory-based intervention 
design to promote daily activity.  An individualized 
programme was provided by a certified fitness 
professional (week 1), in a group based-session.  In an 
effort to foster social support, group based structured 
exercises sessions were every 2 weeks (1, 3, 5, 7, 9, 11) 
of the 12 weeks programme. 
Significant positive improvement from T1 to T2 for physical 
activity (P<0.01), fitness parameters (P<0.01), and increases in 
role functions (P<0.03) and fatigue (P<0.05) of the EORTC-C30.  
Global QoL increased but did not reach significance (PP=0.13).  4 
months fatigue severity scores increased, and global QoL scores 
decreasing significantly to below baseline levels (P<0.05).   
 
LIMITATIONS:  Small sample size, lack of a control group to 
evaluate the changes reported.  Physical actives relied on self-
report measure questionnaire; methods such as a pedometer 
reading would have provided an objective measure.   
Pendo et al., 
(2006) 
USA 
31/32 96% – 
B1 
Assess the 
efficacy of 
intervention 
study on 
HRQoL  
PARTICIPANTS:  N=592 contacted, N=271 screened, N=169 
refused, N=339 excluded, leaving N=93 enrolled in the study.  
 
DEMOGRAPHICS:  Age 65.5 mean (SD 7.6), Education years 
of education 12 mean (SD 3.5) years, Race 62% 
Cuban/American, 15% Colombian/American, 10% Central 
American countries, 4% other south American counties, 8% 
DESIGN:  RCT (2 groups) 
 
TIME POINTS:  Baseline (before intervention) and 12-13 
after baseline assessment. 
 
MEASURES:  Demographic and clinical data, Charleston 
Co-morbidity Index, FACT-G, EPIC, All participants were 
Control Measures – higher income was associated with greater 
total well-being (r=.23, P<0.06), lower co-morbid conditions (r =-
.35, P<0.01) were associated with greater physical well-being, and 
a higher educational level was associated with greater emotional 
well-being (r=.20, P=.09).  These variables were controlled for at 
relevant analyses of HRQoL. Controlling for relevant co-variants, 
the intervention group condition significantly predicted greater 
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did not identify their country of origin.  Mean years living in 
USA was 27 mean (SD15.5) years.   
 
CLINICAL:  Mean months since diagnosis was 16 (4.9) 
months.  The average number of co-morbidities was 2 (SD 2).    
N=32 RP, N=39 RT all localized disease. 
screened with the Structured Clinical Interview for DSM-
IV/non-patient edition (to exclude individuals suicidal, 
panic attacks, psychosis, substance dependence, etc.)  
 
ATTRITION:  N=53 allocated to intervention, N=1 yet to 
complete assessment, N=1 missing, N=9 withdrawn.  
N=40 allocated to control, N=3 yet to complete 
assessment, N=5 missing, N=2 withdrawn. 
 
CONTROL: Groups of 4-6 participants were invited to 
attend a half-day psycho-educational seminar tailored to 
Spanish speaking men.  4 single 1 hour sessions with 
tailored stress management/relaxation skills delivered by 
clinical psychologist.  
 
INTERVENTION:  10 week Cognitive-Behavioural Stress 
Management (CBSM) intervention, groups met once per 
week, for 2 hour sessions, including stress management 
(coping strategies, assertiveness training, etc.), and 
relaxation training (breathing exercises, deep breathing, 
etc.). 
physical well-being, emotional well-being, sexual-functioning, and 
total well-being after the 10-week intervention period.  CBSM 
improved HRQoL for men treated for localized PC. 
 
LIMITATIONS:  This study has a short follow-up; it is possible that 
the positive effects of this intervention would not be found at 
longer follow-up time points.  Small sample size.  This study used 
a screening for major cognitive impairment and is limited to 
localized disease, thus it limits the generalisabilty to more physical 
and psychologically compromised individuals with PC. 
Fransson, 
2008 
USA 
27/28 - 96%  
-B3 
To examine 
urine toxicity 
and HRQoL 
in localized 
PC 
participants 
with age 
matched 
controls 
PARTICIPANTS:  Participants N = 27 treated with 
radiotherapy for PC, Controls N = 37. 
 
DEMOGRAPHICS:  Age at time of 15 years follow-up 
participants mean 78.1 (range 62-87), controls mean 77.3 
(range 64-89) P=0.376 
 
CLINICAL:  Tumour dose (Gy) 64.8 (range 62.0-67.8).  T-
classification T1b 3, T2 21, T3 3. 
DESIGN:  Prospective longitudinal with matched controls. 
.  The control match group were individuals without 
localized PC living in the same geographical location. 
 
TIMEPOINTS:   All the participants included in the study 
answered questionnaires at 4, 8, and 15 years follow-up. 
 
MEASURES:  Prostate Cancer Symptoms Scale (PCSS), 
EORTC C30 . 
 
ATTRITION: 4 year follow-up study Participants  N = 181, 
Controls N = 141, 8 year follow-up study Participants N = 
88, Controls N = 98, 15 year follow-up study Participants 
N = 41, Controls N= 69. Reponses rates 15 years 
Questionnaires sent out Participants N = 41, Controls 69, 
Questionnaires completed Participants 29 (71%) Controls 
41 (59%), Excluded from the analysis Participants N = 2, 
Controls N = 37.  Total for the analysis Participants N = 
27 and Controls N = 37. 
 
Participants reported a limitation in daily activities caused by 
urinary symptoms at 4, 8, 15 years compared with aged matched 
controls at a significance level of (<P = 0.05).   There were no 
differences in HRQoL stratified by hormonal and non-hormonal 
treatment in the patient group.  15 years follow-up only the role 
function scale on HRQoL differed between the 2 groups at 15 
years, this was lower for the patient group (<P = 0.05).  General 
domain of HRQoL remained stable over the 15 year apart from 
the role function. Participants had worst urinary, pain, diarrhoea 
in comparison with age matched controls 15 years after RT. 
 
LIMITATIONS:  No data was presented about the BL data (pre-
treatment) on the Participants or the Controls.  Small N.  15% of 
the 181 were analysed in this results of this study.  There was no 
evaluation of disease-specific HRQoL to evaluate bowel symptoms 
a known after effects of RT. 
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Smith et al., 
(2006) 
Australia 
20/22 91%  – 
B3 
 
 
To compare 
HRQoL for 
men with PC 
with age 
match 
controls  
PARTICIPANTS:  Participants N=1642, controls N=507   
 
DEMOGRAPHICS:  Age PC participants (mean 61.2 years, 
range 37 to 69 years) Controls (mean 61.2, no range). There 
was no further demographic data available suitable for 
extraction. 
 
CLINICAL:  N=981 had RP (60%), N=289 had either RT and RT 
and hormones (18%) and N=200 was on active surveillance.   
 
Inclusion: Aged 70 years or less, localized disease, with no 
evidence of metastasis, no more than 12 months after 
diagnosis.  
DESIGN:  Prospective longitudinal with match controls. 
Controls randomly assigned electoral register matched 
by age and postcode. 
 
TIME POINTS:  Baseline (mean 3 months after diagnosis, 
range 1 to 12 months), and in the majority of case after 
primary treatment had begun, 1, 2, 3 years follow-up 
after baseline, and 1, 2, and 5 years for the control 
group.     
 
MEASURES:  Limited demographic data collected, clinical 
data, Los Angeles Prostate Cancer Index (LA-PCI), SF-12, 
International Prostate Symptoms Score (IPSS), Total co-
morbidity score.    
 
ATTRITION:  Participants PC groups N=1642 completed 
baseline, N=1599 completed 1 year, N=1530 completed 
2 years, N=1493 completed 3 years.   
 
Control groups N=507 completed baseline, N=433 
completed 2 year, and N=380 completed 5 year. 
The mental component was similar across all the groups.  Men on 
hormone therapy had lower physical score than the controls at 
baseline and 3 years.  RP participants had highest incontinence at 
1 and 3 years.  Bowel problems/function was similar at baselines 
for PC participants and controls.  Radiotherapy participants 
reported most bowel problems.  Sexual function at baseline for 
the controls N=109 (22.3%) and N=128 (27.6%) reported they 
were unable to obtain an erection firm enough for intercourse.  3 
years, nerve sparing RP N=307/494 (67.9%), RP 379/476 (86.7%), 
BT N=20/58 (36.4%), RT N=72/123 (67.9%) were impotent.  After 
controlling for relevant co-variants hormone therapy group had 
the worse sexual function.  
 
LIMITATIONS:  The baseline assessment was undertaken after 
treatment started therefore interpretation of changes in HRQoL is 
difficult.  Different numbers in both groups that may have been 
problematic for analysis. 
Anger et al., 
(2007) 
USA 
16/20 80%  – 
B3 
To compare 
PC 
participants 
access to 
free health 
care and 
men 
currently on 
the waiting 
list for free 
healthcare  
PARTICIPANTS:   Uninsured men with PC we enrolled into a 
free Low Income Uninsured Assess for Men, California 
Initiated Programme (IMPACT).  Group 1, Enrolled, N=83; 
79% recruitment rate). Group 2, Waiting list, N=83, 74% 
recruitment rate.   
 
DEMOGRAPHICS:  Age Group 1 (mean 59.0 years, no SD 
reported), Group 2 (mean 59.2, no SD reported).  Race 
Group 1 (white 21.7%, Hispanic 50.6%, black 18.1, other 
9.3%) Group 2 (white 18.1%, Hispanic 56.6%, black 14.5%, 
other 18.4%).   
 
CLINICAL:  Different cancer stages 
DESIGN:  Prospective longitudinal with matched pairs.  
Group 2 was matched by stage, age and race (P=1.00, 
P=0.88, and P=0.81 respectively). 
 
TIME POINTS:  Group 1 baseline at enrolment, 6 months 
and 18 months after enrolment.  Group 2 not clear from 
the paper, only at enrolment.   
Compared HRQoL at enrolment and assignment onto the 
waiting list. 
 
MEASURES:  RAND Medical Outcomes Study Short Form-
12 (SF-12) for HRQoL, Medical Outcomes Study Mental 
Health Index (MHI-5) for emotional well-being, McCorkle 
and Young’s Symptoms and Degrees of Distress in 
Participants with Cancer Scale (SDS) for cancer distress 
symptoms, Perceived Self-efficacy in Patient-Physician 
Interactions Questionnaire (PEPPI) for perceived self-
efficacy in interacting with physicians, UCLA Prostate 
Cancer Index Short Form, prostate cancer-specific 
HRQoL.  
Significant difference between the groups from the SF-12 was the 
general health subscale Group 1 (enrolled mean score 48) Group 2 
(waiting list mean score 40) P=0.05.  The SD and t value not 
reported.   Group 2 (waiting list) also reported significantly less 
self-efficacy than group 1 (enrolled) PEPPE (score difference of 
2.5; P=0.005).  enrolled men have less symptom distress and 
higher self-efficacy than men not enrolled in the programme.  
Overall, HRQoL was not significantly difference between the 
groups. 
 
LIMITATIONS:  Cross-sectional design does not enable causal 
relationships to be identified.  Limited clinical and demographic 
data, i.e. other co-morbidities that may influence HRQoL in this 
patient group.    Possibility for recruitment bias. 
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ATTRITION:  Only cross-sectional data reported for 
matched pairs N=83 group 1, N=83 groups 2, no missing 
data. 
Jayadevappa 
et al., 2005) 
USA 
20/22 91%  - 
B3 
 
Compare 
HRQoL in 
men <65 
years old 
with PC to 
age matched 
controls. 
PARTICIPANTS:  N=40 participants, N=40 age matched 
controls  
 
DEMOGRAPHICS:  Age PC group mean 57.7 (SD 5.2), control 
group mean 59.3 (SD 3.3) P=0.1347, Race PC group white 
91.4%, control group 91.2%  P=0.9704, Education PC College 
or more 75.53%, control 82.35 P=0.3803 
 
CLINICAL:  No statistical difference was found between the 
groups in urinary frequency, bladder infections, and blood in 
the urine, tiredness and co-morbidity.  Participants mostly 
received RP as primary treatment alone 93.75%, the 
remained received RP + HT/or RT. 
 
DESIGN:  Prospective longitudinal with matched controls. 
 
TIME POINTS:  Baseline (before treatment), 3, 6, 12, 24 
months after treatment.  Control group only completed 
baseline. 
 
MEASURES:  Demographic and clinical, Charleston co- 
morbidity Index (CHI), Medical Outcome Study Short 
Form, UCLA-PCI.   
 
ATTRITION: N= 40 men with PC and N=40 Controls.  
There were no reports of missing data in this study for 
questionnaire follow-up. 
Physical role and function, role emotional and vitality decreased 
at 3 months, improved back to pre-treatment levels at 24 months 
for participants.  Urinary function improved at 12 months and at 
maintained 24 months and   Bowel function recovered at 3 
months for participants.  Sexual function worsened at 24 months 
compared to baseline.  Predictors of 24 months HRQoL subscales: 
Sexual function: married, co-morbidities, BL sexual function. 
Urinary function: married, education, TNM stage, treatment 
Bowel function: married, co-morbidities, treatment. Social 
function: married, income, co-morbidities, baseline social 
function. Bodily pain: age, married, income, co-morbidities,  
treatment  General health: married, co-morbidity, TNM stage, 
baseline general health 
LIMITATIONS:  Small sample size.  The comparison made between 
the participants and the control was cross-sectional, thus not 
causal relationships could be tested. 
Thong et al., 
(2009). 
Netherlands 
19/22 86%   - 
B3 
Compare 
HRQoL for 
long-term PC 
men 
PARTICIPANTS:  N=71 AS and N=71 RT groups  
 
DEMOGRAPHICS:  Age AS N=70 >60 years, N=1<60 years, RT 
71> 60 years (no difference P=0.46).  Marital   Married AS 
55%, Single 14% no significant relationship, Married RT 54%, 
no significant relationship 16% (No difference P=0.92).  
Working AS not working 63%, working 5%, RT not working 
65%, working 5%. 
 
CLINICAL:   Years since diagnosis AS 7.9 mean (SD 1.3), RT 
7.7 mean (SD 1.1) (no difference P=0.33).  All PC participants 
were T1 or T2 disease. 
DESIGN:  Matched Controls (controls are men on active 
surveillance) 
 
TIME POINTS:  Mean follow-up 7.9 (years) after 
diagnosis. 
 
MEASURES:  Demographic and clinical data, Dutch 
version SF-36, Dutch validated Quality of Life – Cancer 
Survivors questionnaire, EPIC, Dutch Sexual Activities 
Module, Charleston co-morbidity Index. 
 
ATTRITION:  N=142 completed the questionnaire, no 
missing data was reported. 
No significant differences found in general HRQoL between both 
AS and RT groups, including physical and psychological well-being.  
RT groups have more symptoms than the AS groups, significantly 
poorer/lower bowel function. No significant differences between 
urinary and urinary bother scores for both groups.  RT group 
significantly worse sexual function than AS group 
 
LIMITATIONS:  Due to the cross-sectional design, the casual 
relationship between variables is not explored.  The results are 
limited to 2 treatment modalities, AS and RT.  There is the 
possibility of recruitment and responder bias as this data was not 
reported.     
Korfage et 
al., (2006) 
Netherlands 
18/20 90%  – 
B3 
 
Assess 
HRQoL for  
men with PC 
and healthy 
controls 
PARTICIPANTS:  Part of a previous PC study cohort, N=63 
were approach to take part; some participants withdrew, 
moved house, died, and loss of contact details.  N=53 men 
were interviewed.  N=53 participants, N=52 controls  
 
DEMOGRAPHICS:  Age participants 67.1 years (SD 4.3), 
controls 62.7 years (SD 4.3) P<0.001.   
 
DESIGN:  Matched pairs. (controls < than 74 years, with 
no previous benign prostate hyperplasia or PC) 
 
TIME POINTS:  Not identified in PC participants 
trajectory. 
 
MEASURES:  Interactive Internet Questionnaire 1) 
respondents level of functioning, 2) ranking of health 
No different in either group for evaluations of 5 common health 
states after the treatment of PC, no difference in the evaluation of 
urine, bowel and sexual dysfunction between the 2 groups.   
 
LIMITATIONS:  No demographic data was reported this would 
have introduced possible confounding variables.  No co-morbidity 
data was reported on the control group was this could have 
introduced a potential bias in their valuations of the patient state. 
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CLINICAL: Different treatment modalities.    descriptions, 3) evaluations of Man 1 to Man 5 by time-
trade offs (TTO). 
 
ATTRITION:  No missing data reported. 
 
Krupski et al., 
(2005) 
USA 
18/22  81% – 
B3 
 
 
 
Compare 
HRQoL for 
low-income 
men with PC, 
and age-
match 
controls 
PARTICIPANTS:  N=277 were approached of which N=181 
(79%) consented.  Non-recruits were more likely to be older 
and have progression of disease (P<0.05) 
 
DEMOGRAPHICS:  Age  60.5 mean years, Race  Hispanic 
52.5%, black 17.7%, white 22.6%, other 7.2%, Education high 
school and less 93.9%,. 
 
CLINICAL:  All participants with non-metastatic disease.   
Limited clinical data reported. 
DESIGN: Cross-sectional – matched to age controls 
 
TIME POINTS:  At enrolment of the IMPACT programme. 
 
MEASURES:  Demographic and clinical data, Charleston 
Co-morbidity Index, SF-12,   
 
ATTRITION:  N=181, N=136 were reported for this 
analysis 
HRQoL all domains participants scored <50 points below the age-
matched normative sample.  (P<0.0001).  Predictors of HRQoL: 
Physical component: Hispanic.  Mental component: co-morbidity. 
Urinary function: RP. Sexual function: age, ethnicity, RP.  Bowel 
function: Hispanic.  General and prostate cancer-specific HRQoL 
was negatively affected in low-income men with PC, compared to 
older men without prostate cancer. 
LIMITATIONS:  Treatment data was not reported the study does 
not control for clinical variation between participants.  Cross-
section design therefore the causal relationships cannot be 
identified.  Time of since diagnosis or treatment completion is not 
controlled for can introduce bias. 
Queenan et 
al., (2008) 
Canada 
18/18 100% 
– B3 
 
 
Assess the 
impact of 
social 
support on 
HRQoL for 
men with PC 
PARTICIPANTS:  N=513 participants met the inclusion 
criteria.  Random sample of N=250 were selected, and 
N=234 were mailed out.  
 
DEMOGRAPHICS:   Age 55-64 12,7%, 65-69 28.7%, 70-74 
32.5%, 75-82 26.1%.,  Marital married/partner 85.9%, 
Education College and above 39.5%,   
 
CLINICAL: All men were treated with RT.  12-72 months after 
treatment localised/locally advanced cancer. 
DESIGN:  Cross-sectional random samples. 
 
TIME POINTS:  1 time point 
 
MEASURES: Demographic and clinical data, Functional 
Support Index derived from the Multiple Outcomes 
Study Social Support Survey, structural support was 
measured using questions from the National Populations 
Health Survey, EORTC-C30. 
 
ATTRITION:  N=234, N=169 returned the questionnaire 
(84%).  . 
12.6% (moderated problem), 68.2% (big problems) with sexual 
function, 19% had a moderate/big problem with urinary function 
and 17% reported moderate/big problem with bowel function.  
General domains of HRQoL were unaffected.  Predictors of HRQoL 
were co-morbidity, urinary, bowel, sexual, hot flashes, weight 
changes, and current hormone therapy.   
LIMITATIONS:  Cross-section nature, and the causal relationship 
between social support and HRQoL cannot identified.  Selection 
bias is possible  
Jayadevappa 
et al., 2006 
USA 
26/26 100% 
–  B3 
 
Assess 
HRQoL for 
men with PC  
PARTICPANTS: N=115 (>65years) with prostate cancer  
 
DEMOGRAPHICS: Age mean: 69.5 (SD4.5) years, RP 67.4 (SD 
1.5) years, RT 71.3 (SD3.5) years (p<0.001):  Race Caucasian 
RP 97.2%, RT 65.3%  African-American RP 2.8%, RT 34.7%: 
Education High school education and less RP 27.8%, RT 49% 
College degree and more RP 72.2%, RT 51% 
 
CLINICAL: RP (n=69), RT (n=46) 
DESIGN: Prospective longitudinal. 
 
TIME POINTS: 1-2 weeks after study enrolment before 
treatment, 3, 6, 12 months after treatment 
 
MEASURES: Short Form-36, University of California Los 
Angeles Prostate Cancer Index (UCLA-PCI), Client 
Satisfaction with Care (CSQ-8), Demographic (age, 
ethnicity and health insurance data was collected). 
Charleston co morbidity score (CHS). 
 
ATTRITION: N=115, n=107 3months, n=105 6months, 
n=102 12months. 
The RP group at baseline higher physical function, role physical, 
social function and general health compared to RT group.  Bodily 
pain was lower in the RT group than the RP group.   Cancer-
specific HRQoL, the RP group reported higher scores on urinary 
function, bowel function and bowel bother at baseline.  RT group 
reported higher sexual bother at baseline.  RP group reported 
improvement after an initial decline at 3M, and had values similar 
to baseline by 12M across HRQoL domains. RT group did not show 
an improvement over the baseline values at 12M for general 
HRQoL.  Cancer-specific HRQoL at 12M for RT had better urine 
and sexual function, but worst bowel function compared to the RP 
group.  Predictors of higher 12M HRQoL: Caucasian, married, 
higher education, lower TNM classification.  
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LIMITATIONS:  Sample biased in favour of white men, and results 
limited to RT and RP. Selection and attrition bias are possible. 
Feigenberg 
et al., 2005 
USA 
24/ 23 -  96% 
– B3 
Assess 
HRQoL for 
men treated 
with BT 
PARTICPANTS: 98 participants with localised PC treated with 
BT only. 
  
DEMOGRAPHIC:  Age <70 n=65, >70 n=33: Race White n=90, 
Black n=5, Asian n=2, Other N=1: Marital Status Married/in 
relationship n= 81, Single/divorced/Widowed n=9, Unknown 
n=8:  Education Grade 1-8 only n=3, Some High School n= 11, 
High School Graduate n=22, Attended College n=49, 
Unknown n=13 
 
CLINICAL:  T1c or T2a, all treated with BT 
 
 
DESIGN:  Prospective longitudinal  
 
TIME POINTS:  Baseline before BT, 3M, 6M, 9M and 12M 
after BT  
 
MEASURES:  Functional Assessment of Cancer Therapy 
for Prostate Cancer (FACT-P) and the FACT-G (General 
measure for HRQoL).  A higher overall score indicated a 
better quality of life.  The IPSS, modified version of the 
Sexual Adjustment Questionnaire 
 
ATTRITION: 101 participants enrolled.   3 participants 
were eligible, 1 because of concurrent malignancy, 1 hip 
prosthesis and PSA performed before registration >30.   
Total of 98 participants included for the analysis.    
 
The percentage of men who reported the ability to have an 
erection decreased from 73% at baseline to 58% at 3M and 
remained stable at 12M, 59% of men.   Urinary incontinence 
increased at 14% at 6M and returned to BL level at 9months, and 
then improved below BL to 1% at 12M.    78% participants at 12M 
state they can achieve an erection with or without assistance), 
almost 50% has a worse sexual function at 12M. 
 
LIMITATIONS: 
Large proportion of missing data was reported (unclear how this 
was managed in analysis).  Sample biased in favour of white 
married men.   
 
Wickstrom 
Ene et al., 
2006 
Sweden 
23/24 - 96% 
B3 
To explore 
HRQoL for 
men treated 
by RP 
PARTICIPANTS:  Recruited from 2 hospitals 3 weeks before 
surgery. 183 participants were approached and 155 
participants consented (85%)  
 
DEMOGRAPHICS:  Age 63.1 years (range 43-73), Marital 
status 91% were married, Education about 36% have 
elementary education.   
 
CLINICAL:  Participants had to wait >3 months for their 
operation.  Pain relief at baseline; Continuous epidural 
analgesia (EDA) N=90, Intrathecal analgesia (ITA)  N=50, 
Systemic analgesia N =15 
DESIGN:  Prospective longitudinal. 
 
TIMEPOINTS:  Demographics and the SF-36 was 
completed at recruitment, the HADS was completed the 
day before surgery.  Participants post-operative 
experience was evaluated 24, 48,72 hours.  3 months 
after the operation participants were mailed the SF-36, 
HADS and questions asking about their pain experience.   
 
MEASURES: SF-36, HADS, Demographic form, ASA, pain 
treatment, length of stay in hospital. 
 
ATTRITION:  N=155 consented into the study, N= 140 
completed the 3 month follow-up (N=15 lost to follow-
up) 
 
 
Correlations between high post-operative pain in hospital and the 
length of stay in hospital (<P=0.01).  Discharge N=40 reported 
moderate/severe pain after discharge, skin incision pain, 
abdominal pain were the most commonly reported.  Patient with 
high scores for depression decreased from N=13 preoperatively, 
to N=11 at 3 months follow-up.  3 months after surgery 84% (60%) 
of the participants has reached baseline HRQoL components 
except for vitality.  The physical functioning and role-physical 
functioning had significantly decreased (<P=0.001) when 
compared with baseline.  3 months after surgery anxiety and 
depression were negatively correlated with all components of the 
SF-36 (<P=0.01).   
 
LIMITATIONS:  Recruitment bias may have been possible. 
Ficarra et al., 
2005 
Italy 
22/24 - 92% 
B3 
Evaluate 
HRQoL for 
men treated 
by RP 
PARTICIPANTS:  N=150, N=105 (70%) consented, N=30 
excluded (28.5%) because of delays in returning their 
questionnaires.  N=75 participants (71.5%). 
 
DEMOGRAPHICS:  Age 64.4 (SD 5.6, range 51-72) years, Race  
all were Caucasians, Marital status  89% were married, 7% 
DESIGN:  Prospective longitudinal. 
 
TIMEPOINTS:  Baseline before surgery, 3, 6 and 12 
months follow-up. 
 
MEASURES:  SF-36, urinary incontinence was evaluated 
The baseline values for all the SF-36 components overlapped by 
12 months.  Predictors of lower general HRQoL at 12 months: >65 
years, lower educational level, and extracapsular extension of the 
primary tumour.  3 months after surgery N=15 (20%), N=9 at 6 
months, and N=6 at 12 months were incontinent.  Men with no 
ED had significantly higher scores for general health perceptions, 
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unmarried, 1% separated and 3% widowers, Education  60% 
had no secondary school diploma, 31% had a diploma, 9% 
had a college degree. 
 
CLINICAL:   Localised cancer all treated by RP.   
 
 
using and institutional developed measure.  
International Index of Erectile Function. 
 
ATTRITION: no reported 
emotional well-being, role limitations due to physical health 
problems and energy/fatigue.  HRQoL scores were lowest at 3 
months, with a gradual improvement over the 12 months follow-
up.   
 
LIMITATIONS:  Urinary function did not report reliability or 
validity.  This study did not report participant attrition and 
selection bias is possible. 
Glabraith et 
al., (2008) 
USA 
23/34 -  95%  
- B3 
Explore 
HRQoL for 
couples 
dealing with 
PC.   
PARTICIPANTS:  N=216  
 
DEMOGRAPHICS:  Age mean  67.8 years (SD was not 
reported),  the oldest patient group was watchful waiting 
age mean 73 years,  and the youngest patient group was 
those receiving surgery age mean 61 years. Race 86% of 
participants all were Caucasians, Marital status participants 
reported being married for an average of 34.8 years, 
Education 74% had some form of college education. 
 
CLINICAL:  Participants had localised disease for stage 1 and 
stage 2.  The treatment that men underwent watchful 
waiting (N=12), Surgery N=39), conventional radiotherapy 
(N=8), Mixed beam radiotherapy (N=48) and proton beam 
radiotherapy (N=109).   
DESIGN:  Prospective longitudinal. 
 
TIMEPOINTS:  Participants and partners completed 
questionnaires just before treatment, 6 months, 12 
months and 18 months after treatment.      
 
MEASURES:  Demographic and clinical data was 
collected.  Quality of Life Index (QLI), SF-36, Dyadic 
Adjustment Scale (DAS) which is designed to evaluate 
the quality of marriage and satisfaction with the 
relationship.   
 
ATTRITION:  N=216 couples, 6 months N=198 couples, 12 
months N=187 couples, 18 months N=161 couples 
(overall attrition rate was 26%). 
 
 
Before treatment patient group reported better physical role 
functioning, emotional role functioning, mental health, less pain 
than their partners.  However partners reported higher better 
general health than the men.   6 months partners reported better 
HRQoL, but men reported better mental health at 6 months.  12 
months partners had better HRQoL and general health than 
participants at 12 months.  Men continued to have better mental 
health than their partners at each follow-up.   
 
LIMITATIONS:  Findings of HRQoL did not identify the differences 
in individual treatment modalities, with uneven participant 
numbers in each treatment modality group, thus making 
statistical comparison difficult to interpret.  Attrition rate of 26%, 
bias could be possible in the couples that dropped out who had 
different experiences with diagnosis’ and treatments.  Selection 
bias is also possible. 
Roeloffzen et 
al., (2009). 
USA 
22/22 100% 
– B3 
Assess 
HRQoL 
overtime for 
men treated 
by 
brachythera
py  
PARTICIPANTS:  N=127  
 
DEMOGRAPHICS:  Age mean 65 years (SD not reported), 
range 50-78.  No further demographic data was presented. 
 
CLINICAL: T1 or T2 treated by BT 
DESIGN:  Prospective longitudinal. 
 
TIMEPOINTS: Before treatment, 1 month, 6 months, 1 
year, and 6 years after treatment.   
 
MEASURES:  Clinical data.  RAND-36 generic health 
survey, EORTC-C30 and EORTC prostate specific module 
(PR-25) 
 
ATTRITION:  N=127 before treatment, 1 months, 6 
months and 12 months after treatment.  All participants 
were re-contacted median follow-up 6.4 years N= 102 
completed the questionnaire, of the 25 non-responders 
15 participants had died, 7 were lost to follow-up and 3 
refused to complete the questionnaire. 
 
(SF-36) Worse physical functioning 6 years compared to baseline, 
better mental health and less pain levels at 6 years compared to 
baseline. C30 physical functioning worsened at 6 years.  Emotional 
functioning, insomnia and pain levels improved at 6 years.  
Urinary symptoms/problems, bowel function and sexual function 
got worse at 6 years compared to baseline. Predictors of 6 years 
urinary symptoms: hormonal treatment, initial PSA level. Bowel 
function: prostate volume.   Older age was associated with 
diminished sexual activity at years.  Age, hormonal therapy, initial 
PSA level were predictors of poorer sexual functioning.   
 
LIMITATIONS:  Recruitment bias may have been possible, social 
and demographic data was not collected in this study, this may 
have influence HRQoL.   
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Diefenback 
et al., (2007) 
USA 
22/22 100% 
– B3 
Explored 
decisional 
regret and 
its 
associations 
with HRQoL. 
PARTICIPANTS:  N=1370 participants were contacted and 
N=986 consented and completed and return baselines 
questionnaire (72% up-take into the study). 
 
DEMOGRAPHICS:  Age (mean 65.57 years, SD 7.62, range 39-
82 years), Race 91.8% were Caucasian, Marital 82.5% were 
married, Education 24.1% had either college education or 
post-graduate education.  
  
CLINICAL:  T1 or T2 stage disease, undecided about 
treatment options.  All participants had completed their 
treatment at 6 months follow-up.   N=437 (52.1%) 
radiotherapy, N=220 (26.3%) brachytherapy, N=136 (16.2%) 
prostatectomy, N=39 (4.7%) watchful waiting, N=6 (0.7%) 
hormone therapy.  
DESIGN:  Prospective longitudinal. 
 
TIMEPOINTS: Baseline at diagnosis, 6 months and 12 
months.   
 
MEASURES: Demographic and clinical data, to reduce 
questionnaire burden only 3 items from the Sexual 
Adjustment Questions (SAQ) were used, only 3 items 
from the American Urological Association (AUA) 
symptoms index, and only 2 items from the Decision 
Regret Scale (DRS).            
 
ATTRITION:  N=986 completed baselines questionnaire, 
N=923 completed at 6 months, and N=838 completed 12 
months questionnaires. Attrition bias: results showed 
that Caucasian, married, and retired participants were 
more likely to stay in the study (P=0.01).      
 
 
Participants reported increasing sexual problems across all the 
groups at baseline, 6 and 12 months.  Overall men reported less 
urinary problems compared to sexual function problems.   
Participants’ perceptions of sexual and urinary bother were strong 
predictors of decisional regret; with decisional regret highest in 
the RP group, and HRQoL is impaired due to treatment side-
effects. 
 
LIMITATIONS:  Majority of participants (70%) were recruited for a 
radiology department, thus making a treatment bias possible for 
the highest number of participants opting for RT.  This study did 
not use the full measures of the questionnaires to reduce 
questionnaire burden, Cronbach’s alpha = ranged from .60 to 74 
for the items.   The study is limited to participants with localised 
disease; decisional regret may be different for men with more 
advance or recurrent disease.   
Guedea et 
al., (2009) 
Spain 
18/22 82%  – 
B3 
Compare 
HRQoL for 3 
treatments 
modalities 
(RP, BT and 
radiotherapy
)  localised 
PC  
PARTICIPANTS:  N=304   
 
DEMOGRAGHICS:  Age N=114 RP (mean 63.9, SD 5.8), N=134 
Conformal Radiotherapy (mean 68.8, SD 5.7), N=56 BT (mean 
67.5, SD 5.9).  No further demographics were collected.       
 
CLINICAL:  T1 or T2 disease.    Men treated by RP, BT or 
radiotherapy. 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Before treatment, 1, 3, 6, 12, and 24 
months. 
 
MEASURES:  No demographic data was collected.  
Clinical data, SF-36, FACT, Expanded Prostate Cancer 
Index Composite (EPIC).     
 
ATTRITION:  Attrition was not reported.  
Participants receiving RP were significantly younger, PSA level was 
significantly higher in the radiotherapy group than the other 
groups and BT group has the lowest mean Gleason Scores.  
Hormone therapy usage was more frequent in radiotherapy 
group.  1 month irritative and obstructive urinary symptoms were 
substantially worst in all 3 groups with recovery 3 months, except 
for the BT which was worst.  Only 15% across all groups reported 
irritative urinary symptoms at 24 months. RP had the worst 
urinary incontinence from 1 to 24months follow-up compared to 
other groups.  RP had substantially worse sexual function 
compared to other treatments.  No significant changes were 
found for the SF-36 physical or mental component across the 3 
groups over the 2 year period. Noticeable side-effects or 
brachytherapy was urinary irritation, RP incontinence and sexual 
function had a most negative impact. There were no pronounced 
noticeable effects for the radiotherapy group.   
 
LIMITATIONS:  Potential for attrition and recruitment bias is 
present.  The treatments were not randomized therefore there 
were several between group differences at baseline. 
Diefenback 
et al., (2008) 
Assess the 
impact of 
PARTICIPANTS:    N=1370 contacted, N=986 consented and 
completed baseline measures (approx 70% up-take to the 
DESIGN: Prospective longitudinal 
 
Employed participants were more likely to report worries of 
cancer recurrence, longer expected survival time and better 
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USA 
22/22 -100% 
– B3 
age on 
HRQoL for 
men with PC 
study).   
 
DEMOGRAPHICS:  Age older patient group >68 years N=192, 
Middle age group <68 years N=199, Marital Older group 
82.8% married, Middle group 52.8%., Education  Older group 
26% >college, Middle group 22.6>college, Race Older group 
95.3% Caucasian, Middle group 87.4% Caucasian.  
 
CLINICAL:  N=500 (50.7%) RT, N-215 (25.5%)  BT, N=164 
(16.9%) RP and N=62 (6.3%) active surveillance. 
TIME POINTS:  Before treatment, 6 months, and 12 
months after treatment. 
 
MEASURES:  Demographics and clinical data, Impact 
Event Scale, Decisional Regret Scale, 2 items for Worry of 
Cancer Recurrence, 1 item for Subjective Life 
Expectancy, FACT-P. 
 
ATTRITION:  Analysis limited to N=391 all EXRT 
participants and completed the 3 follow-up time points. 
functional well-being compared to unemployed.  Married men 
had better functional and social well-being compared to 
unmarried men.  Middle aged group had lower psychological 
distress and better emotional and physical well-being.  Decisional 
regret was associated with lower levels of emotional, functional, 
physical and social well-being.   Positive associations were found 
with Gleason scores and psychological distress, worries about 
cancer recurrence.   
 
LIMITATIONS:  Treatment bias, as large majority recruited from 
radiation oncology department.  Unfortunate not to report finding 
on other treatment groups and change over time.  
Davidson et 
al., (2007) 
Canada 
22/22 100% 
– B3 
Explored 
changes in 
HRQoL for 
men 
undergoing 
RP and 
decisional 
regret. 
PARTICIPANTS:  N=155 were approached, N=130 (84%) 
completed baseline data collection. 
 
DEMOGRAPHICS:  Age (mean 62.05, SD 6.02) years, 
Education 71% had more than high school education, 
Marital 85% married, Employment 56% either in part-time 
or full-time employment Race all participants were 
Caucasian. 
 
CLINICAL:  PSA 82% of men <10ng/mL, Gleason 88% between 
3-6. 
 
N=39 (30%) of study participants received neoadjuvant 
hormone therapy 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Before RP and I year follow-up. 
 
MEASURES:  Demographical and clinical data, Decisional 
Regret Scale, Control Preferences Scale, EORTC-C30 and 
EORTC-PR-25, Sexual Health Inventory for Men (SHIM) 
 
ATTRITION:  From the N=130 before surgery, at year 1 
N=25 (16%) did not return questionnaire.  A comparison 
was made between responders and non-responders no 
significant difference in age, education or sexual function 
at baseline.  
Sexual function significantly worsened at 1 year. Before RP N=99 
(76%) reported having none or mild ED.  At 1 year N=76 (77%) 
reported having moderate/severe ED.  Men who received 
hormone therapy has the worse sexual function. Change overtime 
C30: worse physical functioning 1 year compared to BL.  Improved 
emotional functioning and social functioning at 1 year.  PR-25 
significant improvement in treatment related symptoms at 1 year.  
Pain levels , worsened from before RP to 1 years.  Anorexia 
improved at 1 year.  Financial difficulties were significantly higher 
at 1 year compared to baseline. 
 
LIMITATIONS:  The number of men who received nerve-sparing 
surgery and prescribed medication for ED was not documented, 
i.e. self-management may have influenced HRQoL.  Sample biased 
in favour of white educated men 
Gellekom et 
al., (2005) 
Netherlands 
20/22 91%  - 
B3 
To assess 
changes in 
HRQoL in 
men who 
received BT. 
PARTICIPANTS:  N=127 participants consented.  Data was not 
reported on the number of participants approached. 
 
DEMOGRAPHICS:  No demographic data was reported. 
 
CLINICAL:  Cancer stage T1 and T2. 
DESIGN: Prospective longitudinal 
 
TIME POINTS:  Before BT, 1 month, 6 months, 1 year, 2 
years after implant. 
 
MEASURES:  No demographic data was reported.  Clinical 
data, EORTC-C30 and EORTC-PR-25, RAND-36 health 
survey, IPSS. 
 
PARTICIPANTS: N=127,  N=103, N=117, N=120, N=115 
and N=87 completed questionnaires (Before BT, 1 
month, 6 months, 1 year, 2 years after implant) 
respectively. 
Summary, Global HRQoL was worse 4 weeks after BT treatment 
compared with other time points, but returned to pre-treatment 
scores at 1 year.  EORTC-C30 role functioning worsened at all time 
point compared to baseline.  Emotional functioning significantly 
improved overtime at all time points and exceeded pre-treatment 
values at 2 years.  Pain scores significantly worsened overtime at 
all time points and never regained pre-treatment scores at 2 
years.  PR25- Urinary symptoms significantly worsened at all time 
points and were problematic at 2 years.   Urinary problems were 
most problematic 1 month after BT. Bowel problems significantly 
changed worsened at all time points compared to baseline scores.  
Sexual function was worse at all time points compared to 
baseline. 
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LIMITATIONS:  No demographic data was provided as this may 
have influenced HRQoL, in addition to other co-morbidities.  
Potential for recruitment bias. 
Ash et al., 
(2007) 
UK 
13/18 72% – 
B3 
Assess 
changes in 
HRQoL in 
participants 
receiving BT 
overtime. 
 
 
 
 
 
 
 
PARTICIPANTS:  N=150 were invited to take part, N=127 
consented and returned baseline data (84.7%)  
 
DEMOGRAPHICS:  No demographic data reported. 
 
CLINICAL:  Neoadjuvant hormone therapy and BT.  The 
hormone therapy was discontinued after BT.  N=67 (58%) 
received hormone therapy. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Before BT, 6 weeks, 6 months, 10 months, 
18months, 24 months.  (Based in clinical follow-up time 
points).   
 
MEASURES:  No demographic or clinical data.  
International Prostate Symptom Score (IPSS), Expanded 
Prostate Index Composite (EPIC) 
 
PARTICIPANTS:  N=150, N=116 at all time points (77%) 
response rate.  Differences between responders and 
non-responders were not reported. 
Urinary function worsened at 6 weeks and urinary function 
gradually improved over the first year.   6 weeks there was 
considerable urinary irritation and obstruction and some 
incontinence.   Bowel function at baseline was not high in this 
patient group, at 6 weeks bowel symptoms worsened from BL 
92.2 summary score, to 6 weeks after BT to 84.7 summary score, 
most common symptom loose stools. Sexual functions 
significantly lower for men treated by hormone therapy.  
 
LIMITATIONS:  No measure of general HRQoL.  Selection and 
attrition bias are possible.  No demographic data and no co-
morbidity data as possible confounders.  
White et al., 
(2008) 
USA 
14/24 58%  – 
B3 
Assess 
HRQoL of 
men with 
locally 
advanced 
PC. 
PARTICIPANTS:  Total 13, 740 men in the CaPSURE database, 
N=608 had locally advanced PC, N=151 completed the 
questionnaires at all the time points. (25%). 
 
DEMOGRAPHICS:  Age (mean 68, range 44-91).  No further 
demographics reported. 
 
CLINICAL:  N=31 RP, N=12 cyrotherapy, N=26 BT, N=82 HT.   
DESIGN: Prospective longitudinal. 
 
TIME POINTS:  Baseline (not clear what baseline is), 1, 2, 
3 years after treatment. 
 
MEASURES:  Age, clinical data, SF-36 and the UCLA-PCI. 
 
ATTRITION  A comparison between responders and non-
responders was not reported for all treatment groups. 
Age had a significant impact on all aspects of the SF-36, in 
addition to urinary function/bother and bowel function. Mental 
well-being (SF-36) gradually improves over time and exceeded 
baseline values.  Urinary and sexual problems also significantly 
worse at 1, 2, 3 years compared to baseline.   Urinary function 
gradually improved at 1, 2, 3 years compared to baseline.  No 
significant change over time for bowel dysfunction, this could be 
explained as no participants received RT in this reported paper. 
 
LIMITATIONS:  Selection and attrition bias are possible.  The 
usages of nerve sparing surgical techniques are not identified, as 
previous research identifies significant differences in HRQoL using 
this technique.  HRQoL of men received RT was also not reported.   
Choo et al., 
(2006) 
USA 
21/24 87% – 
B3 
Examine the 
effects for 
combined 
treatment in 
participants 
with T3 
cancer on 
HRQoL  
PARTICIPANTS:  N=78  
 
DEMOGRAPHICS:  Age 61years old (median) at time of RP.   
 
CLINICAL:  N=48 had undetectable PSA levels 3 months post-
op, N=30 has detectable PSA.   
 
All men were treated with radiotherapy (median time 4.2 
months) post-op.  HT was started within 2 weeks of receiving 
radiotherapy for 2 years.  N=13 of the N=78 terminated HT 
prematurely, at a mean of (13 months).   
DESIGN:   Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment), 3 weeks in to 
RT, 6 weeks in to RT treatment, 2 months at the start of 
HT, 6 months HT, 10 months, 14 months, 18 months, 22 
months. 
 
MEASURES:  Age, clinical, EORTC-C30 + PR25. 
 
ATTRITION:  N=78, N=70 completed the 2 year follow-up, 
N=8 had incomplete follow-up data.  All the follow-up 
data was included in an intention to treat analysis. 
Bowel dysfunction significantly worsened at the end of 
radiotherapy and improved at 6 months.  Urinary dysfunction was 
maximal at the end of RT.  The increase in urinary dysfunction lost 
statistical significance at the 2 months visit, and there was no 
significant change from baseline function.  Fatigue, pain, insomnia 
and diarrhoea statistically worsened from baseline though out the 
follow-up.  None of the global or functional domains reached any 
statistical significant change from baseline.  N=13 of the N=78 
terminated HT prematurely, at a mean of (13 months).  The most 
common reasons reported was hot flushes in N=5, fatigue in N=2, 
gynecomastia, elevated liver enzymes, deep vein thrombosis, 
arthralgia, hypertension, and a rash, N=1 respectively.  
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LIMITATIONS:  Selection and attrition bias are possible.   
Buron et al., 
(2007) 
France 
19/20 95%  – 
B3  
  
Compares 
HRQoL for 
participants 
treated with 
either BT or 
RP.  
PARTICIPANTS:  N=435 
 
DEMOGRAPHICS:  Age RP (mean 62.7, SD 6.0), BT (mean 
65.2, SD 6.3), P=0.0003.  Education RP low 39.3%, middle 
27.9%, high 32.8%, BT low 32.0, middle 32.0, high 36.0, 
P=0.0083.  
 
CLINICAL:  N=308 BT, N=127 RP.  RP 86% treated with 
retropubic, 14% treated laparoscopic.  N=9 (7%) received 
adjuvant RT.   
 
 
 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment), end of 
treatment, 2, 6, 12, 18, 24 months after hospital 
discharge. 
 
MEASURES:  Demographic, clinical, EORTC-C30 and PR25, 
cost measures. 
 
ATTRITION:  N=435 , RP 41%, BT 65% completed the full 
follow-up at 24 months.  Overall response rate baseline 
92%, 6 months 72%, and at 24 months 58% for all the 
men in the study.  Men in the BT group were more likely 
to return the questionnaires than the RP group. 
 
 
 
 
 
 
 
 
 
 
BT group showed an initial decrease in global HRQoL between T1 
and T2 (-5.8 points, P<0.0001) this was the largest decrease.  At 
subsequently follow-up the global HRQoL change was not 
significant.  RP group also showed an initial decrease in global 
HRQoL from baseline to the end of treatment (-18.0, P<0.0001), 
and recovered rapidly between 2 and 6 months which was no 
longer significant subsequent follow-up time points.  Better role 
function was in favour of BT group.   No significant changes in any 
other subscales of the C30 for both groups.  Urinary incontinence 
problems were more frequently reported in the RP than the BT at 
all time points.  Urinary symptoms, faecal incontinence and rectal 
bleeding were more frequently reported in the BT than the RP 
group.  Erectile function was at its worse for the RP at 6 months, 
88% of sexually active men reported poorer erectile function than 
at baseline, compared to 50.8% of BT.  Problems persisted at 18 
months RP 83.3%, BT 45.8%, reported poor erectile function.  
Treatment for impotence was more common in the RP 32% vs. 
12.5% BT group.  
 
LIMITATIONS:   An RCT would have potentially controlled for 
confounders that may have entered in the analysis.  Different 
questionnaire response rate for BT and RP, may have introduced 
potential bias.  In addition, the studies aim was to compare both 
BT and RP, however, a larger proportion of the BT had had 
hormone therapy, from existing evidence HT has a worsening 
effect on HRQoL. 
Chen et al., 
(2008) 
USA 
22/22 100%  
- B3 
 
Assess 
HRQoL for 
men with 
localized 
prostate 
cancer. 
PARTICIPANTS:  N=522  
 
DEMOGRAPHICS:  Age RP (median 60, range 46-74), NSRP 
(median 59, range 46-72), NNRP (median 62, range 50-74), 
RT (median 69, range 51-82), BT (median 64, range 47-77).  
Education College and above RP 90%, NRP 88%, NNRP 94%, 
RT 76%, BT, 87%, Marital married 91%, NRP 89%, NNRP 94%, 
RT 83%, BT 83%, Race white RP 99%, NRP 99%, NNRP 100%, 
RT 95%, BT 91%. 
 
CLINICAL:  RP N=127: NRP N=74, NNRP N=53, RT N=190, BT 
82.   
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline before treatment, 3, 12, 24, 36 
months after treatment. 
 
MEASURES:  Demographic and clinical data, Index of Co-
Existent disease, PCIS. 
ATTRITION:  N=522, N=84 withdrawn participation 
before the 36 months follow-up, N=438 (84%) response 
rate.  Comparisons were made between responders and 
non-responders and no statistical difference reported.  
Only N=409 results are reported based on the most 
common treatments RP, RT and BT. 
RP and BT men were significantly younger and had less co-
morbidity than the RT group. All treatment groups reported 
worsening sexual dysfunction over time.  Bowel problems were 
different based on treatment modality, RP did not lose function, 
whereas RT did.  Urinary incontinence developed in more than 
twice as many surgical participants as RT and BT participants at 36 
months.  Summary, participants’ baseline function significantly 
influences the magnitude of change HRQoL at follow-up. 
 
LIMITATIONS:  This study has a large proportion of white 
educated participants that reduces generalisabilty.  It is possible 
for recruitment bias. 
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Caffo et al., 
(2006) 
Italy 
21/22 95% – 
B3 
Assess 
HRQoL in 
participants 
with 
localized PC 
treated with 
BT. 
PARTICIPANTS:  N=206 approached, N=29 refused, N=30 did 
not receive the baseline questionnaires because of 
organisation failure.  N=147 in the follow-up study.   
 
DEMOGRAPHICS:  Age  67 (median, range 52-77) Race not 
reported, Marital married N=124 (84.5%), Education  47.6% 
only went to primary education, 19.3% middle school, 23.5% 
high school, 7.5% university, 2.1 unknown.    
 
CLINICAL:  all men T1-T2 treated with BT.  HT N=70 (47.3%) 
received treatment. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  I week before BT, 1 month, 1, 2, 3,4 years 
after treatment. 
 
MEASURES:  Clinical and demographic, HRQoL measure 
(the title not reported, but they report that this is a 
validated tool) used in PC studies. 
 
ATTRITION:  N=147, only N=16 questionnaires were lost 
to follow-up.  A comparison between responders and 
non-responders were not reported. 
Urinary function worsened at 1 month after treatment and 
gradually improved overtime, final follow-up was not significantly 
different from baseline.  Bowel function significantly worsened 
after BT but improved at 1 year.  N=74 declared regular sexual 
activity, N=70 no activity at baseline.  Reported predictors of 
better sexual function were age ≤67 years, not receiving HT, and 
those who did not have PVD.  No significant difference was 
observed for general physical well-being, mental well-being, social 
relationships, and physical anatomy at 1 month after treatment.   
 
LIMITATIONS:  Authors identify caution is required when 
interpreting the findings because the men may view BT as a 
modern technique that avoided the symptoms of the well-known 
traditional treatments, therefore their optimistic view may 
influence their responses.  Attrition bias is possible 
Brar et al., 
(2005) 
USA 
22/24 91%  - 
B3 
Assess 
HRQoL in 
men PC 
living in 
poverty. 
PARTICIPANTS:  N=184, N=41 excluded because of 
metastatic disease, N=5 with second primary cancer, leaving 
sample N=138 for the analysis.   
 
DEMOGRAPHICS:  Age <60 N=38 (28%), 60-65 N=79 (57%), 
>65 N=21 (15%), Race white N=35 (25%), Latino N=73 (53%), 
African American N=22 (16%), other N=8 (6%), Marital 
married/living with partner N=85 (62%), significant other but 
not living together N=17 (12%), no significant other N=36 
(26%), Monthly income $0 N=85 (62%), $1-1500 N=91 (66%), 
>$1500 N=11 (8%), Education High school non graduate 
N=58 (42%).  
 
CLINICAL:  HT N=7 (5%), RP N=78 (57%), WW  
N=8 (6%), RT N=45 Co-morbidities 0-1 N=81 (62%), ≥2 N=49 
(38%)  
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (3 months after enrolment of the 
IMPACT programme) and 6 months follow-up. 
 
MEASURES:  Clinical and demographic data, UCLA-CPI 
short form-15, SF-12, Medical Outcomes 5-item study 
Mental Health Index. 
 
ATTRITION:  N=138, N=85 (61%) did not complete all the 
measures.  Comparisons were made between 
responders and non-responders no significant difference 
was found in the demographic or clinical data.  
Controlling for age, race, baseline HRQoL measures and treatment 
effects, participants with higher Gleason scores experienced more 
negative effects on HRQoL.  Men with less than high school 
education had the greatest improvements in mental well-being.  
Bowel and urine function improved from baseline to 6 months.  
Prostate cancer-specific HRQoL components showed an 
improvement at follow-up in all domains except for sexual 
function.  
 
LIMITATIONS:  Limited follow-up of 6 months, potential for 
selection bias. 
Dalkin et al., 
(2005) 
USA 
19/22 86%  - 
B3 
To assess 
HRQoL from 
a single 
surgeon for 
participants 
being 
treated with 
RP.   
PARTICIPANTS:  N=176 men enrolled 
 
DEMOGRAPHICS:  Age (mean 62.9, range 35-79).  No further 
demographic data reported. 
 
CLINICAL:  PSA (mean 8.5 ng/mL, range 0.5-60), Gleason (5-6 
= 67%, 7 = 27%, 8-10 = 6%) 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before surgery), 1 and 2 years 
after treatment. 
 
MEASURES:  Age, clinical data and SF-26 and the UCLA-
PCI. 
ATTRITION:  N=176, N=158 (90%) complete 1 year 
follow-up, and N= 105 (82%) completed the 2 year 
follow-up.   
There were no significant changes in general components of 
HRQoL at year 1 or year 2.  Men reported being pad free from 
urinary incontinence pad-free in 82% at years 1, and 89% at year 
2.  N=22 used it as a safety liner, N=6 truly needed a pad at 1 year.  
Younger men (<60 years) and having NRP did not have any better 
urinary function.  Sexual function worsened at 1 and 2 years.   
 
LIMITATIONS: Selection and attrition bias are possible and limited 
demographic data provided and therefore limited the 
generalisabilty of the findings.   
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Couper et al., 
(2009) 
Australia 
22/24 91  - 
B3 
Compare 
anxiety, 
depression 
and HRQoL 
in men PC.   
PARTICIPANTS:  N=211  
 
DEMOGRAPHICS:  Age (mean 66.15, SD 8.26, range 43-92), 
Marital married/living with partner 78.3%, Occupation 
employed 36.8%, Retired/unemployed 63.2%.  
 
CLINICAL:  WW N=61, RP N=38, HT N=56, RT N=193 [at time 
1].  The distribution of treatments for the full N=211 is not 
reported. 
DESIGN:  Prospective longitudinal. This study used WW 
as the control group. 
 
TIME POINTS:  Baseline (before treatment), after 
treatment and 1 year after treatment. 
 
MEASURES:  Demographic and clinical data.  SF-36, Brief 
Symptoms Inventory (BSI-53) to measure anxiety and 
depression. 
 
ATTRITION:  Of the N-211, N=193 completed time 1 data, 
and N=172 (89.1%) completed time 2 data.  The 
difference between responders and non-responders was 
not reported. 
Time 1 HT, RP and RT experienced worse HRQoL than the WW 
group.  The HT groups had significantly worse depression scores 
than the WW group. Role physical function was significantly lower 
at time 1 for 3 treatment groups in comparison to the WW group.  
Vitality scores in the HT and RT groups were also significantly 
worse at time 1 compared to the WW group.  1 year the HT group 
had significantly worse scores on anxiety, depression, physical 
function, role physical function, pain, general health and vitality.  
3 groups treatment groups experienced initial worse HRQoL 
compared to the WW group, however the HT group continued to 
report worse HRQoL at 1 year and an increase in anxiety and 
depression. 
 
LIMITATIONS:  This paper acknowledges that recruitment in clinics 
introduces the possibility of recruitment selection bias, as not all 
men with PC in the community have the opportunity to be 
recruited.  Attrition bias is also possible.  There was no measure of 
prostate cancer-specific HRQoL. 
Sanda et al., 
(2008) 
USA 
22/22 100% 
– B3 
Assess 
HRQoL in 
men and 
their 
partners 
treated for 
localized 
prostate 
cancer. 
PARTICIPANTS:  N=1201 participants and N=625 partners 
consented.   
 
DEMOGRAPHICS:  Age (median age 63 years, range 38-84), 
Race  white RP 91%, white RT 82%, BT white 85%, Education 
College graduate and above RP 62%, RT 52%, BT 55%, 
Marital married RP 87%, RT 77%, BT 70%.  Partners of who 
99% were female, Age (median 59 years, range23-89) and 
younger than participants P<0.001.   
 
CLINICAL:  RP=602, RT N=292, BT N=306. BT group N=35 
received combination BT and RT/and also HT.  RT N=90 
received RT + HT.   
 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Patients: baseline before treatment, 2, 6, 
12, 24 months after treatment.  Partners: 2, 6, 12, 24 
months.   
 
MEASURES:  Demographic and clinical data. Expanded 
Prostate Cancer Index Composite, Service Satisfaction 
Scale for Cancer Care (SCA),  
 
PARTICIPANTS:  N=1201 N=112 did not complete the 
follow-up for the following reasons; N=12 died (from 
other causes not related to PC), N=84 withdrew, N=16 
missing data.  There was not reported comparison 
between responders and non-responders. 
Key predictors of HRQoL stratified by treatment group: sexual 
function: RP group: age, PSA level, nerve sparing technique.  RT 
group: age, prostate size, neoadjuvant HT. 
BT group: age, PSA score.  Urinary incontinence: RP group: age, 
black race.  RT group: PSA level.  BT group: neoadjuvant HT, 
combination with RT. Urinary irritation or obstruction: RP group: 
prostate size. RT group: prostate size, neoadjuvant HT. BT group: 
prostate size, PSA level, clinical stage, neoadjuvant HT.   Bowel 
dysfunction: RP group: co-morbidity. BT group: Gleason score 
above 7.  Vitality: RP group: obesity. RT group: obesity, prostate 
size, neoadjuvant HT, co-morbidity. BT group: prostate size, age, 
neoadjuvant HT, combination boost with RT. 
Urinary incontinence was at its worse by 2 months after surgery 
and gradually improved in most patients, whereas symptoms of 
urinary irritation/obstruction improved after treatment in the RP 
group.   In the RT group urinary symptoms resolved at 12 months 
and improved over baseline score at 24 months.  The BT group 
had the worse urinary irritation at all the follow-up time points 
compared to baseline (P=0.001).  BT and RT reported significantly 
worse bowel function compared to baseline, but recovered at 1 
year.   
Sexual function was better in participants that received NRP, 
compared to those men who did not.  RT group sexual function 
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was worse for men who received HT compared to those who did 
not.  Worsening reports of sexual function from patients were 
reflected by distress from partners RP 44%, RT 22%, BT 13% by 
partners. 
  
LIMITATIONS:  selection and attrition bias are possible and limits 
the generalisabilty of the findings.  
Gacci et al., 
(2009) 
Italy 
19/24 79% –  
C1 
Assess 
HRQoL in PC 
men who are 
disease free 
at 5 years. 
PARTICIPANTS:  N=367. 
 
DEMOGRAPHICS:  Age mean 64.8 (median 66, range 47-77). 
 
CLINICAL:  PSA mean 14.6 ng/mL, TNM stage T2 N=222 
(60.5%), pT3a N=77 (21%), pT3b N=59 (16%), T4 N=9 (2.4%).  
NRP was performed in N=125 (34%).N=76 (20.7%) received 
adjuvant HT. 
DESIGN:  Prospective longitudinal only one time point 
reported 
 
TIME POINTS: N=307 5 year follow-up (mean 95.5 
months, range 61 to 156), N=60 the follow-up was 60 
months.   N=60 had a follow-up at 5 years, N-146 had 
follow-up 7-7 years, N=81 follow-up 8-9 years, N=80 
follow-up 10 years and more.  
 
MEASURES: Age and clinical data, Italian version of the 
UCLA-PCI. 
 
ATTRITION:  N=367, no missing data reported 
Associations of HRQoL: Urine function: age, PSA, TNM stage, 
Gleason, HT.  Sexual function: age, follow-up time, PSA, TNM 
stage, Gleason, HT.  Age, clinical variables, and HT were associated 
with worsening function and bother. 
 
LIMITATIONS:  This study lacked baseline HRQoL for a comparison 
of outcomes at 5 years.  No general HRQoL measure was used.  
Demographic data for this patient group was not reported and 
selection bias possible that reduced the generalisabilty of the 
findings.. 
Van de Poll-
Franse et al., 
(2008) 
USA 
21/22 95% -  
B3 
Assess the 
impact of 
cardiovascul
ar disease 
(CVD) on 
HRQoL in 
men with PC. 
PARTICIPANTS:  N=830 (Cancer of the Prostatic Strategic 
Urological Research Endeavour (CaPSURE). The recruitment 
rate 74%. 
 
DEMOGRAPHICS:  Age stratified by Total Illness Burden Index 
(TIBI): none N=293 (mean 63.7, SD 7.8), TIBI Mild N=293 
(mean 64.9, SD 7.8), TIBI Moderate N=51 (mean 66.9, SD 
7.3), TIBI Severe N=51 (mean 67.2, SD 7.1): P<0.0001. Race 
white TIBI no 93%, TIBI Mild 94%, TIBI 97%, TIBI Moderate 
97%, TIBI Severe 88%: P=0.10.   
 
CLINICAL:  Men had stage T1-T3 disease, treated with RP, BT 
or RT.   
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (pre-treatment), 6, 12, 18, 24 
months after treatment. 
 
MEASURES:  Demographic and clinical data. RAND 36 
Health Survey, UCLA- PCI, Total Illness Burden Index 
(TIBI). 
 
ATTIRTION:  Of the N=830, N=78 had 2, N=216 had 3, 
and N=536 had 4 completed questionnaires.  Differences 
between responders and non-responders were not 
reported. 
At BL generic and disease-specific HRQoL was negatively 
associated with increasing CVD P<0.0001 in all sub-components.  
HRQoL scores were worse for men treated with RT.  Men with 
moderate or severe CVD had the worse SF-36 physical and mental 
scores, and worse bowel function at all-time points (P=0.05).  Men 
with severe CVD also experienced a slower recovery for physical 
functioning and sexual functioning.  In summary, men with PC 
who have CVD can experience lower HRQoL and a slower return 
to baseline over time. 
 
LIMITATIONS:  The presence of TIBI was only checked at baseline; 
therefore, the co-morbidity of disease may have change overtime 
for the study participants. Recruitment and attrition bias are 
possible.      
Fransson et 
al., (2009) 
Sweden 
21/24 87% – 
B3 
Assess 
HRQoL in 
men with 
localised PC 
in 
participants 
receiving RT 
PARTICIPANTS:  N=72, N=54 (77% response). 
 
DEMOGRAPHICS:  Age RT (median 77 years, range 54-87), 
WW (median 78, range 65-88).  No further demographics 
reported.  
CLINICAL:  T1 or T2, N=27 (RT) and N=27 (WW) 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  4 years after diagnosis and 10 years. 
 
MEASURES:   Age and clinical data, EORTC-C30, PCSS. 
ATTRTION:  Missing data occurred in RT 3% and WW 4%, 
no differences were found between responders and non-
Cognitive score change for the RT (difference of -11.3; P=0.034) 
indicating a worsening function.  In the WW group the physical 
functioning (difference of -11.5; P=0.041) worsened over the 
follow-up time period also.  RT group fatigue was worse over 
time.  WW group worsening insomnia and financial difficulties 
over time.  N=5 (19%) in the RT group, N=2 (7%) in the WW group 
used pads to manage urinary incontinence at 10 years. No 
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and WW. responders. significant difference was found in bowel function for the groups. 
No significant difference in erectile function in either group over 
time.   
 
LIMITATIONS:  Small N.  This study lacked baseline data, thus 
caution is given for interpretation of the study findings.   
Galbraith et 
al., (2005) 
USA 
23/24 95%  – 
B3 
Assess 
HRQoL in 
men with 
localised PC  
PARTICIPANTS:  Participants N=192 approached, N=137 
completed (71%); Partners N=126 approached N=104 
completed (83%). 
 
DEMOGRAPHICS:  Age participants (mean 70 years) with 
WW participants being the oldest and RP being the youngest 
(F=5.1, P<0.001).  Marital 80% participants married.  
Education 71% attended college and more.  Race white 86%, 
hispanic 6%, black 5%, Asian 2%, undisclosed race 1%.   
 
CLINICAL:  WW N= 21, RP N=39, convention RT N=18, Proton 
beam RT N=21, Mixed beam RT N=37, low dose mixed beam 
RT N=25, high dose mixed beam RT N=31. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  2.5, 3.5, 4.5, 5.5 years after treatment. 
 
MEASURES:  Demographic and clinical, Quality of Life 
Index, SF-36, Southwest Oncology Group Prostate 
Treatment-Specific Symptoms Measures, Dyadic 
Adjustment Scale. 
 
ATTRITION:  N=20 died (N=4 from prostate cancer), N=6 
from other illnesses such as cardiac disease and other 
cancers, N=10 from unknown causes.   
HRQoL decreased for all groups over the 4 years of follow-up.  At 
5.5 years WW groups had lowest HRQoL scores.  Men in the low 
dose mixed beam RT group had better physical role function than 
men in the RP group.  Vitality decreased in all groups.  Social 
functioning score differed in all the groups, however the WW 
reported the worse scores after treatment.  General health 
decreased in all the groups over the follow-up.  Low dose mixed 
beam RT groups reported better general health, fewer GI 
symptoms than the high beam mixed dose RT and the WW group.  
Urinary symptoms increased over the study for all the groups, but 
WW group reported the most urinary symptoms.   Sexual 
dysfunction was problematic for all groups at each time point.  7% 
reported that their erections were adequate for intercourse, 66% 
reported that their erections were not adequate to be able for 
penetration.  Only 27% received treatment for erectile 
dysfunction.   
 
LIMITATIONS:  No baseline data reported in this patient group 
that make change over time and interpretation of the findings 
difficult.  Selection bias is possible.   
Zavala et al., 
(2009) 
USA 
22/24 91%  -  
B3 
Assess the 
impact of 
spirituality 
on HRQoL in 
men with 
metastatic 
PC.  
PARTICIPANTS:  N=144, N=101 consented 
 
DEMOGRAPHICS:  Age <60year 31%, 60-65 38%, >65 30%.  
Race  white 20%, Latino 62%, African-American 10%, other 
8%).  Martial in a significant relationship 71%, no significant 
relationship 29%.  Education high school <46%, high school 
graduate 41%, College graduate 14%.   
 
CLINICAL:  Co-morbidities 0-1 79%, >2 21%.  Gleason >6 97%, 
Treatments RP N=16, RT N=10, HT N=83, Chemotherapy 
N=20, Ketoconozole and hydrocortisone N=5.   
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  At enrolment to IMPACT, and 6 months 
follow-up. 
 
MEASURES:  Demographic, clinical data, FACIT-Sp, UCLA-
PCI, SF-12, PEPPI, Charleston Score (co-morbidities). 
 
ATTRITION:  N=101, N=1 was excluded because an 
administrative form was not completed, N=88 
completed the questionnaires, N=2 did not complete the 
spirituality questionnaire. Leaving total sample in this 
study N=86. 
Ethnicity was a predictor of dichotomised high and low spirituality 
scores .  Highest spirituality scores were in less-educated, Latino 
and African-American men.  Spirituality was significantly 
associated with physical, mental component, bowel function, SF-
12 pain and self-efficacy.  In sum, reported higher spirituality 
scores were associated with higher HRQoL domains. 
 
LIMITATIONS:  Small N, High percentage of Latinos, the sample did 
not have an even spread of ethnic individuals, thus bias may have 
been possible and limits generalisabilty. 
Stephens et 
al., (2006) 
Assessing 
HRQoL in 
PARTICIPANTS:  Trial data. N=862 participants were enrolled, 
N=843 were randomised in 25 centres in the UK, Australia 
DESIGN:  Prospective longitudinal. 
 
Sexual function score worsened during the short time on receiving 
HT.  No improvement was found for urinary function over time.  
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UK 
20/22 90% – 
B3 
 
participants 
receiving 
neoadjuvant 
hormone 
therapy 
before RT. 
and New Zealand.  N=290, N=319 and N=290 had data 
available to answer the hypothesis in this paper. 
 
DEMOGRAPHICS:  Age (median 67, range 63-71).  No further 
demographic data reported. 
 
CLINICAL:  Stage T1 to T3, PSA <50ng/mL, no previous PC 
treatment.  Participants received androgen suppression 
using LHRH at 4 weekly intervals in conjunction with an anti-
androgen to prevent ‘flare’ initially. 
TIME POINTS:  Before HT treatment and before RT. 
 
MEASURES:  Age, clinical and UCLA-PCI, PACT-P. 
 
ATTRITION:  All data was available. 
Participants’ physical well-being declined whilst being on HT. 
Overall, men’s ability on HT showed the greatest decline in their 
ability to maintain sexual function. 
 
LIMITATIONS:  There was no control group to establish the full 
extent of treatment effects such as a control group match base 
age, pre-existing co-morbidity and socio-economic variables.  .   
Sullivan et 
al., (2006) 
USA 
21/24 87%   - 
B3  
Assess 
changes in 
HRQoL in 
men with 
Hormone 
Refractory 
PC (HRPC). 
PARTICIPANTS:  Data for the paper was collected as part of a 
phase III trial.  N=809. 
 
DEMOGRAPHICS:  Age median age 72 years. 
 
CLINICAL:  Median survival time was 491 days, the medial 
time to disease progression was 85 days, the median time to 
bone pain was 86 days.  N=690 had bone metastasis, N=97 
soft tissue metastasis, N=22 no metastasis. 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline study entry, 4 weeks, and every 
12 weeks. 
 
MEASURES:  Age and clinical data, EORTC-C30, FACT-G 
and the FACT-P, FACT Advanced Prostate Symptom 
Index.   
 
ATTRITION:   Before baseline data collection N=29 died, 
N=262 had disease progression.  Baseline and 12 weeks 
HRQoL compliance was 95-96% and 88% to 90% for the 
FACT, and EORTC, respectively. 
In participants with HRPC, Gleason scores, PSA, Bone alkaline 
phosphatase, lactate dehydrogenase and performance scores 
(Karnofsky Performance scale) were all significant predictors of 
mortality.  When baseline HRQoL was added to the model, scores 
greater than the median was a significant predictor of mortality.  
Better baseline HRQoL scores predicted better survival, time to 
disease progression and pain prognosis than those with worse 
baseline HRQoL scores.  It appears that greater deterioration in 
HRQoL scores is prognostic for rapid disease progression.   
 
LIMITATIONS:  No demographic data was presented in this study, 
and limits the generalisabilty of the findings. 
Lev et al., 
(2009) 
USA 
21/22 95%  – 
B3 
 
 
Assess 
HRQoL for 
men treated 
with RP, 
Intensity 
Modulated 
Radiotherap
y (IMRT) + 
High Dose 
Radiation 
(IMRT + 
HDR), or 
IMRT + BT. 
PARTICIPANTS:  N=159 
 
DEMOGRAPHICS:  Age mean 63.8 (range 42-82 years).  Race 
white 86%, Education approx 50% college graduate. 
Employment approx 50% employed. 
 
CLINICAL:  RP N=49, IMRT+HDR N=49, IMRT +BR N=61 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment) 6, 12 months 
after treatment. 
 
MEASURES:  Demographic and clinical data, Prostate 
Symptom Self Report (PSSR), Symptoms Checklist 90 
Revised Anxiety Subscale (SCL-90-R Anxiety Subscale), 
PSS, The Centre of Epidemiological Studies Depression 
Scale (CES-D), Strategies Used by Participants to Promote 
Health (SUPPH), FACT-P,  
 
ATTRITION:   The present study was based on N=150, 
attrition was not reported, in full, however there was no 
significant difference between the responders and non-
responders (the results not reported). 
Predictors of Global HRQoL at 6 months: Age,  urinary symptoms,  
bowel function, sexual function, depression, physiological 
efficacy, performance efficacy, baseline HRQoL. 
Predictors of Global HRQoL at 12 months: Urinary symptoms, 
stress, depression, coping, baseline HRQoL, race and being 
married.  HDR group reported higher bowel symptoms scores 
than men who received RP baseline, 6 and 12 months.  BT group 
reported higher bowel symptoms at 6 and 12 months compared 
to the RP group.  Urinary symptoms were worse of BT at  6 and 12 
months compared to the RP group.  
 
LIMITATIONS:  There was not control/report of co-morbidities 
which may have biased the findings.  The possibility for 
recruitment bias is also possible. 
Latini et al., 
(2006) 
Evaluate the 
impact of 
PARTICIPANTS:  N=1248 were divided into 2 groups N=117 
who had RP with diabetes mellitus (DM) and N=1131 
DESIGN:  Prospective longitudinal. 
 
Urinary function was the only significant difference for men with 
DM compared to men without DM.  Sexual function also showed a 
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USA 
20/22 90% -  
B3 
diabetes in 
men 
receiving RP 
for PC in 
relation to 
reported of 
HRQoL. 
without DM.   
 
DEMOGRAPHICS:  Age RP no DM <65 years (66%), >65 years 
(34%), RP + DM <65 years 53%, >65 years (47%) P<0.01, Race 
White RP no DM 93%, White RP + DM 84%, P<0.01, 
Education RP no DM college graduate 52%, RP + DM 40%, 
P<0.01. Marital married RP no DM 95%, RP + DM 91% 
P+0.15. 
 
CLINICAL:  Stage T1 to T3, had RP as monotherapy, PSA 
<10ng/mL, Gleason <7.  
TIME POINTS:  Baseline (pre-treatment) and 12 months 
after treatment. 
 
MEASURES:  Demographic and Clinical data, UCLA-PCI 
 
PARTICIPANTS:   Total sample N=1248 no attrition 
reported. 
decrease in mean scores in both groups.  Bowel function was  
over time for the study sample. 
 
LIMITATIONS:  A limitation of the CaPSURE data is that DM is only 
self-reported by the participants at baseline, and thus the length 
of diagnosis and additional co-morbidity is unknown and can 
introduce bias in the study.   
Eller et al., 
(2006) 
USA 
20/22 90% – 
B3 
Compare 
HRQoL for 
men 
receiving 
intensity 
modulated 
radiotherapy 
with RP. 
PARTICIPANTS:  N=159. 
 
DEMOGRAPHICS:  Age RP 58.8 years (SD7.1), IMRT+HDR 68.4 
years (SD 7.3), IMRT +BT 67.2 years (SD6.9), (P<0.001), Race 
RP white 85.7%, IMRT + HDR white 89.8%, IMRT + BT  white 
82% (P=0.486) Employment RP employed 79.8%, IMRT + 
HDR employed 38.8 %, IMRT + BT 49.2% (P<0.001).  
Education College and above RP 81.6%, IMRT + HDR  69.4%, 
IMRT + BT 60.6% (P=0.027). 
 
CLINICAL:  T1 to T2 disease, N=49 RP, IMRT + HDR N=49, 
IMRT + BT N=61 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment), 1 and 3 
months. 
 
MEASURES:  Demographic and clinical, Prostate 
Symptom Self-Report (PSSR), Symptom checklist (SCL-90) 
Anxiety Subscale, Epidemiological Studies for Depression 
Scale, Ways of Coping, SUPPH, FACT-P. 
 
ATTRITION:  N=159, the analysis was based on N=124 
who completed data at all time points.  There were no 
significant differences between responders and non-
responders.   
Men in the RP group were more likely to be younger, higher 
education and working Predictors of HRQoL: Physical well-being: 
bowel symptoms, Sexual dysfunction, Depression, coping.  Social 
well-being,: sexual symptoms, Depression, positive coping. 
Emotional well-being: urinary symptoms, sexual symptoms, 
depression.  Functional well-being: bowel symptoms, sexual 
symptoms, depression, perceived stress, positive attitude.  
Treatment type did not contribute to any of the regression 
models.   Thus physical and psychosocial factors significantly 
predictor HRQoL in men with PC.  Depressive symptoms and 
urinary symptoms were highest in the IMRT + BT after treatment.   
 
LIMITATIONS:  Selection bias is possible. The follow-up period is 
short and limited to acute phase after treatment. 
Miller et al., 
(2005) 
USA 
18/22, 81%  
– B3 
Assess 
HRQoL in 
men with PC 
4 and 8 years 
after 
treatment  
PARTICIPANTS:    N=964, N=709 consented (73.5%).  There 
were not differences between responders and non-
responders. 
 
DEMOGRAPHICS:  Age median control 69.1 years, RP 67.2 
years, RT 75.7 years, BT 70.4 years. Marital married control 
79.4%, RP 875, RT 89.7%, BT 93.4%, Race white control 97%, 
RP 96.6%,   RT 94.4%, BT 88.7%.  Education high school 
control 100%, RP 94.3%, RT 95.4%, BT 91.8%.   
 
CLINICAL:  T1-T3 disease, RP N=665 , RT N=147, BT, 84, 
Controls N=112 Median years since primary therapy RP 6.5 
years, RT 6.3 years, BT 5.4 years.   
 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  4 and 8 years after treatment. 
 
MEASURES:  Demographic and clinical data, SF-12, EPIC. 
 
ATTRITION:  Attrition and missing data not reported. 
RP group reported most problems with urinary and sexual 
function.  BT participants reported significantly worse urinary 
irritation-obstructive, urinary incontinence, bowel and sexual 
function.  All groups has similar general HRQoL (SF-12) for the 
treatment groups.  No significant change in SF-12 at 4 and 8 years 
in either group.  Significant improvements were reported for 
urinary irritative/obstructive in the BT group,  over time.  RP 
group urinary, bowel and sexual function were similar at follow-
up  Predictors at 8 years: age was associated with urinary 
incontinence 
LIMITATIONS:  No pre-treatment HRQoL evaluation undertaken 
thus the study was not able to control for baseline HRQoL 
between groups.  Recruitment and non-responder bias may 
influence the results. 
Wu et al., 
(2008) 
To evaluate 
HRQoL for 
PARTICIPANTS:  N=2204  
 
DESIGN:  Prospective longitudinal. 
 
Hormone therapy adjuvant to RP, BT, or RT there was a temporary 
worsening of sexual functioning that began to improve at 9 
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USA 
22/24 91% – 
B3 
men treated 
with 
multimodal 
therapy for 
men with PC. 
DEMOGRAPHICS:  The majority of men were approx <60 
years, white ethnicity, and well educated.  
 
CLINICAL: RP N=1427, RT N=267, BT N=510.  All patients 
would receive multimodal treatment for PC.  RP alone 
N=1290, RP and ADT N=121, RP + RT N=16, RT alone N=83, 
RT and ADT N=184, BT alone N=246, BT + RT N=144, BT + RT 
+ ADT N=59. 
 
The average length of ADT was 5 years mean (SD 3.7 years).   
TIME POINTS:  Baseline (before treatment) to 2 years 
after treatment. 
 
MEASURES:  Demographic and clinical data, Charleston 
Co-morbidity rating scale, RAND SF-36, UCLA-PCI  
 
ATTRITION:  No missing data was reported. 
months post treatment.   When RT was given in conjunction with 
BT there was continuous worsening of urinary function at 2 years 
follow-up.  Multimodal therapy can cause declines in HRQoL in 
urinary, sexual and bowel domains for men with PC. 
 
LIMITATIONS:  The analysis of RP + RT is very small and makes 
generalisabilty of the findings difficult.  Possible bias between the 
responders and non-responders as part of the larger CaPSURE 
database. 
Sullivan et 
al., (2007) 
USA 
21/24 87%  – 
B3 
 
Assess 
HRQoL for 
men with 
HRPC. 
PARTICIPANTS:  N=280.     
 
DEMOGRAPHICS:  Age mean age was 72 years, Race white 
98%. 
 
CLINICAL: HRPC, mean PSA was 235, 345, 410, 421, baseline, 
3, 6, 9 months respectively. 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  At consent, 3, 6, 9 months follow-up. 
 
MEASURES:  Demographic and clinical data, EORTC-C30, 
FACT-P, EQ-5D. 
PARTICIPANTS:  Non-responses varied FACT-P and EORTC 
89-95%; EQ-5D 90-04%.  Missing data at 9 months was 
higher than at baseline. 
 
ATTRITION: From consent to the 9 months follow-up, the 
sample size decreased by 44% to N=157.  N=83 deaths 
30% died within the 9 months follow-up reflected the rapid 
progression of reduced HRQoL over the 9 months follow-up. 
The domains of HRQoL that did not reach significance were 
cognitive functioning, insomnia, diarrhoea, and financial 
difficulties. 40% of sample reported worse pain overtime.   
 
LIMITATIONS:   There were numerous treatments for HRPC and 
these were not taken into consideration in the analysis, which 
could have influenced the results.  There is also the potential for 
recruitment bias.   
 
Rogers et al., 
(2006). 
USA 
17/20 85%  – 
B3 
Assess 
HRQoL in 
men 
receiving LRP 
PARTICIPANTS:  N= 424  
 
DEMOGRAPHICS:  Age mean 57.9 (SD not reported).  No 
further demographics reported.   
 
CLINICAL:  Stage T1 to T2.  Bilateral nerve sparing was 
performed on 65.7%, and unilateral 26.2% of the 
participants receiving LRP.  .  
DESIGN:  Prospective longitudinal  
 
TIME POINTS:  Before surgery, 3, 6, 12 months after 
surgery. 
 
MEASURES:  Age and clinical, SF-12, EPIC. (Group 1 
<50years, Group 2 50-59 years, Group 3 >60 years) 
 
ATTRITION:  N=424 over all response rate was 89%.  
Differences between responders and non-responders 
were not reported. 
88% of the men reported using 1 pad or less daily at one year. 
Younger men were more likely to achieve using only 1 pad or less 
at 12 months P<0.01). 60.5% bilateral nerve sparing LRP were 
engaging in intercourse at 12 months without phosphodiesterase-
5-inhibitors P=0.01.  Nerve sparing LRP was not predictive of men 
returning to baseline urinary function, but was the only predictor 
of return to baseline sexual function. No men older than 50 years 
experienced significant urinary incontinence. 
 
LIMITATIONS:  There was control for co-morbid conditions.  In 
addition, recruitment bias and attrition bias are possible and 
limits the generalisabilty of findings. 
Montgomery 
et al., (2006). 
USA 
20/22 90% – 
B3 
Examine the 
effects of 
obesity on 
men treated 
with RP. 
PARTICIPANTS:  575 men undergoing RP was approached. 
N=472 consented 82% response rate. 
 
DEMOGRAPHICS:  Age 59.2 years (mean, SD not reported).  
Race the number of black men was small N=13, however a 
large proportion was obese or severely obese compared to 
white men (black 53.8% vs. white 26.5%, P=0.008).  Married 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS: Baseline (before surgery), 1, 4, 12, 24, 36 
months after surgery. 
 
MEASURES:  Demographic and clinical, EPIC and SF-12. 
 
At 36 months the rate of PC recurrence for obese and severely 
obese was significant.  Obese and severely obese participants also 
needed adjuvant HT at high rate than normal BMI men.  No 
significant difference in clinical stages, Gleason scores, positive 
surgical margins between the groups divided by BMI.  Higher BMI 
group had worse scores on hormonal/vitality function.  no 
differences between urinary, bowel and sexual function in HRQoL 
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the large majority of men were married 90+%.  Education 
approx 80% were college and higher. 
 
CLINICAL:  BMI distribution 22.1% normal BMI, 51.6% 
overweight, 19.7% obese, 6.6% severely obese.   All men T1 
to T2 disease.  Co-morbidities the majority of men has 0-1 
85%. 
ATTRITION:  N=472, N=376 completed at least one 
questionnaire. 
in BMI groups. 
 
LIMITATIONS:  Nerve-sparing procedures were not reported as 
this may have influenced outcomes.   It is possible for attrition 
bias., the influence of additional co-morbidity was not explored. 
 
 
Kubler et al., 
(2006) 
USA 
18/22 81%  – 
B3 
 
 
Assess the 
impact of 
nerve-
sparing 
techniques 
for RP and 
HRQoL  
PARTICIPANTS:  N=265  
 
DEMOGRAPHICS:  Age median 60.6 years.  Me undergoing 
nerve-sparing were younger 59.2 years, non-nerve sparing 
62.1 years (P=0.002).  No other demographics reported. 
 
CLINICAL:  N=153 non nerve sparing, N=112 nerve sparing.  
All T1 to T3 disease stage 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Preoperative, 3, 6, after surgery. 
 
MEASURES:  Age and clinical data, EPIC.   
 
PARTICIPANTS:  for the N=265 attrition or missing data is 
not reported. 
Participants reported an erection firm enough for intercourse at 
23.8 months in the nerve-sparing groups, in contrast to the non-
nerve sparing groups.  Median time to continence (not wearing a 
pad) was 4.8 months in the nerve-sparing group, and 6.1 in the 
non-nerve sparing group (P<0.0001).  Predictor variables:  using 
multivariate logistical regression 
Erectile function: nerve sparing techniques,  better pre-operative 
sexual function.  Urine function: nerve sparing technique, age.  In 
sum, nerve-sparing techniques may increase the chances of 
higher levels of potency and improved urinary function compared 
to non-nerve sparing techniques. 
 
LIMITATIONS:  It is possible for recruitment and attrition bias, this 
was not addressed in this paper. There was also limited 
demographic data presented for this study sample and limits 
generalisabilty. 
 
Namiki et al., 
(2006) 
Japan 
21/22 95%  – 
B3 
Assessed 
HRQoL 
comparing 
IMRT and 
conformal 
RT (con RT). 
PARTICIPANTS:  N=140. 
 
DEMOGRAPHICS:  Age con RT median 73.5 years (range 47-
83), IMRT median 72 years (range 56-83).  Marital married 
Con RT N=107, not married N=3, IMRT married N=28, not 
married N=1.   
 
CLINICAL: T1-T3 Con RT N=110, IMRT N=30, most frequent 
co-morbidity reported was hypertension in both groups. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (after diagnosis), 3, 6, 12, 18, 24. 
 
MEASURES: Demographic and clinical data, SF-36, UCLA-
PCI. 
 
ATTRITION: No comparison was made between 
responders and non-responders. 
The 2 groups were not significantly difference for age, Gleason, 
PSA, for tumour staging.  HRQoL baseline no different in either 
group.  Con RT group reported more problems with role 
limitations, emotional problems and physical problems compared 
to the IMRT.  Urinary function problems were not significantly 
different at any of the time points in either group.  Bowel function 
problems at 3 and 6 months more problematic for con RT 
compared to the IMRT.  Sexual function was better at 18 months 
for the IMRT group than the con RT group.  The impact of HT did 
not yield any significant impact on urinary, bowel of sexual 
function.   In sum, the comparison of these treatments conveys a 
different trajectory for recovery for men receiving con RT and 
IMRT on HRQoL. 
 
LIMITATIONS:  Caution is drawn to the statistical power to 
compare the treatment groups due to small N in the IMRT group.  
Possible for selection and attrition bias.     
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Kato et al., 
(2007) 
Japan 
18/20 90%  – 
B3 
 
 
Assess 
HRQoL for 
men with PC 
receiving HT. 
PARTICIPANTS:  N=289, were asked to complete 
questionnaires pre-diagnosis (at prostate biopsies).  N=123 
has confirmed PC , N=56 received HT.   
 
DEMOGRAPHICS:  Age mean 76.0 years (SD 6.7).  No further 
demographics reported. 
 
CLINICAL:  T1-T2 N=77, T3 N=17, T4-N1 N=18    
DESIGN: Prospective longitudinal. 
 
TIME POINTS:  pre-diagnosis, 3, 6, 12 months after 
treatment. 
 
MEASURES:  Age, clinical, UCLA-PCI, SF-36 
 
ATTRITION:  N=56, 3 months 71.4%, 6 months 76.8 %, 12 
months 66.1%, response  
Change over time for HRQoL in men with localised disease SF-36 
scales, only a decline in vitality at 6 and 12 months.  Metastatic 
disease group improvements in pain at 3 and 12 months , vitality 
at 12 months, emotional-role and mental well-being  at 6 months.  
Urinary function improved at 3 months, 6 months, and 12 months 
in metastatic group. All mens did not report any significant 
difference in score changes for bowel function or bother at any 
follow-up time points.  As sexual function deteriorated over time 
at 3, 6 and 12 months. In summary, patient with metastatic 
disease on HT was found to have the greatest improvement in 
pain, vitality, mental well-being and role-emotional over time, 
compared to localized disease. 
 
LIMITATIONS:  Study sample biased toward Japanese men, thus 
limits the generalisabilty of the results.  Potential for recruitment 
bias, the impact of co-morbid conditions were not reported. 
Namiki et al., 
(2005) 
Japan 
20/22 90% – 
B3 
 
Assess the 
impact of 
men 
receiving RP 
with or 
without HT 
for PC. 
PARTICIPANTS:  N=109 
 
DEMOGRAPHICS:  Age RP mean 66.8 years (SD 5.1, RP + HT 
mean 68.3 years (SD 5.1) (P=0.176).Martial married RP 94%, 
RP+ HT married 92%.  Employment retired RP 47%, Retired 
RP + HT 54%.   
 
CLINICAL: RP N=72, RP + HT N=26  
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Before RP (but not before hormonal 
therapy), 3, 6, 12 months after RP. 
 
MEASURES:  Demographic and clinical data, SF-36, UCLA-
PCI. 
 
ATTRITION:  3 months 87%, 6 months 84%, 12 months 
83%  
RP group physical role limitations and emotional problems 
significantly worsened 3 months. Mental well-being improved 
over time compared to baseline.  The RP + HT group reported 
significantly worse scores for role limitation due to physical 
problems, social functioning and mental health at baseline 
compared to RP group.  Urinary function decreased at 3 months, 
and then started to recover at 6 and 12 months (P<0.05), however 
was still substantially lower than baseline.  Bowel function was 
problematic in either group.  Sexual function was not significantly 
different in the 2 groups, and reported substantial worsening 
scores at all follow-up times.   
 
LIMITATIONS:   No control for baseline HRQoL before participants 
started their HT, this introduced bias in results.  Potential for 
recruitment bias, ethnicity was not reported, as this may limit the 
generalisabilty of the results. 
 
Pinkawa et 
al., (2007) 
USA 
19/24 79% – 
B3 
Assess the 
impact of 
prostate 
volume on 
HRQoL for 
participants 
treated with 
RT.  
PARTICIPANTS:  N=224  
 
DEMOGRAPHICS: Age small prostate 71 (median, range 45-
82), large prostate 72 (median, range 55-85).  No further 
demographics reported.  
 
CLINICAL: 3 most frequent co-morbidities coronary heart 
disease 50%, hypertension 47%, diabetes 26%, T stage <2 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baselines (before RT), on the last day of 
RT, 2 month (median, range 6 weeks - 6 months) and 16 
months (median, range 12-20 months) 
 
MEASURES: Age no further demographics were 
reported.  Clinical and the Expanded Prostate Cancer 
Adjuvant HT participants reported significantly worse urinary 
function and urinary incontinence scores at all follow up time 
points (P=<0.01).  Significantly worse bowel function scores were 
found before and after 1 year after radiotherapy (median 92 with 
HT vs. 96 without HT) at baseline and median of 16 months.  
Significant predictors of a worse urinary function were a large size 
of prostate volume, small bladder volume and use of HT. 
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small prostate 71%, large prostate 87%, HT small prostate 
41%, large prostate 19% (P=0.01).   
Index,  
 
ATTRITION:  N=224, N=204 baseline, N=131 on the last 
day of RT, N=180 at 2 months (median), N=204 at 16 
months (median). 
LIMITATIONS:  No demographic data was presented, known 
predictors of disease-specific HRQoL.  There is the possibility of 
selection bias. 
Soderdahl et 
al., (2005) 
USA 
19/22 86%  – 
B3 
 
Compare 
HRQoL of 
men treated 
with RP, LRP 
and BT. 
PARTICIPANTS: N =453 
 
DEMOGRAPHICS:  Age RP median 59, LRP median 61, BT 
median 68 (P<0.001), Race white RP 70.9 %, LRP 75.3, BT 
77.5%.  
 
CLINICAL:  N=117 LRP, N=186 RP, N=150 BT.  All groups 
reported 1 as the number of co-morbidities. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment), 1, 3, 6, 9, 12 
months after treatment. 
 
MEASURES:  Demographic and clinical, SF-36, UCLA PCI, 
American Urological Association Symptom Index. 
 
ATTRITION:  N=453, attrition was not reported.  In the 
discussion, it was reported that the RP groups data 
completion was below 50%, thus responder bias is 
possible. 
SF-36  general domains across all treatment groups reported an 
initial decline, which returned to baseline at 12 months.  Prostate 
cancer-specific HRQoL affected the difference treatment in 
different ways.  The RP and LRP reported the worse sexual 
function and the worse urinary function in the 12 months follow-
up.  Reduced bowel function was initial worse for the BT group, 
however at 12 months all the treatment modality groups reported 
similar scores. BT group reported worse urinary function at 1 
month, 3 months, and 6 months, however at 12 months the 
means scores were very similar.  Sexual function at 1 month 
across all treatments groups was significantly worse and at 12 
months scores did not reach baseline function.  Nerve-sparing 
surgery did not affect sexual function at any of the follow-up time 
points.  RP, LRP and BT has little impact on general HRQoL, but 
significant impacts on disease-specific HRQoL over time. 
LIMITATIONS:  Potential for responder and non-responder bias.  
The LRP had an excellent response rate, which the authors report 
the surgeons had a proactive approach to take part in the study.   
Lips et al., 
(2008) 
Netherlands 
21/22 95% – 
B3 
Assess 
HRQoL  after 
high dose 
intensity 
modulated 
radiotherapy 
(IMRT) using 
gold fiducial 
markers 
position 
verification. 
PARTICIPANTS:  N=116.   
 
DEMOGRAPHICS: Age 68 years (mean, range 46-79).  No 
further demographic data reported. 
 
CLINICAL:  Locally advanced cancer. HT no treatment 62%, 
short-term less than 6 months 27%, long-term <36 months 
11%.   
DESIGN:  Prospective longitudinal 
 
TIME POINTS: Baseline (before treatment), 1, 6, 36 
months after treatment.   
 
MEASURES:  Age and clinical data. SF-26, EORTC C30 + 
PR25. 
 
ATTRITION:  N=116, N=15 lost to follow-up, N=6 died.  
The overall response rate was reported high, except for 
sexual activity. The analysis is based on N=95. 
 
 
Within the 3 years N=2 developed GI toxicity radiation proctitis.  
This paper used a 10> score difference as a clinically meaning fully 
difference.  No significant differences in the general HRQoL 
domains.  Sexual function/activity showed a clinically relevant 
decrease of 12 points after 3 years, initially worse at 1 month and 
persisted at 6 months and 3 years.  Mental health and emotional 
role scores consistently improved over all the follow-up time 
points and exceeded baseline values.  Participants treated with HT 
had worse baseline sexual function, but similar reports to sexual 
function for participants who did not receive treatment.  HRQoL 
returned to baseline and had no significant or clinically 
meaningful differences apart from sexual function at 3 years. 
 
LIMITATIONS:  There is the potential for selection bias. 
Hashine et 
al., (2009) 
Japan  
20/22 91% – 
Assess 
HRQoL for 
men treated 
with RP and 
PARTICIPANTS:  N=96 treated for RP and N=88 for BT.  The 
total number of participants approached and decline were 
N=8.  
 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment), 1, 3, 6, 12 
months follow-up after treatment.   
HRQoL scores were worse at baseline for the RP compared to the 
BT. 1 month HRQoL scores were significantly worse than baseline 
for physical functioning, role physical, bodily pain, vitality and 
social functioning for RP with recovery at 3 months except for 
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B 3 
 
  
BT for PC. DEMOGRAPHICS:  No demographic data 
 
CLINICAL:  RP N=96, BT N=88.  Nerve-sparing surgery was 
performed in N=12 participants, N=6 had RT after BT.   
 
MEASURES:  Demographic and clinical data.  SF-8 
(Japanese version, validity and reliability not reported).  
EPIC.   
 
ATTRITION:   Response rates were 82.1% in the RP and 
89.1% in the BT 
bodily pain, which recovered at 6 months.  Physical functioning, 
role physical, vitality and social functioning exceed baseline 
reported scores at 6 and 12 months in RP.  BT group, role physical 
and social functioning at 1 month was worse that the baseline 
score and recovered 3 months, mental health component 
improved over baseline scores at 12 months.  At 3 months HRQoL 
were worse in the RP, but there were no significant difference in 
either group at 6 months.  Urinary incontinence in the BT was 
recovered by three month, but remained worse than RP group 
until 12 months follow-up. Urinary irritative/obstruction was 
worse than baseline at 1 month in both groups, RP recovered and 
improved baseline score at 3 months.  BT group reported 
deteriorating urinary irritative/obstructive at 6 months.  Bowel 
function was worse in the BT group at 3 and 6 months compared 
to RP.  Nerve sparing surgery gradually improved sexual function 
over time compared to non-nerve sparing techniques.  BT group 
had better overall HRQoL except for urinary irritative and bowel 
function, however these resolved overtime. 
 
LIMITATIONS:  Study sample biased in favour of Japanese men.  
There is the potential for selection bias and attrition bias.   
Hoffman et 
al., (2006) 
USA 
21/22 95%  - 
B3 
Assess 
HRQoL for 
men with PC. 
PARTICIPANTS:  Total N=11 137 (CAP Sure database), N=5672 
were suitable.  N=3533 (62% completed questionnaires) at 6 
and 12 months.  The current analysis used data collected 
from men aged 75 to 84 years at diagnosis.   RP and RT 
N=175, HT or AC/WW N=290.   
 
DEMOGRAPHICS:  Age 75-79 years N=327 (70.25), 80-84 
years N=138 (29.8%).  Race White N=364 (84.2%), Marital 
married N=343 (72.6%), Education college and higher 68.6%. 
 
CLINICAL:  All participants had localized prostate cancer.  
Some men had reported co-morbidities.  Most men at 
baseline had no urine or bowel problems.  29% reported 
having moderate to big sexual problems.  N=39 RP, N=137 
RT, N=290 were manage conservatively on HT and N=174 no 
treatment. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS: baseline and 12 and 24 months after 
diagnosis  
 
MEASURES:  Demographic and clinical data, SF-36, 
Charleston Index, Disease-specific, (the name of the 
measure is not reports). 
 
ATTRITION:  No attrition reported at used data from an 
observational database, so not having missing data at 
baseline was one of the criteria for inclusion.  At 24 
months follow-up overall 74% completed the 
questionnaire.  There was a difference between 
responders and non-responders, responders were more 
likely to be white, educated and married, the results not 
reported. 
 
 
Men receiving aggressive treatment (RP RT) has overall worse 
urinary function, than the conservative group (HT AS). Men in the 
aggressive group were more likely to worse HRQOL 24 months 
after diagnosis.  Men who received aggressive treatment had 
significantly higher general health (66.8 vs. 59.2, P=0.04) but more 
physical problems (60.8 vs. 47.7, P=0.04) than men being 
conservatively managed. 
 
LIMITATIONS:  Attrition bias was reported as a possibility in this 
study.   
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Howlett et 
al., (2010) 
USA 
22/22 100% 
– B3 
Assess 
HRQoL for 
men 
undergoing 
RT  
PARTICIPANTS:  N=180, N=82 (43.6%) consented.  No 
differences in demographics between the responders and 
non-responders. 
 
DEMOGRAPHICS:  Age mean 67.1 years (SD not reported), 
Race white 79%, Education well educated mean 16.3 years.   
 
CLINICAL:  Most men had T1 stage disease 51%, 53% 
received neoadjuvant HT before RT, 76% underwent whole 
pelvis with conformal boast.   
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Before treatment and at the end of RT. 
 
MEASURES:  Demographic and clinical data, Karnofsky 
Performance Status, Centre of Epidemiological Studies-
Depression Scale, Spielberg State Anxiety Scale,  QoL 
Scale Patient Version, and single item question “is your 
sexuality impacted by your illness?” 
 
ATTRITION:  Limited attrition data reported.   Only 70 
men completed the sexual function question. 
 Baseline 50% reported a problem with sexual function.  Men with  
no urinary, bowel and sexual dysfunction reported significantly 
less anxiety and depression and higher HRQoL atT1 and T2 
 
LIMITATIONS:  Large proportion of participants were white, 
educated and married, thus has the potential to limit the 
generalizability of the results. 
Hashine et 
al., 2008 
Japan 
19/22 86%  - 
B3 
Assess 
HRQoL for 
men treated 
with RP and 
BT. 
PARTICIPANTS:  N=122 treated with RP and N=82 treated 
with BT.  To number of men approached was not reported. 
 
DEMOGRAPHICS:  Age median in the RP 68 years, BT 70.5 
years,   
 
CLINICAL:  Neoadjuvant HT was used in N=18 of the men in 
the BT and N=8 in the RP.  Nerve-sparing was performed in 
N=22 participants.   
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment), 1, 3, 6, 12 
months after treatment. 
 
MEASURES:  Age and clinical data, SF-36, UCLA-PCI,  
 
ATTRITION:  The response rates were RP 70.8% and BT 
76.2%. 
RP group all of the HRQoL components (except for general health 
and mental health) were significantly worse at 1 month after 
surgery but recovered at 3 months.   However, role physical and 
bodily pain was worse at 3 months compared to baseline.  HRQoL 
scores were better for men in the BT compared to the RP.  At 1 
months BT participants reported significantly worse urinary 
bother than the RP group that lost significance at subsequent 
follow-up.  HRQoL recovered at 3 months in the RP group.   
 
LIMITATIONS:  There is the possibility for section bias.  No 
measure of co-morbidity that may have confounded the results. 
Namiki et al., 
(2009) 
Japan 
20/22 90%  – 
B3 
 
 
Assess 
HRQoL for 
men with Pc 
older than 
70 years old  
PARTICIPANTS:  N=750, N=319 consented   
 
DEMOGRAPHICS: Age 73.5 (mean, SD 2.8) years.  No further 
demographics reported. 
 
CLINICAL:  Men treated by RP and RT.  Most of the RT 
participants received HT.  43% did not undergo nerve-
sparing procedures.  Co-morbidities were reported.   
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment), 3, 6, 12, 18, 
24 months after treatment. 
 
MEASURES:  Age and clinical data, SF-36, UCLA-PCI. 
 
ATTRITION:   N=319, N=4 died, N=8 excluded because of 
disease recurrence, only participants with baseline and 
one of the last 2 follow-up time points were included, 
N=284 (N=166 RP and N=118 RT)  Response rates at time 
points above starting with  baseline; 100%, 95%, 97%, 
91%, 87%, 92%. 
RP had better scores for  baseline physical function, role limitation 
due to physical and role emotional problems compared to RT 
group.  RP reported better sexual function compared to the RT at 
baseline.  No difference in urine and bowel function in either 
group.  RP had a worse urine function at 3months, but improved 
over the 6, 12, 18 and 24 months, but at 24 months function was 
still statistically lower than baseline.  Nerve-sparing group 
reported significantly better sexual function compared to the 
participants who did not received nerve sparing surgery. 
Predictors at 24 months HRQoL: RT was associated with better 
urinary function and less sexual bother compared to RP. 
 
LIMITATIONS:  Potential for selection bias, also the use of sexual 
aids and urinary function aids were not reported this may 
influence the results. 
Namiki et al., 
(2009) 
Japan 
Assess 
HRQoL for 
men 
PARTICIPANTS:  N=97 treated for 3D conformal RT and N=36 
from IMRT (N=133 total participants in study).   
 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline (after diagnosis), 3, 6, 12, 18, 24, 
The SF-36 no significant differences between the groups or at any 
of the follow-up time points.   UCLA-PCI no difference in either 
group for urinary function and bother at any time point.  Bowel 
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19/22 86% – 
B3 
comparing 
IMRT and 3D 
conformal 
RT 
DEMOGRAPHICS:  Age IMRT 71 (SD 6) years, 3D RT 73 (SD 4) 
years P=0.05, Marital  married IMRT 94%, 3DRT 94% P=0.50.  
Employment Retired IMRT 75%, 3DRT 63%. 
 
CLINICAL:  Co-morbidities IMRT none 28%, 3DRT 21%. 
60 months after diagnosis. 
 
MEASURES:  Demographic and clinical data, SF-36, UCLA-
PCI 
 
ATTRITION:  N=133, N=115, N=109, N=110, N=108, 
N=114 at baseline, 3, 6, 12, 18, 24, 60 months 
respectively.  The differences between responders and 
non-responders were not reported. 
function had no significant differences at baseline for the 2 
groups.  60 months after treatment, the 3DRT group had 
significantly bowel function and bother scores compared to the 
IMRT group. 3DRT group were more likely to reported rectal 
urgency, diarrhoea, cramp pain than those in the IMRT group.  
Sexual function was worse in the 3DRT group, significant decline 
at 3 months and remained significantly lower than at baseline. 
3DRT group showed no significant difference at 2 years (either 
improvement or worsening).    There were no significant changes 
in the IMRT group for sexual function and bother for the follow-up 
time points. 
 
LIMITATIONS:  There was small N=in the IMRT group.  This study 
did not include the use of sexual aids which may have been a 
possible bias.  Selection bias and attrition bias is possible.  
Namiki et al., 
(2009) 
Japan 
20/22 90% – 
B3 
 
 
Assess 
HRQoL over 
5 years for 
men treated 
with RP for 
PC. 
PARTICIPANTS:  N=154  
 
DEMOGRAPHICS:  Of the N=143 Age 65.8 (SD 5.6) years, 
Marital 94%, Employment Retired 48%. 
 
CLINICAL:  All T1-T3, nerve sparing 61%, Salvage therapy 
none 83%, co-morbidity none 31%, 1-2 63%.       
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before RP), 3, 6, 12, 18, 24, 36, 
48, 60 months after RP. 
 
MEASURES:  Demographic and clinical data, SF-36 and 
UCLA-PCI. 
 
ATTRITION:  The questionnaire response rates were 95%, 
97%, 100%, 91%, 99%, 100%, 91%, 87%, at 3, 6, 12, 18, 
24, 36, 48, 60 months respectively.  Testing for attrition 
bias was not reported. 
SF-36 role limitations due to physical problems and bodily pain 
significantly decreased at 3 months. Social functioning scores 
were statistically higher at 2 years than at baseline.  Mental health 
scores significantly improved at all-time points compared to 
baseline. Urinary control significantly declined at 3 months and 
urinary control was still significantly lower than baseline function 
at all-time points.  Nerve-sparing techniques did not have any 
relationship with recovery of urinary function. 
No significant differences were observed for bowel function or 
bowels bother.  Sexual function was statistically worse at all time 
points.  60 months 34% had regained baseline sexual function 
scores.   
 
LIMITATIONS:  Selection bias may have been possible, the use of 
sexual aids was not reported which introduces bias. 
Namiki et al., 
(2009) 
Japan 
20/22 90%, – 
B3 
Assess 
HRQoL for 
men >70 
years old  
PARTICIPANTS: N=205 
 
DEMOGRAPHICS:  Age 72.5 (SD1.9) years, Marital N=177 
married, N=18 no other significant partner (not in 
relationship).  Employment retired N=135, N=60 working.  
 
CLINICAL:  Stage T1-T3 all RP, Co-morbidities 1> N=161, 
Salvage therapy N=167 none.  Nerve-sparing techniques 
none N=78 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before RP), 3, 6, 12, 18, 25 
months after RP. 
 
MEASURES:  demographic and clinical data, SF-36 and 
UCLA-PCI 
 
ATTRITION:  Response rates were 100%, 90%, 91%, 95%, 
83%, 85%, at baseline, 3, 6, 12, 18, 24 months 
respectively.   
Role limitations due to physical problems decreased at 3months 
and recovered at 6 months. Mental health scores at 12 months 
were statistically higher than at baseline score.  Urinary function 
significantly worsened at 3 months and remained statistically 
lower at 25 months compared to baseline.  There were no 
significant differences in bowel function at any of the follow-up 
time points.  Sexual function scores declines over the 24 months.   
 
LIMITATIONS:  It is possible for selection bias and attrition bias.  
The used of sexual aids was not reported as this may have 
influenced the findings.  Study sample bias in favour of Japanese 
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men. 
Namiki et al., 
(2008) 
USA 
18/20 90% H 
– B3 
 
Compare 
HRQoL for 
men treated 
with RP or 
RT in  Japan 
and USA 
PARTICIPANTS:  N=477 Japanese men, N=385 American men 
consented.   
 
DEMOGRAPHICS:  Age Japan 67.2 (SD 5.5) years, American 
60.1 (SD 7.2) years (P=0.008).  Race Japan Asian 100%, 
American, White 85% 
 
CLINICAL:  All T1-T3.  Japan N=153 RT, RP N=324. America 
N=78 RT, RP N=307.Nerve-sparing Japan  69%, American 
91%. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment), 1, 2, 3, 4, 6, 
8, 12, 18 , 24 months after treatment. 
 
MEASURES:  Demographics and clinical data.  UCLA-PCI 
and the American Urological Association Symptom Index 
(AUASI). 
 
ATTRITION:  No attrition was reported. 
PR group had better urinary function at baseline than RT group.  
Increasing age and co-morbidity predicted worse urinary function.  
1 month after RP American men reported worse urinary function 
than Japanese men. Both groups regained urinary control over 
time and reported less distress.  Trend of recovery of symptoms 
differed significantly by county. 
  
LIMITATIONS:  Selection bias is possible and attrition bias 
possible.  Potential bias secondary to cultural differences in 
interpretation of the questionnaire items.  Additional 
demographics such as marital status employment, education 
demographic variables may have also influenced the findings. 
Gore et al, 
(2009). 
USA 
20/20 100%  
– B3 
Assess 
HRQoL for 
localizes 
prostate 
cancer  
PARTICIPANTS:  N=475  
 
DEMOGRAPHICS:  Age RP 60.1 (SD 7.1) years, RT 70.8 (SD 
7.3) years BT 68.4 (SD6.9) years (P<0.001). Marital 
Married/partner RP 83.4%, RT 82.0 %, BT 80% (P=0.75).  
Education College and more RP 73.6%, RT 71.8%, BT 59.6% 
(P=0.04) 
 
CLINICAL:  RP N=307, RT N=78, BT N=90.  All T1 to T3.  Co-
morbidity counts none RP 38.1%, RT 28.2%, BT 34.4 % 
(P=0.60) .   
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline (before treatment), 1, 2, 4, 8, 12, 
18, 24, 36, 42, 48. 
 
MEASURES:  Demographic and clinical data.  SF-38, 
UCLA-PCI and AUASI. 
 
ATTRITION:  Participants who completed the 48 month 
survey were older 63.7 (SD 8.1), than those who did not 
complete it 60.2 (SD 7.1) P=0.001. 
Physical and mental well-being were largely unaffected by the 
treatments for localized prostate cancer. Urinary function was 
worse for the RP.   Incontinences was more prevalent in RP than 
the BT group.  Sexual function was negatively affected in all 
treatment groups.  RT group experienced a gradual decline in 
sexual function over 28 months.  However, the BT participants 
experienced a gradual improvement over time.   
RT and BT reported more bowel dysfunction than the RP 
participants.   
 
LIMITATIONS:  Participants in the RP had better baseline function 
of HRQoL compared to the other groups and may have cause a 
bias in the results.  Selection bias is possible.  The used of 
hormone therapy was not evaluated on HRQoL as this may have 
influenced the reported results. 
Pinkawa et 
al., (2009) 
Germany 
21/24 87% -  
B3 
Compare 
HRQoL for 
participants 
treated with 
BT and RT 
for PC. 
PARTICIPANTS:  BT N=52, RT N=52.    
 
DEMOGRAPHICS:  Age BT 68 mean (range 51-72) years, RT 
68 mean (range 48-77) years. No further demographics 
reported.  
 
CLINICAL: T1 to T2 staging.  Co-morbidities BT 52%, RT 48%.  
Most common co-morbidity Hypertension BT 21%, RT 21%. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Before BT or RT, at the last day of RT or 1 
months after BT, and f6 months after treatment. 
 
MEASURES:  Age and clinical data, EPIC 
 
ATTRITION:  Response rate 98%, at baseline and 65% for 
all other questionnaires.   
Obstructive/irritative symptoms were reported higher in the BT 
compared to the RT at baselines and at 16 months. Sexual 
function statistically worsened in both groups with no significant 
difference between the groups.  Bowel function problems were 
more frequently reported in the RT group.  BT participants are 
more likely to experience urinary irritative symptoms and less 
proctitis.  RT participants are more like to experience proctitis 
than urinary irritative symptoms.   
 
LIMITATIONS:  General HRQoL was not measured.  No additional 
demographic data was reported known predictors of HRQoL.  
Selection bias and attrition bias’ is possible. 
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Namiki et al., 
(2006) 
Japan 
21/22 95%  – 
B3 
Assess 
HRQoL for 
men treated 
with BT and 
RP for PC.  
PARTICIPANTS: N=70 BT and N=67 RP (total N=137).   
 
DEMOGRAPHICS:  Age RP 64.3 mean (SD6.5) years BT 67 
mean (6.5) (P=0.024).  No further demographics reported. 
 
CLINICAL:  All T1 to T2.  Nerve-sparing procedures performed 
in N=56 RP participants.   
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment), 1, 3, 6, and 
12 months after treatment. 
 
MEASURES:  Age and clinical data.  SF-36 and the UCLA-
PCI, IPSS 
 
ATTRITION: N=137, N=117, N=130, N=119 and N=115 
returned questionnaires at baseline, 1, 3, 6, and 12 
months.  . 
RP group significantly worse role limitation due to physical 
problems, emotional problems, social functioning, bodily pain and 
mental health and vitality at 3 months and improved at 6 months.  
BT reported no significant worsening in general HRQoL during any 
of the follow-up.  Urinary function worsened for RP group but a 
gradual trend of improvement was seen overtime, but remained 
statistically worse at all-time points.  Sexual function in the RP 
group improved for participants who were treated with nerve-
sparing surgery compared to men who did not receive nerve-
sparing surgery. RP group had significantly worse sexual function 
than the BT group at all-time points. BT participants reported a 
doubled IPSS score at 3 months post treatment but recovered by 
12 months. 
 
LIMITATIONS:  Possibility of selection and attrition bias.   
Arredondo et 
al., (2007) 
USA 
22/24 91%  – 
B3 
 
Assess 
HRQoL for 
men with 
biochemical 
relapse  
PARTICIPANTS:  N=897 analysis for RP alone, N=175 subset 
for secondary analysis. 
 
DEMOGRAPHICS:  Age RP only <60 years 36.6%, 60-70 years 
55.4%, >70 years 8.1%, RP + secondary treatment <60 30.7%, 
60-70 years 56.8%, >70 years 12.5 (P=0.10).  Race white RP 
only 87.2%, RP + treatment 90.3%.  Education college and 
above RP only 65.7%, RP+ treatment 56.5% 
 
CLINICAL:  Performed nerve-sparing surgery RP only 63.8%, 
RP + treatment 49.2% (P<0.001).   
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  compared data 27 months before the 
second treatment for biochemical relapse up to 39 
months after second treatment. 
 
MEASURES: Demographic and clinical, SF-36, UCLA-PCI 
 
ATTRITION:  Participants in this study had to, at 
minimum complete 1 questionnaire before and 1 
questionnaire after their second treatment.  The 
participants that were excluded for not returning the 
questionnaires were not statistically difference from 
those included. 
Across all HRQoL RP + treatment reported worse scores than RP 
alone, these differences were still maintained after adjusting for 
baseline clinical and demographic characteristics.  HRQoL is 
affected at 15 months before initiation of the second treatment.  
HRQoL show differences in all domains over time, with role-
physical and sexual functioning being the largest clinically 
significant decline.  HRQoL is not only affected by second 
treatment but start to decline approximately 15 months before 
treatment begins. 
 
LIMITATIONS:  Selection bias is possible.  Results are limited to RP 
patient only thus limited the generalisabilty of the findings. 
Peters et al., 
(2008) 
USA 
19/22 86%  – 
B3 
Assess the 
impact of 
single 
nucleotide 
polymorphis
ms as a 
predictor of 
HRQoL. 
PARTICIPANTS:  N=141  
 
DEMOGRAPHICS:  Age 66 years (range 46-79), Race White 
77%, no further demographics reported. 
 
CLINICAL:  All participants treated with RT.   
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Before treatment and at 6 monthly 
intervals (median follow-up 51.3 months, range 12 to 
138 months) 
 
MEASURES:  Demographic and clinical data. IPSS, 
International Index Erectile Function.  Lymphocyte and 
DNA extraction data.   
 
ATTRITION:  Attrition data not reported. 
An association of certain TGFBI genotypes and the development 
of both erectile dysfunction and late rectal bleeding.  3% reported 
(N=4 out of N=141) overall poor urinary function measured by the 
IPSS. No association found with genotypes and urinary disease-
specific HRQoL. 
 
LIMITATIONS:  Selection and attrition bias is possible.  Reported 
that the study was underpowered. 
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Robinson et 
al., (2009). 
Canada 
20/22 90%   
– B3  
Compare 
HRQoL for 
RT and 
cryoablation  
PARTICIPANTS:  N-244  
 
DEMOGRAPHICS:  Age Cryoablation median 69.4 (range 52.8 
to 81.4) years, RT 68.6 (range 53.2 to 78.6) years. No further 
demographics reported. 
 
CLINICAL:  All patients were T1 to T3.  N=122 Cryoablation, 
N=122 RT.  All participants were taking HT. 
DESIGN:  Prospective longitudinal  
 
TIME POINTS:  Before treatment, 1.5, 3, 6, 12, 18, 24, 36 
months after treatment.  
 
MEASURES:  Age and clinical data, EORTC-C30 UCLA-PCI 
 
ATTRITION:  Attrition was reported 87% approximately. 
3 months the cryoablation urinary function improved compared 
to RT group. No difference in bowel function for either group.  
Cryoablation group had worse sexual function scores than RT, no 
group recovered to baseline sexual function.  RT group reported 
better sexual function and better urinary function at 3 month and 
had better long-term sexual functioning compared to 
cryoablation.   
 
LIMITATIONS:  All participants were taking HT, therefore it is 
possible that this would have influenced their HRQoL outcomes.  
Attrition bias is possible, use of self-management techniques no 
identifies as this may influence HRQoL. 
Miller et al., 
(2007) 
USA 
19/22 86% – 
B3 
Compare 
HRQoL for 
men for men 
with RP and 
LRP.   
PARTICIPANTS:  N=162.  
 
DEMOGRAPHICS:  Age 60.8 mean (SD not reported) years. 
No further demographics reported. 
 
CLINICAL:  N=42 (26%) underwent LRP, N=120 (74% 
underwent RP.  All T1-T2.  The was no statistical difference 
between the groups for age.   
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline (pre-operatively 1 week recall), 
1, 2, 3, 4, 5, 6 weeks post-op.   
 
MEASURES:  Age, clinical data, SF-12,  
 
ATTRITION:  overall response for the questionnaire was 
80%, the proportion of missing data was 60%.   
LRP group significantly better physical HRQoL compared to the RP.  
The mental HRQoL scale was not related to the surgical 
procedure.  Return to baseline was assess and it was estimated 
that for the LRP was weeks 5-6 and for the RP was 6-7.  LRP group 
had higher physical HRQoL and faster recovery of HRQoL than 
men in the RP group.  LRP reported a higher baseline mental 
health summary score than the RP, this may have been due to 
optimistic believes about the new surgical procedures. 
 
LIMITATIONS:  Retrospective memory recall bias.  Attrition bias is 
also possible.  Lack of demographics and co-morbidities.  Unequal 
numbers in the surgical groups. 
Kershaw et 
al., (2008) 
USA 
20/22 90%  – 
B3 
Assess stress 
and coping 
model on 
HRQoL  
PARTICIPANTS:  N=429 dyads approached N=263 68.7%) 
recruitment rate. 
 
DEMOGRAPHICS:  Race white 86%, African –American 
13%,marriage length 31.8 mean (SD14)  year, Education 16.1 
mean (3.7) years patients, 14.9 mean (SD2.8) spouses. 
 
CLINICAL:  N=121 patients, newly diagnosed (67%), advanced 
(20%) biochemical relapse (13%).  Average length since 
diagnosis was 8 months 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline at recruitment, 4 months and 8 
months after recruitment. 
 
MEASURES:  Demographic and clinical data, SF-12, Brief 
COPE, Appraisal of Caregiving Scales, Becks Hopelessness 
Scale, Mishel Uncertainty in Illness Scale, Current 
Concerns, Lewis Cancer Self Efficacy Scale, Personal 
Resources Questionnaire, Lewis Mutuality and 
Interpersonal Sensitivity Scale, General Symptom 
Distress of the Omega Screening Questionnaire. 
 
ATTRITION:  Attrition not reported. 
Predictors of better mental HRQoL – Participants had a better 
mental QoL at the 8 months follow-up if they had more active 
coping β=+.19, lower avoidant coping at 8 months β=-.31, less 
hopelessness at 4 months β=-.32, fewer baseline symptoms β=-
34.  Predictors of physical HRQoL – Participants had a better 
physical QoL at 8 months if they had a negative appraisal of their 
illness at 4 months β=-.30, fewer baseline symptoms β=-.26 and 
were in diagnosed phase of their disease B=+.25. Participants with 
more social support β=+.33 used more active coping at 8 months.  
 
LIMITATIONS:  The sample may not be representative of all 
prostate cancer participants.  Attrition not reported thus possible 
bias. 
Jayadevappa 
et al., (2007) 
USA 
Assess the 
impact of 
ethnic 
PARTICIPANTS:  N=214 
 
DEMOGRAPHICS:  Age white group 69.87 mean (SD4.5) years 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline (before treatment) 3, 6, 12 
African American (AA) low HRQoL at diagnosis.  AA was a 
predictor of worse role physical, role emotional, bodily pain, 
urinary function and bother at 12 months.   
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21/22 94% – 
B3 
 
variation as 
a predictor 
of HRQoL  
African-American (AA) 71.25 mean (SD 4.1) years (p<0.05).  
Education white college and more 68.57%, AA 30.51% 
(P=0.001).  Marital married white group 77.54%, AA group 
57.63% (P=0.004). 
 
CLINICAL:  Staging T1-T3, treated with RP or RT.   
months after treatment. 
 
MEASURES:  Demographic and clinical data, SF-36, UCLA-
PCI, Client Satisfaction Questionnaire, Charlson Co-
morbidity Index 
 
ATTRITION:  N=195, N=184, N=182, completed 3, 6, 12 
months questionnaires respectively. 
 
LIMITATIONS:  Selection bias and attrition bias is possible.   
Ward-Smith 
and Mehl, 
(2007) 
USA 
19/22 86% – 
B3 
Assess 
HRQoL for 
men treated 
with RP. 
PARTICIPANTS:   N=92, N=56 consented (61%) 
 
DEMOGRAPHICS:  Age mean 50.2 (range 43-65) years, Race 
100% white, Marital married 82%, Education College and 
higher 75%. Employment working 57%. 
 
CLINICAL:  All men received RP.  Nerve-sparing surgery was 
not reported, no further clinical data reported. 
DESIGN:  Protective longitudinal. 
 
TIME POINTS:  Before surgery, 1 and 6 months after. 
 
MEASURES:  Demographic and FACT-P 
 
ATTRITION:   100% completed all follow-up data 
collection. 
Social well-being worsened from baseline to 3 months and 6 
months.    
 
LIMITATIONS:  This sample was homogeneous, thus limits the 
generalizability of results.  Selection bias is possible.     
Vodermark 
et al., (2009). 
Germany 
20/22 90%  – 
B3 
 
Assess 
HRQoL for 
men treated 
with BT. 
PARTICIPANTS:  N=74, N=72 consented (97.4% selection 
rate). 
 
DEMOGRAPHICS:  Age 67mean (SD 6) years.  No further 
demographics reported. 
 
CLINICAL:  N=17 (23%) received neoadjuvant HT.  All T1 to T2 
Gleason <7 and PSA <10ng/mL. 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Pre-treatment, 1 month and 1 years after 
BT. 
 
MEASURES: Age and clinical data.   EORTC-C30 and PR-25 
 
ATTRITION:  87.8% and 89.2%, at 1 and 12 months after 
BT respectively. 
 
All functional scales (C30) were significantly worse at 1 month 
compared to baseline but recovered by 12 months.  The 
emotional function scale improved over pre-treatment reports.  
Global HRQoL was not affected at any of the follow-up time 
points, and was similar scores to age match controls of a German 
population.  Constipation was significantly worse at 1 and 12 
months. Urinary symptom increased at both 1 month and 12 
months compared to baseline.  Sexual function questions were 
only completed by a minority of participants (54%).  Thus limited 
the analysis of this function. 
 
LIMITATIONS:  The use of sexual aids was not reported, and 
limited demographics as this is known to be predictive of HRQoL.   
Zavala et al., 
(2009) 
USA 
23/24 95%  – 
B3 
Assess 
HRQoL for 
low-income 
men with PC. 
PARTICIPANTS:  N=447, N=357 consented (80% selection 
rate).  N=65 with metastatic disease which were excluded 
yielding a final sample of N=291. 
 
DEMOGRAPHICS:  Age 73% were >60 years, Marital  75% 
were in a committed relationship, Race 53% Hispanic, 23% 
white Education 85% had high school education and less. All 
men 200% below federal poverty 
 
CLINICAL:  PC all treatment and stages, except metastatic 
disease. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  At IMPACT enrolment, 6 and 15 months 
after enrolment.  
 
MEASURES:  Demographic and clinical, UCLA-PCI, SF-36, 
Charleston Co-morbidity Index,  
 
ATTRITION:  N=291, N=291, N=182, at enrolment, 6 
months, 15 months respectively.   
RP group had worse urinary, bowel and sexual function at 15 
months follow-up compared to other treatments.  Men not in a 
committed relationship had significantly lower physical and 
mental components of HRQoL, urinary and bowel bother.  A 
higher co-morbidity, less education predicted worse physical 
components summary scores. 
 
LIMITATIONS:  This sample homogeneous sample of low-income 
men with PC, thus limits the generalizability.   
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DePuy et al., 
(2006) 
USA 
17/20 85%– 
B3 
 
Assess 
HRQoL in 
men with 
skeletal 
related 
events (SRE) 
with 
metastatic 
PC. 
PARTICIPANTS:  N=643 participants consented.  Among 
participants who survived 6 months after randomization 
N=471 (73%) were included in the analysis. 
 
DEMOGRAPHICS:  Age 71.7 mean (SD 7.4).  No further 
demographics reported. 
 
CLINICAL:  Participants with no SRE at 6 months (N=355), 
participants with 1 SRE at 6 months (N=78), participants with 
2 SRE at 6 months (N=38).   
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline, 3, 6, weeks and every 6 weeks 
up to 24 months. 
 
MEASURES:  Age and clinical, FACT-G, Brief Pain 
Inventory 
 
ATTRITION:  Attrition not reported. 
2 or more SRE predicted significantly worse physical well-being 
and worse levels of pain.  Higher number of SREs predicted worse 
survival than patient without SREs.   Significant differences were 
found between pain, physical, emotional and functional subscales 
with participants experiencing single vs. multiple SREs.   
 
LIMITATIONS:  Using a different cut off might have yielded 
difference results, rather than 6 months for estimating the 
development of SREs. 
Namiki et al., 
(2007) 
Japan 
20/20 100% 
– B3 
Assess 
HRQoL for 
men treated 
with RP with 
biochemical 
relapse and 
without 
relapse. 
PARTICIPANTS:  N=249 underwent a 2 year follow-up, N=46 
men showed biochemical relapse.  . 
 
DEMOGRAPHICS: There were no significant differences in 
age, marital status or co-morbidities.   
 
CLINICAL:  N=46 RP with biochemical relapse, N=203 with RP 
with relapse.  
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Before RP and 24 months after RP. 
 
MEASURES:   Demographic and clinical data, UCLA-PCI 
and SF-36 
 
ATTRITION:  There was no attrition in this study, 
completion was 100%. 
SF-36, physical problems, emotional problems, bodily pain and 
mental health (P=0.03) for men with biochemical relapse.  Men 
without biochemical relapse had better mental health and social 
functioning and men with biochemical relapse.  No difference in 
prostate cancer-specific HRQoL in either group at baseline.  
Urinary function worsened in both groups at 2 years and 
statistical difference in either group. Sexual function worsened in 
both groups at 2 years.  Nerve-sparing surgical techniques group 
had better sexual functioning than non-nerve sparing.  Younger 
men predicted better sexual and urine function.  
 
LIMITATIONS:   It is possible for selection bias and small N in the 
biochemical relapse group.  
Lips et al., 
(2007) 
Netherlands 
17/20 85%  – 
B3 
Compare 
conformal 
RT with 
IMRT in men  
PARTICIPANTS:  N=78 conformal RT (70Gy), N=92 IMRT 
(76Gy).   
 
DEMOGRAPHICS:  Age conformal 67 mean (range 47-78) 
years, IMRT 67 mean (range 49-79) years.  No further 
demographics reported. 
 
CLINICAL:  All T1-T4, no significant differences were found in 
clinical characteristic between the groups.  Conformal N=9, 
IMRT N=24 treated with HT. 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline (before treatment), 1 and 6 
months. 
 
MEASURES:   Age and clinical data, EORTC-C30 and PR25, 
SF-36 
 
ATTRITION:  Attrition not clear from the paper. 
The IMRT group reported less deterioration in HRQoL for all scales 
than the conformal RT group.   Adjuvant HT participants reported 
more treatment related symptoms.  HRQoL change overtime all 
participants: 
Baseline vs. 1 month: SF-36:  Physical role restriction -15.0 
(P<0.0001), vitality – 3.7 (P<0.01, C30: Emotional functioning 7.6 
(P<0.0001), fatigue 6.0 (P<0.0001), constipation 4.4 (P<0.002), 
Diarrhoea 6.8 (P=0.002) 
PR25:  Bowel symptoms 5.1 (P<0.0001), treatment related 
symptoms 3.2 (P<0.0001), sexual activity -9.8 (P<0.0001). Baseline 
vs. 6 months:SF-36:  Emotional role restriction 10.6 (P=0.002), 
Mental health 3.8 (P=0.0002) 
C30:  Emotional functioning 8.5 (P<0.0001) PR25:  Treatment 
related symptoms 3.5 (P<0.0001), sexual activity -13.9 (P<0.0001). 
IMRT can provide a higher dose of radiation without a further 
deterioration on HRQoL. 
 
LIMITATIONS:  the use of sexual aids and demographics were not 
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reported, which could be a possible bias of the study. 
Lit win et al., 
(2006) 
USA 
 
21/22 95%  – 
B3 
Compare 
HRQoL for 
treatment 
for localized 
PC. 
PARTICIPANTS:  N=307 RP, N=78 RT, N=90 BT were treated 
for localized PC.  81.9% selection rate. 
 
DEMOGRAPHICS:  Age RP 60.1 mean (SD 7.2) years, RT 70.8 
mean (SD 7.3), BT 68.4 mean (SD 6.9) years (P<0.001).  Race 
white RP 85.3%, RT White 84.6 %, BT 78.9 (P=0.34), Marital 
partnered RP 83.4%, RT 82%, BT 80% (P=0.75), Education 
college and more RP 73.6%, RT 71.8%, BT 59.6% (P<0.05) 
 
CLINICAL:  , N=307 RP, N=78 RT, N=90 BT, all T1-T3   
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline (before treatment), 1, 2, 4, 8, 12, 
18, 24 months after treatment. 
 
MEASURES:  Demographic and clinical data, SF-36, UCLA-
PCI, AUASI. 
 
ATTRITION:  Attrition was well reported for each time 
point.  72% response rate at 24 months. 
All treatment groups HRQoL was worse at 1 month post 
treatment. BT group reported moderate to severe urinary 
obstruction and irritation. No significant change was seen in the 
physical or mental domain.  RP group has the worse urinary 
control and sexual functioning than the radiation nerve-sparing 
surgery predicted better sexual function.  Obstructive and 
irritative urinary symptoms were common in BT group.  Urinary 
control and sexual function were better after RT than BT  Among 
potent men, recovery of sexual function was best after RT and 
was equivalent to nerve-sparing surgery or BT.  Sexual bother was 
more common thank urinary or bowel bother after all 3 treatment 
groups.  Bowel dysfunction was more common in RT and BT than 
RP.  Different treatment for localized PC affects HRQoL differently.   
 
LIMITATIONS:  This study did not account for men receiving HT, 
co-morbidities or the use of sexual aids.  Selection and attrition 
bias is possible. 
Monahan et 
al., (2007) 
USA 
20/22 90%  – 
B3 
 
 
Assess 
predictors 
(depressive 
symptoms 
and 
treatment 
type) of 
HRQoL. 
PARTICIPANTS:  N=105 
 
DEMOGRAPHICS:   Age 64.3 mean (SD 8.1) years, Race white 
88%, Education College and higher 57%, Marital married 
95%   
 
CLINICAL:  Stage T1 to T3, RP N=58 (55%), RT N=28 (27%), BT 
N=19 (18%), NS-RPN=34 (58%) 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  within 4 weeks of initial treatment 
completion, 4, 7, 12 months after treatment. 
 
MEASURES:  Demographic and clinical data, Prostate 
Cancer Quality of Life Instrument (PC-QoL), SF-36, CES-D 
(depression instrument). 
 
ATTRITION:  Attrition not reported in this paper. 
Treatment type and age did not predict depression scores.  Age 
was significantly associated with treatment type.  RP participants 
were the youngest and RT were the oldest.  African American and 
other races (not white) where more likely to choose.  Higher 
education predicted higher depressive symptoms.  Poorer sexual 
function predicted depressive symptoms.  BT and RT generally 
reported better urinary function that RP participants. Depressive 
symptoms predicted all three prostate cancer-specific HRQoL.  
Depressive symptoms had a significant relationship with generic 
aspects of general HRQoL.   BT group reported worse pain at 12 
months, role limitations due to emotional problems at 7 months 
and social functioning at 7 months, compared to RT participants.  
Depressive symptoms measures at 4 weeks post treatment 
significantly predicted subsequent 4, 7, 12 months global HRQoL 
after adjusting for treatment, age, education, race and marital 
status.  Depressive symptom was a stronger predictor of HRQoL 
than treatment types.   
 
LIMITATIONS:  Although this study found that depressive 
symptoms predicted HRQoL, however it is possible that low 
HRQoL causes depressive symptoms?  Research is needed to 
disentangle this relationship.  Depressive symptoms were 
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measures at 4 week post treatment but a pre-treatment baseline 
would have enabled a clearer understanding of the relationship 
without the influence of treatment effects. 
Moinpour et 
al., (2008) 
USA 
22/22 100%  
– B3 
Assess 
HRQoL for 
participants 
treated with 
RP, 
randomly 
assigned to 
HT or 
observation 
only. 
PARTICIPANTS:  N=425 
  
DEMOGRAPHICS:    Age RP only 66 mean (range 57-79) 
years, RP + HT 64 mean (ranges 45-78) years, Race  white RP 
only  N=71, RP + HT 74%. 
 
CLINICAL:  RP only N=107, RP + HT N=110, no significant 
differences were reported between clinical variables. 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline (at randomization), 6 weeks, and 
annually for 5 years. 
 
MEASURES:  Demographic and clinical data SF-20 and SF-
36, disease-specific HRQoL (with a developed measure 
for this study) 
 
ATTRITION:  Attrition rates were 95%, 91%, 90%, 88%, 
76%, 73%, 72%, 67%, at baseline, 6 weeks, 6 months, 1, 
2, 3, 4, 5 years respectively. N=217 in analysis. 
RP + HT experienced more bowel dysfunction than patient 
receiving RP only.  Urinary frequency was reported as more of a 
problem in the RP + HT group over the entire follow-up. RP + HT 
group had normal HRQoL by 5 years (51%) compared with 
participants on the RP had (69%).  RP + HT had significantly higher 
symptom distress with increasing time (P=0.02).   
 
LIMITATIONS:  The disease-specific HRQoL measure did not 
reported psychometric properties.     
Korfage et 
al., (2005) 
Netherlands 
21/22 95%  – 
B3 
Assess the 
impact on 
mental and 
HRQoL for 
men newly 
diagnosed 
with PC. 
PARTICIPANTS:  N=4193, N=3800 (88% response rate) of 
which N=52 men were diagnosed with PC which this paper is 
reporting on. 
 
DEMOGRAPHICS:  Age 67.3 mean (SD 4.4) years.  No further 
demographics reported. 
 
CLINICAL:  RP N=18, RT N=1, BT N=13, WW N=1, Undecided 
N=1. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  2 Months before diagnosis, 1, 7 months 
after diagnosis. 
 
MEASURES:  Age and clinical data, SF-36, EQ-5D 
 
ATTRITION: N=1 refused the second data collection.   
Mental health significantly decreased from pre-diagnosed reports 
to 1 month after diagnosis.  A PC diagnosis from a PSA screening 
can have a negative impact on men’s mental health and self-
rating of their health status. Thus evaluating men’s health post-
diagnosis/pre-treatment may lead to an underestimation of their 
mental health. 
LIMITATIONS:  Different treatment would have influenced HRQoL 
at 7 months.   
 
 
Kobuke et 
al., (2009) 
Japan 
18/20 90% – 
B3 
 
 
Assess 
HRQoL for 
men treated 
with RP and 
BT. 
PARTICIPANTS:  N=73 
 
DEMOGRAPHICS:  Age RP 67 median (range 54-75), BT 67 
median (range 53-76) No further demographics reported. 
 
CLINICAL:  N=37 RP, N=36 BT, Stage T1-T2, Nerve-sparing 
N=13, neoadjuvant HT RP N=13, BT N=0  Recurrences at 12 
months RP N=3, BT N=0 
 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before treatment), 1, 3, 6, 12 
months after treatment. 
 
MEASURES:  Age and clinical data, SF-36, UCLA-PCI, IPSS 
 
ATTRITION:  The average response rate was 92.4% RP 
and 92.2% BT, there was no statistical difference 
reported for clinical or age variables. 
RP group: role physical functioning, bodily pain, social functioning 
and role emotional functioning was worse at 1 month but 
recovered at 3 months.  Mental health scores improved over 
baseline after 6 months.  BT group general HRQoL domains were 
not affected and did not change from baseline.  General health 
domain of HRQoL was better in the RP than the BT group 
(P=0.031).  RP group experienced urinary, bowel and sexual 
dysfunction 1 month.  BT group experienced urinary and bowel 
dysfunction but non-significant. General and mental health scores 
were lower in the BT participants than the RP participants at 12 
months. 
 
LIMITATIONS:  Possible bias of HT and use of sexual aids.  
Selection bias is also possible. 
Spry et al., 
(2006) 
Assess the 
intermittent 
PARTICIPANTS:  N=250  
 
DESIGN:  Prospective longitudinal. 
 
9 months of HT led to worsening of 22 of the 23 scales with most 
dramatic declines reported in the first 3 months.  The only 
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Australia 
22/22 100% 
– B3 
 
 
effect of 
androgen 
blockade for 
men with PC. 
DEMOGRAPHICS:  Age <70 years N=86 (34.4.%), 70-79 years 
N=130 (52%), >80 years N=34 (13.6%), Marital married 
N=210 (84%) 
 
CLINICAL: Locally advanced N=66 (26.4%), locally recurrent 
N=116 (46.4), Metastatic N=34 (13.6%) 
TIME POINTS:  Baseline (before treatment) and then 
every 3 months for 3 years. 
 
MEASURES:  Demographic and clinical  data, EORTC-C30 
+PR25 
 
ATTRITION:  Response rate of the questionnaires was 
80%.  . 
clinically significant difference was reported for sexual function, 
hot flushes, sleep disturbances and loss of maleness. Higher 
baseline testosterone was associated with a greater weight gain, 
no other scales were influenced.   
9 months period of HT was associated with simultaneous and 
progressive deterioration of broad ranges of HRQoL domains.  
During androgen recovery (off the HT) there was a slight 
improvement, smaller magnitude and slower recovery, taking 
approx 9-12 months.   Increasing age was associated with poorer 
function.  However, disease staging did not predict changes in 
HRQoL following HT.   
 
LIMITATIONS:  Selection bias is possible, the use of sexual aids 
were not reported, thus a possible bias. 
Inoue et al., 
(2009). 
Japan 
19/20 95%  – 
B3 
Assess 
HRQoL over 
5 years from 
men treated 
with RP. 
PARTICIPANTS:  N=194  
 
DEMOGRAPHICS:  Age 50-59 N=10 (5.2%), 60-69 N=80 
(41.2%), 70-79 N=102 (52.6%), >80 N=2 (1%).  No further 
demographics reported. 
 
CLINICAL:  All staging T1-T3, Nerve-sparing 59% 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baselines (before RP), 3 and 6 months, 1, 
2, 3, 4, 5 years after RP. 
 
MEASURES:  Age and clinical data, SF-36 and UCLA-PCI 
 
ATTRITION:  Response rates 100%, 82.1%, 86.2%, 87.4%, 
86.6%, 79.7%, 75% at baseline, 3 and 6 months, 1, 2, 3, 
4, 5, years, respectively. 
SF-36: decrease in role limitation due to physical problem and 
social functioning at 3 months but recovered at 6 months.  Year 2 
and 3, role limitations due to physical and emotional problems, 
mental health scores were significantly better than baseline 
values.  Urinary function significantly worsened at 3 months for 
49% of the participants and improved at baseline scores at 5 years 
for 92% of participants.  Bowel domains were not affected by the 
RP.  Significant predictor of recovery of sexual function was NS 
surgery, not age. 
 
LIMITATIONS:  Selection bias is possible and the use of sexual aids 
was not reported as this would have influences sexual function. 
Rees et al., 
(2005) 
UK 
19/22 86% – 
B3 
 
Assess 
response 
shift (RS) in 
HRQoL in 
participants 
with 
advanced 
PC. 
PARTICIPANTS:  N=55 participants and N=43 partners 
consented.   
 
DEMOGRAPHICS:  Age 72.9 mean (SD 8.5) years.  No further 
demographics reported. 
 
CLINICAL:  PSA range 4.4 to 5050ng/mL, median 57.2 ng/mL, 
N=13 with distant metastasis, N=44 locally advanced disease.  
N=44 treated HT only, N=8 RP in additional to neoadjuvant 
HT, N=3 no treatment either AS/WW. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (at diagnosis) 3 and 6 months 
 
MEASURES:  Age and clinical data, Prostate Cancer 
Patient and Partner Questionnaire. 
 
ATTRITION: N=55, N=2 participants died, leaving a total 
of N=53 and N=41 partners that completed all data 
collection points. 
Partners of participants reported significantly higher cancer-
related distress at all time points compared to participants.  
Advanced prostate cancer predicted worse HRQoL at 3 and 6 
months.  The method of testing response shift was using 
retrospective questionnaires then comparing the magnitude of 
difference in actual and retrospective responses.  HRQoL 
evaluated over a longitudinal study identified response shift 
(changing internal standards of HRQoL (recalibration) and 
redefinition of HRQoL (reconceptualization). 
 
LIMITATIONS:  It is not clear whether there is evidence of 
response shift, or whether this change was a result of memory 
recall bias.  Selection bias is possible. 
Roberts et 
al., (2006) 
Assess the 
impact of 
PARTICIPANTS:  N=93 
 
DESIGN:  Prospective longitudinal. 
 
Social support did not predict physical functioning, but 
significantly predicted better mental functioning.  Social support 
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USA 
20/20 100% - 
B3 
 
 
social 
support on 
HRQoL for 
men with 
localized PC. 
DEMOGRAPHICS:  Age 65.7 mean (SD 6.48) years, Race white 
91%, Employment working 52.8%, retired 47.2%, Education 
college and higher 60.6%, Marital married 85.4%. 
 
CLINICAL:  RP 61.8%. BT 18%, RT 13.5%, BT and RT 4.5% 
TIME POINTS:  baseline (close to after treatment was 
complete) and 3 months follow-up 
 
MEASURES:  Demographic and clinical data, SF-36, 
adapted Impact of Events Scale (measuring intrusive 
thoughts), 2 questions “How often have you found 
yourself searching to make sense of your illness? How 
often have you found yourself wondering why you got 
cancer or asking why me?” (Searching for meaning 
variables).  Social Provisions Scale (SPS) – perceived 
support. 
 
ATTRITION:  N=93, N=89 (96%) response rate. 
and negative coping were not related to physical functioning.  
Social support at T1 was positively and significantly related to T2 
mental functioning (β=4.08,SE β=2.01 P<0.05), accounting for 5% 
of the variance.  T1 social support was negatively associated with 
T1 negative coping( β=-0.50, SE =0.15, P<0.01).  Negative coping 
mediated the relationship mediated the relationship between T1 
social support and T2 mental functioning.  Men with higher 
perceived social support predicted of better mental functioning.  
 
LIMITATIONS:  Biased in favour of white and well-educated, thus a 
limits the generalizability of the findings. Men may have also 
wanted to represent themselves in a socially desirable way, if they 
did not have adequate support or lower mental health.  Selection 
and attrition bias are possible. 
Robinson et 
al., (2006) 
Canada 
20/22 90% – 
B3 
Assess 
HRQoL for 
participants 
treated with 
salvage 
cryosurgery. 
PARTICIPANTS:  N=46 consented.   
 
DEMOGRAPHICS:  Age 70 mean (range 57-79) years. No 
further demographics reported. 
 
CLINICAL:  Failure of RT and were treated with cryotherapy 
N=12 were treated with HT, PSA mean <10 ng/mL before 
cryosurgery, 12 and 24 PSA <0.3 ng/mL for 87% of 
participants. 
DESIGN:  Prospective longitudinal  
 
TIME POINTS:  Baseline (before cryosurgery), 6 weeks, 3, 
6, 12, 18, 24 months after treatment. 
 
MEASURES: Age and clinical data, EORTC-C30, PCI 
 
ATTRITION:  Response rate ranged from baseline 97.8%, 
to 24 months 83.8%.  Differences between responders 
and non-responders were not reported. 
Bowel dysfunction significantly worsened at 6 weeks but returned 
to baseline scores by 24 months.  No statistically significant 
differences in baseline scores and 24 months scores for any 
domains of the C30.  Main long-term effect of treatment reported 
was urinary and sexual function problems. 
 
LIMITATIONS:    Selection and attrition bias is possible.  
Demographic data was not reported, known predictors of HRQoL. 
Monga et al., 
(2005) 
USA  
18/20 90% – 
B3 
Assess 
HRQoL in 
men treated 
with RT. 
PARTICIPANTS:  N=89, N=62 consented 
 
DEMOGRAPHICS:  Age 67.8 mean (range 55-78) years, 
Education mean number of years of education was 12.4 
(range 6-18) years, Marital married N=28 (70%) 
 
CLINICAL:  All participants had localized PC.  The intent for RT 
was for curative treatment.   
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  baseline (before RT), mid-way through RT,  
completed RT, 4 weeks after RT and 8 weeks after RT. 
 
MEASURES:  Demographic and clinical data, FACT-P, 
Becks Depression Inventory (BDI), Epworth Sleepiness 
Scle (ESS), Piper Fatigue Scale (PFS) 
 
ATTRITION: N=62, N=22 had incomplete data, data was 
reported comparing responders and non-responders . 
N=18 (45%) developed mild to moderate symptoms of proctitis 
during RT.  Physical well-being worsened mid-way through RT, 
complete RT and at 4 weeks after treatment and 8 weeks.   No 
significant changes in the depression scores at any of the follow-
up time points.  A significant relationship was found between 
depression and overall HRQoL.   Prostate cancer-specific HRQoL 
significantly worsened mid-RT, complete RT and 4 weeks.  At 8 
weeks the scores returned to pre-RT levels and were significantly 
higher (P=0.001), suggesting improvement symptoms.  
  
LIMITATIONS:  There was not a control group for comparisons, 
and the follow-up was limited.  There was not an individual break 
down for the prostate cancer-specific domain, overall score. 
Ball et al., 
(2006) 
USA 
21/22 95%  - 
Assess short-
term HRQoL 
for 5 surgical 
approached 
PARTICIPANTS:  N=719.  
 
Open RP, (ORP) N=135 
LRP N= 124 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (pre-surgery), 1, 3 , 6  months 
 
Urinary function significantly worsened for ORP, LRP, dVP at 1 
month.  The overall percentage of participants return of 
continence (ORP 38%, LRP 25%, dVP 39%, P=0.03) this favouring 
earlier return of continence after ORP and dVP. At 1 month, BT 
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B3 for treating 
men with 
localized PC. 
Da Vinci robotic prostatectomy (dVP) N= 82 
103Pd (BT) N= 118 
Prostate Cryoblation N= 39 
 
DEMOGRAPHICS:  Age Group 1 ORP 59 mean (SD 6) years, 
LRP 61 mean (SD 7), dVP 60 mean (SD 7), Group 2 BT 67 
mean (SD7), PCryo 72 mean (SD 7). Race white ORP 76%, LRP 
79%, dVP 83%, BT 75%, PCryo 76%.  No further 
demographics reported. 
 
CLINICAL:  Non-nerve sparing surgery was performed OPR 
30%, LRP 54%, dVP 22%, HT was given only to 23% of BT 
participants, 28% of PSryo participants.  Participants were all 
T1-T3 
MEASURES:  Demographic and clinical data, UCLA-PCI 
and the AUA-SI. 
 
ATTRITION:  N=719,  N=498 included in the analysis. 
Response rates of participants completing at least one 
data collection ranged from 95% to 27% 
participants reported worse urinary function and urinary irritative 
and obstruction, worse bowel function, and worse sexual 
function.   1 month, PCryo group also reported worse  urinary 
function and irritative and obstruction urinary symptoms, worse 
bowel and sexual function.  At 3 months, ORP, LRP and dVP 
reported worse sexual function, the percentage of patient 
returning to baseline score (ORP 27%, LRP 21%, and dVP 31%, 
favouring dVP). 3 months, BT reported an improvement in bowel 
function, but reduced sexual function was still significant.  For the 
PCryo group, urinary obstructive and irritative symptoms 
improved, significantly worse bowel and sexual function.  6 
months all treatment groups <50% of participants returning to 
baseline scores for urinary, bowel and sexual function.  A trend of 
improvement can be seen, however still a large proportion of 
patient managing dysfunction.  
 
 
LIMITATIONS:  Selection and attrition bias are possible.   
Truong et al., 
(2006) 
Canada 
18/22  81% – 
B3 
 
 
Assess the 
impact of 
fatigue and 
HRQoL for 
men treated 
with RT. 
PARTICIPANTS:  N=28  
 
DEMOGRAPHICS:  Age median 69 years (range 57-84).  No 
further demographics reported. 
 
CLINICAL:  Majority of participants had T2 and T3 (46% and 
32%, respectively), median Gleason was 7 (range 6-10), 
median PSA at diagnosis was 9.0 ng/mL (range 2.5-103).  All 
participants were treated with HT median duration was 12.2 
month (range 2.5-103 ng/mL) 
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline (before RT), mid-way through RT 
(3-5 weeks during), end of RT, median 6.5 weeks after 
RT.       
 
MEASURES:   Age, clinical data, Brief Fatigue Index. 
 
ATTRITION:  There was no attrition reported in this 
study. 
Fatigue significantly worsened during RT, the end of RT and 6.5 
weeks follow-up compared to baseline.  Fatigue predicted 
worsening general activity, mood, walking ability, normal work, 
relation to others and enjoyment of life.  The scores were 
significantly lower than baseline (peaked severity at the end of 
RT), improved at the 6.5 weeks follow-up, but were significantly 
worse than baseline (P=0.009). At the end of the RT 71% reported 
some degree of fatigue. 
 
LIMITATIONS:   Selection bias is possible.  This influence of HT had 
the potential of interfering with participants reports of fatigue, as 
a side effect of HT, rather than RT. 
Nguyen et 
al., (2009) 
USA 
18/22 81%  – 
B3 
Assess 
HRQoL for 
participants 
treated with 
salvage BT. 
PARTICIPANTS:  N=25  
 
DEMOGRAPHICS:  No demographics reported 
 
CLINICAL:  No participants received HT with the salvage BT.  
All men had T1 to T2 disease, maximum Gleason of 7, 92% 
PSA <10ng/mL. 
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  Baseline (before salvage BT), 3, 15, 27 
months after treatment. 
 
MEASURES:  Clinical data, prostate specific HRQoL 
questions (not named in this paper, reports validity). 
 
ATTRITION:   80% of the participants completed all of the 
data collection questionnaires. No significant differences 
between the responders and non-responders. 
Sexual dysfunction significantly worsened at 27 months compared 
to baseline. At baseline 14/22 (64%) had at least partial erections 
firm enough for penetration, but by 27 months, only 4/22 (18%) 
had erections firm enough for penetration (P=0.005).  Urinary 
obstruction/irritation, significantly worsened at 3 months and was 
non-significant at 27 months.  
Bowel dysfunction significantly  worsened overtime to 15 months 
but was no longer significant at 27 months.  Gradual decline in 
sexual function at all follow-up periods.  For urinary and bowel 
symptoms, generally there was an acute worsening of symptoms 
until 15 months, but at the 27 months follow-up improvement in 
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these side-effects were identified. 
 
LIMITATIONS:  Limited follow-up, as toxicity maybe have 
developed after 27 months, for example one patient developed a 
rectourinary fistula requiring colostomy/urostomy at 29 months.  
Small N.  Selection bias is also possible. 
Prezioso et 
al., (2007) 
Italy 
21/22 95% – 
B3 
Assess 
HRQoL for 
men treated 
with HT 
modalities. 
PARTICIPANTS:  N=587  
 
DEMOGRAPHICS:  Age median 73.3.  No further 
demographics reported. 
 
CLINICAL:  Median time after diagnosis was 21.7 months.  
42.9% treated with LHRH and AA combined therapy, 31.2% 
LHRH only, 24.6% AA only.   
DESIGN:  Prospective longitudinal. 
 
TIME POINTS:  At enrolment, 6 and 12 months after 
enrolment. 
 
MEASURES:  Age and clinical data,  EORTC-C30 
 
ATTRITION:  548/587 completed baseline having at least 
3 months HT, 499/587 completed 6 months data 
collection, 471/587 completed 12 months data 
collection. 
Anti-androgen (AA) monotherapy was significantly associated 
with a better HRQoL than LHRH treatment in all functional scales 
but emotional function.  Worsening physical function and general 
health status was observed in all groups, however, AA had 
significantly better HRQoL than LHRH treatments.  LHRH is 
associated with reduced HRQoL, particularly physical function, 
energy, general health status.  AA had a better HRQoL profile than 
LHRH. 
 
LIMITATIONS:  Other previous main PC treatments (for example 
RP) are possible in this patient group, thus introduced bias in their 
reports of HRQoL.  Selection bias is possible.  Demographics were 
not reported known predictors of HRQoL. 
Kouba et al., 
(2007) 
USA 
18/22 81%  -  
B3 
Assess short-
term HRQoL 
for men 
treated with 
RP. 
PARTICIPANTS:  N=121  
 
DEMOGRAPHICS:  Age African American (AA) 60.7 mean 
years, Caucasian Americans (CA) 60.6 mean years, Race AA 
N=38 (31%), CA N=83 (69%).  No further demographics 
reported. 
 
CLINICAL:  PSA mean 8.4ng/mL, estimated blood loss (EBL) 
493 mls during operation,  Short-term complications <30 
days N=10 urinary retention, haematuria, pelvic haematoma, 
AF, DVT.  
DESIGN:  Prospective longitudinal 
 
TIME POINTS:  Baseline (before RP), 1, 2, 3, 4, 5, 6 weeks 
after surgery. 
 
MEASURES:  Demographic and clinical data, SF-12 
 
ATTRITION:  Overall return rate of the questionnaire was 
80%, but once missing data was taken into account, 
approx 60% of the data was usable for analysis. 
Physical component significantly worsens at 6 weeks. Physical 
component did not differ by race; however age had a significant 
association with the physical component.  At baseline younger 
men <60 had a higher physical component than older men (59.4 
vs. 54.8 respectively, P<0.0001).  Mental component significantly 
improved over baseline scores up to 6 weeks.  Mental component 
at baseline was significantly lower for African Americans 
compared to white ethnic background, but was no longer 
significant at 6 weeks This study did not find PSA, clinical stage or 
pathological stage a significant predictor of HRQoL components. 
 
LIMITATIONS:  This study did not use a disease-specific HRQoL 
measure, to evaluate the changes in urine, bowel sexual 
dysfunction during this acute stage.  Selection and responder bias 
is possible.  Limited demographics reported and confounders are 
possible. 
Hedestig et 
al., (2005) 
Sweden 
13/16  81%  
– B3 
 
Explore 
participants’ 
experiences 
of living after 
a LRP. 
PARTICIPANTS:    N=10  
 
DEMOGRAPHICS:  Age range 61-69 years, Marital N=9 
married N=1 widowed, All were retired. 
 
CLINICAL:  All treated with LRP, no co-morbidities that 
DESIGN:  Qualitative – narrative interviews – Content 
Analysis. 
 
TIME POINTS: Cross-sectional interviews, 30-60 minutes 
in the participants’ home.  Audio-recorded and kept 
reflective diary. 
Main themes emerged, becoming a changed man, striving to gain 
a sense of control in a new life situation, managing a new life 
situation, striving to become reconciled to the new life situation.  
Losing their erectile function radically changed their sex life, 
which gave them a sense of grief.  Losing erections men expressed 
detracting from their manliness.  Most of the men said that they 
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affected daily life, had surgery between >6 months and <3 
years.   
 
MEASURES:  Examples of questions; what did it mean for 
you to receive a diagnosis of PC?   What is your 
experience of having been operated on for PC?  Probing 
questions such as what do you mean? What did you do?  
Tell me about your thoughts and feelings? 
 
 
did not feel like a “whole man.”  Men reported having to wear 
daily pads as a result for urinary incontinence.  Some men 
changed their clothes several times a day despite pads.  They 
described living a social life was something impossible to do.  To 
try and maintain urinary incontinence men focused on 
consumption of drinks, toilets visits, how they dressed in cold 
weather, and how they avoided stressful situations and activities 
that could worsen their incontinence.  They also reported worries 
about the odour from their wet pads when people were around 
them. PSA testing gave men a sense of control over their 
progression of their illness. 2 men did not understand why they 
needed their PSA checked since their prostate gland had been 
removed. 
 
LIMITATIONS:  The results can’t be generalized however the 
meaning of the men’s experience can be a useful insight to further 
understanding of issues around men HRQoL after RP.  The 
theoretical framework to guide this study was not reported.  
Ames et al., 
(2008) 
USA 
18/20 90%  – 
B3 
Explore the 
psychologica
l need of 
men with 
biochemical 
recurrence 
of PC. 
PARTICIPANTS:  N=28  
 
DEMOGRAPHICS:  Age 76 mean (range 58-87), Race white 
86%, black 14%, Education College and above 72%, Marital  
married/partner 85%, Employment  retired 88%.  
 
CLINICAL:  For RT recurrence is defined as 3 consecutive rises 
in PSA >0.2 ng/mL, or a substantial rise that triggers 
hormone therapy.  Surgical recurrence is a PSA level greater 
than 0.2ng/mL. 
DESIGN:  Mixed methods (focus groups and 
questionnaire based).  The questionnaires were 
compared to normative data. 
 
TIME POINTS:  Completion of the questionnaire 
immediately before the focus group.   
 
MEASURES:  Focus groups, 2 hour focus groups 
containing 4-6 men per group.  Semi-structured focus 
group guide, audio recorded and conducted by an 
experienced moderator.  Demographic and clinical data, 
FACT-P, SF-36, Profile of Mood States – Brief (POMS-B),  
Life Experiences Survey,  Perceived Stress Scale 
 
 
From the FACT-P the sample had a lower physical well-being 
(23.6, SD 4.7) thank normative data (26.2, SD 2.8) P<0.0001.  
However, this sample reported higher emotional well-being (20.3, 
SD 3.5) with normative data 23.5 (4.3) P<0.0001.Similar result 
were reported for the SF-36, general health and emotional well-
being were higher than normative samples (P<0.05 and P<0.01, 
respectively). 
The themes identified from the focus groups were; 
1) Meaning of quality of life , no limitations in activities, 
maintenance of good social relationships, ability to remain 
active both physically and mentally, freedom from health 
problems, including side-effects, Representative quote: “the 
extent to which one’s life conforms to the norm…doing 
those things that a person with reasonable health enjoys” 
2)  Physical effects of prostate cancer, decreased libido and 
erectile function, hot flashes from hormone treatment, 
frequent urination and incontinence, fatigue, loss of muscle 
strength, Representative quote: “Sex life is zero”. 
3) Psychological effects of prostate cancer, anxiety about 
recurrence/location of cancer in the body, anger, knowing 
that there is no cure, physical side effects of treatment (e.g. 
fatigue, sexual dysfunction, hot flashes, incontinence) causes 
anxiety and distress, Representative quote: “It’s always on 
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the back burner” 
4) Impact of PSA testing on quality of life, anxiety about PSA 
testing, anxiety about recurrence, anxiety in circumscribed 
to 12-24 hour period prior to testing, Representative quote: 
“Every time it (PSA) went up, it threw me into dithers”. 
5) Strategies used to cope with prostate cancer, social support 
from friends and family, particularly from spouse, use of 
distraction (e.g. staying busy with work, hobbies, 
volunteering), Use of health denial (i.e. positive avoidance), 
exercise and strength training, making healthier diet choices 
(reduced fat, increased soy), Representative quote: I”I just 
accepted it…it’s there…I just don’t think about it anymore…I 
don’t fight it”. 
 
LIMITATIONS:  Small sample size, therefore limits the 
generalisabilty of the findings.   The individual patient’s 
treatments were not reported, and therefore might have 
influenced their reports of HRQoL    The normative sample 
comparisons were difficult to make meaningful comparison, for 
example the population for the PSS is an undergraduate sample of 
students. 
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Appendix 2.1 Extracted Data for Social Support Review 
Ordered by study design 
First author 
and year 
(quality 
assessment) 
Aim Participants Method Findings 
Carmack  
Taylor et 
al., (2006) 
USA 26/32 
81% - B2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carmack  
Taylor et 
al., (2007) 
Evaluating 
the efficacy 
of a group 
based 
lifestyle 
programme 
to improve 
HRQoL - 3 
groups  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Secondary 
analysis of 
lifestyle 
PARTICIPANTS:  N=1093 approached, 
N=134 participants consented.    
 
DEMOGRAPHICS:   Age 69.2 years (range 
44.8-89.0).  Race white 73.1%, 
Black/African American 20.1%, Other 
6.7%.  Employment 54.4% retired, 40.3% 
working, 6.7% other.  Education College 
degrees or advanced degree 76%. Marital 
married 82.8%.   
 
CLINICAL:  At baseline participants has 
been on the androgen-ablation therapy 
average of 32.7 months.   
 
N=46 allocated to the Lifestyle 
programme. 
N=51 allocated to the Education Support 
N=37 Standard Care. 
 
ALLOCATION:  Adaptive allocation, which 
takes in to account study participants 
characteristics, aimed at achieving a 
better group balance.  Allocation taken 
into account QoL, BMI and time on HT.   
Randomized by statistician or data 
manager. 
 
See publication above (number 1) for 
participant details. 
DESIGN:  Intervention study/Quasi experimental 
 
TIME POINTS:  Baseline, 6 months and 12 months. 
 
MEASURES:  Demographic/clinical data, SF-36, Centres for Epidemiological Studies 
(CES-D), State Scale of the State/Trait Inventory (STAI) Brief Pain Inventory (Short 
Form), Interpersonal Support Evaluation List (ISEL), 7-Day physical Activity Recall, 
Stage of Motivational Readiness for Physical Activity, Process for Change of 
Physical Activity, Decisional Balance for Physical Activity Questionnaire, Physical 
Activity Self-Efficacy Questionnaire.  Six-minute walk test, Body Mass Index (BMI) 
Attrition:  Overall, 6 months data was collected in 83%, 12 months 84% of the 
sample. 
 
INTERVENTION:  Approx 8 men per group.  Orientation session and then for 6 
months 16 weekly sessions, and 4 biweekly sessions, lasting 1 and half hours each 
for each intervention group.  
 
Lifestyle Programme:  Participants encouraged to take regular exercise, though 
self-monitoring, goal-setting, overcoming barriers, understanding their caloric 
intake and exercise expenditure.  No physical activity was undertaken other than 
demonstration of exercises.   
Educational Support: Topic included by group discussion was diet and prostate 
cancer, side-effects of androgen-ablation and sexuality. 
Control group: Standard Care. 
 
 
 
 
See publication above (number 1) for participant details. 
No intervention effect was identified on HRQoL.  There 
were no significant differences between HRQoL at 6 or 12 
months between the groups (across all the components of 
the measures).  Social support did not significantly change 
(increase) at 6 or 12 months follow-up.   Mediation of 
social support and physical activity analysis were not 
performed because QOL did not change (DV of interest). 
 
LIMITATIONS:  Validity and reliability was not reported on 
all the measures.  It was reported that the sample size 
lacked power to run the study analysis.  Bias is possible as 
a result of the allocation process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At 6 months, participation in a group (lifestyle or 
educational support) benefited those with greater distress 
(anxiety and depression) or with limited support, 
compared to the control group. 
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USA  26/32 
81% – B2 
intervention  
Weber et 
al,. (2004) 
USA 
26/28  
92.8%  B2 
 
 
To evaluate 
the effect of 
a Dyadic 
intervention 
(one-to-one)  
PARTICIPANTS: N-100 approached, N=51 
refused, N=21 excluded for various. N=32 
(N=2 withdrew due to fear of 
incontinence), final sample N=30 
 
DEMOGRAPHICS: Age 58, range 48-67 
years), Race white 82%, Martial 79%, 
Education high school and higher 85%, 
Employed 62%.   
 
CLINICAL: All men radical prostatectomy 6 
weeks post-surgery 
ALLOCATION: Randomisation procedure 
was not described 
Methods:  intervention study/Quasi experimental 
 
TIMEPOINTS:  6 weeks, 4 weeks and 8 weeks 
 
MEASUREMENTS: Modified inventory of social support, Stanford inventory of 
cancer patient adjustment (self-efficacy), Geriatric depression scale, UCLA 
Prostate cancer index, Charleston Index, Satisfaction with intervention written by 
supportive partners 
 
INTERVENTION: Supportive partners long-term survivors of prostate cancer (9 
white 1 black), mean age 68.2 years, stable PSA for year prior to the study, men 
underwent a 2 hour training session. 
Each dyad met 8 times during an 8 week period. 
There were no significant differences in social support or 
HRQoL. 
 
LIMITATIONS: Sample was mostly white, married and 
educated. High refusal for participants (potential for 
selection bias).   
 
Scholz 
(2008) 
Germany 
21/22 
95.4% -  B3 
12 
To test, 
moderating 
role of social 
support on 
HRQOL . 
PARTICIPANTS:  Men treated by LRP and 
their partners N=77 
 
DEMOGRAPHICS: Age 61.6, SD 6.03 years, 
Education 48.4% reported 9-10 years of 
education, Employment 58.9% retired 
 
CLINICAL:  All men treated by LRP. 
DESIGN:  Prospective longitudinal survey 
 
TIMEPOINTS:  2 weeks and 6 months after surgery 
 
MEASURES:  Received social support was measured by 2 subscales from  the 
Berlin Social support scale (BSSS), spouses provided social support, 2 items from 
the BSSS, SF-12 
 
ATTRITION:  T2 response rate was 81.8%. 
There were no main effects of received or provided social 
support on HRQOL.  A moderating effect was found which 
identified those men who had low mental or physical 
HRQoL at BL had better HRQoL at 6 months when received 
social support was high at BL. 
 
LIMITATIONS:  Small sample size, limited question items to 
assess social support. 
Roberts et 
al, 2006 
USA 
18/18 - B3 
 
 
Examine the 
influence of 
social 
support on 
HRQoL 
PARTICIPANTS:   N=93  
 
DEMOGRAPHICS:  Age 49.1-76.9 years, 
65.7, SD 6.48 years, Ethnicity white 91%, 
Employment 50.6% employed, 47.2% 
retired, Marital 84.5% married 
 
CLINICAL: Time since treatment range 7-
120 days, mean 46.7 days RP 61.8%, BT 
18%, EBRT 13.5%, BT and EBRT 4.5%.  All 
had localised disease.   
DESIGN:  Prospective longitudinal survey 
 
TIMEPOINTS:  BL (close after treatment was completed), and 3 months follow-up 
 
MEASURES:   Demographic variables, SF-36, Impact Events Scale (intrusive 
thoughts), Searching for meaning (2 items questions), Social Provisions Scale 
(perceived social support).  
  
ATTRITION:  N=93, 96% completed questionnaires at the time points. 
T1 social support was positively related to T2 HRQoL 
(β=4.08, P<0.05) accounting for 5% of the variance.  Social 
support was negatively and significantly related to coping 
(β=-.50, P<0.01).  Coping and social support accounted for 
24% of the variance of HRQoL. A reduction of the strength 
of T1 social support with T2 HRQoL due to T1 coping Sobel 
test (Z=2.84, P=0.004) 
 
LIMITATIONS:  Did not have a representative sample for 
men from minority groups.  Limited follow-up. 
Kershaw et 
al, 2008 
USA 
18/22 81% - 
To test the 
stress and 
coping 
model  
PARTICIPANTS: N=429 patient-spouse 
dyads approached.  N=46 did not meet 
inclusion, N=120 declined, leaving N=263 
consented (68.7%). 
DESIGN:  Prospective longitudinal survey 
 
TIMEPOINTS:  BL (consent), 4 and 8 months. 
 
Participants with more BL social support used more 
positive coping at 8 months.  Coping and appraisal was 
found to predict HRQoL. Social support did not have a 
main effect on HRQoL. 
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B3 
 
 
DEMOGRAPHICS:  Ethnicity white 86%, 
Marital length of marriage was 31.8, SD 
14 years,  
 
CLINICAL:  N=121 control newly diagnosed 
67%, advanced disease 20%, biochemical 
recurrence 13%.   
MEASURES:  SF-12, Brief COPE, Appraisal of illness or appraisal of Caregivers, 
Personal resource Questionnaire (perceived social support), Lewis Mutuality and 
Interpersonal Sensitivity Scale (communication about the illness) Symptom 
distress scale (general symptom distress) 
 
ATTRITION: N=134 control group, 90% completed 8 months.   
 
 
 
LIMITATIONS: The sample was mostly white, wealthy and 
educated.    
Andel et al 
2004 
Netherlands 
22/22 100% 
-B3 
 
Explore 
psycho-
social factors 
in relation to 
HRQoL  
PARTICIPANTS:  N=138, total number of 
men approached was not reported. 
 
DEMOGRAPHICS:  RP Age 62.1, SD 5.8, 
Marital 88.9%, EBRT Age 70.0, SD 6.2, 
Marital 90.7%. 
 
CLINICAL: N=65 RP, N=73 EBRT. 
DESIGN:  Prospective longitudinal survey 
 
TIMEPOINTS:  BL (before treatment) 1 year 
 
MEASURES:  Socio-economic, EORTC C30 (general HRQoL), International Prostate 
Score (urine), Incontinence, Sexual Behaviour Questionnaire, EORTC CR38 (bowel 
function), Utrecht Coping List, Profile of Mood states, Impact of Event Scale, 
Expression and non-expression of emotions, Social support Questionnaire 
(perceived social support), Life Experience Survey (life events). 
 
ATTRITION:  N=138 completed BL, N=129 completed 1 year (93% response).  
HRQoL was significantly related negative coping and social 
support (spearmen rank correlations).  No moderation or 
mediation analyses were performed. 
 
LIMITATIONS:  Limited assessment of social support and 
selection bias is possible. 
Visser et al, 
2003 
Amsterdam 
21/22 95% - 
B3 
 
 
To explore 
the psycho-
social factors 
the influence 
HRQoL  
PARTICIPANTS:  N=84. Number of 
participants approached was not 
reported. 
 
DEMOGRAPHICS:   Age 63.3 years, range 
65-75 years, Marital married 83%, 
Education no education or primary 
education 45%. 
 
CLINICAL: N=23 PC (clinical profiles not 
known), N=37 BPH. 
DESIGN:  Prospective longitudinal survey 
 
TIMEPOINTS:  Before diagnosis, 3 months after completion of BL. 
 
MEASURES:  Socio-economic data, EORTC C30+PR25 (HRQoL), International Profile 
Symptom Score (IPSS) (urinary function), Sexual Behaviour Questionnaire (sexual 
function), Standardised COPE (coping), Profile of Mood States (distress), Life 
Experience Survey (Life events), Social Support Questionnaires (Perceived social 
support), Social desirability, Health Behaviours (smoking, drinking, etc.) 
 
ATTRITION:  PC N=31 BL, N= 23 (74.2%) returned 3 months questionnaires, BPH 
N=51 BL, N=38 (74.5%) returned T2.  There were no significant differences 
between responders and non-responders. 
Diagnosis is the most important factor to influence a 
significant decline in HRQoL after 3 months for men 
suffering from PC.  HRQoL was also associated with social 
support and positive coping.  HRQoL decreased for men 
with PC, but remained stable overtime for men with BPH.   
 
LIMITATIONS:  Small sample size, lack of treatment 
information for men with PC.  Selection bias is possible. 
Zhoe et al 
2010 
USA 
17 - 85% - 
B3 
 
 
 
 
To test the 
relationship 
with social 
support and 
perceived 
stress on 
HRQoL  
 
 
PARTICIPANTS: N=175  
 
DEMOGRAPHICS:  Age 64.8 (SD 7.5), 
Marital 84% married/partner, Ethnicity 
white 40%, Hispanic, 41%, African 
American 18%.     
 
CLINICAL:  Localised PC, Surgery 48%, 
EBRT 52%. 
DESIGN:  Prospective longitudinal survey 
 
TIMEPOINTS:  BL (study consent), 3, 10 months and 2 years. BL approximately 15.5 
(SD 6.2 since diagnosis. 
 
MEASURES:  Demographic variables, Perceived Stress Scale (PSS), Social Support 
Instrument (ESSI [perceived social support]), FACT-G (HRQoL) 
 
ATTRITION: Selection and attrition bias were not reported in this study. 
Greater social support at BL significantly predicted higher 
HRQoL (physical well-being) scores at 2 years (β=.16, 
P<0.05.  The results indicated that partial mediation 
between the relationship of social support and HRQoL 
partially mediated by perceived stress (sobel test=1.99, 
P<0.05) 
 
LIMITATIONS:  BL reports prior to treatment were no 
measured, thus BL within this study are likely to not 
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Zhou et al, 
2010 
USA 
19/22 86% -
B3 
 
 
 
 
 
To test 
mediation, 
whether PS 
mediates the 
relationship 
between SS 
and HRQoL. 
 
 
 
 
 
 
 
PARTICPANTS: N=180 
 
DEMOGRAPHIC: Race White 40%, 
Hispanic 41%, African American 19%  Age 
64.9 SD 7.5: Marital Status 84% married: 
Education in years 13.7 SD 3.4  
 
CLINICAL:   Months since Tx 10.6 SD 4.8: 
Months since diagnosis 15.4 SD 6.2: RP 
48%, EBRT 52%.   Localised PC. 
Excluded if on HT or Hx of other cancers. 
 
 
 
 
 
 
Same study as above  
 
 
 
 
accurately capture change over time throughout the 
patient trajectory.  Limited evaluation of other social 
support elements, selection and attrition bias are possible.  
Excluded participants with psychological co-morbidity. 
 
Mediation:  HRQoL was associated with social support 
(β=.053, P<0.001, positive coping was associated with 
social support (β=0.36, P<0.01).  Partial mediation results 
indicated the relationship between social support and 
HRQoL was partially mediated by positive coping (Sobel 
test z = -2.29, <0.05). 
Moderation was not performed. 
LIMITATIONS: as above 
Poole et al, 
2001 
Canada 
13/20 65% - 
C1  
 
Explore the 
effect of 
social 
support 
groups on 
HRQoL 
PARTICIPANTS:  Men recruited through 13 
prostate cancer support groups in 
Columbia, Canada.  N=240 (60%) selection 
rate for support groups, (55%) for men 
approached In clinics. 
 
DEMOGRAPHICS:  Majority of men were 
white, married and retired and had 
postsecondary education. Age 67.7, SD7.9 
years. 
 
CLINICAL:  Time since diagnosis was 27 
months, SD 34.7.   
DESIGN:  Cross-sectional survey 
 
TIMEPOINTS:  Various stages of the cancer journey 
 
MEASURES:  Perceptions of support survey-patient version (perceived social 
support), Social support questionnaire, perceived social support (social network 
and satisfaction), FACT-P, Coping (adapted measure 4 items), Demographic data. 
 
ATTRITION: N/A. 
Attenders were more likely to source information from 
fellow participants and non-attenders were more likely to 
rely on medical staff.  No significant differences were 
found between attenders and non-attenders for positive 
coping, HRQoL, or satisfaction with their social support. 
 
LIMITATIONS:  Cross-sectional design, lack of clinical 
information, frequency of attenders using the support 
group was not reported and may have biased the results.   
Rondorf-
Klym et al 
2003 
USA 
16/22 72% - 
C1  
 
To explore 
the influence 
of psycho-
social factors 
on HRQoL  
PARTICIPANTS:  N=132 mailed out, N=97 
(response (73%), N=88 completed in the 
analysis 
 
DEMOGRAPHICS:  Age 66 years (SD not 
reported), large majority of men were 
married/partner 84%, and had high level 
of education 
 
CLINICAL: RP 12-24 months after surgery 
DESIGN:  Cross-sectional survey 
 
TIMEPOINTS:  12-24 following RP. 
 
MEASURES:  UCLA-Prostate cancer index, Rosenberg self-esteem scale, anger 
suppression scale, personal resource questionnaire 85 part 2, Centre for 
epidemiological studies questionnaire, multidimensional health locus of control, 
The Quality of life scale. 
 
ATTRITION: N/A. 
Perceived social support had a main effect on HRQoL.  It 
was reported that social support was a mediator variable 
for HRQoL.  However, it is not clear/not reported 
identifying the independent variable, for which social 
support mediated the relationship. 
 
LIMITATIONS:  Cross-sectional design and lack of clarity on 
the strategies to test for mediation effects of social 
support. 
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T1or T2 disease staging. 
Mehnert et 
al 2009 
Germany 
19/24 79% - 
C1 
 
Examine 
perceived 
stress, social 
support on 
HRQoL 
PARTICIPANTS:  N=511. Number of 
participants approached was not 
reported. 
 
DEMOGRAPHICS:  Age 64 years Marital 
88% married, Education High school 66%, 
Employment 68% retired.  
 
CLINICAL:  All RP, time since surgery was 
27 months (mean), ranging from 2 to 141 
weeks.  Sample – all stages of cancer. 
DESIGN:  Cross-sectional survey 
 
TIMEPOINTS:  Varying time post diagnosis.  
 
MEASURES:  Posttraumatic Stress Disorder checklist, Illness Specific Social 
Support, SF-8, HADS. 
 
ATTRITION: N/A. 
 
 
Married men had significantly higher perceived social 
support compared to single men (P<0.0001).    Social 
support has a main effect on HRQoL . 
 
LIMITATIONS: Selection bias is possible, limited assessment 
of social support, cross-sectional design. 
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Appendix 3.1 Extracted Data for Self-Management Review 
Ordered by study design 
Author 
(year) 
Quality 
score 
Aim Participants (demographics and 
clinical data)  
Methods (Study Design, sampling method) Overall findings and limitations 
Wilson et 
al,. (2010) 
USA 
B2 14/26 
53.8% 
Interventions 
study (3 groups) 
designed to 
promote self-care 
behaviours 
PARTICIPANTS:  N=70 
consented the total number of 
participants approached was 
not reported. 
DEMOGRAPHICS:  Race 60% 
African American, 38% white; 
Age 67.4 (SD 7.1) years; 
Education years of education 
was 13.3 years 
CLINICAL:  Men treated with 
EBRT.  No additional clinical 
data was reported. 
DESIGN:  Quasi-experimental design 
TIMEPOINTS:  Baseline (pre-treatment), 
mid-treatment (3 weeks into EBRT), final 
treatment and 3 and 6 month follow-up. 
MEASURES:  Rapid Estimate of Adult 
Literacy in Medicine (REALM [adult literacy 
in healthcare]), Side-effect Interview 
(Dodd, 1982), Self-care Management 
Techniques checklist (Mood and Bickes, 
1992 [instrument further developed based 
on Dodd work). 
ATTRITION:  no attrition reported. 
CONTROL (usual care) n=24. 
EDUCATION (N=24) intervention delivery at 
pre-treatment, treatment and post 
treatment (post-treatment not defined).  
Educational video covering the following 
topics 1) introduction to EBRT, 2) side-
effects, 3) emotional reactions, this was 
supplemented by written easy to read 
written instructions.   
EDUCATION AND CONTRACTING GROUP 
(N=23) same educational intervention with 
the addition of mutually agreed goals 
(relating to physical, emotional and social 
side effects) formed as a written 
contracted agreed and discussed with the 
nurse and the patient. Goals achieved were 
rewarded (e.g. skin care products, movies, 
oral product, etc.).  The contracted was 
reviewed weekly by the nurse and patient.  
Mean of 8 EBRT side-effects were reported, with a min of 1 and max of 
27 reported symptoms.  Side-effects onset developed at 11 days (SD 6) 
into EBRT and lasted from approx 8 days.  Severity of symptoms 2.8 
(mean, SD 0.6), ranged from 1.0 to 4.3 (5 point scale, with 5 being the 
most severe).   
 The intervention and literacy levels did not have any association with 
the symptom.  
Most common side effects reported were: skin reactions, dietary 
problems, emotional reactions and fatigue.   
Maintaining skin integrity was reported by n=52 and used on average 2 
out of 5 self-care behaviours, most common reported “was avoiding 
exposure of treated area to direct sunlight”.   
Self-care diet was reported in n=57, and used 5 of the 12 self-care 
options, most common “ eating foods high in protein”, reducing risk of 
infection by avoiding crowds and with people with colds and washing 
hands often” 
Self-care for emotional adjustment was reported in n=53, they 
reported using 6 of the 12 self-care options.  Most frequently reported 
self-care was “making a special effort to maintain a positive attitude 
and consciously trying to think more positively”. 
60% of participants reported taking more rest periods as self-care 
strategies to alleviate fatigue. 
The number of self-care actions significantly increased overtime from 
BL to 6M (12.2, SD 7.0 vs. 13.9 SD 6.1; t=1.94, P=.05).     
LIMIATIONS: Selection and attrition bias are possible.  No description of 
the randomization procedure.  The increase of self-care behaviours 
could have been related the progression of symptoms overtime and 
not was a result of the interventions as the authors suggest.    
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Oliffe et al,. 
(2009) 
 
Canada 
B3 28/30 
93.3% 
To describe the 
self-care strategies 
for men 
undertaking active 
surveillance. 
PARTICIPANTS:  N=45 
approached, N=25 consented 
(reasons for non-participation 
are described but differences 
were not identified by statistical 
analysis). 
DEMOGRAPHICS:  Age 48-77 
years mean 68 (SD not 
reported); Marital majority of 
men married (n=19), Education 
(n=19) completed 
postsecondary education.  No 
further demographic 
information provided. 
CLINICAL:  Low-risk cancer, Men 
been on AS for less than 2 
years.  PSA≤10, Gleason score 
≤6 cancer stage localised 
disease. 
DESIGN:  Qualitative, cross-sectional 
design. Interpretive description, constant 
comparison, data analysis facilitated by 
NVivo.   
Questions examples:  “what as the AS 
experience been like for you?”, “How as 
the AS impacted on your lifestyle?” When 
do you feel pressured to make a treatment 
decision, and how to you cope with that?”   
TIMEPOINTS:  Different trajectories but 
majority less than 2 years on the AS 
programme.  
ATTRITION:  N/A. 
Overarching theme of “Uncertainly” emerged “…when you are told you 
have cancer, I mean it sticks with you, cancer is cancer, I don’t care if I 
have low grade or not and nobody could tell me that there’s no cancer 
growth there, there’s no, um, spreading of cancer, they can’t tell men 
that, which really frustrates me”. 
The self-care management of uncertainty was managed by 2 strategies 
“living a normal life” and “doing something extra”.   
The theme of living a normal life reflected men’s positions to view their 
cancer as benign (n=14) “get out of jail free card”. 
The 2nd emergent theme for self-care was men’s accounts of “doing 
something extra”, which could focus on dietary modifications “ to go 
on AS has more to do with diet change…it goes hand in hand”.  Men 
reported eating less, taking supplements including saw palmetto, green 
tea, tomatoes, pomegranate juice.   
LIMITATIONS:  Cross-sectional design, likely that man’s self-care actions 
will change overtime.  Specific understandings how self-care changes 
with and between men overtime time would not be explored.  
Potential for disparity with self-reports and men’s actual self-care 
behaviour. 
Hamm, et 
al,. (2000). 
UK 
C1 9/22 
40.9% 
 
To assess 
feasibility and 
participants 
experiences of 
self-injecting 
hormone therapy.   
PARTICPANTS:  N=20 
consented; total number 
approached was not reported. 
DEMOGRAPHICS: Age 70.9 (SD 
not reported) 53-85 years, No 
additional demographic 
information was presented. 
CLINICAL:  excluded if they had 
life expectancy < 6 months, 
needle phobia, or GP was 
reluctant for them to 
participate.   
DESIGN:  Prospective longitudinal survey. 
TIMEPOINTS:  Different trajectories, but all 
assessed over 5 visits (1, 2, 3, 4, 12 
months).  
MEASUREMENTS:  EORTC C30, HADS, PSA 
and testosterone levels (to measure 
compliance).  
ATTRITION:  n= 6 participants withdrew 
from the study at the first visit, n= 1 after 
the second visit, n-1 after 4th visit due to 
long standing alcohol problems, n=1 died, 
N=11  
No significant changes in the HADs and C30 were reported.  Actual 
statistical tests and results were not reported, testing of the groups 
between those who continued and those individual who did not were 
not reported. 
Men self-injection demonstrated good compliance.  Men injected 5 
times over 12 months.  The results identified the potential a group of 
participants to administer HT via injection.   No additional self-care was 
reported in this publication. 
LIMIATIONS:  Selection and attrition bias are possible.  No description 
about the statistical approach to the analysis of HRQoL or anxiety and 
depression scores overtime. No data was presented for HRQoL or 
HADS.  Self-efficacy was not measured a potential bias in accounting 
for self-injection compliance.  
Mroz et al,. 
(2010) 
 
Canada 
B3 26/28 
92.8% 
To explore men’s 
perceptions of 
their diet following 
a prostate cancer 
diagnosis. 
PARTICIPANTS:  N=14 total 
number approached not 
reported, mainly convenience 
sampling. 
DEMOGRAPHICS:  Age range 48-
78 years, mostly retired, college 
educated and middle class.   
CLINICAL: Variation in 
treatment modalities, cancer 
DESIGN:  Grounded theory qualitative 
methodology.  Cross-sectional design.  
Social constructive perspective, constant 
comparison, triangulation (interviews, food 
journals and field notes) 
TIMEPOINTS: Diagnosed with prostate 
cancer no longer than 5 years 
MEASUREMENT:  Individual semi-
structured interview lasting 60-90 minutes 
A decision for men to make a diet change as a self-care behaviour was 
complex involving multiple factors; pre-cancer diet perceptions, diet 
and health understandings, perceptions of prostate cancer, and their 
need to “do something” for self-care. 
Cancer was viewed as a chronic condition required on-going 
management and therefore expressed needs to “do something” about 
it.  “…PSA shows up well then I’ll probably get a little excited again and 
then go on, figure out what to do.  But then I’ll probably start learning a 
lot more about fine-tuning my diet or whatever…” 
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trajectory.   conducted in the participants home, food 
diary (paper and pen record of eating 
events over 1 week), and field notes.   
ATTRITION: N/A 
Overall perceptions influenced the dietary eating habits and included a 
number of sub-themes: 1) already had a healthy diet; “I’ve always 
eaten healthily and I will continue to eat healthily but I’m not expecting 
it to cure cancer”, 2) diet does not affect prostate cancer recovery “It’s 
not a disease that once you have got it diet’s going to do much for 
you”.  3) Won the war, “you might as well go out and do what you 
want”, 4) diet and health understandings, “I want to live a longer life 
and I want to live it well in the absence of disease.  And diet is one of 
the few things I can do that would help”.  
Men described a variety of dietary patterns.  4 main themes emerged 
“eating as usual”, “intensifying efforts”, “adding on”, “overhauling diet”   
LIMITATIONS:  Demographics homogeneity limits the transferability of 
the findings. Research context was a nutritional student which may 
have influenced the findings for health and eating.  
Kim (2011) 
 
Korea 
B2 18/20 
93.3% 
Intervention study 
(2 groups) to 
promote self-care 
and quality of life 
PARTICPANTS:  N=69 consented 
total number approached was 
not reported. 
DEMOGRPAHICS: Age majority 
61-70 years; mostly high school 
education or less; 
approximately equal 
distributions for employed and 
unemployment 
CLINICAL:  All men treated for 
radical prostatectomy.   
Homogeneity of the control and 
experimental group was 
reported across clinical and 
demographic variables. 
 
DESIGN: Quasi-experimental, intervention 
study. 
TIMEPOINTS:  Pre-surgery, during 
intervention and post intervention (2 
months after surgery).   
MEASUREMENTS:  Self-as-Career Inventory 
(measurement of self-care capability), 
Adapted tool based on the self-care activity 
measurement tool, TACT-P. 
CONTROL: n=34: INTERVENTION: n=35 
educational (symptoms management, 
catheter management, self-care of urinary 
incontinence, post-surgery exercise, diet 
and defecation, pelvic floor and 
biofeedback).  Materials included written 
and visual information provisions.  
1st visit (pre-op 1 month/30mins) 
2nd visit (3-4 weeks pre-op/30 mins) 
3rd visit (pre-op 1 day/60mins) 
4th visit (2-3 days post-op/60mins) 
5th visit (5-7 days post op/60mins) 
6th visit (1 month post-op/90mins) 
The interventional group reported higher self-care capabilities 
compared to the control group, analysis based on before and after 
intervention.   
Self-care activity scores (using the self-care activity measurement tools) 
identified no significant differences in self-care behaviours between the 
2 groups.  The actual self-care strategies were not reported. 
Self-care agency (self-care capability) – men who participated in the 
intervention reported higher self-care agency compared to the control 
group.    
There was no significant difference in the quality of life scores across 
both groups.  The items from the FACT-P were not reported. 
LIMITATIONS:  A longer evaluation of intervention effect is needed.  
Unclear what the “control groups” provision of nursing care involved.  
There was no randomization to the control/intervention group.  
Selection bias is possible.   
378 
 
 
 
Appendix 4.1 Study Consent Form 
 
                            
  
REC Number:  10/S1402/7 
Patient Identification Number for this study: 
 
CONSENT FORM 
 
Title of Project: Exploring prostate cancer patients’ self-management demands and 
social support experiences using questionnaire and behavioural diaries: Does 
support buffer the relationship between coping and HRQoL? 
 
Name of Researcher:  Catherine Paterson                       Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 20/03/2010 
(Version 3) for the above study and have had the opportunity to ask questions. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw  
at any time without giving any reason, without any medical care or legal rights 
being affected. 
 
 
3. I understand that relevant sections of my medical notes and data collected during 
the study may be looked at by individuals from the University of Dundee or from  
NHS Tayside, where it is relevant to my taking part in this research.  I give permission  
for these individuals to have access to my records. 
 
 
4. I agree to my personal contact details being kept by researchers directly involved  
in this  study, so that the researcher can contact me to deliver relevant follow-up 
questionnaires. 
 
 
5. I agree to my GP being informed of my participation in the study.  Should my  
questionnaires reveal that I am at risk of having anxiety and depression I agree 
to my GP being informed. 
 
6. 
 
 
7. 
 
 
8. 
I agree to complete the questionnaire pack for this study at consent and at 6  
months follow-up in the post.   
 
I agree to complete the electronic diary for this study.  I understand the diary  
section will involve a brief 30 minute interview after completion of the diary.   
 
I agree to the audio recording of this interview. 
 
 
Name of Patient Date Signature 
 
Researcher                                          Date                               Signature 
 
 
 
 
 
 
 
 
379 
 
 
 
 
Appendix 4.2 Participant Information Sheet 
 
PARTICIPANT INFORMATION SHEET 
                       
 ‘Exploring prostate cancer patients’ self-management demands and social 
support experiences using questionnaire and behavioural diaries: Does support 
buffer the relationship between coping and health-related quality of life (HRQoL)? 
 
(A study exploring self-care demands and the effects of social support in prostate 
cancer patients) 
 
My name is Catherine Paterson and I am required to undertake a project as part of 
my Ph.D. course and invite you to take part in the following study.  However, before 
you decide to do so, I need to be sure that you understand firstly why I am doing it, 
and secondly what it would involve if you agreed.  I am therefore providing you with 
the following information.  Please read it carefully and be sure to ask any questions 
you might have and, if you want, discuss it with others including your friends and 
family.  I will do my best to explain the project to you and provide you with any 
further information you may ask for now or later. 
 
Aim 
The present study aims to find out whether social support affects patient’s health 
and adjustment to having a prostate cancer.  The findings from the present study will 
help to advise healthcare professionals on the self-care activities that men with 
prostate cancer carry out, how patients cope, and the impact that different types of 
social support can have on patients.  Self-care means actions that people take to 
improve health, prevent further disease, and improve symptoms.   
 
Why have I been invited? 
You are being asked to participate as you have recently been diagnosed with prostate 
cancer.  Your surgeon has identified that you would be eligible to help us with this.   
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form.  
If you decide to take part you are still free to withdraw at any time and without giving 
a reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect my medical care.   
 
What will happen if I agree to help? 
If you agree to take part in this study it will involve you filling in questionnaires and 
the option of completing an electronic diary.  The first questionnaire will be given to 
you in person after you consent, and we will then send you the same questionnaire 6 
months later.  A prepaid envelope will enable you to send back your questionnaires 
to the research nurse.  The questionnaires will ask a number of questions regarding 
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how you are feeling.  All your responses will be treated entirely confidentially. 
However, if you feel unable to answer any parts of the questionnaire, that will not be 
a problem. If you feel that you need to discuss your responses with someone, the 
study nurse will be available to help you.  If you consent, we will collect all the other 
data we need related to your cancer diagnosis from your case notes.   
 
The second stage of the study is optional, you will be asked by the research nurse 
involved in the study whether you would agree to complete an electronic diary for a 
total of 1 month.  Only a small number of patients, who agree to complete the diary, 
will actually be selected to go on and complete the diary.  The participants selected 
to complete the diary will be based on the stage of their cancer and existing social 
support.   
 
If you are selected to complete the electronic diary, the research nurse involved in 
this study will contact you to explain how to use it, and provide an opportunity to ask 
questions.  The completion of the electronic diary will be for a maximum of 1 month, 
and you will be prompted to complete the diary 3 times per day as you go about your 
usual activities.  The diary asks you about how you are feeling, your self-care 
activities and what social support experiences you have had.  The diary will prompt 
you to complete the diary midmorning, late afternoon and night time.  The precise 
timing of the diary entries may be different for each individual depending on their 
daily self-care routines; the aim is to make the timing of the diary as convenient as 
possible for the person completing the diary.  On completion of the electronic diary 
after 1 month, the research nurse involved in this study will interview you to ask you 
about your experiences of having, and completing the electronic diary.  With your 
permission, we would like to audio record the interview so that we have an accurate 
account of what was said.  A contact telephone number will be given so that you can 
contact the research nurse directly should you need help or have questions whilst 
completing the diary.   
 
There should be no harmful effect on you if you choose to participate in the study. 
The information we gather may not benefit you directly, but we hope that it will be 
of help in the future to people with the same condition.  
 
Should your response to the questionnaires reveal that you are distressed, with your 
permission we would like to inform your GP.   
 
What if there is a problem? 
If you have a concern about any aspect of the study, you should speak to the 
researchers who will do their best to answer your questions.  The contact details are 
listed below.  If you believe that you have been harmed in any way by taking part in 
this study, you have the right to pursue a complaint and seek any resulting 
compensation through the University of Dundee who are acting as the research 
sponsor.  Details about this are available from the research team.  Also, as a patient 
of the NHS, you have the right to pursue a complaint through the usual NHS process.  
To do so, you can submit a written complaint to the Patient Liaison Manager, 
Complaints Office, Ninewells Hospital (Freephone 0800 027 5507).  Note that the 
NHS has no legal liability for non-negligent harm.  However, if you are harmed and 
this is due to someone’s negligence, you may have grounds for a legal action against 
NHS Tayside but you may have to pay your legal costs.   
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Who will disclose, use and/or receive my health information?  
All information which is collected about you during the course of the research will be 
kept strictly confidential. Any information about you which leaves the hospital will 
have your name and address removed so that you cannot be recognised from it.    
Identifiable data will be stored for 6-12 months after the study has ended, and 
unidentifiable data will stored for 5 years.  All study data will be stored safely and 
securely in a locked filing cabinet in a locked room at the University of Dundee. If 
participants decided to withdraw from the study all identifiable data will be 
withdrawn, however, unidentifiable data will be retained. 
 
The Tayside Committee on Medical Research Ethics, which has responsibility for 
scrutinizing all proposals for medical research on humans in Tayside, has examined 
the proposal and has raised no objections from the point of view of medical ethics.  It 
is a requirement that your records in this research, together with any relevant 
medical records, be made available for scrutiny by monitors from NHS Tayside and 
the Regulatory Authorities, whose role is to check that research is properly 
conducted and the interests of those taking part are adequately protected.  Once the 
results are ready we hope to publish them in a medical journal so that other 
healthcare professionals can benefit from the results.  At the end of the study, we 
will send you a newsletter describing the results of the study.   
 
The study has been organised and co-coordinated at the School of Nursing and 
Midwifery, Dundee University. 
 
Contact 
For further information/help regarding this study please contact:  Catherine Paterson 
the Research Nurse  
(Chief Investigator)   Tel 01382 388645    Email: c.x.paterson@dundee.ac.uk 
 
If you are unhappy about any aspect of the study please contact Dr Martyn Jones 
supervisor of this research  
Tel 01382 388656 Email: m.c.jones@dundee.ac.uk 
 
Thank you for considering taking part 
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Appendix 4.3 Case Record Form 
                                                                
 
Study Number:   
 
BASELINE DEMOGRAPHIC DETAILS 
Name:  
 
Address:                                                                               GP: 
 
 
Postcode: 
Date of entry: 
 
Age at study entry: 
 
Date of birth: 
 
CHI number: 
 
Marital Status:   
 
Single  Married   Divorced   Separated   Widowed   Co-habiting 
 
Employment:   
In employment/self-employed    
Retired                                              
Student                                             
Seeking work                                   
Other                                                  …………………………. 
What age did you leave school? 
 
Do you have any of the following? (Tick all that applies) 
SD/O levels                                      BA                         
Highers/A levels                              BS/BA (Hons.)     
SVQ                                                    MSc                      
NC                                                       Ph.D.                      
HNC                                                    Trade qualification/equivalent    
HND                           
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Nationality:   
 
Willing to complete PDA – EMA?     Yes              No     
 
Reason for not willing to complete: 
 
 
 
          
Study Number: 
BASELINE CLINICAL DATA 
Cancer details: 
Prostate:       
 Localised       Locally Advanced     Metastatic    
Watchful waiting    RRP     Perineal Prostatectomy    
Laparoscopic Prostatectomy    Brachytherapy     Radical Radiotherapy      
Hormone Manipulation     Active Surveillance       Cryotherapy    
High Intensity Focused Ultrasound    Chemotherapy    Other   
Pathological Stage (pre-op) :   
Pathological Stage (post-op): 
 
Date treatment started:  
 
PSA: 
 
Date Cancer Diagnosed: 
 
 
CO-MORBIDITIES                                                                    (Circle) 
Diabetes                                                                                    Yes      No 
Depression                                                                      Yes        No 
Myocardial Infarction                                              Yes        No 
Angina                                                                                        Yes        No 
Cerebrovascular Disease/Stroke                                             Yes        No 
Peripheral Vascular Disease                                                    Yes        No 
Chronic Obstructive Airways Disease(Asthma or COPD Yes       No 
Multiple Sclerosis                                                             Yes        No 
Other…………………………………………………………………………………….. 
Neurological Disorder: state……………………………………………………………… 
Other Malignancies: state……………………………….Year diagnosis………………. 
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Additional Cancer Support 
 
1.  Do you use a Prostate Cancer Support Group? (Tick all that applies) 
      Dundee Group               Perth Group                     Fife Group     
 
     If ’yes’ how often do you use this centre? 
 
      Several times weekly    Several times monthly       Monthly   
      Every several months    Yearly      
 
2. Do you use the Maggie’s Centre? (Please tick to indicate your answer) 
 
        Yes                  No    
  
       If ’yes’ how often do you use this centre? 
 
       Daily    Several times weekly    Several times monthly       Monthly   
       Every several months     Yearly      
 
Please indicate the type of support services you use at the Maggie’s Centre: 
                                                                                              (please tick all that apply) 
Benefits Advice                                        
Online Forum                                                     
Support Group   
           Men at Maggie’s Group                         
           Prostate Cancer Networking Group      
Individual Psychology Session                           
Relaxation Therapy                                              
Art/Writing Workshop                                        
Drop-In (Informational/Support Session)         
 
3.  Do you use any other cancer support services?        Yes                  No    
 
If ‘yes’ please describe this cancer support 
service…………………………………………………………………..…… 
……………………………………………………………………………………………………………………………… 
 
How often do you use this cancer support service? 
 
Daily    Several  times weekly    Several times monthly      Monthly   
Every several months     Yearly      
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Study Number: 
6 MONTHS CLINICAL DATA 
Cancer details: 
Prostate:       
 Localised       Locally Advanced     Metastatic     
Watchful waiting    RRP     Perineal Prostatectomy    
Laparoscopic Prostatectomy    Brachytherapy     Radical Radiotherapy      
Hormone Manipulation     Active Surveillance     Cryotherapy    
High Intensity Focused Ultrasound    Chemotherapy    Other   
 
Change to treatment:  Yes                            No        
Pathological Stage (pre-op) :   
Pathological Stage (post-op): 
 
Date treatment started: 
 
PSA: 
CO-MORBIDITIES                                                                  (Circle) 
 
Diabetes                                                                                     Yes           No 
Depression                                                                                Yes           No 
Myocardial Infarction                                                             Yes          No 
Angina                                                                                        Yes           No 
Cerebrovascular Disease/Stroke                                           Yes            No 
Peripheral Vascular Disease                                                   Yes            No 
Chronic Obstructive Airways Disease(Asthma or COPD)   Yes           No 
Multiple Sclerosis                                                                     Yes           No 
Other………………………………………………………………………………………. 
Neurological Disorder: state………………………………………………………………. 
Other Malignancies: state……………………………….Year diagnosis………………… 
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Appendix 4.4 Letter of Invitation 
          Mr C Goodman  
                                                                            Urology Department 
                                                               NHS Tayside 
     Ninewells Hospital 
                                                                                                           Dundee 
 
      Date: 
Dear NAME 
 
INVITATION TO TAKE PART IN A RESEARCH STUDY – TITLE ‘Exploring prostate 
cancer patients’ self-management demands and social support experiences using 
questionnaire and behavioural diaries: Does support buffer the relationship 
between coping and HRQoL?’ 
 
I note that it is coming up for approximately 1 month after your diagnosis.  You have 
an outpatient appointment on DATE, TIME and VENUE.  I would like to bring to your 
attention a research study that you may be interested participating in.  This study is 
looking at how social support may affect patients’ health, and how patients cope 
with having a prostate cancer.  This study will inform us of the best types of social 
support that can help patients.  I have attached a Patient Information Sheet about 
the research study that will enable you to decide; whether or not you would like to 
take part.  This research has been designed and is being undertaken by Catherine 
Paterson (Research Nurse) based at the University of Dundee.     
 
If you are interested in taking part in the study, Catherine will be available to discuss 
this further at your clinic appointment.  If you decide then to participate, Catherine 
will ask you some questions and give you some questionnaires whilst you are 
attending the clinic.   Please complete the reply slip enclosed as appropriate to 
indicate if you are considering participating in this study.  Please hand the reply slip 
to the receptionist on arrival at your urology appointment, and Catherine will arrange 
to discuss the study further.   Should you wish to speak with Catherine directly before 
this appointment, her telephone number is 01382 388645, please feel free to contact 
her at any time. 
 
Thank you for your time and consideration for this research. 
Yours sincerely 
 
Mr Goodman 
Consultant Urologist Surgeon 
Enc: Patient Information Sheet, Reception Reply Slip  
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Reply Slip to be handed to the receptionist on arrival at my 
urology clinic appointment on [DATE and TIME]. 
 
I 
____________________________________________________
___ agree/do not agree* to meet with Catherine Paterson 
(Research Nurse) to discuss the study further with a view to 
take part. 
 
I understand that this will take an additional 20 mins 
(approximately) of my time at the clinic.  During this time, I 
understand that I will have the opportunity to ask questions and 
have the study explained further.  If I agree to take part, I will sign 
a study consent form, and Catherine will do her first data 
collection.     
 
* Delete as appropriate. 
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      Mr C Goodman 
Urology Department 
NHS Tayside 
Ninewells Hospital 
Dundee 
 
Date 
 
Dear NAME 
 
INVITATION TO TAKE PART IN A RESEARCH STUDY – TITLE ‘Exploring prostate 
cancer patients’ self-management demands and social support experiences using 
questionnaire and behavioural diaries: Does support buffer the relationship 
between coping and HRQoL?’ 
 
I note that it is coming up for approximately 1 month after your diagnosis.  I would 
like to bring to your attention a research study that you may be interested in 
participating in.  This study is looking at how social support may affect patients’ 
health, and how patients cope with having a prostate cancer.  This study will inform 
us of the best types of social support that can help patients.  I have attached a 
Patient Information Sheet about the research study that will enable you to decide 
whether or not you would like to take part.  This research has been designed and is 
being undertaken by Catherine Paterson (Research Nurse) based at the University of 
Dundee.     
 
If you would like to participate in this study, we would like to offer you an 
appointment on Friday DATE, at TIME, VENUE.  At this time, Catherine will discuss the 
study further, and if you then agree to take part will ask you to complete some 
questionnaires.  Can you please complete the reply slip enclosed to indicate whether 
or not you agree to attend this appointment.  If this time is not suitable, but you 
would like to meet with Catherine about this study, please leave your telephone 
number and she will contact you at home to arrange this appointment.  Catherine’s 
telephone numbers is 01382 388645, if you have any questions about this study, 
please feel free to contact her at any time. 
 
Thank you for your time and consideration for this research, 
Yours sincerely 
 
Mr Goodman 
Consultant Urologist Surgeon 
Enc: Patient Information Sheet, Reply Slip and pre-paid envelope  
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Reply Slip to be returned in the pre-paid envelope. 
 
I 
____________________________________________________
___ agree/do not agree* to meet with Catherine Paterson 
(Research Nurse), on Friday, at TIME, at the urology clinic, 
HOSPITAL to discuss the study further with a view to take part. 
 
If this time is not suitable, but you would like to meet with 
Catherine to discuss the study please leave your telephone 
number so that she can contact you to arrange this. 
  My Telephone number _____________________ 
 
I understand that the appointment with Catherine will take 20 
mins (approximately) of my time at the clinic.  During this time, I 
understand that I will have the opportunity to ask questions and 
have the study explained further.  If I agree to take part, I will sign 
a study consent form, and Catherine will do her first data 
collection.     
 
* Delete as appropriate. 
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Appendix 4.5 GP Letter 
 
                        
                       
                                                       Catherine Paterson 
  Research Nurse  
  School of Nursing and Midwifery 
  11 Airlie Place 
          Dundee 
   DD1 4HJ 
 
   01382 388645 
 
                                                                                                               [STUDY NUMBER] 
 
Dear [Dr FIRST, SURNAME] 
 
Title ‘‘Exploring prostate cancer patients’ self-management demands and social 
support experiences using questionnaire and behavioural diaries: Does support 
buffer the relationship between coping and HRQoL? 
(REC: 10/S1402/7)   
 
[RE: Patients name, address, DOB, CHI) 
 
The above research study aims to determine the effect of social support on health 
outcomes (quality of life/anxiety and depression) and better understand the self-care 
activities for men who are diagnosed with a prostate cancer.  Your patient has agreed 
to take part in the study which will involve completing questionnaires (baseline and 6 
months follow-up), with the opportunity to complete the second optional stage of 
the study.  The second stage of the study is the completion of an electronic 
behavioural diary for 1 month.  Only small number (12) patients will actually be 
selected to complete the behavioural diary as individual single-case studies.   
 
We would be extremely grateful if you could help us by sticking the label provided on 
their notes and contacting Tel: 01382 388645 should any significant events occur, for 
example, death of a patient, or change of address. 
 
Please find enclosed a copy of the consent and patient information sheet for your 
records.  Please do not hesitate to contact me if you would like any further 
information about the study or to discuss the participation of your patient. 
 
Yours sincerely 
 
Catherine Paterson 
(Research Nurse, CI) 
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Enc: Patient Information sheet and study consent form 
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Appendix 4.6 GP Letter Notifying the HADS Scores  
                        
                         
Catherine Paterson 
Research Nurse 
School of Nursing and 
Midwifery 
  11 Airlie Place 
Dundee 
DD1 4HJ 
     
                      Telephone: 01382 388645 
                                                                                                       
                                                                                                     [STUDY NUMBER] 
Dear [Dr FIRST, SURNAME] 
 
Title ‘‘Exploring prostate cancer patients’ self-management demands and social 
support experiences using questionnaire and behavioural diaries: Does support 
buffer the relationship between coping and HRQoL? 
(REC: 10/S1402/7)   
 
[RE: Patients name, address, DOB, CHI) 
 
This patient has agreed to take part in the above study.  As part of this research your 
patient completed a number of questionnaires assessing social support, health-
related quality of life, self-care activities and anxiety and depression.  In particular, 
the Hospital Anxiety and Depression Scale (HADS) provide a brief state of measure 
for both anxiety (7 question items) and depression (7 question items).  This tool 
facilitates the detection of clinical cases of anxiety and depression.  On evaluation of 
[Name] questionnaire it was identified that they may be at risk of having anxiety and 
depression, the results from evaluation are as follows: 
 
HADS Results: 
 
Depression:   Borderline 8-10 
Anxiety:          Borderline 8-10  
 
Your patient is aware that I am writing to you informing you of their results.  If you 
would like to discuss this further, or require further information please don’t hesitate 
to contact me on telephone number 01382 388645.  
 
Yours sincerely 
 
Catherine Paterson 
(Research Nurse, Chief Investigator) 
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Appendix 4.7 Six Months Questionnaire Cover 
Letter                            
     
 
                        
 
                                                                                        Catherine Paterson 
                                                                                        Research Nurse  
 School of Nursing and Midwifery 
                                                                                        11 Airlie Place 
                                                                                        Dundee 
                                                                                        DD1 4HJ   
        
                                                                                        Telephone: 01382 388645 
 
                                                                                                                  [STUDY NUMBER] 
  
Dear [TITLE, FIRST, SURNAME] 
 
Study ‘exploring self-care demands and the effects of social support in prostate 
cancer patients: 6 months follow-up questionnaire’ 
 
Thank you very much for your time, effort and continued participation in the above 
study.  Please find enclosed your six months follow-up questionnaire and a pre-paid 
envelope.  I would be extremely grateful if you could complete the questionnaire as 
best as you can, and return it to me at your earliest convenience in the pre-paid 
envelope. 
 
Your participation in this research has now ended following completion of this 
questionnaire.  I would also like to take this opportunity to express my sincere thanks 
for your help, as without your time and effort this research would not have been 
possible.    
 
Once the findings from the study are concluded, a newsletter informing you for the 
study findings will be available. 
 
Thank you very much for you time and help, it is greatly appreciated. 
Yours sincerely 
 
 
Catherine Paterson 
(Research Nurse, Chief Investigator) 
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Appendix 4.8 Fourteen Day Questionnaire 
Reminder Cover Letter 
                       
               
                         
              CATHERINE PATERSON 
          RESEARCH NURSE (CI) 
          SCHOOL OF NURSING AND MIDWIFERY 
                                                                                         11 AIRLIE PLACE 
                                                                                         DUNDEE 
                            DD11 4HJ 
        
                                                                                                                   Telephone: 01382 388645 
 
     [DATE] 
  
 
                                                                                                          [STUDY NUMBER] 
  
 
Dear [TITLE, FIRST, SURNAME] 
 
A study exploring self-care demands and the effects of social support in prostate 
cancer patients: Questionnaire Reminder 
 
According to our records we have not yet received your study questionnaire.  I would 
be grateful if you could complete the enclosed questionnaire and return it to me in 
the pre-paid envelope.  However, if you have completed your questionnaire and sent 
it back to me, please ignore this letter and accept my apologies for any 
inconvenience caused. 
 
Thank you very much again, 
 
Yours sincerely 
 
 
 
 
Catherine Paterson 
(Research Nurse, Chief Investigator) 
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Appendix 4.9 Study Questionnaires  
 
 
Questionnaire Pack 
 
         
 
 
Social support and self-care in prostate cancer 
patients 
 
        
 
Study Number: 
 
Initials: 
 
Date: 
 
 
 
Return to: 
Catherine Paterson 
Chief Investigator 
11 Airlie Place 
School of Nursing and Midwifery 
Dundee University 
Dundee 
DD1 4HJ 
Telephone:  01382 388645
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Hospital Anxiety and Depression Scale 
 
This questionnaire is designed to help your clinician know how you feel.  Ignore the 
numbers printed on the left of the questionnaire.  Read each item and underline the reply 
which comes closest to how you have been feeling in the past week. 
 
Don’t take too long over your replies; your immediate reaction to each item will probably 
be more accurate than a long thought-out response. 
 
A I feel tense or ‘wound up’: 
3   Most of the time 
2   A lot of the time 
1   From time to time, occasionally 
0   Not at all 
 
D I still enjoy the things I used to enjoy: 
0   Definitely as much 
1   Not quite as much 
2   Only a little 
3   Hardly at all 
 
A I get a sort of frightened feeling as if something awful is about to happen: 
3   Very definitely and quite badly 
2   Yes, but not too badly 
1   A little, but it doesn’t worry me 
0   Not at all 
 
D I can laugh and see the funny side of things: 
0   As much as I always could 
1   Not quite so much now 
2   Definitely not so much now 
3   Not at all 
 
A Worrying thoughts go through my mind: 
3   A great deal of the time 
2   A lot of the time 
1   From time to time but not too often 
0   Only occasionally 
 
D I feel cheerful: 
3   Not at all 
2   Not often 
1   Sometimes 
0   Most of the time 
 
A I can sit at ease and feel relaxed: 
0   Definitely 
1   Usually 
2   Not often 
3   Not at all 
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D I feel as if I am slowed down: 
3   Nearly all the time 
2   Very often 
1   Sometimes 
0   Not at all 
 
A I get a sort of frightened feeling like ‘butterflies’ in the stomach: 
0   Not at all 
1   Occasionally 
2   Quite often 
3   Very often 
 
D I have lost interest in my appearance: 
3   Definitely 
2   I don’t take as much care as I should 
1   I may not take quite as much care 
0   I take just as much care as ever 
 
A I feel restless as if I have to be on the move: 
3   Very much indeed 
2   Quite a lot 
1   Not very much 
0   Not at all 
 
D I look forward with enjoyment to things: 
0   As much as ever I did 
1   Rather less than I used to 
2   Definitely less than I used to 
3   Hardly at all 
 
A I get sudden feelings of panic: 
3   Very often indeed 
2   Quite often 
1   Not very often 
0   Not at all 
 
D I can enjoy a good book or radio or TV programme: 
0   Often 
1   Sometimes 
2   Not often 
3   Very seldom 
 
 
 
Now check that you have answered all the questions 
 
 
 
For office use only: 
D:  Borderline 8-10 
A:  Borderline 8-10  
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Watson, Greer and Bliss (1989) The NFER-NELSON Publishing Company   
MAC Scale 
INSTRUCTIONS:  A number of statements are given below which describes people’s 
reactions to having cancer.  Please circle the appropriate number to the right of each 
statement, indicating how far it applies to you at present.  For example, if the statement 
definitely does not apply to you, then you should circle 1 in the first column. 
 
                                 Definitely            Does not        Applies        Definitely 
                   does not    apply             to me          applies 
                   apply to me        to me                   to me  
1. I have been doing things that I believe will   
improve my health e.g. changed my diet.   1         2             3  4 
 
2. I feel I can’t do anything to cheer myself up.         1         2              3  4 
 
3. I feel that problems with my health prevent me     1         2                  3  4 
from planning ahead. 
  
4. I believe that my positive attitude will benefit         1         2                  3  4 
my health. 
 
5. I don’t dwell on my illness.    1         2                  3  4 
 
6. I firmly believe that I will get better.   1         2                  3  4 
 
7. I feel that nothing I can do will make a  
difference.       1         2                  3  4 
   
8. I’ve left it all up to my doctors.           1         2                  3  4 
 
9. I feel that life is hopeless.                                     1         2                  3  4 
 
10. I have been doing things that I believe will        1         2                  3  4 
improve my health e.g. exercising. 
 
11. Since my cancer diagnosis, I now realize how     1         2                  3  4 
precious life is and I’m making the most of it. 
 
12. I’ve put myself in the hands of God.           1         2                  3  4
  
 
13. I have plans for the future e.g. holidays, jobs,      1         2                  3  4 
housing. 
 
14.  I worry about the cancer returning  
       or getting worse.      1         2                  3  4 
 
15. I’ve had a good life; what’s left is a bonus.  1         2                  3  4 
  
16. I think my state of mind can make a lot of  
      difference to my health.     1        2                  3  4 
 
17. I feel that there is nothing I can do to help 
      myself.       1        2                  3  4 
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                                  Definitely         Does not       Applies          Definitely 
                   does not   apply        to me             applies 
                  apply to me        to me                  to me 
 
18. I try to carry on my life as I’ve always done. 1     2          3  4    
 
19. I would like to make contact with others in  1     2          3  4 
the same boat. 
 
20. I am determined to put it all behind me.  1     2          3  4 
 
21. I have difficulty in believing that this happened, 1     2          3  4 
to me. 
 
22. I suffer great anxiety about it.   1     2          3  4 
 
23. I am not very hopeful about the future.  1     2          3  4 
 
24. At the moment I take one day at a time.  1     2          3  4 
 
25. I feel like giving up.    1     2          3  4 
 
26. I try to keep a sense of humour about it.  1     2          3  4 
 
27. Other people worry about me more than I do. 1     2          3  4 
 
28. I think of other people who are worst off.  1     2          3  4 
 
29. I am trying to get as much information as I can 1     2          3  4 
about cancer. 
 
30. I feel that I can’t control what is happening. 1     2          3  4 
 
31. I try to keep a very positive attitude.  1     2          3  4 
 
32. I keep quite busy, so I don’t have time to think 1     2          3  4 
about it. 
 
33. I avoid finding out more about it.   1     2          3  4 
 
34. I see my illness as a challenge.   1     2          3  4 
 
35. I feel fatalistic about it.    1     2          3  4 
 
36. I feel completely at a loss about what to do. 1     2          3  4 
 
37. I feel very angry about what has happened to  
me.      1     2          3  4 
 
38. I don’t really believe that I had cancer.  1     2          3  4 
 
39. I count my blessings.    1     2          3  4 
 
40. I try to fight the illness.    1     2          3  4 
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QLQ – C30 (version 3) 
 
We are interested in some things about you and your health.  Please answer all of the questions yourself 
by circling the number that best applies to you.  There are no “right” or “wrong” answers.  The information 
that you provide will remain strictly confidential. 
 
 
During the past week: Not at 
all 
A  
little 
Quite 
a bit 
Very 
much 
1 Do you have any trouble doing strenuous activities,  
like carrying a heavy shopping bag or suitcase? 
1 2 3 4 
2 Do you have any trouble taking a long walk? 
 
1 2 3 4 
3 Do you have any trouble taking a short walk 
outside of the house? 
 
1 2 3 4 
4 Do you need to stay in bed or a chair during the 
day? 
 
1 2 3 4 
5 Do you need help with eating, dressing, washing 
yourself or using the toilet? 
1 2 3 4 
 
During the past week: Not at 
all 
A 
little 
Quite 
a bit 
Very 
much 
6 Were you limited in doing either your work or other 
daily activities? 
1 2 3 4 
7 Were you limited in pursuing your hobbies or other 
leisure time activities? 
 
1 2 3 4 
8 Were you short of breath? 
 
1 2 3 4 
9 Have you had pain? 
 
1 2 3 4 
10 Did you need to rest? 
 
1 2 3 4 
11 Have you had any trouble sleeping? 
 
1 2 3 4 
12 Have you felt weak? 
 
1 2 3 4 
13 Have you lacked appetite? 
 
1 2 3 4 
14 Have you felt nauseated? 
 
1 2 3 4 
15 Have you vomited? 
 
1 2 3 4 
 
During the past week: Not at 
all 
A little Quite 
a bit 
Very 
much 
     
16 Have you been constipated? 
 
1 2 3 4 
17 Have you had diarrhoea? 
 
1 2 3 4 
18 Were you tired? 
 
1 2 3 4 
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19 Did pain interfere with your daily activities? 
 
1 2 3 4 
20 Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 
 
1 2 3 4 
21 Did you feel tense? 
 
1 2 3 4 
22 Did you worry? 
 
1 2 3 4 
23 Did you feel irritable? 
 
1 2 3 4 
24 Did you feel depressed? 
 
1 2 3 4 
25 Have you had difficulty remembering things? 
 
1 2 3 4 
26 Has your physical condition or medical treatment 
interfered with your family life? 
 
1 2 3 4 
27 Has your physical condition or medical treatment 
interfered with you social activities? 
 
1 2 3 4 
28 Has your physical condition or medical treatment 
caused you financial difficulties? 
 
1 2 3 4 
For the following questions, please circle the number between 1 and 7 that best 
applies to you 
 
29 How would you rate your overall health during the past week? 
 
 1 2 3 4 5 6 7 
 Very poor      Excellent 
 
30 How would you rate your overall quality of life during the past week? 
 
 1 2 3 4 5 6 7 
 Very poor      Excellent 
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EORTC  QLQ - PR25  
 
Patients sometimes report that they have the following symptoms or problems. 
Please indicate the extent to which you have experienced these symptoms or 
problems during the past week. Please answer by circling the number that best 
applies to you. 
  
During the past week Not A Quite Very  
 at all little a bit much 
31. Have you had to urinate frequently during the day? 1 2 3 4 
32. Have you had to urinate frequently at night? 1 2 3 4 
33.  When you felt the urge to pass urine, did you    1  2     3 4 
        have to hurry to get to the toilet? 
34. Was it difficult for you to get enough sleep, because  
 you needed to get up frequently at night to urinate? 1 2 3 4 
35. Have you had difficulty going out of the house  
 because you needed to be close to a toilet? 1 2 3 4 
36. Have you had any unintentional release (leakage) of urine? 1 2 3 4 
37. Did you have pain when you urinated? 1 2 3 4 
38. Answer this question only if you wear an incontinence aid.  
Has wearing an incontinence aid been a problem for you? 1 2 3 4 
39. Have your daily activities been limited by your urinary  
       problems? 1 2 3 4 
 
40. Have your daily activities been limited by your bowel  1 2 3 4 
       problems?  
 
41. Have you had any unintentional release (leakage) of stools? 1 2 3 4 
42. Have you had blood in your stools? 1 2 3 4 
43. Did you have a bloated feeling in your abdomen? 1 2 3 4 
44. Did you have hot flushes? 1 2 3 4 
45. Have you had sore or enlarged nipples or breasts? 1 2 3 4 
46. Have you had swelling in your legs or ankles? 1 2 3 4 
 
Please go to the next page 
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During the last 4 weeks…  Not A Quite Very  
 at all little a bit much 
47. Has weight loss been a problem for you? 1 2 3 4 
48. Has weight gain been a problem for you? 1 2 3 4 
49. Have you felt less masculine as a result of your  
 illness or treatment?      1   2     3 4 
50. To what extent were you interested in sex? 1 2 3 4 
51. To what extent were you sexually active  
 (with or without intercourse)? 1 2 3 4 
  
PLEASE ANSWER THE NEXT FOUR QUESTIONS ONLY IF YOU HAVE BEEN 
SEXUALLY ACTIVE OVER THE LAST 4 WEEKS 
 
52. To what extent was sex enjoyable for you? 1 2 3 4 
53. Did you have difficulty getting or maintaining an erection? 1 2 3 4 
54. Did you have ejaculation problems (eg dry ejaculation)? 1 2 3 4 
55. Have you felt uncomfortable about being sexually intimate? 1 2 3 4 
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When completing the questions below, please think about what you do to 
look after yourself (self-care activities) since your diagnosis.  Please circle 
the number which best describes your answer to the statements below. 
 
 
Not at all  Barely               Moderately   Exactly 
true   true               true                          true 
1   2               3               4 
        
                        
        
Please circle your answer 
 
 
1. I can always manage to complete  1  2  3  4 
self-care activities that are difficult  
for me. 
 
2. It is easy for me to stick to my   1  2  3  4 
self-care activities and make sure  
that I carry them out well. 
 
3. I am confident in carrying out my  1  2  3  4 
self-care activities. 
  
4. Thanks to my resourcefulness, I  1  2  3  4 
know how to handle difficult  
self-care problems.  
 
5. If I have problems with self-care,  1  2  3  4 
I can solve it if I invest the  
necessary effort.  
 
6. I can remain calm when facing   1  2  3  4 
difficulties with self-care because  
I can rely on my coping abilities. 
 
7. If a new challenge faces me with  1  2  3  4 
self-care I’m usually able to handle it. 
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Self Care Diary 
We are interested in knowing about the actions (self-care) you take to look after yourself.  
We would like you to think about the things that you have done within the last month to 
improve the health difficulties you have faced with your prostate cancer experience. 
 
For each of the difficulties listed, please tick () if this has been a problem for you.  If you 
tick NO, go to the next page.  
 
If you tick YES, please using the number ratings below and circle the number that best 
indicates how much relief each action worked in improving the problem.   
 
EXAMPLE 
 
0 = Not used at all 
1 = Used, but no relief 
2 = Used, got a little relief 
3 = Used, got some relief 
4 = Used, got quite a bit of relief 
5 = Used, was completely relieved 
 
 
Took advice from the dietician..................... 0 1 2 3 4 5 
 
 
 
 
1. In the past month, have you had urine (water work) problems?      
 
YES                NO              
(If NO go to Q2 
on next page) 
 
If yes, please circle the number which best describes how well each action worked 
for you: 
 
0 = Not used at all 
1 = Used, but no relief 
2 = Used, got a little relief 
3 = Used, got some relief 
4 = Used, got quite a bit of relief 
5 = Used, was completely relieved 
         (Please circle your answer) 
 
a) Used absorbent pads/pants................ 0 1 2 3 4 5 
b) Used urine sheaths (application like a  
condom)…………………   0 1 2 3 4 5 
c) Used urine catheters........................  0 1 2 3 4 5 
d) Avoided constipation.........................  0 1 2 3 4 5 
e) Drank plenty of water (2 litres or 3-4 
 pints per day)..    0 1 2 3 4 5 
f) Avoided or reduced liquids that may  
irritate my bladder such as caffeine based  
 1 
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drinks (e.g. coffee, coke)    0 1 2 3 4 5 
g) Did pelvic floor exercises.... ...................       0 1 2 3 4 5 
h) Did bladder retraining (kept record of  
urine passed times, and amounts, with the aim of  
increasing the length between toilet times  0 1 2 3 4 5 
i) Information seeking...................................... 0 1 2 3 4 5 
j) Had counselling............................................. 0 1 2 3 4 5 
k) Followed advice from the physiotherapist.... 0 1 2 3 4 5 
l) Followed advice from continence advisor..... 0 1 2 3 4 5 
m) Shared my feelings and thoughts………… 0 1 2 3 4 5 
n) Avoided heavy lifting..................................... 0 1 2 3 4 5 
o) Other (please write in)______________ 0 1 2 3 4 5 
____________________________________________ 
 
2. In the past month, have you had bowel problems?   YES                 NO               
(If NO go to Q3 on next 
page) 
 
If yes, please circle the number which best describes how well each action worked 
for you: 
 
0 = Not used at all 
1 = Used, but no relief 
2 = Used, got a little relief 
3 = Used, got some relief 
4 = Used, got quite a bit of relief 
5 = Used, was completely relieved 
               (Please circle your answer) 
a) Used absorbent pads/pants................... 0 1 2 3 4 5 
b) Took medication (foams/suppositories).. 0 1 2 3 4 5 
c) Used anal plugs 
(from continence advisor)................. 0 1 2 3 4 5 
d) Took medication for the pain/discomfort 0 1 2 3 4 5 
e) Took anti-diarrhoeal medication............ 0 1 2 3 4 5 
f) Took rest/sleep naps.............................. 0 1 2 3 4 5 
g) Did pelvic floor exercises....................... 0 1 2 3 4 5 
h) Kept a record of bowel movements, 
to make going to the toilet more  
predictable.      0 1 2 3 4 5 
i) Took advice from the dietician   ............. 0 1 2 3 4 5 
j) Took advice from the continence  
advisor..................    0 1 2 3 4 5 
k) Shared my feelings and thoughts…… 0 1 2 3 4 5 
l) Found out information............................. 0 1 2 3 4 5 
m) Changed eating habits (e.g. 6 smaller 
meals)..........     0 1 2 3 4 5 
n) Changed diet.......................................... 0 1 2 3 4 5 
o) Increased fluid intake............................ 0 1 2 3 4 5 
p) Used comfort measures (hot water bottle) 0 1 2 3 4 5 
q) Used fibre supplements to make stools  
more bulky..      0 1 2 3 4 5 
r) Other (please write in)______________  0 1 2 3 4 5 
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3. In the past month, have you had erectile dysfunction (impotence) problems?    
YES              NO             (If NO go to Q4 on next page) 
 
If yes, please circle the number which best describes how well each action worked 
for you: 
 
0 = Not used at all 
1 = Used, but no relief 
2 = Used, got a little relief 
3 = Used, got some relief 
4 = Used, got quite a bit of relief 
5 = Used, was completely relieved 
       (Please circle your answer) 
 
a) Had counselling..................................... 0 1 2 3 4 5 
b) Took medication (e.g. Viagra, cialis).....  0 1 2 3 4 5 
c) Used injections or insertions (e.g. MUSE) 0 1 2 3 4 5 
d) Used a vacuum penis pump.................... 0 1 2 3 4 5 
e) Tried to lose weight (if you are overweight) 0 1 2 3 4 5 
f) Took regular exercise.............................. 0 1 2 3 4 5 
g) Moderated alcohol intake...................... 0 1 2 3 4 5 
h) Stopped smoking(if you smoked).......... 0 1 2 3 4 5 
i) Took more rest/sleep.............................. 0 1 2 3 4 5 
j) Took advise from the specialist nurse.... 0 1 2 3 4 5 
k) Took advice from the doctor.................. 0 1 2 3 4 5 
l) Shared my feelings and thoughts…  0 1 2 3 4 5 
m) Found out information............................. 0 1 2 3 4 5 
n) Found ways to reduce stress................. 0 1 2 3 4 5 
o) Other (please write in)______________  0 1 2 3 4 5 
_____________________________________________ 
 
4. Use this space to list any other problems you have experienced in the past month, 
that have not been included already.  If you did not experience any other prostate 
cancer related problems, please TICK  NONE. 
 
NONE    (Go to Question 5) 
 
a) Are you having any other problems associated with your prostate cancer 
(please write in)? 
Problem 1. 
____________________________________________________________ 
 
_____________________________________________________________ 
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If you wrote in a problem, how severe is it?      How frequent is the problem? 
 
Please TICK      Please TICK  
        
Not at all      once a month 
A little       twice a month 
Moderately      once a week 
Quite a bit      3-4 times per week 
Extremely      Daily 
       Several times daily 
Please write in each action (self-care) you took to deal with the problem.  Circle the 
number which best describes your use of each of the action you have listed below: 
 
0 = Not used at all 
1 = Used, but no relief 
2 = Used, got a little relief 
3 = Used, got some relief 
4 = Used, got quite a bit of relief 
5 = Used, was completely relieved 
     (Please circle your answer) 
a) ______________________________0 1 2 3 4 5 
b) ______________________________0 1 2 3 4 5 
c) ______________________________0 1 2 3 4 5 
d) ______________________________0 1 2 3 4 5 
e) ______________________________0 1 2 3 4 5 
 
 
b) Are you having any other problems associated with your prostate cancer 
(please write in)? 
 
Problem 2. 
_____________________________________________________________ 
 
__________________________________________________________ 
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If you wrote in a problem, how severe is it?    How frequent is the problem? 
 
Please TICK      Please TICK  
         
Not at all      once a month 
A little       twice a month 
Moderately      once a week 
Quite a bit      3-4 times per week 
Extremely      Daily 
       Several times daily 
 
Please write in each action (self-care) you took to deal with the problem.  Circle 
the number which best describes your use of each of the action you have listed 
below: 
 
0 = Not used at all 
1 = Used, but no relief 
2 = Used, got a little relief 
3 = Used, got some relief 
4 = Used, got quite a bit of relief 
5 = Used, was completely relieved 
 
      (Please circle your 
answer) 
f) _________________________________0 1 2 3 4 5 
g) _________________________________0 1 2 3 4 5 
h) _________________________________0 1 2 3 4 5 
i) _________________________________0 1 2 3 4 5 
j) _________________________________0 1 2 3 4 5 
 
 
5. In general, can you please TICK  to tell us who provided ideas, suggestions for 
your actions (self-care).  Tick all responses that apply. 
 
Partner  ___________ 
Family   ___________ 
Friends  ___________ 
Specialist nurses ___________ 
Doctors  ___________ 
Other cancer patients___________ 
Physiotherapists ___________ 
Other_______________________________ (please write in) 
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Perceived Stress Scale 
 
The questions in this scale ask you about feelings and thoughts during the last month.  
To complete the questions below, please circle the appropriate answer for how often you 
have felt or thought a certain way. 
 
0 = Never 1 = Almost never 2 = Sometimes 3 = Fairly often 4 = Very 
often 
 
 
1. In the last month, how often have you been   0 1 2 3 4 
upset because of something that happened unexpectedly? 
 
2. In the last month, how often have you felt that you 0 1 2 3 4 
were unable to control the important things in your life? 
 
3. In the last month, how often have you felt nervous 0 1 2 3 4  
and “stressed”? 
 
4. In the last month, how often have you felt confident  0 1 2 3 4 
about your ability to handle your personal problems? 
 
5. In the last month, how often have you felt that   0 1 2 3 4 
things were going your way? 
 
6. In the last month, how often have you found that  0 1 2 3 4 
you could not cope with all the things that you had to do? 
 
7. In the last month, how often have you been able  0 1 2 3 4 
to control your irritations in your life? 
 
8. In the last month, how often have you felt that you  0 1 2 3 4 
were on top of things? 
 
9. In the last month, how often have you been angered 0 1 2 3 4 
because of things that were outside of your control? 
 
10. In the last month, how often have you felt difficulties  0 1 2 3 4 
were piling up so high that you could not overcome them? 
 
In the last 6 months have you experienced any life events for example (death of a 
spouse, moving house, birth of a grandchild, divorce, etc)? 
 
Please List 
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
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Berlin Social Support Scale (BSSS). 
Please indicate using the scale below how much you agree with each statement 
over the last four weeks. 
    1= Strongly agree   2= Somewhat agree    3=Somewhat disagree    4=Strongly 
disagree 
1.   There are some people who truly like me.    1 2 3 4 
2.   Whenever I am not feeling well, other people show me that  1 2 3 4
     
      they are fond of me.     
3.   Whenever I am sad, there are people who cheer me up.  1 2 3 4 
4.   There is always someone there for me when I need   1 2 3 4  
      comforting. 
5.   I know some people upon whom I can always rely.   1 2 3 4 
6.   When I am worried, there is someone who helps me.  1 2 3 4 
7.   There are people who offer me help when I need it.  1 2 3 4 
8.   When everything becomes too much for me to handle,  1 2 3 4
  
      others are there to help me.  
 9.   When I am down, I need someone who boosts my spirits.  1 2 3 4 
 10.  It is important for me always to have someone who  1 2 3 4                               
        listens to me. 
 
11.   Before making any important decisions, I absolutely  1 2 3 4         
        need a second opinion.  
12.   I get along best without any outside help.     1 2 3 4 
13.   In critical situations, I prefer to ask others for their advice. 1 2 3 4 
14.    Whenever I am down, I look for someone to cheer me   1 2 3 4 
         up again. 
15.   When I am worried, I reach out to someone to talk to.   1 2 3 4 
16.   If I do not know how to handle a situation, I ask others what  1 2 3 4
  
        they would do.  
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17.   Whenever I need help, I ask for it.      1 2 3 4 
 
Please think about the person who is closest to you when answering the following 
questions: 
1= Strongly agree   2= Somewhat agree    3=Somewhat disagree    4=Strongly disagree 
18.   I kept all bad news from him/her.      1 2 3 4 
19.   I avoided everything that could upset him/her.    1 2 3 4 
20.   I showed strength in his/her presence.    1 2 3 4 
21.   I did not let him/her notice how bad and depressed I really felt.  1 2 3 4 
22.   I avoided any criticism.       1 2 3 4 
23. I pretended to be very strong, although I did not feel that way.  1 2 3 4 
Still thinking about the person who is closest to you, how did this person react to you 
during the last month?  
1= Strongly agree   2= Somewhat agree    3=Somewhat disagree    4=Strongly disagree 
24.   This person showed me that he/she loves and accepts me.  1 2 3 4 
25.   This person was there when I needed him/her.    1 2 3 4 
26.   This person comforted me when I was feeling bad.   1 2 3 4 
27.   This person left me alone.       1 2 3 4 
28.   This person did not show much empathy for my situation  1 2 3 4 
29.  This person complained about me.     1 2 3 4 
30.   This person took care of many things for me.    1 2 3 4 
31.   This person made me feel valued and important.    1 2 3 4 
32.   This person expressed concern about my condition.   1 2 3 4 
33. This person assured me that I can rely completely on him/her. 1 2 3 4 
34. This person helped me find something positive in my situation. 1 2 3 4 
35. This person suggested activities that might distract me.   1 2 3 4 
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36. This person encouraged me not to give up.    1 2 3 4 
37. This person took care of things I could not manage on my own. 1 2 3 4 
38. In general, I am very satisfied with the way this person behaved. 1 2 3 4 
 This question asks about people in your environment who provide you help or 
support. List all the people you know, excluding yourself, whom you can count on.  
Please write in their relationship to you (see example below).  
 Who can you really count on to care about you, regardless of what is happening to 
you? 
 EXAMPLE 
 1) NO ONE        tick ()   2) Husband  3) Daughter 
 
 4) Friend     5) Doctor  6) Reverent 
 
 7)      8)    9) 
Question 1 
 Who can you really count on to care about you, regardless of what is 
happening to you? 
1) NO ONE        tick ()   2)    3)  
 
 4)      5)    6)  
 
 7)      8)    9) 
Thank you very much. 
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Appendix 4.10 Steering Group Documentation 
          
      
Steering Group Minutes 
 
Meeting 3 (15th March, 2010) 
 
Present: Catherine Paterson (CP) (chair) 
  Dr. Martyn Jones (MJ) 
  Dr. Janice Rattray (JR) 
  Andy Wallace (AW) 
  Bob Cromb (BC) 
  Cara Taylor (CT) 
 
Apologies: Prof Billy Lauder 
    
  
1. Apologies were given on behalf of the absentees.  The minutes taken from the 
last meeting were agreed as being an accurate account for what was discussed.   
2. CP provided a brief reminder introduction to the research background and 
methods.  
3. CP identified that all the necessary approvals are secured for this research 
(sponsorship, ethics and R & D), with the funding for this research coming from 
Alliance for Self-Care Research. 
4. CP has piloted the study materials.  The questionnaire survey takes approx 15-20 
minutes to complete with no large quantities of missing data.  The diary has been 
piloted to 13 individuals so far.  The Behavioural Diary User Guide has been 
modified as directed from the pilot. 
5. The members from the group present discussed the paper copies of the research 
materials.  The PIS had a few typographical errors, these will be corrected.  
Within the baseline demographics, the educational element will be further 
broken down, i.e. what age did you leave school, and listing the qualifications.  
Within the clinical data – ‘Other’ will be added to the co-morbid conditions.  The 
additional cancer support services, requires modifications, adding in prostate 
cancer patient support group user, and clarity to the different support services at 
the Maggie’s centre.  CP will modify cancer support services sheet and email this 
around to the group members for comment. 
6. The questionnaire pack will need to checked through ‘word’ by ‘word’ to ensure 
that there are no typographical errors present. 
7. There were a few modifications to the questionnaire pack, CP contact details will 
be on the cover, with a few modifications to the self-care diary, rewording of the 
example, numbering the other self-care problems, and removing the initials from 
the network support question. 
8. The group then discussed the diary.  There was a consensus to change the 
anchors in several of the questions.  The revised versions are as follows, coping – 
not at all and always, self-efficacy questions – not at all and always, self-care 
demand – not at all and extremely, control – not at all and completely, symptoms 
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– not at all and always, discussing thoughts and feelings – not at all and always.  
Within the incident entry the support questions were agreed to be modified to 
how much support did you have? – none and alot, and, Was that enough 
support? - Not at all and always. 
9. AW kindly suggested engaging with members of the prostate cancer support 
group to help to pilot the diary.  CP and AW will be in contact via email to arrange 
this. 
10. CP highlighted that Mr Nabi (Consultant Urologist) would be willing to join the 
steering group for this research.  The group is excited about this further 
collaboration.  CP will engage with Mr Nabi to finalise this. 
 
 
Next meeting date:  3 months after recruitment has begun. 
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Appendix 4.11 Electronic Behavioural Diary Pilot 
Results 
 
Phase 1 – Colleagues and acquaintances  
Gender (age) 
 
 
Pilot number 1: 
Female (32 years 
old) 
 
Duration of 
pilot  
 
1 week 
 
Pilot feedback issues 
 
 
1)  The individual was unable to complete the 
diary data collection because of a limited time 
period to respond to the audio alarm.  The audio 
alarm was set to 3 minutes.  If the participant 
did not respond to the alarm within the 3 
minutes, they could not provide their data entry.  
This time window was not long enough, given 
the distraction and activities of daily life. 
 
 
2)  The Access data base did not open the 
missed entries for the pilot participant, and did 
not provide data on the usage of the snooze 
function.   
Researcher action 
 
 
The time period for the audio 
alarm reminder was increase for 
future pilots. 
 
 
 
 
 
 
 
The software developer of Pocket 
Interview was informed of the 
problem with the Access 
database.  The problem was 
fixed, and a newer version of the 
software was up-dated to 
prevent this problem happening 
in the future. 
Pilot 2: Female 
(52 years of age) 
2 weeks 1) Missed end of day entries because of limited 
alarm window, (was set within the same 
parameters as pilot 1, 3 minutes)   
 
 
 
 
 
 
 
 
 
 
 
 
2) This participant was not clear on the term 
‘fatalistic’. 
This time period for the audio 
reminders was extended for 
future pilots.  This was based on 
the feedback from pilot 1 and 2.  
The audio alarm was 
programmed to 30 seconds, 
every 10 minutes, for 1 hour.  
This was the maximum   alarm 
capacity of the diary, due to 
limitations in the software.  The 
audio alarm reminders were 
incorporated into the working 
version of the SOP. 
 
 
This comment was reflected 
upon, within the context of 
future pilot feedback. 
Pilot 3: Female 
(29 years of age) 
2 weeks 1)  If there was a missed entry at ‘end of day’ 
data entry, the participant was prompted to 
complete the ‘end of day entry’ the next 
morning.    
The software programmer 
corrected this problem by 
recoding the software 
programme.  Aiming to ensure 
that if an entry was missed at 
end of day, the participant did 
not have an opportunity to 
complete this the next morning.  
An up-dated version of the 
software correcting this problem 
was the working version for 
future pilots.  The latest version 
of the software to piloted to 
check that this particular 
problem was corrected by the 
programmer.  
Pilot 4: Male (30 
years of age) 
2 weeks No problems reported about alarm duration, or 
issues about completing the end of day entry the 
following morning. 
 
Pilot 5: Female 
(51 years of age) 
3 weeks  1) The user was able to exist the Pocket 
Interview software on the diary, altogether.  This 
was done by tapping a small Windows icon at 
the top of the PDA screen.  
 
1) Ensuring that the full-screen 
option is selected within PDA 
systems, will prevents 
participants being able to existing 
the Pocket Interview software.  
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2)  Qualitative text entries in the diary data was 
missing, because the pilot participant did not tap 
first into the white text box.  Resulting in missing 
data because the cursor was not in the white 
box.   This was despite the users tapping the 
letters to form words. 
 
 
 
This maximised the Pocket 
Interview display on the screen, 
and as a result the small 
Windows icon is no longer 
visible.   This was incorporated 
into the working version of the 
SOP. 
 
2) The programmer improved the 
software so that the cursor 
automatically starts in the box 
without the user having to tap in 
this first.  This will prevent future 
problems with missing qualitative 
text in the future.  The Pocket 
Interview software was up-dated 
and was the working version for 
future pilots 
 
 
Pilot 6: Female 
(62 years of age) 
4 weeks No problems reported with the qualitative text 
of any additional software problems. 
 
Pilot 7:  Female 
(26 years of age) 
4 weeks 1) Problems with the end of day self-care 
questions.  The start of the question was half 
way down the screen, and reports problems 
with having to scroll to the top of the screen to 
read the question.   
1) The programmer improved the 
software, so that all of the 
questions are displayed first at 
the top of each the screen.  This 
software was up-dated and was 
the working version for future 
pilots. 
Pilot 8:  Male (59 
years of age) 
4 weeks No problems reported.  The start of the diary 
questions were displayed at the top of the PDA 
screen. 
 
Pilot 9:  Male (60 
years of age) 
4 weeks  1) The researcher also identified that dates for 
the data entries were recorded incorrectly.  
Randomly changing the date and month around.    
1)  The programmer corrected 
this problem, which enabled the 
dates for the data points to be 
correctly formatted for date, 
month, and year.   
 
This software was up-dated to 
correct this error, and was the 
working version for future pilots. 
Pilot 10:  Male 
(36 years of age) 
4 weeks No problems, questions understandable and 
easy to complete. 
 
The date formatting was correctly displayed for 
the individual data points. 
 
Pilot 11: Female 
(86 years old) 
4 weeks 1)  Initially found navigating around the screen 
difficult for the end of day self-care, although 
managed to complete the data entry.   
 
No software problems were reported. 
1) The ‘Users guide to the 
behavioural diary’ was modified 
to clearly identify how to 
navigate around the screen.   
 
Phase 2 – Men with prostate cancer  
Gender (age) 
 
 
Pilot number 1: 
Male (56 years 
old) 
 
Duration 
of pilot  
 
1 week 
 
Pilot feedback  
 
 
1) The system crashed, because the user 
‘unsnoozed’ an ‘unsnoozed’ diary.  This was a 
technical problem with the software.   
 
2) The user reported that he felt that the 
coping question was slightly ambiguous, ‘it 
asks which statement best describes how you 
have coped…’  It is unclear to the patient, 
whether they rate one of the statements, or 
provide ratings for each statement.   
 
3) The pilot participant had no problems with 
charging the PDA battery, or dexterity 
problems in completing the diary. 
 
Researcher action 
 
 
The programmer up-dated the 
software to correct the problem.   
 
The researcher re-piloted the newer 
version of the software with herself.  
From the researchers’ pilot, the 
newer version prevented the system 
from crashing, when ‘unsnoozing’ an 
‘unsnoozed’ diary.  However, a new 
problem was detected when 
‘unsnoozing’ an ‘unsnoozed’ diary, in 
that an extra alarm for a data entry 
was randomly added to the schedule.   
 
The programmer corrected the 
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4)  The User Guide for the behavioural diary 
was informative, concise and helpful.   
 
5)  The pilot participant felt that the content 
of the interview schedule was very relevant to 
his diary experience.  
 
problem of additional alarm in the 
schedule, and a newer software 
version was available.  The researcher 
re-piloted the diary using the most 
up-to-date version, no further 
problems were detected. 
 
The wording of the question was 
modified to prompt the participant to 
provide ratings for each of the coping 
statements. 
 
Pilot 2: Male (62 
years of age) 
2 weeks 1)  No technical problems were reported with 
the software.   
 
2)  The pilot participant had no problems with 
charging the PDA battery, or dexterity 
problems in completing the diary. 
 
3)  The User Guide for the behavioural diary 
was informative and useful.  Having the 
researchers contact details, for addition 
guidance, if required was reassuring to him.   
 
4)  He reports that, as a man with prostate 
cancer he felt that completion of the diary was 
a positive experience.  He felt that men with 
prostate cancer may find the diary experience 
therapeutic.   
 
5) The pilot participant felt that the content of 
the interview schedule was very appropriate 
to his thoughts of completing the diary. 
 
Pilot 3: Male (67 
years of age) 
4 weeks 1)  The diary questions were all very relevant 
to his prostate cancer, however, felt that over 
the course of the month they became slightly 
repetitive. 
 
2)  The pilot participant had no problems with 
charging the PDA battery, or dexterity 
problems in completing the diary. 
 
3)  The User Guide for the electronic diary was 
helpful to look after the researcher explained 
the diary.  It was a useful reminder of how to 
complete the data entries. 
5)  The researcher had a problem with 
transferring the data from the PDA to the 
Access database.   
 
 
 
The software programmer was able 
to retrieve the data.   
 
To prevent future problems, the 
researcher re-piloted the diary with 
herself to try and isolate the problem.  
It was found that special characters 
for example ‘apostrophes’ caused the 
problems with transferring the data.  
The XML coding was not formatted 
correctly to handle this data.  The 
programmer up-dated the software 
to correct this technical problem. 
 
The researcher re-piloted the diary, 
again with herself using the latest 
version of the software, and 
rechecked all of the previously 
reported problems.  No problems 
were detected; therefore the diary 
was ready for ‘live data collection’. 
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Appendix 4.12 Standard Operating Procedure for 
Electronic Diary 
 
1. Check the battery status of the PDA.  [Start, Settings, System, Power].  Ensure the automatic 
switching off of the devise is set to preserve battery life [tap turn off the devise if not used in 
3 minutes]. 
 
2. Locate the battery charging lead and the PDA cover protector. 
 
3. Ensure all the software is appropriately installed onto the PDA. [Client Manager, Install Net 
Compact Framework 2.0, Install Client].  Should any problems be encountered with client 
manager [errors], the software developer recommended that a hard reset should be done. It 
is essential that the software applications are not open on the PDA whilst performing this 
task. 
 
4. Load the questionnaire on the PDA. [Open Pocket interview program, questionnaire manager, 
Load, Select FinalPhDquestionnaire Questionnaire, Open, Copy to PDA] 
 
5. Ensure that the schedule is suitable for the participant, in particular, considerations to 
sleeping patterns.  Ensure evenly data points for the schedule i.e. 10am, 4pm, and 10pm.  
Make the Schedule for the data collection.  [Click on the Schedule Manager].  Populate the 
labels for the schedule, by selecting the FinalPhDquestionnaire [Select questionnaire].  Use 
the [Individual Prompts] to produce the schedule, 2 standard entries and end of day entry 
(the 3rd standard entry is prompted automatically before the end of day entry, therefore it is 
only necessary to populate 2 standard entries) per day for a total duration on one month.  
Select the date, time and appropriate label 1) diary entry, 2) End of day entry.  Use the 
[repeat function] to populate for the full month.   
 
6. Save the schedule, by participant study number. [Click the save button].  Load the schedule to 
the PDA [click the Copy Schedule to Pocket PC]. 
 
7. Click Initialise on the Pocket PC.  
 
8. Quality check the schedule on the Pocket PC, ensuring that schedule is accurate and present.  
[System, View Schedule]. 
 
9. Change the username on the Pocket PC to the unique study number for the participant. 
[System, type the username then click Change User]. 
 
10. Ensure that the reminders for the diary entry are set [30 secs, 5 reminders and time between 
the reminders as 10].  Ensure that the full-screen button is ‘checked’, this is essential as it may 
allow the use to exit the programme.  Tap on the more button and ensure that that [check 
after snooze for missed is checked]. 
 
11. Provide training and support for the participant and provide the ‘users guide for the 
behavioural diary’.  [Click on the Demo Mode].  Highlight to the participant, that once the PDA 
is alarming to prompt data collection, it is too late to activate use the snooze facility.  Ensure 
that the participant is aware to charge the diary every several days.  Ensure that the demo 
mode is off when the participant is ready to commence their data collection. 
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12. Ensure that the participant has the PDA support/training pack to contact the Researcher; the 
Researcher will contact the participant 24 hours into their data collection, to offer support 
and answer any questions if necessary. 
 
13. On completion of the data collection.  Use the docking system for the PC and the Pocket PC.  
Rest the Pocket PC in to the Dell Cradle.  [click the Data Manager, click copy files from the 
Pocket PC, enter the encryption password, select new database saving by the unique 
participant number, and then add data to the participant specific database].  To retrieve the 
missed entries and the use of the snooze function sync the PDA to the computer [within the 
Microsoft ActiveSync click explore, my windows, programme files, copy both files mdbpilot1 + 
zbdpilot1 (e.g. pilot 1 is the name allocated to the PDA) copy files to database folder, open 
excel and open files as XML format].  
 
14. Check the data has been copied across from the Pocket PC. [Click in the System, List Entries, 
ensuring that this is now blank]. 
 
15. View the data in access.  This database is separated by; Missed Entries, Records of snooze 
function being used, and the 3 questionnaire schedules, Diary Entries, End of Day Entry and 
Incident Report.  The time and date is also recorded when the participant started and stopped 
each questionnaire sequence. 
 
 
16. Record in the participants CRF that their behavioural diary data has been successfully and 
securely downloaded and stored. 
 
17. Acknowledge many thanks to the participant for their time undertaking the diary data 
collection. 
 
18. End.  
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Appendix 4.13 Written Instruction for the 
Electronic Behavioural Diary    
 
   USERS GUIDE TO THE BEHAVIOURAL DIARY  
 
The Behavioural Diary 
 
 
The diary will sound an alarm at certain intervals throughout the 
day based on your own preference and guided by the researcher.  
When the diary makes a sound alarm, this means a diary entry is 
due for you to complete.  If you do not fill in an entry within a 
short time then the diary will sound again. This will continue for 60 
minutes.  The diary will continue to alarm until you make an entry.  
If it is inconvenient to make an entry, then you can activate the 
“snooze” function before you know that the diary is due to alarm.  
This will allow you to delay the diary entry from 5 or 60 minutes.  
Tap “snooze” and select a snooze duration time (5 to 60 minutes), 
the diary will then after this time, audio prompt you for the entry.  
The diary will ask you if you are sure that you would like to 
“snooze” tap “yes” to confirm.  If you do not wish to snooze the 
diary tap “no” and then tap ”back” this takes you back to the main 
menu.   
 
Stylus (pointer) 
Power Button 
“on/off” 
Protective Cover 
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On the main menu there is a systems button, this is for the 
research team involved in the study.  Please do not tap “system”.  
In the event of accidently taping the “system” button please tap 
“cancel”. 
Charging the Battery 
 
 
It is necessary to charge the diary battery each day/every second 
day.  To do this, put the plug into the socket ensuring the power 
supply is on.  Gently squeeze the two buttons on the side of the 
dell connector.  Ensure that the Dell logo is face up on the 
connector; now connect this to the base of the diary still squeezing 
the buttons until the connector is firmly attached to the base of 
the diary.  The picture above will give you some guidance.  The 
power button “on/off” button should now have a light on, this 
means that the battery is successfully charging.  When the diary 
battery is fully charged this light should be “green”.      
 
Completing the Diary 
 
When completing the diary questions, don’t think over you 
answers for too long.  Please remember that there are no right or 
wrong answers.    
 
Recording a diary entry  
· Remove the stylus (the pointer) from the diary, by lifting it 
out of the back right hand corner. 
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· Tap “Diary Entry” on the screen with the stylus (pointer). 
· The screens that follow will ask you questions. To answer 
these tap the stylus on the sliding scale or tap the 
appropriate box to provide your answer to the question. 
· When you have completed a screen of questions tap “Next”. 
· Follow the same procedure for the next 14 screens. 
· Once this is done, tap “Finish”. 
· The diary will then return to the main menu.  
· You have successfully completed the diary entry.  Thank you 
and Well Done. 
 
You will repeat this 3 times during the day.  At the end of the day, 
your last diary entry (3rd entry) will be slightly longer that the 2 
previous diary entries.  There are a few more questions to answer 
for the 3rd diary entry.  Follow the same procedure as before when 
making the diary entry, tap your answer to the question, then tap 
“next”, continue to follow this procedure, when you have 
answered all the questions tap “finish”.  The diary will return to 
the main menu.  Well done. 
 
Recording an incident 
You can record an incident/distressing experience at any time 
throughout the day.  A distressing experience can be anything 
related to your prostate cancer.  Again, there are no right or wrong 
answers, so please tell us as much as you can about the distressing 
experiences/incidents that you encounter.  If you record an 
incident/distressing experience after a regular diary entry you will 
be asked similar questions but these relate specifically to the 
incident.   
· Tap “incident entry” and follow the same procedure as 
before when you made your diary entry. 
· On the fourth screen you can enter details of the incident. 
To do this, first tap anywhere in the “white box”, this will 
make the cursor flash in the white box ready for your entry.  
You should now see cursor (small vertical black line flash on 
and off) in the box.  Once you see this, you are now ready to 
tap your details of your experience.  To do this, use the small 
keyboard at the bottom of the screen.  Tap each letter to 
spell out words.  Once you have finished describing your 
experience, tap “next”.  Continue answering the questions 
as before, when you are at the end of the entry tap “finish” 
this will take you back to the main menu.    
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· You have successfully completed the incident Entry.  Again 
thank you and well done. 
 
Pointers/Tips 
 
Typing words - Use the key board to tap the letters to spell words.  
You should see the letters that you are typing on the screen.   
 
Navigating/changing the diary screen view - You will have to 
change the view on the screen to read the questions on the diary 
(only at the end of day entry).   
 
 
   
If you have any questions or are experiencing difficulties 
completing the diary.  Please contact Catherine Paterson: 
Work number: 01382  
388645; Email: c.x.paterson@dundee.ac.uk.  Thank you. 
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Appendix 4.14 PDA Diary Schedule 
 
STANDARD ENTRY (COMPLETED 3 TIMES PER DAY, TOTAL OF 1 MONTH) 
 
Q1 How are you feeling just now? (MOOD) 
 
Alert    Not at all_____________________________________________Extremely 
Tired        Not at all_____________________________________________Extremely 
Happy     Not at all_____________________________________________Extremely 
Nervous    Not at all_____________________________________________Extremely 
Frustrated Not at all_____________________________________________Extremely 
Sad     Not at all_____________________________________________Extremely 
Energetic  Not at all_____________________________________________Extremely 
Angry     Not at all_____________________________________________Extremely 
Stressed    Not at all_____________________________________________Extremely 
 
Q2 Please rate each of the following statements which describes how you have 
coped in the last few hours with your self-care tasks? (COPING) 
 
I tried to keep a positive attitude    
Not at all____________________________________________Always 
I felt like giving up   
 Not at all____________________________________________Always 
I felt problems with my health prevent me from planning ahead     
 Not at all____________________________________________Always 
I felt that nothing I can do will make a difference 
 Not at all____________________________________________Always 
I tried not to think about it 
Not at all____________________________________________Always 
 
Q3 Think about the last few hours.   
 
I can always manage to complete self-care activities that are difficult for me. 
Not at all_____________________________________________Always 
 
I am confident in carrying out my self-care activities. 
 Not at all_____________________________________________Always 
 
 
Q4.   Think about self-care activity in the past few hours. 
 
a) How demanding has self-care been for you? 
 
Demanding 
Not at all_________________________________Extremely 
 
b) How much control have you had over your self-care? 
Control 
Not at all_________________________________Completely 
 
Q5 Have you sought out support in the last few hours? 
 
No     Yes 
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Q6 How much support have you had in the last few hours? (RECEIVED SUPPORT) 
 
Financial  None_________________________Alot 
Emotional  None_________________________Alot 
Informational  None_________________________Alot 
Practical  None_________________________Alot 
 
Q7 Do you have enough available support from people around you? (PERCEIVED 
SUPPORT)  
 
Financial  Not at all_____________________Alot 
Emotional  Not at all_____________________Alot 
Information  Not at all_____________________Alot 
Practical  Not at all_____________________Alot 
 
 
*END OF STANDARD ENTRY* 
 
 
 
 
 
END OF DAY ENTRY (IMMEDIATELY FOLLOWING 3RD STANDARD ENTRY) 
 
Q1 What types of self-care have you used today to help with your water works 
(urine)?  
 
None  (if ticked Q2) 
 
Took medication 
Found out information  
Increased fluid intake 
Used pads 
Used catheters 
Used urine sheaths 
Pelvic floor exercises 
Avoided heavy lifting 
Kept a toileting diary 
Avoided caffeine based  
Drinks 
Shared my feelings 
 
Other  
 
Please describe text box. 
 
Generally, did your self-care actions relieve the problem? 
 
Not at all_____________________________________Completely 
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Q2 What types of self-care have you used today to help with your bowels? 
 
None      (if ticked Q3) 
 
Took medication 
Increased fluid intake 
Changed diet 
Used pads 
Did pelvic floor exercises 
Kept a toileting diary 
Found out information 
Comfort (hot water bottle) 
Shared my feelings 
Other  
 
Please describe text box. 
 
 
Generally, did your self-care actions relieve the problem? 
 
Not at all_____________________________________Completely 
 
 
Q3 What types of self-care have you used today to help with your sexual function? 
 
None        (if ticked Q4) 
 
 
Took Medication 
Found out information 
Tried to lose weight (if overweight) 
Limited alcohol intake 
Stopped smoking (if smoke) 
Used a penis pump 
Took exercise 
Found ways to reduce stress 
Shared my feelings 
 
Other  
Please describe  
 
Generally, did your self-care actions relieve the problem? 
 
Not at all_____________________________________Completely 
 
Q4 Overall today I feel that: 
 
I can always manage to complete self-care activities that are difficult for me. 
Not at all_____________________________________________Always 
 
I am confident in carrying out my self-care activities. 
 Not at all_____________________________________________Always 
 
Q5 To what extent have you experienced the following symptoms today? (EORTC) 
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Blood in urine  Not at all_____________________________________Always 
Constipation Not at all_____________________________________Always 
Diarrhoea Not at all_____________________________________Always 
Nausea  Not at all_____________________________________Always 
Pain  Not at all_____________________________________Always 
Tiredness Not at all_____________________________________Always 
Unable to sleep Not at all_____________________________________Always 
Urgency to pass Not at all_____________________________________Always 
urine   
Urinate frequently Not at all_____________________________________Always 
(day)  
Urinate frequently Not at all_____________________________________Always 
 (night)  
Vomiting       Not at all_____________________________________Always 
Impotence       Not at all_____________________________________Always 
 
Q6 Did you use any other self-care activities (not already mentioned) to help alleviate 
your symptoms/problems today? 
 
Yes   (if yes Q7)  No (if no Q8) 
Q7 Please describe the problem/symptom for which you carried out your self-care? 
 
Problem/symptom 
Text box 
 
Please describe the self-care tasks 
Text Box 
 
Generally, did your self-care actions relieve this problem? 
 
Not at all_____________________________________Completely 
 
Q8 What was your most demanding self-care task that you had to do today? 
 
Please describe. 
 
Q9 How satisfied were you with your support today? (SATISFIED SUPPORT)  
 
Financial  Not at all_____________________Extremely 
Emotional  Not at all_____________________Extremely 
Informational  Not at all_____________________Extremely 
Practical  Not at all_____________________Extremely 
 
Q10  Were you able to discuss your thoughts and feelings today? 
 
Not at all_____________________Always 
 
 Did you want to discuss your thoughts and feelings today? 
  
Not at all_____________________Always 
 
 Q11 Has there been any change to your treatment/medication today? 
 
Yes   (If yes please describe)   No   
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Please describe what the treatment change was. 
 
Q12 How would you rate your quality of life today? (EORTC) 
 
Very poor______________________________________Excellent 
 
 
*END OF ‘END OF DAY ENTRY’* 
 
 
 
EVENT CONTINGENT (‘INCIDENT ENTRY’ CAN BE COMPLETED AT ANY TIME WITHIN 
THE 1 MONTH PERIOD)  
 
Q1 How are you feeling just now?  (MOOD) 
 
Alert     Not at all_____________________________________________Extremely 
Tired    Not at all_____________________________________________Extremely 
Happy     Not at all_____________________________________________Extremely 
Nervous    Not at all_____________________________________________Extremely 
Frustrated Not at all_____________________________________________Extremely 
Sad     Not at all_____________________________________________Extremely 
Energetic  Not at all_____________________________________________Extremely 
Angry     Not at all_____________________________________________Extremely 
Stressed    Not at all_____________________________________________Extremely 
 
Q2 Please describe your experience that was very demanding for you? 
 
What happened 
 
Free text 
 
Q3 Please rate the following statements which describes how you have coped with 
this experience? (MAC Scale) 
 
I tried to keep a positive attitude    
Not at all____________________________________________Always 
I felt like giving up   
 Not at all____________________________________________Always 
I felt problems with my health prevent me from planning ahead     
 Not at all____________________________________________Always 
I felt that nothing I can do will make a difference 
 Not at all____________________________________________Always 
I tried not to think about it 
Not at all____________________________________________Always 
 
Q4 Did you seek support to help with this experience? 
 
 No   Yes 
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Q5 Did you have enough support available from people around you? (PERCEIVED 
SUPPORT)  
 
Not at all_____________________Alot 
Was that enough support? 
Not at all_____________________Always 
 
 Thank you       *END OF INCIDENT ENTRY* 
 
 
 
 
                 
  
   
4
3
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Appendix 4.15 Sampling Framework: Reviewed Studies using the Berlin Social Support Scales 
(BSSS, Schulz and Schwarzer, 2003). 
Authors Item number Sample Time point social support 
assessed (trajectory) 
Mean and SD 
Schwarzer et al 
(2006) 
Received emotional support 
6 items  
Cronbach’s alpha= 0.87 T1 
                                = 0.83 T2 
                               = 0.79 T3 
N=117 (73 men and 44 women) 
mixed cancer sites, age 62.7, SD 
10.4 
T1 before cancer surgery 
T2 I month  
T3 12 months 
T1 3.81 SD 0.30 
T2 3.77 SD 0.39 
T3 3.73 SD 0.38 
Scored 1, 2, 3, 4 
Total maximum mean score 4 
Scholz et al 
(2008) 
Received social support 
2 items for 2 subscales (emotional 
and instrumental) support.  4 items 
in total 
Cronbach’s alpha reported = 0.67 
All men under went 
laparoscopic radical 
prostatectomy for PC  N=77 
Assessed 2 weeks after surgery 2.66 SD 0.47 
Scored 0, 1, 2, 3, total score min 0 max 12 
Total maximum mean score 3 
Boehmer et al 
(2007) 
Received social support 
10 items (6 items emotional, 3 
items instrumental, 1 item 
satisfaction) 
Cronbach’s alpha= 0.89 
N=240 1 month after surgery 
for varying malignant sites and 
gender (58% men, 42% women)  
63 years SD 10.3  (range 22-86) 
1 month after surgery 3.80 SD 0.37 range 2.0-4.0 
 
Scored 1, 2, 3, 4, total score min 10, max  40 
 
Total maximum mean score 4 
Luszcynska et al 
(2005) 
Received social support (emotional, 
instrumental and informational)  
Total item 10  (items not broken 
down) Cronbach’s alpha= 0.87 
N=255 with varying site of 
malignant tumours, 61.9 % 
men, 62.8 years SD 10,9 (range 
24-86) 
1 month after surgery 3.72 SD 0.38 
Scored 1 – 4, total score min 10, max  40 
 
Total maximum mean score 4 
Luszcynska et al 
(2007) 
 
 
 
Received social support emotional 
support (6 items) 
Cronbach’s alpha= 0.85 
 
 
N= 480 cancer patients 
recruited 3 days before surgery 
, N=294 I month after surgery, 
N=233 patients 6 months after 
surgery 
Mixed cancer sites, 60.2% men, 
age 62 SD 11.8 
 
T1 3 days before surgery 
T2 I month after 
T3 6 months 
Men T1 3.89 SD 0.26 n=108 
          T2 3.90 SD 0.21 
          T3 3.89 SD 0.27 
Women T1 3.85 SD  0.28 
                T2 3.79 SD 0.38 
                T3 3.65 SD 0.42 
Both T1 3.87 SD 0.27 
         T2 3.89 SD 0.29 
          T3 3.80 SD 0.35 
Scored 1 – 4, total score min 6, max  24, Total maximum mean 
score 4 
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Appendix 5.1 Associations with Demographic and 
Clinical Variables with the Questionnaire Survey 
Data 
Categorical variable Anxiety (square root) Depression (log) Global quality of life 
(square root) 
Demographic: 
Socio-economic 
Education level 
 
F(4, 63)=2.341, p=.065 
F(2, 65)=1.064, p=.315 
 
F(4, 63)=.574, p=.682 
F(2, 65)=.270, p=.515 
 
F(4, 62)=1.204, p=.318 
F(2, 64)= 1.477, p=.236 
Clinical variables: 
 
Cancer staging 
Treatments 
Gleason score 
 
 
F(2, 65)=.594, p=.555 
F(5, 61)=1.371, p=.241 
F(3, 64)=.644, p=.590 
 
 
F(2, 65)=2.741,p=.183 
F(5, 62)=1.429,p=.227 
F(3, 64)=.258, p=.856 
 
 
F(2, 64)=2.742, p=.072 
F(5, 61)=1.367, p=.249 
F(3, 63)=.682, p=.566 
 
Categorical variable Self-efficacy Perceived Stress Social support 
Demographic: 
Socio-economic 
 
 
 
 
 
 
Education level 
 
F(4, 64)=.516, p=.673 
 
 
 
 
 
 
F(2, 65)=.328, p=.721 
 
F(4, 63)=1.799, 
p=.140 
 
 
 
 
 
F(2, 65)=.862, p=.427 
 
Perceived: F(4, 63)=1.499, 
p=.213  
Received: F(4, 63)=.638, 
p=.638  
Satisfaction: F(4, 63)=1.069, 
p=.308  
 
Perceived: F(2, 65)= .617, 
p=.534  
Received: F(2, 64)=.783, 
p=.461  
Satisfaction: F(2, 63)=.717, 
p=.492 
Clinical variables: 
Cancer staging 
 
 
 
 
 
 
 
Treatments 
 
 
 
 
 
 
 
Gleason score 
 
F(2, 65)=2.123, 
p=.128 
 
 
 
 
 
 
F(5, 62)=1.523, 
p=.196 
 
 
 
 
 
 
F(3, 64)=.526, p=.673 
 
F(2, 65)=.021, p=.979 
 
 
 
 
 
 
 
F(5, 62)=1.434, 
p=.225 
 
 
 
 
 
 
F(3, 64)=.317, p=.813 
 
Perceived: F(2, 65)=1.534, 
p=.122  
Received: F(2, 64)=.207, 
p=.814  
Satisfaction: F(2, 63)=.409, 
p=.666 
 
 
Perceived: F(5, 62)=.851, 
p=.519  
Received: F(5, 61)=.623, 
p=.683  
Satisfaction: F(5, 60)=.231, 
p=.948  
 
 
Perceived: F(3, 64)=.1.287, 
p=.286  
Received: F(3, 63)=.906, 
p=.443  
Satisfaction: F(3, 62)=.746, 
p=.529 
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Appendix 6.1 Standard Operating Procedure: 
Analysis Guidance Points: N-of-1 Diary Data 
 
Summary definition points: 
 
Lag: Time period between two observations. 
 
Autocorrelation: Correlations among sequential scores at different lags. 
 
Autocorrelation function:  The pattern of autocorrelations in a series at numerous lags. 
 
Partial autocorrelation function: The pattern of partial autocorrelations in a series at 
numerous lags after partialling out the effects of autocorrelations at intervening lags. In 
summary, this provides a “clearer” picture of the presence of autocorrelation in a time series.  
 
Moderation: A moderator variable alters the strength of the relationship between a predictor 
variable and dependent variable. 
 
Mediator:  A mediator variable explains the causal relationship between the predictor 
variable and dependent variable.   
 
Linearity:  Is a way of describing the relationship between variables.  The mean values of the 
outcome and mean values of the predictor variable(s) are plotted against a straight line.   
 
Independence of the errors (no serial correlation):  is an assumption in regression analysis; this 
means that there should be no correlation for any 2 residuals.  Residuals should all be 
independent.  This assumption can be checked with the Durbin-Watson test and by checking 
the autocorrelations and partial autocorrelation functions of the residuals. 
 
Homoscedasticity (constant variance): is a requirement that should be met in regression 
analysis.  This term means that the spread of the residuals should be fairly constant in the 
model. 
 
Multicollinearity: this is a term used to describe that there should be no perfect linear 
relationship between two or more predictors in the regression analysis.  Multicollinearity 
indicates that the predictor variables should not be correlated too highly, that is to say, 
correlations above R=<0.90. 
 
(Tabachnick and Fidell, 2007, Field, 2005) 
 
Steps in SPSS: Standard entry analysis to test for main, moderation, and mediation 
effects in relation to the 3rd research question. 
 
Section A:    
 
1) Screen the data for normality, outliners and missing data. 
 
2) Plot a time series of the variables to explore and get a feel of the data.  This is 
performed in SPSS →Time Series, Sequence Charts.  Do a visual check for any trends in 
the data over time for each variable (Tabachnick and Fidell, 2007). 
 
3) Check autocorrelation/partial correlation functions.  Autocorrelation is defined as the 
correlations among sequential scores at different lags (lag is defined as the time 
periods between 2 observations).  For example, a lag of 1, the pair at time 1 and time 2, 
the pair at time 3 and time 4, and so on.  A lag of 2 autocorrelation coefficient is similar 
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to correlations between the pairs of scores at 2 time points apart; for example, the pair 
at time point 1, and time point 3, and the pair at time point 2 and time point 4, and so 
on.  Autocorrelations Function (ACF) is the pattern of autocorrelations in a time series 
at numerous lags.  Partial autocorrelation function (PACF) is the pattern of partial 
autocorrelations in a series at numerous lags after removing the effects of 
autocorrelations at intervening lags.  The autocorrelation function tells researchers 
about the structure of serial dependence in each data series (Cromwell et al., 1994).   
 
· This is performed in SPSS → Autocorrelations → check the residuals from the 
regression model.  Apply this question whilst doing a visual check of the output, 
“what do the lags tell us about the data series?”  It is good practice to run ACF and 
PACF for unaltered variables and transformed/standardised variables, as a quality 
check.   
 
4) If autocorrelation is detected in the series it is necessary to pre-whiten the variables, 
this is an essential part of multivariate time series analysis to reduce random noise.  
Pre-whitening means generating a series that has approximately the same level of 
power at all frequencies or white noise (white light has equal contributions at different 
frequencies and therefore, it is termed pre-whitening, Tabachnick and Fidell, 2007).    
 
a) First the researcher should generate new lagged variables [SPSS, Transform, Create 
time series, move the DV into the variable view, then select lag variable from the 
drop down window, then click continue].    
 
b) Now the researcher has created a pre-whitened variable in linear regression.  It is 
necessary to regress the variable on the lagged variable and store the standardised 
residual, this is our new pre-whitened variable (Cromwell et al., 1994).  To do this 
[analyse, regression, linear, move the variable to dependant viewer and move the 
lagged variable into the independent variable viewer.  In “save” ensure; “save the 
standardised residuals” is checked, in the main regression window click “ok”].  
Change the variable name and variable label in the viewer for the new pre-whitened 
variable. 
 
c) Now check that the ACF and PCF for the pre-whitened variable.  Do a quality check to 
establish if the pre-whitening procedure has worked on the variable. 
 
5) If pre-whitening procedure on the variable has worked effectively, it is appropriate to 
run the regression.   
 
6) For data (particularly DV), where appropriate; undertake appropriate transformations 
to meet the assumption of normally (see Tabachnick and Fidell, 2007). 
 
7) A correlation analysis between the independent and dependent variables should be 
performed to check for significant correlations; which will subsequently inform the 
moderation/mediation analysis to address the third research question.   
 
8) Standardise the IV and moderator variables; and it is worthwhile re-checking the time 
series plot using the standardised variables.   STANDARDISING: The first step in testing 
moderation is standardising the continuous variables.   The rationale for this is because 
the predictor variables and moderator variables are generally highly correlated when 
the interaction term is created.  Standardisation of the variables reduces the problem 
of multicollinearity (Frazier et al., 2004).  It is appropriate to standardise the 
independent variable and the moderator variable. 
 
1. SPSS →Analyse → Descriptive statistics → Descriptive →Select the variable 
→Click Standard values as variables (Field, 2005) 
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9) Testing moderation effects: CREATING PRODUCT TERMS using pre-whitened (if 
necessary) one multiplies together the predictor and moderator variables using the 
standardised variables (Frazier et al., 2004).  This can be done in compute variables. 
 
10) STRUCTURING THE EQUATION FOR MODERATION:  Enter the variables into the 
regression equation through specified blocks/steps.  Step 1: Enter the independent, 
moderator and dependent variable, Step 2: enter the integration term (independent 
variable X moderator variable).  
 
11) To establish whether testing moderation/mediation is appropriate using ordinary least 
squares regression.  There are 4 principle assumptions that must be checked, a) 
linearity of the relationship between dependent and independent variables, b) 
independence of the errors (no serial correlation), c) homoscedasticity (constant 
variance) of the errors, d) normality. 
 
12)  To answer this question the researcher must examine the model’s residuals (SPSS ®, 
2004).  
 
13)  Run the regression.  In SPSS → Analyse → Regression → Linear.  
 
a) Click statistics → select Estimates, Confidence intervals, Model fit, R square 
change, descriptive, Part and partial correlations, Collinearity diagnostics, Durbin-
Watson, Casewise diagnostics and set outliners to 2 standard deviations in the 
residuals group → Click continue.    
 
b) Click plots → select normal probability plot, and plot *ZRESID (y axis) against 
*ZPRED (x-axis); this will check the assumptions of random errors and 
heteroscedasticity.   
 
c) Click Save → select Predicted values Unstandardized, Standardised, Adjusted → 
Distances Mahalanobis, Cook’s and Leverage values → Residuals select; 
unstandardized Standardised, deleted and studentized residuals → click continue.   
 
d) Click OK → run the regression. 
 
14) Check the autocorrelation of the residuals.  Look the results of the Durbin-Watson 
statistic, which is a measure of the first-order (lag 1) autocorrelation of the residuals.  
This provides a check of the assumption of the uncorrelated residuals.  The values 
range from 0 to 4, values near 2 indicated non-autocorrelation, values towards 0 
indicates positive autocorrelation and values towards 4 indicates negative 
autocorrelation (Tabachnick and Fidell, 2007; SPSS ®, 2004).  It may also be necessary 
to look up the “Durbin-Watson” significance tables.  It is also appropriate to plot the 
autocorrelation/partial correlation functions of the residuals. 
 
15)  From the output: look at the “Correlation” matrix for multicollinearity, that is checking 
predictors are not too highly correlated with each other, R>0.90.   
 
a) The fit of the regression model can be checked using “Model Summary” and 
“ANOVA” from the tables in SPSS.  Looking at the R² will identify the proportion of 
variance explained by the model.  ANOVA will evaluate whether the model is a good 
overall fit of the data (P<0.05).  
 
b) Check the Durbin-Watson test to check that the assumption that the errors 
(residuals) are independent (it is likely to be met if the value is close to 2).    
 
c) The individual contributions of the variables to the regression model can be found in 
the “Coefficients” the beta values and their level of significance (P<0.05).   
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d) To further check of no multicollinearity, use the variance inflation factor (VIF) values 
from the coefficients tables.  If these values are less than 10 this indicates that 
generally this assumption has been met.   
 
e) Outliners that might be influencing the model can be checked by the “Mahalanobis 
and Cooks distance” values.  For interpretation of the Cook’s distance generally 
values greater than 1 maybe cause for concern, and for the Mahalanobis a crude 
check is to look for values above 15 in samples smaller than 100.   
 
f) Check the assumptions of the following: normality, linearity and Homoscedasticity 
of residuals.  This is done by a visual check of the P-P plot and the histograms.  If the 
histogram and the P-P plot are normal in distribution, then these assumptions are 
likely to be met. 
 
16)   INTERPRETING THE RESULTS:  First interpreting the results of the effects of the 
predictor and moderator variables, second testing the significance of the moderator 
effect.   
 
17)   If it was necessary to pre-whiten the data look at the relationships in the raw data in 
addition to the pre-whitened data.  This is done in SPSS →Correlations.  Are there any 
significant relationships?  If relationships are present in the pre-whitened variables on 
the not in the standard variables try and establish why.   
 
Section B: Testing from mediation 
 
1) To test for mediation requires the estimation of three regression equations: a) 
regressing the independent variable on the dependent variable b) regressing the 
independent variable on the mediator c) then regressing both the independent 
variable and the mediator variable on the dependent variable (Baron and Kenny, 
1986, Frazier et al, 2004).   
2) To establish mediation, the following conditions must hold 1) the independent 
variable must affect the mediator in the first regression, 2) the independent variable 
must affect the dependent variable, 3) the mediator must affect the dependent 
variable in the third regression.  If mediation is present then the effect of the 
independent variable on the dependent variable in the third equation should be less 
in the third equation than the second (Baron and Kenny, 1986; Frazier et al, 2004).   
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Appendix 6.2  Mr D’s Additional Self-Management 
Behaviours 
Date Symptom  Self-management behaviour Relief 
0-100 
31/01/2011 
 
01/02/2011 
 
 
02/02/2011 
 
 
03/02/2011 
 
 
04/02/2011 
 
 
 
 
05/02/2011 
 
 
 
06/02/2011 
 
 
 
07/02/2011 
 
 
 
08/02/2011 
 
 
 
09/02/2011 
 
 
 
 
10/02/2011 
 
 
 
11/02/2011 
 
 
 
 
 
12/02/2011 
 
 
 
13/02/2011 
 
 
14/02/2011 
 
Swollen ankles 
 
Swollen ankles 
 
 
Swollen ankles 
 
 
Swollen ankles 
 
 
Swollen ankles.  Pus 
oozing out from 
wound in stomach 
region 
 
Swollen ankles.  
Leakage from drain 
wound 
 
Swollen ankles.  
Leakage from drain 
wound 
 
Swollen ankles.  
Leakage from drain 
wound 
 
Swollen ankles.  
Leakage from drain 
wound 
 
Swollen ankles.  
Leakage from drain 
wound 
 
 
Swollen ankles.  
Leakage from drain 
wound 
 
Swollen ankles.  
Leakage from drain 
wound 
 
 
 
Swollen ankles.  
Leakage from drain 
wound 
 
Leakage of drain 
wound 
 
Leakage from drain 
wound 
Went for a walk 
 
Go for walks, elevate feet when sitting, took 
furosamide pills 
 
Go for walks, elevate feet when sitting, took 
furosamide pills, had a foot massage 
 
Go for walks, elevate feet when sitting, took 
furosamide pills 
 
Took furosamide pill, walking, dressed wound 
 
 
 
 
Took furosamide pills, walking, dressed wound 
 
 
 
Took furosamide pills, walking, dressed wound 
twice today 
 
 
Took furosamide pills, walking, dressed wound 
twice today 
 
 
Took furosamide pills, walking, dressed wound 
twice today 
 
 
Took furosamide pill, took exercise and elevated 
legs when sitting.  Went to local outpatient 
department where a nurse examined and dressed 
wound 
 
Took furosamide pill, took exercise and elevated 
legs when sitting.  Wound was redressed at local 
outpatients dept. 
 
Took furosamide pill, took exercise and elevated 
legs when sitting.  Went to Ninewells to have a bag 
attached to drain wound to collect discharge after 
my practice doctors contacted the consultant.  
Also shown how to drain and change bag. 
 
Took furosamide pill, took exercise and elevated 
legs when sitting.  Checking bag on drain wound 
was secure and emptying bag when needed. 
 
Replaced bag with a new one 
 
 
Bag attached to drain wound to collect discharge 
 
14 
 
0 
 
 
22 
 
 
8 
 
 
37 
 
 
 
 
23 
 
 
 
22 
 
 
 
8 
 
 
 
17 
 
 
 
48 
 
 
 
 
15 
 
 
 
46 
 
 
 
 
 
46 
 
 
 
100 
 
 
100 
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15/02/2011 
 
 
16/02/2011 
 
 
17/02/2011 
 
 
18/02/2011 
 
 
19/02/2011 
 
 
20/02/2011 
 
 
21/02/2011 
 
 
22/02/2011 
 
 
23/02/2011 
 
 
24/02/2011 
 
 
 
 
 
25/02/2011 
 
 
26/02/2011 
 
 
27/02/2011 
 
 
28/02/2011 
 
 
29/02/2011 
 
Discharge from drain 
wound 
 
Discharge from drain 
wound 
 
Discharge from drain 
wound 
 
Discharge from drain 
wound 
 
Discharge from drain 
wound 
 
Discharge from drain 
wound 
 
Discharge from drain 
wound 
 
Discharge from drain 
wound 
 
Slight discharge from 
drain wound 
 
Red patch on skin 
above drain wound.  
Diagnosed by GP as 
an infection 
 
Red patch on skin 
above drain wound 
 
Red patch on skin 
above drain wound 
 
Red patch on skin 
above drain wound 
 
Red patch on skin 
above drain wound 
 
Red patch on skin 
above drain wound 
Making sure bag at drain site is not leaking and 
emptying bag when necessary 
 
Making sure bag at drain site is not leaking and 
emptying bag when necessary 
 
Making sure bag at drain site is not leaking and 
emptying bag when necessary 
 
Making sure bag at drain site is not leaking and 
emptying bag when necessary 
 
Changing drain wound bag 
 
 
Emptying bag when necessary 
 
 
Very little discharge from wound.  Replaced bag 
with dressing 
 
Change dressing when necessary 
 
 
Change dressing when necessary 
 
 
Prescribed antibiotics by GP who said if the patch 
increased in size and there was no improvement in 
48 hours I should contact Ninewells 
 
 
Taking antibiotics and checking red patch does not 
increase in size 
 
Taking antibiotics which seem to be helping 
 
 
Taking antibiotics which seem to be effective 
 
 
Taking antibiotics which seem to be helping 
 
 
Taking antibiotic which seem to be clearing up the 
infection 
100 
 
 
100 
 
 
100 
 
 
100 
 
 
100 
 
 
100 
 
 
81 
 
 
100 
 
 
88 
 
 
0 
 
 
 
 
17 
 
 
44 
 
 
51 
 
 
67 
 
 
76 
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Appendix 6.3 Preliminary Analysis of 10 Single-Case 
Studies (Mr B to Mr K) 
Case report Mr B  
Mr B is 61 years old, married man who was diagnosed with localised prostate cancer and was monitored 
through active surveillance.   A number of autocorrelations were found for positive coping (at a lag 1), 
negative coping (at a lag of 3), self-management demand (at a lag of 2), negative affect (at a lag of 2), 
positive affect (at a lag of 1) and perceived social support (at a lag of 1).  Pre-whitening successfully 
removed these autocorrelations.    No other variables displayed autocorrelation.                                                                                                                                                                                                                                                                                                                
 
Positive affect (PreW lag 1) displayed positive kurtosis (P<0.001) and the K-M was significant (83) = 0.103, 
P=0.031.  A constant of 35 was added to the transformation (the largest of the negative values was -34.1) 
because without a constant the negative data points would have been lost because the square roots of 
negative numbers cannot be calculated.  A SQRT transformation (+ 35) improved normality (K-M [83] = 
0.083, P=0.200) for positive affect (PreW lag 1).   Transformations (Tabachnick and Fidell, 2007) were applied 
to positive coping (PreW lag 1), negative coping (PreW lag 3), and self-management demand (PreW lag 2), but did not 
achieve normality, and were left untransformed. 
Descriptive statistics of study variables – Mr B 
Mr B reported moderate (71.2, SD 22.6) perceived social support and very little received social support, 
see table 1.  He was also dissatisfied with his social support, see table 2.  These data suggest that he was 
not able to discuss his thoughts and feelings and he did not want to.  Mr B did not complete any incident 
reports. 
Table 1 Mr B: Standard entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Self-care demand 
Self-care control 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
84 
84 
84 
84 
84 
84 
84 
84 
84 
0 
62 
80 
1 
0 
17.3 
99.5 
0 
38.5 
6 
100 
100 
28.2 
16.6 
100 
100 
26.5 
100 
0.27 
99.5 
99.3 
23.5 
0.5 
55.1 
99.9 
0.6 
71.2 
0.9 
4.1 
3.5 
5.9 
2.0 
14.3 
0.1 
3.0 
22.6 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
Table 2 Mr B: End of day entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.  
Standard entry variables N Minimum Maximum Mean SD 
Satisfaction with social support  
 
Were you able to discuss your 
thoughts and feelings today?  
 
Did you want to discuss your feelings 
today? 
 
Overall, self-care self-efficacy 
 
29 
 
29 
 
 
29 
 
 
29 
 
23.7 
 
0 
 
 
0 
 
 
100.0 
 
100 
 
4 
 
 
3 
 
 
100 
 
61.1 
 
0.3 
 
 
0.3 
 
 
100.0 
 
18.5 
 
0.9 
 
 
0.7 
 
 
0.0 
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Quality of life 29 69 100 97.8 7.9 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Descriptive statistics for Mr B’s symptoms are presented in table 3.  The frequently experienced 
symptoms were urinary urgency and frequency.   
Table 3 Mr B: Self-reports of symptoms enquired about at end of day entry.  Means, standard 
deviations, minimum and maximum values, untransformed.   
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the day 
Urinate frequently at night 
Vomiting 
29 
29 
29 
29 
29 
29 
29 
29 
29 
29 
29 
29 
0 
0 
0 
0 
0 
0 
0 
0 
40 
38 
20 
0 
43 
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5 
4 
7 
5 
31 
25 
57 
56 
52 
5 
4.2 
0.3 
0.6 
0.3 
0.5 
0.6 
3.6 
2.2 
51.0 
49.7 
44.1 
0.7 
12.0 
0.8 
1.4 
0.9 
1.4 
1.4 
8.9 
5.9 
4.0 
3.8 
9.7 
1.6 
The ratings (0=not at all, 100=always).  A higher score is interpreted as the higher frequency of the symptom. 
 
A correlation analysis was undertaken between all the variables (including unaltered and altered 
variables) see table 4.  
 
  
   
4
4
1
 
Table 4 Pearson’s product moment correlation coefficients between all variables (unaltered and altered variables) for Mr B 
                                                            1 2     3   4  5  6 7      8         9          10           11      12     13     14     15 16 
1) Positive coping                                      1 
2) Positive coping PreW lag 1               0.945** 1 
3) Negative coping                                 -0.050  -0.117 1 
4) Negative coping PreW lag 3            -0.007  -0.046  0.946**  1 
5) Demand                                                0.054  0.130 -0.522** -0.319** 1 
6) Demand PreW lag 2                             0.256* 0.309** -0.406** -0.245* 0 .939** 1 
7) Control                                                 -0.021 -0.015 -0.029  -0.014 0.031  0.019 1 
8) Negative affect                                   -0.453**-0.433** -0.236*  -0.201 0.351** 0.264** 0.030  1 
9) Negative affect PreW lag 2                -0.382** -0.360** -0.089  0.035 0.202 0.158 0.018 0.910**  1 
10) Positive affect                  0 .012    -0.002 -0.022  0.050 0.120 0.106 0.008 -0.126  -0.190 1 
11) Positive affect PreW lag 1                  -0.015   -0.024  0.036  0.021 0.056 0.070 0.029 -0.116 -0.169 0.966** 1 
12) SQRT positive affect PreW lag 1       -0.008   -0.013  0.022  0.013 0.069 0.101 0.018 -0.136 -0.175 0.939** 0.974** 1 
13) Self-efficacy         -0.021   -0.015  0.422**          -     -0.082  -0.022 -0.012 -0.102  -0.103 0.039 -0.013 -0.024  1 
14) Received social support   0.041   0.161  -0.599** -0.562** 0.458 0.767** 0.023 0.147 0.199 0.201 0.029  -0.042 -0.059  1 
15) Perceived social support          -0.247*  -0.178  -0.090  -0.038 -0.026   -0.112 0.103 0.178   0.084 0.254* 0.258* 0.173 -0.141 0.023   1 
16) Perceived social support PreW lag  -0.225* -0.187 -0.038 -0.028 -0.024  -0.082 0.063 0.110 0.043    0.404**  0.376**  0.293** -0.088    0.007   0.896*   1 
*p<0.05, **p<0.01 (2-tailed) 
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Case report Mr C  
Mr C was 51 year old, married gentleman who was diagnosed with localised prostate cancer and treated 
by laparoscopic radical prostatectomy (LRP).    A number of significant autocorrelations were found at a 
lag of 1 for the following variables: self-management demand,  negative affect, self-efficacy, received and 
perceived social support.  The pre-whitening procedure was applied to each of these variables, and 
successfully removed the presence of autocorrelation.   
 
Self-management demand (Pre-W lag 1) displayed positive skewness and the K-S was significant D (80) = 0.506, 
p<0.001.  A square root transformation (+ constant of 36 [lowest negative number was -35.21]) was 
successful in reducing the impact of univariate outliner and improved normality, K-S D(79)= 0.077, 
p=0.200.  Negative affect (pre-W lag 1) displayed a univariate outliner and a square root transformation (+ 
constant of 12 [the lowest negative value was -11.64]) effectively reduced the impact of the outliner and 
improved normality.   
Descriptive statistics for Mr C 
Mr C reported little received social support and had high perceived social support; with overall 
satisfaction (see table 5 and 6).  He experienced reduced quality of life and experienced a number of 
symptoms (see table 6 and 7). 
Table 5 Mr C: Standard entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Positive coping  
Negative coping  
Self-care demand 
Self-care control 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
80 
80 
80 
80 
80 
80 
80 
80 
80 
52 
8.5 
0 
11 
0 
36 
69.5 
0 
0 
100 
66 
100 
100 
36.6 
100 
100 
57.7 
100 
97.6 
36.9 
32.1 
42.3 
6.7 
72.5 
97.5 
4 
97.1 
9.1 
9.7 
20.5 
20.4 
6.6 
16.4 
5.4 
12.9 
12.9 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Table 6 Mr C: End of day entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Satisfaction with social support  
 
Were you able to discuss your 
thoughts and feelings today?  
 
Did you want to discuss your feelings 
today? 
 
Overall, self-care self-efficacy 
 
Quality of life 
32 
 
32 
 
 
32 
 
 
32 
 
32 
77.2 
 
0 
 
 
0 
 
 
21.5 
 
34 
100 
 
100 
 
 
100 
 
 
100 
 
100 
97.1 
 
93.6 
 
 
95.7 
 
 
94.7 
 
86.5 
3.6 
 
21.0 
 
 
18.1 
 
 
14.7 
 
16.1 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Mr C experienced a range of symptoms (see table 7) and these included: impotence, tiredness, urgency 
and urinary frequency.  Mr C did not experience any bowel dysfunction.   
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Table 7 Mr C: Self-reports of symptoms enquired about at end of day entry.  Means, standard 
deviations, minimum and maximum values, untransformed.   
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the day 
Urinate frequently at night 
Vomiting 
32 
32 
32 
32 
32 
32 
32 
32 
32 
32 
32 
32 
0 
0 
0 
0 
0 
0 
0 
0 
3 
7 
0 
0 
12 
0 
0 
100 
0 
20 
70 
41 
100 
100 
84 
0 
0.94 
0 
0 
84.8 
0 
1.47 
28.9 
1.9 
33.5 
42.3 
25.8 
0 
3.0 
0 
0 
17.2 
0 
4.3 
17.9 
7.7 
25.8 
28.3 
23.4 
0 
The ratings (0=not at all, 100=always).  A higher score is interpreted as the higher frequency of the symptom 
 
Four incident entries were completed (see table 8).   Mr C’s incident reports were related to urinary 
dysfunction and rectal pain. He experienced negative affect (23.4, SD 22.9) and reported low perceived 
social support (45.5, SD 45.4) at the time of his incident entries. 
Table 8 Mr C: Incident entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Incident entry variables N Minimum Maximum Mean SD 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Received social support 
Perceived social support 
4 
4 
4 
4 
4 
4 
41 
29.7 
0 
20.7 
0 
0 
100 
57 
49 
70.7 
100 
100 
81.5 
40.7 
23.4 
49.2 
35.5 
45.5 
27.9 
11.6 
22.9 
23.2 
46.2 
45.4 
Incident entry date and 
time: 
01.02.2011 17:16 
02.02.2011 19:24 
 
05.02.2011 03:59 
 
 
26.02.2011 19:34 
 
Sought 
support 
No 
No 
 
No 
 
 
No 
 
Description of the incident 
 
Passed urine when coughing. 
I feel that my bladder control is non-existent at the moment and it 
is getting extremely frustrating for me now.  
Due to the retracted penis pouch becoming unstuck, as a result of 
this the bed got very wet and everything needed changing. 
Severe rectal pain came on very suddenly.  Tramadol taken for pain 
and also movicol. 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
The bivariate correlation analysis for Mr C is presented in table 9.   
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Table 9 Pearson’s product moment correlation for all variables for Mr C 
                                                            1 2     3   4  5  6 7      8         9          10           11      12     13     14     15 16 17 
1) Negative coping                                      1 
2) Positive coping                              -0.260*  1            
3)  Demand   0.327** -0.335** 1 
4)  Demand pre-W lag 1   0.280** -0.301*** 0.942**   1 
5)  SQRT Demand pre-W lag 1   0.0272** -0.245** 0.902** 0.976** 1 
6)  Control           -0.080  -0.056    -0.082       -0.108    -0.151 1 
7) SQRT Control    -0.050   -0.072   -0.033  -0.064   -0.103 0.989** 1 
8)  Positive affect       -0.073 0.285*   -0.230* -0.200    -0.180   -0.149  -0.133 1 
9)  Negative affect                             0.465** -0.663** 0.575** 0.465** 0.376** -0.016 0.015  -0.148  1 
10) Negative affect pre-W lag 1           0.465** -0.626** 0.502** 0.472** 0.406** 0.018    0.052  -0.182 0.841** 1 
11)  SQRT Negative affect pre-W lag 1  0.440**  -0.525** 0.459** 0.430** 0.376** -0.017 0.013   -0.169 0.761** 0.975** 1 
12)  Self-efficacy                                        -0.248** 0.300**  -0.408**  -0.291** -0.214 0.014    0.010 0.299** -0.561**  -0.371** -0.308** 1 
13)  Self-efficacy pre-W lag 1       -0.307**  0.206   -0.384**  -0.344**  -0.301** 0.057 0.048   0.229*   -0.348** -0.288* -0.267** 0 .774**   1 
14)  Received social support           0.085    -0.173   0.230* 0.197     0.108     0.033 0.017 0.162     0.363** 0.280* 0.167   -0.489**  -0.297** 1 
15)  Received social support pre-W lag 1   0.316**  -0.210 0.167   0.118    0.048    -0.008   -0.032   0.166      0.428** 0.287* 0.192     -0.455**  -0.304** 0.959** 1 
16)  Perceived social support           -0.104 0.209   -0.102    -0.130   -0.122  -0.131  -0.145      0.218  -0.238**  -0.128   -0.056    0.230*   0.151  -0.273* -0.188 1 
17)  Perceived social support pre-W lag 1  -0.120  0.027   0.006 -0.026     -0.054 -0.122   -0.135     0.171   -0.073    -0.008   0 .040       0.132    0.086     -0.149   -0.134 0.941**  1                 
*p<0.05, **p<0.01 (2-tailed) 
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Case report Mr D  
Mr D was a 59 year old married gentleman, treated by LRP for his localised prostate.  A number of 
significant autocorrelations were found for the following variables:  negative coping (at lag of 2), negative 
effect, received and perceived social support (all at a lag of 1), and positive affect (at a lag of 3).  The pre-
whitening procedure was applied to each of these variables, and successfully removed the presence of 
autocorrelation.  Pre-whitened negative coping displayed kurtosis p<0.001, the K-S statistic significant 
D(92)=.119, p=0.002.  A constant of 11 was added to the square root transformation (the largest of the 
negative values was -10.12) and this was effective in improving the normality of this negative coping (Pre-W 
lag 2).    
Descriptive statistics for Mr D 
Social support scores were low for perceived and received social support (see table 10); with overall low 
satisfaction scores, see table 11.  Mr D reported reduced quality of life and also experienced a number of 
symptoms (see table 12).        
Table 10 Mr D: Standard entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Positive coping  
Negative coping  
Self-care demand 
Self-care control 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
90 
90 
90 
90 
90 
90 
90 
90 
90 
99 
11 
0 
80 
0 
15 
97.5 
4.7 
9 
100 
33.5 
32 
100 
10.2 
77.7 
100 
62 
88.7 
99.9 
19.8 
1.5 
99.7 
0.34 
50.8 
99.9 
13.7 
20.1 
0.1 
4.3 
4.5 
2.3 
1.32 
14.1 
0.3 
9.2 
14.5 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Table 11 Mr D: End of day entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Satisfaction with social support  
 
Were you able to discuss your 
thoughts and feelings today?  
 
Did you want to discuss your feelings 
today? 
 
Overall, self-care self-efficacy 
 
Quality of life 
31 
 
31 
 
 
31 
 
 
31 
 
31 
8.5 
 
66 
 
 
69 
 
 
100 
 
49 
48.2 
 
100 
 
 
100 
 
 
100 
 
85 
18.8 
 
98.9 
 
 
98.5 
 
 
100 
 
70 
11.0 
 
6.1 
 
 
6.0 
 
 
0 
 
8.3 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Among his most frequently experienced symptoms included the following: frequency at night, unable to 
sleep, tiredness and pain.   
 
 
 
 
446 
 
  
Table 12 Mr D: Self-reports of symptoms enquired about at end of day entry.  Means, standard 
deviations, minimum and maximum values, untransformed.  .   
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the day 
Urinate frequently at night 
Vomiting 
31 
31 
31 
31 
31 
31 
31 
31 
31 
31 
31 
31 
0 
0 
0 
0 
0 
0 
7 
10 
0 
0 
52 
0 
2 
0 
24 
48 
0 
50 
57 
54 
0 
28 
100 
0 
0.6 
0 
0.7 
2.9 
0 
13.3 
24.9 
23.3 
0 
3.6 
70.3 
0 
0.3 
0 
4.3 
11.4 
0 
10.6 
14.7 
12.2 
0 
7.8 
14.2 
0 
The ratings (0=not at all, 100=always).  A higher score is interpreted as the higher frequency of the symptom 
Four incident entries were completed see table 13.  The incident entries were related to Mr D’s self-
management for his post-operative wound complications.    
Table 13  Mr D: Incident entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Incident entry variables N Minimum Maximum Mean SD 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Tiredness 
Received social support 
Perceived social support 
4 
4 
4 
4 
4 
4 
4 
100 
9 
0 
22.3 
0 
47 
50 
100 
25.5 
12.2 
61.3 
75 
100 
100 
100 
16.5 
4.5 
43.4 
34.7 
85.5 
83.3 
0 
7.4 
5.5 
20.1 
33.1 
25.7 
23.6 
Incident entry date and 
time: 
04.02.2011 14:36 
 
 
 
 
 
04.02.2011 17:07 
 
 
 
09.02.2011 10:25 
 
 
 
 
 
23.02.2011 16:13 
 
Sought support 
 
Yes 
 
 
 
 
Yes 
 
 
 
Yes 
 
 
 
 
 
Yes 
 
 
 
Description of the incident 
 
Started having pain in the lower abdomen region.  A drain 
had been taken out 4 days ago and the wound appeared to 
be healing ok but when showering it opened up and yellow 
pus oozed out. 
 
Unable to complete diary at 4pm because I was trying to 
stem the flow of yellowish pus from drain wound in 
stomach area. 
 
Wound still oozing pus and small amount of blood. 
Contacted district nurse who suggested I go to the 
treatment room at local medical centre to get wound 
dressed with more suitable dressings than I have been able 
to buy at chemist. 
 
Just above the drain wound, a small, slightly risen, bright 
red patch has appeared. It looks as if it could be a local 
infection in that area. Have made an appointment to see my 
GP tomorrow. 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
The results of the bivariate correlations analysis for Mr D are presented in table 14.   
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Table 14 Pearson’s product moment correlation between all the variables for Mr D 
                                                                  1 2     3   4  5  6 7      8         9          10            11      12     13     14     15 
1) Positive coping                            1 
2) Negative coping     0 .036   1 
3) Negative coping PreW lag 2        0.028 0.835**   1 
4) SQRT Negative coping PreW lag 2     0.022 0.827** 0.970** 1 
5) Negative affect                       0.026   0.202* 0.132   0.139  1 
6)  Negative affect PreW lag 1          0.020   0.192 0.120   0.124 0.968** 1 
7) Positive affect                  -0.057    0.215*  0.254*  0.229* -0.307** -0.307** 1 
8) Positive affect PreW lag 3       -0.034  0.000 0.040 0.021  -0.409**  -0.442** 0.780** 1 
9) Received social support      0 .005   0.329** 0.226* 0.218* 0.241* 0.168  -0.054    -0.164  1 
10) Received social support preW lag 1    -0.002   0.304** 0.176 0.176 0.243* 0.183  -0.049  -0.197 0.974** 1 
11) Perceived social support       0.054     0.473**   0.166 0.188   0.103   0.089      0.054     -0.100 0.485** 0.548** 1 
12) Perceived social support preW lag 1 0 .025   0.222* 0.045 0.083 0.112   0.073     -0.013 -0.187 0.555** 0.596**  0.826**  1 
13) Self-efficacy                   0.176      0.051   0.115 0.159   0.039   0.027    0.077    0.015    0.054 0.046   -0.075 -0.029   1 
14) Demand                       0.033      0.228 0.127 0.134 0.743** 0.746**  -0.408** -0.447** 0.131 0.105 0.150      0.119  0.050   1 
15) Control      -0.014    -0.238*  -0.195   -0.198 -0.847** -0.884** 0.258* 0.489** -0.292** -0.314**  -0.148  -0.209* -0.021 -0.720** 1 
*p<0.05, **p<0.01 (2-tailed) 
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Case report Mr E 
Mr E was 65 year old married gentleman treated with neoadjuvant hormone therapy and radiotherapy 
for his locally advanced prostate cancer.  A significant autocorrelation was found for positive coping (at a 
lag of 4) and positive affect and perceived social support (both at a lag of 1).  No other variables in the 
data series displayed autocorrelation.  The pre-whitening procedure was successfully applied to these 
variables.  Negative coping displayed positive skewness and kurtosis and the Kolmogorov-Smirnov test 
was significant, D (94) = 0.510, p<0.001.  A square root transformation was applied to negative coping and 
this reduced the impact of outliners and achieved normality.   
Descriptive statistics of study variables – Mr E 
Perceived social support and received social support were low (see table 15); with overall reduced 
satisfaction with his support (see table 16).  Mr E reported good quality of life and experienced a number 
of symptoms (see table 17).  
 
Table 15 Mr E: Standard entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Self-care demand 
Self-care control 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
94 
94 
94 
94 
94 
94 
94 
94 
94 
0 
0 
99 
14.7 
0 
50 
90 
24 
24.5 
0 
100 
100 
54.3 
0.2 
95 
100 
35 
99.8 
0 
95.7 
99.9 
30 
0.0 
75.4 
99.9 
25.1 
24.8 
0 
20.2 
0.2 
5.8 
0.0 
7.5 
1 
1.2 
11.2 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
 
Table 16 Mr E: End of day entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Satisfaction with social support  
 
Were you able to discuss your 
thoughts and feelings today?  
 
Did you want to discuss your feelings 
today? 
 
Overall, self-care self-efficacy 
 
Quality of life 
32 
 
32 
 
 
32 
 
 
32 
 
32 
25 
 
99 
 
 
0 
 
 
99.5 
 
91 
61 
 
100 
 
 
100 
 
 
100 
 
100 
53.7 
 
99.9 
 
 
88.3 
 
 
99.9 
 
99.2 
10.5 
 
0.2 
 
 
27.3 
 
 
0.2 
 
2.3 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
The most frequently experienced symptoms included the following: impotence, urinary frequency and 
urinary urgency.  Data suggests that bowel complaints were not problematic for Mr E.  
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Table 17 Mr E: Self-reports of symptoms enquired about at end of day entry.  Means, standard 
deviations, minimum and maximum values, untransformed.  All scales are from 0-100.   
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the day 
Urinate frequently at night 
Vomiting 
32 
32 
32 
32 
32 
32 
32 
32 
32 
32 
32 
32 
0 
0 
0 
99 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
27 
100 
0 
7 
29 
9 
79 
86 
89 
0 
0 
0 
0.84 
99.9 
0 
0.2 
8.3 
0.5 
13.3 
17.4 
14.3 
0 
0 
0 
4.7 
0.1 
0 
1.2 
9.6 
1.9 
20.8 
21.5 
20.7 
0 
 
A correlation analysis was undertaken between all the variables (including unaltered and altered 
variables).  The results of the analysis can be seen in table 18 for Mr E.   
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Table 18 Pearson product moment correlations between all variables for Mr E.  
                                                                  1 2     3   4  5  6 7      8         9          10            11      12     13  
1) Positive coping                              1 
2) Positive coping preW lag 4        0.869** 1 
3) Negative coping      0.173  -0.129  1 
4) SQRT negative coping    0.229*  -0.146 0.993** 1 
5) Negative affect     0.025     -       0.129   0.136 1 
6) Positive affect                 -0.031 -0.054    -0.028  -0.022 0.092 1 
7) Positive affect preW lag 1        -0.072 -0.110 -0.072   -0.058 -      0.950**  1 
8) Self-efficacy                        -0.031 -0.010 -0.003  -0.009 0.013 -0.004  -0.053  1 
9) Received social support            0.076 0.042 0.017    0.027 0.440** 0.060 0.003    0.010    1 
10) Perceived social support         -0.334** -0.158  -0.038    -0.070 0.670** 0.062   0.033 -0.433** 0.269**  1 
11) Perceived social support preW lag 1 -0.261* -0.143  -0.035     -0.054 -      0.046    0.102   -0.735**  -0.035 0.843 1 
12) Demand                                 -          -             -       -         -         -        -        -       -    -    - 1       
13) Control                              -0.050    -0.016 0.054 0.049   0.022    0.231* 0.208* -0.027   0.014 0.028   0.010   -    1 
*p<0.05, **p<0.01 (2-tailed) 
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Case report Mr F  
Mr F was a 57 year old married gentleman, treated for his locally advanced prostate cancer with 
neoadjuvant hormone therapy and radiotherapy.  A significant autocorrelation was found for received 
social support (at lag 6) and the pre-whitening procedure successfully removed the autocorrelation.  No 
other variables in the data series displayed autocorrelation.  Negative affect displayed positive skewness 
and the K-S test was significant, D(78) =0.210, p<0.001.  A logarithmic transformation was applied 
successfully to negative affect and achieved normalisation of this variable.  Negative coping displayed 
positive skewness and kurtosis, and the Kolmogorov-Smirnov test was significant, D(78) =0.205, p<0.001.  
A logarithmic transformation was applied successfully to negative coping and achieved normality in 
distribution.   
Descriptive statistics of study variables – Mr F 
Mr F reported high perceived social support and low received social support (see table 19), but with 
overall satisfaction with his support (see table 20).   He also reported good quality of life (see table 20).    
Table 19 Mr F: Standard entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.  
Standard entry variables N Minimum Maximum Mean SD 
Self-care demand 
Self-care control 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
84 
84 
84 
84 
84 
84 
84 
84 
84 
0 
6 
3 
1 
2 
39 
98 
0 
97.0 
12 
100 
100 
49 
75 
100 
100 
100 
100 
3.1 
97.7 
98.8 
13.1 
11.2 
85.5 
99.9 
15.1 
99.9 
2.2 
14.0 
10.5 
6.5 
11.2 
15.5 
0.2 
31.7 
0.4 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Table 20 Mr F: End of day entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.  All scales are from 0-100.   
Standard entry variables N Minimum Maximum Mean SD 
Satisfaction with social support  
 
Were you able to discuss your 
thoughts and feelings today?  
 
Did you want to discuss your feelings 
today? 
 
Overall, self-care self-efficacy 
 
Quality of life 
25 
 
25 
 
 
25 
 
 
25 
 
25 
26 
 
91 
 
 
3 
 
 
100 
 
86 
100 
 
100 
 
 
100 
 
 
100 
 
100 
93.3 
 
99.6 
 
 
67.2 
 
 
100 
 
96.6 
20.2 
 
1.8 
 
 
35.1 
 
 
0 
 
4.6 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
The most frequently experienced symptoms included the following: impotency, tiredness, 
unable to sleep, urinary frequency and urinary urgency (see table 22).  Data suggests that bowel 
complaints were seldom experienced.  
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Table 22 Mr F: Self-reports of symptoms enquired about at end of day entry.  Means, standard 
deviations, minimum and maximum values, untransformed.  
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the day 
Urinate frequently at night 
Vomiting 
25 
25 
25 
25 
25 
25 
25 
25 
25 
25 
25 
25 
0 
1 
0 
76 
0 
2 
11 
9 
7 
4 
7 
1 
35 
5 
31 
100 
6 
6 
78 
58 
50 
31 
57 
6 
3.92 
2.6 
6.3 
98.2 
2.4 
3.5 
28.4 
21.40 
21.5 
14.9 
21.0 
3.2 
6.8 
1.2 
8.0 
5.5 
1.4 
1.1 
17.6 
12.2 
11.1 
7.0 
12.5 
0.9 
The ratings (0=not at all, 100=always).  A higher score is interpreted as the higher frequency of the symptom 
 
Mr F did not complete any incident reports.  The results of Mr F’s correlations are presented in table 23. 
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Table 23 Pearson product moment correlations between all variables for Mr F.  
                                                                  1 2     3   4  5  6 7      8         9          10            11 
1)  Received support Pre-W lag 6 1 
2)  Received support    0.949**  1 
3)  Negative affect   -0.125  -0.111  1 
4)  Negative affect (log)     -0.155  -0.104  0.834** 1 
5)  Negative coping                     -0.151 -0.161 0.148      0.243* 1 
6)  Negative coping (log)  -0.145  -0.108 0.178     0.266* 0.872** 1 
7)  Positive affect 0.028    0.037 -0.004   -0.048   0.108 0.141 1 
8)  Self-efficacy  0.034 0.042 -0.006     -0.053 0.111   0.143   1.0**   1 
9)  Demand   0.160    0.169 -0.015   -0.014 -0.072 -0.098   -0.043  -0.042  1             
10)  Control   -0.349** -0.201   0.058   0.052 0.240* 0.523** -0.019 -0.018 -0.265* 1 
11)  Perceived support  -0.473**  -0.403** 0.080    0.143 0.206   0.467** -0.021 -0.021   0.025 0.447** 1 
*p<0.05, **p<0.01 (2-tailed) 
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Case report Mr G  
Mr G was a 64 year old married gentleman, diagnosed with locally advanced prostate cancer and treated 
with neoadjuvant hormone therapy and radiotherapy.  Mr G also had pre-existing health problems and 
these included: asthma, hypertension and depression.  A number of significant autocorrelations were 
found at a lag of 1 for the following variables: positive coping, negative coping, negative affect and 
received social support.  Positive affect displayed autocorrelation at a lag of 3, and self-management 
control at a lag of 4.  Pre-whitening procedure was applied to each of these variables, and removed the 
autocorrelation.  Negative affect (pre-w lag 1) displayed kurtosis and skewness p<0.001, the K-S statistic was 
also significant D(95)=0.170, p<0.001.  A square root transformation (and a constant of 21 [the largest of 
the negative values was -20.74]) achieved normality in distribution.  Pre-whitened received social support 
had a number of outliners visible from the SPSS box plot, and the K-S D(95)=0.284, p<0.001, kurtosis 
p<0.001.  A square root transformation (+ constant of 6 [lowest value -5.9]) improved the normality 
distribution and reduced the impact of the outliners.   
Descriptive statistics for Mr G 
Mr G reported little received social support and reduced perceived social support scores (see table 24).  
Mr G was highly dissatisfied with his social support (table 25).  His quality of life was reduced and he 
experienced a number of symptoms (see table 25 and 26)..    
Table 24 Mr G: Standard entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Positive coping  
Negative coping  
Self-care demand 
Self-care control 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
Tired 
96 
96 
96 
96 
96 
96 
96 
96 
96 
96 
32 
26.3 
0 
1 
0 
17 
1 
0 
33.7 
0 
93 
63.3 
68 
100 
68.6 
78 
100 
40.5 
79.75 
93 
58 
39.8 
10.7 
89.9 
12.9 
41.7 
93.9 
3 
43.5 
60.9 
11.3 
5.2 
16.1 
19.3 
14.5 
15.5 
10.2 
6.2 
4.5 
24.6 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Table 25 Mr G: End of day entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Satisfaction with social support  
 
Were you able to discuss your 
thoughts and feelings today?  
 
Did you want to discuss your feelings 
today? 
 
Overall, self care self-efficacy 
 
Quality of life 
33 
 
33 
 
 
33 
 
 
33 
 
33 
6.5 
 
57 
 
 
29 
 
 
88 
 
21 
59 
 
93 
 
 
95 
 
 
99 
 
89 
18.8 
 
69.6 
 
 
62.6 
 
 
94.2 
 
65.1 
7.9 
 
8.3 
 
 
14.7 
 
 
2.5 
 
13.8 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
The most frequently experienced symptoms included: tiredness, unable to sleep, urinary frequency, 
urinary urgency and constipation (see table 26).   
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Table 26 Mr G: Self-reports of symptoms enquired about at end of day entry.  Means, standard 
deviations, minimum and maximum values, untransformed.   
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the day 
Urinate frequently at night 
Vomiting 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
0 
0 
0 
0 
0 
0 
3 
1 
0 
2 
0 
0 
83 
4 
5 
4 
23 
46 
94 
91 
79 
83 
71 
5 
35.4 
.88 
1.39 
1.21 
2.36 
4.64 
63.8 
43.2 
10.9 
47.2 
28.5 
1.79 
27.9 
1.1 
1.2 
1.5 
4.1 
10.2 
19.3 
24.9 
19.7 
25.7 
29.1 
1.5 
The ratings (0=not at all, 100=always).  A higher score is interpreted as the higher frequency of the symptom 
Three incident entries were completed and these related to bowel self-management, table 27.  Mr G 
reported a composite of positive and negative coping styles and high perceived social support, although 
he did not seek social support to help with his incident experience. 
Table 27 Mr G: Incident entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Incident entry variables N Minimum Maximum Mean SD 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Received social support 
Perceived social support 
3 
3 
3 
3 
3 
3 
56 
28.5 
5 
27 
0 
94 
91 
37 
18.4 
53.3 
2 
100 
74.7 
33.5 
12.8 
43 
1 
96.3 
17.6 
4.4 
6.9 
14.1 
1 
3.2 
Incident entry date and time: 
18.11.2010 16:07. 
 
01.12.2010 10:05. 
 
 
 
17.12.2010 11:19 
Sought 
support 
No 
 
No 
 
 
No 
Description of the incident 
 
1) Sudden need to have a bowel movement. 
                         
2) Had to rush to the toilet to empty bowels and was late for diary 
entry. 
 
3) Accidentally defecated into my underpants. 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
A bivariate correlation analysis was undertaken between all the variables (including unaltered and altered 
variables), see table 28.   
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Table 28 Pearson product moment correlations between all variables for Mr G  
                                                             1 2     3   4  5  6 7      8         9          10   11      12     13     14     15 16 17 
 1) Positive coping                                             1                
2)Positive coping (PreW lag1)   0.836* 1                
3) Negative coping                                          -0.110 -0.217*  1                  
4) Negative coping (PreW lag 1)    -0.125 -0.110  0.924** 1               
5) Positive affect        0.228*  0.144    0.007  -0.075  1              
6) Positive affect (preW lag 3)    0.058 0.075  - 0.101   -0.115  0.938**  1             
7) Negative affect          0.259* 0.108      0.411**  0.240*    0.144 -0.014   1                
8) Negative affect (preW lag 1)       0.116 0.092    0.278**  0.224*   0.064 -0.015   0.926**   1            
9)  SQRT Negative affect(preW lag 1)     0 .088 0.069    0.243*  0.197    0.078 0.001  0.870**   0.971** 1 
10) Received social support                        0 .372**  0.175     0.175 0.006 0.228* 0.063 0.259*     0.080   0.080   1           
11)  Received social support(preW lag 1)      0.186    0.183   0.034 0.052 0.102 0.071 0.117     0.135  0.145 0.959**  1          
12)  SQRT Received social support(preW lag1) 0.180   0.180     0.069   0.083   0.100 0.072    0.134       0.145    0.159 0.894** 0.969** 1 
13) Perceived social support                           -0.096   -0.158   0.245*   0.172 0.016  0.031    0.061      0.051    0.039   0.188      0.007 0 .001  1      
14) Self-care demand                                        0.031    -0.012  -0.008 -0.049     -0.084  -0.102   -0.060      -0.054     -0.067 0.054   -0.007   -0.061 0.029  1 
15) Self-care control                                          0.059    0.066   0.024    0.045   0.035 0.085  -0.030   -0.034    -0.061    0.033  0.022   0.056      0.067   -0.191 1  
16) Self-care control(preW lag4)                             0.071    0.060 -0.006  0.008    0.063 0.063    0.032    0.046   0.016    0.095   0.087   0.093  -0.021  -0.097  0.947**  1  
17) Self-care self-efficacy       0.008    0.037   0.047 0.140     0.129   0.110  -0.075   -0.046   -0.057   0.027     0.049   0.028   -0.047 0.122    -0.056   -0.039    1 
*p<0.05, **p<0.01 (2-tailed) 
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Case report Mr H  
Mr H was a 73 year gentleman who was divorced with no partner.  He was diagnosed with locally 
advanced prostate cancer and treated with neoadjuvant hormone therapy and radiotherapy.  A 
significant autocorrelation was found for negative affect, received and perceived social support (at a lag 
1).  The pre-whitening procedure was applied and effectively removed the presence of autocorrelation.  
No other variables in the data series displayed autocorrelation.  A log transformation was successfully 
applied to self-management demand.  Several transformations (Tabachnick and Fidell, 2004) were applied 
self-efficacy, self-management control and negative coping however; were unsuccessful, and so these 
variables were left untransformed.   
Descriptive statistics of study variables – Mr H 
Mr H reported little received social support and moderate perceived social support (see table 29).  He 
also experienced a moderate degree of negative affect and a composite of positive and negative coping 
styles.  Mr H was dissatisfied with his social support and experienced a reduced quality of life (see table 
30) and experienced variety of symptoms (see table 31).   
Table 29 Mr H: Standard entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.  
Standard entry variables N Minimum Maximum Mean SD 
Self-care demand 
Self-care control 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
91 
91 
91 
91 
91 
91 
91 
91 
91 
4 
10 
65 
5.2 
8.6 
7 
51 
2.5 
3.5 
69 
99 
100 
53.3 
80.8 
77.7 
98.5 
73 
93.5 
18.6 
84.1 
90.2 
29.8 
39.9 
49.1 
90.5 
22.5 
46.7 
11.5 
17.4 
6.5 
10.5 
15.5 
12.6 
5.7 
12.1 
20.7 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Table 30 Mr H: End of day entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Satisfaction with social support  
 
Did you want to discuss your feelings 
today? 
 
Were you able to discuss your 
thoughts and feelings today?  
 
Overall, self-care self-efficacy 
 
Quality of life 
32 
 
32 
 
 
32 
 
 
32 
 
32 
21 
 
9 
 
 
10 
 
 
54.5 
 
13 
98 
 
96 
 
 
100 
 
 
98.5 
 
99 
53.6 
 
29.4 
 
 
28.8 
 
 
91.5 
 
57.6 
19.1 
 
23.3 
 
 
32.1 
 
 
7.7 
 
20.9 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Mr H experienced a number of symptoms (see table 31) including: constipation, diarrhoea, impotence, 
nausea, pain, tiredness and unable to sleep, urinary frequency and urgency. 
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Table 31 Mr H: Self-reports of symptoms enquired about at end of day entry.  Means, standard 
deviations, minimum and maximum values, untransformed.   
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the day 
Urinate frequently at night 
Vomiting 
32 
32 
32 
32 
32 
32 
32 
32 
32 
32 
32 
32 
15 
6 
5 
67 
6 
11 
25 
11 
11 
79 
61 
1 
91 
71 
93 
100 
66 
98 
95 
95 
98 
100 
96 
22 
49.5 
15.3 
31.6 
91.3 
23.8 
44.8 
72.4 
64.1 
84.5 
91.3 
88.9 
12.5 
18.5 
13.5 
22.8 
6.1 
16.9 
33.1 
16.9 
25.4 
19.1 
5.1 
6.7 
4.2 
The ratings (0=not at all, 100=always).  A higher score is interpreted as the higher frequency of the symptom 
 
Mr H did not complete any incident entries throughout the course of his data collection.  A correlation 
analysis was undertaken between all the variables (including unaltered and altered variables) and the 
results of the analysis are displayed in table 32.   
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Table 32 Pearson product moment correlations between all variables for Mr H.  
 
                                                                  1 2     3   4  5  6 7      8         9          10            11      12     13  
1) Positive coping   1 
2) Negative coping -0.089           1 
3) Positive affect  0.194      -0.290**      1 
4) Negative affect  -0.258*     0.357**   -0.577**      1 
5) Negative affect(PreW lag 1)  -0.278**    0.331**   -0.468**     0.888**    1 
6) Demand    -0.296**  0.161  -0.244* 0.310**  0.351**      1 
7) Demand log     -0.356**   0.188   -0.266* 0.339**  0.359**   0.920**        1 
8) Control  -0.055     -0.121    0.174   -0.286**  -0.240*    -0.122  -0.066          1 
9) Received social support  0.092      0.109    0.074   0.234*   0.210*   0.018    0.098     -0.029         1 
10) Received social support(PreW lag 1)   -0.008      0.179    -0.065  0.299**  0.184     0.027  0.124     -0.026 0.915**   1 
11) Perceived social support  0.283** -0.261*  0.387** -0.412**  -0.272**   -0.210*    -0.221*   0.078   0.205    0.102      1 
12) Perceived social support(PreW lag 1)   0.266* -0.197     0.252*  -0.299**  -0.266*     -0.240*  -0.198     0.038   0.160     0.198   0.881**        1 
13) Self-efficacy  0.223*  -0.020    0.073     0.040   -0.018   -0.038 -0.040     -0.032    0.145   0.071   0.123     0.170       1 
*p<0.05, **p<0.01 (2-tailed) 
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Case report Mr I  
Mr I is a 73 year old single gentleman who was also treated for his locally advanced prostate cancer 
treated by neoadjuvant hormone therapy and radiotherapy.  Mr I had pre-existing health problems and 
these included asthma and hypertension. 
Preliminary analysis– Mr I 
Autocorrelation was present for positive coping, positive affect, received social support and perceived 
social support (at a lag of 2), and for negative coping and self-care demand (at a lag of 1).  These variables 
underwent the pre-whitening procedure and successfully removed the autocorrelation.  Self-care demand 
(PreW lag 1) was negatively skewed and the K-S was significant (75)=0.120, P=0.009.  A square root 
transformation (and a constant + 30 [lowest negative value -29.7]) achieved normality of self-care demand 
(PreW lag 1).  Self-care control was negatively skewed and displayed positive kurtosis, and the K-M was 
significant (76)=0.130, P=0.003.  Transformation (Tabachnick and Fidell, 2004) were applied and were 
unsuccessful in improving normality and reducing the impact of outliners (case number 11 [value 55] and 
case number 16 [value 52]).  The values of the two univariate outliners were replaced with one unit 
smaller than the next extreme value in the distribution (Tabachnick and Fidell, 2004) (case number 11 
value was replaced with 51) and (case number 11 value was replaced with 50).  This was successful in 
improving the assumptions for this variable K-S (76)= 0.086, P=0.200.    Negative affect displayed positive 
kurtosis and the K-S was significant (76)=0.110, P=0.024.  A SQRT transformation was applied to negative 
affect and was successful in reducing the kurtosis, K-S (76)=0.083, P=0.200.  Received social support (PreW lag 
2) was positively skewed and kutotic, the K-S was significant (74)=0.120,P=0.010.  A square root 
transformation and constant of 11 (lowest negative value for this variable was -10.4) achieved normality in 
distribution for received social support (PreW lag 2), K-M (74)=0.080, P=0.200.  Perceived social support (PreW lag 
2) displayed positive kurtosis, a square root transformation (+ constant of 8, lowest negative value was -
7.07) achieved normality K-S (74)=0.060, P=0.200. 
Descriptive statistics of study variables 
Mr I received little social support and had low perceived social support (see table 33); and was highly 
dissatisfied with his support (see table 34).  Mr I reported reduced quality of life and he experienced a 
number of symptoms (see table 34 and 35).    
Table 33 Mr I: Standard entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
  N Minimum Maximum Mean SD 
Self-care demand 
Self-care control 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
76 
76 
76 
76 
76 
76 
76 
76 
76 
0 
66 
50 
4 
6 
11 
74.5 
0.7 
15.7 
70 
98 
94 
16.5 
36.8 
71.3 
94.5 
41.5 
40 
28.8 
82.8 
71.7 
7.5 
17.9 
42.1 
82.8 
12.5 
24.3 
13.7 
6.8 
8.8 
2.1 
4.9 
15.6 
3.6 
6.7 
4.8 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
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Table 34 Mr I: End of day entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Satisfaction with social support  
 
Did you want to discuss your 
feelings today? 
 
Were you able to discuss your 
thoughts and feelings today?  
 
 
Overall, self-care self-efficacy 
 
Quality of life 
30 
 
30 
 
 
30 
 
 
 
30 
 
30 
15 
 
44 
 
 
20 
 
 
 
70 
 
19 
39.7 
 
98 
 
 
99 
 
 
 
90 
 
69 
26.8 
 
80.1 
 
 
64.8 
 
 
 
81.1 
 
46.9 
6.8 
 
12.3 
 
 
22.7 
 
 
 
4.5 
 
12.5 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Mr I experienced a number of symptoms (see table 42) these included: constipation, impotence, pain, 
tiredness and unable to sleep, and urinary frequency and urgency. 
 
Table 35 Mr I: Self-reports of symptoms enquired about at end of day entry.  Means, standard 
deviations, minimum and maximum values, untransformed.   
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the day 
Urinate frequently at night 
Vomiting 
30 
30 
30 
30 
30 
30 
30 
30 
30 
30 
30 
30 
0 
0 
0 
82 
0 
13 
20 
20 
2 
41 
51 
0 
78 
56 
3 
100 
3 
54 
78 
84 
100 
88 
97 
3 
13.8 
8.6 
0.9 
95.2 
1.3 
23.6 
55.1 
58.1 
90.3 
64.7 
74.8 
1.3 
20.9 
14.8 
0.9 
5.3 
.9 
8.1 
14.3 
17 
24.2 
11.2 
13.2 
0.9 
The ratings (0=not at all, 100=always).  A higher score is interpreted as the higher frequency of the symptom. 
 
Mr I did not report any incident reports throughout his data collection.  Bivariate correlation coefficients 
for Mr I are displayed in table 36.        
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Table 36 Pearson product moment correlations between all variables for Mr I.  
                                                             1 2     3   4  5  6 7      8         9          10   11      12     13     14     15 16 17 18  19 
1) Positive coping                                       1 
2) Positive coping(PreW lag 2)              0.884**   1 
3) Negative coping                          0.171  0.233*       1 
4) Negative coping(PreW lag 1)                      0.093     0.191    0.954**        1 
5) Demand      -0.382** -0.318** -0.174    -0.151        1 
6) Demand (PreW lag 1)   -0.261    -0.257*    -0.081    -0.111    0.929**       1 
7) SQRT Demand (PreW lag 1)      -0.199    -0.169      -0.029     -0.063     0.890** 0.972**       1 
8) Control     0.245*    0.191       0.065     -0.099    -0.264*   -0.198    -0.160         1 
9) Positive affect   0.169      0.099      -0.273*  -0.477** -0.146    -0.126   -0.161    0.239*         1 
10) Positive affect (PreW lag 2)    0.216      0.168      -0.348**  -0.397** -0.180   -0.209    -0.251*  0.187   0.944**      1 
11) Negative affect                -0.026     0.025       0.085       0.172     -0.037      -0.094    -0.136    0.176   0.077    0.112        1 
12) SQRT negative affect        -0.015     0.061       0.121      0.216     -0.063      -0.116    -0.149    0.147    0.048   0.093  0.992**       1 
13) Self-efficacy                            0.093      0.064      -0.254*  -0.133     -0.091      -0.133    -0.134    0.292*  0.092    0.086   -0.024  -0.088       1 
14) Received social support    -0.217     0.124     -0.231*   -0.206      0.030      -0.027    -0.019   -0.027    0.096    0.137   -0.058     -0.038  -0.088          1 
15) Received social support (PreW lag 2)           -0.151    -0.115      -0.227    -0.198       0.047      -0.007    -0.006   0.017    0.068     0.117  -0.074      -0.063  -0.075   0.950**       1 
16) SQRT received social support(Prew lag 2)  -0.136    0.099     -0.179     -0.145       0.065       0.032    -0.029  -0.013    0.047     0.092   -0.140     -0.124  -0.137   0.910**  0.972**       1 
17) Perceived social support          -0.190   -0.172     -0.081    -0.297**    0.090        0.134    0.109   0.013    0.169     0.136   -0.185    -0.216    0.159   0.546**  0.542**  0.517**   1 
18) Perceived social support(PreW lag 2)           -0.058    0.021     -0.169     -0.136        0.065        0.080     0.087  -0.130   0.072      0.124  -0.196     -0.196   0.103   0.554**  0.546** 0.557**  0.879**    1 
19) SQRT Perceived social support(PreW lag 2) -0.041   0.029      -0.133    -0.103        0.088       0.109     0.115   -0.141   0.027     0.085   -0.195    -0.192    0.083  0.551**  0.558**  0.584**  0.850** 0.982*  1 
*p<0.05, **p<0.01 (2-tailed) 
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Case report Mr J 
Mr J was a 73 year old, married gentleman, who was diagnosed with metastatic prostate cancer.  He was 
being treated with hormone therapy.  Significant autocorrelations were found at a lag of 1 for positive 
coping, negative coping, self-efficacy, received social support, and for demand (at a lag of 2) and control 
(at a lag of 3).  The pre-whitening procedure was applied and was successful in removing the presence of 
autocorrelation.  Positive coping (PreW lag 1), negative affect (PreW lag 1), self-efficacy (PreW lag 1), perceived social 
support, demand (PreW lag 2) and control (PreW lag 3) displayed normality and the results of the K-S were non-
significant.  Negative coping (PreW lag 1) displayed positive skewness P<0.001, and the K-S (87) = 0.249, 
P<0.01.  A square root transformation (and a constant of + 10 [lowest negative value -9.5]) was successful 
in reducing the skewness and achieved normality of negative coping (PreW lag 1).   
Descriptive statistics of study variables – Mr J 
Mr J reported moderate social support with reduced perceived social support (see table 37); but had 
overall satisfaction (see table 38).  He reported reduced quality of life and experienced number symptoms 
(see table 39).  
 
Table 37 Mr J: Standard entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Self-care demand 
Self-care control 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
88 
88 
88 
88 
88 
88 
88 
88 
88 
2 
57 
66 
3.5 
3.4 
57 
60.5 
7.5 
46.5 
12 
93 
89 
25.4 
9.4 
78.7 
91.5 
78.5 
85.7 
7.1 
76.2 
75.4 
8.1 
6.3 
71.5 
75.6 
65.4 
69.5 
2.1 
5.5 
4.5 
4.3 
1.4 
4.5 
4.4 
11.9 
5.5 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Table 38 Mr J: End of day entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Satisfaction with social support  
 
Were you able to discuss your 
thoughts and feelings today?  
 
Did you want to discuss your feelings 
today? 
 
Overall, self care self-efficacy 
 
Quality of life 
28 
 
28 
 
 
28 
 
 
28 
 
28 
60.5 
 
25 
 
 
3 
 
 
68 
 
61 
86.75 
 
81 
 
 
68 
 
 
85.5 
 
90 
67.5 
 
65.3 
 
 
13 
 
 
75.5 
 
72.1 
5.3 
 
10.6 
 
 
11.9 
 
 
4.1 
 
6.5 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Impotence and urinary urgency and urinary frequency were experienced by Mr J, see table 39.   
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Table 39 Mr J: Self-reports of symptoms enquired about at end of day entry.  Means, standard 
deviations, minimum and maximum values, untransformed.   
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the day 
Urinate frequently at night 
Vomiting 
28 
28 
28 
28 
28 
28 
28 
28 
28 
28 
28 
28 
2 
2 
3 
61 
2 
4 
1 
2 
6 
45 
46 
3 
10 
11 
29 
88 
8 
9 
22 
17 
79 
77 
76 
11 
5.7 
6.1 
8.2 
70.8 
5.7 
6.6 
7.9 
8.1 
57.5 
61.5 
62.3 
6.7 
1.9 
2.2 
5.9 
5.7 
1.7 
1.4 
5.3 
3.4 
14.1 
7.7 
7.2 
1.8 
The ratings (0=not at all, 100=always).  A higher score is interpreted as the higher frequency of the symptom. 
 
Mr J did not complete any incident entries and the results of the correlation analysis (including unaltered 
and altered variables) are displayed in table 40.   
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Table 40  Pearson product moment correlations between all variables for Mr J.  
                                                             1 2     3   4  5  6 7      8         9          10            11      12     13     14     15 16 17 
 1) Positive coping  1 
2) Positive coping (PreW lag 1)  0.892**     1 
3) Negative coping  0.462**   0.272*      1 
4) Negative coping (PreW lag 1)  0.127      0.108     0.824**     1 
5) SQRT negative coping (PreW lag 1)  0.034     0.040     0.695**   0.961**       1 
6) Negative affect      0.389*   0.281**   0.427**   0.239*   0.198          1 
7) Negative affect (PreW lag 1)     0.302**  0.297**   0.249*    0.175    0.161    0.908**     1 
8) Positive affect                 -0.007     0.118      -0.101      0.087    0.096     -0.216**  -0.067          1 
9) Self-efficacy                       0.541**  0.336**    0.528**  0.128     0.027     0.455**  0.296*    -0.037           1 
10) Self-efficacy (PreW lag 1)    0.259*     0.224* 0.253*   0.034   -0.031    0.259* 0.226*    0.095   0.773**      1   
11) Received social  support    -0.426**   -0.199  -0.635**  -0.353** -0.235*   -0.281**  -0.110     0.319**  -0.565**  -0.295**     1 
12) Received social  support (PreW lag 1)    0.024 0.108     -0.222*  -0.211*    -0.127    -0.129      -0.052     0.353**  -0.099  -0.067     0.682**    1 
13) Perceived social support  0.003      0.061     -0.213*   -0.389** -0.380**   0.005        0.072       0.075   -0.013  0.053     0.478**  0.470**     1 
14) Demand    0.159      0.094      0.245*   0.183    0.158     0.506**   0.430**   0.009   0.205   0.154     0.024      0.083    -0.015        1 
15) Demand (PreW lag 2)   0.239*    0.135      0.254*    0.175    0.138      0.479**   0.413**   -0.068  0.268*  0.218*  -0.057    0.006     0.009    0.949**   1    
16) Control    0.519**  0.301**  0.550**  0.225*   0.143    0.460**   0.298**  -0.126   0.770** 0.524**  -0.545**  -0.164    -0.093 0.151  0.180      1 
17) Control (PreW lag 3)   0.253*     0.197       0.249*   0.144     0.132     0.250*    0.187        0.092    0.456**  0.392**   -0.081   0.082   0.048  0.106    0.094   0.815**    1 
*p<0.05, **p<0.01 (2-tailed) 
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Case report Mr K  
Mr K was a 72 year old married gentleman who was diagnosed with metastatic prostate cancer and 
treated with hormone therapy.  Significant autocorrelations were found at a lag of 1 for the following 
variables: negative affect, negative coping, positive affect, and self-care self-efficacy, received and 
perceived social support.  Positive affect had a significant correlation at a lag of 3.  The pre-whitening 
procedure effectively removed the presence of autocorrelation for these variables.  Negative coping (PreW 
lag of 1) was positively skewed and kurtotic, P<0.001 and the K-S was significant (84)=0.352, P<0.001.  A 
square root transformation (and a constant of + 5 [4.69 was the lowest value]) achieved normality in 
distribution for negative coping (PreW lag of 1), K-S (84) =0.071, P=0.200.  Received social support (PreW lag of 1) 
displayed kurtosis, P<0.001, and a square root transformation (and constant of 7 [lowest value was -6.87]) 
was applied and achieved normality in distribution, K-S (84) = 0.069, P=0.200.   
Descriptive statistics of study variables – Mr K 
Mr K received little social support and scored moderately for perceived social support (see table 41); with 
reduced satisfaction with social support scores (see table 42).   Mr K experienced a number of symptoms 
and these are displayed in table 43.   
Table 41 Mr K: Standard entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.  
Standard entry variables N Minimum Maximum Mean SD 
Self-care demand 
Self-care control 
Positive coping 
Negative coping 
Negative affect 
Positive affect 
Self-care self-efficacy 
Received social support 
Perceived social support 
85 
85 
85 
85 
85 
85 
85 
85 
85 
0 
81 
79 
9.3 
0 
46.3 
85 
4.3 
32.3 
20 
100 
100 
32.7 
13.6 
90.7 
100 
21.7 
97.7 
1.34 
94.6 
93.3 
24.6 
0.6 
73.5 
94.2 
9.8 
77.8 
2.7 
4.6 
4.2 
3.4 
1.7 
10.1 
3.4 
3.8 
9.3 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Table 42 Mr K: End of day entry: means, standard deviations, minimum and maximum values for 
psychological and social support variables, untransformed.   
Standard entry variables N Minimum Maximum Mean SD 
Satisfaction with social support  
 
Did you want to discuss your feelings 
today? 
 
Were you able to discuss your 
thoughts and feelings today?  
 
Overall, self-care self-efficacy 
 
Quality of life 
29 
 
29 
 
 
29 
 
 
29 
 
29 
56 
 
0 
 
 
93 
 
 
84 
 
66 
89.7 
 
59 
 
 
100 
 
 
98.5 
 
87 
67.7 
 
6.3 
 
 
95.8 
 
 
93.6 
 
74 
8.9 
 
13.5 
 
 
2.4 
 
 
3.9 
 
4.5 
All scales are from 0-100.  A higher number is interpreted as a higher score of that variable 
 
Mr K experienced the following symptoms: urinary urgency and frequency, pain, tiredness and unable to 
sleep (see table 43).   
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Table 43 Mr K: Self-reports of symptoms enquired about at end of day entry.  Means, standard 
deviations, minimum and maximum values, untransformed.   
Daily ratings of symptom N Minimum Maximum Mean SD 
Constipation 
Blood in the urine 
Diarrhoea 
Impotence 
Nausea 
Pain 
Tiredness 
Unable to sleep 
Urgency to pass urine 
Urinate frequently during the day 
Urinate frequently at night 
Vomiting 
29 
29 
29 
29 
29 
29 
29 
29 
29 
29 
29 
29 
0 
0 
0 
0 
0 
16 
11 
0 
20 
21 
12 
0 
9 
7 
52 
7 
7 
39 
29 
26 
85 
75 
66 
2 
0.6 
0.4 
3.4 
0.5 
0.6 
27.4 
21.9 
17.7 
36.6 
34.3 
30.1 
0.2 
1.7 
1.4 
11.7 
1.4 
1.6 
5.4 
4.7 
6.6 
14.1 
11.6 
10.9 
0.6 
The ratings (0=not at all, 100=always).  A higher score is interpreted as the higher frequency of the symptom. 
 
Mr K did not complete any incident entries throughout the course of his data collection. The results of Mr 
K’s bivariate correlation are displayed in table 44.   
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Table 44 Pearson product moment correlations between all variables for Mr K.  
                                                             1 2     3   4  5  6 7      8         9          10   11      12     13     14     15 16 17 18
   
1) Positive affect                                                        1 
2) Positive affect (PreW lag 3)        0.704**       1 
3) Negative affect                    0.164    0.217         1 
4) Negative affect (PreW lag 1)  0.172     0.138     0.660**      1 
5) Negative coping                                 -0.485**  -0.264*      -0.422**  -0.012        1 
6) Negative coping (PreW lag 1)    -0.339**   -0.313**     0.130        -0.190  0.744**      1 
7) SQRT negatve coping (PreW lag 1)     -0.328**   -0.280*     0.108         -0.141 0.764**     0.979**    1 
8) Positive coping                                0.198      0.033       -0.019          0.163    0.232*     0.187     0.207        1 
9) Positive coping (PreW lag 1)            0.199      0.037        0.257*        0.093    0.112     0.223*    0.238*   0.944**      1 
10) Self-efficacy                                      0.151       0.098        0.048        0.153     0.152    0.196      0.213     0.450**  0.385**     1 
11) Self-efficacy (PreW lag 1)        0.096       0.080       0.242*       0.041     0.078   0.242*    0.253*   0.345**  0.350**  0.933**      1 
12) Received social  support               -0.445**   -0.326**   -0.081        -0.182     0.402** 0.348**  0.348** -0.110   -0.071      -0.055   -0.027        1 
13) Received social  support (PreW lag 1)    -0.232*   -0.235*      0.038        -0.172     0.201       0.263**   0.255*   -0.156    -0.108      -0.037    0.001   0.800**      1 
14) SQRT received social support (PreW lag 1) -0.237*    -0.214      0.018       -0.143      0.212       0.250*     0.247*   -0.146    -0.111      -0.027   0.009    0.740**  0.976**      1 
15) Perceived social support                           -0.546**   0.150       0.430**     0.360**  -0.321** -0.080    -0.085  0.203      0.251*    0.328*  0.294**  -0.239*    -0.080     -0.095       1 
16) Perceived social support (preW lag 1)    0.264*     -0.041      0.314**      0.223*    -0.130       0.016     -0.001      0.052      0.098     0.236*  0.237*    -0.044       0.078     0.062      0.813**     1 
17) Demand                                                       -0.113      -0.081    0.288**      0.100     -0.044       0.113       0.052    -0.197    -0.210      -0.018   0.039     -0.123      -0.143  -0.124    0.014       -0.035        1 
18) Control                                    0.191        0.038     -0.033 0.135       0.122       0.124     0.113     0.488**  0.421**   0.462   0.326** -0.105       -0.007     -0.007     0.238*       0.144    -0.013         1 
*p<0.05, **p<0.01 (2-tailed) 
 
 
 
